molecule_chembl_id,target_chembl_id,target_pref_name,standard_type,standard_relation,standard_value,standard_units,assay_chembl_id,assay_type,assay_description,document_chembl_id,readout,smiles
CHEMBL423694,CHEMBL233,Mu opioid receptor,IC50,=,5250.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2cccc(OC)c2)cc1
CHEMBL278078,CHEMBL233,Mu opioid receptor,IC50,=,3480.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2ccccc2OC)cc1
CHEMBL13470,CHEMBL233,Mu opioid receptor,IC50,=,320.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL127802,CHEMBL233,Mu opioid receptor,IC50,=,4130.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCCCN1CCC(=C(c2ccccc2)c2ccc(C(=O)N(CC)CC)cc2)CC1
CHEMBL338980,CHEMBL233,Mu opioid receptor,IC50,=,8150.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(c2ccccc2)N2CCNCC2)cc1
CHEMBL415521,CHEMBL233,Mu opioid receptor,IC50,=,3800.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2ccccc2)cc1
CHEMBL126884,CHEMBL233,Mu opioid receptor,IC50,=,1020.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2c(C)cccc2C)cc1
CHEMBL126255,CHEMBL233,Mu opioid receptor,IC50,=,3330.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,C=CCN1CCC(=C(c2ccccc2)c2ccc(C(=O)N(CC)CC)cc2)CC1
CHEMBL126857,CHEMBL233,Mu opioid receptor,IC50,=,2590.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2ccc(Cl)c(Cl)c2)cc1
CHEMBL339457,CHEMBL233,Mu opioid receptor,IC50,=,3570.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2cccc(F)c2)cc1
CHEMBL129315,CHEMBL233,Mu opioid receptor,IC50,=,5440.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2cccs2)cc1
CHEMBL340131,CHEMBL233,Mu opioid receptor,IC50,=,2740.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2cccc([N+](=O)[O-])c2)cc1
CHEMBL127788,CHEMBL233,Mu opioid receptor,IC50,=,3390.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(CC3CC3)CC2)c2ccccc2)cc1
CHEMBL129693,CHEMBL233,Mu opioid receptor,IC50,=,6760.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2ccc(SC)cc2)cc1
CHEMBL129034,CHEMBL233,Mu opioid receptor,IC50,=,817.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2cccc3ccccc23)cc1
CHEMBL127495,CHEMBL233,Mu opioid receptor,IC50,=,5980.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2cccc(N)c2)cc1
CHEMBL340476,CHEMBL233,Mu opioid receptor,IC50,=,597.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(C3CCCCC3)CC2)c2ccccc2)cc1
CHEMBL126141,CHEMBL233,Mu opioid receptor,IC50,=,1030.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(CC=C(C)C)CC2)c2ccccc2)cc1
CHEMBL126370,CHEMBL233,Mu opioid receptor,IC50,=,2980.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2ccccc2F)cc1
CHEMBL339922,CHEMBL233,Mu opioid receptor,IC50,=,5440.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2ccc(OC)cc2)cc1
CHEMBL339898,CHEMBL233,Mu opioid receptor,IC50,=,1510.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2cccc(C(F)(F)F)c2)cc1
CHEMBL129300,CHEMBL233,Mu opioid receptor,IC50,=,3290.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2cccc(C(C)=O)c2)cc1
CHEMBL127007,CHEMBL233,Mu opioid receptor,IC50,=,5050.0,nM,CHEMBL749749,B,Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2ccc(Cl)cc2)cc1
CHEMBL1790709,CHEMBL233,Mu opioid receptor,IC50,=,8.2,nM,CHEMBL757306,B,Binding affinity towards Opioid receptor mu 1 was evaluated,CHEMBL1133766,IC50,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(=O)N[C@@H](CO[C@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@H]1O)C(N)=O
CHEMBL1790710,CHEMBL233,Mu opioid receptor,IC50,=,4.0,nM,CHEMBL757306,B,Binding affinity towards Opioid receptor mu 1 was evaluated,CHEMBL1133766,IC50,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(=O)N[C@@H](CO)C(N)=O
CHEMBL80,CHEMBL233,Mu opioid receptor,IC50,=,2.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL332697,CHEMBL233,Mu opioid receptor,IC50,=,960.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,COc1cc(/C=C/C(=O)N2CCC(n3c(O)nc4ccccc43)CC2)c([N+](=O)[O-])cc1OC
CHEMBL324297,CHEMBL233,Mu opioid receptor,IC50,=,1.5,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,O=[N+]([O-])c1cc2c(cc1CN1CCC(n3c(O)nc4ccccc43)CC1)OCO2
CHEMBL115229,CHEMBL233,Mu opioid receptor,IC50,=,19.3,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,O=[N+]([O-])c1cc2c(cc1CN1CC=C(n3c(O)nc4ccccc43)CC1)OCO2
CHEMBL115444,CHEMBL233,Mu opioid receptor,IC50,=,147.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,O=C(OCc1cc2c(cc1Cl)OCO2)N1CCC(n2c(O)nc3ccccc32)CC1
CHEMBL115549,CHEMBL233,Mu opioid receptor,IC50,=,1050.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,O=C(OCc1cc2c(cc1[N+](=O)[O-])OCO2)N1CCC(n2c(O)nc3ccccc32)CC1
CHEMBL420863,CHEMBL233,Mu opioid receptor,IC50,=,2.4,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,Cc1ccc2nc(O)n(C3CCN(Cc4cc5c(cc4Cl)OCO5)CC3)c2c1
CHEMBL114280,CHEMBL233,Mu opioid receptor,IC50,=,235.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,Oc1nc2ccccc2n1CCCNCc1cc2c(cc1Cl)OCO2
CHEMBL2096625,CHEMBL233,Mu opioid receptor,IC50,=,1.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O=S(=O)(O)O
CHEMBL596,CHEMBL233,Mu opioid receptor,IC50,=,1.3,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL325674,CHEMBL233,Mu opioid receptor,IC50,=,1470.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,O=C(OC1CCc2ccccc21)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL419214,CHEMBL233,Mu opioid receptor,IC50,=,2890.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,Cc1ncc([N+](=O)[O-])n1CCNC(=O)N1CCC(c2cc(-c3ccc(Cl)cc3Cl)[nH]n2)CC1
CHEMBL115222,CHEMBL233,Mu opioid receptor,IC50,=,0.9,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,CNC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cc4c(cc3Cl)OCO4)CC2)C1=O
CHEMBL115284,CHEMBL233,Mu opioid receptor,IC50,=,2590.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,O=C(OCc1cc2c(cc1Cl)OCO2)N1CCC(N2C(=O)CNc3ccccc32)CC1
CHEMBL325697,CHEMBL233,Mu opioid receptor,IC50,=,2285.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,O=C(c1cc2cc(Cl)ccc2[nH]1)N1CCN(S(=O)(=O)c2ccc([N+](=O)[O-])cc2[N+](=O)[O-])CC1
CHEMBL325750,CHEMBL233,Mu opioid receptor,IC50,=,24.9,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,O=C1NCN(c2ccccc2)C12CCN(Cc1ccc3nsnc3c1)CC2
CHEMBL2368861,CHEMBL233,Mu opioid receptor,IC50,=,1.7,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5.Cl
CHEMBL111918,CHEMBL233,Mu opioid receptor,IC50,=,735.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,O=C(O)CN1CN(c2ccccc2)C2(CCN(C(=O)OCc3cc4c(cc3Cl)OCO4)CC2)C1=O
CHEMBL114379,CHEMBL233,Mu opioid receptor,IC50,=,1.2,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,Oc1nc2ccccc2n1C1CCN(Cc2cc3c(cc2Cl)OCO3)CC1
CHEMBL324479,CHEMBL233,Mu opioid receptor,IC50,=,4955.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,COC(=O)c1csc(S(=O)(=O)N2CCN(C(=O)c3ccccc3Nc3ccccc3)CC2)c1OC
CHEMBL607,CHEMBL233,Mu opioid receptor,IC50,=,315.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,CCOC(=O)C1(c2ccccc2)CCN(C)CC1
CHEMBL651,CHEMBL233,Mu opioid receptor,IC50,=,4.1,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1
CHEMBL333843,CHEMBL233,Mu opioid receptor,IC50,=,2480.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,O=C(NCCCn1c(O)nc2ccccc21)OCc1cc2c(cc1Cl)OCO2
CHEMBL112191,CHEMBL233,Mu opioid receptor,IC50,=,16.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,COc1ccc(CN2CCC(n3c(O)nc4ccccc43)CC2)c(Cl)c1
CHEMBL895,CHEMBL233,Mu opioid receptor,IC50,=,1.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL326320,CHEMBL233,Mu opioid receptor,IC50,=,1235.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,Cc1ccc2nc(O)n(C3CCN(C(=O)OCc4cc5c(cc4Cl)OCO5)CC3)c2c1
CHEMBL420500,CHEMBL233,Mu opioid receptor,IC50,=,2285.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,O=C(OCc1ccc2c(c1)OCO2)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL326962,CHEMBL233,Mu opioid receptor,IC50,=,16.7,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,O=C1NCN(c2ccccc2)C12CCN(Cc1ccc3c(c1)OCO3)CC2
CHEMBL369475,CHEMBL233,Mu opioid receptor,IC50,=,520.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.O
CHEMBL115076,CHEMBL233,Mu opioid receptor,IC50,=,1730.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,O=C(OCc1cc2c(cc1Cl)OCO2)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL1707,CHEMBL233,Mu opioid receptor,IC50,=,1.5,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1.Cl
CHEMBL115280,CHEMBL233,Mu opioid receptor,IC50,=,83.5,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,O=C1NCN(c2ccccc2)C12CCN(Cc1cccc(Oc3ccccc3)c1)CC2
CHEMBL325842,CHEMBL233,Mu opioid receptor,IC50,=,6.3,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,O=C1CNc2ccccc2N1C1CCN(Cc2cc3c(cc2Cl)OCO3)CC1
CHEMBL115652,CHEMBL233,Mu opioid receptor,IC50,=,2.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,O=C1NCN(c2ccccc2)C12CCN(Cc1cc3c(cc1Cl)OCO3)CC2
CHEMBL114825,CHEMBL233,Mu opioid receptor,IC50,=,179.0,nM,CHEMBL757060,B,Binding affinity against mu-opiate receptor (human) using [3H]DAMGO radioligand,CHEMBL1134447,IC50,CNC(=O)CN1CN(c2ccccc2)C2(CCN(C(=O)OCc3cc4c(cc3Cl)OCO4)CC2)C1=O
CHEMBL64809,CHEMBL233,Mu opioid receptor,IC50,=,4280.0,nM,CHEMBL749747,B,Binding affinity towards mu opioid receptor by the displacement of [125I]Enkephalin,CHEMBL1135372,IC50,N#Cc1cccc(-c2cccn(C(CN3CCCC3)c3ccccc3)c2=O)c1
CHEMBL146191,CHEMBL233,Mu opioid receptor,IC50,=,780.0,nM,CHEMBL753179,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1 in CHO cells,CHEMBL1132115,IC50,Oc1nc2ccccc2n1C1CCN(CC2CCCCCCC2)CC1
CHEMBL304263,CHEMBL233,Mu opioid receptor,IC50,=,1200.0,nM,CHEMBL749747,B,Binding affinity towards mu opioid receptor by the displacement of [125I]Enkephalin,CHEMBL1135372,IC50,COc1ccccc1-c1cccn(C(CN2CCCC2)c2ccccc2)c1=O
CHEMBL304404,CHEMBL233,Mu opioid receptor,IC50,=,2680.0,nM,CHEMBL749747,B,Binding affinity towards mu opioid receptor by the displacement of [125I]Enkephalin,CHEMBL1135372,IC50,O=c1c(-c2ccc3ccccc3c2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL357076,CHEMBL233,Mu opioid receptor,IC50,=,2200.0,nM,CHEMBL749745,B,Binding affinity in CHO cells stably expressing cloned human Opioid receptor mu 1 by displacing diprenorphine,CHEMBL1132115,IC50,CCn1c(=O)n([C@@H]2CCN(CC3CCCCCCC3)C[C@H]2CO)c2ccccc21
CHEMBL59995,CHEMBL233,Mu opioid receptor,IC50,=,1680.0,nM,CHEMBL749747,B,Binding affinity towards mu opioid receptor by the displacement of [125I]Enkephalin,CHEMBL1135372,IC50,O=c1c(-c2ccccc2C(F)(F)F)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL440765,CHEMBL233,Mu opioid receptor,IC50,=,248.0,nM,CHEMBL749746,B,Binding affinity towards Opioid receptor mu 1 by the displacement of [125I]Enkephalin; Not determined,CHEMBL1135372,IC50,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL300616,CHEMBL233,Mu opioid receptor,IC50,=,1700.0,nM,CHEMBL749745,B,Binding affinity in CHO cells stably expressing cloned human Opioid receptor mu 1 by displacing diprenorphine,CHEMBL1132115,IC50,Oc1nc2ccccc2n1C1CCN(Cc2ccccc2)CC1
CHEMBL61426,CHEMBL233,Mu opioid receptor,IC50,=,1100.0,nM,CHEMBL749747,B,Binding affinity towards mu opioid receptor by the displacement of [125I]Enkephalin,CHEMBL1135372,IC50,O=c1c(-c2ccc(OC(F)(F)F)cc2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL146013,CHEMBL233,Mu opioid receptor,IC50,=,950.0,nM,CHEMBL753179,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1 in CHO cells,CHEMBL1132115,IC50,CCn1c(=O)n(C2CCN(CC3CCCCCCC3)CC2)c2ccccc21
CHEMBL61212,CHEMBL233,Mu opioid receptor,IC50,=,2064.0,nM,CHEMBL749747,B,Binding affinity towards mu opioid receptor by the displacement of [125I]Enkephalin,CHEMBL1135372,IC50,O=c1c(-c2ccc(Cl)c(Cl)c2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL294174,CHEMBL233,Mu opioid receptor,IC50,=,308.0,nM,CHEMBL749747,B,Binding affinity towards mu opioid receptor by the displacement of [125I]Enkephalin,CHEMBL1135372,IC50,O=c1c(-c2cccc(Cl)c2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL280037,CHEMBL233,Mu opioid receptor,IC50,=,2716.0,nM,CHEMBL749747,B,Binding affinity towards mu opioid receptor by the displacement of [125I]Enkephalin,CHEMBL1135372,IC50,O=c1c(-c2ccc(C(F)(F)F)cc2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL293143,CHEMBL233,Mu opioid receptor,IC50,=,1240.0,nM,CHEMBL749747,B,Binding affinity towards mu opioid receptor by the displacement of [125I]Enkephalin,CHEMBL1135372,IC50,COc1ccc(Cl)cc1-c1cccn(C(CN2CCCC2)c2ccccc2)c1=O
CHEMBL60030,CHEMBL233,Mu opioid receptor,IC50,=,4840.0,nM,CHEMBL749747,B,Binding affinity towards mu opioid receptor by the displacement of [125I]Enkephalin,CHEMBL1135372,IC50,O=c1c(-c2ccc(Cl)cc2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL293619,CHEMBL233,Mu opioid receptor,IC50,=,3910.0,nM,CHEMBL749747,B,Binding affinity towards mu opioid receptor by the displacement of [125I]Enkephalin,CHEMBL1135372,IC50,O=c1c(-c2cccc([N+](=O)[O-])c2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL146462,CHEMBL233,Mu opioid receptor,IC50,=,3300.0,nM,CHEMBL749745,B,Binding affinity in CHO cells stably expressing cloned human Opioid receptor mu 1 by displacing diprenorphine,CHEMBL1132115,IC50,CCn1c(=O)n([C@H]2CCN(CC3CCCCCCC3)C[C@@H]2CO)c2ccccc21
CHEMBL305552,CHEMBL233,Mu opioid receptor,IC50,=,1464.0,nM,CHEMBL749747,B,Binding affinity towards mu opioid receptor by the displacement of [125I]Enkephalin,CHEMBL1135372,IC50,COc1ccc(-c2cccn(C(CN3CCCC3)c3ccccc3)c2=O)cc1
CHEMBL146054,CHEMBL233,Mu opioid receptor,IC50,=,43.0,nM,CHEMBL749745,B,Binding affinity in CHO cells stably expressing cloned human Opioid receptor mu 1 by displacing diprenorphine,CHEMBL1132115,IC50,CC(c1ccccc1Cl)N1CCC(n2c(O)nc3ccccc32)CC1
CHEMBL64284,CHEMBL233,Mu opioid receptor,IC50,=,3460.0,nM,CHEMBL749747,B,Binding affinity towards mu opioid receptor by the displacement of [125I]Enkephalin,CHEMBL1135372,IC50,COc1ccc(F)cc1-c1cccn(C(CN2CCCC2)c2ccccc2)c1=O
CHEMBL362991,CHEMBL233,Mu opioid receptor,IC50,=,320.0,nM,CHEMBL756578,B,Inhibitory activity against non-selective opiate receptor,CHEMBL1136639,IC50,NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL8072,CHEMBL233,Mu opioid receptor,IC50,=,15000.0,nM,CHEMBL756578,B,Inhibitory activity against non-selective opiate receptor,CHEMBL1136639,IC50,NCCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)O
CHEMBL276502,CHEMBL233,Mu opioid receptor,IC50,=,1800.0,nM,CHEMBL756578,B,Inhibitory activity against non-selective opiate receptor,CHEMBL1136639,IC50,NCCCC[C@H](C(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@H](CC(=O)O)C(=O)O
CHEMBL410260,CHEMBL233,Mu opioid receptor,IC50,=,6900.0,nM,CHEMBL756578,B,Inhibitory activity against non-selective opiate receptor,CHEMBL1136639,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)[C@@H](C)O)[C@@H](C)CC
CHEMBL8234,CHEMBL233,Mu opioid receptor,IC50,=,9500.0,nM,CHEMBL756578,B,Inhibitory activity against non-selective opiate receptor,CHEMBL1136639,IC50,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL428276,CHEMBL233,Mu opioid receptor,IC50,=,10000.0,nM,CHEMBL756578,B,Inhibitory activity against non-selective opiate receptor,CHEMBL1136639,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)[C@@H](C)O)[C@@H](C)CC
CHEMBL144261,CHEMBL233,Mu opioid receptor,IC50,=,17000.0,nM,CHEMBL874639,B,Inhibitory concentration against Opioid receptor mu 1 using [3H]DAMGO ligand,CHEMBL1132477,IC50,c1ccc(C2(c3ccccc3)CCNCC2)cc1
CHEMBL144894,CHEMBL233,Mu opioid receptor,IC50,=,27000.0,nM,CHEMBL874639,B,Inhibitory concentration against Opioid receptor mu 1 using [3H]DAMGO ligand,CHEMBL1132477,IC50,Cc1cc(C)cc(C2(c3cc(C)cc(C)c3)CCNCC2)c1
CHEMBL344967,CHEMBL233,Mu opioid receptor,IC50,=,6000.0,nM,CHEMBL874639,B,Inhibitory concentration against Opioid receptor mu 1 using [3H]DAMGO ligand,CHEMBL1132477,IC50,Cc1ccc(C2(c3ccccc3C)CCNCC2)cc1
CHEMBL1052,CHEMBL233,Mu opioid receptor,IC50,=,1100.0,nM,CHEMBL874639,B,Inhibitory concentration against Opioid receptor mu 1 using [3H]DAMGO ligand,CHEMBL1132477,IC50,CCOC(=O)C1(c2ccccc2)CCNCC1
CHEMBL485,CHEMBL233,Mu opioid receptor,IC50,=,105.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
CHEMBL3707097,CHEMBL233,Mu opioid receptor,IC50,=,500.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,Brc1ccc2c(c1)[C@H]1c3cc(Br)ccc3[C@H](C2)N2CCC[C@@H]12
CHEMBL592,CHEMBL233,Mu opioid receptor,IC50,=,0.13,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL3707102,CHEMBL233,Mu opioid receptor,IC50,=,8.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(NCc4ccccc4)ccc3C[C@@H](c3ccc(NCc4ccccc4)cc32)N1C
CHEMBL3707078,CHEMBL233,Mu opioid receptor,IC50,=,103.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,Fc1ccc2c(c1)[C@H]1c3cc(F)ccc3[C@H](C2)N2CCC[C@@H]12
CHEMBL3706646,CHEMBL233,Mu opioid receptor,IC50,=,764.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@H]1[C@@H]2c3ccccc3C[C@H](c3ccccc32)N1CCO
CHEMBL3707100,CHEMBL233,Mu opioid receptor,IC50,=,230.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3ccccc3C[C@@H](c3ccccc32)N1C
CHEMBL3707076,CHEMBL233,Mu opioid receptor,IC50,=,120.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,Brc1ccc(CNc2ccc3c(c2)[C@H]2c4cc(NCc5ccc(Br)cc5)ccc4[C@H](C3)N3CCC[C@@H]23)cc1
CHEMBL3707093,CHEMBL233,Mu opioid receptor,IC50,=,690.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(N4CCOCC4)ccc3C[C@@H](c3ccc(N4CCOCC4)cc32)N1C
CHEMBL2112842,CHEMBL233,Mu opioid receptor,IC50,=,1010.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,CC(C)C[C@H]1[C@H]2c3ccccc3C[C@H](c3ccccc32)N1C
CHEMBL3707098,CHEMBL233,Mu opioid receptor,IC50,=,1080.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3ccccc3C[C@@H](c3ccccc32)N1CC1CC1
CHEMBL3707081,CHEMBL233,Mu opioid receptor,IC50,=,200.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,CC(=O)Oc1ccc2c(c1)[C@H]1c3cc(OC(C)=O)ccc3[C@H](C2)N(C)[C@@H]1C
CHEMBL3706645,CHEMBL233,Mu opioid receptor,IC50,=,404.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@H]1[C@@H]2c3ccccc3C[C@H](c3ccccc32)N1CO
CHEMBL3707088,CHEMBL233,Mu opioid receptor,IC50,=,690.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(N4CCN(C)CC4)ccc3C[C@@H](c3ccc(N4CCN(C)CC4)cc32)N1CC1CC1
CHEMBL3707077,CHEMBL233,Mu opioid receptor,IC50,=,220.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,CC(=O)Oc1ccc2c(c1)[C@H]1c3cc(OC(C)=O)ccc3[C@H](C2)N2CCC[C@@H]12
CHEMBL3707096,CHEMBL233,Mu opioid receptor,IC50,=,160.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,COc1ccc2c(c1)[C@H]1c3cc(OC)ccc3[C@H](C2)N2CCC[C@@H]12
CHEMBL2112835,CHEMBL233,Mu opioid receptor,IC50,=,1150.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,CN1[C@@H]2Cc3ccccc3[C@@H](c3ccccc32)[C@@H]1CCCO
CHEMBL2112838,CHEMBL233,Mu opioid receptor,IC50,=,611.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@H]1[C@H]2c3ccccc3C[C@H](c3ccccc32)N1C
CHEMBL3707099,CHEMBL233,Mu opioid receptor,IC50,=,2000.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C=CCN1[C@H](C)[C@H]2c3ccccc3C[C@H]1c1ccccc12
CHEMBL3706637,CHEMBL233,Mu opioid receptor,IC50,=,390.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,c1ccc2c(c1)C[C@@H]1c3ccccc3[C@H]2[C@@H]2CCCCN12
CHEMBL3707094,CHEMBL233,Mu opioid receptor,IC50,=,53.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(N4CCN(C)CC4)ccc3C[C@@H](c3ccc(N4CCN(C)CC4)cc32)N1C
CHEMBL2112841,CHEMBL233,Mu opioid receptor,IC50,=,1050.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,CN1[C@@H]2Cc3ccccc3[C@@H](c3ccccc32)[C@@H]1Cc1ccccc1
CHEMBL3707086,CHEMBL233,Mu opioid receptor,IC50,=,360.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(Br)ccc3C[C@@H](c3ccc(Br)cc32)N1C
CHEMBL3707089,CHEMBL233,Mu opioid receptor,IC50,=,7.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(NCc4ccccc4)ccc3C[C@@H](c3ccc(NCc4ccccc4)cc32)N1CC1CC1
CHEMBL3707083,CHEMBL233,Mu opioid receptor,IC50,=,16.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(O)ccc3C[C@@H](c3ccc(O)cc32)N1C
CHEMBL3707095,CHEMBL233,Mu opioid receptor,IC50,=,56.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(Nc4ccccc4)ccc3C[C@@H](c3ccc(Nc4ccccc4)cc32)N1C
CHEMBL3707080,CHEMBL233,Mu opioid receptor,IC50,=,44.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,CC(=O)Oc1ccc2c(c1)[C@H]1c3cc(OC(C)=O)ccc3[C@H](C2)N(CC2CC2)[C@@H]1C
CHEMBL3707103,CHEMBL233,Mu opioid receptor,IC50,=,82.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(Nc4ccccc4)ccc3C[C@@H](c3ccc(Nc4ccccc4)cc32)N1CC1CC1
CHEMBL70,CHEMBL233,Mu opioid receptor,IC50,=,0.57,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL3707082,CHEMBL233,Mu opioid receptor,IC50,=,6.4,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(O)ccc3C[C@@H](c3ccc(O)cc32)N1CC1CC1
CHEMBL3707087,CHEMBL233,Mu opioid receptor,IC50,=,59.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,c1ccc2c(c1)C[C@H]1c3ccccc3[C@H]2[C@@H]2CCCN12
CHEMBL2112843,CHEMBL233,Mu opioid receptor,IC50,=,695.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,CC(C)[C@H]1[C@H]2c3ccccc3C[C@H](c3ccccc32)N1C
CHEMBL2112844,CHEMBL233,Mu opioid receptor,IC50,=,650.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@H]1N[C@@H]2Cc3ccccc3[C@H]1c1ccccc12
CHEMBL3707084,CHEMBL233,Mu opioid receptor,IC50,=,420.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,COc1ccc2c(c1)[C@H]1c3cc(OC)ccc3[C@H](C2)N(C)[C@@H]1C
CHEMBL3707101,CHEMBL233,Mu opioid receptor,IC50,=,1030.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,COc1ccc2c(c1)[C@H]1c3cc(OC)ccc3[C@H](C2)N(CC2CC2)[C@@H]1C
CHEMBL3707075,CHEMBL233,Mu opioid receptor,IC50,=,130.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,Oc1ccc2c(c1)[C@H]1c3cc(O)ccc3[C@H](C2)N2CCC[C@@H]12
CHEMBL3707085,CHEMBL233,Mu opioid receptor,IC50,=,2050.0,nM,CHEMBL753178,B,In vitro binding affinity against cloned human Opioid receptor mu 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(Br)ccc3C[C@@H](c3ccc(Br)cc32)N1CC1CC1
CHEMBL91760,CHEMBL233,Mu opioid receptor,IC50,=,4.7,nM,CHEMBL744603,B,In vitro binding affinity towards mu opioid receptors was determined using [3H][p-Cl-Phe]- 4] DPDPE or [3H]deltorphin II,CHEMBL1131989,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NN
CHEMBL319822,CHEMBL233,Mu opioid receptor,IC50,=,8.3,nM,CHEMBL744603,B,In vitro binding affinity towards mu opioid receptors was determined using [3H][p-Cl-Phe]- 4] DPDPE or [3H]deltorphin II,CHEMBL1131989,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NNC(=O)[C@H](N)Cc1ccccc1
CHEMBL424328,CHEMBL233,Mu opioid receptor,IC50,=,100.0,nM,CHEMBL754564,B,Inhibitory activity was determined in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor mu 1 in chinese Hamster Ovary (CHO)membranes,CHEMBL1145905,IC50,O=C(CCCCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL146756,CHEMBL233,Mu opioid receptor,IC50,=,610.0,nM,CHEMBL754564,B,Inhibitory activity was determined in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor mu 1 in chinese Hamster Ovary (CHO)membranes,CHEMBL1145905,IC50,O=C(/C=C/C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL405131,CHEMBL233,Mu opioid receptor,IC50,=,90.0,nM,CHEMBL754564,B,Inhibitory activity was determined in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor mu 1 in chinese Hamster Ovary (CHO)membranes,CHEMBL1145905,IC50,O=C(CCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL200199,CHEMBL233,Mu opioid receptor,IC50,=,1.4,nM,CHEMBL744603,B,In vitro binding affinity towards mu opioid receptors was determined using [3H][p-Cl-Phe]- 4] DPDPE or [3H]deltorphin II,CHEMBL1131989,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NNC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL413512,CHEMBL233,Mu opioid receptor,IC50,=,1.8,nM,CHEMBL754564,B,Inhibitory activity was determined in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor mu 1 in chinese Hamster Ovary (CHO)membranes,CHEMBL1145905,IC50,O=C(CCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL357334,CHEMBL233,Mu opioid receptor,IC50,=,130.0,nM,CHEMBL754564,B,Inhibitory activity was determined in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor mu 1 in chinese Hamster Ovary (CHO)membranes,CHEMBL1145905,IC50,COC(=O)CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL358104,CHEMBL233,Mu opioid receptor,IC50,=,90.0,nM,CHEMBL754564,B,Inhibitory activity was determined in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor mu 1 in chinese Hamster Ovary (CHO)membranes,CHEMBL1145905,IC50,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL92286,CHEMBL233,Mu opioid receptor,IC50,=,2.0,nM,CHEMBL744603,B,In vitro binding affinity towards mu opioid receptors was determined using [3H][p-Cl-Phe]- 4] DPDPE or [3H]deltorphin II,CHEMBL1131989,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NNC(=O)[C@H](N)Cc1c[nH]c2ccccc12
CHEMBL147511,CHEMBL233,Mu opioid receptor,IC50,=,16.0,nM,CHEMBL754564,B,Inhibitory activity was determined in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor mu 1 in chinese Hamster Ovary (CHO)membranes,CHEMBL1145905,IC50,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL214929,CHEMBL233,Mu opioid receptor,IC50,=,5.9,nM,CHEMBL744603,B,In vitro binding affinity towards mu opioid receptors was determined using [3H][p-Cl-Phe]- 4] DPDPE or [3H]deltorphin II,CHEMBL1131989,IC50,CCCC[C@@H](N)C(=O)NNC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL49269,CHEMBL233,Mu opioid receptor,IC50,=,1.7,nM,CHEMBL754564,B,Inhibitory activity was determined in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor mu 1 in chinese Hamster Ovary (CHO)membranes,CHEMBL1145905,IC50,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL328443,CHEMBL233,Mu opioid receptor,IC50,=,1.3,nM,CHEMBL744603,B,In vitro binding affinity towards mu opioid receptors was determined using [3H][p-Cl-Phe]- 4] DPDPE or [3H]deltorphin II,CHEMBL1131989,IC50,CCCC[C@H](N)C(=O)NNC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL433697,CHEMBL233,Mu opioid receptor,IC50,=,170.0,nM,CHEMBL754564,B,Inhibitory activity was determined in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor mu 1 in chinese Hamster Ovary (CHO)membranes,CHEMBL1145905,IC50,O=C(CCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL432041,CHEMBL233,Mu opioid receptor,IC50,=,1.6,nM,CHEMBL744603,B,In vitro binding affinity towards mu opioid receptors was determined using [3H][p-Cl-Phe]- 4] DPDPE or [3H]deltorphin II,CHEMBL1131989,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NNC(=O)[C@H](N)Cc1ccc(O)cc1
CHEMBL328902,CHEMBL233,Mu opioid receptor,IC50,=,0.74,nM,CHEMBL744603,B,In vitro binding affinity towards mu opioid receptors was determined using [3H][p-Cl-Phe]- 4] DPDPE or [3H]deltorphin II,CHEMBL1131989,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NNC(=O)[C@H](N)Cc1ccccc1
CHEMBL92503,CHEMBL233,Mu opioid receptor,IC50,=,0.88,nM,CHEMBL744603,B,In vitro binding affinity towards mu opioid receptors was determined using [3H][p-Cl-Phe]- 4] DPDPE or [3H]deltorphin II,CHEMBL1131989,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NNC(=O)[C@@H](N)Cc1ccccc1
CHEMBL346436,CHEMBL233,Mu opioid receptor,IC50,=,360.0,nM,CHEMBL754564,B,Inhibitory activity was determined in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor mu 1 in chinese Hamster Ovary (CHO)membranes,CHEMBL1145905,IC50,O=C(CCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL133719,CHEMBL233,Mu opioid receptor,IC50,=,720.0,nM,CHEMBL756439,B,Binding affinity towards Opioid receptor mu 1 using [3H]- CTOP as radioligand,CHEMBL1145107,IC50,Cc1cc(O)cc(C)c1[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)O)C(C)(C)S)C(C)(C)S
CHEMBL134652,CHEMBL233,Mu opioid receptor,IC50,=,77000.0,nM,CHEMBL756439,B,Binding affinity towards Opioid receptor mu 1 using [3H]- CTOP as radioligand,CHEMBL1145107,IC50,Cc1cc(O)cc(C)c1[C@@H](C)[C@@H](N)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)O)C(C)(C)S)C(C)(C)S
CHEMBL294616,CHEMBL233,Mu opioid receptor,IC50,=,610.0,nM,CHEMBL756439,B,Binding affinity towards Opioid receptor mu 1 using [3H]- CTOP as radioligand,CHEMBL1145107,IC50,CC1(C)SSC(C)(C)[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H]1C(=O)O
CHEMBL334369,CHEMBL233,Mu opioid receptor,IC50,=,4300.0,nM,CHEMBL756439,B,Binding affinity towards Opioid receptor mu 1 using [3H]- CTOP as radioligand,CHEMBL1145107,IC50,Cc1cc(O)cc(C)c1[C@@H](C)[C@H](N)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)O)C(C)(C)S)C(C)(C)S
CHEMBL38874,CHEMBL233,Mu opioid receptor,IC50,=,1.6,nM,CHEMBL872833,B,Binding activity against human Opioid receptor mu 1 using [3H]DAMGO as a radioligand,CHEMBL1135899,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL127761,CHEMBL233,Mu opioid receptor,IC50,=,785.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2cccc3c2OC(C)(C)C3)N2CCNCC2)cc1
CHEMBL24035,CHEMBL233,Mu opioid receptor,IC50,=,5064.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,C=CCN1CCN(C(c2ccccc2)c2ccc(C(=O)N(CC)CC)cc2)CC1
CHEMBL127434,CHEMBL233,Mu opioid receptor,IC50,=,620.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2cccc(OC)c2)N2CC(C)(C)NCC2C)cc1
CHEMBL128006,CHEMBL233,Mu opioid receptor,IC50,=,5330.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2ccc(Cl)cc2)N2CCNCC2)cc1
CHEMBL123679,CHEMBL233,Mu opioid receptor,IC50,=,486.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCCCN1CCN(C(c2ccccc2)c2ccc(C(=O)N(CC)CC)cc2)CC1
CHEMBL25230,CHEMBL233,Mu opioid receptor,IC50,=,2.1,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(O)c2)C[C@H]1C
CHEMBL125742,CHEMBL233,Mu opioid receptor,IC50,=,5290.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2cccc(OC)c2)N2CCNCC2)cc1
CHEMBL338436,CHEMBL233,Mu opioid receptor,IC50,=,6970.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2ccccc2)N(C)CCNC)cc1
CHEMBL340834,CHEMBL233,Mu opioid receptor,IC50,=,5647.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2cccc(F)c2)N2CCNCC2)cc1
CHEMBL126819,CHEMBL233,Mu opioid receptor,IC50,=,1016.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2ccc3cccnc3c2)N2CCNCC2)cc1
CHEMBL127638,CHEMBL233,Mu opioid receptor,IC50,=,4538.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2ccc(OC)cc2)N2CCNCC2)cc1
CHEMBL434817,CHEMBL233,Mu opioid receptor,IC50,=,284.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2cccc(OC)c2)N2CC(C)NCC2(C)C)cc1
CHEMBL126223,CHEMBL233,Mu opioid receptor,IC50,=,2677.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2ccc3ccccc3c2)N2CCNCC2)cc1
CHEMBL338980,CHEMBL233,Mu opioid receptor,IC50,=,8150.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2ccccc2)N2CCNCC2)cc1
CHEMBL129420,CHEMBL233,Mu opioid receptor,IC50,=,632.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2cccc3cccnc23)N2CCNCC2)cc1
CHEMBL128005,CHEMBL233,Mu opioid receptor,IC50,=,7092.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2ccc(C)cc2)N2CCNCC2)cc1
CHEMBL2112649,CHEMBL233,Mu opioid receptor,IC50,=,2222.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2ccc3cc[nH]c3c2)N2CCNCC2)cc1
CHEMBL127507,CHEMBL233,Mu opioid receptor,IC50,=,2290.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2ccccc2)N2CCCNCC2)cc1
CHEMBL125734,CHEMBL233,Mu opioid receptor,IC50,=,777.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2cccc3ccccc23)N2CCNCC2)cc1
CHEMBL340724,CHEMBL233,Mu opioid receptor,IC50,=,185.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(C2CCCCC2)N2CCNCC2)cc1
CHEMBL126366,CHEMBL233,Mu opioid receptor,IC50,=,1477.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2cccc3cnccc23)N2CCNCC2)cc1
CHEMBL13470,CHEMBL233,Mu opioid receptor,IC50,=,320.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL125248,CHEMBL233,Mu opioid receptor,IC50,=,2398.0,nM,CHEMBL749744,B,Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2ccccc2)N2CCN(CC3CC3)CC2)cc1
CHEMBL417260,CHEMBL233,Mu opioid receptor,IC50,=,3910.0,nM,CHEMBL754565,B,Inhibition of [125I]Enkephalin binding to human mu opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,COc1cccc(OC)c1-c1cccn(C(CN2CCC(O)C2)c2ccccc2)c1=O
CHEMBL15264,CHEMBL233,Mu opioid receptor,IC50,=,10000.0,nM,CHEMBL754565,B,Inhibition of [125I]Enkephalin binding to human mu opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(Nc2ccc(C(F)(F)F)cc2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL15428,CHEMBL233,Mu opioid receptor,IC50,=,190.0,nM,CHEMBL754565,B,Inhibition of [125I]Enkephalin binding to human mu opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,COc1ccc(Cl)cc1-c1cccn(C(CN2CCC(O)C2)c2ccccc2)c1=O
CHEMBL15257,CHEMBL233,Mu opioid receptor,IC50,=,9600.0,nM,CHEMBL754565,B,Inhibition of [125I]Enkephalin binding to human mu opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2ccc(Cl)cc2Cl)cncn1C(CN1CCCC1)c1ccccc1
CHEMBL275176,CHEMBL233,Mu opioid receptor,IC50,=,2220.0,nM,CHEMBL754565,B,Inhibition of [125I]Enkephalin binding to human mu opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,COc1ccc(OC)c(-c2cccn(C(CN3CCC(O)C3)c3ccccc3)c2=O)c1
CHEMBL280037,CHEMBL233,Mu opioid receptor,IC50,=,2716.0,nM,CHEMBL754565,B,Inhibition of [125I]Enkephalin binding to human mu opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2ccc(C(F)(F)F)cc2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL14969,CHEMBL233,Mu opioid receptor,IC50,=,2100.0,nM,CHEMBL754565,B,Inhibition of [125I]Enkephalin binding to human mu opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2ccc(Cl)cc2Cl)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL440765,CHEMBL233,Mu opioid receptor,IC50,=,250.0,nM,CHEMBL754565,B,Inhibition of [125I]Enkephalin binding to human mu opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL14653,CHEMBL233,Mu opioid receptor,IC50,=,1750.0,nM,CHEMBL754565,B,Inhibition of [125I]Enkephalin binding to human mu opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,CC(=O)c1ccc(-c2cccn(C(CN3CCC(O)C3)c3ccccc3)c2=O)cc1
CHEMBL14959,CHEMBL233,Mu opioid receptor,IC50,=,2910.0,nM,CHEMBL754565,B,Inhibition of [125I]Enkephalin binding to human mu opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,Nc1cccc(-c2cccn(C(CN3CCC(O)C3)c3ccccc3)c2=O)c1
CHEMBL115249,CHEMBL233,Mu opioid receptor,IC50,=,1690.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,CCOc1ccc(CCOC(=O)N2CCN(CCCc3ccccc3)CC2)cc1
CHEMBL324297,CHEMBL233,Mu opioid receptor,IC50,=,1.5,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=[N+]([O-])c1cc2c(cc1CN1CCC(n3c(O)nc4ccccc43)CC1)OCO2
CHEMBL324479,CHEMBL233,Mu opioid receptor,IC50,=,4955.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,COC(=O)c1csc(S(=O)(=O)N2CCN(C(=O)c3ccccc3Nc3ccccc3)CC2)c1OC
CHEMBL116735,CHEMBL233,Mu opioid receptor,IC50,=,3660.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=C(CCc1ccc(F)cc1)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL116463,CHEMBL233,Mu opioid receptor,IC50,=,6545.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,N#Cc1ccc(CCOC(=O)NC2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
CHEMBL420863,CHEMBL233,Mu opioid receptor,IC50,=,2.4,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,Cc1ccc2nc(O)n(C3CCN(Cc4cc5c(cc4Cl)OCO5)CC3)c2c1
CHEMBL326263,CHEMBL233,Mu opioid receptor,IC50,=,1470.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,N#Cc1ccc(CCOC(=O)N2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
CHEMBL114379,CHEMBL233,Mu opioid receptor,IC50,=,1.2,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,Oc1nc2ccccc2n1C1CCN(Cc2cc3c(cc2Cl)OCO3)CC1
CHEMBL115229,CHEMBL233,Mu opioid receptor,IC50,=,19.3,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=[N+]([O-])c1cc2c(cc1CN1CC=C(n3c(O)nc4ccccc43)CC1)OCO2
CHEMBL325945,CHEMBL233,Mu opioid receptor,IC50,=,6.3,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=c1[nH]c2ccccc2n(C2CCN(Cc3cc4c(cc3Cl)OCO4)CC2)c1=O
CHEMBL543876,CHEMBL233,Mu opioid receptor,IC50,=,3530.0,nM,CHEMBL755357,B,Binding affinity against mu opioid receptor using [3H]DAMGO,CHEMBL1134625,IC50,Cl.Cl.Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
CHEMBL332697,CHEMBL233,Mu opioid receptor,IC50,=,960.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,COc1cc(/C=C/C(=O)N2CCC(n3c(O)nc4ccccc43)CC2)c([N+](=O)[O-])cc1OC
CHEMBL3215749,CHEMBL233,Mu opioid receptor,IC50,=,2690.0,nM,CHEMBL755357,B,Binding affinity against mu opioid receptor using [3H]DAMGO,CHEMBL1134625,IC50,Cl.Cl.Fc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccc(F)cc2)cc1
CHEMBL333843,CHEMBL233,Mu opioid receptor,IC50,=,2480.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=C(NCCCn1c(O)nc2ccccc21)OCc1cc2c(cc1Cl)OCO2
CHEMBL115709,CHEMBL233,Mu opioid receptor,IC50,=,197.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,N#Cc1ccc(CCOC(=O)N2CCN(C/C=C/c3ccccc3)CC2)cc1
CHEMBL113956,CHEMBL233,Mu opioid receptor,IC50,=,4545.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,CCOc1ccc(CCNC(=O)N2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
CHEMBL115549,CHEMBL233,Mu opioid receptor,IC50,=,1050.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=C(OCc1cc2c(cc1[N+](=O)[O-])OCO2)N1CCC(n2c(O)nc3ccccc32)CC1
CHEMBL115280,CHEMBL233,Mu opioid receptor,IC50,=,83.5,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=C1NCN(c2ccccc2)C12CCN(Cc1cccc(Oc3ccccc3)c1)CC2
CHEMBL115076,CHEMBL233,Mu opioid receptor,IC50,=,1730.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=C(OCc1cc2c(cc1Cl)OCO2)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL114825,CHEMBL233,Mu opioid receptor,IC50,=,179.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,CNC(=O)CN1CN(c2ccccc2)C2(CCN(C(=O)OCc3cc4c(cc3Cl)OCO4)CC2)C1=O
CHEMBL326320,CHEMBL233,Mu opioid receptor,IC50,=,1235.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,Cc1ccc2nc(O)n(C3CCN(C(=O)OCc4cc5c(cc4Cl)OCO5)CC3)c2c1
CHEMBL325697,CHEMBL233,Mu opioid receptor,IC50,=,2285.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=C(c1cc2cc(Cl)ccc2[nH]1)N1CCN(S(=O)(=O)c2ccc([N+](=O)[O-])cc2[N+](=O)[O-])CC1
CHEMBL325750,CHEMBL233,Mu opioid receptor,IC50,=,29.4,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=C1NCN(c2ccccc2)C12CCN(Cc1ccc3nsnc3c1)CC2
CHEMBL117537,CHEMBL233,Mu opioid receptor,IC50,=,3810.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=C(CCCc1ccccc1)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL420500,CHEMBL233,Mu opioid receptor,IC50,=,2285.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=C(OCc1ccc2c(c1)OCO2)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL325674,CHEMBL233,Mu opioid receptor,IC50,=,1470.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=C(OC1CCc2ccccc21)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL115222,CHEMBL233,Mu opioid receptor,IC50,=,0.9,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,CNC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cc4c(cc3Cl)OCO4)CC2)C1=O
CHEMBL420499,CHEMBL233,Mu opioid receptor,IC50,=,3950.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,COc1ccc(CN2CCN(C(=O)CCn3cc(C)c4ccccc43)CC2)cc1OCc1ccccc1
CHEMBL114280,CHEMBL233,Mu opioid receptor,IC50,=,235.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,Oc1nc2ccccc2n1CCCNCc1cc2c(cc1Cl)OCO2
CHEMBL111918,CHEMBL233,Mu opioid receptor,IC50,=,735.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=C(O)CN1CN(c2ccccc2)C2(CCN(C(=O)OCc3cc4c(cc3Cl)OCO4)CC2)C1=O
CHEMBL325516,CHEMBL233,Mu opioid receptor,IC50,=,4015.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=C(OCCc1ccc(F)cc1)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL325258,CHEMBL233,Mu opioid receptor,IC50,=,800.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,N#Cc1ccc(CCOC(=O)N2CCN(CCCc3ccccc3)CC2)cc1
CHEMBL114299,CHEMBL233,Mu opioid receptor,IC50,=,2590.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=C(OCc1cc2c(cc1Cl)OCO2)N1CCC(n2c(=O)c(=O)[nH]c3ccccc32)CC1
CHEMBL114484,CHEMBL233,Mu opioid receptor,IC50,=,16.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,Cc1ccc(CN2CCC(n3c(O)nc4ccccc43)CC2)c(Cl)c1
CHEMBL1423,CHEMBL233,Mu opioid receptor,IC50,=,372.0,nM,CHEMBL755357,B,Binding affinity against mu opioid receptor using [3H]DAMGO,CHEMBL1134625,IC50,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL115652,CHEMBL233,Mu opioid receptor,IC50,=,2.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=C1NCN(c2ccccc2)C12CCN(Cc1cc3c(cc1Cl)OCO3)CC2
CHEMBL419214,CHEMBL233,Mu opioid receptor,IC50,=,2890.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,Cc1ncc([N+](=O)[O-])n1CCNC(=O)N1CCC(c2cc(-c3ccc(Cl)cc3Cl)[nH]n2)CC1
CHEMBL326962,CHEMBL233,Mu opioid receptor,IC50,=,16.7,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=C1NCN(c2ccccc2)C12CCN(Cc1ccc3c(c1)OCO3)CC2
CHEMBL552659,CHEMBL233,Mu opioid receptor,IC50,=,2410.0,nM,CHEMBL755357,B,Binding affinity against mu opioid receptor using [3H]DAMGO,CHEMBL1134625,IC50,Cl.Cl.Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1
CHEMBL115444,CHEMBL233,Mu opioid receptor,IC50,=,147.0,nM,CHEMBL757059,B,Binding affinity against mu opiate receptor,CHEMBL1134625,IC50,O=C(OCc1cc2c(cc1Cl)OCO2)N1CCC(n2c(O)nc3ccccc32)CC1
CHEMBL2114977,CHEMBL233,Mu opioid receptor,IC50,=,1140.0,nM,CHEMBL757307,B,Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacing 125 I-FK-33824,CHEMBL1132761,IC50,COc1ccc(-c2ccc3c(c2)CN(C(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)[C@H](C(=O)O)C3)cc1
CHEMBL2114982,CHEMBL233,Mu opioid receptor,IC50,=,2870.0,nM,CHEMBL757307,B,Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacing 125 I-FK-33824,CHEMBL1132761,IC50,COc1ccc2c(c1)CN(C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)[C@H](C(=O)O)C2
CHEMBL421520,CHEMBL233,Mu opioid receptor,IC50,=,36.0,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C/N=C(/S)NC(C)(C)C
CHEMBL44732,CHEMBL233,Mu opioid receptor,IC50,=,2160.0,nM,CHEMBL757307,B,Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacing 125 I-FK-33824,CHEMBL1132761,IC50,Cc1cc(O)cc(C)c1CC(N)C(=O)N1Cc2cc(O)ccc2C[C@H]1C(=O)O
CHEMBL2114980,CHEMBL233,Mu opioid receptor,IC50,=,635.0,nM,CHEMBL757307,B,Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacing 125 I-FK-33824,CHEMBL1132761,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2cc(-c3ccccc3)ccc2C[C@H]1C(=O)O
CHEMBL76573,CHEMBL233,Mu opioid receptor,IC50,=,1.3,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNCC(C)(C)C
CHEMBL297452,CHEMBL233,Mu opioid receptor,IC50,=,2280.0,nM,CHEMBL757307,B,Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacing 125 I-FK-33824,CHEMBL1132761,IC50,COc1ccc2c(c1)CN(C(=O)C(N)Cc1c(C)cc(O)cc1C)[C@H](C(=O)O)C2
CHEMBL80464,CHEMBL233,Mu opioid receptor,IC50,=,83.2,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CN(C)C
CHEMBL2114978,CHEMBL233,Mu opioid receptor,IC50,=,587.0,nM,CHEMBL757307,B,Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacing 125 I-FK-33824,CHEMBL1132761,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2cc(-c3ccc(F)cc3)ccc2C[C@H]1C(=O)O
CHEMBL75802,CHEMBL233,Mu opioid receptor,IC50,=,5.4,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C/N=C(/S)Nc1ccccc1
CHEMBL418080,CHEMBL233,Mu opioid receptor,IC50,=,142.0,nM,CHEMBL757307,B,Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacing 125 I-FK-33824,CHEMBL1132761,IC50,Cc1cc(O)cc(C)c1CC(N)C(=O)N1Cc2cc(-c3ccsc3)ccc2C[C@H]1C(=O)O
CHEMBL308128,CHEMBL233,Mu opioid receptor,IC50,=,421.0,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CO
CHEMBL80319,CHEMBL233,Mu opioid receptor,IC50,=,108.0,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,C=CCOC[C@@H]1Cc2ccccc2CN1C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C
CHEMBL76846,CHEMBL233,Mu opioid receptor,IC50,=,94.6,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CN=[N+]=[N-]
CHEMBL309236,CHEMBL233,Mu opioid receptor,IC50,=,12.8,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CN=C(N)N
CHEMBL309307,CHEMBL233,Mu opioid receptor,IC50,=,0.98,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNC(=O)c1ccccc1
CHEMBL2115434,CHEMBL233,Mu opioid receptor,IC50,=,8130.0,nM,CHEMBL757307,B,Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacing 125 I-FK-33824,CHEMBL1132761,IC50,Cc1cc(O)cc(C)c1C[C@@H](N)C(=O)N1Cc2c(cc(Br)c(O)c2Br)C[C@H]1C(=O)O
CHEMBL571492,CHEMBL233,Mu opioid receptor,IC50,=,894.0,nM,CHEMBL757307,B,Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacing 125 I-FK-33824,CHEMBL1132761,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O
CHEMBL48098,CHEMBL233,Mu opioid receptor,IC50,=,2650.0,nM,CHEMBL757307,B,Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacing 125 I-FK-33824,CHEMBL1132761,IC50,COc1ccc(-c2ccc3c(c2)CN(C(=O)C(N)Cc2c(C)cc(O)cc2C)[C@H](C(=O)O)C3)cc1
CHEMBL307889,CHEMBL233,Mu opioid receptor,IC50,=,25.3,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNC(=O)C(C)(C)C
CHEMBL309783,CHEMBL233,Mu opioid receptor,IC50,=,169.0,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,CCNC(=O)NC[C@@H]1Cc2ccccc2CN1C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C
CHEMBL317956,CHEMBL233,Mu opioid receptor,IC50,=,225.0,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,CC(C)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)NCC(N)=O)C(C)C
CHEMBL80823,CHEMBL233,Mu opioid receptor,IC50,=,16.1,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,CC(=O)NC[C@@H]1Cc2ccccc2CN1C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C
CHEMBL47564,CHEMBL233,Mu opioid receptor,IC50,=,7220.0,nM,CHEMBL757307,B,Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacing 125 I-FK-33824,CHEMBL1132761,IC50,COc1cc2c(cc1-c1ccc(F)cc1)C[C@@H](C(=O)O)N(C(=O)C(N)Cc1c(C)cc(O)cc1C)C2
CHEMBL416788,CHEMBL233,Mu opioid receptor,IC50,=,894.0,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C(NC(=O)C1Cc2ccccc2CN1)C(=O)O
CHEMBL80463,CHEMBL233,Mu opioid receptor,IC50,=,1.0,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNC(=O)Nc1ccccc1
CHEMBL2114981,CHEMBL233,Mu opioid receptor,IC50,=,1670.0,nM,CHEMBL757307,B,Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacing 125 I-FK-33824,CHEMBL1132761,IC50,COc1c(Br)cc2c(c1Br)CN(C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)[C@H](C(=O)O)C2
CHEMBL312792,CHEMBL233,Mu opioid receptor,IC50,=,4.7,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,CC(=O)OC[C@@H]1Cc2ccccc2CN1C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C
CHEMBL310146,CHEMBL233,Mu opioid receptor,IC50,=,33.2,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,CC(=N)NC[C@@H]1Cc2ccccc2CN1C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C
CHEMBL2114986,CHEMBL233,Mu opioid receptor,IC50,=,1240.0,nM,CHEMBL757307,B,Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacing 125 I-FK-33824,CHEMBL1132761,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2c(cc(Br)c(O)c2Br)C[C@H]1C(=O)O
CHEMBL80197,CHEMBL233,Mu opioid receptor,IC50,=,113.0,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CN
CHEMBL46160,CHEMBL233,Mu opioid receptor,IC50,=,2440.0,nM,CHEMBL757307,B,Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacing 125 I-FK-33824,CHEMBL1132761,IC50,Cc1cc(O)cc(C)c1CC(N)C(=O)N1Cc2cc(-c3cc4ccccc4o3)ccc2C[C@H]1C(=O)O
CHEMBL2115430,CHEMBL233,Mu opioid receptor,IC50,=,8240.0,nM,CHEMBL757307,B,Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacing 125 I-FK-33824,CHEMBL1132761,IC50,COc1c(Br)cc2c(c1Br)CN(C(=O)[C@H](N)Cc1c(C)cc(O)cc1C)[C@H](C(=O)O)C2
CHEMBL77196,CHEMBL233,Mu opioid receptor,IC50,=,3.0,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C
CHEMBL2115429,CHEMBL233,Mu opioid receptor,IC50,=,1940.0,nM,CHEMBL757307,B,Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacing 125 I-FK-33824,CHEMBL1132761,IC50,Cc1cc(O)cc(C)c1C[C@@H](N)C(=O)N1Cc2cc(-c3ccccc3)ccc2C[C@H]1C(=O)O
CHEMBL76089,CHEMBL233,Mu opioid receptor,IC50,=,12.5,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1COCc1ccccc1
CHEMBL77001,CHEMBL233,Mu opioid receptor,IC50,=,0.65,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNCc1ccccc1
CHEMBL76493,CHEMBL233,Mu opioid receptor,IC50,=,458.0,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,COC[C@@H]1Cc2ccccc2CN1C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C
CHEMBL310842,CHEMBL233,Mu opioid receptor,IC50,=,61.8,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNC(=O)NC(C)(C)C
CHEMBL45842,CHEMBL233,Mu opioid receptor,IC50,=,4640.0,nM,CHEMBL757307,B,Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacing 125 I-FK-33824,CHEMBL1132761,IC50,COc1ccc(-c2cc3c(cc2OC)CN(C(=O)C(N)Cc2c(C)cc(O)cc2C)[C@H](C(=O)O)C3)cc1
CHEMBL77804,CHEMBL233,Mu opioid receptor,IC50,=,1.1,nM,CHEMBL757823,B,Binding affinity at cloned human mu-opioid receptor,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNC(=O)NC12CC3CC(CC(C3)C1)C2
CHEMBL98800,CHEMBL233,Mu opioid receptor,IC50,=,6837.0,nM,CHEMBL754684,B,Binding affinity for micro receptors by the inhibition of binding of [3H]DAMGO to Opioid receptor mu 1 in human cloned receptors.,CHEMBL1130143,IC50,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(C(C)C)C(C)C)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL430675,CHEMBL233,Mu opioid receptor,IC50,=,4470.0,nM,CHEMBL754684,B,Binding affinity for micro receptors by the inhibition of binding of [3H]DAMGO to Opioid receptor mu 1 in human cloned receptors.,CHEMBL1130143,IC50,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N3CCCCCC3)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL102150,CHEMBL233,Mu opioid receptor,IC50,=,3340.0,nM,CHEMBL754684,B,Binding affinity for micro receptors by the inhibition of binding of [3H]DAMGO to Opioid receptor mu 1 in human cloned receptors.,CHEMBL1130143,IC50,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CCCC)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL431276,CHEMBL233,Mu opioid receptor,IC50,=,12110.0,nM,CHEMBL754684,B,Binding affinity for micro receptors by the inhibition of binding of [3H]DAMGO to Opioid receptor mu 1 in human cloned receptors.,CHEMBL1130143,IC50,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(C)CC)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL101231,CHEMBL233,Mu opioid receptor,IC50,=,6186.0,nM,CHEMBL754684,B,Binding affinity for micro receptors by the inhibition of binding of [3H]DAMGO to Opioid receptor mu 1 in human cloned receptors.,CHEMBL1130143,IC50,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N3CCCC3)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL316845,CHEMBL233,Mu opioid receptor,IC50,=,9724.0,nM,CHEMBL754684,B,Binding affinity for micro receptors by the inhibition of binding of [3H]DAMGO to Opioid receptor mu 1 in human cloned receptors.,CHEMBL1130143,IC50,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(C)C)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL98691,CHEMBL233,Mu opioid receptor,IC50,=,5999.0,nM,CHEMBL754684,B,Binding affinity for micro receptors by the inhibition of binding of [3H]DAMGO to Opioid receptor mu 1 in human cloned receptors.,CHEMBL1130143,IC50,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N3CCCCC3)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL13470,CHEMBL233,Mu opioid receptor,IC50,=,4785.0,nM,CHEMBL754684,B,Binding affinity for micro receptors by the inhibition of binding of [3H]DAMGO to Opioid receptor mu 1 in human cloned receptors.,CHEMBL1130143,IC50,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL101316,CHEMBL233,Mu opioid receptor,IC50,=,6083.0,nM,CHEMBL754684,B,Binding affinity for micro receptors by the inhibition of binding of [3H]DAMGO to Opioid receptor mu 1 in human cloned receptors.,CHEMBL1130143,IC50,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CCC)CCC)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL434944,CHEMBL233,Mu opioid receptor,IC50,=,3550.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,COC(=O)CN1C(=O)C2(CCN(CC3CCCCCCC3)CC2)c2ccccc21
CHEMBL373190,CHEMBL233,Mu opioid receptor,IC50,=,1410.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,CC(=O)OCCN1C(=O)C2(CCN(CC3CCCCCCC3)CC2)c2ccccc21
CHEMBL380603,CHEMBL233,Mu opioid receptor,IC50,=,1690.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,O=C1N(CCO)c2ccccc2C12CCN(CC1CCCCCCC1)CC2
CHEMBL199248,CHEMBL233,Mu opioid receptor,IC50,=,1110.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,O=C1Nc2ccccc2C12CCN(CC1CCCCCCC1)CC2
CHEMBL372184,CHEMBL233,Mu opioid receptor,IC50,=,960.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,O=C1N(Cc2ccccc2)c2ccccc2C12CCN(CC1CCCCCCC1)CC2
CHEMBL198867,CHEMBL233,Mu opioid receptor,IC50,=,840.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,O=C1N(CC2CO2)c2ccccc2C12CCN(CC1CCCCCCC1)CC2
CHEMBL370613,CHEMBL233,Mu opioid receptor,IC50,=,500.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,O=C1N(CC(O)CNCCN2CCOCC2)c2ccccc2C12CCN(CC1CCCCCCC1)CC2
CHEMBL198604,CHEMBL233,Mu opioid receptor,IC50,=,620.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,CCN(Cc1ccc(C)cc1)CC(O)CN1C(=O)C2(CCN(CC3CCCCCCC3)CC2)c2ccccc21
CHEMBL197959,CHEMBL233,Mu opioid receptor,IC50,=,10000.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,COc1ccc2c(c1)N(CC1CC1)C(=O)C21CCN(CC2CCCCCCC2)CC1
CHEMBL381429,CHEMBL233,Mu opioid receptor,IC50,=,1610.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,COc1ccc2c(c1)N(C)C(=O)C21CCN(CC2CCCCCCC2)CC1
CHEMBL199095,CHEMBL233,Mu opioid receptor,IC50,=,1460.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,CCN1C(=O)C2(CCN(CC3CCCCCCC3)CC2)c2ccc(OC)cc21
CHEMBL194200,CHEMBL233,Mu opioid receptor,IC50,=,1300.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,CN1C(=O)C2(CCN(CC3CCCCCCC3)CC2)c2ccccc21
CHEMBL199011,CHEMBL233,Mu opioid receptor,IC50,=,6470.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,Cc1ccc2c(c1)N(C)C(=O)C21CCN(CC2CCCCCCC2)CC1
CHEMBL369945,CHEMBL233,Mu opioid receptor,IC50,=,4280.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,Cc1ccc2c(c1)C1(CCN(CC3CCCCCCC3)CC1)C(=O)N2C
CHEMBL437505,CHEMBL233,Mu opioid receptor,IC50,=,480.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,Cc1cccc2c1C1(CCN(CC3CCCCCCC3)CC1)C(=O)N2C
CHEMBL198600,CHEMBL233,Mu opioid receptor,IC50,=,5310.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,CN1C(=O)C2(CCN(CC3CCCCCCC3)CC2)c2cc(C(F)(F)F)ccc21
CHEMBL197727,CHEMBL233,Mu opioid receptor,IC50,=,1010.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,CN1C(=O)C2(CCN(CC3CCCCCCC3)CC2)c2cc(F)ccc21
CHEMBL197895,CHEMBL233,Mu opioid receptor,IC50,=,980.0,nM,CHEMBL880418,B,Binding affinity against human opioid receptor mu 1 expressed in HEK293 cells using [3H]DAMGO radioligand,CHEMBL1143642,IC50,CC(C)c1ccc2c(c1)C1(CCN(CC3CCCCCCC3)CC1)C(=O)N2C
CHEMBL383610,CHEMBL233,Mu opioid receptor,IC50,=,150.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,O=C1NCN(c2ccccc2)C12CCN([C@H]1CCCC[C@H]1c1ccccc1)CC2
CHEMBL200621,CHEMBL233,Mu opioid receptor,IC50,=,4400.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,COc1ccc(N2CNC(=O)C23CCN([C@@H]2CCCC[C@@]2(O)c2ccc(Cl)cc2)CC3)cc1
CHEMBL372567,CHEMBL233,Mu opioid receptor,IC50,=,2400.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,O=C1NCN(c2ccc(F)cc2)C12CCN([C@@H]1CCCC[C@@]1(O)c1ccc(Cl)cc1)CC2
CHEMBL200883,CHEMBL233,Mu opioid receptor,IC50,=,2200.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,O=C1NCN(c2ccc(Cl)cc2)C12CCN([C@@H]1CCCC[C@@]1(O)c1ccc(F)cc1)CC2
CHEMBL436295,CHEMBL233,Mu opioid receptor,IC50,=,4000.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,O=C1NCN(c2ccc(F)cc2)C12CCN([C@@H]1CCCC[C@@]1(O)c1ccc(F)cc1)CC2
CHEMBL372995,CHEMBL233,Mu opioid receptor,IC50,=,1000.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CCCC[C@@]1(O)c1ccncc1)CC2
CHEMBL200695,CHEMBL233,Mu opioid receptor,IC50,=,1800.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CCCC[C@@]1(O)c1cccnc1)CC2
CHEMBL371550,CHEMBL233,Mu opioid receptor,IC50,=,1420.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CCCC[C@@]1(O)c1ccccn1)CC2
CHEMBL373198,CHEMBL233,Mu opioid receptor,IC50,=,2170.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,COc1cccc([C@]2(O)CCCC[C@H]2N2CCC3(CC2)C(=O)NCN3c2ccccc2)c1
CHEMBL200882,CHEMBL233,Mu opioid receptor,IC50,=,1090.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CCCC[C@@]1(O)c1cccc(Cl)c1)CC2
CHEMBL381419,CHEMBL233,Mu opioid receptor,IC50,=,260.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,Cc1ccccc1[C@]1(O)CCCC[C@H]1N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL425753,CHEMBL233,Mu opioid receptor,IC50,=,4000.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CCCC[C@@]1(O)c1ccc(F)cc1)CC2
CHEMBL200227,CHEMBL233,Mu opioid receptor,IC50,=,3700.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CCCC[C@@]1(O)c1ccc(Cl)c(Cl)c1)CC2
CHEMBL373170,CHEMBL233,Mu opioid receptor,IC50,=,3600.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CCCC[C@@]1(O)c1ccc(Cl)cc1)CC2
CHEMBL200257,CHEMBL233,Mu opioid receptor,IC50,=,3000.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,Cc1ccc([C@]2(O)CCCC[C@H]2N2CCC3(CC2)C(=O)NCN3c2ccccc2)cc1
CHEMBL371966,CHEMBL233,Mu opioid receptor,IC50,=,2500.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,COc1ccc([C@]2(O)CCCC[C@H]2N2CCC3(CC2)C(=O)NCN3c2ccccc2)cc1
CHEMBL371267,CHEMBL233,Mu opioid receptor,IC50,=,540.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CCCC[C@H]1c1ccccc1)CC2
CHEMBL200199,CHEMBL233,Mu opioid receptor,IC50,=,1.4,nM,CHEMBL870570,B,Displacement of [3H]DAMGO from mu opioid receptor,CHEMBL1147769,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NNC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL200129,CHEMBL233,Mu opioid receptor,IC50,=,0.6,nM,CHEMBL870570,B,Displacement of [3H]DAMGO from mu opioid receptor,CHEMBL1147769,IC50,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL372787,CHEMBL233,Mu opioid receptor,IC50,=,130.0,nM,CHEMBL870570,B,Displacement of [3H]DAMGO from mu opioid receptor,CHEMBL1147769,IC50,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL373053,CHEMBL233,Mu opioid receptor,IC50,=,3200.0,nM,CHEMBL864595,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1148567,IC50,O=C1NCN(CCc2ccccc2)C12CCN([C@H]1CCCC[C@H]1c1ccccc1)CC2
CHEMBL200728,CHEMBL233,Mu opioid receptor,IC50,=,2200.0,nM,CHEMBL864595,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1148567,IC50,CCCCCN1CNC(=O)C12CCN([C@H]1CCCC[C@H]1c1ccccc1)CC2
CHEMBL425929,CHEMBL233,Mu opioid receptor,IC50,=,230.0,nM,CHEMBL864595,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1148567,IC50,O=C1NCN(c2ccc(Cl)cc2)C12CCN([C@H]1CCCC[C@H]1c1ccccc1)CC2
CHEMBL383539,CHEMBL233,Mu opioid receptor,IC50,=,41.0,nM,CHEMBL864595,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1148567,IC50,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CCCC[C@@H]1c1ccccc1)CC2
CHEMBL371267,CHEMBL233,Mu opioid receptor,IC50,=,540.0,nM,CHEMBL864595,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1148567,IC50,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CCCC[C@H]1c1ccccc1)CC2
CHEMBL383610,CHEMBL233,Mu opioid receptor,IC50,=,150.0,nM,CHEMBL864595,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1148567,IC50,O=C1NCN(c2ccccc2)C12CCN([C@H]1CCCC[C@H]1c1ccccc1)CC2
CHEMBL200053,CHEMBL233,Mu opioid receptor,IC50,=,2500.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CCOC[C@@]1(O)c1ccccc1)CC2
CHEMBL201226,CHEMBL233,Mu opioid receptor,IC50,=,5300.0,nM,CHEMBL860261,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1147765,IC50,O=C1NCN(c2ccccc2)C12CCN([C@@H]1COCC[C@@]1(O)c1ccccc1)CC2
CHEMBL357076,CHEMBL233,Mu opioid receptor,IC50,=,3400.0,nM,CHEMBL867088,B,Displacement of [3H]diprenorphin from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1149384,IC50,CCn1c(=O)n([C@@H]2CCN(CC3CCCCCCC3)C[C@H]2CO)c2ccccc21
CHEMBL201945,CHEMBL233,Mu opioid receptor,IC50,=,6700.0,nM,CHEMBL867088,B,Displacement of [3H]diprenorphin from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1149384,IC50,O=C(NCCCN1CCC2(CC1)OCc1ccccc12)[C@H]1CCCN1Cc1ccccc1
CHEMBL202225,CHEMBL233,Mu opioid receptor,IC50,=,4300.0,nM,CHEMBL867088,B,Displacement of [3H]diprenorphin from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1149384,IC50,O=C(NCCCN1CCC2(CCc3ccccc32)CC1)[C@H]1CCCN1Cc1ccccc1
CHEMBL379021,CHEMBL233,Mu opioid receptor,IC50,=,5300.0,nM,CHEMBL865906,B,Inhibition of mu opioid receptor,CHEMBL1149431,IC50,[2H]C([2H])([2H])Oc1cccc([C@@]2(O)CCCC[C@@H]2CN(C([2H])([2H])[2H])C([2H])([2H])[2H])c1
CHEMBL201556,CHEMBL233,Mu opioid receptor,IC50,=,43.0,nM,CHEMBL865906,B,Inhibition of mu opioid receptor,CHEMBL1149431,IC50,[2H]C([2H])([2H])N(C[C@H]1CCCC[C@]1(O)c1cccc(O)c1)C([2H])([2H])[2H]
CHEMBL1400,CHEMBL233,Mu opioid receptor,IC50,=,47.0,nM,CHEMBL865906,B,Inhibition of mu opioid receptor,CHEMBL1149431,IC50,CN(C)C[C@H]1CCCC[C@]1(O)c1cccc(O)c1
CHEMBL1237044,CHEMBL233,Mu opioid receptor,IC50,=,7600.0,nM,CHEMBL865906,B,Inhibition of mu opioid receptor,CHEMBL1149431,IC50,COc1cccc(C2(O)CCCCC2CN(C)C)c1
CHEMBL377164,CHEMBL233,Mu opioid receptor,IC50,=,7640.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,O=C1NCC(c2ccccc2)C12CCN(C1(c3ccccc3)CCCCC1)CC2
CHEMBL211422,CHEMBL233,Mu opioid receptor,IC50,=,19800.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,O=C1NCC(c2ccccc2)C12CCN(C1(c3ccc(Cl)cc3)CCCCC1)CC2
CHEMBL211422,CHEMBL233,Mu opioid receptor,IC50,=,3600.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,O=C1NCC(c2ccccc2)C12CCN(C1(c3ccc(Cl)cc3)CCCCC1)CC2
CHEMBL213592,CHEMBL233,Mu opioid receptor,IC50,=,9120.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,Cc1ccc(C2(N3CCC4(CC3)C(=O)NCC4c3ccccc3)CCCCC2)cc1
CHEMBL213592,CHEMBL233,Mu opioid receptor,IC50,=,11900.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,Cc1ccc(C2(N3CCC4(CC3)C(=O)NCC4c3ccccc3)CCCCC2)cc1
CHEMBL380244,CHEMBL233,Mu opioid receptor,IC50,=,8040.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,O=C1NCC(c2ccccc2)C12CCN(C1(c3cccc(F)c3)CCCCC1)CC2
CHEMBL380244,CHEMBL233,Mu opioid receptor,IC50,=,13500.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,O=C1NCC(c2ccccc2)C12CCN(C1(c3cccc(F)c3)CCCCC1)CC2
CHEMBL377114,CHEMBL233,Mu opioid receptor,IC50,=,7800.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,O=C1NCC(c2ccc(F)cc2)C12CCN(C1(c3ccc(F)cc3)CCCCC1)CC2
CHEMBL377114,CHEMBL233,Mu opioid receptor,IC50,=,7400.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,O=C1NCC(c2ccc(F)cc2)C12CCN(C1(c3ccc(F)cc3)CCCCC1)CC2
CHEMBL436752,CHEMBL233,Mu opioid receptor,IC50,=,7180.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,O=C1NCC(c2ccc(F)cc2)C12CCN(C1(c3cccc(F)c3)CCCCC1)CC2
CHEMBL209380,CHEMBL233,Mu opioid receptor,IC50,=,7830.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,Cc1cccc(C2(N3CCC4(CC3)C(=O)NCC4c3ccc(F)cc3)CCCCC2)c1
CHEMBL209380,CHEMBL233,Mu opioid receptor,IC50,=,24830.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,Cc1cccc(C2(N3CCC4(CC3)C(=O)NCC4c3ccc(F)cc3)CCCCC2)c1
CHEMBL378665,CHEMBL233,Mu opioid receptor,IC50,=,3851.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,Cc1ccccc1C1(N2CCC3(CC2)C(=O)NCC3c2ccc(F)cc2)CCCCC1
CHEMBL213683,CHEMBL233,Mu opioid receptor,IC50,=,2760.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,CCCC1CNC(=O)C12CCN(C1(c3ccccc3)CCCCC1)CC2
CHEMBL214057,CHEMBL233,Mu opioid receptor,IC50,=,3030.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,CCCC1CNC(=O)C12CCN(C1(c3ccc(F)cc3)CCCCC1)CC2
CHEMBL540110,CHEMBL233,Mu opioid receptor,IC50,=,2730.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,CCCC1CNC(=O)C12CCN(C1(c3ccccc3)CCCCC1)CC2.Cl
CHEMBL213683,CHEMBL233,Mu opioid receptor,IC50,=,1870.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,CCCC1CNC(=O)C12CCN(C1(c3ccccc3)CCCCC1)CC2
CHEMBL377164,CHEMBL233,Mu opioid receptor,IC50,=,5500.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,O=C1NCC(c2ccccc2)C12CCN(C1(c3ccccc3)CCCCC1)CC2
CHEMBL403515,CHEMBL233,Mu opioid receptor,IC50,=,15.0,nM,CHEMBL864838,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1145308,IC50,O=C1NCN(c2ccccc2)C12CCN(C1(c3ccccc3)CCCCC1)CC2
CHEMBL387193,CHEMBL233,Mu opioid receptor,IC50,=,1550.0,nM,CHEMBL863601,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1138975,IC50,O=C1NC[C@@H](c2ccc(F)cc2)C12CCN([C@H]1CCCC[C@H]1c1ccc(F)cc1)CC2
CHEMBL378330,CHEMBL233,Mu opioid receptor,IC50,=,6700.0,nM,CHEMBL863601,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1138975,IC50,O=C1NC[C@H](c2ccc(F)cc2)C12CCN([C@@H]1CCCC[C@@H]1c1ccc(F)cc1)CC2
CHEMBL378686,CHEMBL233,Mu opioid receptor,IC50,=,1090.0,nM,CHEMBL863601,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1138975,IC50,O=C1NC[C@@H](c2ccc(F)cc2)C12CCN([C@@H]1CCCC[C@@H]1c1ccc(F)cc1)CC2
CHEMBL386658,CHEMBL233,Mu opioid receptor,IC50,=,3490.0,nM,CHEMBL863601,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1138975,IC50,O=C1NC[C@H](c2ccccc2)C12CCN([C@H]1CCCC[C@H]1c1ccccc1)CC2
CHEMBL211568,CHEMBL233,Mu opioid receptor,IC50,=,5480.0,nM,CHEMBL863601,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1138975,IC50,O=C1NC[C@H](c2ccccc2)C12CCN([C@@H]1CCCC[C@@H]1c1ccccc1)CC2
CHEMBL214039,CHEMBL233,Mu opioid receptor,IC50,=,3920.0,nM,CHEMBL863601,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1138975,IC50,O=C1NCC(c2ccccc2)C12CCN(C1CCCCC1c1ccccc1)CC2
CHEMBL383610,CHEMBL233,Mu opioid receptor,IC50,=,150.0,nM,CHEMBL863601,B,Displacement of [3H]naloxone from mu opioid receptor expressed in BHK cells,CHEMBL1138975,IC50,O=C1NCN(c2ccccc2)C12CCN([C@H]1CCCC[C@H]1c1ccccc1)CC2
CHEMBL377140,CHEMBL233,Mu opioid receptor,IC50,=,150.0,nM,CHEMBL871496,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1138974,IC50,O=C1NCN(c2ccccc2)C12CCN(C1CCCCC1c1ccccc1)CC2
CHEMBL211373,CHEMBL233,Mu opioid receptor,IC50,=,2700.0,nM,CHEMBL871496,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1138974,IC50,O=C1NCN(c2ccccc2)C12CCN(C1CCCCC1(O)c1ccccc1)CC2
CHEMBL2096837,CHEMBL233,Mu opioid receptor,IC50,=,3920.0,nM,CHEMBL871496,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1138974,IC50,O=C1NC[C@@H](c2ccccc2)C12CCN(C1CCCCC1c1ccccc1)CC2
CHEMBL214122,CHEMBL233,Mu opioid receptor,IC50,=,24000.0,nM,CHEMBL871496,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in BHK cells,CHEMBL1138974,IC50,O=C1NCC(c2ccccc2)C12CCN(C1CCCCC1(O)c1ccc(F)cc1)CC2
CHEMBL1237044,CHEMBL233,Mu opioid receptor,IC50,=,7600.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,COc1cccc(C2(O)CCCCC2CN(C)C)c1
CHEMBL258336,CHEMBL233,Mu opioid receptor,IC50,=,2590.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,CO[C@]1(c2ccccc2)CCCC[C@@H]1CN(C)C
CHEMBL407563,CHEMBL233,Mu opioid receptor,IC50,=,84.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,CNC[C@@H]1CCCC[C@@]1(OC)c1cccc(O)c1
CHEMBL402116,CHEMBL233,Mu opioid receptor,IC50,=,48.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,CNC[C@H]1CCCC[C@]1(OC)c1cccc(O)c1
CHEMBL402116,CHEMBL233,Mu opioid receptor,IC50,=,122.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,CNC[C@H]1CCCC[C@]1(OC)c1cccc(O)c1
CHEMBL256902,CHEMBL233,Mu opioid receptor,IC50,=,8000.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,COc1cccc([C@@]2(OCCCO)CCCC[C@@H]2CN(C)C)c1
CHEMBL257264,CHEMBL233,Mu opioid receptor,IC50,=,190.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,CN(C)C[C@H]1CCCC[C@]1(OCCO)c1cccc(O)c1
CHEMBL258336,CHEMBL233,Mu opioid receptor,IC50,=,4750.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,CO[C@]1(c2ccccc2)CCCC[C@@H]1CN(C)C
CHEMBL255768,CHEMBL233,Mu opioid receptor,IC50,=,130.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,CN(C)C[C@H]1CCCC[C@]1(OCC1CC1)c1cccc(O)c1
CHEMBL270570,CHEMBL233,Mu opioid receptor,IC50,=,97.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,CCCCO[C@]1(c2cccc(O)c2)CCCC[C@@H]1CN(C)C
CHEMBL270786,CHEMBL233,Mu opioid receptor,IC50,=,190.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,CCCO[C@]1(c2cccc(O)c2)CCCC[C@@H]1CN(C)C
CHEMBL272063,CHEMBL233,Mu opioid receptor,IC50,=,130.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,CCO[C@]1(c2cccc(O)c2)CCCC[C@@H]1CN(C)C
CHEMBL270642,CHEMBL233,Mu opioid receptor,IC50,=,56.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,CO[C@]1(c2cccc(O)c2)CCCC[C@@H]1CN(C)C
CHEMBL404197,CHEMBL233,Mu opioid receptor,IC50,=,7670.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,COc1cccc([C@@]2(OCC3CC3)CCCC[C@@H]2CN(C)C)c1
CHEMBL258140,CHEMBL233,Mu opioid receptor,IC50,=,6490.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,CCCCO[C@]1(c2cccc(OC)c2)CCCC[C@@H]1CN(C)C
CHEMBL256227,CHEMBL233,Mu opioid receptor,IC50,=,7900.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,CCCO[C@]1(c2cccc(OC)c2)CCCC[C@@H]1CN(C)C
CHEMBL272533,CHEMBL233,Mu opioid receptor,IC50,=,7870.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,COc1cccc([C@@]2(OC)CCCC[C@@H]2CN(C)C)c1
CHEMBL1400,CHEMBL233,Mu opioid receptor,IC50,=,47.0,nM,CHEMBL948139,B,Binding affinity to mu opioid receptor,CHEMBL1141623,IC50,CN(C)C[C@H]1CCCC[C@]1(O)c1cccc(O)c1
CHEMBL250699,CHEMBL233,Mu opioid receptor,IC50,=,10000.0,nM,CHEMBL935652,B,Displacement of [3H]DAMGO from opioid mu receptor,CHEMBL1142222,IC50,COc1cc(NC(=O)c2ccc(-c3ccc(Cl)cc3)o2)cc(OC)c1
CHEMBL407325,CHEMBL233,Mu opioid receptor,IC50,=,3100.0,nM,CHEMBL931350,B,Displacement of [3H]diprenorphin from human cloned mu opioid receptor expressed in CHO cell membrane,CHEMBL1143092,IC50,CCC(CC)Sc1nc2cc(Cl)c(N3CCN(CCO)CC3)cc2[nH]1
CHEMBL263918,CHEMBL233,Mu opioid receptor,IC50,=,2800.0,nM,CHEMBL931350,B,Displacement of [3H]diprenorphin from human cloned mu opioid receptor expressed in CHO cell membrane,CHEMBL1143092,IC50,CCC(C)(CC)Sc1nc2cc(Cl)c(N3CCN(CCO)CC3)cc2[nH]1
CHEMBL263917,CHEMBL233,Mu opioid receptor,IC50,=,1400.0,nM,CHEMBL931350,B,Displacement of [3H]diprenorphin from human cloned mu opioid receptor expressed in CHO cell membrane,CHEMBL1143092,IC50,CC1(Sc2nc3cc(Cl)c(N4CCN(CCO)CC4)cc3[nH]2)CCCCC1
CHEMBL408901,CHEMBL233,Mu opioid receptor,IC50,=,520.0,nM,CHEMBL931350,B,Displacement of [3H]diprenorphin from human cloned mu opioid receptor expressed in CHO cell membrane,CHEMBL1143092,IC50,OCCN1CCN(c2cc3[nH]c(SC4CCCCC4)nc3cc2Cl)CC1
CHEMBL263919,CHEMBL233,Mu opioid receptor,IC50,=,3500.0,nM,CHEMBL931350,B,Displacement of [3H]diprenorphin from human cloned mu opioid receptor expressed in CHO cell membrane,CHEMBL1143092,IC50,CCC(C)(C)Sc1nc2cc(Cl)c(N3CCN(CCO)CC3)cc2[nH]1
CHEMBL259185,CHEMBL233,Mu opioid receptor,IC50,=,4400.0,nM,CHEMBL931350,B,Displacement of [3H]diprenorphin from human cloned mu opioid receptor expressed in CHO cell membrane,CHEMBL1143092,IC50,CC(C)(C)Sc1nc2cc(Cl)c(N3CCN(CCO)CC3)cc2[nH]1
CHEMBL263904,CHEMBL233,Mu opioid receptor,IC50,=,3100.0,nM,CHEMBL931350,B,Displacement of [3H]diprenorphin from human cloned mu opioid receptor expressed in CHO cell membrane,CHEMBL1143092,IC50,CC(C)Sc1nc2cc(Cl)c(N3CCN(CCO)CC3)cc2[nH]1
CHEMBL431660,CHEMBL233,Mu opioid receptor,IC50,=,421.0,nM,CHEMBL961463,B,Binding affinity at mu opioid receptor,CHEMBL1150369,IC50,COc1ccc(C[C@H]2CN3C(=NC[C@@H]3C)N2CCCC2CCCCC2)cc1
CHEMBL339254,CHEMBL233,Mu opioid receptor,IC50,=,20286.0,nM,CHEMBL961463,B,Binding affinity at mu opioid receptor,CHEMBL1150369,IC50,COc1ccc(C[C@@H]2CN3C(=NC[C@@H]3C)N2CCC2CC3CCC2C3)cc1
CHEMBL494350,CHEMBL233,Mu opioid receptor,IC50,=,1900.0,nM,CHEMBL953421,B,Displacement of [3H]diprenorphin from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1150320,IC50,C[C@@H]1CN(CCO)CCN1c1cc2[nH]c(SC(C)(C)C)nc2cc1Cl
CHEMBL495402,CHEMBL233,Mu opioid receptor,IC50,=,67.0,nM,CHEMBL953421,B,Displacement of [3H]diprenorphin from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1150320,IC50,C[C@H]1CN(CCO)CCN1c1cc2[nH]c(SC(C)(C)C)nc2cc1Cl
CHEMBL259185,CHEMBL233,Mu opioid receptor,IC50,=,4400.0,nM,CHEMBL953421,B,Displacement of [3H]diprenorphin from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1150320,IC50,CC(C)(C)Sc1nc2cc(Cl)c(N3CCN(CCO)CC3)cc2[nH]1
CHEMBL461571,CHEMBL233,Mu opioid receptor,IC50,=,1860.0,nM,CHEMBL980777,B,Displacement of radioligand from mu opioid receptor,CHEMBL1139415,IC50,Cc1c(C(=O)c2ccc(Cl)cc2)c2ccc(OC(F)(F)F)cc2n1Cc1cccc(O[C@H](C)C(=O)O)c1
CHEMBL522143,CHEMBL233,Mu opioid receptor,IC50,=,2.29,nM,CHEMBL995937,B,Binding affinity to wild type mu opioid receptor expressed in CHO cells,CHEMBL1140920,IC50,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1
CHEMBL522201,CHEMBL233,Mu opioid receptor,IC50,=,5.42,nM,CHEMBL995937,B,Binding affinity to wild type mu opioid receptor expressed in CHO cells,CHEMBL1140920,IC50,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cc2ccccc2cn1
CHEMBL470951,CHEMBL233,Mu opioid receptor,IC50,=,4400.0,nM,CHEMBL953931,B,Displacement of [3H]diprenorphin from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1157430,IC50,Cc1cccnc1-n1cc(CN2CCC3(CC2)OCc2ccccc23)c(C)n1
CHEMBL512520,CHEMBL233,Mu opioid receptor,IC50,=,7400.0,nM,CHEMBL953931,B,Displacement of [3H]diprenorphin from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1157430,IC50,Cc1nn(-c2ncccc2Cl)cc1CN1CCC2(CC1)OCc1ccccc12
CHEMBL460893,CHEMBL233,Mu opioid receptor,IC50,=,3200.0,nM,CHEMBL953931,B,Displacement of [3H]diprenorphin from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1157430,IC50,Cc1nn(-c2ccccc2)cc1CN1CCC2(CC1)OCc1ccccc12
CHEMBL38874,CHEMBL233,Mu opioid receptor,IC50,=,2.5,nM,CHEMBL983893,B,Inhibition of human mu opioid receptor,CHEMBL1155111,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL450500,CHEMBL233,Mu opioid receptor,IC50,=,69.0,nM,CHEMBL1030679,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1152717,IC50,COCCNC1c2ccccc2CCC1c1ccsc1
CHEMBL512394,CHEMBL233,Mu opioid receptor,IC50,=,5.3,nM,CHEMBL1030679,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1152717,IC50,COCCN[C@@H]1c2ccccc2CC[C@H]1c1ccsc1
CHEMBL518489,CHEMBL233,Mu opioid receptor,IC50,=,4862.0,nM,CHEMBL1030679,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)c1cc(C)nn1C)C1c2ccccc2CCC1c1ccsc1
CHEMBL460623,CHEMBL233,Mu opioid receptor,IC50,=,126.0,nM,CHEMBL1030679,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)c1ccco1)C1c2ccccc2C=CC1N1CCN(c2ccccc2)CC1
CHEMBL460832,CHEMBL233,Mu opioid receptor,IC50,=,443.0,nM,CHEMBL1030679,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)c1ccc(Cl)c(Cl)c1)C1c2ccccc2C=CC1N1CCN(c2ccccc2)CC1
CHEMBL459573,CHEMBL233,Mu opioid receptor,IC50,=,211.0,nM,CHEMBL1030679,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)COCc1ccccc1)C1c2ccccc2C=CC1N1CCN(c2ccccc2)CC1
CHEMBL459783,CHEMBL233,Mu opioid receptor,IC50,=,151.0,nM,CHEMBL1030679,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)Cc1cccc(OC)c1)C1c2ccccc2C=CC1N1CCN(c2ccccc2)CC1
CHEMBL459784,CHEMBL233,Mu opioid receptor,IC50,=,181.0,nM,CHEMBL1030679,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)Cc1ccc(Cl)cc1)C1c2ccccc2C=CC1N1CCN(c2ccccc2)CC1
CHEMBL460631,CHEMBL233,Mu opioid receptor,IC50,=,100.0,nM,CHEMBL1030679,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)c1sccc1Cl)C1c2ccccc2C=CC1N1CCN(c2ccccc2)CC1
CHEMBL461050,CHEMBL233,Mu opioid receptor,IC50,=,58.0,nM,CHEMBL1030679,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)c1sccc1Cl)[C@@H]1c2ccccc2C=C[C@H]1N1CCN(c2ccccc2)CC1
CHEMBL461257,CHEMBL233,Mu opioid receptor,IC50,=,245.0,nM,CHEMBL1030679,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)COc1ccc(Cl)cc1)C1c2cc(OC)c(OC)cc2CCC1N(C)C
CHEMBL461258,CHEMBL233,Mu opioid receptor,IC50,=,351.0,nM,CHEMBL1030679,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)c1ccc(Cl)c(Cl)c1)C1c2cc(OC)c(OC)cc2CCC1N(C)C
CHEMBL459387,CHEMBL233,Mu opioid receptor,IC50,=,1122.0,nM,CHEMBL1030679,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)Cc1ccc(Cl)cc1)C1c2cc(OC)c(OC)cc2CCC1N(C)C
CHEMBL459388,CHEMBL233,Mu opioid receptor,IC50,=,4828.0,nM,CHEMBL1030679,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)Cc1ccccc1Br)C1c2cc(OC)c(OC)cc2CCC1N(C)C
CHEMBL457247,CHEMBL233,Mu opioid receptor,IC50,=,772.0,nM,CHEMBL1030679,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1152717,IC50,COCCN[C@H]1c2ccccc2CC[C@@H]1c1ccsc1
CHEMBL461481,CHEMBL233,Mu opioid receptor,IC50,=,2800.0,nM,CHEMBL1030679,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)c1sccc1Cl)[C@H]1c2ccccc2C=C[C@@H]1N1CCN(c2ccccc2)CC1
CHEMBL470585,CHEMBL233,Mu opioid receptor,IC50,=,17000.0,nM,CHEMBL1010736,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells by scintillation counting,CHEMBL1152790,IC50,CC(C)N[C@H]1CCn2c(=O)[nH]c3cccc(c32)[C@@H]1O.Cl
CHEMBL513390,CHEMBL233,Mu opioid receptor,IC50,=,320000.0,nM,CHEMBL1010736,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells by scintillation counting,CHEMBL1152790,IC50,CC(C)N[C@@H]1CCn2c(=O)[nH]c3cccc(c32)[C@H]1O.Cl
CHEMBL513390,CHEMBL233,Mu opioid receptor,IC50,=,31000.0,nM,CHEMBL1010736,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells by scintillation counting,CHEMBL1152790,IC50,CC(C)N[C@@H]1CCn2c(=O)[nH]c3cccc(c32)[C@H]1O.Cl
CHEMBL466648,CHEMBL233,Mu opioid receptor,IC50,=,5600.0,nM,CHEMBL1007472,B,Displacement of [3H]diprenorphin from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1136941,IC50,Cc1ncc(-c2c(C)c(CN[C@H]3CC[C@@H](F)C3)nn2-c2ncccc2Cl)cc1F
CHEMBL494350,CHEMBL233,Mu opioid receptor,IC50,=,1900.0,nM,CHEMBL972467,B,Displacement of [3H]diprenorphin from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1136886,IC50,C[C@@H]1CN(CCO)CCN1c1cc2[nH]c(SC(C)(C)C)nc2cc1Cl
CHEMBL467057,CHEMBL233,Mu opioid receptor,IC50,=,840.0,nM,CHEMBL972467,B,Displacement of [3H]diprenorphin from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1136886,IC50,CCN1CCN(c2cc3[nH]c(S[C@]4(C)CC[C@@H](N(C)C(C)=O)CC4)nc3cc2Cl)CC1
CHEMBL564840,CHEMBL233,Mu opioid receptor,IC50,=,4500.0,nM,CHEMBL1025186,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1158463,IC50,Cl.O=c1n(C[C@@H](O)CO)c2ccccc2n1C1CCN(C[C@H]2[C@H]3CC[C@H](C3)C23CC3)CC1
CHEMBL563980,CHEMBL233,Mu opioid receptor,IC50,=,2700.0,nM,CHEMBL1025186,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1158463,IC50,Cl.O=c1n(C[C@H](O)CO)c2ccccc2n1C1CCN(C[C@H]2[C@H]3CC[C@H](C3)C23CC3)CC1
CHEMBL563657,CHEMBL233,Mu opioid receptor,IC50,=,6200.0,nM,CHEMBL1025186,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1158463,IC50,Cl.O=c1n(C(CO)CO)c2ccccc2n1C1CCN(C[C@H]2[C@H]3CC[C@H](C3)C23CC3)CC1
CHEMBL584993,CHEMBL233,Mu opioid receptor,IC50,=,0.81,nM,CHEMBL1058518,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells after 90 mins by scintillation counting,CHEMBL1154775,IC50,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCN(N=C=S)N=C=S)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)O
CHEMBL574142,CHEMBL233,Mu opioid receptor,IC50,=,0.11,nM,CHEMBL1058518,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells after 90 mins by scintillation counting,CHEMBL1154775,IC50,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCN(C(=O)CBr)C(=O)CBr)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)O
CHEMBL584994,CHEMBL233,Mu opioid receptor,IC50,=,4.25,nM,CHEMBL1058518,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells after 90 mins by scintillation counting,CHEMBL1154775,IC50,CC(=O)N(CCC[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)O)C(C)=O
CHEMBL584995,CHEMBL233,Mu opioid receptor,IC50,=,0.38,nM,CHEMBL1058518,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells after 90 mins by scintillation counting,CHEMBL1154775,IC50,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCCN(N=C=S)N=C=S)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)O
CHEMBL575349,CHEMBL233,Mu opioid receptor,IC50,=,5.23,nM,CHEMBL1058518,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells after 90 mins by scintillation counting,CHEMBL1154775,IC50,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCCN(C(=O)CBr)C(=O)CBr)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)O
CHEMBL574143,CHEMBL233,Mu opioid receptor,IC50,=,29.8,nM,CHEMBL1058518,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells after 90 mins by scintillation counting,CHEMBL1154775,IC50,CC(=O)N(CCCC[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)O)C(C)=O
CHEMBL278789,CHEMBL233,Mu opioid receptor,IC50,=,0.72,nM,CHEMBL1058518,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells after 90 mins by scintillation counting,CHEMBL1154775,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
CHEMBL1163015,CHEMBL233,Mu opioid receptor,IC50,=,190.0,nM,CHEMBL1048159,B,Binding affinity to human mu opioid receptor,CHEMBL1156007,IC50,COc1cc(N)c(Cl)cc1C(=O)NCCN(C)CC1CCCCC1(O)c1cccc(O)c1
CHEMBL572038,CHEMBL233,Mu opioid receptor,IC50,=,4500.0,nM,CHEMBL1048159,B,Binding affinity to human mu opioid receptor,CHEMBL1156007,IC50,COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)CCNC(=O)c2cc(Cl)c(N)cc2OC)c1
CHEMBL569357,CHEMBL233,Mu opioid receptor,IC50,=,340.0,nM,CHEMBL1048159,B,Binding affinity to human mu opioid receptor,CHEMBL1156007,IC50,COc1cc(N)c(Cl)cc1C(=O)NCCN(C)C[C@H]1CCCC[C@]1(O)c1cccc(O)c1
CHEMBL572248,CHEMBL233,Mu opioid receptor,IC50,=,5100.0,nM,CHEMBL1048159,B,Binding affinity to human mu opioid receptor,CHEMBL1156007,IC50,COc1cc(N)c(Cl)cc1C(=O)NCCN(C)C[C@@H]1CCCC[C@@]1(O)c1cccc(O)c1
CHEMBL585567,CHEMBL233,Mu opioid receptor,IC50,=,410.0,nM,CHEMBL1048159,B,Binding affinity to human mu opioid receptor,CHEMBL1156007,IC50,COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(C[C@@H]2CCCC[C@@]2(O)c2cccc(O)c2)C[C@H]1OC
CHEMBL38874,CHEMBL233,Mu opioid receptor,IC50,=,2.0,nM,CHEMBL1114660,B,Displacement of [3H]naloxone from mu opioid receptor expressed in CHO cell membrane,CHEMBL1157800,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL1762381,CHEMBL233,Mu opioid receptor,IC50,=,468.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCNCc4ccc(OCc5ccccc5C(=O)Nc5ccc6nc(C)cc(N)c6c5)cc4)cc3)ccc2n1
CHEMBL1762382,CHEMBL233,Mu opioid receptor,IC50,=,1590.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCNCc4ccc(OCc5ccccc5C(=O)Nc5ccc6nc(C)cc(N)c6c5)cc4)cc3)ccc2n1
CHEMBL1762383,CHEMBL233,Mu opioid receptor,IC50,=,2505.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCNCc4ccc(OCc5ccccc5C(=O)Nc5ccc6nc(C)cc(N)c6c5)cc4)cc3)ccc2n1
CHEMBL1762384,CHEMBL233,Mu opioid receptor,IC50,=,1390.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCNCc4ccc(OCc5ccccc5C(=O)Nc5ccc6nc(C)cc(N)c6c5)cc4)cc3)ccc2n1
CHEMBL1762385,CHEMBL233,Mu opioid receptor,IC50,=,1038.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCCNCc4ccc(OCc5ccccc5C(=O)Nc5ccc6nc(C)cc(N)c6c5)cc4)cc3)ccc2n1
CHEMBL1762386,CHEMBL233,Mu opioid receptor,IC50,=,1900.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCCCNCc4ccc(OCc5ccccc5C(=O)Nc5ccc6nc(C)cc(N)c6c5)cc4)cc3)ccc2n1
CHEMBL1762387,CHEMBL233,Mu opioid receptor,IC50,=,1160.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCCCCNCc4ccc(OCc5ccccc5C(=O)Nc5ccc6nc(C)cc(N)c6c5)cc4)cc3)ccc2n1
CHEMBL1762388,CHEMBL233,Mu opioid receptor,IC50,=,1320.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCCCCCNCc4ccc(OCc5ccccc5C(=O)Nc5ccc6nc(C)cc(N)c6c5)cc4)cc3)ccc2n1
CHEMBL1762397,CHEMBL233,Mu opioid receptor,IC50,=,3345.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCCNCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1762398,CHEMBL233,Mu opioid receptor,IC50,=,5114.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCCCNCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1762399,CHEMBL233,Mu opioid receptor,IC50,=,4453.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCCCCNCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1762400,CHEMBL233,Mu opioid receptor,IC50,=,2593.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCCCCCNCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1762401,CHEMBL233,Mu opioid receptor,IC50,=,1977.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCCCCCCNCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1762402,CHEMBL233,Mu opioid receptor,IC50,=,4339.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCCCCCCCNCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1762403,CHEMBL233,Mu opioid receptor,IC50,=,2171.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCCCCCCCCNCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1762404,CHEMBL233,Mu opioid receptor,IC50,=,2755.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCCCCCCCCCNCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1762405,CHEMBL233,Mu opioid receptor,IC50,=,1402.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCN)cc3)ccc2n1
CHEMBL1762406,CHEMBL233,Mu opioid receptor,IC50,=,5333.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCN)cc3)ccc2n1
CHEMBL1762407,CHEMBL233,Mu opioid receptor,IC50,=,4885.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCN)cc3)ccc2n1
CHEMBL1760025,CHEMBL233,Mu opioid receptor,IC50,=,5999.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCN)cc3)ccc2n1
CHEMBL1762408,CHEMBL233,Mu opioid receptor,IC50,=,9978.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCCN)cc3)ccc2n1
CHEMBL1762409,CHEMBL233,Mu opioid receptor,IC50,=,325.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCCCN)cc3)ccc2n1
CHEMBL1762410,CHEMBL233,Mu opioid receptor,IC50,=,7071.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCCCCN)cc3)ccc2n1
CHEMBL1762411,CHEMBL233,Mu opioid receptor,IC50,=,1401.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCCCCCN)cc3)ccc2n1
CHEMBL140979,CHEMBL233,Mu opioid receptor,IC50,=,1507.0,nM,CHEMBL1764074,B,Displacement of [3H]-naltrindole from human mu opioid receptor expressed in CHO cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1811938,CHEMBL233,Mu opioid receptor,IC50,=,7200.0,nM,CHEMBL1814860,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,CHEMBL1811804,IC50,CCCCC/C=C/c1c(O)cc(CC=C(C)C)c(O)c1C=O
CHEMBL508112,CHEMBL233,Mu opioid receptor,IC50,=,3113.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,c1ccc2sc(SSc3nc4ccccc4s3)nc2c1
CHEMBL290106,CHEMBL233,Mu opioid receptor,IC50,=,5507.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O
CHEMBL296419,CHEMBL233,Mu opioid receptor,IC50,=,1492.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
CHEMBL633,CHEMBL233,Mu opioid receptor,IC50,=,19037.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1
CHEMBL1403281,CHEMBL233,Mu opioid receptor,IC50,=,2427.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
CHEMBL64894,CHEMBL233,Mu opioid receptor,IC50,=,2145.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1.[Cl-]
CHEMBL808,CHEMBL233,Mu opioid receptor,IC50,=,5693.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
CHEMBL30008,CHEMBL233,Mu opioid receptor,IC50,=,5236.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1
CHEMBL726,CHEMBL233,Mu opioid receptor,IC50,=,20745.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
CHEMBL691,CHEMBL233,Mu opioid receptor,IC50,=,26769.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C
CHEMBL54,CHEMBL233,Mu opioid receptor,IC50,=,2443.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
CHEMBL139835,CHEMBL233,Mu opioid receptor,IC50,=,2183.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
CHEMBL1255837,CHEMBL233,Mu opioid receptor,IC50,=,850.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CS(=O)(=O)O
CHEMBL104,CHEMBL233,Mu opioid receptor,IC50,=,1802.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
CHEMBL964,CHEMBL233,Mu opioid receptor,IC50,=,3511.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
CHEMBL411,CHEMBL233,Mu opioid receptor,IC50,=,5778.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1
CHEMBL71,CHEMBL233,Mu opioid receptor,IC50,=,14397.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
CHEMBL43064,CHEMBL233,Mu opioid receptor,IC50,=,2272.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL219916,CHEMBL233,Mu opioid receptor,IC50,=,4218.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1
CHEMBL1479,CHEMBL233,Mu opioid receptor,IC50,=,14079.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C
CHEMBL584,CHEMBL233,Mu opioid receptor,IC50,=,14432.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
CHEMBL19019,CHEMBL233,Mu opioid receptor,IC50,=,4.083,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1618305,CHEMBL233,Mu opioid receptor,IC50,=,7.196,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2/C(=N/N=C2\CC[C@@]4(O)[C@H]6Cc7ccc(O)c8c7[C@@]4(CCN6CC=C)[C@H]2O8)CC[C@@]3(O)[C@H]1C5
CHEMBL91,CHEMBL233,Mu opioid receptor,IC50,=,6059.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
CHEMBL80,CHEMBL233,Mu opioid receptor,IC50,=,20.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL1276308,CHEMBL233,Mu opioid receptor,IC50,=,2457.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
CHEMBL841,CHEMBL233,Mu opioid receptor,IC50,=,1.445,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
CHEMBL895,CHEMBL233,Mu opioid receptor,IC50,=,24.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL141343,CHEMBL233,Mu opioid receptor,IC50,=,10747.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,Cc1c(C)c2c(c(C)c1O)CCC(C)(CN1CCN(c3cc(N4CCCC4)nc(N4CCCC4)n3)CC1)O2
CHEMBL772,CHEMBL233,Mu opioid receptor,IC50,=,4152.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC
CHEMBL18797,CHEMBL233,Mu opioid receptor,IC50,=,33668.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CSc1ccc(/C=C2/C(C)=C(CC(=O)O)c3cc(F)ccc32)cc1
CHEMBL83,CHEMBL233,Mu opioid receptor,IC50,=,17594.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
CHEMBL163,CHEMBL233,Mu opioid receptor,IC50,=,65542.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
CHEMBL114,CHEMBL233,Mu opioid receptor,IC50,=,9625.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1
CHEMBL81,CHEMBL233,Mu opioid receptor,IC50,=,1176.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12
CHEMBL118865,CHEMBL233,Mu opioid receptor,IC50,=,234.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)C1CCC2(CCCO2)CC1N1CCCC1
CHEMBL1946015,CHEMBL233,Mu opioid receptor,IC50,=,2330.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2cccc(F)c2)cc1
CHEMBL1946016,CHEMBL233,Mu opioid receptor,IC50,=,1250.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2ccccn2)cc1
CHEMBL1946017,CHEMBL233,Mu opioid receptor,IC50,=,1200.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2cccnc2)cc1
CHEMBL1946018,CHEMBL233,Mu opioid receptor,IC50,=,6800.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2ccncc2)cc1
CHEMBL1944652,CHEMBL233,Mu opioid receptor,IC50,=,420.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2cccc3cccnc23)cc1
CHEMBL1946019,CHEMBL233,Mu opioid receptor,IC50,=,990.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,CCN(C)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2ccccc2NC(C)=O)cc1
CHEMBL1946020,CHEMBL233,Mu opioid receptor,IC50,=,63.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2cccc(NC(C)=O)c2)cc1
CHEMBL1946021,CHEMBL233,Mu opioid receptor,IC50,=,170.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2ccc(NC(C)=O)cc2)cc1
CHEMBL1946022,CHEMBL233,Mu opioid receptor,IC50,=,1600.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2ccccc2NC(=O)OC)cc1
CHEMBL1946023,CHEMBL233,Mu opioid receptor,IC50,=,33.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2cccc(NC(=O)OC)c2)cc1
CHEMBL1946024,CHEMBL233,Mu opioid receptor,IC50,=,490.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3ccc(F)cc3)CC2)c2ccc(NC(=O)OC)cc2)cc1
CHEMBL1946025,CHEMBL233,Mu opioid receptor,IC50,=,180.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(Cc3cscn3)CC2)c2cccc3cccnc23)cc1
CHEMBL1946026,CHEMBL233,Mu opioid receptor,IC50,=,140.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,O=C(c1ccc(C(=C2CCN(Cc3cscn3)CC2)c2cccc3cccnc23)cc1)N1CCCC1
CHEMBL1946027,CHEMBL233,Mu opioid receptor,IC50,=,340.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,CCN(C)C(=O)c1ccc(C(=C2CCN(Cc3cscn3)CC2)c2cccc3cccnc23)cc1
CHEMBL1946028,CHEMBL233,Mu opioid receptor,IC50,=,330.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,O=C(c1ccc(C(=C2CCN(Cc3cscn3)CC2)c2cccc3cccnc23)cc1)N1CCC1
CHEMBL1946029,CHEMBL233,Mu opioid receptor,IC50,=,350.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,CN(C)C(=O)c1ccc(C(=C2CCN(Cc3cscn3)CC2)c2cccc3cccnc23)cc1
CHEMBL1946615,CHEMBL233,Mu opioid receptor,IC50,=,480.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,O=C(c1ccc(C(=C2CCN(Cc3cscn3)CC2)c2cccc3cccnc23)cc1)N1CCOCC1
CHEMBL1946616,CHEMBL233,Mu opioid receptor,IC50,=,200.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,CN1CCN(C(=O)c2ccc(C(=C3CCN(Cc4cscn4)CC3)c3cccc4cccnc34)cc2)CC1
CHEMBL1946617,CHEMBL233,Mu opioid receptor,IC50,=,220.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,O=C(c1ccc(C(=C2CCN(Cc3cscn3)CC2)c2cccc3cccnc23)cc1)N1CCC(O)CC1
CHEMBL1946618,CHEMBL233,Mu opioid receptor,IC50,=,460.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,CN(CCO)C(=O)c1ccc(C(=C2CCN(Cc3cscn3)CC2)c2cccc3cccnc23)cc1
CHEMBL1946621,CHEMBL233,Mu opioid receptor,IC50,=,5400.0,nM,CHEMBL1947874,B,Displacement of radiolabeled FK33-824 from mu opioid receptor expressed in HEK293 cell membranes,CHEMBL1944587,IC50,CN(C)C(=O)c1ccc(C(=C2CCN(Cc3cscn3)CC2)c2ccccn2)cc1
CHEMBL2158541,CHEMBL233,Mu opioid receptor,IC50,=,3200.0,nM,CHEMBL2162310,B,Displacement of [3H]DAMGO from human recombinant mu-opioid receptor expressed in CHO cells after 60 mins by liquid scintillation assay,CHEMBL2157908,IC50,CC(C)C[C@H](CN(C=O)[C@H](Cc1ccccc1)CN(C=O)CCN(C=O)CCN(C=O)[C@@H](CN)Cc1ccc(O)cc1)NS(C)(=O)=O
CHEMBL38874,CHEMBL233,Mu opioid receptor,IC50,=,0.74,nM,CHEMBL2394995,B,Binding affinity to mu opioid receptor (unknown origin) by radioligand displacement assay,CHEMBL2390917,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL38874,CHEMBL233,Mu opioid receptor,IC50,=,20.0,nM,CHEMBL2395088,B,Displacement of [3H]Diprenorphine from human recombinant mu opioid receptor expressed in CHOK1 cells after 60 mins,CHEMBL2390918,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL38874,CHEMBL233,Mu opioid receptor,IC50,=,0.68,nM,CHEMBL2394939,B,Binding affinity to human mu-type opioid receptor by radioligand displacement assay,CHEMBL2390830,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL522201,CHEMBL233,Mu opioid receptor,IC50,=,5.42,nM,CHEMBL2444609,B,Binding affinity to wild type MOR (unknown origin) expressed in CHO cells after 15 mins by Ca2+ mobilization assay,CHEMBL2440098,IC50,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cc2ccccc2cn1
CHEMBL522143,CHEMBL233,Mu opioid receptor,IC50,=,2.29,nM,CHEMBL2444609,B,Binding affinity to wild type MOR (unknown origin) expressed in CHO cells after 15 mins by Ca2+ mobilization assay,CHEMBL2440098,IC50,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1
CHEMBL19019,CHEMBL233,Mu opioid receptor,IC50,=,3.9,nM,CHEMBL2444609,B,Binding affinity to wild type MOR (unknown origin) expressed in CHO cells after 15 mins by Ca2+ mobilization assay,CHEMBL2440098,IC50,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL522201,CHEMBL233,Mu opioid receptor,IC50,=,150.0,nM,CHEMBL2444608,B,Antagonist activity at MOR (unknown origin) assessed as inhibition of DAMGO-induced agonism,CHEMBL2440098,IC50,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cc2ccccc2cn1
CHEMBL522143,CHEMBL233,Mu opioid receptor,IC50,=,19.5,nM,CHEMBL2444608,B,Antagonist activity at MOR (unknown origin) assessed as inhibition of DAMGO-induced agonism,CHEMBL2440098,IC50,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1
CHEMBL80,CHEMBL233,Mu opioid receptor,IC50,=,1.87,nM,CHEMBL3088793,B,Displacement of radiolabeled DAMGO from human recombinant mu opioid receptor expressed in OPRM1 cells,CHEMBL3085664,IC50,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL70,CHEMBL233,Mu opioid receptor,IC50,=,2.5,nM,CHEMBL3088793,B,Displacement of radiolabeled DAMGO from human recombinant mu opioid receptor expressed in OPRM1 cells,CHEMBL3085664,IC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL1474387,CHEMBL233,Mu opioid receptor,IC50,=,580.0,nM,CHEMBL3088793,B,Displacement of radiolabeled DAMGO from human recombinant mu opioid receptor expressed in OPRM1 cells,CHEMBL3085664,IC50,Cc1c(P(=S)(c2ccccc2)c2ccccc2)n2ccccc2[n+]1C/C=C/c1ccccc1.[Br-]
CHEMBL3099899,CHEMBL233,Mu opioid receptor,IC50,=,5020.0,nM,CHEMBL3102176,B,Inhibition of human mu opioid receptor,CHEMBL3098111,IC50,COc1ccc(CNC(=O)c2cc(-c3cc(Cl)cc(Cl)c3)cnc2-c2cccnc2)cc1OC
CHEMBL3264446,CHEMBL233,Mu opioid receptor,IC50,=,343.0,nM,CHEMBL3268181,B,Antagonist activity at human cloned mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]-GTP[gammaS] binding,CHEMBL3259577,IC50,COC(=O)c1cc(Br)cnc1N1CC[C@@H](NC2CCCCC2)[C@H](O)C1
CHEMBL1736339,CHEMBL233,Mu opioid receptor,IC50,=,10300.0,nM,CHEMBL3268193,B,Inhibition of mu opioid receptor (unknown origin) using DAMGO by high content imaging beta-arrestin translocation assay,CHEMBL3259577,IC50,CCN(CCNC(=O)c1ccc(CNS(=O)(=O)c2ccc(C)cc2)cc1)Cc1ccccc1
CHEMBL1713967,CHEMBL233,Mu opioid receptor,IC50,=,1390.0,nM,CHEMBL3268193,B,Inhibition of mu opioid receptor (unknown origin) using DAMGO by high content imaging beta-arrestin translocation assay,CHEMBL3259577,IC50,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C(C)(C)C)cc2)cc1
CHEMBL1702620,CHEMBL233,Mu opioid receptor,IC50,=,30900.0,nM,CHEMBL3268193,B,Inhibition of mu opioid receptor (unknown origin) using DAMGO by high content imaging beta-arrestin translocation assay,CHEMBL3259577,IC50,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4c(C)ccnc43)CC2)c(OC)c1
CHEMBL1711929,CHEMBL233,Mu opioid receptor,IC50,=,10300.0,nM,CHEMBL3268193,B,Inhibition of mu opioid receptor (unknown origin) using DAMGO by high content imaging beta-arrestin translocation assay,CHEMBL3259577,IC50,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4cc(Br)cnc43)CC2)cc1
CHEMBL3265238,CHEMBL233,Mu opioid receptor,IC50,=,8200.0,nM,CHEMBL3266313,B,Inhibition of mu opioid receptor (unknown origin),CHEMBL3259666,IC50,COc1cccc(NC[C@H](F)Cn2c3ccc(Br)cc3c3cc(Br)ccc32)n1
CHEMBL3290766,CHEMBL233,Mu opioid receptor,IC50,=,21900.0,nM,CHEMBL3296312,B,Inhibition of mu opioid receptor (unknown origin),CHEMBL3286182,IC50,Cn1ncc(C(=O)N2CCC(Nc3cc(=O)[nH]c4ccccc34)CC2)c1Cl
CHEMBL3290767,CHEMBL233,Mu opioid receptor,IC50,=,-28100.0,nM,CHEMBL3296312,B,Inhibition of mu opioid receptor (unknown origin),CHEMBL3286182,IC50,Cn1ncc(C(=O)N2CCC(Nc3cc(=O)[nH]c4ccc(F)cc34)CC2)c1Cl
CHEMBL3394742,CHEMBL233,Mu opioid receptor,IC50,=,1190.0,nM,CHEMBL3395052,B,Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation counting,CHEMBL3393026,IC50,CCCCN(Cc1ccccc1)C[C@H](O)CN1CN(c2ccc(F)cc2)C2(CCN(CC3CCCCCCC3)CC2)C1=O
CHEMBL3394743,CHEMBL233,Mu opioid receptor,IC50,=,29.0,nM,CHEMBL3395052,B,Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation counting,CHEMBL3393026,IC50,COc1ccc(CNC[C@H](O)CN2CN(c3ccccc3)C3(CCN(CCc4ccccc4-c4cccs4)CC3)C2=O)cc1
CHEMBL3394744,CHEMBL233,Mu opioid receptor,IC50,=,110.0,nM,CHEMBL3395052,B,Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation counting,CHEMBL3393026,IC50,COc1ccc(CNC[C@@H](O)CN2CN(c3ccccc3)C3(CCN(CCc4ccccc4-c4cccs4)CC3)C2=O)cc1
CHEMBL3394745,CHEMBL233,Mu opioid receptor,IC50,=,36.0,nM,CHEMBL3395052,B,Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation counting,CHEMBL3393026,IC50,CCCCN(Cc1ccccc1)C[C@H](O)CN1CN(c2ccccc2)C2(CCN(CCc3ccccc3-c3cccs3)CC2)C1=O
CHEMBL3394746,CHEMBL233,Mu opioid receptor,IC50,=,47.0,nM,CHEMBL3395052,B,Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation counting,CHEMBL3393026,IC50,CCCCN(Cc1ccccc1)C[C@@H](O)CN1CN(c2ccccc2)C2(CCN(CCc3ccccc3-c3cccs3)CC2)C1=O
CHEMBL3394747,CHEMBL233,Mu opioid receptor,IC50,=,29.0,nM,CHEMBL3395052,B,Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation counting,CHEMBL3393026,IC50,O=C1N(C[C@@H](O)CNCc2cccs2)CN(c2ccccc2)C12CCN(CCc1ccccc1-c1cccs1)CC2
CHEMBL3394748,CHEMBL233,Mu opioid receptor,IC50,=,80.0,nM,CHEMBL3395052,B,Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation counting,CHEMBL3393026,IC50,O=C1N(C[C@H](O)CNCc2cccs2)CN(c2ccccc2)C12CCN(CCc1ccccc1-c1cccs1)CC2
CHEMBL3394749,CHEMBL233,Mu opioid receptor,IC50,=,69.0,nM,CHEMBL3395052,B,Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation counting,CHEMBL3393026,IC50,Cc1ccccc1CNC[C@H](O)CN1CN(c2ccccc2)C2(CCN(CCc3ccccc3-c3cccs3)CC2)C1=O
CHEMBL3394750,CHEMBL233,Mu opioid receptor,IC50,=,103.0,nM,CHEMBL3395052,B,Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation counting,CHEMBL3393026,IC50,Cc1ccccc1CNC[C@@H](O)CN1CN(c2ccccc2)C2(CCN(CCc3ccccc3-c3cccs3)CC2)C1=O
CHEMBL3394751,CHEMBL233,Mu opioid receptor,IC50,=,79.0,nM,CHEMBL3395052,B,Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation counting,CHEMBL3393026,IC50,COc1ccc(CCNC[C@@H](O)CN2CN(c3ccccc3)C3(CCN(CCc4ccccc4-c4cccs4)CC3)C2=O)cc1OC
CHEMBL3394752,CHEMBL233,Mu opioid receptor,IC50,=,57.0,nM,CHEMBL3395052,B,Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation counting,CHEMBL3393026,IC50,CC(C)(C)NC[C@@H](O)CN1CN(c2ccccc2)C2(CCN(CCc3ccccc3-c3cccs3)CC2)C1=O
CHEMBL3394753,CHEMBL233,Mu opioid receptor,IC50,=,990.0,nM,CHEMBL3395052,B,Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation counting,CHEMBL3393026,IC50,COc1ccc(CCNC[C@H](O)CN2CN(c3ccc(F)cc3)C3(CCN(CC4CCCCCCC4)CC3)C2=O)cc1OC
CHEMBL3394754,CHEMBL233,Mu opioid receptor,IC50,=,540.0,nM,CHEMBL3395052,B,Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation counting,CHEMBL3393026,IC50,Cc1cccc(SC[C@H](O)CN2CN(c3ccc(F)cc3)C3(CCN(CC4CCCCCCC4)CC3)C2=O)c1
CHEMBL3394755,CHEMBL233,Mu opioid receptor,IC50,=,2600.0,nM,CHEMBL3395052,B,Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation counting,CHEMBL3393026,IC50,COc1ccc(CCOC[C@H](O)CN2CN(c3ccc(F)cc3)C3(CCN(CC4CCCCCCC4)CC3)C2=O)cc1OC
CHEMBL3394756,CHEMBL233,Mu opioid receptor,IC50,=,820.0,nM,CHEMBL3395052,B,Displacement of [3H]DAMGO from human Mu opioid receptor expressed in HEK293 cells after 2 hrs by scintillation counting,CHEMBL3393026,IC50,Cc1ccc(CN(C[C@H](O)CN2CN(c3ccc(F)cc3)C3(CCN(CC4CCCCCCC4)CC3)C2=O)C(=O)[C@H](N)C(C)C)cc1
CHEMBL3403995,CHEMBL233,Mu opioid receptor,IC50,=,1000.0,nM,CHEMBL3406663,B,Inhibition of mu opioid receptor (unknown origin),CHEMBL3400053,IC50,COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2OC(=O)NCc2ccccc2)C(C)C)ccc1OC
CHEMBL435746,CHEMBL233,Mu opioid receptor,IC50,=,29.0,nM,CHEMBL3705131,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,IC50,C[C@H]1CN2C[C@H](Cc3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219495,CHEMBL233,Mu opioid receptor,IC50,=,21.0,nM,CHEMBL3705131,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,IC50,C[C@H]1CN2CCN(CCc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL426523,CHEMBL233,Mu opioid receptor,IC50,=,0.53,nM,CHEMBL3705131,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,IC50,C[C@H]1CN2C[C@H](c3ccccc3)CC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218520,CHEMBL233,Mu opioid receptor,IC50,=,26.0,nM,CHEMBL3705131,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,IC50,C[C@H]1CN2C[C@H](c3ccccc3)N(C)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL376690,CHEMBL233,Mu opioid receptor,IC50,=,11.0,nM,CHEMBL3705131,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,IC50,C[C@H]1CN2CCN(Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218404,CHEMBL233,Mu opioid receptor,IC50,=,21.0,nM,CHEMBL3705131,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,IC50,C[C@H]1CN2CCN(C(=O)c3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219319,CHEMBL233,Mu opioid receptor,IC50,=,12.0,nM,CHEMBL3705131,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,IC50,C[C@H]1CN2C[C@H](c3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL438389,CHEMBL233,Mu opioid receptor,IC50,=,19.95,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,IC50,CC(C)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299402,CHEMBL233,Mu opioid receptor,IC50,=,13.18,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccc(I)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299466,CHEMBL233,Mu opioid receptor,IC50,=,89.13,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,IC50,CC(C)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299371,CHEMBL233,Mu opioid receptor,IC50,=,1.66,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299390,CHEMBL233,Mu opioid receptor,IC50,=,2.344,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299423,CHEMBL233,Mu opioid receptor,IC50,=,1.905,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299415,CHEMBL233,Mu opioid receptor,IC50,=,2.818,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N(C)[C@@H](Cc1ccc(F)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299479,CHEMBL233,Mu opioid receptor,IC50,=,8.318,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,IC50,CC(C)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccc(F)cc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299483,CHEMBL233,Mu opioid receptor,IC50,=,4.677,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccc(Cl)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299476,CHEMBL233,Mu opioid receptor,IC50,=,10.96,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccc(Br)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL285479,CHEMBL233,Mu opioid receptor,IC50,=,36.7,nM,CHEMBL3762577,B,Binding affinity at mu opioid receptor (unknown origin),CHEMBL3758122,IC50,C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
CHEMBL70,CHEMBL233,Mu opioid receptor,IC50,=,6.3,nM,CHEMBL3766870,B,Agonist activity at human MOR expressed in CHO cells assessed as induction of membrane potential change measured every 3 secs for 30 secs by fluorescent membrane potential assay,CHEMBL3763066,IC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL38874,CHEMBL233,Mu opioid receptor,IC50,=,2.5,nM,CHEMBL3766870,B,Agonist activity at human MOR expressed in CHO cells assessed as induction of membrane potential change measured every 3 secs for 30 secs by fluorescent membrane potential assay,CHEMBL3763066,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL3764157,CHEMBL233,Mu opioid receptor,IC50,=,66.9,nM,CHEMBL3766870,B,Agonist activity at human MOR expressed in CHO cells assessed as induction of membrane potential change measured every 3 secs for 30 secs by fluorescent membrane potential assay,CHEMBL3763066,IC50,NC(=O)NCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)CCCCNC(=O)CNC(=O)[C@H](Cc2ccc(O)cc2)NC1=O
CHEMBL3765741,CHEMBL233,Mu opioid receptor,IC50,=,130.7,nM,CHEMBL3766870,B,Agonist activity at human MOR expressed in CHO cells assessed as induction of membrane potential change measured every 3 secs for 30 secs by fluorescent membrane potential assay,CHEMBL3763066,IC50,N=C(N)NCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)CCCCNC(=O)CNC(=O)[C@H](Cc2ccc(O)cc2)NC1=O
CHEMBL3763985,CHEMBL233,Mu opioid receptor,IC50,=,32.0,nM,CHEMBL3766870,B,Agonist activity at human MOR expressed in CHO cells assessed as induction of membrane potential change measured every 3 secs for 30 secs by fluorescent membrane potential assay,CHEMBL3763066,IC50,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CCCCNC(=O)CNC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccncc2)NC1=O
CHEMBL3763920,CHEMBL233,Mu opioid receptor,IC50,=,11.1,nM,CHEMBL3766870,B,Agonist activity at human MOR expressed in CHO cells assessed as induction of membrane potential change measured every 3 secs for 30 secs by fluorescent membrane potential assay,CHEMBL3763066,IC50,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CCCCNC(=O)CNC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2cccnc2)NC1=O
CHEMBL3763452,CHEMBL233,Mu opioid receptor,IC50,=,1250.0,nM,CHEMBL3766870,B,Agonist activity at human MOR expressed in CHO cells assessed as induction of membrane potential change measured every 3 secs for 30 secs by fluorescent membrane potential assay,CHEMBL3763066,IC50,N[C@@H](Cc1ccc(O)cc1)C(=O)[C@H]1CCCCNC(=O)CNC(=O)[C@H](Cc2ccc(O)cc2)N2Cc3cc(O)ccc3C[C@H]2C(=O)N1
CHEMBL3764234,CHEMBL233,Mu opioid receptor,IC50,=,677.8,nM,CHEMBL3766870,B,Agonist activity at human MOR expressed in CHO cells assessed as induction of membrane potential change measured every 3 secs for 30 secs by fluorescent membrane potential assay,CHEMBL3763066,IC50,N[C@@H](Cc1ccc(O)cc1)C(=O)[C@H]1CCCCNC(=O)CNC(=O)[C@H](Cc2ccc(O)cc2)N2Cc3ccccc3C[C@H]2C(=O)N1
CHEMBL3764556,CHEMBL233,Mu opioid receptor,IC50,=,24.0,nM,CHEMBL3766870,B,Agonist activity at human MOR expressed in CHO cells assessed as induction of membrane potential change measured every 3 secs for 30 secs by fluorescent membrane potential assay,CHEMBL3763066,IC50,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CCCCNC(=O)CNC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC1=O
CHEMBL3763905,CHEMBL233,Mu opioid receptor,IC50,=,70.4,nM,CHEMBL3766870,B,Agonist activity at human MOR expressed in CHO cells assessed as induction of membrane potential change measured every 3 secs for 30 secs by fluorescent membrane potential assay,CHEMBL3763066,IC50,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CCCCNC(=O)CNC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O
CHEMBL3765059,CHEMBL233,Mu opioid receptor,IC50,=,2.3,nM,CHEMBL3766870,B,Agonist activity at human MOR expressed in CHO cells assessed as induction of membrane potential change measured every 3 secs for 30 secs by fluorescent membrane potential assay,CHEMBL3763066,IC50,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CCCCNC(=O)CNC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC1=O
CHEMBL38874,CHEMBL233,Mu opioid receptor,IC50,=,0.43,nM,CHEMBL3779735,B,Displacement of [3H]DAMGO from human recombinant Mu-type opioid receptor expressed in CHO cells,CHEMBL3774372,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL3775378,CHEMBL233,Mu opioid receptor,IC50,=,12000.0,nM,CHEMBL3776148,B,Inhibition of human recombinant mu1 opioid receptor expressed in HEK293 cells,CHEMBL3774369,IC50,CC(C)CN1[C@H](c2ccc(/C=C/C(=O)O)cc2)c2ccc(O)cc2C[C@H]1C
CHEMBL38874,CHEMBL233,Mu opioid receptor,IC50,=,0.43,nM,CHEMBL3876380,B,Displacement of [3H]DAMGO from human recombinant mu-opioid receptor expressed in HEK293 cells measured after 120 mins by scintillation counting method,CHEMBL3875185,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL4115660,CHEMBL233,Mu opioid receptor,IC50,=,4.2,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,NC(=O)c1ccc2c(c1O)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL4108846,CHEMBL233,Mu opioid receptor,IC50,=,2.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(C(N)=O)c(O)c4[C@@]2(CCN3CC2CCC2)C1
CHEMBL3948892,CHEMBL233,Mu opioid receptor,IC50,=,1.3,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,C=C1CC[C@H]2[C@H]3Cc4ccc(C(N)=O)c(O)c4[C@@]2(CCN3CC2CCC2)C1
CHEMBL3986245,CHEMBL233,Mu opioid receptor,IC50,=,14.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@@H]1CC[C@H](O)C3
CHEMBL3954177,CHEMBL233,Mu opioid receptor,IC50,=,1.1,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@@H]1CCC(=O)C3
CHEMBL3983967,CHEMBL233,Mu opioid receptor,IC50,=,5.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,NC(=O)c1ccc2c(c1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL4114524,CHEMBL233,Mu opioid receptor,IC50,=,3.7,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@@H]1CC[C@@H](O)C3
CHEMBL4114677,CHEMBL233,Mu opioid receptor,IC50,=,34.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,CC(C)=CCN1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13
CHEMBL4114707,CHEMBL233,Mu opioid receptor,IC50,=,51.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(C(N)=O)c(O)c4[C@@]2(CCN3CC=C(C)C)C1
CHEMBL3903900,CHEMBL233,Mu opioid receptor,IC50,=,14.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,C[C@H]1[C@H]2Cc3ccc(C(N)=O)cc3[C@]1(C)CCN2CC1CCC1
CHEMBL370029,CHEMBL233,Mu opioid receptor,IC50,=,2.2,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@]1(O)CCC(=O)C3
CHEMBL512150,CHEMBL233,Mu opioid receptor,IC50,=,47.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@]1(O)CC[C@H](O)C3
CHEMBL511645,CHEMBL233,Mu opioid receptor,IC50,=,3.8,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@]1(O)CC[C@@H](O)C3
CHEMBL4110274,CHEMBL233,Mu opioid receptor,IC50,=,3.3,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,CC1[C@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2[C@H](C)C1CC1
CHEMBL3971916,CHEMBL233,Mu opioid receptor,IC50,=,950.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,CC1[C@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2[C@@H](C)C1CC1
CHEMBL4109400,CHEMBL233,Mu opioid receptor,IC50,=,85.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,CC1C2Cc3ccc(O)cc3[C@]1(C)CCN2CC1(C)CC1
CHEMBL4113472,CHEMBL233,Mu opioid receptor,IC50,=,210.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,CC1C2Cc3ccc(O)cc3[C@]1(C)CCN2CC(C)(C)O
CHEMBL3958318,CHEMBL233,Mu opioid receptor,IC50,=,26.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,COCCN1CC[C@@]2(C)c3cc(O)ccc3C[C@@H]1[C@@H]2C
CHEMBL4108042,CHEMBL233,Mu opioid receptor,IC50,=,44.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,CC1C2Cc3ccc(C(N)=O)cc3[C@]1(C)CCN2CC1(C)CC1
CHEMBL3977887,CHEMBL233,Mu opioid receptor,IC50,=,47.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,C[C@H]1[C@H]2Cc3ccc(C(=O)NCCc4ccc(-c5ccc(O)nc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL3928839,CHEMBL233,Mu opioid receptor,IC50,=,18.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,C[C@H]1[C@H]2Cc3ccc(C(=O)NCCc4ccc(-c5cn[nH]c5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL4106879,CHEMBL233,Mu opioid receptor,IC50,=,1.5,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(C(=O)NCCc5ccc(-c6cccnc6)cc5)c(O)c4[C@@]2(CCN3CC2CC2)C1
CHEMBL3919938,CHEMBL233,Mu opioid receptor,IC50,=,170.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,C[C@@]12CCCCC[C@@H](Cc3ccc(C(N)=O)cc31)[C@@H]2N
CHEMBL3919938,CHEMBL233,Mu opioid receptor,IC50,=,170.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,C[C@@]12CCCCC[C@@H](Cc3ccc(C(N)=O)cc31)[C@@H]2N
CHEMBL3946804,CHEMBL233,Mu opioid receptor,IC50,=,340.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,CCCCCCN1CCC(C(=O)N(C)CC)(c2cccc(O)c2)CC1
CHEMBL4108042,CHEMBL233,Mu opioid receptor,IC50,=,44.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,CC1C2Cc3ccc(C(N)=O)cc3[C@]1(C)CCN2CC1(C)CC1
CHEMBL4114285,CHEMBL233,Mu opioid receptor,IC50,=,1.7,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,C[C@H](C1CC1)N1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(C(N)=O)cc13
CHEMBL3895359,CHEMBL233,Mu opioid receptor,IC50,=,0.65,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,C[C@@H](C1CC1)N1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13
CHEMBL4108566,CHEMBL233,Mu opioid receptor,IC50,=,43.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,C[C@H](C1CC1)N1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13
CHEMBL4115016,CHEMBL233,Mu opioid receptor,IC50,=,38.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,C[C@H](C1CCC1)N1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13
CHEMBL3911427,CHEMBL233,Mu opioid receptor,IC50,=,14.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,COCCN1CC[C@@]2(C)c3cc(C(N)=O)ccc3C[C@@H]1[C@@H]2C
CHEMBL4114055,CHEMBL233,Mu opioid receptor,IC50,=,7.8,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,NC(=O)c1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL4108288,CHEMBL233,Mu opioid receptor,IC50,=,1.5,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,NC(=O)c1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CC1)CC3
CHEMBL3939227,CHEMBL233,Mu opioid receptor,IC50,=,58.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,C[C@H]1[C@H]2Cc3ccc(C(N)=O)cc3[C@@]1(C)CCN2C[C@H]1CCCO1
CHEMBL3039334,CHEMBL233,Mu opioid receptor,IC50,=,88.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,Oc1ccc2c3c1OC1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL3917891,CHEMBL233,Mu opioid receptor,IC50,=,0.45,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,IC50,CO[C@@H]1C([C@](C)(O)C(C)(C)C)[C@H]2CC[C@@]13Oc1c(O)ccc4c1[C@@]31CCN(CC3CC3)[C@H](C4)C21
CHEMBL895,CHEMBL233,Mu opioid receptor,IC50,=,752.0,nM,CHEMBL3888042,B,"GTPyS binding assay: Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addition of SPA beads for another 60 minutes at 30° C. The reaction is initiated by 0.3 nM [35S]GTP gamma S for an additional 30 minutes incubation period. Test compound-induced increase of [35S]GTP gamma S binding by 50 percent or more (250%) relative to the receptor subtype-specific agonist response indicates possible opiate receptor agonist activity. 0.1 uM DPDPE, 1 uM U-69593 and 1 uM DAMGO were used as the specific agonists for the delta, kappa and mu opioid receptors respectively. Opioid receptor antagonist activity was measured using inhibition of agonist-induced increase of [35S]GTP gammaS binding response by 50 percent or more (250%). Nalbuphine, 6-O-mPEG3-Nalbuphine, 6-O-mPEG6-Nalbuphine, 6-O-mPEG9-Nalbuphine were screened at concentrations of 10, 1, 0.1, 0.01 and 0.001 uM in both agonist and antagonist mode. EC50 or IC50 values were calculated from the dose-response curves as a measure of the agonist or antagonist activity of the test compounds respectively.",CHEMBL3886551,IC50,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL3954154,CHEMBL233,Mu opioid receptor,IC50,=,398.0,nM,CHEMBL3888042,B,"GTPyS binding assay: Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addition of SPA beads for another 60 minutes at 30° C. The reaction is initiated by 0.3 nM [35S]GTP gamma S for an additional 30 minutes incubation period. Test compound-induced increase of [35S]GTP gamma S binding by 50 percent or more (250%) relative to the receptor subtype-specific agonist response indicates possible opiate receptor agonist activity. 0.1 uM DPDPE, 1 uM U-69593 and 1 uM DAMGO were used as the specific agonists for the delta, kappa and mu opioid receptors respectively. Opioid receptor antagonist activity was measured using inhibition of agonist-induced increase of [35S]GTP gammaS binding response by 50 percent or more (250%). Nalbuphine, 6-O-mPEG3-Nalbuphine, 6-O-mPEG6-Nalbuphine, 6-O-mPEG9-Nalbuphine were screened at concentrations of 10, 1, 0.1, 0.01 and 0.001 uM in both agonist and antagonist mode. EC50 or IC50 values were calculated from the dose-response curves as a measure of the agonist or antagonist activity of the test compounds respectively.",CHEMBL3886551,IC50,COCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL3947626,CHEMBL233,Mu opioid receptor,IC50,=,284.0,nM,CHEMBL3888042,B,"GTPyS binding assay: Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addition of SPA beads for another 60 minutes at 30° C. The reaction is initiated by 0.3 nM [35S]GTP gamma S for an additional 30 minutes incubation period. Test compound-induced increase of [35S]GTP gamma S binding by 50 percent or more (250%) relative to the receptor subtype-specific agonist response indicates possible opiate receptor agonist activity. 0.1 uM DPDPE, 1 uM U-69593 and 1 uM DAMGO were used as the specific agonists for the delta, kappa and mu opioid receptors respectively. Opioid receptor antagonist activity was measured using inhibition of agonist-induced increase of [35S]GTP gammaS binding response by 50 percent or more (250%). Nalbuphine, 6-O-mPEG3-Nalbuphine, 6-O-mPEG6-Nalbuphine, 6-O-mPEG9-Nalbuphine were screened at concentrations of 10, 1, 0.1, 0.01 and 0.001 uM in both agonist and antagonist mode. EC50 or IC50 values were calculated from the dose-response curves as a measure of the agonist or antagonist activity of the test compounds respectively.",CHEMBL3886551,IC50,COCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL3919846,CHEMBL233,Mu opioid receptor,IC50,=,1010.0,nM,CHEMBL3888042,B,"GTPyS binding assay: Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addition of SPA beads for another 60 minutes at 30° C. The reaction is initiated by 0.3 nM [35S]GTP gamma S for an additional 30 minutes incubation period. Test compound-induced increase of [35S]GTP gamma S binding by 50 percent or more (250%) relative to the receptor subtype-specific agonist response indicates possible opiate receptor agonist activity. 0.1 uM DPDPE, 1 uM U-69593 and 1 uM DAMGO were used as the specific agonists for the delta, kappa and mu opioid receptors respectively. Opioid receptor antagonist activity was measured using inhibition of agonist-induced increase of [35S]GTP gammaS binding response by 50 percent or more (250%). Nalbuphine, 6-O-mPEG3-Nalbuphine, 6-O-mPEG6-Nalbuphine, 6-O-mPEG9-Nalbuphine were screened at concentrations of 10, 1, 0.1, 0.01 and 0.001 uM in both agonist and antagonist mode. EC50 or IC50 values were calculated from the dose-response curves as a measure of the agonist or antagonist activity of the test compounds respectively.",CHEMBL3886551,IC50,COCCOCCOCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL4128926,CHEMBL233,Mu opioid receptor,IC50,=,1.1,nM,CHEMBL4121496,B,Displacement of [3H]DAMGO from human recombinant mu receptor after 120 mins by scintillation counting analysis,CHEMBL4118122,IC50,CC(C)(C)NS(=O)(=O)c1ccc(-c2sc(C(=O)N[C@H]3C[C@H](C(=O)O)C3)nc2CC2CCCCC2)c2ccccc12
CHEMBL278789,CHEMBL233,Mu opioid receptor,IC50,=,2.4,nM,CHEMBL4136384,B,Binding affinity to Mu-type opioid receptor (unknown origin),CHEMBL4130566,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
CHEMBL4164328,CHEMBL233,Mu opioid receptor,IC50,=,79.43,nM,CHEMBL4137281,B,Agonist activity at mu1-opioid receptor (unknown origin),CHEMBL4130628,IC50,CN(C)CCNC(=O)[C@H]1c2ccccc2C[C@@H]1NC(=O)c1cc2ccccc2[nH]1
CHEMBL3091687,CHEMBL233,Mu opioid receptor,IC50,=,14900.0,nM,CHEMBL4149807,B,Inhibition of mu opioid receptor (unknown origin),CHEMBL4145594,IC50,NCCCCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21
CHEMBL4174290,CHEMBL233,Mu opioid receptor,IC50,=,11300.0,nM,CHEMBL4149807,B,Inhibition of mu opioid receptor (unknown origin),CHEMBL4145594,IC50,c1ccc2c(c1)CN[C@@H](CN(CC[C@H]1CCCNC1)[C@H]1CCCc3cccnc31)C2
CHEMBL4445674,CHEMBL233,Mu opioid receptor,IC50,=,600.0,nM,CHEMBL4337221,B,Inhibition of MOR (unknown origin),CHEMBL4334472,IC50,O=C(Oc1cccc(Cl)c1)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL4437106,CHEMBL233,Mu opioid receptor,IC50,=,60000.0,nM,CHEMBL4360384,B,Inhibition of OPRM (unknown origin),CHEMBL4359817,IC50,CO[C@H](C(=O)Nc1nnc(N[C@@H]2CCN(c3cccnn3)C2)s1)c1ccccc1
CHEMBL4582676,CHEMBL233,Mu opioid receptor,IC50,=,1085000.0,nM,CHEMBL4409295,B,Inhibition of mu opioid receptor (unknown origin),CHEMBL4406853,IC50,CC(C)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)C1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL3183148,CHEMBL233,Mu opioid receptor,IC50,=,4590.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCOC(=O)c1cc(C(=O)OC)c(C)nc1N1CCC(NC2CCCCC2O)CC1
CHEMBL4461337,CHEMBL233,Mu opioid receptor,IC50,=,31.1,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,Cc1cnc(N2CC[C@H](NC3CCCCC3)[C@@H](O)C2)c(-c2nc(C)no2)c1
CHEMBL4526669,CHEMBL233,Mu opioid receptor,IC50,=,176.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,Cc1ccc2nc(N3CCC(NCC(C)C)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4471169,CHEMBL233,Mu opioid receptor,IC50,=,829.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,Cc1ccc2nc(N3CCC(NCC4CC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4464264,CHEMBL233,Mu opioid receptor,IC50,=,4390.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCc1ccc2nc(N3CCC(NCC(C)C)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4540091,CHEMBL233,Mu opioid receptor,IC50,=,2930.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCc1ccc2nc(N3CCC(NCC4CC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4461844,CHEMBL233,Mu opioid receptor,IC50,=,183.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCc1ccc2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4523014,CHEMBL233,Mu opioid receptor,IC50,=,3330.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCc1ccc2nc(N3CCC(N[C@@H](C)C(C)C)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4576339,CHEMBL233,Mu opioid receptor,IC50,=,583.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCc1ccc2nc(N3CCC(N[C@H]4CCCC[C@@H]4O)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4459625,CHEMBL233,Mu opioid receptor,IC50,=,1460.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCc1ccc2nc(N3CCC(N[C@@H]4CCCOC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4572131,CHEMBL233,Mu opioid receptor,IC50,=,1500.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCc1ccc2nc(N3CCC(N[C@H]4CCCOC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4584410,CHEMBL233,Mu opioid receptor,IC50,=,1200.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4443303,CHEMBL233,Mu opioid receptor,IC50,=,6200.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(N[C@H]4CCCOC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4566736,CHEMBL233,Mu opioid receptor,IC50,=,6400.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(N[C@@H]4CCOC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4525666,CHEMBL233,Mu opioid receptor,IC50,=,6500.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(N[C@H]4CCOC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4544914,CHEMBL233,Mu opioid receptor,IC50,=,100.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(N[C@@H]4CCCOC4)CC3)c(-c3nc(C)no3)c(C)c2c1
CHEMBL4440683,CHEMBL233,Mu opioid receptor,IC50,=,400.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(N[C@H]4CCCOC4)CC3)c(-c3nc(C)no3)c(C)c2c1
CHEMBL4456582,CHEMBL233,Mu opioid receptor,IC50,=,1100.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(N[C@@H]4CCOC4)CC3)c(-c3nc(C)no3)c(C)c2c1
CHEMBL4549826,CHEMBL233,Mu opioid receptor,IC50,=,1400.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(N[C@H]4CCOC4)CC3)c(-c3nc(C)no3)c(C)c2c1
CHEMBL4440935,CHEMBL233,Mu opioid receptor,IC50,=,79.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,Cc1ccc2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4583245,CHEMBL233,Mu opioid receptor,IC50,=,1400.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(N[C@@H]4CCCOC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4592045,CHEMBL233,Mu opioid receptor,IC50,=,110.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)c(C)c2c1
CHEMBL3264446,CHEMBL233,Mu opioid receptor,IC50,=,323.0,nM,CHEMBL4424269,B,Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migration preincubated for 30 mins followed by agonist addition and measured after 3 hrs by PathHunter assay,CHEMBL4422661,IC50,COC(=O)c1cc(Br)cnc1N1CC[C@@H](NC2CCCCC2)[C@H](O)C1
CHEMBL58362,CHEMBL233,Mu opioid receptor,IC50,=,34.0,nM,CHEMBL4429824,B,Inhibition of DAMGO-induced beta-arrestin-2 recruitment at mu opioid receptor-1 (unknown origin) expressed in CHO cells preincubated for 30 mins followed by DAMGO addition measured after 90 mins by beta-galactosidase complementation assay,CHEMBL4428076,IC50,CC[C@@H]1CN2CC[C@]3(Nc4cccc(OC)c4C3=O)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL61630,CHEMBL233,Mu opioid receptor,IC50,=,725.0,nM,CHEMBL4429824,B,Inhibition of DAMGO-induced beta-arrestin-2 recruitment at mu opioid receptor-1 (unknown origin) expressed in CHO cells preincubated for 30 mins followed by DAMGO addition measured after 90 mins by beta-galactosidase complementation assay,CHEMBL4428076,IC50,CC[C@@H]1CN2CC[C@@]3(O)C(=Nc4cccc(OC)c43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL506616,CHEMBL233,Mu opioid receptor,IC50,=,260.0,nM,CHEMBL4430532,B,Binding affinity to MOR (unknown origin),CHEMBL4428100,IC50,O=C1N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H]1Cc1c[nH]c2ccccc12
CHEMBL4750644,CHEMBL233,Mu opioid receptor,IC50,=,9549.93,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(C)=O)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O
CHEMBL4754961,CHEMBL233,Mu opioid receptor,IC50,=,645.65,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O
CHEMBL4787539,CHEMBL233,Mu opioid receptor,IC50,=,3548.13,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](C)Cc1c(C)cc(O)cc1C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL4779988,CHEMBL233,Mu opioid receptor,IC50,=,1621.81,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(C)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4754076,CHEMBL233,Mu opioid receptor,IC50,=,1621.81,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](C)Cc1c(C)cc(O)cc1C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4784791,CHEMBL233,Mu opioid receptor,IC50,=,1.82,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4757601,CHEMBL233,Mu opioid receptor,IC50,=,13.18,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL4760958,CHEMBL233,Mu opioid receptor,IC50,=,8.71,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL3091687,CHEMBL233,Mu opioid receptor,IC50,=,15000.0,nM,CHEMBL5048803,B,Inhibition of mu opioid receptor (unknown origin),CHEMBL5046278,IC50,NCCCCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21
CHEMBL5085511,CHEMBL233,Mu opioid receptor,IC50,=,20000.0,nM,CHEMBL5048803,B,Inhibition of mu opioid receptor (unknown origin),CHEMBL5046278,IC50,c1cnc2c(c1)CN[C@@H](CN(CCCCNC1CCOCC1)[C@H]1CCCc3cccnc31)C2
CHEMBL5083458,CHEMBL233,Mu opioid receptor,IC50,=,21000.0,nM,CHEMBL5048803,B,Inhibition of mu opioid receptor (unknown origin),CHEMBL5046278,IC50,c1cnc2c(c1)CN[C@@H](CN(CCCCNC1COC1)[C@H]1CCCc3cccnc31)C2
CHEMBL518924,CHEMBL233,Mu opioid receptor,IC50,=,12000.0,nM,CHEMBL5048803,B,Inhibition of mu opioid receptor (unknown origin),CHEMBL5046278,IC50,NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc21
CHEMBL4848517,CHEMBL233,Mu opioid receptor,IC50,=,2200.0,nM,CHEMBL5127643,B,Inhibition of MOP (unknown origin),CHEMBL5126521,IC50,C=C[C@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4859858,CHEMBL233,Mu opioid receptor,IC50,=,5700.0,nM,CHEMBL5127643,B,Inhibition of MOP (unknown origin),CHEMBL5126521,IC50,CC[C@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4546925,CHEMBL233,Mu opioid receptor,IC50,=,4200.0,nM,CHEMBL5127643,B,Inhibition of MOP (unknown origin),CHEMBL5126521,IC50,CC[C@@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL5191541,CHEMBL233,Mu opioid receptor,IC50,=,1200.0,nM,CHEMBL5152352,B,Binding affinity to MOP (unknown origin),CHEMBL5150013,IC50,CC(C)OCCn1c2cc[nH]c2c(=O)[nH][11c]1=S
CHEMBL349816,CHEMBL233,Mu opioid receptor,IC50,=,36.7,nM,CHEMBL5258058,B,Inhibition of MOR (unknown origin),CHEMBL5257037,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(N)=O
CHEMBL3319610,CHEMBL233,Mu opioid receptor,IC50,=,0.21,nM,CHEMBL5358730,B,Inhibition of mu opioid receptor (unknown origin),CHEMBL5356986,IC50,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cc2ccccc2[nH]1
CHEMBL108417,CHEMBL233,Mu opioid receptor,Ki,=,10620.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,CC(c1ccccc1)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL322717,CHEMBL233,Mu opioid receptor,Ki,=,1591.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,CCCCCCC(c1ccccc1)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL110138,CHEMBL233,Mu opioid receptor,Ki,=,801.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,Cc1ccc(C(c2ccc(C)cc2)N2CC[C@H]2[C@H](N)c2cccc(Cl)c2)cc1
CHEMBL110379,CHEMBL233,Mu opioid receptor,Ki,=,1599.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,CCCCC(c1cccc(F)c1)N1CC[C@H]1[C@H](N)c1cccc(Cl)c1
CHEMBL448155,CHEMBL233,Mu opioid receptor,Ki,=,865.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,COc1ccc([C@H](N)[C@@H]2CCN2C(c2ccccc2)c2ccccc2)cc1
CHEMBL321462,CHEMBL233,Mu opioid receptor,Ki,=,2176.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,N[C@H](c1cccc(Cl)c1)[C@@H]1CCN1C(c1ccc(F)cc1)c1ccc(F)cc1
CHEMBL107288,CHEMBL233,Mu opioid receptor,Ki,=,2248.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,CCCCC(c1ccccc1)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL108893,CHEMBL233,Mu opioid receptor,Ki,=,1815.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,CCCCC(c1ccccc1)N1CC[C@H]1[C@H](N)c1cccc(Cl)c1
CHEMBL327118,CHEMBL233,Mu opioid receptor,Ki,=,7159.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,N[C@H](c1cccc(Cl)c1)[C@@H]1CCN1C(c1cccc(Cl)c1)c1cccc(Cl)c1
CHEMBL108904,CHEMBL233,Mu opioid receptor,Ki,=,586.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,N[C@@H](c1ccc(Cl)cc1)[C@@H]1CCN1C(c1ccccc1)c1ccccc1
CHEMBL324895,CHEMBL233,Mu opioid receptor,Ki,=,5551.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,CCCCC(c1cc(F)cc(F)c1)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL317479,CHEMBL233,Mu opioid receptor,Ki,=,516.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,N[C@H](c1cccc(C(F)(F)F)c1)[C@H]1CCN1C(c1ccccc1)c1ccccc1
CHEMBL320804,CHEMBL233,Mu opioid receptor,Ki,=,7217.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,CCC(c1ccccc1)N1CC[C@H]1[C@H](N)c1cccc(Cl)c1
CHEMBL110933,CHEMBL233,Mu opioid receptor,Ki,=,4130.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,CCCC(c1ccccc1)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL106084,CHEMBL233,Mu opioid receptor,Ki,=,2148.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,CCCCCC(c1ccccc1)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL106190,CHEMBL233,Mu opioid receptor,Ki,=,4705.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,CCCCC(c1cccc(F)c1)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL316961,CHEMBL233,Mu opioid receptor,Ki,=,1967.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,N[C@@H](c1cccc(C(F)(F)F)c1)[C@@H]1CCN1C(c1ccccc1)c1ccccc1
CHEMBL110126,CHEMBL233,Mu opioid receptor,Ki,=,488.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,Cc1ccc([C@H](N)[C@@H]2CCN2C(c2ccccc2)c2ccccc2)cc1
CHEMBL106359,CHEMBL233,Mu opioid receptor,Ki,=,9666.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,CCCCC(CCCC)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL324897,CHEMBL233,Mu opioid receptor,Ki,=,4317.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,N[C@H](c1cccc(Cl)c1)[C@@H]1CCN1C(c1cccc(F)c1)c1cccc(F)c1
CHEMBL108995,CHEMBL233,Mu opioid receptor,Ki,=,1939.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,CCCCCC(c1ccccc1)N1CC[C@H]1[C@H](N)c1cccc(Cl)c1
CHEMBL108900,CHEMBL233,Mu opioid receptor,Ki,=,3975.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,CCCCC(c1cc(F)cc(F)c1)N1CC[C@H]1[C@H](N)c1cccc(Cl)c1
CHEMBL106235,CHEMBL233,Mu opioid receptor,Ki,=,8067.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,CCC(c1ccccc1)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL108894,CHEMBL233,Mu opioid receptor,Ki,=,152.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,Cc1ccc([C@H](N)[C@@H]2CCN2C(c2ccccc2)c2ccccc2)cc1F
CHEMBL419179,CHEMBL233,Mu opioid receptor,Ki,=,4245.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,N[C@@H](c1cc(F)cc(F)c1)[C@@H]1CCN1C(c1ccccc1)c1ccccc1
CHEMBL106155,CHEMBL233,Mu opioid receptor,Ki,=,1494.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,CCCCCCC(c1ccccc1)N1CC[C@H]1[C@H](N)c1cccc(Cl)c1
CHEMBL316961,CHEMBL233,Mu opioid receptor,Ki,=,6088.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,N[C@@H](c1cccc(C(F)(F)F)c1)[C@@H]1CCN1C(c1ccccc1)c1ccccc1
CHEMBL106785,CHEMBL233,Mu opioid receptor,Ki,=,3452.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,N[C@H](c1cccc(Cl)c1)[C@@H]1CCN1C(c1ccc(Cl)cc1)c1ccc(Cl)cc1
CHEMBL320582,CHEMBL233,Mu opioid receptor,Ki,=,2502.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,N[C@H](c1cccc(Cl)c1)[C@@H]1CCN1C(c1ccc(Br)cc1)c1ccc(Br)cc1
CHEMBL324635,CHEMBL233,Mu opioid receptor,Ki,=,1654.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,N[C@@H](c1cccc(Cl)c1)[C@@H]1CCN1C(c1ccccc1)c1ccccc1
CHEMBL106043,CHEMBL233,Mu opioid receptor,Ki,=,5401.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,N[C@@H](c1ccc(Oc2ccccc2)cc1)[C@@H]1CCN1C(c1ccccc1)c1ccccc1
CHEMBL431445,CHEMBL233,Mu opioid receptor,Ki,=,1766.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,N[C@@H](c1cccc(F)c1)[C@@H]1CCN1C(c1ccccc1)c1ccccc1
CHEMBL106366,CHEMBL233,Mu opioid receptor,Ki,=,6015.0,nM,CHEMBL751582,B,Binding affinity at human opioid receptor mu 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.12 nM,CHEMBL1134945,KI,CCCC(c1ccccc1)N1CC[C@H]1[C@H](N)c1cccc(Cl)c1
CHEMBL63563,CHEMBL233,Mu opioid receptor,Ki,=,59.0,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3c2cccn2C)c2ccccc2)cc1
CHEMBL217379,CHEMBL233,Mu opioid receptor,Ki,=,35.4,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL2369408,CHEMBL233,Mu opioid receptor,Ki,=,2750.0,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL1161417,CHEMBL233,Mu opioid receptor,Ki,=,1.6,nM,CHEMBL753391,B,Displacement of [3H]DAMGO from human Opioid receptor mu 1 expressing CHO cells,CHEMBL1145973,KI,Cc1cc(O)cc(C)c1C[C@H](N)[C@H](O)C/C=C/[C@@H](O)[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL1161413,CHEMBL233,Mu opioid receptor,Ki,=,0.24,nM,CHEMBL753391,B,Displacement of [3H]DAMGO from human Opioid receptor mu 1 expressing CHO cells,CHEMBL1145973,KI,Cc1cc(O)cc(C)c1C[C@H](N)[C@H](O)C/C=C/[C@H](O)[C@@H](Cc1ccccc1)C(=O)NCCc1ccccc1
CHEMBL302801,CHEMBL233,Mu opioid receptor,Ki,=,72.0,nM,CHEMBL882430,B,Binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCN(CC)C(=O)c1ccc(/C(=C2\C[C@H]3CC[C@@H](C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL610046,CHEMBL233,Mu opioid receptor,Ki,=,1.4,nM,CHEMBL843459,B,Tested for binding activity against mu opioid receptor using [3H]DAMGO ligand,CHEMBL1127619,KI,O=C1[C@@H](Cc2ccccc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL101519,CHEMBL233,Mu opioid receptor,Ki,=,1.9,nM,CHEMBL843459,B,Tested for binding activity against mu opioid receptor using [3H]DAMGO ligand,CHEMBL1127619,KI,O=C1/C(=C\c2ccccc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL2369407,CHEMBL233,Mu opioid receptor,Ki,=,15500.0,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL413729,CHEMBL233,Mu opioid receptor,Ki,=,5250.0,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL1161415,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL753391,B,Displacement of [3H]DAMGO from human Opioid receptor mu 1 expressing CHO cells,CHEMBL1145973,KI,Cc1cc(O)cc(C)c1C[C@H](N)[C@H](O)C/C=C/[C@H](O)[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL63651,CHEMBL233,Mu opioid receptor,Ki,=,0.26,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(/C(=C2\C[C@H]3CC[C@@H](C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL65259,CHEMBL233,Mu opioid receptor,Ki,=,2.52,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3CC=C(C)C)c2cccc(O)c2)cc1
CHEMBL67326,CHEMBL233,Mu opioid receptor,Ki,=,13.48,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3Cc2cccs2)c2ccc(OC)cc2)cc1
CHEMBL1161429,CHEMBL233,Mu opioid receptor,Ki,=,0.37,nM,CHEMBL753391,B,Displacement of [3H]DAMGO from human Opioid receptor mu 1 expressing CHO cells,CHEMBL1145973,KI,Cc1cc(O)cc(C)c1C[C@H](N)[C@@H](O)C/C=C/[C@@H](O)[C@@H](Cc1ccccc1)C(=O)NCCc1ccccc1
CHEMBL304214,CHEMBL233,Mu opioid receptor,Ki,=,57.74,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3Cc2ccccc2Cl)c2cccc(OC)c2)cc1
CHEMBL68342,CHEMBL233,Mu opioid receptor,Ki,=,10.52,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,C=CCN1[C@@H]2CC[C@H]1C/C(=C(/c1ccccc1)c1ccc(C(=O)NCC)cc1)C2
CHEMBL610550,CHEMBL233,Mu opioid receptor,Ki,=,0.19,nM,CHEMBL843459,B,Tested for binding activity against mu opioid receptor using [3H]DAMGO ligand,CHEMBL1127619,KI,Oc1ccc2c3c1O[C@H]1[C@@H](Nc4ccccc4)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL2369394,CHEMBL233,Mu opioid receptor,Ki,=,19500.0,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O
CHEMBL279638,CHEMBL233,Mu opioid receptor,Ki,=,122.0,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3Cc2ccccc2Cl)c2ccc(OC)cc2)cc1
CHEMBL306463,CHEMBL233,Mu opioid receptor,Ki,=,61.0,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3Cc2[nH]cnc2C)c2ccccc2)cc1
CHEMBL292332,CHEMBL233,Mu opioid receptor,Ki,=,76.0,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3CCO)c2ccccc2)cc1
CHEMBL1161412,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL753391,B,Displacement of [3H]DAMGO from human Opioid receptor mu 1 expressing CHO cells,CHEMBL1145973,KI,Cc1cc(O)cc(C)c1C[C@H](N)[C@@H](O)C/C=C/[C@@H](O)[C@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL2369393,CHEMBL233,Mu opioid receptor,Ki,=,15100.0,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL269483,CHEMBL233,Mu opioid receptor,Ki,=,11.9,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O
CHEMBL1161419,CHEMBL233,Mu opioid receptor,Ki,=,0.69,nM,CHEMBL753391,B,Displacement of [3H]DAMGO from human Opioid receptor mu 1 expressing CHO cells,CHEMBL1145973,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)Cc1ccccc1
CHEMBL1161414,CHEMBL233,Mu opioid receptor,Ki,=,0.17,nM,CHEMBL753391,B,Displacement of [3H]DAMGO from human Opioid receptor mu 1 expressing CHO cells,CHEMBL1145973,KI,Cc1cc(O)cc(C)c1C[C@H](N)[C@@H](O)C/C=C/[C@H](O)[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL307973,CHEMBL233,Mu opioid receptor,Ki,=,1.01,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,O=C(NC1CC1)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL303148,CHEMBL233,Mu opioid receptor,Ki,=,717.0,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,O=C(NC1CCCCC1)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL303875,CHEMBL233,Mu opioid receptor,Ki,=,13.8,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,C=CCN1C2CCC1CC(=C(c1ccc(C(=O)NCC)cc1)c1cccc(OC)c1)C2
CHEMBL304466,CHEMBL233,Mu opioid receptor,Ki,=,4242.0,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,O=C(Nc1ccccc1)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL416680,CHEMBL233,Mu opioid receptor,Ki,=,101.0,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3Cc2c[nH]cn2)c2ccccc2)cc1
CHEMBL302142,CHEMBL233,Mu opioid receptor,Ki,=,19.09,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,C=CCN1[C@@H]2CC[C@H]1C/C(=C(\c1ccccc1)c1ccc(C(=O)NCC)cc1)C2
CHEMBL1161425,CHEMBL233,Mu opioid receptor,Ki,=,0.45,nM,CHEMBL753391,B,Displacement of [3H]DAMGO from human Opioid receptor mu 1 expressing CHO cells,CHEMBL1145973,KI,Cc1cc(O)cc(C)c1C[C@H](N)[C@@H](O)C/C=C/[C@H](O)[C@@H](Cc1ccccc1)C(=O)O[C@@H](Cc1ccccc1)C(N)=O
CHEMBL67289,CHEMBL233,Mu opioid receptor,Ki,=,0.654,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2cccc(OC)c2)cc1
CHEMBL1161427,CHEMBL233,Mu opioid receptor,Ki,=,0.16,nM,CHEMBL753391,B,Displacement of [3H]DAMGO from human Opioid receptor mu 1 expressing CHO cells,CHEMBL1145973,KI,Cc1cc(O)cc(C)c1C[C@H](N)[C@@H](O)C/C=C/[C@H](O)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)Cc1ccccc1
CHEMBL66800,CHEMBL233,Mu opioid receptor,Ki,=,84.0,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2c[nH]c3ccccc23)c2ccccc2)cc1
CHEMBL63912,CHEMBL233,Mu opioid receptor,Ki,=,265.0,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3)c2ccc(O)cc2)cc1
CHEMBL2369366,CHEMBL233,Mu opioid receptor,Ki,=,1660.0,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL433500,CHEMBL233,Mu opioid receptor,Ki,=,14.98,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3Cc2ccccc2Cl)c2cccc(O)c2)cc1
CHEMBL252172,CHEMBL233,Mu opioid receptor,Ki,=,13.3,nM,CHEMBL843459,B,Tested for binding activity against mu opioid receptor using [3H]DAMGO ligand,CHEMBL1127619,KI,O=C1/C(=C/c2ccccc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL67144,CHEMBL233,Mu opioid receptor,Ki,=,163.0,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,COCCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL63309,CHEMBL233,Mu opioid receptor,Ki,=,0.14,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CNC(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL610293,CHEMBL233,Mu opioid receptor,Ki,=,1.4,nM,CHEMBL843459,B,Tested for binding activity against mu opioid receptor using [3H]DAMGO ligand,CHEMBL1127619,KI,O=C1[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)CC12Cc1ccccc1C2
CHEMBL67428,CHEMBL233,Mu opioid receptor,Ki,=,53.0,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,O=C(Nc1nccs1)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL67735,CHEMBL233,Mu opioid receptor,Ki,=,2.99,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,O=C(NCCF)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL67894,CHEMBL233,Mu opioid receptor,Ki,=,4.8,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3CCCc2ccccc2)c2ccccc2)cc1
CHEMBL67088,CHEMBL233,Mu opioid receptor,Ki,=,93.0,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3CCOc2ccccc2)c2ccccc2)cc1
CHEMBL567175,CHEMBL233,Mu opioid receptor,Ki,=,14.4,nM,CHEMBL843459,B,Tested for binding activity against mu opioid receptor using [3H]DAMGO ligand,CHEMBL1127619,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL1161416,CHEMBL233,Mu opioid receptor,Ki,=,0.42,nM,CHEMBL753391,B,Displacement of [3H]DAMGO from human Opioid receptor mu 1 expressing CHO cells,CHEMBL1145973,KI,Cc1cc(O)cc(C)c1C[C@H](N)[C@@H](O)C/C=C/[C@@H](O)[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL66955,CHEMBL233,Mu opioid receptor,Ki,=,39.6,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,NC(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL2369391,CHEMBL233,Mu opioid receptor,Ki,=,12600.0,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O
CHEMBL68412,CHEMBL233,Mu opioid receptor,Ki,=,0.664,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3Cc2cccs2)c2cccc(O)c2)cc1
CHEMBL67893,CHEMBL233,Mu opioid receptor,Ki,=,42.46,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(/C(=C2/C[C@H]3CC[C@@H](C2)N3C)c2ccccc2)cc1
CHEMBL2369395,CHEMBL233,Mu opioid receptor,Ki,=,16200.0,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL66954,CHEMBL233,Mu opioid receptor,Ki,=,7.16,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(/C(=C2/C[C@H]3CC[C@@H](C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL610290,CHEMBL233,Mu opioid receptor,Ki,=,5.2,nM,CHEMBL843459,B,Tested for binding activity against mu opioid receptor using [3H]DAMGO ligand,CHEMBL1127619,KI,Oc1ccc2c3c1O[C@H]1C4(CC[C@@]5(O)[C@@H](C2)N(CC2CC2)CC[C@]315)Oc1ccccc1O4
CHEMBL2369390,CHEMBL233,Mu opioid receptor,Ki,=,6030.0,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O
CHEMBL291357,CHEMBL233,Mu opioid receptor,Ki,=,17.0,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3Cc2ccccn2)c2ccccc2)cc1
CHEMBL64933,CHEMBL233,Mu opioid receptor,Ki,=,96.0,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3)c2cccc(OC)c2)cc1
CHEMBL419621,CHEMBL233,Mu opioid receptor,Ki,=,0.222,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2cccc(O)c2)cc1
CHEMBL67615,CHEMBL233,Mu opioid receptor,Ki,=,1.6,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL63232,CHEMBL233,Mu opioid receptor,Ki,=,8.72,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3Cc2ccccc2Cl)c2ccc(O)cc2)cc1
CHEMBL8234,CHEMBL233,Mu opioid receptor,Ki,=,55.0,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL1161430,CHEMBL233,Mu opioid receptor,Ki,=,0.29,nM,CHEMBL753391,B,Displacement of [3H]DAMGO from human Opioid receptor mu 1 expressing CHO cells,CHEMBL1145973,KI,Cc1cc(O)cc(C)c1C[C@H](N)[C@@H](O)C/C=C/[C@H](O)[C@@H](Cc1ccccc1)C(=O)NCCc1ccccc1
CHEMBL1161428,CHEMBL233,Mu opioid receptor,Ki,=,0.64,nM,CHEMBL753391,B,Displacement of [3H]DAMGO from human Opioid receptor mu 1 expressing CHO cells,CHEMBL1145973,KI,Cc1cc(O)cc(C)c1C[C@H](N)[C@@H](O)C/C=C/[C@@H](O)[C@H](Cc1ccccc1)C(=O)NCCc1ccccc1
CHEMBL2369389,CHEMBL233,Mu opioid receptor,Ki,=,6200.0,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(N)=O
CHEMBL1161424,CHEMBL233,Mu opioid receptor,Ki,=,0.24,nM,CHEMBL753391,B,Displacement of [3H]DAMGO from human Opioid receptor mu 1 expressing CHO cells,CHEMBL1145973,KI,Cc1cc(O)cc(C)c1C[C@H](N)[C@@H](O)C/C=C/[C@H](O)[C@@H](Cc1ccccc1)C(=O)OCCc1ccccc1
CHEMBL67781,CHEMBL233,Mu opioid receptor,Ki,=,608.0,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CC(C)(C)NC(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL216640,CHEMBL233,Mu opioid receptor,Ki,=,5.62,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL265813,CHEMBL233,Mu opioid receptor,Ki,=,8.0,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL573214,CHEMBL233,Mu opioid receptor,Ki,=,79.4,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL68113,CHEMBL233,Mu opioid receptor,Ki,=,317.0,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCN(CC)C(=O)c1ccc(/C(=C2/C[C@H]3CC[C@@H](C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL67240,CHEMBL233,Mu opioid receptor,Ki,=,2.04,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3CC=C(C)C)c2cccc(OC)c2)cc1
CHEMBL434018,CHEMBL233,Mu opioid receptor,Ki,=,9.58,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,C=CCN1C2CCC1CC(=C(c1ccc(C(=O)NCC)cc1)c1cccc(O)c1)C2
CHEMBL67790,CHEMBL233,Mu opioid receptor,Ki,=,6.77,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3Cc2cccs2)c2ccc(O)cc2)cc1
CHEMBL303381,CHEMBL233,Mu opioid receptor,Ki,=,21.7,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccc(O)cc2)cc1
CHEMBL1161422,CHEMBL233,Mu opioid receptor,Ki,=,0.72,nM,CHEMBL753391,B,Displacement of [3H]DAMGO from human Opioid receptor mu 1 expressing CHO cells,CHEMBL1145973,KI,Cc1cc(O)cc(C)c1C[C@H](N)[C@H](O)C/C=C/[C@@H](O)[C@@H](Cc1ccccc1)C(=O)NCCc1ccccc1
CHEMBL67123,CHEMBL233,Mu opioid receptor,Ki,=,6.1,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccc(OC)cc2)cc1
CHEMBL68341,CHEMBL233,Mu opioid receptor,Ki,=,304.0,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(/C(=C2\C[C@H]3CC[C@@H](C2)N3C)c2ccccc2)cc1
CHEMBL610292,CHEMBL233,Mu opioid receptor,Ki,=,1.4,nM,CHEMBL843459,B,Tested for binding activity against mu opioid receptor using [3H]DAMGO ligand,CHEMBL1127619,KI,Oc1ccc2c3c1O[C@H]1[C@H](Nc4ccccc4)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL2369365,CHEMBL233,Mu opioid receptor,Ki,=,2340.0,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(N)=O
CHEMBL68358,CHEMBL233,Mu opioid receptor,Ki,=,21.7,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCCCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL307525,CHEMBL233,Mu opioid receptor,Ki,=,74.73,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(/C(=C2/C[C@H]3CC[C@@H](C2)N3)c2ccccc2)cc1
CHEMBL407832,CHEMBL233,Mu opioid receptor,Ki,=,23.8,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
CHEMBL63188,CHEMBL233,Mu opioid receptor,Ki,=,40.6,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,3.63,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL2369370,CHEMBL233,Mu opioid receptor,Ki,=,3100.0,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O
CHEMBL66741,CHEMBL233,Mu opioid receptor,Ki,=,3.79,nM,CHEMBL756359,B,In vitro binding affinity towards opioid receptor mu 1,CHEMBL1147544,KI,CCNC(=O)c1ccc(C(=C2CC3CCC(C2)N3Cc2cccs2)c2cccc(OC)c2)cc1
CHEMBL293465,CHEMBL233,Mu opioid receptor,Ki,=,38.0,nM,CHEMBL754712,B,In vitro binding affinity to human Opioid receptor mu 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
CHEMBL1161423,CHEMBL233,Mu opioid receptor,Ki,=,0.44,nM,CHEMBL753391,B,Displacement of [3H]DAMGO from human Opioid receptor mu 1 expressing CHO cells,CHEMBL1145973,KI,Cc1cc(O)cc(C)c1C[C@H](N)[C@@H](O)C/C=C/[C@H](O)[C@@H](Cc1ccccc1)C(=O)O[C@H](CO)Cc1ccccc1
CHEMBL110816,CHEMBL233,Mu opioid receptor,Ki,=,22.97,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,CCC(=O)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL326875,CHEMBL233,Mu opioid receptor,Ki,=,219.16,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,CCCCC(=N)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL573214,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL107655,CHEMBL233,Mu opioid receptor,Ki,=,4.8,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,CCCCNC(=O)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL286411,CHEMBL233,Mu opioid receptor,Ki,=,959.0,nM,CHEMBL753236,B,Binding affinity towards opioid receptor mu 1 using [3H]- diprenophine as radioligand from membrane preparations of recombinant HEK293 cells,CHEMBL1147615,KI,CC(C)C1CCC(N2CCC(N3C(=O)N[C@@H]4CCCC[C@H]43)CC2)CC1
CHEMBL283301,CHEMBL233,Mu opioid receptor,Ki,=,199.0,nM,CHEMBL753236,B,Binding affinity towards opioid receptor mu 1 using [3H]- diprenophine as radioligand from membrane preparations of recombinant HEK293 cells,CHEMBL1147615,KI,CCN1C(=O)N(C2CCN(Cc3ccc4ccccc4c3)CC2)[C@@H]2CCCC[C@H]21
CHEMBL323987,CHEMBL233,Mu opioid receptor,Ki,=,26.35,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,CCC(=N)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL324644,CHEMBL233,Mu opioid receptor,Ki,=,31.59,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,CCCCC(=O)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL108938,CHEMBL233,Mu opioid receptor,Ki,=,40.79,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,CCCC(=N)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL106758,CHEMBL233,Mu opioid receptor,Ki,=,13.48,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,CCC/N=C(\N)Cc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL2113273,CHEMBL233,Mu opioid receptor,Ki,=,279.0,nM,CHEMBL753236,B,Binding affinity towards opioid receptor mu 1 using [3H]- diprenophine as radioligand from membrane preparations of recombinant HEK293 cells,CHEMBL1147615,KI,CCN1C(=O)N(C2CCN(C3CCC4CCCCC4C3)CC2)[C@@H]2CCCC[C@H]21
CHEMBL27018,CHEMBL233,Mu opioid receptor,Ki,=,716.0,nM,CHEMBL753236,B,Binding affinity towards opioid receptor mu 1 using [3H]- diprenophine as radioligand from membrane preparations of recombinant HEK293 cells,CHEMBL1147615,KI,CCN1C(=O)N(C2CCN(Cc3ccccc3)CC2)[C@@H]2CCCC[C@H]21
CHEMBL323726,CHEMBL233,Mu opioid receptor,Ki,=,47.4,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,CC(C)CC(=N)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL323398,CHEMBL233,Mu opioid receptor,Ki,=,13.58,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,CCCCCCNC(=O)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL2113262,CHEMBL233,Mu opioid receptor,Ki,=,208.0,nM,CHEMBL753236,B,Binding affinity towards opioid receptor mu 1 using [3H]- diprenophine as radioligand from membrane preparations of recombinant HEK293 cells,CHEMBL1147615,KI,O=C1N[C@@H]2CCCC[C@H]2N1C1CCN(C2CCC3CCCCC3C2)CC1
CHEMBL27539,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL753236,B,Binding affinity towards opioid receptor mu 1 using [3H]- diprenophine as radioligand from membrane preparations of recombinant HEK293 cells,CHEMBL1147615,KI,O=C1N[C@@H]2CCCC[C@H]2N1C1CCN(CCC(c2ccccc2)c2ccccc2)CC1
CHEMBL432403,CHEMBL233,Mu opioid receptor,Ki,=,56.62,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,CCCCCCC/N=C(\N)Cc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL109009,CHEMBL233,Mu opioid receptor,Ki,=,37.05,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,O=C(NCCCCc1ccccc1)c1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL284217,CHEMBL233,Mu opioid receptor,Ki,=,1402.0,nM,CHEMBL753236,B,Binding affinity towards opioid receptor mu 1 using [3H]- diprenophine as radioligand from membrane preparations of recombinant HEK293 cells,CHEMBL1147615,KI,O=C1N[C@@H]2CCCC[C@H]2N1C1CCN(C2CCCCCCC2)CC1
CHEMBL91683,CHEMBL233,Mu opioid receptor,Ki,=,22.32,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,CC(=N)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL108024,CHEMBL233,Mu opioid receptor,Ki,=,61.91,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,CCCCCCCNC(=O)c1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL108083,CHEMBL233,Mu opioid receptor,Ki,=,23.53,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,O=C(NCCc1ccccc1)c1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL280778,CHEMBL233,Mu opioid receptor,Ki,=,1071.0,nM,CHEMBL753236,B,Binding affinity towards opioid receptor mu 1 using [3H]- diprenophine as radioligand from membrane preparations of recombinant HEK293 cells,CHEMBL1147615,KI,O=C1N[C@@H]2CCCC[C@H]2N1C1CCN(CC2CCCCCCC2)CC1
CHEMBL281322,CHEMBL233,Mu opioid receptor,Ki,=,395.0,nM,CHEMBL753236,B,Binding affinity towards opioid receptor mu 1 using [3H]- diprenophine as radioligand from membrane preparations of recombinant HEK293 cells,CHEMBL1147615,KI,CCN1C(=O)N(C2CCN(C(C)CCC(C)C)CC2)[C@@H]2CCCC[C@H]21
CHEMBL29571,CHEMBL233,Mu opioid receptor,Ki,=,1237.0,nM,CHEMBL753236,B,Binding affinity towards opioid receptor mu 1 using [3H]- diprenophine as radioligand from membrane preparations of recombinant HEK293 cells,CHEMBL1147615,KI,O=C1N[C@@H]2CCCC[C@H]2N1C1CCN(Cc2ccc3ccccc3c2)CC1
CHEMBL110487,CHEMBL233,Mu opioid receptor,Ki,=,30.97,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,CCCC(=O)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL110894,CHEMBL233,Mu opioid receptor,Ki,=,25.29,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,CCCCC/N=C(\N)Cc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL282376,CHEMBL233,Mu opioid receptor,Ki,=,2165.0,nM,CHEMBL753236,B,Binding affinity towards opioid receptor mu 1 using [3H]- diprenophine as radioligand from membrane preparations of recombinant HEK293 cells,CHEMBL1147615,KI,CCCC1CCC(N2CCC(N3C(=O)N(CC)[C@@H]4CCCC[C@H]43)CC2)CC1
CHEMBL418197,CHEMBL233,Mu opioid receptor,Ki,=,267.0,nM,CHEMBL753236,B,Binding affinity towards opioid receptor mu 1 using [3H]- diprenophine as radioligand from membrane preparations of recombinant HEK293 cells,CHEMBL1147615,KI,CCN1C(=O)N(C2CCN(CCC(c3ccccc3)c3ccccc3)CC2)[C@@H]2CCCC[C@H]21
CHEMBL431060,CHEMBL233,Mu opioid receptor,Ki,=,4.64,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,COc1ccc(CNC(=O)c2ccc3[nH]c4c(c3c2)C[C@@]2(O)C3Cc5ccc(O)c6c5[C@@]2(CCN3CC2CC2)[C@H]4O6)cc1
CHEMBL111530,CHEMBL233,Mu opioid receptor,Ki,=,43.95,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,O=C(NCc1ccccc1)c1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL26909,CHEMBL233,Mu opioid receptor,Ki,=,426.0,nM,CHEMBL753236,B,Binding affinity towards opioid receptor mu 1 using [3H]- diprenophine as radioligand from membrane preparations of recombinant HEK293 cells,CHEMBL1147615,KI,CC(C)CCC(C)N1CCC(N2C(=O)N[C@@H]3CCCC[C@H]32)CC1
CHEMBL26681,CHEMBL233,Mu opioid receptor,Ki,=,435.0,nM,CHEMBL753236,B,Binding affinity towards opioid receptor mu 1 using [3H]- diprenophine as radioligand from membrane preparations of recombinant HEK293 cells,CHEMBL1147615,KI,CCCC1CCC(N2CCC(N3C(=O)N[C@@H]4CCCC[C@H]43)CC2)CC1
CHEMBL321408,CHEMBL233,Mu opioid receptor,Ki,=,37.64,nM,CHEMBL751571,B,Ability to displace [3H]DAMGO from human recombinant Opioid receptor mu 1 in CHO cells,CHEMBL1145106,KI,CCNC(=O)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL26464,CHEMBL233,Mu opioid receptor,Ki,=,909.0,nM,CHEMBL753236,B,Binding affinity towards opioid receptor mu 1 using [3H]- diprenophine as radioligand from membrane preparations of recombinant HEK293 cells,CHEMBL1147615,KI,CCN1C(=O)N(C2CCN(C3CCCCCCC3)CC2)[C@@H]2CCCC[C@H]21
CHEMBL282195,CHEMBL233,Mu opioid receptor,Ki,=,421.0,nM,CHEMBL753236,B,Binding affinity towards opioid receptor mu 1 using [3H]- diprenophine as radioligand from membrane preparations of recombinant HEK293 cells,CHEMBL1147615,KI,CCN1C(=O)N(C2CCN(C3CCC(C(C)C)CC3)CC2)[C@@H]2CCCC[C@H]21
CHEMBL169552,CHEMBL233,Mu opioid receptor,Ki,=,0.6,nM,CHEMBL841684,B,Binding affinity towards human mu opioid receptor in CHO cells using [3H]- DAMGO as radioligand,CHEMBL1132136,KI,CO[C@@]12CCC3(C[C@H]1[C@@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4C3(CCN1C)[C@H]2O5
CHEMBL29953,CHEMBL233,Mu opioid receptor,Ki,=,448.0,nM,CHEMBL753236,B,Binding affinity towards opioid receptor mu 1 using [3H]- diprenophine as radioligand from membrane preparations of recombinant HEK293 cells,CHEMBL1147615,KI,CCN1C(=O)N(C2CCN(CC3CCCCCCC3)CC2)[C@@H]2CCCC[C@H]21
CHEMBL117319,CHEMBL233,Mu opioid receptor,Ki,=,943.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCN1CC[C@@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL117183,CHEMBL233,Mu opioid receptor,Ki,=,15.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL114203,CHEMBL233,Mu opioid receptor,Ki,=,54.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,C[C@H]1C2Cc3ccc(O)cc3[C@@]1(C)CCN2
CHEMBL114123,CHEMBL233,Mu opioid receptor,Ki,=,39.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL114358,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL324505,CHEMBL233,Mu opioid receptor,Ki,=,756.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL115998,CHEMBL233,Mu opioid receptor,Ki,=,259.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL325052,CHEMBL233,Mu opioid receptor,Ki,=,4186.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCN1CC[C@@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL116643,CHEMBL233,Mu opioid receptor,Ki,=,318.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCN1CC[C@@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL113703,CHEMBL233,Mu opioid receptor,Ki,=,3.4,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL115917,CHEMBL233,Mu opioid receptor,Ki,=,4.2,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,C[C@H]1C2Cc3ccc(O)cc3[C@@]1(C)CCN2C
CHEMBL326548,CHEMBL233,Mu opioid receptor,Ki,=,183.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL116738,CHEMBL233,Mu opioid receptor,Ki,=,59.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL326103,CHEMBL233,Mu opioid receptor,Ki,=,16.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL324392,CHEMBL233,Mu opioid receptor,Ki,=,776.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCN1CC[C@@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL114163,CHEMBL233,Mu opioid receptor,Ki,=,160.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL117321,CHEMBL233,Mu opioid receptor,Ki,=,126.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL117128,CHEMBL233,Mu opioid receptor,Ki,=,1378.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,C[C@@H]1C2Cc3ccc(O)cc3[C@]1(C)CCN2C
CHEMBL116354,CHEMBL233,Mu opioid receptor,Ki,=,997.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL326571,CHEMBL233,Mu opioid receptor,Ki,=,1241.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCN1CC[C@@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL117379,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL326370,CHEMBL233,Mu opioid receptor,Ki,=,1721.0,nM,CHEMBL746681,B,Inhibition against mu receptor from displacement studies using 0.5 nM [3H]-DAMGO in rhesus monkey cortex membrane,CHEMBL1127360,KI,C[C@@H]1C2Cc3ccc(O)cc3[C@]1(C)CCN2
CHEMBL2112373,CHEMBL233,Mu opioid receptor,Ki,=,5.69,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,N=C(N)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610799,CHEMBL233,Mu opioid receptor,Ki,=,22.44,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,CCCN/C(=N\CC1CC1)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610040,CHEMBL233,Mu opioid receptor,Ki,=,14.16,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,N/C(=N/Cc1cccc(O)c1)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610032,CHEMBL233,Mu opioid receptor,Ki,=,26.28,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,N/C(=N/Cc1ccc([N+](=O)[O-])cc1)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610034,CHEMBL233,Mu opioid receptor,Ki,=,18.27,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,CCCC/N=C(\NCCCC)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL2112374,CHEMBL233,Mu opioid receptor,Ki,=,36.9,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,N=C(N)NCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610038,CHEMBL233,Mu opioid receptor,Ki,=,7.78,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,N/C(=N\CCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5)NCc1ccc(N)cc1
CHEMBL610033,CHEMBL233,Mu opioid receptor,Ki,=,9.21,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,N/C(=N\CCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5)NCc1ccc([N+](=O)[O-])cc1
CHEMBL610037,CHEMBL233,Mu opioid receptor,Ki,=,17.73,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccc(N/C(=N/CC6CC6)NCc6ccccc6)cc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL610036,CHEMBL233,Mu opioid receptor,Ki,=,14.67,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,N/C(=N/Cc1ccc(O)cc1)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610044,CHEMBL233,Mu opioid receptor,Ki,=,7.89,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,N/C(=N/Cc1ccc(N)cc1)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL573214,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL610041,CHEMBL233,Mu opioid receptor,Ki,=,7.74,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,N/C(=N\CCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5)NCc1ccc(Cl)cc1
CHEMBL610039,CHEMBL233,Mu opioid receptor,Ki,=,7.89,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,CCCC/N=C(\NCCCC)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610043,CHEMBL233,Mu opioid receptor,Ki,=,10.47,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,N/C(=N/Cc1ccccc1)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610035,CHEMBL233,Mu opioid receptor,Ki,=,9.83,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,CCC/N=C(\NCCC)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610042,CHEMBL233,Mu opioid receptor,Ki,=,3.54,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,N/C(=N\CCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5)NCc1ccccc1
CHEMBL610045,CHEMBL233,Mu opioid receptor,Ki,=,29.78,nM,CHEMBL753390,B,Binding affinity against cloned human Opioid receptor mu 1 transfected into chinese hamster ovary cells using [3H]DAMGO as radioligand,CHEMBL1145928,KI,N/C(=N/Cc1ccc(Cl)cc1)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL326171,CHEMBL233,Mu opioid receptor,Ki,=,0.29,nM,CHEMBL744604,B,Compound was tested for binding affinity against mu opioid receptor binding assay,CHEMBL1131909,KI,CC1(C)SSC[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H]1C(N)=O
CHEMBL324390,CHEMBL233,Mu opioid receptor,Ki,=,13.6,nM,CHEMBL744604,B,Compound was tested for binding affinity against mu opioid receptor binding assay,CHEMBL1131909,KI,CC1(C)SSC[C@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H]1C(N)=O
CHEMBL2111836,CHEMBL233,Mu opioid receptor,Ki,=,9.2,nM,CHEMBL751580,B,Binding affinity determined against Opioid receptor mu 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2)=NC[C@@H]1CCNC(=O)c1cccs1
CHEMBL384227,CHEMBL233,Mu opioid receptor,Ki,=,1740.0,nM,CHEMBL753234,B,Binding affinity towards Opioid receptor mu 1 using [3H]DAMGO as radioligand,CHEMBL1135684,KI,CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL544956,CHEMBL233,Mu opioid receptor,Ki,=,1400.0,nM,CHEMBL756355,B,Binding affinity towards Opioid receptor mu 1 was determined,CHEMBL1124535,KI,CN(C(=O)Cc1csc2ccccc12)[C@@H]1CCCC[C@H]1N1CCCC1.Cl
CHEMBL362991,CHEMBL233,Mu opioid receptor,Ki,=,150.0,nM,CHEMBL756580,B,Binding affinity towards non-selective opiate receptor,CHEMBL1136639,KI,NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL541804,CHEMBL233,Mu opioid receptor,Ki,=,560.0,nM,CHEMBL755058,B,Binding affinity towards opioid receptor mu was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2sccc12)[C@@H]1CCCC[C@H]1N1CCC(CO)C1.Cl
CHEMBL216696,CHEMBL233,Mu opioid receptor,Ki,=,1.97,nM,CHEMBL753234,B,Binding affinity towards Opioid receptor mu 1 using [3H]DAMGO as radioligand,CHEMBL1135684,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL567175,CHEMBL233,Mu opioid receptor,Ki,=,7.2,nM,CHEMBL751580,B,Binding affinity determined against Opioid receptor mu 1 from human cloned receptor,CHEMBL1144935,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL555100,CHEMBL233,Mu opioid receptor,Ki,=,650.0,nM,CHEMBL755058,B,Binding affinity towards opioid receptor mu was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2ccsc12)[C@@H]1CCCC[C@H]1N1CCCC1.Cl
CHEMBL124015,CHEMBL233,Mu opioid receptor,Ki,=,26.3,nM,CHEMBL751580,B,Binding affinity determined against Opioid receptor mu 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccc(Cl)cc2C(c2ccccc2)=NCC1CCNC(=O)c1cccs1
CHEMBL545182,CHEMBL233,Mu opioid receptor,Ki,=,4800.0,nM,CHEMBL756357,B,Binding affinity towards mu opioid receptor was determined,CHEMBL1124535,KI,Cl.O=C(Cc1cccc2sccc12)N[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL2111838,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL751580,B,Binding affinity determined against Opioid receptor mu 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2F)=NC[C@@H]1CCNC(=O)c1ccsc1
CHEMBL536550,CHEMBL233,Mu opioid receptor,Ki,=,475.0,nM,CHEMBL755058,B,Binding affinity towards opioid receptor mu was determined,CHEMBL1124535,KI,CN(C(=O)Cc1ccc2sccc2c1)[C@@H]1CCCC[C@H]1N1CCCC1.Cl
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,3.0,nM,CHEMBL751580,B,Binding affinity determined against Opioid receptor mu 1 from human cloned receptor,CHEMBL1144935,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,1.8,nM,CHEMBL756357,B,Binding affinity towards mu opioid receptor was determined,CHEMBL1124535,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL544960,CHEMBL233,Mu opioid receptor,Ki,=,410.0,nM,CHEMBL755058,B,Binding affinity towards opioid receptor mu was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2sccc12)[C@@H]1CCCC[C@H]1N1CCCC1.Cl
CHEMBL556414,CHEMBL233,Mu opioid receptor,Ki,=,2800.0,nM,CHEMBL755058,B,Binding affinity towards opioid receptor mu was determined,CHEMBL1124535,KI,CO[C@H]1C[C@H](N(C)C(=O)Cc2cccc3sccc23)[C@@H](N2CCCC2)C[C@H]1OC.Cl
CHEMBL8072,CHEMBL233,Mu opioid receptor,Ki,=,7500.0,nM,CHEMBL756580,B,Binding affinity towards non-selective opiate receptor,CHEMBL1136639,KI,NCCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)O
CHEMBL276502,CHEMBL233,Mu opioid receptor,Ki,=,1000.0,nM,CHEMBL756580,B,Binding affinity towards non-selective opiate receptor,CHEMBL1136639,KI,NCCCC[C@H](C(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@H](CC(=O)O)C(=O)O
CHEMBL542102,CHEMBL233,Mu opioid receptor,Ki,=,5200.0,nM,CHEMBL755058,B,Binding affinity towards opioid receptor mu was determined,CHEMBL1124535,KI,CCCCCN(CCN1CCCC1)C(=O)Cc1cccc2sccc12.Cl
CHEMBL553665,CHEMBL233,Mu opioid receptor,Ki,=,760.0,nM,CHEMBL755058,B,Binding affinity towards opioid receptor mu was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2occc12)[C@@H]1CCCC[C@H]1N1CCC(COC(=O)CCCC(=O)OCC2CCN([C@H]3CCCC[C@@H]3N(C)C(=O)Cc3cccc4occc34)C2)C1.Cl.Cl
CHEMBL2111837,CHEMBL233,Mu opioid receptor,Ki,=,27.4,nM,CHEMBL751580,B,Binding affinity determined against Opioid receptor mu 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccc(Cl)cc2C(c2ccccc2)=NC[C@@H]1CCNC(=O)c1cccs1
CHEMBL555990,CHEMBL233,Mu opioid receptor,Ki,=,17500.0,nM,CHEMBL756357,B,Binding affinity towards mu opioid receptor was determined,CHEMBL1124535,KI,Cl.O=C(Cc1cccc2sccc12)N1CC2CCCN2[C@@H]2CCCC[C@H]21
CHEMBL2448130,CHEMBL233,Mu opioid receptor,Ki,=,24.8,nM,CHEMBL751580,B,Binding affinity determined against Opioid receptor mu 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2F)=NC[C@H]1CCNC(=O)c1ccsc1
CHEMBL543780,CHEMBL233,Mu opioid receptor,Ki,=,700.0,nM,CHEMBL756357,B,Binding affinity towards mu opioid receptor was determined,CHEMBL1124535,KI,CN(C(=S)Cc1cccc2sccc12)[C@@H]1CCCC[C@H]1N1CCCC1.Cl
CHEMBL545654,CHEMBL233,Mu opioid receptor,Ki,=,3340.0,nM,CHEMBL755058,B,Binding affinity towards opioid receptor mu was determined,CHEMBL1124535,KI,Cl.O=C(Cc1cccc2sccc12)O[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL410260,CHEMBL233,Mu opioid receptor,Ki,=,3900.0,nM,CHEMBL756580,B,Binding affinity towards non-selective opiate receptor,CHEMBL1136639,KI,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)[C@@H](C)O)[C@@H](C)CC
CHEMBL127828,CHEMBL233,Mu opioid receptor,Ki,=,3.0,nM,CHEMBL751580,B,Binding affinity determined against Opioid receptor mu 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2F)=NCC1CCNC(=O)c1ccsc1
CHEMBL553010,CHEMBL233,Mu opioid receptor,Ki,=,3600.0,nM,CHEMBL755058,B,Binding affinity towards opioid receptor mu was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2sccc12)[C@@H]1CCC[C@H]1N1CCCC1.Cl
CHEMBL555835,CHEMBL233,Mu opioid receptor,Ki,=,820.0,nM,CHEMBL756357,B,Binding affinity towards mu opioid receptor was determined,CHEMBL1124535,KI,CO[C@H]1C[C@H](N(C)C(=O)Cc2cccc3occc23)[C@@H](N2CCCC2)C[C@H]1OC.Cl
CHEMBL558227,CHEMBL233,Mu opioid receptor,Ki,=,425.0,nM,CHEMBL755058,B,Binding affinity towards opioid receptor mu was determined,CHEMBL1124535,KI,CN(C(=O)Cc1ccc2ccsc2c1)[C@@H]1CCCC[C@H]1N1CCCC1.Cl
CHEMBL555649,CHEMBL233,Mu opioid receptor,Ki,=,14300.0,nM,CHEMBL755058,B,Binding affinity towards opioid receptor mu was determined,CHEMBL1124535,KI,CN(CCc1cccc2sccc12)[C@@H]1CCCC[C@H]1N1CCCC1.Cl
CHEMBL127969,CHEMBL233,Mu opioid receptor,Ki,=,9.4,nM,CHEMBL751580,B,Binding affinity determined against Opioid receptor mu 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2)=NCC1CCNC(=O)c1cccs1
CHEMBL8234,CHEMBL233,Mu opioid receptor,Ki,=,4800.0,nM,CHEMBL756580,B,Binding affinity towards non-selective opiate receptor,CHEMBL1136639,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL2448128,CHEMBL233,Mu opioid receptor,Ki,=,54.8,nM,CHEMBL751580,B,Binding affinity determined against Opioid receptor mu 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2)=NC[C@H]1CCNC(=O)c1cccs1
CHEMBL266538,CHEMBL233,Mu opioid receptor,Ki,=,1.12,nM,CHEMBL753234,B,Binding affinity towards Opioid receptor mu 1 using [3H]DAMGO as radioligand,CHEMBL1135684,KI,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(C)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL540277,CHEMBL233,Mu opioid receptor,Ki,=,800.0,nM,CHEMBL755058,B,Binding affinity towards opioid receptor mu was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2occc12)[C@@H]1CCCC[C@H]1N1CCC(COC(=O)CCC(=O)OCC2CCN([C@H]3CCCC[C@@H]3N(C)C(=O)Cc3cccc4occc34)C2)C1.Cl.Cl
CHEMBL2448129,CHEMBL233,Mu opioid receptor,Ki,=,33.2,nM,CHEMBL751580,B,Binding affinity determined against Opioid receptor mu 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccc(Cl)cc2C(c2ccccc2)=NC[C@H]1CCNC(=O)c1cccs1
CHEMBL43104,CHEMBL233,Mu opioid receptor,Ki,=,833.0,nM,CHEMBL755058,B,Binding affinity towards opioid receptor mu was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2[nH]ccc12)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL554205,CHEMBL233,Mu opioid receptor,Ki,=,10000.0,nM,CHEMBL755058,B,Binding affinity towards opioid receptor mu was determined,CHEMBL1124535,KI,Cl.O=C(Cc1cccc2sccc12)NCCN1CCCC1
CHEMBL428276,CHEMBL233,Mu opioid receptor,Ki,=,5100.0,nM,CHEMBL756580,B,Binding affinity towards non-selective opiate receptor,CHEMBL1136639,KI,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)[C@@H](C)O)[C@@H](C)CC
CHEMBL538230,CHEMBL233,Mu opioid receptor,Ki,=,1000.0,nM,CHEMBL756357,B,Binding affinity towards mu opioid receptor was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2sccc12)[C@@H]1CCCCC[C@H]1N1CCCC1.Cl
CHEMBL545185,CHEMBL233,Mu opioid receptor,Ki,=,20300.0,nM,CHEMBL756357,B,Binding affinity towards mu opioid receptor was determined,CHEMBL1124535,KI,CN(Cc1cccc2occc12)C(=O)[C@@H]1CCCC[C@H]1N1CCCC1.Cl
CHEMBL543301,CHEMBL233,Mu opioid receptor,Ki,=,4100.0,nM,CHEMBL756357,B,Binding affinity towards mu opioid receptor was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2occc12)[C@@H]1CCCC[C@H]1N1CCC(CO)C1.Cl
CHEMBL242756,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL749650,B,Inhibition of [3H]-DAMGO binding to Opioid receptor mu 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL299713,CHEMBL233,Mu opioid receptor,Ki,=,200.0,nM,CHEMBL749650,B,Inhibition of [3H]-DAMGO binding to Opioid receptor mu 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,Nc1nc2cc3c(cc2s1)C(=O)[C@@H]1C2CCCC[C@]32CCN1CC1CCC1
CHEMBL332947,CHEMBL233,Mu opioid receptor,Ki,=,7.32,nM,CHEMBL747704,B,Binding affinity towards human opioid Mu receptor transfected into Chinese hamster ovary (CHO) cells using [3H]DAMGO as radioligand,CHEMBL1131901,KI,CN1CCC23c4c5ccc(O)c4OC2c2nc(N)ncc2CC3(O)C1C5
CHEMBL1169583,CHEMBL233,Mu opioid receptor,Ki,=,1.6,nM,CHEMBL751577,B,Binding affinity against cloned human opioid mu receptors transfected onto CHO cells using [3H]DAMGO,CHEMBL1132936,KI,CO[C@H](C)[C@@H]1CC23C=C[C@]1(OC)[C@H]1Oc4c(O)ccc5c4C12CCN(C)C3C5
CHEMBL2113671,CHEMBL233,Mu opioid receptor,Ki,=,0.64,nM,CHEMBL751575,B,Binding affinity against cloned human Opioid receptor mu 1 transfected onto CHO cells using [3H]DAMGO,CHEMBL1132936,KI,CO[C@]12C=C[C@@]3(C[C@H]1[C@@H](C)OCc1ccccc1)[C@H]1Cc4ccc(O)c5c4C3(CCN1C)[C@@H]2O5
CHEMBL301701,CHEMBL233,Mu opioid receptor,Ki,=,8.3,nM,CHEMBL749650,B,Inhibition of [3H]-DAMGO binding to Opioid receptor mu 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,C[C@H]1[C@H]2Cc3cc4sc(N)nc4cc3[C@]1(C)CCN2CC1CCC1
CHEMBL112656,CHEMBL233,Mu opioid receptor,Ki,=,7.34,nM,CHEMBL747704,B,Binding affinity towards human opioid Mu receptor transfected into Chinese hamster ovary (CHO) cells using [3H]DAMGO as radioligand,CHEMBL1131901,KI,CN1CCC23c4c5ccc(O)c4OC2c2nc(-c4ccccc4)ncc2CC3(O)C1C5
CHEMBL294168,CHEMBL233,Mu opioid receptor,Ki,=,30.0,nM,CHEMBL749650,B,Inhibition of [3H]-DAMGO binding to Opioid receptor mu 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,CN1CC[C@]23c4c5cc6sc(N)nc6c4OC2[C@@H](O)CCC3[C@H]1C5
CHEMBL59092,CHEMBL233,Mu opioid receptor,Ki,=,0.32,nM,CHEMBL749650,B,Inhibition of [3H]-DAMGO binding to Opioid receptor mu 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,C[C@H]1C2Cc3ccc(O)cc3[C@]1(C)CCN2CC1CC1
CHEMBL2113672,CHEMBL233,Mu opioid receptor,Ki,=,0.67,nM,CHEMBL751576,B,Binding affinity against cloned human opioid Opioid receptor mu 1 transfected onto CHO cells using [3H]DAMGO,CHEMBL1132936,KI,CO[C@]12C=C[C@@]3(C[C@H]1[C@H](C)OCc1ccccc1)[C@H]1Cc4ccc(O)c5c4C3(CCN1C)[C@@H]2O5
CHEMBL356584,CHEMBL233,Mu opioid receptor,Ki,=,4000.0,nM,CHEMBL758204,B,Binding affinity against Opioid receptor mu 1,CHEMBL1132477,KI,CCC1=C(C(N)=O)C(c2ccc(F)c(F)c2)N(C(=O)NCCCN2CCC(C(=O)OC)(c3ccccc3)CC2)C(=O)N1
CHEMBL48241,CHEMBL233,Mu opioid receptor,Ki,=,3.3,nM,CHEMBL749650,B,Inhibition of [3H]-DAMGO binding to Opioid receptor mu 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,O=C1c2ccc(O)cc2[C@@]23CCCC[C@H]2[C@@H]1N(CC1CCC1)CC3
CHEMBL1766021,CHEMBL233,Mu opioid receptor,Ki,=,130.0,nM,CHEMBL749650,B,Inhibition of [3H]-DAMGO binding to Opioid receptor mu 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1cc2sc(N)nc2cc13
CHEMBL431074,CHEMBL233,Mu opioid receptor,Ki,=,5.26,nM,CHEMBL747704,B,Binding affinity towards human opioid Mu receptor transfected into Chinese hamster ovary (CHO) cells using [3H]DAMGO as radioligand,CHEMBL1131901,KI,Cc1ncc2c(n1)C1Oc3c(O)ccc4c3C13CCN(C)C(C4)C3(O)C2
CHEMBL112035,CHEMBL233,Mu opioid receptor,Ki,=,1.72,nM,CHEMBL747704,B,Binding affinity towards human opioid Mu receptor transfected into Chinese hamster ovary (CHO) cells using [3H]DAMGO as radioligand,CHEMBL1131901,KI,CN1CCC23c4c5ccc(O)c4OC2c2n[nH]cc2CC3(O)C1C5
CHEMBL592,CHEMBL233,Mu opioid receptor,Ki,=,0.21,nM,CHEMBL749650,B,Inhibition of [3H]-DAMGO binding to Opioid receptor mu 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL56356,CHEMBL233,Mu opioid receptor,Ki,=,48.0,nM,CHEMBL749650,B,Inhibition of [3H]-DAMGO binding to Opioid receptor mu 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,C[C@H]1[C@H]2Cc3cc4sc(N)nc4cc3[C@]1(C)CCN2CC1CC1
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,0.88,nM,CHEMBL749650,B,Inhibition of [3H]-DAMGO binding to Opioid receptor mu 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL1169582,CHEMBL233,Mu opioid receptor,Ki,=,4.8,nM,CHEMBL751575,B,Binding affinity against cloned human Opioid receptor mu 1 transfected onto CHO cells using [3H]DAMGO,CHEMBL1132936,KI,CO[C@@H](C)[C@@H]1CC23C=C[C@]1(OC)[C@H]1Oc4c(O)ccc5c4C12CCN(C)C3C5
CHEMBL49269,CHEMBL233,Mu opioid receptor,Ki,=,0.062,nM,CHEMBL749650,B,Inhibition of [3H]-DAMGO binding to Opioid receptor mu 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL1766021,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL749650,B,Inhibition of [3H]-DAMGO binding to Opioid receptor mu 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1cc2sc(N)nc2cc13
CHEMBL390866,CHEMBL233,Mu opioid receptor,Ki,=,7.1,nM,CHEMBL749650,B,Inhibition of [3H]-DAMGO binding to Opioid receptor mu 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CCC1
CHEMBL114803,CHEMBL233,Mu opioid receptor,Ki,=,3.75,nM,CHEMBL747704,B,Binding affinity towards human opioid Mu receptor transfected into Chinese hamster ovary (CHO) cells using [3H]DAMGO as radioligand,CHEMBL1131901,KI,CN1CCC23c4c5ccc(O)c4OC2c2nc(O)ncc2CC3(O)C1C5
CHEMBL301160,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL749650,B,Inhibition of [3H]-DAMGO binding to Opioid receptor mu 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL140979,CHEMBL233,Mu opioid receptor,Ki,=,102.0,nM,CHEMBL754711,B,"Binding affinity for opioid receptor type, human Opioid receptor mu 1 expressed in membrane homogenates of COS-1 or CHO cells",CHEMBL1135663,KI,CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL266609,CHEMBL233,Mu opioid receptor,Ki,=,75.0,nM,CHEMBL754711,B,"Binding affinity for opioid receptor type, human Opioid receptor mu 1 expressed in membrane homogenates of COS-1 or CHO cells",CHEMBL1135663,KI,CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CC[C@H]2SC[C@@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)NC(Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL356210,CHEMBL233,Mu opioid receptor,Ki,=,2700.0,nM,CHEMBL754711,B,"Binding affinity for opioid receptor type, human Opioid receptor mu 1 expressed in membrane homogenates of COS-1 or CHO cells",CHEMBL1135663,KI,CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)NC1S[C@H]2CCC[C@@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)NC(Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL355931,CHEMBL233,Mu opioid receptor,Ki,=,496.0,nM,CHEMBL754711,B,"Binding affinity for opioid receptor type, human Opioid receptor mu 1 expressed in membrane homogenates of COS-1 or CHO cells",CHEMBL1135663,KI,CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)NC1CC[C@H]2CCC[C@@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)NC(Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL2371034,CHEMBL233,Mu opioid receptor,Ki,=,368.0,nM,CHEMBL754711,B,"Binding affinity for opioid receptor type, human Opioid receptor mu 1 expressed in membrane homogenates of COS-1 or CHO cells",CHEMBL1135663,KI,CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N1[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccc(Cl)cc2)C(N)=O)CC[C@@H]1C(C)(C)C
CHEMBL358403,CHEMBL233,Mu opioid receptor,Ki,=,53.0,nM,CHEMBL754711,B,"Binding affinity for opioid receptor type, human Opioid receptor mu 1 expressed in membrane homogenates of COS-1 or CHO cells",CHEMBL1135663,KI,CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CC[C@@H]2SC[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)NC(Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL396460,CHEMBL233,Mu opioid receptor,Ki,=,270.0,nM,CHEMBL754711,B,"Binding affinity for opioid receptor type, human Opioid receptor mu 1 expressed in membrane homogenates of COS-1 or CHO cells",CHEMBL1135663,KI,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O
CHEMBL2113380,CHEMBL233,Mu opioid receptor,Ki,=,4.91,nM,CHEMBL754376,B,Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.,CHEMBL1144921,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(CCCc2ccccc2)C1C5
CHEMBL401093,CHEMBL233,Mu opioid receptor,Ki,=,363.0,nM,CHEMBL754376,B,Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.,CHEMBL1144921,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(O)[C@H]1C5
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,14.0,nM,CHEMBL753399,B,In vitro potency was measured against human Opioid receptor mu 1,CHEMBL1131022,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL2113379,CHEMBL233,Mu opioid receptor,Ki,=,29.3,nM,CHEMBL754376,B,Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.,CHEMBL1144921,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(NC(=O)Cc2ccccc2)C1C5
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,17.0,nM,CHEMBL753399,B,In vitro potency was measured against human Opioid receptor mu 1,CHEMBL1131022,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL2113377,CHEMBL233,Mu opioid receptor,Ki,=,37.2,nM,CHEMBL754376,B,Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.,CHEMBL1144921,KI,CCCCN[C@@]12Cc3c([nH]c4ccccc34)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)C2C5
CHEMBL2113383,CHEMBL233,Mu opioid receptor,Ki,=,76.3,nM,CHEMBL754376,B,Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.,CHEMBL1144921,KI,CCN[C@@]12Cc3c([nH]c4ccccc34)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)C2C5
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,0.5,nM,CHEMBL754376,B,Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.,CHEMBL1144921,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL2113378,CHEMBL233,Mu opioid receptor,Ki,=,10.2,nM,CHEMBL754376,B,Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.,CHEMBL1144921,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(NCCCc2ccccc2)C1C5
CHEMBL2113376,CHEMBL233,Mu opioid receptor,Ki,=,1051.0,nM,CHEMBL754376,B,Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.,CHEMBL1144921,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(N)C1C5
CHEMBL2113372,CHEMBL233,Mu opioid receptor,Ki,=,33.4,nM,CHEMBL754376,B,Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.,CHEMBL1144921,KI,CCCCCCC(=O)N[C@@]12Cc3c([nH]c4ccccc34)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)C2C5
CHEMBL2113382,CHEMBL233,Mu opioid receptor,Ki,=,1.68,nM,CHEMBL754376,B,Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.,CHEMBL1144921,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(NCCc2ccccc2)C1C5
CHEMBL440765,CHEMBL233,Mu opioid receptor,Ki,=,1145.0,nM,CHEMBL754376,B,Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.,CHEMBL1144921,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL573214,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL754376,B,Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.,CHEMBL1144921,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL88560,CHEMBL233,Mu opioid receptor,Ki,=,1.6,nM,CHEMBL753399,B,In vitro potency was measured against human Opioid receptor mu 1,CHEMBL1131022,KI,CN1CCNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C1
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL754376,B,Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.,CHEMBL1144921,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL294616,CHEMBL233,Mu opioid receptor,Ki,=,504.0,nM,CHEMBL754376,B,Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.,CHEMBL1144921,KI,CC1(C)SSC(C)(C)[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H]1C(=O)O
CHEMBL2113373,CHEMBL233,Mu opioid receptor,Ki,=,9.61,nM,CHEMBL754376,B,Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.,CHEMBL1144921,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(NC(=O)CCc2ccccc2)C1C5
CHEMBL567175,CHEMBL233,Mu opioid receptor,Ki,=,6.3,nM,CHEMBL754376,B,Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.,CHEMBL1144921,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL2113381,CHEMBL233,Mu opioid receptor,Ki,=,51.1,nM,CHEMBL754376,B,Displacement of [3H]DAMGO from human recombinant Opioid receptor mu 1 on CHO cell membranes.,CHEMBL1144921,KI,CCCCC(=O)N[C@@]12Cc3c([nH]c4ccccc34)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)C2C5
CHEMBL555713,CHEMBL233,Mu opioid receptor,Ki,=,0.744,nM,CHEMBL753400,B,Inhibition of [3H]- diprenorphine binding on Opioid receptor mu 1 expressed in human embryonic kidney (HEK) cells,CHEMBL1135490,KI,Cl.O=Cc1cc2ccc(C(=O)N[C@@H]3CC[C@@]4(O)C5Cc6ccc(O)c7c6[C@@]4(CCN5CC4CC4)[C@H]3O7)cc2cc1C=O
CHEMBL610541,CHEMBL233,Mu opioid receptor,Ki,=,0.45,nM,CHEMBL756360,B,Inhibition of [3H]- diprenorphine binding to Opioid receptor mu 1 (83 fmol/mg protein) stably expressed in membranes from CHO cells,CHEMBL1133757,KI,O=Cc1ccc(C(=O)NCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5C3(CCN4CC3CC3)C2O6)cc1C=O
CHEMBL386272,CHEMBL233,Mu opioid receptor,Ki,=,0.46,nM,CHEMBL755063,B,Displacement of radioligand [3H]- DAMGO on Opioid receptor mu 1 in monkey brain membranes,CHEMBL1133634,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL610542,CHEMBL233,Mu opioid receptor,Ki,=,0.54,nM,CHEMBL755064,B,Displacement of radioligand [3H]- DAMGO on Opioid receptor mu 1 in monkey brain membranes range; Value ranges from (0.32-0.91),CHEMBL1133634,KI,O=C(/C=C/c1ccc(Cl)cc1)NC12CCC(=O)C3Oc4cccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL386492,CHEMBL233,Mu opioid receptor,Ki,=,0.25,nM,CHEMBL755063,B,Displacement of radioligand [3H]- DAMGO on Opioid receptor mu 1 in monkey brain membranes,CHEMBL1133634,KI,O=C(/C=C/c1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL66387,CHEMBL233,Mu opioid receptor,Ki,=,9643.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(C(=C2CC3CCC(C2)N3CC(=O)c2ccccc2)c2ccccc2)cc1
CHEMBL2112214,CHEMBL233,Mu opioid receptor,Ki,=,571.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CC1CCCC(C)N1C(=O)c1ccc(/C(=C2\C[C@H]3CC[C@@H](C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL307327,CHEMBL233,Mu opioid receptor,Ki,=,693.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(C(=C2CC3CCC(C2)N3C)c2cccc(OC)c2)cc1
CHEMBL67846,CHEMBL233,Mu opioid receptor,Ki,=,855.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(/C(=C2\C[C@H]3CC[C@@H](C2)N3)c2ccccc2)cc1
CHEMBL304989,CHEMBL233,Mu opioid receptor,Ki,=,4400.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,C=CCN1[C@@H]2CC[C@H]1C/C(=C(/c1ccccc1)c1ccc(C(=O)N(CC)CC)cc1)C2
CHEMBL67068,CHEMBL233,Mu opioid receptor,Ki,=,294.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,COCCN(CCOC)C(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL65151,CHEMBL233,Mu opioid receptor,Ki,=,630.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(C(=C2CC3CCC(C2)N3CCOc2ccccc2)c2ccccc2)cc1
CHEMBL13403,CHEMBL233,Mu opioid receptor,Ki,=,11565.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,C=CCN1CCC(N(c2ccccc2)c2ccc(C(=O)N(CC)CC)cc2)CC1
CHEMBL67545,CHEMBL233,Mu opioid receptor,Ki,=,3650.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,C=CCN1[C@@H]2CC[C@H]1CC(N(c1ccccc1)c1ccc(C(=O)N(CC)CC)cc1)C2
CHEMBL67734,CHEMBL233,Mu opioid receptor,Ki,=,451.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(C(=C2CC3CCC(C2)N3CCC2CCCCC2)c2ccccc2)cc1
CHEMBL292794,CHEMBL233,Mu opioid receptor,Ki,=,644.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCCN(CCC)C(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL67192,CHEMBL233,Mu opioid receptor,Ki,=,22.4,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(C(=C2CC3CCC(C2)N3Cc2ccc3c(c2)OCO3)c2ccccc2)cc1
CHEMBL67673,CHEMBL233,Mu opioid receptor,Ki,=,291.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CCO)C(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL302801,CHEMBL233,Mu opioid receptor,Ki,=,72.3,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(/C(=C2\C[C@H]3CC[C@@H](C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL63732,CHEMBL233,Mu opioid receptor,Ki,=,322.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,C=CCN1[C@@H]2CC[C@H]1C/C(=C(\c1ccccc1)c1ccc(C(=O)N(CC)CC)cc1)C2
CHEMBL67996,CHEMBL233,Mu opioid receptor,Ki,=,727.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(C(=C2CC3CCC(C2)N3C)c2cccc(O)c2)cc1
CHEMBL63213,CHEMBL233,Mu opioid receptor,Ki,=,337.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2c[nH]c3ccccc23)c2ccccc2)cc1
CHEMBL68416,CHEMBL233,Mu opioid receptor,Ki,=,276.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,O=C(c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccccc2)cc1)N1CCCC1
CHEMBL63477,CHEMBL233,Mu opioid receptor,Ki,=,2310.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(/C(=C2/C[C@H]3CC[C@@H](C2)N3)c2ccccc2)cc1
CHEMBL305225,CHEMBL233,Mu opioid receptor,Ki,=,103.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CC(C)N(C(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccccc2)cc1)C(C)C
CHEMBL65772,CHEMBL233,Mu opioid receptor,Ki,=,417.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2cccc(OC)c2)cc1
CHEMBL302121,CHEMBL233,Mu opioid receptor,Ki,=,194.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(C(=C2CC3CCC(C2)N3C)c2ccc(O)cc2)cc1
CHEMBL66668,CHEMBL233,Mu opioid receptor,Ki,=,1281.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2cccs2)c2ccccc2)cc1
CHEMBL63948,CHEMBL233,Mu opioid receptor,Ki,=,237.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,O=C(c1ccc(C(=C2CC3CCC(C2)N3CCc2ccccc2)c2ccccc2)cc1)N1CCOCC1
CHEMBL68113,CHEMBL233,Mu opioid receptor,Ki,=,317.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(/C(=C2/C[C@H]3CC[C@@H](C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL13470,CHEMBL233,Mu opioid receptor,Ki,=,1300.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL63571,CHEMBL233,Mu opioid receptor,Ki,=,289.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCCN1C2CCC1CC(=C(c1ccccc1)c1ccc(C(=O)N(CC)CC)cc1)C2
CHEMBL63597,CHEMBL233,Mu opioid receptor,Ki,=,2910.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(/C(=C2\C[C@H]3CC[C@@H](C2)N3C)c2ccccc2)cc1
CHEMBL67157,CHEMBL233,Mu opioid receptor,Ki,=,1499.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(C(=C2CC3CCC(C2)N3C)c2ccc(OC)cc2)cc1
CHEMBL307775,CHEMBL233,Mu opioid receptor,Ki,=,9730.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(/C(=C2/C[C@H]3CC[C@@H](C2)N3C)c2ccccc2)cc1
CHEMBL304196,CHEMBL233,Mu opioid receptor,Ki,=,5040.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(N(c2ccccc2)C2C[C@H]3CC[C@@H](C2)N3)cc1
CHEMBL308928,CHEMBL233,Mu opioid receptor,Ki,=,442.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(C(=C2CC3CCC(C2)N3)c2ccc(O)cc2)cc1
CHEMBL2112215,CHEMBL233,Mu opioid receptor,Ki,=,229.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,C=C(C)CN(CC)C(=O)c1ccc(/C(=C2\C[C@H]3CC[C@@H](C2)N3CCc2ccccc2)c2ccccc2)cc1
CHEMBL63400,CHEMBL233,Mu opioid receptor,Ki,=,393.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(C(=C2CC3CCC(C2)N3CCc2ccc(F)cc2)c2ccccc2)cc1
CHEMBL63750,CHEMBL233,Mu opioid receptor,Ki,=,104.0,nM,CHEMBL756358,B,Binding affinity for mu opioid receptor,CHEMBL1148435,KI,CCN(CC)C(=O)c1ccc(C(=C2CC3CCC(C2)N3CCCc2ccccc2)c2ccccc2)cc1
CHEMBL216640,CHEMBL233,Mu opioid receptor,Ki,=,7.6,nM,CHEMBL753235,B,Binding affinity towards cloned human Opioid receptor mu 1 in CHO cell membranes.,CHEMBL1133465,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL573214,CHEMBL233,Mu opioid receptor,Ki,=,56.0,nM,CHEMBL753235,B,Binding affinity towards cloned human Opioid receptor mu 1 in CHO cell membranes.,CHEMBL1133465,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL269377,CHEMBL233,Mu opioid receptor,Ki,=,1700.0,nM,CHEMBL753235,B,Binding affinity towards cloned human Opioid receptor mu 1 in CHO cell membranes.,CHEMBL1133465,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL407389,CHEMBL233,Mu opioid receptor,Ki,=,5700.0,nM,CHEMBL753235,B,Binding affinity towards cloned human Opioid receptor mu 1 in CHO cell membranes.,CHEMBL1133465,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL405097,CHEMBL233,Mu opioid receptor,Ki,=,3200.0,nM,CHEMBL753235,B,Binding affinity towards cloned human Opioid receptor mu 1 in CHO cell membranes.,CHEMBL1133465,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL405190,CHEMBL233,Mu opioid receptor,Ki,=,67.0,nM,CHEMBL753235,B,Binding affinity towards cloned human Opioid receptor mu 1 in CHO cell membranes.,CHEMBL1133465,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)NC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL413729,CHEMBL233,Mu opioid receptor,Ki,=,8300.0,nM,CHEMBL753235,B,Binding affinity towards cloned human Opioid receptor mu 1 in CHO cell membranes.,CHEMBL1133465,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL108608,CHEMBL233,Mu opioid receptor,Ki,=,6.3,nM,CHEMBL751581,B,Binding affinity for human Opioid receptor mu 1 transfected into chinese hamster ovary cells by displacing [3H]DAMGO radioligand,CHEMBL1145844,KI,COc1ccc2c(c1O)[C@]13CCN(C)C(C2)[C@@]12C/C(=C\c1ccccc1)[C@@H]3c1[nH]c3ccccc3c1C2
CHEMBL567175,CHEMBL233,Mu opioid receptor,Ki,=,6.3,nM,CHEMBL751581,B,Binding affinity for human Opioid receptor mu 1 transfected into chinese hamster ovary cells by displacing [3H]DAMGO radioligand,CHEMBL1145844,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL567175,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL757311,B,Displacement of [3H]DAMGO from Opioid receptor mu 1,CHEMBL1134426,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL109040,CHEMBL233,Mu opioid receptor,Ki,=,0.43,nM,CHEMBL751581,B,Binding affinity for human Opioid receptor mu 1 transfected into chinese hamster ovary cells by displacing [3H]DAMGO radioligand,CHEMBL1145844,KI,COc1ccc2c(c1O)[C@]13CCN(C)C(C2)[C@]12CCC(=O)[C@H]3/C(=C/c1ccccc1)C2
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL751581,B,Binding affinity for human Opioid receptor mu 1 transfected into chinese hamster ovary cells by displacing [3H]DAMGO radioligand,CHEMBL1145844,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL414369,CHEMBL233,Mu opioid receptor,Ki,=,331.0,nM,CHEMBL758207,B,Binding affinity towards Opioid receptor mu 1 using [3H]DAMGO as radioligand in Chinese hamster ovary cells expressing cloned opioid receptors,CHEMBL1136748,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL322875,CHEMBL233,Mu opioid receptor,Ki,=,254.0,nM,CHEMBL751581,B,Binding affinity for human Opioid receptor mu 1 transfected into chinese hamster ovary cells by displacing [3H]DAMGO radioligand,CHEMBL1145844,KI,CC(C)=CC[C@@]12Cc3c([nH]c4ccccc34)[C@]3(C)Oc4c(O)ccc5c4[C@]13CCN(C)C2C5
CHEMBL263595,CHEMBL233,Mu opioid receptor,Ki,=,339.0,nM,CHEMBL758207,B,Binding affinity towards Opioid receptor mu 1 using [3H]DAMGO as radioligand in Chinese hamster ovary cells expressing cloned opioid receptors,CHEMBL1136748,KI,CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL102690,CHEMBL233,Mu opioid receptor,Ki,=,3590.0,nM,CHEMBL756364,B,The compound was tested for binding affinity against Opioid receptor mu 1 by using [3H]DAMGO as a radioligand,CHEMBL1132332,KI,CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O
CHEMBL320306,CHEMBL233,Mu opioid receptor,Ki,=,122.0,nM,CHEMBL751581,B,Binding affinity for human Opioid receptor mu 1 transfected into chinese hamster ovary cells by displacing [3H]DAMGO radioligand,CHEMBL1145844,KI,C/C=C1\C[C@@]23Cc4c([nH]c5ccccc45)[C@@H]1[C@@]21CCN(C)C3Cc2ccc(OC)c(O)c21
CHEMBL329719,CHEMBL233,Mu opioid receptor,Ki,=,1300.0,nM,CHEMBL757311,B,Displacement of [3H]DAMGO from Opioid receptor mu 1,CHEMBL1134426,KI,C=C(C)CN1CCC23c4c5ccc(O)c4O[C@H]2c2oc4ccccc4c2C[C@@]3(O)C1C5
CHEMBL407084,CHEMBL233,Mu opioid receptor,Ki,=,1.97,nM,CHEMBL756364,B,The compound was tested for binding affinity against Opioid receptor mu 1 by using [3H]DAMGO as a radioligand,CHEMBL1132332,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL107420,CHEMBL233,Mu opioid receptor,Ki,=,13.4,nM,CHEMBL751581,B,Binding affinity for human Opioid receptor mu 1 transfected into chinese hamster ovary cells by displacing [3H]DAMGO radioligand,CHEMBL1145844,KI,COc1ccc2c(c1O)[C@]13CCN(C)C(C2)[C@@]12C/C(=C(/C)c1ccccc1)[C@@H]3c1[nH]c3ccccc3c1C2
CHEMBL98324,CHEMBL233,Mu opioid receptor,Ki,=,2000.0,nM,CHEMBL757311,B,Displacement of [3H]DAMGO from Opioid receptor mu 1,CHEMBL1134426,KI,C=C(C)CN1CCC23c4c5ccc(O)c4O[C@H]2C(=O)C2(Cc4ccccc4C2)C[C@@]3(O)C1C5
CHEMBL412248,CHEMBL233,Mu opioid receptor,Ki,=,251.0,nM,CHEMBL756364,B,The compound was tested for binding affinity against Opioid receptor mu 1 by using [3H]DAMGO as a radioligand,CHEMBL1132332,KI,CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL316930,CHEMBL233,Mu opioid receptor,Ki,=,140.0,nM,CHEMBL757311,B,Displacement of [3H]DAMGO from Opioid receptor mu 1,CHEMBL1134426,KI,C=C(C)CN1CCC23c4c5ccc(O)c4O[C@H]2c2n[nH]cc2C[C@@]3(O)C1C5
CHEMBL110124,CHEMBL233,Mu opioid receptor,Ki,=,4.54,nM,CHEMBL751581,B,Binding affinity for human Opioid receptor mu 1 transfected into chinese hamster ovary cells by displacing [3H]DAMGO radioligand,CHEMBL1145844,KI,COc1ccc2c(c1O)[C@]13CCN(C)C(C2)[C@]12CCC(=O)[C@H]3/C(=C(\C)c1ccccc1)C2
CHEMBL438571,CHEMBL233,Mu opioid receptor,Ki,=,251.0,nM,CHEMBL758207,B,Binding affinity towards Opioid receptor mu 1 using [3H]DAMGO as radioligand in Chinese hamster ovary cells expressing cloned opioid receptors,CHEMBL1136748,KI,CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL95319,CHEMBL233,Mu opioid receptor,Ki,=,7900.0,nM,CHEMBL757311,B,Displacement of [3H]DAMGO from Opioid receptor mu 1,CHEMBL1134426,KI,C=C(C)CN1CCC23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(O)C1C5
CHEMBL319592,CHEMBL233,Mu opioid receptor,Ki,=,4500.0,nM,CHEMBL757311,B,Displacement of [3H]DAMGO from Opioid receptor mu 1,CHEMBL1134426,KI,C=C(C)CN1CCC23c4c5ccc(O)c4O[C@H]2C(=O)/C(=C/c2ccccc2)C[C@@]3(O)C1C5
CHEMBL110461,CHEMBL233,Mu opioid receptor,Ki,=,43.8,nM,CHEMBL751581,B,Binding affinity for human Opioid receptor mu 1 transfected into chinese hamster ovary cells by displacing [3H]DAMGO radioligand,CHEMBL1145844,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@@]2(C)c2[nH]c4ccccc4c2C[C@@]3(C/C=C/c2ccccc2)C1C5
CHEMBL107207,CHEMBL233,Mu opioid receptor,Ki,=,330.0,nM,CHEMBL751581,B,Binding affinity for human Opioid receptor mu 1 transfected into chinese hamster ovary cells by displacing [3H]DAMGO radioligand,CHEMBL1145844,KI,COc1ccc2c(c1O)[C@]13CCN(C)C(C2)[C@@]12CC(=C(C)C)[C@@H]3c1[nH]c3ccccc3c1C2
CHEMBL356584,CHEMBL233,Mu opioid receptor,Ki,=,4000.0,nM,CHEMBL756444,B,Binding affinity against opioid receptor using [3H]-DAMGO as radioligand.,CHEMBL1132478,KI,CCC1=C(C(N)=O)C(c2ccc(F)c(F)c2)N(C(=O)NCCCN2CCC(C(=O)OC)(c3ccccc3)CC2)C(=O)N1
CHEMBL47544,CHEMBL233,Mu opioid receptor,Ki,=,919.0,nM,CHEMBL757825,B,Binding affinity towards human mu-opioid receptors in CHO (Chinese hamster ovary) cell lines,CHEMBL1134438,KI,CC[C@H](NC(=O)c1c(CN2CCC(N3CCCCC3)CC2)c(-c2ccccc2)nc2ccccc12)c1ccccc1
CHEMBL435084,CHEMBL233,Mu opioid receptor,Ki,=,3.3,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,O=C(Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)c1cccc(C(=O)Oc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)c1
CHEMBL47412,CHEMBL233,Mu opioid receptor,Ki,=,172.0,nM,CHEMBL757825,B,Binding affinity towards human mu-opioid receptors in CHO (Chinese hamster ovary) cell lines,CHEMBL1134438,KI,C[C@H](NC(=O)c1c(CN2CCNCC2)c(-c2ccccc2)nc2ccccc12)C1CCCCC1
CHEMBL33868,CHEMBL233,Mu opioid receptor,Ki,=,15.8,nM,CHEMBL757825,B,Binding affinity towards human mu-opioid receptors in CHO (Chinese hamster ovary) cell lines,CHEMBL1134438,KI,CC[C@H](NC(=O)c1c(CN2CCN(C3CCCCC3)CC2)c(-c2ccccc2)nc2ccccc12)c1ccccc1
CHEMBL424328,CHEMBL233,Mu opioid receptor,Ki,=,1.8,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,O=C(CCCCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL47775,CHEMBL233,Mu opioid receptor,Ki,=,195.0,nM,CHEMBL757825,B,Binding affinity towards human mu-opioid receptors in CHO (Chinese hamster ovary) cell lines,CHEMBL1134438,KI,CC(C)N1CCN(Cc2c(-c3ccccc3)nc3ccccc3c2C(=O)N[C@@H](C)C2CCCCC2)CC1
CHEMBL146756,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,O=C(/C=C/C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL47739,CHEMBL233,Mu opioid receptor,Ki,=,1320.0,nM,CHEMBL757825,B,Binding affinity towards human mu-opioid receptors in CHO (Chinese hamster ovary) cell lines,CHEMBL1134438,KI,C[C@H](NC(=O)c1c(CN2CCC(N3CCCCC3)CC2)c(-c2ccccc2)nc2ccccc12)C1CCCCC1
CHEMBL424327,CHEMBL233,Mu opioid receptor,Ki,=,48.0,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CCCN1CC[C@]24CCCC[C@H]2[C@H]1Cc1ccc(O)cc14)CC3
CHEMBL405131,CHEMBL233,Mu opioid receptor,Ki,=,0.89,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,O=C(CCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL151872,CHEMBL233,Mu opioid receptor,Ki,=,66.0,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,c1cc2c(cc1OCCCCCCCCCCOc1ccc3c(c1)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL346885,CHEMBL233,Mu opioid receptor,Ki,=,3.3,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,O=C(CCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL45362,CHEMBL233,Mu opioid receptor,Ki,=,226.0,nM,CHEMBL757825,B,Binding affinity towards human mu-opioid receptors in CHO (Chinese hamster ovary) cell lines,CHEMBL1134438,KI,CC(C)N1CCN(Cc2c(-c3ccccc3)nc3ccccc3c2C(=O)NC2CCCCC2)CC1
CHEMBL413512,CHEMBL233,Mu opioid receptor,Ki,=,0.14,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,O=C(CCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL592,CHEMBL233,Mu opioid receptor,Ki,=,0.21,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL357334,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,COC(=O)CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL358104,CHEMBL233,Mu opioid receptor,Ki,=,0.93,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL356889,CHEMBL233,Mu opioid receptor,Ki,=,52.0,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CCCCCCN1CC[C@]24CCCC[C@H]2[C@H]1Cc1ccc(O)cc14)CC3
CHEMBL44722,CHEMBL233,Mu opioid receptor,Ki,=,1680.0,nM,CHEMBL757825,B,Binding affinity towards human mu-opioid receptors in CHO (Chinese hamster ovary) cell lines,CHEMBL1134438,KI,CC[C@H](NC(=O)c1c(CN(C)C)c(-c2ccccc2)nc2ccccc12)c1ccccc1
CHEMBL296857,CHEMBL233,Mu opioid receptor,Ki,=,120.0,nM,CHEMBL757825,B,Binding affinity towards human mu-opioid receptors in CHO (Chinese hamster ovary) cell lines,CHEMBL1134438,KI,CC(C)[C@H](NC(=O)c1c(CN2CCN(C(C)C)CC2)c(-c2ccccc2)nc2ccccc12)c1ccccc1
CHEMBL149074,CHEMBL233,Mu opioid receptor,Ki,=,4.7,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,O=C(Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)c1ccc(C(=O)Oc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL10188,CHEMBL233,Mu opioid receptor,Ki,=,1860.0,nM,CHEMBL757825,B,Binding affinity towards human mu-opioid receptors in CHO (Chinese hamster ovary) cell lines,CHEMBL1134438,KI,CC[C@H](NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1ccccc1
CHEMBL432301,CHEMBL233,Mu opioid receptor,Ki,=,1780.0,nM,CHEMBL757825,B,Binding affinity towards human mu-opioid receptors in CHO (Chinese hamster ovary) cell lines,CHEMBL1134438,KI,C[C@H](NC(=O)c1c(CN2CCC(N)CC2)c(-c2ccccc2)nc2ccccc12)C1CCCCC1
CHEMBL147511,CHEMBL233,Mu opioid receptor,Ki,=,0.09,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL49269,CHEMBL233,Mu opioid receptor,Ki,=,0.062,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL47713,CHEMBL233,Mu opioid receptor,Ki,=,98.6,nM,CHEMBL757825,B,Binding affinity towards human mu-opioid receptors in CHO (Chinese hamster ovary) cell lines,CHEMBL1134438,KI,CC[C@H](NC(=O)c1c(CN2CCN(C(C)C)CC2)c(-c2ccccc2)nc2ccccc12)c1ccccc1
CHEMBL150061,CHEMBL233,Mu opioid receptor,Ki,=,0.28,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,O=C(Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)[C@H]1C[C@H]1C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL301160,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL433697,CHEMBL233,Mu opioid receptor,Ki,=,0.16,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,O=C(CCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL348023,CHEMBL233,Mu opioid receptor,Ki,=,29.0,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,c1cc2c(cc1OCCCCOc1ccc3c(c1)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL318859,CHEMBL233,Mu opioid receptor,Ki,=,22.0,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,CN(C(=O)Cc1cccc2occc12)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL346436,CHEMBL233,Mu opioid receptor,Ki,=,0.97,nM,CHEMBL753407,B,Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand,CHEMBL1145905,KI,O=C(CCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL47408,CHEMBL233,Mu opioid receptor,Ki,=,203.0,nM,CHEMBL757825,B,Binding affinity towards human mu-opioid receptors in CHO (Chinese hamster ovary) cell lines,CHEMBL1134438,KI,CC[C@H](NC(=O)c1c(CN2CCNCC2)c(-c2ccccc2)nc2ccccc12)c1ccccc1
CHEMBL10872,CHEMBL233,Mu opioid receptor,Ki,=,33.1,nM,CHEMBL754713,B,Binding affinity towards human cloned Opioid receptor mu 1 using [3H]DAMGO,CHEMBL1145840,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccccc2CN1
CHEMBL575508,CHEMBL233,Mu opioid receptor,Ki,=,8.86,nM,CHEMBL754713,B,Binding affinity towards human cloned Opioid receptor mu 1 using [3H]DAMGO,CHEMBL1145840,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1C
CHEMBL415247,CHEMBL233,Mu opioid receptor,Ki,=,0.96,nM,CHEMBL754713,B,Binding affinity towards human cloned Opioid receptor mu 1 using [3H]DAMGO,CHEMBL1145840,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1
CHEMBL573214,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL754713,B,Binding affinity towards human cloned Opioid receptor mu 1 using [3H]DAMGO,CHEMBL1145840,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL2112473,CHEMBL233,Mu opioid receptor,Ki,=,3.8,nM,CHEMBL754713,B,Binding affinity towards human cloned Opioid receptor mu 1 using [3H]DAMGO,CHEMBL1145840,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC[C@H]1Cc2ccc(O)cc2CN1
CHEMBL2112474,CHEMBL233,Mu opioid receptor,Ki,=,13.2,nM,CHEMBL754713,B,Binding affinity towards human cloned Opioid receptor mu 1 using [3H]DAMGO,CHEMBL1145840,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1C(=O)CN(C)C
CHEMBL319536,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL757310,B,Binding affinity against Opioid receptor mu 1 using [3H]naloxone as radioligand.,CHEMBL1131144,KI,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL318723,CHEMBL233,Mu opioid receptor,Ki,=,80.0,nM,CHEMBL757310,B,Binding affinity against Opioid receptor mu 1 using [3H]naloxone as radioligand.,CHEMBL1131144,KI,C[C@H]1CN(C)CC[C@@]1(C)c1cccc(O)c1
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.56,nM,CHEMBL758205,B,Binding affinity against Opioid receptor mu 1 using [3H]naloxone as radioligand.,CHEMBL1131144,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL336381,CHEMBL233,Mu opioid receptor,Ki,=,610.0,nM,CHEMBL756356,B,Binding affinity towards Opioid receptor mu 1 was determined,CHEMBL1145107,KI,CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O)N(C)C(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL430298,CHEMBL233,Mu opioid receptor,Ki,=,5.7,nM,CHEMBL756356,B,Binding affinity towards Opioid receptor mu 1 was determined,CHEMBL1145107,KI,CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O)N(C)C(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL411201,CHEMBL233,Mu opioid receptor,Ki,=,136.0,nM,CHEMBL756356,B,Binding affinity towards Opioid receptor mu 1 was determined,CHEMBL1145107,KI,CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O)N(C)C(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL265595,CHEMBL233,Mu opioid receptor,Ki,=,5200.0,nM,CHEMBL756356,B,Binding affinity towards Opioid receptor mu 1 was determined,CHEMBL1145107,KI,CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O)N(C)C(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CC(=O)O
CHEMBL132314,CHEMBL233,Mu opioid receptor,Ki,=,25.0,nM,CHEMBL756356,B,Binding affinity towards Opioid receptor mu 1 was determined,CHEMBL1145107,KI,CCCC[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N(C)[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL206974,CHEMBL233,Mu opioid receptor,Ki,=,20.0,nM,CHEMBL756356,B,Binding affinity towards Opioid receptor mu 1 was determined,CHEMBL1145107,KI,CCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL136838,CHEMBL233,Mu opioid receptor,Ki,=,3.2,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,C[C@H]1CN(Cc2ccc(C(C)(C)C)cc2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL336234,CHEMBL233,Mu opioid receptor,Ki,=,4.7,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL342479,CHEMBL233,Mu opioid receptor,Ki,=,13.0,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,Cc1nn(-c2ccccc2)c(C)c1CN1CC[C@@](C)(c2cccc(C(N)=O)c2)[C@@H](C)C1
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,38.0,nM,CHEMBL843458,B,Compound was evaluated for the binding affinity to mu opioid receptor,CHEMBL1126435,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL136612,CHEMBL233,Mu opioid receptor,Ki,=,150.0,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(N)c1
CHEMBL138473,CHEMBL233,Mu opioid receptor,Ki,=,9.7,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,C[C@H]1CN(Cc2cccc(Cl)c2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL138408,CHEMBL233,Mu opioid receptor,Ki,=,15.0,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,COc1cccc(CN2CC[C@@](C)(c3cccc(C(N)=O)c3)[C@@H](C)C2)c1
CHEMBL538806,CHEMBL233,Mu opioid receptor,Ki,=,545.0,nM,CHEMBL843458,B,Compound was evaluated for the binding affinity to mu opioid receptor,CHEMBL1126435,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H]1c2ccccc2CC[C@@H]1N1CCCC1.Cl
CHEMBL138036,CHEMBL233,Mu opioid receptor,Ki,=,11.0,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(CO)c1
CHEMBL138778,CHEMBL233,Mu opioid receptor,Ki,=,5.3,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,C[C@H]1CN(Cc2ccc(N(C)C)cc2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL138653,CHEMBL233,Mu opioid receptor,Ki,=,8.3,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,C[C@H]1CN(Cc2cccn2S(=O)(=O)c2ccccc2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL423726,CHEMBL233,Mu opioid receptor,Ki,=,850.0,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,COC(=O)c1cccc([C@]2(C)CCN(CCc3ccccc3)C[C@@H]2C)c1
CHEMBL138910,CHEMBL233,Mu opioid receptor,Ki,=,6.2,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,C[C@H]1CN(Cc2cc3ccccc3o2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL140138,CHEMBL233,Mu opioid receptor,Ki,=,69.0,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,C[C@H]1CN(CC2CCCCC2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL136421,CHEMBL233,Mu opioid receptor,Ki,=,71.0,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,CNC(=O)c1cccc([C@]2(C)CCN(CCc3ccccc3)C[C@@H]2C)c1
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,3.7,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL136196,CHEMBL233,Mu opioid receptor,Ki,=,3.1,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,C[C@H]1CN(CCCc2ccccc2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL334700,CHEMBL233,Mu opioid receptor,Ki,=,53.0,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,C[C@H]1CN(CC2CC2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL138448,CHEMBL233,Mu opioid receptor,Ki,=,1200.0,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(C(=O)N(C)C)c1
CHEMBL343063,CHEMBL233,Mu opioid receptor,Ki,=,16.0,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,C[C@H]1CN(Cc2ccccc2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL141261,CHEMBL233,Mu opioid receptor,Ki,=,8.8,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,COc1ccc(CN2CC[C@@](C)(c3cccc(C(N)=O)c3)[C@@H](C)C2)c(OC)c1
CHEMBL350943,CHEMBL233,Mu opioid receptor,Ki,=,304.0,nM,CHEMBL843458,B,Compound was evaluated for the binding affinity to mu opioid receptor,CHEMBL1126435,KI,COc1cccc2c1CC[C@H](N1CCCC1)[C@H]2N(C)C(=O)Cc1ccc(Cl)c(Cl)c1.CS(=O)(=O)O
CHEMBL441765,CHEMBL233,Mu opioid receptor,Ki,=,825.0,nM,CHEMBL843458,B,Compound was evaluated for the binding affinity to mu opioid receptor,CHEMBL1126435,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL336664,CHEMBL233,Mu opioid receptor,Ki,=,1.7,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,CSc1ccc(CN2CC[C@@](C)(c3cccc(C(N)=O)c3)[C@@H](C)C2)cc1
CHEMBL337341,CHEMBL233,Mu opioid receptor,Ki,=,8.0,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,C[C@H]1CN(Cc2ccc3ccccc3n2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL138930,CHEMBL233,Mu opioid receptor,Ki,=,0.5,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,CC(CCN1CC[C@@](C)(c2cccc(C(N)=O)c2)[C@@H](C)C1)CC(C)(C)C
CHEMBL138465,CHEMBL233,Mu opioid receptor,Ki,=,29.0,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,C[C@H]1CN(Cc2cccc(O)c2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL139180,CHEMBL233,Mu opioid receptor,Ki,=,5.0,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,CC(CCN1CC[C@@](C)(c2cccc(C(N)=O)c2)[C@@H](C)C1)c1ccccc1
CHEMBL319536,CHEMBL233,Mu opioid receptor,Ki,=,1.9,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL138750,CHEMBL233,Mu opioid receptor,Ki,=,68.0,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,CC(=O)Nc1cccc([C@]2(C)CCN(CCc3ccccc3)C[C@@H]2C)c1
CHEMBL138842,CHEMBL233,Mu opioid receptor,Ki,=,5.5,nM,CHEMBL753397,B,"Inhibition of binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human mu opioid receptor",CHEMBL1136497,KI,COc1ccc(CN2CC[C@@](C)(c3cccc(C(N)=O)c3)[C@@H](C)C2)cc1
CHEMBL109659,CHEMBL233,Mu opioid receptor,Ki,=,192.0,nM,CHEMBL756362,B,Tested for binding affinity towards Opioid receptor mu 1 in rat and guinea pig brain membrane binding assays,CHEMBL1134161,KI,Cc1cc(O)cc(C)c1C[C@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(N)=O
CHEMBL606959,CHEMBL233,Mu opioid receptor,Ki,=,41.7,nM,CHEMBL873929,B,Binding affinity using [3H]diprenorphine as the radioligand against K303E Opioid receptor mu 1 in COS-7 cells,CHEMBL1133722,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4c(c2C[C@@]3(O)[C@H]1C5)C[C@@]1(O)[C@H]2Cc3ccc(O)c5c3[C@@]1(CCN2C)[C@H]4O5
CHEMBL287752,CHEMBL233,Mu opioid receptor,Ki,=,102.0,nM,CHEMBL757366,B,Binding affinity using [3H]diprenorphine as the radioligand against wild-type Opioid receptor mu 1 in COS-7 cells,CHEMBL1133722,KI,CC(=O)N1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4c(c2C[C@@]3(O)[C@H]1C5)C[C@@]1(O)[C@H]2Cc3ccc(O)c5c3[C@@]1(CCN2CC1CC1)[C@H]4O5
CHEMBL287752,CHEMBL233,Mu opioid receptor,Ki,=,42.0,nM,CHEMBL873929,B,Binding affinity using [3H]diprenorphine as the radioligand against K303E Opioid receptor mu 1 in COS-7 cells,CHEMBL1133722,KI,CC(=O)N1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4c(c2C[C@@]3(O)[C@H]1C5)C[C@@]1(O)[C@H]2Cc3ccc(O)c5c3[C@@]1(CCN2CC1CC1)[C@H]4O5
CHEMBL610524,CHEMBL233,Mu opioid receptor,Ki,=,165.0,nM,CHEMBL757366,B,Binding affinity using [3H]diprenorphine as the radioligand against wild-type Opioid receptor mu 1 in COS-7 cells,CHEMBL1133722,KI,COc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2C)[C@H]5O4
CHEMBL610524,CHEMBL233,Mu opioid receptor,Ki,=,52.0,nM,CHEMBL873929,B,Binding affinity using [3H]diprenorphine as the radioligand against K303E Opioid receptor mu 1 in COS-7 cells,CHEMBL1133722,KI,COc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2C)[C@H]5O4
CHEMBL609747,CHEMBL233,Mu opioid receptor,Ki,=,40.0,nM,CHEMBL757366,B,Binding affinity using [3H]diprenorphine as the radioligand against wild-type Opioid receptor mu 1 in COS-7 cells,CHEMBL1133722,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4c(c2C[C@H]3[C@H]1C5)C[C@@]1(O)[C@H]2Cc3ccc(O)c5c3[C@@]1(CCN2CC1CC1)[C@H]4O5
CHEMBL609747,CHEMBL233,Mu opioid receptor,Ki,=,0.16,nM,CHEMBL873929,B,Binding affinity using [3H]diprenorphine as the radioligand against K303E Opioid receptor mu 1 in COS-7 cells,CHEMBL1133722,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4c(c2C[C@H]3[C@H]1C5)C[C@@]1(O)[C@H]2Cc3ccc(O)c5c3[C@@]1(CCN2CC1CC1)[C@H]4O5
CHEMBL281786,CHEMBL233,Mu opioid receptor,Ki,=,0.27,nM,CHEMBL757366,B,Binding affinity using [3H]diprenorphine as the radioligand against wild-type Opioid receptor mu 1 in COS-7 cells,CHEMBL1133722,KI,CO[C@]12CC[C@@]3(C[C@@H]1C(C)(C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL281786,CHEMBL233,Mu opioid receptor,Ki,=,0.33,nM,CHEMBL873929,B,Binding affinity using [3H]diprenorphine as the radioligand against K303E Opioid receptor mu 1 in COS-7 cells,CHEMBL1133722,KI,CO[C@]12CC[C@@]3(C[C@@H]1C(C)(C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL326235,CHEMBL233,Mu opioid receptor,Ki,=,0.492,nM,CHEMBL756362,B,Tested for binding affinity towards Opioid receptor mu 1 in rat and guinea pig brain membrane binding assays,CHEMBL1134161,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(N)=O
CHEMBL610523,CHEMBL233,Mu opioid receptor,Ki,=,276.0,nM,CHEMBL757366,B,Binding affinity using [3H]diprenorphine as the radioligand against wild-type Opioid receptor mu 1 in COS-7 cells,CHEMBL1133722,KI,COc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL610523,CHEMBL233,Mu opioid receptor,Ki,=,2.7,nM,CHEMBL873929,B,Binding affinity using [3H]diprenorphine as the radioligand against K303E Opioid receptor mu 1 in COS-7 cells,CHEMBL1133722,KI,COc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL573214,CHEMBL233,Mu opioid receptor,Ki,=,70.0,nM,CHEMBL757366,B,Binding affinity using [3H]diprenorphine as the radioligand against wild-type Opioid receptor mu 1 in COS-7 cells,CHEMBL1133722,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL573214,CHEMBL233,Mu opioid receptor,Ki,=,0.94,nM,CHEMBL873929,B,Binding affinity using [3H]diprenorphine as the radioligand against K303E Opioid receptor mu 1 in COS-7 cells,CHEMBL1133722,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL8234,CHEMBL233,Mu opioid receptor,Ki,=,9.43,nM,CHEMBL756362,B,Tested for binding affinity towards Opioid receptor mu 1 in rat and guinea pig brain membrane binding assays,CHEMBL1134161,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL420653,CHEMBL233,Mu opioid receptor,Ki,=,286.0,nM,CHEMBL757312,B,Binding affinity for Opioid receptor mu 1,CHEMBL1134942,KI,CS[C@H]1Cc2ccc(O)cc2C(C)(C)[C@@H]1N
CHEMBL107737,CHEMBL233,Mu opioid receptor,Ki,=,135.0,nM,CHEMBL757312,B,Binding affinity for Opioid receptor mu 1,CHEMBL1134942,KI,CC[C@H]1Cc2ccc(O)cc2C(C)(C)[C@@H]1N
CHEMBL331883,CHEMBL233,Mu opioid receptor,Ki,=,0.013,nM,CHEMBL751574,B,Binding affinity against Opioid receptor mu 1,CHEMBL1133578,KI,CCC(=O)N(c1ccccc1)[C@H]1CCN(C[C@H](O)c2ccccc2)C[C@H]1C
CHEMBL107442,CHEMBL233,Mu opioid receptor,Ki,=,1151.0,nM,CHEMBL757312,B,Binding affinity for Opioid receptor mu 1,CHEMBL1134942,KI,CC1(C)c2cc(O)ccc2C[C@@H](S(C)(=O)=O)[C@H]1N
CHEMBL422551,CHEMBL233,Mu opioid receptor,Ki,=,1.02,nM,CHEMBL872654,B,Tested in vitro for binding affinity against mu opioid receptor,CHEMBL1126961,KI,CC[C@]12CCN(CC3CC3)[C@H](C(=O)c3ccc(O)cc31)[C@@H]2C
CHEMBL596,CHEMBL233,Mu opioid receptor,Ki,=,3.97,nM,CHEMBL751574,B,Binding affinity against Opioid receptor mu 1,CHEMBL1133578,KI,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL104169,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL757312,B,Binding affinity for Opioid receptor mu 1,CHEMBL1134942,KI,CS[C@@H]1Cc2ccc(O)cc2C(C)(C)[C@@H]1N
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,3.96,nM,CHEMBL757312,B,Binding affinity for Opioid receptor mu 1,CHEMBL1134942,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL108068,CHEMBL233,Mu opioid receptor,Ki,=,0.79,nM,CHEMBL757312,B,Binding affinity for Opioid receptor mu 1,CHEMBL1134942,KI,C[C@@]12CCCCS[C@@H](Cc3ccc(O)cc31)C2N
CHEMBL104200,CHEMBL233,Mu opioid receptor,Ki,=,163.0,nM,CHEMBL757312,B,Binding affinity for Opioid receptor mu 1,CHEMBL1134942,KI,CC1(C)c2cc(O)ccc2C[C@@H](S)[C@H]1N
CHEMBL121403,CHEMBL233,Mu opioid receptor,Ki,=,0.06,nM,CHEMBL751574,B,Binding affinity against Opioid receptor mu 1,CHEMBL1133578,KI,CCC(=O)N(c1ccccc1)[C@@H]1CCN(C[C@@H](O)c2ccccc2)C[C@H]1C
CHEMBL421038,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL757312,B,Binding affinity for Opioid receptor mu 1,CHEMBL1134942,KI,CC[C@@H]1Cc2ccc(O)cc2C(C)(C)[C@@H]1N
CHEMBL435380,CHEMBL233,Mu opioid receptor,Ki,=,47.7,nM,CHEMBL751574,B,Binding affinity against Opioid receptor mu 1,CHEMBL1133578,KI,CCC(=O)N(c1ccccc1)[C@@H]1CCN(C[C@H](O)c2ccccc2)C[C@@H]1C
CHEMBL290429,CHEMBL233,Mu opioid receptor,Ki,=,0.024,nM,CHEMBL751574,B,Binding affinity against Opioid receptor mu 1,CHEMBL1133578,KI,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCc2ccccc2)CC1
CHEMBL107334,CHEMBL233,Mu opioid receptor,Ki,=,204.0,nM,CHEMBL757312,B,Binding affinity for Opioid receptor mu 1,CHEMBL1134942,KI,CC1(C)c2cc(O)ccc2C[C@@H](O)[C@H]1N
CHEMBL12391,CHEMBL233,Mu opioid receptor,Ki,=,0.02,nM,CHEMBL751574,B,Binding affinity against Opioid receptor mu 1,CHEMBL1133578,KI,CCC(=O)N(c1ccccc1)[C@H]1CCN(CCc2ccccc2)C[C@H]1C
CHEMBL609147,CHEMBL233,Mu opioid receptor,Ki,=,0.089,nM,CHEMBL751574,B,Binding affinity against Opioid receptor mu 1,CHEMBL1133578,KI,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2ccccc2)CC1
CHEMBL106432,CHEMBL233,Mu opioid receptor,Ki,=,1.8,nM,CHEMBL757312,B,Binding affinity for Opioid receptor mu 1,CHEMBL1134942,KI,CO[C@@H]1Cc2ccc(O)cc2C(C)(C)[C@@H]1N
CHEMBL107533,CHEMBL233,Mu opioid receptor,Ki,=,1056.0,nM,CHEMBL757312,B,Binding affinity for Opioid receptor mu 1,CHEMBL1134942,KI,C[S+]([O-])[C@@H]1Cc2ccc(O)cc2C(C)(C)[C@@H]1N
CHEMBL170603,CHEMBL233,Mu opioid receptor,Ki,=,3350.0,nM,CHEMBL872654,B,Tested in vitro for binding affinity against mu opioid receptor,CHEMBL1126961,KI,O=C(Cc1cccc2occc12)NCC12CCCN1CCC2
CHEMBL107533,CHEMBL233,Mu opioid receptor,Ki,=,2000.0,nM,CHEMBL757312,B,Binding affinity for Opioid receptor mu 1,CHEMBL1134942,KI,C[S+]([O-])[C@@H]1Cc2ccc(O)cc2C(C)(C)[C@@H]1N
CHEMBL3144469,CHEMBL233,Mu opioid receptor,Ki,=,90.0,nM,CHEMBL751578,B,Binding affinity against human Opioid receptor mu 1 (hMOR) was determined using [3H]diprenorphine in vitro transfected to COS-1 cells,CHEMBL1149132,KI,CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC1CCCCC1)C(=O)N[C@H]1CC[C@H]2CCC[C@@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL431002,CHEMBL233,Mu opioid receptor,Ki,=,398.11,nM,CHEMBL747707,B,Displacement of [3H]naloxone from human mu opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2ccccc2F)C12CCN(C1Cc3cccc4cccc1c34)CC2
CHEMBL77877,CHEMBL233,Mu opioid receptor,Ki,=,7.943,nM,CHEMBL747707,B,Displacement of [3H]naloxone from human mu opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2cccc(C(F)(F)F)c2)C12CCN(C1Cc3cccc4cccc1c34)CC2
CHEMBL28198,CHEMBL233,Mu opioid receptor,Ki,=,0.14,nM,CHEMBL753392,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing Opioid receptor mu 1,CHEMBL1132995,KI,CCC(=O)N(c1ccccc1)[C@@]1(C(=O)OC)CCN(CCc2ccccc2)C[C@H]1C
CHEMBL346879,CHEMBL233,Mu opioid receptor,Ki,=,16.8,nM,CHEMBL753389,B,Binding affinity towards recombinant human Opioid receptor mu 1 transfected in to CHO cells for the displacement of [3H]DAMGO (mu),CHEMBL1135445,KI,Oc1ccc2c3c1O[C@H]1c4c(c(-c5ccccc5)cn4Cc4ccccc4)C[C@@]4(O)C(C2)N(CC2CC2)CC[C@]314
CHEMBL1907858,CHEMBL233,Mu opioid receptor,Ki,=,12.59,nM,CHEMBL747707,B,Displacement of [3H]naloxone from human mu opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2ccccc2)C12CCN([C@H]1Cc3cccc4cccc1c34)CC2
CHEMBL27699,CHEMBL233,Mu opioid receptor,Ki,=,8.9,nM,CHEMBL753393,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor mu 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCc3c(Cl)cccc3C1)CC2
CHEMBL283910,CHEMBL233,Mu opioid receptor,Ki,=,5.9,nM,CHEMBL753393,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor mu 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN([C@H]1CCc3c(Cl)ccc(Cl)c3C1)CC2
CHEMBL348268,CHEMBL233,Mu opioid receptor,Ki,=,52.7,nM,CHEMBL753389,B,Binding affinity towards recombinant human Opioid receptor mu 1 transfected in to CHO cells for the displacement of [3H]DAMGO (mu),CHEMBL1135445,KI,Cc1c(-c2ccccc2)c2c(n1Cc1ccccc1)[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)C(C4)[C@]3(O)C2
CHEMBL3144471,CHEMBL233,Mu opioid receptor,Ki,=,53.0,nM,CHEMBL751578,B,Binding affinity against human Opioid receptor mu 1 (hMOR) was determined using [3H]diprenorphine in vitro transfected to COS-1 cells,CHEMBL1149132,KI,CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC1CCCCC1)C(=O)N[C@H]1CC[C@@H]2SC[C@@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)NC(Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL281274,CHEMBL233,Mu opioid receptor,Ki,=,6.31,nM,CHEMBL747707,B,Displacement of [3H]naloxone from human mu opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2ccccc2)C12CCN(C1Cc3cccc4cccc1c34)CC2
CHEMBL447779,CHEMBL233,Mu opioid receptor,Ki,=,10.9,nM,CHEMBL753393,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor mu 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCc3ccc(Cl)cc3C1)CC2
CHEMBL77324,CHEMBL233,Mu opioid receptor,Ki,=,31.62,nM,CHEMBL747707,B,Displacement of [3H]naloxone from human mu opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2ccc(Cl)cc2)C12CCN(C1Cc3cccc4cccc1c34)CC2
CHEMBL75676,CHEMBL233,Mu opioid receptor,Ki,=,50.12,nM,CHEMBL747707,B,Displacement of [3H]naloxone from human mu opioid receptor,CHEMBL1131838,KI,Cc1ccc(N2CNC(=O)C23CCN(C2Cc4cccc5cccc2c45)CC3)cc1
CHEMBL356473,CHEMBL233,Mu opioid receptor,Ki,=,77.9,nM,CHEMBL753389,B,Binding affinity towards recombinant human Opioid receptor mu 1 transfected in to CHO cells for the displacement of [3H]DAMGO (mu),CHEMBL1135445,KI,Cc1ccc(-c2cn(Cc3ccccc3)c3c2C[C@@]2(O)C4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)cc1
CHEMBL3144468,CHEMBL233,Mu opioid receptor,Ki,=,2555.0,nM,CHEMBL751578,B,Binding affinity against human Opioid receptor mu 1 (hMOR) was determined using [3H]diprenorphine in vitro transfected to COS-1 cells,CHEMBL1149132,KI,CC(=O)N[C@@H](CCCNC(N)=O)C(=O)N[C@H](CC1CCCCC1)C(=O)N[C@H]1CC[C@H]2CCC[C@@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL281274,CHEMBL233,Mu opioid receptor,Ki,=,5.9,nM,CHEMBL753393,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor mu 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1Cc3cccc4cccc1c34)CC2
CHEMBL312021,CHEMBL233,Mu opioid receptor,Ki,=,19.95,nM,CHEMBL747707,B,Displacement of [3H]naloxone from human mu opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2cccc(Cl)c2)C12CCN(C1Cc3cccc4cccc1c34)CC2
CHEMBL419272,CHEMBL233,Mu opioid receptor,Ki,=,12.59,nM,CHEMBL747707,B,Displacement of [3H]naloxone from human mu opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2cccc(Br)c2)C12CCN(C1Cc3cccc4cccc1c34)CC2
CHEMBL280827,CHEMBL233,Mu opioid receptor,Ki,=,31.7,nM,CHEMBL753393,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor mu 1,CHEMBL1132995,KI,Cc1cccc2c1CCCC2N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL283617,CHEMBL233,Mu opioid receptor,Ki,=,16.6,nM,CHEMBL753393,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor mu 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCc3cccc(Cl)c3C1)CC2
CHEMBL26999,CHEMBL233,Mu opioid receptor,Ki,=,15.1,nM,CHEMBL753393,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor mu 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCc3ccccc3C1)CC2
CHEMBL308522,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL747707,B,Displacement of [3H]naloxone from human mu opioid receptor,CHEMBL1131838,KI,Cc1cccc(N2CNC(=O)C23CCN(C2Cc4cccc5cccc2c45)CC3)c1
CHEMBL78156,CHEMBL233,Mu opioid receptor,Ki,=,3.981,nM,CHEMBL747707,B,Displacement of [3H]naloxone from human mu opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2cccc(F)c2)C12CCN(C1Cc3cccc4cccc1c34)CC2
CHEMBL436273,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL753389,B,Binding affinity towards recombinant human Opioid receptor mu 1 transfected in to CHO cells for the displacement of [3H]DAMGO (mu),CHEMBL1135445,KI,Oc1ccc2c3c1O[C@H]1c4[nH]cc(-c5ccccc5)c4C[C@@]4(O)C(C2)N(CC2CC2)CC[C@]314
CHEMBL27729,CHEMBL233,Mu opioid receptor,Ki,=,2.6,nM,CHEMBL753393,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor mu 1,CHEMBL1132995,KI,CN1CN(c2ccccc2)C2(CCN(C3CCc4c(Cl)ccc(Cl)c4C3)CC2)C1=O
CHEMBL28172,CHEMBL233,Mu opioid receptor,Ki,=,26.0,nM,CHEMBL753393,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor mu 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1Cc3ccccc3C1)CC2
CHEMBL78163,CHEMBL233,Mu opioid receptor,Ki,=,19.95,nM,CHEMBL747707,B,Displacement of [3H]naloxone from human mu opioid receptor,CHEMBL1131838,KI,Cc1cc(C)cc(N2CNC(=O)C23CCN(C2Cc4cccc5cccc2c45)CC3)c1
CHEMBL283480,CHEMBL233,Mu opioid receptor,Ki,=,7.2,nM,CHEMBL753393,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor mu 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCc3c(Cl)ccc(Cl)c3C1)CC2
CHEMBL284414,CHEMBL233,Mu opioid receptor,Ki,=,3.4,nM,CHEMBL753392,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing Opioid receptor mu 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCc3ccccc31)CC2
CHEMBL283265,CHEMBL233,Mu opioid receptor,Ki,=,5.9,nM,CHEMBL753393,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor mu 1,CHEMBL1132995,KI,C=CCN1CN(c2ccccc2)C2(CCN(C3CCc4c(Cl)ccc(Cl)c4C3)CC2)C1=O
CHEMBL440179,CHEMBL233,Mu opioid receptor,Ki,=,40.1,nM,CHEMBL753389,B,Binding affinity towards recombinant human Opioid receptor mu 1 transfected in to CHO cells for the displacement of [3H]DAMGO (mu),CHEMBL1135445,KI,CCCN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2c(c(-c4ccccc4)cn2Cc2ccccc2)C[C@@]3(O)C1C5
CHEMBL355202,CHEMBL233,Mu opioid receptor,Ki,=,3.981,nM,CHEMBL747707,B,Displacement of [3H]naloxone from human mu opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2ccccc2)C12CCN([C@@H]1Cc3cccc4cccc1c34)CC2
CHEMBL311185,CHEMBL233,Mu opioid receptor,Ki,=,39.81,nM,CHEMBL747707,B,Displacement of [3H]naloxone from human mu opioid receptor,CHEMBL1131838,KI,COc1cccc(N2CNC(=O)C23CCN(C2Cc4cccc5cccc2c45)CC3)c1
CHEMBL283432,CHEMBL233,Mu opioid receptor,Ki,=,7.5,nM,CHEMBL753392,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing Opioid receptor mu 1,CHEMBL1132995,KI,COCN1CN(c2ccccc2)C2(CCN(C3CCc4cccc(Cl)c4C3)CC2)C1=O
CHEMBL26638,CHEMBL233,Mu opioid receptor,Ki,=,13.3,nM,CHEMBL753392,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing Opioid receptor mu 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN([C@H]1CCCc3ccccc31)CC2
CHEMBL27460,CHEMBL233,Mu opioid receptor,Ki,=,12.8,nM,CHEMBL753392,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing Opioid receptor mu 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCc3ccccc31)CC2
CHEMBL285377,CHEMBL233,Mu opioid receptor,Ki,=,19.2,nM,CHEMBL753393,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor mu 1,CHEMBL1132995,KI,O=C1N(Cc2ccccc2)CN(c2ccccc2)C12CCN(C1CCc3c(Cl)ccc(Cl)c3C1)CC2
CHEMBL3144465,CHEMBL233,Mu opioid receptor,Ki,=,85.0,nM,CHEMBL751578,B,Binding affinity against human Opioid receptor mu 1 (hMOR) was determined using [3H]diprenorphine in vitro transfected to COS-1 cells,CHEMBL1149132,KI,N=C(N)NCCCCC(=O)N[C@H](CC1CCCCC1)C(=O)N[C@H]1CC[C@H]2CCC[C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@H](Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL609998,CHEMBL233,Mu opioid receptor,Ki,=,14.9,nM,CHEMBL758074,B,Binding affinity towards mu-opioid receptor from CHO cells,CHEMBL1134379,KI,O=Cc1ccc(C(=O)Nc2cccc3c4c([nH]c23)C2Oc3c(O)ccc5c3[C@@]23CCN(CC2CC2)[C@H](C5)[C@]3(O)C4)cc1C=O
CHEMBL418020,CHEMBL233,Mu opioid receptor,Ki,=,8.4,nM,CHEMBL753393,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor mu 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CCc3c(Cl)ccc(Cl)c3C1)CC2
CHEMBL567175,CHEMBL233,Mu opioid receptor,Ki,=,6.3,nM,CHEMBL753389,B,Binding affinity towards recombinant human Opioid receptor mu 1 transfected in to CHO cells for the displacement of [3H]DAMGO (mu),CHEMBL1135445,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL306150,CHEMBL233,Mu opioid receptor,Ki,=,25.12,nM,CHEMBL747707,B,Displacement of [3H]naloxone from human mu opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2ccc(F)cc2)C12CCN(C1Cc3cccc4cccc1c34)CC2
CHEMBL27093,CHEMBL233,Mu opioid receptor,Ki,=,77.0,nM,CHEMBL753393,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor mu 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCc3cc(Cl)ccc3C1)CC2
CHEMBL3144467,CHEMBL233,Mu opioid receptor,Ki,=,833.0,nM,CHEMBL751578,B,Binding affinity against human Opioid receptor mu 1 (hMOR) was determined using [3H]diprenorphine in vitro transfected to COS-1 cells,CHEMBL1149132,KI,CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H]1CC[C@H]2CCC[C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@H](Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL26483,CHEMBL233,Mu opioid receptor,Ki,=,61.0,nM,CHEMBL753393,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor mu 1,CHEMBL1132995,KI,O=C(CN1CN(c2ccccc2)C2(CCN(C3CCc4cccc(Cl)c4C3)CC2)C1=O)c1ccccc1
CHEMBL26987,CHEMBL233,Mu opioid receptor,Ki,=,3.3,nM,CHEMBL753393,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor mu 1,CHEMBL1132995,KI,O=C1N(CCO)CN(c2ccccc2)C12CCN(C1CCc3cccc(Cl)c3C1)CC2
CHEMBL27716,CHEMBL233,Mu opioid receptor,Ki,=,12.3,nM,CHEMBL753392,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing Opioid receptor mu 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CCCc3ccccc31)CC2
CHEMBL151476,CHEMBL233,Mu opioid receptor,Ki,=,49.5,nM,CHEMBL753389,B,Binding affinity towards recombinant human Opioid receptor mu 1 transfected in to CHO cells for the displacement of [3H]DAMGO (mu),CHEMBL1135445,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2c(c(-c4ccccc4)cn2Cc2ccccc2)C[C@@]3(O)C1C5
CHEMBL330291,CHEMBL233,Mu opioid receptor,Ki,=,724.44,nM,CHEMBL857863,B,Inhibition of DAMGO binding to human Opioid receptor mu 1,CHEMBL1145102,KI,CN1C[C@@H]2CN(c3ccccc3)C3(CCN(C4CCCCCCCC4)CC3)[C@@H]2C1
CHEMBL101454,CHEMBL233,Mu opioid receptor,Ki,=,29.9,nM,CHEMBL751579,B,Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C2CCCCCCC2)CC1
CHEMBL2112346,CHEMBL233,Mu opioid receptor,Ki,=,660.69,nM,CHEMBL857863,B,Inhibition of DAMGO binding to human Opioid receptor mu 1,CHEMBL1145102,KI,CC(C)[C@H]1CC[C@@H](N2CCC3(CC2)[C@@H]2CN(CC4CC4)C[C@@H]2CN3c2ccc(F)cc2)CC1
CHEMBL97979,CHEMBL233,Mu opioid receptor,Ki,=,210.0,nM,CHEMBL751579,B,Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.,CHEMBL1148282,KI,CC(c1ccc(C2CCCCC2)cc1)N1CCC(N2C(=O)Cc3ccccc32)CC1
CHEMBL511142,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL753233,B,Binding affinity to cloned human Opioid receptor mu 1 transfected into hamster ovary cells using [3H]DAMGO as a radioligand.,CHEMBL1133656,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL99738,CHEMBL233,Mu opioid receptor,Ki,=,22.4,nM,CHEMBL751579,B,Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.,CHEMBL1148282,KI,CC(C)[C@H]1CC[C@H](N2CCC(N3C(=O)Cc4ccccc43)CC2)CC1
CHEMBL100938,CHEMBL233,Mu opioid receptor,Ki,=,27.8,nM,CHEMBL751579,B,Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.,CHEMBL1148282,KI,CC1(C)C2CCC(CN3CCC(N4C(=O)Cc5ccccc54)CC3)C1C2
CHEMBL316699,CHEMBL233,Mu opioid receptor,Ki,=,10.6,nM,CHEMBL751579,B,Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C2CCC3CCCCC3C2)CC1
CHEMBL320182,CHEMBL233,Mu opioid receptor,Ki,=,36.7,nM,CHEMBL751579,B,Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C2CCCC3CCCCC32)CC1
CHEMBL2112343,CHEMBL233,Mu opioid receptor,Ki,=,154.88,nM,CHEMBL857863,B,Inhibition of DAMGO binding to human Opioid receptor mu 1,CHEMBL1145102,KI,CC(C)[C@H]1CC[C@@H](N2CCC3(CC2)[C@@H]2CN(Cc4ccccc4)C[C@@H]2CN3c2ccccc2)CC1
CHEMBL328411,CHEMBL233,Mu opioid receptor,Ki,=,20.2,nM,CHEMBL751579,B,Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.,CHEMBL1148282,KI,CC(c1ccc2c(c1)Cc1ccccc1-2)N1CCC(N2C(=O)Cc3ccccc32)CC1
CHEMBL418980,CHEMBL233,Mu opioid receptor,Ki,=,8.0,nM,CHEMBL751579,B,Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.,CHEMBL1148282,KI,CC(C)[C@H]1CC[C@@H](N2CCC(N3C(=O)Cc4ccccc43)CC2)CC1
CHEMBL281986,CHEMBL233,Mu opioid receptor,Ki,=,0.32,nM,CHEMBL753233,B,Binding affinity to cloned human Opioid receptor mu 1 transfected into hamster ovary cells using [3H]DAMGO as a radioligand.,CHEMBL1133656,KI,CO[C@]12C=CC3(CC14CCC[C@H]4O)C1Cc4ccc(O)c5c4C3(CCN1CC1CC1)[C@@H]2O5
CHEMBL2112345,CHEMBL233,Mu opioid receptor,Ki,=,338.84,nM,CHEMBL857863,B,Inhibition of DAMGO binding to human Opioid receptor mu 1,CHEMBL1145102,KI,CC(C)[C@H]1CC[C@@H](N2CCC3(CC2)[C@@H]2CN(C)C[C@@H]2CN3c2ccccc2)CC1
CHEMBL315551,CHEMBL233,Mu opioid receptor,Ki,=,87.1,nM,CHEMBL857863,B,Inhibition of DAMGO binding to human Opioid receptor mu 1,CHEMBL1145102,KI,CN1C[C@@H]2CN(c3ccccc3)C3(CCN(C4CCCCCCCCC4)CC3)[C@@H]2C1
CHEMBL102900,CHEMBL233,Mu opioid receptor,Ki,=,2.7,nM,CHEMBL751579,B,Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C2C3CCCC2CCC3)CC1
CHEMBL2112407,CHEMBL233,Mu opioid receptor,Ki,=,115.0,nM,CHEMBL751579,B,Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C[C@H]2CC3CCC2C3)CC1
CHEMBL101676,CHEMBL233,Mu opioid receptor,Ki,=,38.9,nM,CHEMBL751579,B,Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C2CCc3ccccc3C2)CC1
CHEMBL2112347,CHEMBL233,Mu opioid receptor,Ki,=,134.9,nM,CHEMBL857863,B,Inhibition of DAMGO binding to human Opioid receptor mu 1,CHEMBL1145102,KI,CC(C)[C@H]1CC[C@@H](N2CCC3(CC2)[C@@H]2CN(c4ccccc4)C[C@@H]2CN3c2ccccc2)CC1
CHEMBL2112344,CHEMBL233,Mu opioid receptor,Ki,=,501.19,nM,CHEMBL857863,B,Inhibition of DAMGO binding to human Opioid receptor mu 1,CHEMBL1145102,KI,CC(C)[C@H]1CC[C@@H](N2CCC3(CC2)[C@@H]2CNC[C@@H]2CN3c2ccccc2)CC1
CHEMBL317152,CHEMBL233,Mu opioid receptor,Ki,=,14.4,nM,CHEMBL751579,B,Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(CC2CCCCCCC2)CC1
CHEMBL320874,CHEMBL233,Mu opioid receptor,Ki,=,91.1,nM,CHEMBL751579,B,Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(Cc2ccccc2)CC1
CHEMBL2112345,CHEMBL233,Mu opioid receptor,Ki,=,537.03,nM,CHEMBL857863,B,Inhibition of DAMGO binding to human Opioid receptor mu 1,CHEMBL1145102,KI,CC(C)[C@H]1CC[C@@H](N2CCC3(CC2)[C@@H]2CN(C)C[C@@H]2CN3c2ccccc2)CC1
CHEMBL2112341,CHEMBL233,Mu opioid receptor,Ki,=,177.83,nM,CHEMBL857863,B,Inhibition of DAMGO binding to human Opioid receptor mu 1,CHEMBL1145102,KI,CC(C)[C@H]1CC[C@@H](N2CCC3(CC2)[C@@H]2CN(CCN4CCOCC4)C[C@@H]2CN3c2ccccc2)CC1
CHEMBL31030,CHEMBL233,Mu opioid receptor,Ki,=,0.59,nM,CHEMBL753233,B,Binding affinity to cloned human Opioid receptor mu 1 transfected into hamster ovary cells using [3H]DAMGO as a radioligand.,CHEMBL1133656,KI,CO[C@]12C=CC3(CC14CCC(C)(C)[C@H]4O)C1Cc4ccc(O)c5c4C3(CCN1CC1CC1)[C@@H]2O5
CHEMBL319307,CHEMBL233,Mu opioid receptor,Ki,=,16.4,nM,CHEMBL751579,B,Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C2CCC3CCCC[C@@H]3C2)CC1
CHEMBL416765,CHEMBL233,Mu opioid receptor,Ki,=,0.26,nM,CHEMBL753233,B,Binding affinity to cloned human Opioid receptor mu 1 transfected into hamster ovary cells using [3H]DAMGO as a radioligand.,CHEMBL1133656,KI,CO[C@]12C=CC3(CC14CCC[C@H]4O)C1Cc4ccc(O)c5c4C3(CCN1C)[C@@H]2O5
CHEMBL2112348,CHEMBL233,Mu opioid receptor,Ki,=,173.78,nM,CHEMBL857863,B,Inhibition of DAMGO binding to human Opioid receptor mu 1,CHEMBL1145102,KI,CC(C)[C@H]1CC[C@@H](N2CCC3(CC2)[C@@H]2CN(CCO)C[C@@H]2CN3c2ccccc2)CC1
CHEMBL316086,CHEMBL233,Mu opioid receptor,Ki,=,416.87,nM,CHEMBL857863,B,Inhibition of DAMGO binding to human Opioid receptor mu 1,CHEMBL1145102,KI,CN1C[C@@H]2CN(c3ccccc3)C3(CCN([C@H]4CC[C@@H]5CCCC[C@@H]5C4)CC3)[C@@H]2C1
CHEMBL100574,CHEMBL233,Mu opioid receptor,Ki,=,227.0,nM,CHEMBL751579,B,Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C(C2CCCCC2)C2CCCCC2)CC1
CHEMBL2112342,CHEMBL233,Mu opioid receptor,Ki,=,275.42,nM,CHEMBL857863,B,Inhibition of DAMGO binding to human Opioid receptor mu 1,CHEMBL1145102,KI,CCCCN1C[C@@H]2CN(c3ccccc3)C3(CCN([C@H]4CC[C@@H](C(C)C)CC4)CC3)[C@@H]2C1
CHEMBL101118,CHEMBL233,Mu opioid receptor,Ki,=,21.2,nM,CHEMBL751579,B,Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C2CCCc3ccccc32)CC1
CHEMBL31605,CHEMBL233,Mu opioid receptor,Ki,=,0.5,nM,CHEMBL753233,B,Binding affinity to cloned human Opioid receptor mu 1 transfected into hamster ovary cells using [3H]DAMGO as a radioligand.,CHEMBL1133656,KI,CO[C@]12C=CC3(CC14CCC(C)(C)[C@H]4O)C1Cc4ccc(O)c5c4C3(CCN1C)[C@@H]2O5
CHEMBL2111608,CHEMBL233,Mu opioid receptor,Ki,=,118.0,nM,CHEMBL751579,B,Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C[C@@H]2CC3CCC2C3)CC1
CHEMBL147949,CHEMBL233,Mu opioid receptor,Ki,=,23.0,nM,CHEMBL751572,B,Displacement of [3H]DAMGO (2 nM ) from opioid receptor mu 1 in human brain,CHEMBL1147404,KI,CCC(=O)N(CCCN=C(N)N)C1CCN(CCc2ccccc2)CC1
CHEMBL140979,CHEMBL233,Mu opioid receptor,Ki,=,102.9,nM,CHEMBL873920,B,Inhibition of [3H]diprenorphine (0.33 nM) binding from human Opioid receptor mu 1 expressed in CHO-K1 cells.,CHEMBL1133540,KI,CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL147044,CHEMBL233,Mu opioid receptor,Ki,=,1.04,nM,CHEMBL751572,B,Displacement of [3H]DAMGO (2 nM ) from opioid receptor mu 1 in human brain,CHEMBL1147404,KI,CCC(=O)N(CCCCCCNC(=N)N)C1CCN(CCc2ccccc2)CC1
CHEMBL147569,CHEMBL233,Mu opioid receptor,Ki,=,477.0,nM,CHEMBL751572,B,Displacement of [3H]DAMGO (2 nM ) from opioid receptor mu 1 in human brain,CHEMBL1147404,KI,CCC(=O)N(CCCCCCCCCCCCNC(=N)N)C1CCN(CCc2ccccc2)CC1
CHEMBL420903,CHEMBL233,Mu opioid receptor,Ki,=,2.3,nM,CHEMBL753402,B,Inhibition of binding of [3H]diprenorphine to cloned human Opioid receptor mu 1 expressed in CHO cell membrane;Range is in between (1.3-3.7),CHEMBL1135552,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSC[C@@H](C(=O)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL596,CHEMBL233,Mu opioid receptor,Ki,=,2.9,nM,CHEMBL751572,B,Displacement of [3H]DAMGO (2 nM ) from opioid receptor mu 1 in human brain,CHEMBL1147404,KI,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL146997,CHEMBL233,Mu opioid receptor,Ki,=,37.0,nM,CHEMBL751572,B,Displacement of [3H]DAMGO (2 nM ) from opioid receptor mu 1 in human brain,CHEMBL1147404,KI,CCC(=O)N(CCCCCCCCNC(=N)N)C1CCN(CCc2ccccc2)CC1
CHEMBL331043,CHEMBL233,Mu opioid receptor,Ki,=,130.0,nM,CHEMBL753404,B,Inhibition of binding of [3H]diprenorphine to cloned human Opioid receptor mu 1 expressed in CHO cell membrane;Range is in between (110-150),CHEMBL1135552,KI,CC1(C)SC[C@@H](C(=O)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H]1NC(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL122321,CHEMBL233,Mu opioid receptor,Ki,=,2.0,nM,CHEMBL753403,B,Inhibition of binding of [3H]diprenorphine to cloned human Opioid receptor mu 1 expressed in CHO cell membrane;Range is in between (1.8-2.2),CHEMBL1135552,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSC[C@H](C(=O)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,17.0,nM,CHEMBL753406,B,Inhibition of binding of [3H]diprenorphine to cloned human Opioid receptor mu 1 expressed in CHO cell membrane;Range is in between (6.8-43),CHEMBL1135552,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL122981,CHEMBL233,Mu opioid receptor,Ki,=,630.0,nM,CHEMBL753405,B,Inhibition of binding of [3H]diprenorphine to cloned human Opioid receptor mu 1 expressed in CHO cell membrane;Range is in between (580-680),CHEMBL1135552,KI,CC1(C)SC[C@H](C(=O)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H]1NC(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL358089,CHEMBL233,Mu opioid receptor,Ki,=,433.0,nM,CHEMBL751572,B,Displacement of [3H]DAMGO (2 nM ) from opioid receptor mu 1 in human brain,CHEMBL1147404,KI,CCC(=O)N(CCNC(=N)N)C1CCN(CCc2ccccc2)CC1
CHEMBL290919,CHEMBL233,Mu opioid receptor,Ki,=,10.3,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,CC(=O)Nc1ccc(CN2CCC[C@@H]2C/N=C(\S)N2Cc3ccccc3C[C@H]2CNC(=O)Nc2ccccc2)cc1
CHEMBL41245,CHEMBL233,Mu opioid receptor,Ki,=,85.5,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,CC(C)(C)NC(=O)NC[C@@H]1Cc2ccccc2CN1C(=S)NC[C@H]1CCCN1
CHEMBL40548,CHEMBL233,Mu opioid receptor,Ki,=,6.0,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,O=C(NC[C@@H]1Cc2ccccc2CN1/C(S)=N/C[C@H]1CCCN1Cc1ccc(O)cc1)Nc1ccccc1
CHEMBL289320,CHEMBL233,Mu opioid receptor,Ki,=,395.0,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,CC(C)(C)NC(=O)NC[C@@H]1Cc2ccccc2CN1/C(S)=N/C[C@H]1CCCN1C(=O)Nc1ccccc1
CHEMBL289512,CHEMBL233,Mu opioid receptor,Ki,=,33.7,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,N#Cc1ccc(CN2CCC[C@@H]2CNC(=S)N2Cc3ccccc3C[C@H]2CNC(=O)Nc2ccccc2)cc1
CHEMBL41946,CHEMBL233,Mu opioid receptor,Ki,=,6.8,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,COc1cccc(CN2CCC[C@@H]2C/N=C(\S)N2Cc3ccccc3C[C@H]2CNC(=O)Nc2ccccc2)c1O
CHEMBL40581,CHEMBL233,Mu opioid receptor,Ki,=,22.7,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,O=C(NC[C@@H]1Cc2ccccc2CN1C(=S)NC[C@H]1CCCN1Cc1ccoc1)Nc1ccccc1
CHEMBL288468,CHEMBL233,Mu opioid receptor,Ki,=,2.7,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,COc1cccc(CN2CCC[C@@H]2C/N=C(\S)N2Cc3ccccc3C[C@H]2CNC(=O)Nc2ccccc2)c1OC
CHEMBL40825,CHEMBL233,Mu opioid receptor,Ki,=,23.2,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,CC(C)(C)NC(=O)NC[C@@H]1Cc2ccccc2CN1/C(S)=N/C[C@H]1CCCN1Cc1ccccc1
CHEMBL40409,CHEMBL233,Mu opioid receptor,Ki,=,11.7,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,O=C(NC[C@@H]1Cc2ccccc2CN1/C(S)=N/C[C@H]1CCCN1Cc1ccccc1O)Nc1ccccc1
CHEMBL41883,CHEMBL233,Mu opioid receptor,Ki,=,303.0,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,CC(C)(C)NC(=O)NC[C@@H]1Cc2ccccc2CN1/C(S)=N/C[C@H]1CCCO1
CHEMBL39968,CHEMBL233,Mu opioid receptor,Ki,=,38.2,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,O=C(NC[C@@H]1Cc2ccccc2CN1C(=S)NC[C@H]1CCCN1)Nc1ccccc1
CHEMBL41245,CHEMBL233,Mu opioid receptor,Ki,=,85.5,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,CC(C)(C)NC(=O)NC[C@@H]1Cc2ccccc2CN1C(=S)NC[C@H]1CCCN1
CHEMBL289137,CHEMBL233,Mu opioid receptor,Ki,=,685.0,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,CC(C)(C)NC(=O)NC[C@@H]1Cc2ccccc2CN1/C(S)=N/CC1CCCO1
CHEMBL285769,CHEMBL233,Mu opioid receptor,Ki,=,17.7,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,COc1ccc(CN2CCC[C@@H]2C/N=C(\S)N2Cc3ccccc3C[C@H]2CNC(=O)Nc2ccccc2)cc1O
CHEMBL40108,CHEMBL233,Mu opioid receptor,Ki,=,40.5,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,O=C(NC[C@@H]1Cc2ccccc2CN1/C(S)=N/C[C@H]1CCCN1Cc1ccccc1F)Nc1ccccc1
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,0.53,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL418241,CHEMBL233,Mu opioid receptor,Ki,=,34.3,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,COc1cccc(CN2CCC[C@@H]2C/N=C(\S)N2Cc3ccccc3C[C@H]2CNC(=O)Nc2ccccc2)c1
CHEMBL41649,CHEMBL233,Mu opioid receptor,Ki,=,22.8,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,COc1ccc(CN2CCC[C@@H]2C/N=C(\S)N2Cc3ccccc3C[C@H]2CNC(=O)Nc2ccccc2)cc1
CHEMBL289494,CHEMBL233,Mu opioid receptor,Ki,=,392.0,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,CC(C)(C)NC(=O)NC[C@@H]1Cc2ccccc2CN1C(=O)NC[C@H]1CCCO1
CHEMBL288205,CHEMBL233,Mu opioid receptor,Ki,=,31.1,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,O=C(NC[C@@H]1Cc2ccccc2CN1C(=S)NC[C@H]1CCCN1Cc1ccccc1)Nc1ccccc1
CHEMBL40528,CHEMBL233,Mu opioid receptor,Ki,=,24.0,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,O=C(NC[C@@H]1Cc2ccccc2CN1C(=S)NC[C@H]1CCCN1Cc1ccsc1)Nc1ccccc1
CHEMBL416788,CHEMBL233,Mu opioid receptor,Ki,=,945.0,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,Cc1cc(O)cc(C)c1C(NC(=O)C1Cc2ccccc2CN1)C(=O)O
CHEMBL416431,CHEMBL233,Mu opioid receptor,Ki,=,62.8,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,O=C(NC[C@@H]1Cc2ccccc2CN1C(=S)NC[C@H]1CCCN1Cc1ccc2ccccc2c1)Nc1ccccc1
CHEMBL290463,CHEMBL233,Mu opioid receptor,Ki,=,56.0,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,O=C(NC[C@@H]1Cc2ccccc2CN1/C(S)=N/C[C@H]1CCCN1Cc1cccc(F)c1)Nc1ccccc1
CHEMBL41736,CHEMBL233,Mu opioid receptor,Ki,=,5.2,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,O=C(NC[C@@H]1Cc2ccccc2CN1/C(S)=N/C[C@H]1CCCN1Cc1cccc(O)c1)Nc1ccccc1
CHEMBL287989,CHEMBL233,Mu opioid receptor,Ki,=,21.4,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,O=C(NC[C@@H]1Cc2ccccc2CN1/C(S)=N/C[C@H]1CCCN1Cc1ccc(O)c(O)c1)Nc1ccccc1
CHEMBL38495,CHEMBL233,Mu opioid receptor,Ki,=,14.8,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,N#Cc1ccccc1CN1CCC[C@@H]1CNC(=S)N1Cc2ccccc2C[C@H]1CNC(=O)Nc1ccccc1
CHEMBL43682,CHEMBL233,Mu opioid receptor,Ki,=,31.1,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,O=C(NC[C@@H]1Cc2ccccc2CN1C(=S)NC[C@H]1CCCN1Cc1ccccn1)Nc1ccccc1
CHEMBL418616,CHEMBL233,Mu opioid receptor,Ki,=,173.0,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,CN1CCC[C@@H]1C/N=C(\S)N1Cc2ccccc2C[C@H]1CNC(=O)NC(C)(C)C
CHEMBL40993,CHEMBL233,Mu opioid receptor,Ki,=,8.8,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,COc1ccccc1CN1CCC[C@@H]1C/N=C(\S)N1Cc2ccccc2C[C@H]1CNC(=O)Nc1ccccc1
CHEMBL287981,CHEMBL233,Mu opioid receptor,Ki,=,137.0,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,CC(C)(C)NC(=O)NC[C@@H]1Cc2ccccc2CN1/C(S)=N/C[C@H]1CCCN1C(C)(C)C
CHEMBL290240,CHEMBL233,Mu opioid receptor,Ki,=,50.4,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,N#Cc1cccc(CN2CCC[C@@H]2CNC(=S)N2Cc3ccccc3C[C@H]2CNC(=O)Nc2ccccc2)c1
CHEMBL41205,CHEMBL233,Mu opioid receptor,Ki,=,26.2,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,O=C(NC[C@@H]1Cc2ccccc2CN1/C(S)=N/C[C@H]1CCCN1Cc1ccc(F)cc1)Nc1ccccc1
CHEMBL39272,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL756354,B,Binding affinity for mu opioid receptor,CHEMBL1136435,KI,COc1cc(O)ccc1CN1CCC[C@@H]1C/N=C(\S)N1Cc2ccccc2C[C@H]1CNC(=O)Nc1ccccc1
CHEMBL291901,CHEMBL233,Mu opioid receptor,Ki,=,47.7,nM,CHEMBL750009,B,Binding affinity for human opioid receptor mu 1 using [3H]- DAMGO as radioligand transfected into CHO cells,CHEMBL1146689,KI,Oc1nc2ccccc2n1[C@H]1CCN2[C@H](CCC[C@H]2c2ccccc2)C1
CHEMBL2370989,CHEMBL233,Mu opioid receptor,Ki,=,1950.0,nM,CHEMBL873069,B,Affinity towards human Opioid receptor mu 1 on CHO cell membranes using [3H]DAMGO displacement.,CHEMBL1133571,KI,NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1Cc2ccccc2CN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL2370979,CHEMBL233,Mu opioid receptor,Ki,=,3280.0,nM,CHEMBL873069,B,Affinity towards human Opioid receptor mu 1 on CHO cell membranes using [3H]DAMGO displacement.,CHEMBL1133571,KI,NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1Cc2ccccc2CN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL2370980,CHEMBL233,Mu opioid receptor,Ki,=,3200.0,nM,CHEMBL873069,B,Affinity towards human Opioid receptor mu 1 on CHO cell membranes using [3H]DAMGO displacement.,CHEMBL1133571,KI,NC(=O)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1Cc2ccccc2CN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL51972,CHEMBL233,Mu opioid receptor,Ki,=,5.24,nM,CHEMBL750009,B,Binding affinity for human opioid receptor mu 1 using [3H]- DAMGO as radioligand transfected into CHO cells,CHEMBL1146689,KI,Oc1nc2ccccc2n1[C@@H]1CCN2[C@H](CCC[C@H]2c2ccccc2)C1
CHEMBL299660,CHEMBL233,Mu opioid receptor,Ki,=,17.6,nM,CHEMBL750009,B,Binding affinity for human opioid receptor mu 1 using [3H]- DAMGO as radioligand transfected into CHO cells,CHEMBL1146689,KI,CCn1c(=O)n([C@H]2CCN3[C@H](CCC[C@H]3c3ccccc3)C2)c2ccccc21
CHEMBL72885,CHEMBL233,Mu opioid receptor,Ki,=,29.6,nM,CHEMBL753394,B,Compound was evaluated for its binding affinity against CHO cells transfected with cloned human Opioid receptor mu 1 by displacing [3H]DAMGO,CHEMBL1132770,KI,NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4C1(CCN2CC1CC1)C3O5
CHEMBL54603,CHEMBL233,Mu opioid receptor,Ki,=,119.0,nM,CHEMBL750009,B,Binding affinity for human opioid receptor mu 1 using [3H]- DAMGO as radioligand transfected into CHO cells,CHEMBL1146689,KI,Oc1nc2ccccc2n1[C@H]1CCN2[C@H](CCC[C@H]2C2CCCCC2)C1
CHEMBL70693,CHEMBL233,Mu opioid receptor,Ki,=,219.2,nM,CHEMBL753394,B,Compound was evaluated for its binding affinity against CHO cells transfected with cloned human Opioid receptor mu 1 by displacing [3H]DAMGO,CHEMBL1132770,KI,CCCCC(=N)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4C1(CCN2CC1CC1)C3O5
CHEMBL573214,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL753396,B,Compound was evaluated for its binding affinity to CHO cells expressing cloned human Opioid receptor mu 1 by displacing [3H]-DAMGO,CHEMBL1132770,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL54735,CHEMBL233,Mu opioid receptor,Ki,=,46.8,nM,CHEMBL750009,B,Binding affinity for human opioid receptor mu 1 using [3H]- DAMGO as radioligand transfected into CHO cells,CHEMBL1146689,KI,Oc1nc2ccccc2n1[C@@H]1CCN2[C@H](CCC[C@H]2C2CCCCC2)C1
CHEMBL2370996,CHEMBL233,Mu opioid receptor,Ki,=,4500.0,nM,CHEMBL873069,B,Affinity towards human Opioid receptor mu 1 on CHO cell membranes using [3H]DAMGO displacement.,CHEMBL1133571,KI,NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1Cc2ccccc2CN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL52604,CHEMBL233,Mu opioid receptor,Ki,=,2.54,nM,CHEMBL750009,B,Binding affinity for human opioid receptor mu 1 using [3H]- DAMGO as radioligand transfected into CHO cells,CHEMBL1146689,KI,CCn1c(=O)n([C@@H]2CCN3[C@H](CCC[C@H]3c3ccccc3)C2)c2ccccc21
CHEMBL1701,CHEMBL233,Mu opioid receptor,Ki,=,920.0,nM,CHEMBL827398,B,Inhibition of [3H]DAMGO binding to mu-opioid receptor,CHEMBL1142692,KI,CCOC(=O)C1(c2ccccc2)CCN(C)CC1.Cl
CHEMBL540360,CHEMBL233,Mu opioid receptor,Ki,=,36800.0,nM,CHEMBL827953,B,Inhibition of [3H]DAMGO binding to mu-opioid receptor at 100 uM,CHEMBL1142692,KI,CN1CCC(C#N)(c2ccc(Cl)cc2)CC1.Cl
CHEMBL536037,CHEMBL233,Mu opioid receptor,Ki,=,17300.0,nM,CHEMBL827953,B,Inhibition of [3H]DAMGO binding to mu-opioid receptor at 100 uM,CHEMBL1142692,KI,CN1CCC(C#N)(c2ccc(I)cc2)CC1.Cl
CHEMBL536034,CHEMBL233,Mu opioid receptor,Ki,=,40600.0,nM,CHEMBL827398,B,Inhibition of [3H]DAMGO binding to mu-opioid receptor,CHEMBL1142692,KI,Cc1ccc(C2(C#N)CCN(C)CC2)cc1.Cl
CHEMBL557576,CHEMBL233,Mu opioid receptor,Ki,=,40000.0,nM,CHEMBL827398,B,Inhibition of [3H]DAMGO binding to mu-opioid receptor,CHEMBL1142692,KI,CN1CCC(C#N)(c2ccc(Cl)c(Cl)c2)CC1.Cl
CHEMBL536265,CHEMBL233,Mu opioid receptor,Ki,=,15400.0,nM,CHEMBL827953,B,Inhibition of [3H]DAMGO binding to mu-opioid receptor at 100 uM,CHEMBL1142692,KI,CN1CCC(C#N)(c2ccc3ccccc3c2)CC1.Cl
CHEMBL539845,CHEMBL233,Mu opioid receptor,Ki,=,1470.0,nM,CHEMBL875216,B,Inhibition of [3H]DAMGO binding to mu-opioid receptor,CHEMBL1142692,KI,CCOC(=O)C1(c2ccc(F)cc2)CCN(C)CC1.Cl
CHEMBL539076,CHEMBL233,Mu opioid receptor,Ki,=,4410.0,nM,CHEMBL827398,B,Inhibition of [3H]DAMGO binding to mu-opioid receptor,CHEMBL1142692,KI,CCOC(=O)C1(c2ccc(Cl)cc2)CCN(C)CC1.Cl
CHEMBL536264,CHEMBL233,Mu opioid receptor,Ki,=,2350.0,nM,CHEMBL827398,B,Inhibition of [3H]DAMGO binding to mu-opioid receptor,CHEMBL1142692,KI,CCOC(=O)C1(c2ccc(I)cc2)CCN(C)CC1.Cl
CHEMBL539075,CHEMBL233,Mu opioid receptor,Ki,=,2670.0,nM,CHEMBL827398,B,Inhibition of [3H]DAMGO binding to mu-opioid receptor,CHEMBL1142692,KI,CCOC(=O)C1(c2ccc(C)cc2)CCN(C)CC1.Cl
CHEMBL541124,CHEMBL233,Mu opioid receptor,Ki,=,2040.0,nM,CHEMBL827398,B,Inhibition of [3H]DAMGO binding to mu-opioid receptor,CHEMBL1142692,KI,CCOC(=O)C1(c2ccc(Cl)c(Cl)c2)CCN(C)CC1.Cl
CHEMBL536952,CHEMBL233,Mu opioid receptor,Ki,=,2030.0,nM,CHEMBL827398,B,Inhibition of [3H]DAMGO binding to mu-opioid receptor,CHEMBL1142692,KI,CCOC(=O)C1(c2ccc3ccccc3c2)CCN(C)CC1.Cl
CHEMBL1330,CHEMBL233,Mu opioid receptor,Ki,=,12.9,nM,CHEMBL839554,B,Inhibition of [3H]-DAMGO binding to recombinant human Opioid receptor mu 1,CHEMBL1141907,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)C=C[C@H]3[C@H]1C5
CHEMBL359534,CHEMBL233,Mu opioid receptor,Ki,=,8.7,nM,CHEMBL839554,B,Inhibition of [3H]-DAMGO binding to recombinant human Opioid receptor mu 1,CHEMBL1141907,KI,COC1[C@H](SC2OC(C(=O)O)C(O)C(O)C2O)C=C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]12CCN3C
CHEMBL359644,CHEMBL233,Mu opioid receptor,Ki,=,5.4,nM,CHEMBL839554,B,Inhibition of [3H]-DAMGO binding to recombinant human Opioid receptor mu 1,CHEMBL1141907,KI,COC1[C@H](SC2OC(CO)C(O)C(O)C2O)C=C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]12CCN3C
CHEMBL362202,CHEMBL233,Mu opioid receptor,Ki,=,3.5,nM,CHEMBL839554,B,Inhibition of [3H]-DAMGO binding to recombinant human Opioid receptor mu 1,CHEMBL1141907,KI,COC1[C@H](NC(=O)CC2OC(CO)C(O)C(O)C2O)C=C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]12CCN3C
CHEMBL366917,CHEMBL233,Mu opioid receptor,Ki,=,0.5,nM,CHEMBL839554,B,Inhibition of [3H]-DAMGO binding to recombinant human Opioid receptor mu 1,CHEMBL1141907,KI,COC1[C@H](NC(=O)CC2OC(COCc3ccccc3)C(OCc3ccccc3)C(OCc3ccccc3)C2OCc2ccccc2)C=C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]12CCN3C
CHEMBL424971,CHEMBL233,Mu opioid receptor,Ki,=,58.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc(Cl)c(OC2(C(O)CN3CCC(n4c(O)nc5ccccc54)CC3)CCCCC2)c1
CHEMBL180402,CHEMBL233,Mu opioid receptor,Ki,=,410.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc(Cl)c(OCCCN2CCC(n3c(O)nc4ccccc43)CC2)c1
CHEMBL182995,CHEMBL233,Mu opioid receptor,Ki,=,56.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,CC(C)C(CCN1CCC(n2c(O)nc3ccccc32)CC1)Oc1cc(F)ccc1Cl
CHEMBL367367,CHEMBL233,Mu opioid receptor,Ki,=,38.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1cc(F)ccc1OC(CCN1CCC(n2c(O)nc3ccccc32)CC1)C(C)C
CHEMBL179797,CHEMBL233,Mu opioid receptor,Ki,=,103.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1cc(OC(CCN2CCC(n3c(O)nc4ccccc43)CC2)C(C)C)ccc1F
CHEMBL183603,CHEMBL233,Mu opioid receptor,Ki,=,118.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc(Cl)c(OC(C)C(O)CN2CCC(n3c(O)nc4ccccc43)CC2)c1
CHEMBL183323,CHEMBL233,Mu opioid receptor,Ki,=,45.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,CCC(Oc1cc(C)ccc1Cl)C(O)CN1CCC(n2c(O)nc3ccccc32)CC1
CHEMBL182410,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,CCCC(Oc1cc(C)ccc1Cl)C(O)CN1CCC(n2c(O)nc3ccccc32)CC1
CHEMBL182144,CHEMBL233,Mu opioid receptor,Ki,=,88.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc(Cl)c(OC(C(C)C)C(O)CN2CCC(n3c(O)nc4ccccc43)CC2)c1
CHEMBL264288,CHEMBL233,Mu opioid receptor,Ki,=,103.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc(Cl)c(OC(C(O)CN2CCC(n3c(O)nc4ccccc43)CC2)C2CCCCC2)c1
CHEMBL178318,CHEMBL233,Mu opioid receptor,Ki,=,166.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc(Cl)c(OC(CC(C)C)C(O)CN2CCC(n3c(O)nc4ccccc43)CC2)c1
CHEMBL181342,CHEMBL233,Mu opioid receptor,Ki,=,355.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc(Cl)c(OC(Cc2ccccc2)C(O)CN2CCC(n3c(O)nc4ccccc43)CC2)c1
CHEMBL182328,CHEMBL233,Mu opioid receptor,Ki,=,114.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc(Cl)c(OC(c2ccccc2)C(O)CN2CCC(n3c(O)nc4ccccc43)CC2)c1
CHEMBL182328,CHEMBL233,Mu opioid receptor,Ki,=,144.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc(Cl)c(OC(c2ccccc2)C(O)CN2CCC(n3c(O)nc4ccccc43)CC2)c1
CHEMBL362240,CHEMBL233,Mu opioid receptor,Ki,=,477.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc(Cl)c(OC2(C(CN3CCC(n4c(O)nc5ccccc54)CC3)n3ccnc3)CCCCC2)c1
CHEMBL183918,CHEMBL233,Mu opioid receptor,Ki,=,102.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc(Cl)c(OC2(C(CN3CCC(n4c(O)nc5ccccc54)CC3)N(C)C)CCCCC2)c1
CHEMBL182819,CHEMBL233,Mu opioid receptor,Ki,=,16.7,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc(Cl)c(OC(CCN2CCC(n3c(O)nc4ccccc43)CC2)c2ccccc2)c1
CHEMBL360326,CHEMBL233,Mu opioid receptor,Ki,=,65.2,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc(Cl)c(OC(CCN2CCC(n3c(O)nc4ccccc43)CC2)C(C)C)c1
CHEMBL369786,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccccc1OC(CCN1CCC(n2c(O)nc3ccccc32)CC1)C(C)C
CHEMBL181830,CHEMBL233,Mu opioid receptor,Ki,=,23.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,CCc1ccccc1OC(CCN1CCC(n2c(O)nc3ccccc32)CC1)C(C)C
CHEMBL183135,CHEMBL233,Mu opioid receptor,Ki,=,24.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,CC(C)C(CCN1CCC(n2c(O)nc3ccccc32)CC1)Oc1ccccc1C(F)(F)F
CHEMBL369540,CHEMBL233,Mu opioid receptor,Ki,=,20.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,CC(C)c1ccccc1OC(CCN1CCC(n2c(O)nc3ccccc32)CC1)C(C)C
CHEMBL361576,CHEMBL233,Mu opioid receptor,Ki,=,67.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc(F)c(OC(CCN2CCC(n3c(O)nc4ccccc43)CC2)C(C)C)c1
CHEMBL182202,CHEMBL233,Mu opioid receptor,Ki,=,62.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc([N+](=O)[O-])c(OC(CCN2CCC(n3c(O)nc4ccccc43)CC2)C(C)C)c1
CHEMBL180499,CHEMBL233,Mu opioid receptor,Ki,=,196.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc([N+](=O)[O-])cc1OC(CCN1CCC(n2c(O)nc3ccccc32)CC1)C(C)C
CHEMBL181389,CHEMBL233,Mu opioid receptor,Ki,=,47.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc(N)cc1OC(CCN1CCC(n2c(O)nc3ccccc32)CC1)C(C)C
CHEMBL183355,CHEMBL233,Mu opioid receptor,Ki,=,65.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc(C)c(OC(CCN2CCC(n3c(O)nc4ccccc43)CC2)C(C)C)c1
CHEMBL427683,CHEMBL233,Mu opioid receptor,Ki,=,59.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)[nH]c4ccccc43)CC2)C(C)C)c1
CHEMBL360326,CHEMBL233,Mu opioid receptor,Ki,=,65.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,Cc1ccc(Cl)c(OC(CCN2CCC(n3c(O)nc4ccccc43)CC2)C(C)C)c1
CHEMBL262104,CHEMBL233,Mu opioid receptor,Ki,=,58.0,nM,CHEMBL829062,B,Binding affinity towards human opioid receptor mu 1 was determined by using [3H]diprenorphine as radioligand expressed in Chinese hamster ovary (CHO) cells,CHEMBL1144273,KI,COc1ccc(Cl)c(OC(CCN2CCC(n3c(O)nc4ccccc43)CC2)C(C)C)c1
CHEMBL184865,CHEMBL233,Mu opioid receptor,Ki,=,294.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,O=S1(=O)NCc2ccccc2N1C1CCN(Cc2ccc3ccccc3c2)CC1
CHEMBL184646,CHEMBL233,Mu opioid receptor,Ki,=,5545.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,O=S1(=O)Nc2ccccc2N1C1CCN(C2CCC3CCCCC3C2)CC1
CHEMBL184698,CHEMBL233,Mu opioid receptor,Ki,=,748.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,CC(C)C1CCC(N2CCC(N3c4ccccc4NS3(=O)=O)CC2)CC1
CHEMBL186773,CHEMBL233,Mu opioid receptor,Ki,=,38.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,CCCCN1Cc2ccccc2N(C2CCN(C3CCC(C(C)C)CC3)CC2)S1(=O)=O
CHEMBL364844,CHEMBL233,Mu opioid receptor,Ki,=,182.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,COC(=O)CN1Cc2ccccc2N(C2CCN(C3CCC(C(C)C)CC3)CC2)S1(=O)=O
CHEMBL181545,CHEMBL233,Mu opioid receptor,Ki,=,289.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,CC(C)C1CCC(N2CCC(N3c4ccccc4CN(CC(=O)OC(C)(C)C)S3(=O)=O)CC2)CC1
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,36.7,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL362160,CHEMBL233,Mu opioid receptor,Ki,=,13.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,O=S1(=O)NCc2ccccc2N1C1CCN(CCC(c2ccccc2)c2ccccc2)CC1
CHEMBL184328,CHEMBL233,Mu opioid receptor,Ki,=,660.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,O=S1(=O)NCc2ccccc2N1C1CCN(C2Cc3ccccc3C2)CC1
CHEMBL184234,CHEMBL233,Mu opioid receptor,Ki,=,91.7,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,O=S1(=O)NCc2ccccc2N1C1CCN(C2CCC3CCCCC3C2)CC1
CHEMBL184127,CHEMBL233,Mu opioid receptor,Ki,=,207.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,CC(C)C1CCC(N2CCC(N3c4ccccc4CNS3(=O)=O)CC2)CC1
CHEMBL184260,CHEMBL233,Mu opioid receptor,Ki,=,188.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,CCCC1CCC(N2CCC(N3c4ccccc4CNS3(=O)=O)CC2)CC1
CHEMBL184381,CHEMBL233,Mu opioid receptor,Ki,=,73.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,CC(C)CCC(C)N1CCC(N2c3ccccc3CNS2(=O)=O)CC1
CHEMBL184451,CHEMBL233,Mu opioid receptor,Ki,=,1376.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,O=S1(=O)NCc2ccccc2N1C1CCN(C2CCCCCCC2)CC1
CHEMBL184127,CHEMBL233,Mu opioid receptor,Ki,=,89.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,CC(C)C1CCC(N2CCC(N3c4ccccc4CNS3(=O)=O)CC2)CC1
CHEMBL184127,CHEMBL233,Mu opioid receptor,Ki,=,112.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,CC(C)C1CCC(N2CCC(N3c4ccccc4CNS3(=O)=O)CC2)CC1
CHEMBL186822,CHEMBL233,Mu opioid receptor,Ki,=,92.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,CC(C)C1CCC(N2CCC(N3c4ccccc4CN(CC(N)=O)S3(=O)=O)CC2)CC1
CHEMBL185415,CHEMBL233,Mu opioid receptor,Ki,=,25.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,CC(C)C1CCC(N2CCC(N3c4ccccc4CN(CC#N)S3(=O)=O)CC2)CC1
CHEMBL364398,CHEMBL233,Mu opioid receptor,Ki,=,86.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,CC(C)C1CCC(N2CCC(N3c4ccccc4CN(CCO)S3(=O)=O)CC2)CC1
CHEMBL182967,CHEMBL233,Mu opioid receptor,Ki,=,106.0,nM,CHEMBL829980,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor mu 1,CHEMBL1137888,KI,CC(C)C1CCC(N2CCC(N3c4ccccc4CN(CCNS(C)(=O)=O)S3(=O)=O)CC2)CC1
CHEMBL320882,CHEMBL233,Mu opioid receptor,Ki,=,53.0,nM,CHEMBL839660,B,Binding affinity for human Mu opioid receptor,CHEMBL1138638,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)C(CN1CCCC1)c1ccccc1
CHEMBL184811,CHEMBL233,Mu opioid receptor,Ki,=,1000.0,nM,CHEMBL839660,B,Binding affinity for human Mu opioid receptor,CHEMBL1138638,KI,O=C1C(c2ccc(Cl)c(Cl)c2)CC=CCN1C(CN1CCCC1)c1ccccc1
CHEMBL186795,CHEMBL233,Mu opioid receptor,Ki,=,0.16,nM,CHEMBL839748,B,Binding affinity for recombinant human mu-opioid receptor was determined by using [3H]- diprenophine radioligand,CHEMBL1137050,KI,CN(C)C(=O)C(CCN1CCC(O)(c2cccc(C(F)(F)F)c2)CC1)(c1ccccc1)c1ccccc1
CHEMBL841,CHEMBL233,Mu opioid receptor,Ki,=,0.53,nM,CHEMBL839748,B,Binding affinity for recombinant human mu-opioid receptor was determined by using [3H]- diprenophine radioligand,CHEMBL1137050,KI,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
CHEMBL421665,CHEMBL233,Mu opioid receptor,Ki,=,0.11,nM,CHEMBL839748,B,Binding affinity for recombinant human mu-opioid receptor was determined by using [3H]- diprenophine radioligand,CHEMBL1137050,KI,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)c(C(F)(F)F)c2)CC1)(c1ccccc1)c1ccccc1
CHEMBL364625,CHEMBL233,Mu opioid receptor,Ki,=,0.11,nM,CHEMBL839748,B,Binding affinity for recombinant human mu-opioid receptor was determined by using [3H]- diprenophine radioligand,CHEMBL1137050,KI,COC(=O)C(CCN1CCC(O)(c2cccc(C(F)(F)F)c2)CC1)(c1ccccc1)c1ccccc1
CHEMBL186300,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL839748,B,Binding affinity for recombinant human mu-opioid receptor was determined by using [3H]- diprenophine radioligand,CHEMBL1137050,KI,COC(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
CHEMBL186938,CHEMBL233,Mu opioid receptor,Ki,=,0.3,nM,CHEMBL839748,B,Binding affinity for recombinant human mu-opioid receptor was determined by using [3H]- diprenophine radioligand,CHEMBL1137050,KI,COC(=O)C(CCN1CCC(O)(c2ccc(Cl)c(C(F)(F)F)c2)CC1)(c1ccccc1)c1ccccc1
CHEMBL187648,CHEMBL233,Mu opioid receptor,Ki,=,331.0,nM,CHEMBL839748,B,Binding affinity for recombinant human mu-opioid receptor was determined by using [3H]- diprenophine radioligand,CHEMBL1137050,KI,O=C(O)C(CCN1CCC(O)(c2cccc(C(F)(F)F)c2)CC1)(c1ccccc1)c1ccccc1
CHEMBL184689,CHEMBL233,Mu opioid receptor,Ki,=,1461.0,nM,CHEMBL839748,B,Binding affinity for recombinant human mu-opioid receptor was determined by using [3H]- diprenophine radioligand,CHEMBL1137050,KI,O=C(O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
CHEMBL187038,CHEMBL233,Mu opioid receptor,Ki,=,489.0,nM,CHEMBL839748,B,Binding affinity for recombinant human mu-opioid receptor was determined by using [3H]- diprenophine radioligand,CHEMBL1137050,KI,O=C(O)C(CCN1CCC(O)(c2ccc(Cl)c(C(F)(F)F)c2)CC1)(c1ccccc1)c1ccccc1
CHEMBL184496,CHEMBL233,Mu opioid receptor,Ki,=,8128.0,nM,CHEMBL839748,B,Binding affinity for recombinant human mu-opioid receptor was determined by using [3H]- diprenophine radioligand,CHEMBL1137050,KI,[O-][N+]1(CCC(c2ccccc2)c2ccccc2)CCC(O)(c2cccc(C(F)(F)F)c2)CC1
CHEMBL322515,CHEMBL233,Mu opioid receptor,Ki,=,1.0,nM,CHEMBL839748,B,Binding affinity for recombinant human mu-opioid receptor was determined by using [3H]- diprenophine radioligand,CHEMBL1137050,KI,OC1(c2cccc(C(F)(F)F)c2)CCN(CCC(c2ccccc2)c2ccccc2)CC1
CHEMBL186426,CHEMBL233,Mu opioid receptor,Ki,=,37.0,nM,CHEMBL839748,B,Binding affinity for recombinant human mu-opioid receptor was determined by using [3H]- diprenophine radioligand,CHEMBL1137050,KI,OC1(c2ccc(Cl)cc2)CCN(CCC(c2ccccc2)c2ccccc2)CC1
CHEMBL325536,CHEMBL233,Mu opioid receptor,Ki,=,4.0,nM,CHEMBL839748,B,Binding affinity for recombinant human mu-opioid receptor was determined by using [3H]- diprenophine radioligand,CHEMBL1137050,KI,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCC(c2ccccc2)c2ccccc2)CC1
CHEMBL111233,CHEMBL233,Mu opioid receptor,Ki,=,2.5,nM,CHEMBL839748,B,Binding affinity for recombinant human mu-opioid receptor was determined by using [3H]- diprenophine radioligand,CHEMBL1137050,KI,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(Cc2ccc3ccccc3c2)CC1
CHEMBL109509,CHEMBL233,Mu opioid receptor,Ki,=,104.0,nM,CHEMBL839748,B,Binding affinity for recombinant human mu-opioid receptor was determined by using [3H]- diprenophine radioligand,CHEMBL1137050,KI,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(Cc2ccc(C(F)(F)F)cc2)CC1
CHEMBL567175,CHEMBL233,Mu opioid receptor,Ki,=,6.3,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL573214,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL188841,CHEMBL233,Mu opioid receptor,Ki,=,114.0,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CN(C)C1CCc2ccc(O)cc2C1(C)C
CHEMBL185763,CHEMBL233,Mu opioid receptor,Ki,=,491.0,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CCCNC1CCc2ccc(O)cc2C1(C)C
CHEMBL186154,CHEMBL233,Mu opioid receptor,Ki,=,85.0,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CCCN(C)C1CCc2ccc(O)cc2C1(C)C
CHEMBL365410,CHEMBL233,Mu opioid receptor,Ki,=,482.0,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CCCN(CCC)C1CCc2ccc(O)cc2C1(C)C
CHEMBL188920,CHEMBL233,Mu opioid receptor,Ki,=,312.0,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CC1(C)c2cc(O)ccc2CCC1NCC1CC1
CHEMBL365228,CHEMBL233,Mu opioid receptor,Ki,=,104.0,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CN(CC1CC1)C1CCc2ccc(O)cc2C1(C)C
CHEMBL188411,CHEMBL233,Mu opioid receptor,Ki,=,422.0,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CC1(C)c2cc(O)ccc2CCC1N(CC1CC1)CC1CC1
CHEMBL188805,CHEMBL233,Mu opioid receptor,Ki,=,202.0,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,C=CCNC1CCc2ccc(O)cc2C1(C)C
CHEMBL442413,CHEMBL233,Mu opioid receptor,Ki,=,1080.0,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,C=CCN(C)C1CCc2ccc(O)cc2C1(C)C
CHEMBL364133,CHEMBL233,Mu opioid receptor,Ki,=,105.0,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,C=CCN(CC=C)C1CCc2ccc(O)cc2C1(C)C
CHEMBL189243,CHEMBL233,Mu opioid receptor,Ki,=,10.7,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CC1(C)c2cc(O)ccc2CCC1NC/C=C/c1ccccc1
CHEMBL365483,CHEMBL233,Mu opioid receptor,Ki,=,39.7,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CN(C/C=C/c1ccccc1)C1CCc2ccc(O)cc2C1(C)C
CHEMBL435305,CHEMBL233,Mu opioid receptor,Ki,=,268.0,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CC1(C)c2cc(O)ccc2CCC1N(C/C=C/c1ccccc1)C/C=C/c1ccccc1
CHEMBL187635,CHEMBL233,Mu opioid receptor,Ki,=,17.5,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CO[C@H]1Cc2ccc(O)cc2C(C)(C)[C@@H]1N
CHEMBL189571,CHEMBL233,Mu opioid receptor,Ki,=,1.63,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CO[C@H]1Cc2ccc(O)cc2C(C)(C)[C@@H]1NC/C=C/c1ccccc1
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL840085,B,Inhibition of [3H]DAMGO binding to human Mu opioid receptor expressed in CHO cells,CHEMBL1137216,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL188553,CHEMBL233,Mu opioid receptor,Ki,=,2980.0,nM,CHEMBL838703,B,Inhibition of [125I]- IOXY binding to human Opioid receptor mu1,CHEMBL1145160,KI,COC(=O)[C@@H]1C[C@H](OC(=O)C(C)C)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL370912,CHEMBL233,Mu opioid receptor,Ki,=,260.0,nM,CHEMBL838703,B,Inhibition of [125I]- IOXY binding to human Opioid receptor mu1,CHEMBL1145160,KI,C=C(C)C(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL363324,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL838703,B,Inhibition of [125I]- IOXY binding to human Opioid receptor mu1,CHEMBL1145160,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL191014,CHEMBL233,Mu opioid receptor,Ki,=,73.0,nM,CHEMBL838703,B,Inhibition of [125I]- IOXY binding to human Opioid receptor mu1,CHEMBL1145160,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2cccnc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL365216,CHEMBL233,Mu opioid receptor,Ki,=,6820.0,nM,CHEMBL838703,B,Inhibition of [125I]- IOXY binding to human Opioid receptor mu1,CHEMBL1145160,KI,COC(=O)[C@@H]1C[C@H](OS(C)(=O)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL190910,CHEMBL233,Mu opioid receptor,Ki,=,5740.0,nM,CHEMBL838703,B,Inhibition of [125I]- IOXY binding to human Opioid receptor mu1,CHEMBL1145160,KI,COC(=O)[C@@H]1C[C@H](O)[C@H](O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL190785,CHEMBL233,Mu opioid receptor,Ki,=,16.0,nM,CHEMBL838703,B,Inhibition of [125I]- IOXY binding to human Opioid receptor mu1,CHEMBL1145160,KI,COC(=O)[C@@H]1C[C@H](OC(=O)Nc2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL191180,CHEMBL233,Mu opioid receptor,Ki,=,640.0,nM,CHEMBL838703,B,Inhibition of [125I]- IOXY binding to human Opioid receptor mu1,CHEMBL1145160,KI,C=CCNC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL189643,CHEMBL233,Mu opioid receptor,Ki,=,478.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(CNS(=O)(=O)Cc2ccccc2)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL190766,CHEMBL233,Mu opioid receptor,Ki,=,1026.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CCS(=O)(=O)NCc1ccc(CC(=O)N(C)[C@H](CN2CC[C@H](O)C2)c2ccccc2)cc1
CHEMBL447185,CHEMBL233,Mu opioid receptor,Ki,=,1100.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CC(C)S(=O)(=O)NCc1ccc(CC(=O)N(C)[C@H](CN2CC[C@H](O)C2)c2ccccc2)cc1
CHEMBL364907,CHEMBL233,Mu opioid receptor,Ki,=,570.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccccc1CNS(C)(=O)=O)[C@H](CN1CCCC1)c1ccccc1
CHEMBL370538,CHEMBL233,Mu opioid receptor,Ki,=,1062.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(CNS(=O)(=O)Cc2cccs2)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL363822,CHEMBL233,Mu opioid receptor,Ki,=,1050.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CCCS(=O)(=O)NCc1ccc(CC(=O)N(C)[C@H](CN2CC[C@H](O)C2)c2ccccc2)cc1
CHEMBL191987,CHEMBL233,Mu opioid receptor,Ki,=,105.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(NS(C)(=O)=O)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL38576,CHEMBL233,Mu opioid receptor,Ki,=,53.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL190030,CHEMBL233,Mu opioid receptor,Ki,=,1900.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1cccc(CNS(C)(=O)=O)c1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL189430,CHEMBL233,Mu opioid receptor,Ki,=,785.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(CCNS(C)(=O)=O)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL189683,CHEMBL233,Mu opioid receptor,Ki,=,440.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(CNS(C)(=O)=O)cc1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL362741,CHEMBL233,Mu opioid receptor,Ki,=,1050.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CCCCS(=O)(=O)NCc1ccc(CC(=O)N(C)[C@H](CN2CC[C@H](O)C2)c2ccccc2)cc1
CHEMBL190600,CHEMBL233,Mu opioid receptor,Ki,=,878.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(CNS(=O)(=O)c2ccccc2)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL192718,CHEMBL233,Mu opioid receptor,Ki,=,319.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(CCCNS(C)(=O)=O)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL192734,CHEMBL233,Mu opioid receptor,Ki,=,2300.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1cccc(CN)c1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL190353,CHEMBL233,Mu opioid receptor,Ki,=,1080.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(CNS(=O)(=O)c2ccc(F)cc2)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL363718,CHEMBL233,Mu opioid receptor,Ki,=,74.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc2c(c1)CN(S(C)(=O)=O)C2)[C@H](CN1CCCC1)c1ccccc1
CHEMBL425897,CHEMBL233,Mu opioid receptor,Ki,=,151.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(CNS(C)(=O)=O)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL539685,CHEMBL233,Mu opioid receptor,Ki,=,1240.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CC(=O)NCc1ccccc1CC(=O)N(C)[C@H](CN1CCCC1)c1ccccc1
CHEMBL192998,CHEMBL233,Mu opioid receptor,Ki,=,703.0,nM,CHEMBL827945,B,Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,Cc1ccc(S(=O)(=O)NCc2ccc(CC(=O)N(C)[C@H](CN3CC[C@H](O)C3)c3ccccc3)cc2)cc1
CHEMBL56695,CHEMBL233,Mu opioid receptor,Ki,=,0.71,nM,CHEMBL828894,B,Binding affinity against Opioid receptor mu 1 expressed in CHO cells using [3H]DAMGO as radioligand,CHEMBL1143538,KI,NC(=O)c1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.11,nM,CHEMBL828894,B,Binding affinity against Opioid receptor mu 1 expressed in CHO cells using [3H]DAMGO as radioligand,CHEMBL1143538,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL426084,CHEMBL233,Mu opioid receptor,Ki,=,0.052,nM,CHEMBL828894,B,Binding affinity against Opioid receptor mu 1 expressed in CHO cells using [3H]DAMGO as radioligand,CHEMBL1143538,KI,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3
CHEMBL195285,CHEMBL233,Mu opioid receptor,Ki,=,11.0,nM,CHEMBL828894,B,Binding affinity against Opioid receptor mu 1 expressed in CHO cells using [3H]DAMGO as radioligand,CHEMBL1143538,KI,COc1c(C(N)=O)ccc2c1[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3
CHEMBL195787,CHEMBL233,Mu opioid receptor,Ki,=,17.0,nM,CHEMBL828894,B,Binding affinity against Opioid receptor mu 1 expressed in CHO cells using [3H]DAMGO as radioligand,CHEMBL1143538,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c(O)c4[C@@]2(CCN3CC2CC2)C1
CHEMBL370029,CHEMBL233,Mu opioid receptor,Ki,=,0.13,nM,CHEMBL828894,B,Binding affinity against Opioid receptor mu 1 expressed in CHO cells using [3H]DAMGO as radioligand,CHEMBL1143538,KI,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@]1(O)CCC(=O)C3
CHEMBL196071,CHEMBL233,Mu opioid receptor,Ki,=,33.0,nM,CHEMBL881218,B,Binding affinity towards opioid receptor mu 1,CHEMBL1140446,KI,CCC(=O)N(CCCCNC(=N)N)C1CCN(CCc2ccccc2)CC1
CHEMBL146997,CHEMBL233,Mu opioid receptor,Ki,=,126.0,nM,CHEMBL881218,B,Binding affinity towards opioid receptor mu 1,CHEMBL1140446,KI,CCC(=O)N(CCCCCCCCNC(=N)N)C1CCN(CCc2ccccc2)CC1
CHEMBL200456,CHEMBL233,Mu opioid receptor,Ki,=,0.13,nM,CHEMBL864530,B,Displacement of [3H]DAMGO from recombinant human mu opioid receptor,CHEMBL1141194,KI,CCC(=O)N(c1ccccc1)C1(C(=O)OC[18F])CCN(CCc2ccccc2)CC1
CHEMBL200392,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL864530,B,Displacement of [3H]DAMGO from recombinant human mu opioid receptor,CHEMBL1141194,KI,CCC(=O)N(c1ccccc1)C1(C(=O)OCC[18F])CCN(CCc2ccccc2)CC1
CHEMBL371268,CHEMBL233,Mu opioid receptor,Ki,=,13.5,nM,CHEMBL864530,B,Displacement of [3H]DAMGO from recombinant human mu opioid receptor,CHEMBL1141194,KI,CCC(=O)N(c1ccccc1)C1CCN(CCCCC[18F])CC1
CHEMBL371710,CHEMBL233,Mu opioid receptor,Ki,=,0.74,nM,CHEMBL864530,B,Displacement of [3H]DAMGO from recombinant human mu opioid receptor,CHEMBL1141194,KI,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCCCC[18F])CC1
CHEMBL197479,CHEMBL233,Mu opioid receptor,Ki,=,2.1,nM,CHEMBL864530,B,Displacement of [3H]DAMGO from recombinant human mu opioid receptor,CHEMBL1141194,KI,CC([18F])C(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL196960,CHEMBL233,Mu opioid receptor,Ki,=,0.13,nM,CHEMBL864530,B,Displacement of [3H]DAMGO from recombinant human mu opioid receptor,CHEMBL1141194,KI,COCC1(N(C(=O)C(C)[18F])c2ccccc2)CCN(CCc2cccs2)CC1
CHEMBL2311157,CHEMBL233,Mu opioid receptor,Ki,=,0.07,nM,CHEMBL864530,B,Displacement of [3H]DAMGO from recombinant human mu opioid receptor,CHEMBL1141194,KI,CCC(=O)N(c1ccccc1)C1(C(=O)O[11CH3])CCN(CCc2ccccc2)CC1
CHEMBL199434,CHEMBL233,Mu opioid receptor,Ki,=,235.0,nM,CHEMBL859856,B,Displacement of [3H]DAMGO from cloned human mu opioid receptor,CHEMBL1148550,KI,Cn1c(N2CCC(c3ccccc3)(c3nccn3Cc3ccccc3)CC2)nc2ccccc21
CHEMBL199518,CHEMBL233,Mu opioid receptor,Ki,=,980.0,nM,CHEMBL859856,B,Displacement of [3H]DAMGO from cloned human mu opioid receptor,CHEMBL1148550,KI,O=S(=O)(Nc1ccccc1)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL200098,CHEMBL233,Mu opioid receptor,Ki,=,1385.0,nM,CHEMBL859856,B,Displacement of [3H]DAMGO from cloned human mu opioid receptor,CHEMBL1148550,KI,COc1cccc(NC(=O)N2CCC(c3ccccc3)(c3nccn3Cc3ccccc3)CC2)c1
CHEMBL201453,CHEMBL233,Mu opioid receptor,Ki,=,1206.0,nM,CHEMBL859856,B,Displacement of [3H]DAMGO from cloned human mu opioid receptor,CHEMBL1148550,KI,O=C(Nc1ccc(F)cc1)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL371266,CHEMBL233,Mu opioid receptor,Ki,=,2520.0,nM,CHEMBL859856,B,Displacement of [3H]DAMGO from cloned human mu opioid receptor,CHEMBL1148550,KI,O=C(Nc1ccccc1F)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL200067,CHEMBL233,Mu opioid receptor,Ki,=,497.0,nM,CHEMBL859856,B,Displacement of [3H]DAMGO from cloned human mu opioid receptor,CHEMBL1148550,KI,CC(c1ccccc1)n1ccnc1C1(c2ccccc2)CCN(C(=O)Nc2ccccc2)CC1
CHEMBL197917,CHEMBL233,Mu opioid receptor,Ki,=,1417.0,nM,CHEMBL859856,B,Displacement of [3H]DAMGO from cloned human mu opioid receptor,CHEMBL1148550,KI,O=C(Nc1ccccc1)N1CCC(c2ccccc2)(c2nccn2Cc2ccccn2)CC1
CHEMBL199289,CHEMBL233,Mu opioid receptor,Ki,=,3246.0,nM,CHEMBL859856,B,Displacement of [3H]DAMGO from cloned human mu opioid receptor,CHEMBL1148550,KI,COc1cccc(Cn2ccnc2C2(c3ccccc3)CCN(C(=O)Nc3ccccc3)CC2)c1
CHEMBL199871,CHEMBL233,Mu opioid receptor,Ki,=,428.0,nM,CHEMBL859856,B,Displacement of [3H]DAMGO from cloned human mu opioid receptor,CHEMBL1148550,KI,O=C(Nc1ccccc1)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2F)CC1
CHEMBL592,CHEMBL233,Mu opioid receptor,Ki,=,0.21,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL146756,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(/C=C/C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL147511,CHEMBL233,Mu opioid receptor,Ki,=,0.09,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL203251,CHEMBL233,Mu opioid receptor,Ki,=,0.16,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCC(=O)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL201219,CHEMBL233,Mu opioid receptor,Ki,=,13.0,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(/C=C/C(=O)Nc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3)Nc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL201220,CHEMBL233,Mu opioid receptor,Ki,=,5.7,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCCCCCCCC(=O)Nc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3)Nc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL372598,CHEMBL233,Mu opioid receptor,Ki,=,3.3,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCC(=O)Nc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3)Nc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL200881,CHEMBL233,Mu opioid receptor,Ki,=,0.65,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3)Nc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL199827,CHEMBL233,Mu opioid receptor,Ki,=,0.44,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccccc1
CHEMBL199931,CHEMBL233,Mu opioid receptor,Ki,=,0.22,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,CN1CC[C@]23c4c5ccc(OC(=O)CCCCCCCCC(=O)Oc6ccc7c(c6)[C@@]68CCCCC6[C@@H](C7)N(CC6CCC6)CC8)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL201271,CHEMBL233,Mu opioid receptor,Ki,=,0.34,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CC1)CC3)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL193039,CHEMBL233,Mu opioid receptor,Ki,=,2.2,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@]13CCCCC1[C@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL383320,CHEMBL233,Mu opioid receptor,Ki,=,0.71,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(O)CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL381750,CHEMBL233,Mu opioid receptor,Ki,=,2.8,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(/C=C/C=C/C(=O)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL372823,CHEMBL233,Mu opioid receptor,Ki,=,14.0,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,C#CCN1CC[C@]23CCCCC2[C@H]1Cc1ccc(OC(=O)CCCCCCCCC(=O)Oc2ccc4c(c2)[C@@]25CCCCC2[C@@H](C4)N(CC#C)CC5)cc13
CHEMBL369919,CHEMBL233,Mu opioid receptor,Ki,=,0.67,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(C[C@@H]1CCCO1)CC3)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(C[C@@H]1CCCO1)CC3
CHEMBL200295,CHEMBL233,Mu opioid receptor,Ki,=,130.0,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@]13CCCCC1[C@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@]13CCCCC1[C@H](C2)N(CC1CCC1)CC3
CHEMBL201038,CHEMBL233,Mu opioid receptor,Ki,=,1100.0,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(O)C(O)c1ccccc1.Oc1ccc2c(c1)[C@]13CCCCC1[C@H](C2)N(CC1CC1)CC3
CHEMBL381117,CHEMBL233,Mu opioid receptor,Ki,=,60.0,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(O)C(O)c1ccccc1.Oc1ccc2c(c1)[C@]13CCCCC1[C@H](C2)N(CC1CCC1)CC3
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,0.88,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL49143,CHEMBL233,Mu opioid receptor,Ki,=,3.7,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1790045,CHEMBL233,Mu opioid receptor,Ki,=,0.003,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,C#CCN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL199832,CHEMBL233,Mu opioid receptor,Ki,=,0.01,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(C[C@@H]1CCCO1)CC3
CHEMBL49269,CHEMBL233,Mu opioid receptor,Ki,=,0.062,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL301160,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL858889,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1148605,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL319536,CHEMBL233,Mu opioid receptor,Ki,=,1.9,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL383094,CHEMBL233,Mu opioid receptor,Ki,=,13.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,CCCCCCCN1C[C@H](C)[C@](C)(c2cccc(O)c2)C[C@H]1CCC
CHEMBL202327,CHEMBL233,Mu opioid receptor,Ki,=,47.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,CCCCCCN1C[C@H](C)[C@](C)(c2cccc(O)c2)C[C@H]1CCC
CHEMBL202200,CHEMBL233,Mu opioid receptor,Ki,=,380.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,CCCCCN1C[C@H](C)[C@](C)(c2cccc(O)c2)C[C@H]1CCC
CHEMBL202150,CHEMBL233,Mu opioid receptor,Ki,=,550.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,CCCCN1C[C@H](C)[C@](C)(c2cccc(O)c2)C[C@H]1CCC
CHEMBL202139,CHEMBL233,Mu opioid receptor,Ki,=,430.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCC
CHEMBL202462,CHEMBL233,Mu opioid receptor,Ki,=,410.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CC
CHEMBL202461,CHEMBL233,Mu opioid receptor,Ki,=,520.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1C
CHEMBL201661,CHEMBL233,Mu opioid receptor,Ki,=,19.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCCc1ccccc1
CHEMBL201296,CHEMBL233,Mu opioid receptor,Ki,=,700.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1Cc1ccccc1
CHEMBL201295,CHEMBL233,Mu opioid receptor,Ki,=,560.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1
CHEMBL383044,CHEMBL233,Mu opioid receptor,Ki,=,230.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,C[C@H]1CN(CCc2ccccc2)[C@H](CCCc2ccccc2)C[C@@]1(C)c1cccc(O)c1
CHEMBL201434,CHEMBL233,Mu opioid receptor,Ki,=,160.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,C[C@H]1CN(CCc2ccccc2)[C@H](CCc2ccccc2)C[C@@]1(C)c1cccc(O)c1
CHEMBL203150,CHEMBL233,Mu opioid receptor,Ki,=,290.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,C[C@H]1CN(CCc2ccccc2)[C@H](Cc2ccccc2)C[C@@]1(C)c1cccc(O)c1
CHEMBL201480,CHEMBL233,Mu opioid receptor,Ki,=,280.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,C[C@H]1CN(CCc2ccccc2)[C@H](c2ccccc2)C[C@@]1(C)c1cccc(O)c1
CHEMBL201845,CHEMBL233,Mu opioid receptor,Ki,=,59.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,C[C@H]1CN(CCc2ccccc2)[C@H](CCNC(=O)c2ccccc2)C[C@@]1(C)c1cccc(O)c1
CHEMBL383491,CHEMBL233,Mu opioid receptor,Ki,=,190.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,CC(=O)NCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCc1ccccc1
CHEMBL201530,CHEMBL233,Mu opioid receptor,Ki,=,780.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,C[C@H]1CN(CCc2ccccc2)[C@H](CCN)C[C@@]1(C)c1cccc(O)c1
CHEMBL202352,CHEMBL233,Mu opioid receptor,Ki,=,110.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,CCCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCc1ccccc1
CHEMBL425758,CHEMBL233,Mu opioid receptor,Ki,=,270.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,CC(C)[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCc1ccccc1
CHEMBL382919,CHEMBL233,Mu opioid receptor,Ki,=,20.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCc1ccccc1
CHEMBL371970,CHEMBL233,Mu opioid receptor,Ki,=,75.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,CC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCc1ccccc1
CHEMBL203307,CHEMBL233,Mu opioid receptor,Ki,=,15.0,nM,CHEMBL866380,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1149448,KI,C[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCc1ccccc1
CHEMBL210514,CHEMBL233,Mu opioid receptor,Ki,=,1400.0,nM,CHEMBL870232,B,Binding affinity to human mu opiate receptor,CHEMBL1148507,KI,COc1nc(NCCCN2CCOCC2)nc(OC)c1NC(=O)c1ccc(Oc2cc3c(cc2C)CCC3(C)C)o1
CHEMBL212525,CHEMBL233,Mu opioid receptor,Ki,=,170.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Cn1cc(C2CCN(C3Cc4cccc5cccc3c45)CC2O)c2cccnc21
CHEMBL212630,CHEMBL233,Mu opioid receptor,Ki,=,530.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,OCCn1cc(C2CCN(C3Cc4cccc5cccc3c45)CC2)c2cccnc21
CHEMBL379657,CHEMBL233,Mu opioid receptor,Ki,=,900.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Cn1cc(C2CCN(C3Cc4cccc5cccc3c45)CC2)c2cccnc21
CHEMBL379297,CHEMBL233,Mu opioid receptor,Ki,=,390.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,c1cc2c3c(cccc3c1)C(N1CCC(c3c[nH]c4ncccc34)CC1)C2
CHEMBL378633,CHEMBL233,Mu opioid receptor,Ki,=,2000.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,c1cnc2[nH]cc(C3CCN(CC4CCCCCCC4)CC3)c2c1
CHEMBL377402,CHEMBL233,Mu opioid receptor,Ki,=,340.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,c1ccc2c(CN3CCC(c4c[nH]c5ncccc45)CC3)cccc2c1
CHEMBL377033,CHEMBL233,Mu opioid receptor,Ki,=,330.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,c1ccc(Oc2ccc(CN3CCC(c4c[nH]c5ncccc45)CC3)cc2)cc1
CHEMBL208862,CHEMBL233,Mu opioid receptor,Ki,=,260.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Clc1cccc2c(C3CCN(C4Cc5cccc6cccc4c56)CC3)c[nH]c12
CHEMBL427395,CHEMBL233,Mu opioid receptor,Ki,=,430.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Clc1cccc2c(C3CCN(CC4CCCCCCC4)CC3)c[nH]c12
CHEMBL379971,CHEMBL233,Mu opioid receptor,Ki,=,760.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,CN(C)C[C@@H](O)Cn1cc(C2CCN(C3Cc4cccc5cccc3c45)CC2)c2ccc(F)cc21
CHEMBL377237,CHEMBL233,Mu opioid receptor,Ki,=,900.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Fc1ccc2c(C3CCN(C4Cc5cccc6cccc4c56)CC3)c[nH]c2c1
CHEMBL384681,CHEMBL233,Mu opioid receptor,Ki,=,2700.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,CN(C)C[C@@H](O)Cn1cc(C2CCN(CC3CCCCCCC3)CC2)c2cc(F)ccc21
CHEMBL211722,CHEMBL233,Mu opioid receptor,Ki,=,500.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Fc1ccc2[nH]cc(C3CCN(C4Cc5cccc6cccc4c56)CC3)c2c1
CHEMBL211846,CHEMBL233,Mu opioid receptor,Ki,=,1080.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Fc1ccc2[nH]cc(C3CCN(CC4CCCCCCC4)CC3)c2c1
CHEMBL378458,CHEMBL233,Mu opioid receptor,Ki,=,500.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Fc1ccc2[nH]cc(C3CCN(Cc4cccc5ccccc45)CC3)c2c1
CHEMBL212575,CHEMBL233,Mu opioid receptor,Ki,=,260.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Cc1[nH]c2ccc(Cl)cc2c1C1CCN(C2Cc3cccc4cccc2c34)CC1
CHEMBL212574,CHEMBL233,Mu opioid receptor,Ki,=,1360.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Cc1[nH]c2ccc(Cl)cc2c1C1CCN(CC2CCCCCCC2)CC1
CHEMBL438965,CHEMBL233,Mu opioid receptor,Ki,=,880.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Cc1[nH]c2ccc(Cl)cc2c1C1CCN(Cc2cccc3ccccc23)CC1
CHEMBL210770,CHEMBL233,Mu opioid receptor,Ki,=,230.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Clc1ccc2[nH]cc(C3CCN(Cc4ccccc4)CC3)c2c1
CHEMBL378453,CHEMBL233,Mu opioid receptor,Ki,=,4140.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,N#Cc1ccc2c(c1)c(C1=CCN(C3Cc4cccc5cccc3c45)CC1)cn2C[C@H](O)CN
CHEMBL211723,CHEMBL233,Mu opioid receptor,Ki,=,500.0,nM,CHEMBL871097,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Clc1ccc2[nH]cc(C3=CCN(Cc4ccccc4)CC3)c2c1
CHEMBL211543,CHEMBL233,Mu opioid receptor,Ki,=,19.9,nM,CHEMBL865967,B,Binding affinity to mu opioid receptor,CHEMBL1138032,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H]1Cc2ccccc2CN(Cc2nc3ccccc3[nH]2)C1=O
CHEMBL377392,CHEMBL233,Mu opioid receptor,Ki,=,1.48,nM,CHEMBL865967,B,Binding affinity to mu opioid receptor,CHEMBL1138032,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H]1Cc2ccccc2CN(CC(=O)Nc2ccccc2)C1=O
CHEMBL208683,CHEMBL233,Mu opioid receptor,Ki,=,0.46,nM,CHEMBL865967,B,Binding affinity to mu opioid receptor,CHEMBL1138032,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H]1Cc2ccccc2CN(CC(=O)NCc2ccccc2)C1=O
CHEMBL333357,CHEMBL233,Mu opioid receptor,Ki,=,0.69,nM,CHEMBL865967,B,Binding affinity to mu opioid receptor,CHEMBL1138032,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL2375157,CHEMBL233,Mu opioid receptor,Ki,=,0.5,nM,CHEMBL865967,B,Binding affinity to mu opioid receptor,CHEMBL1138032,KI,Cc1cc(O)cc(C)c1C[C@@H](C)CN1Cc2ccccc2C[C@H]1C(=O)NCC(=O)NCc1nc2ccccc2[nH]1
CHEMBL501451,CHEMBL233,Mu opioid receptor,Ki,=,0.16,nM,CHEMBL865967,B,Binding affinity to mu opioid receptor,CHEMBL1138032,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C(=O)NCC(=O)Nc1ccccc1
CHEMBL458631,CHEMBL233,Mu opioid receptor,Ki,=,0.16,nM,CHEMBL865967,B,Binding affinity to mu opioid receptor,CHEMBL1138032,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C(=O)NCC(=O)NCc1ccccc1
CHEMBL377904,CHEMBL233,Mu opioid receptor,Ki,=,4000.0,nM,CHEMBL869296,B,Inhibition of (-)-[9-3H]bremazocine binding to mu opioid receptor expressed in HEK293 cells,CHEMBL1138930,KI,CN(C)c1nnc(-c2ccc(C(C)(C)C)cc2)n1-c1cccc(O)c1
CHEMBL212743,CHEMBL233,Mu opioid receptor,Ki,=,1000.0,nM,CHEMBL869296,B,Inhibition of (-)-[9-3H]bremazocine binding to mu opioid receptor expressed in HEK293 cells,CHEMBL1138930,KI,Oc1cccc(-n2cnnc2-c2cccc(-c3ccccc3)c2)c1
CHEMBL377340,CHEMBL233,Mu opioid receptor,Ki,=,850.0,nM,CHEMBL869296,B,Inhibition of (-)-[9-3H]bremazocine binding to mu opioid receptor expressed in HEK293 cells,CHEMBL1138930,KI,CC(C)(C)c1cccc(-c2nncn2-c2cccc(O)c2)c1
CHEMBL607069,CHEMBL233,Mu opioid receptor,Ki,=,0.6,nM,CHEMBL854558,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cells,CHEMBL1146036,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(C)CC[C@]314
CHEMBL610883,CHEMBL233,Mu opioid receptor,Ki,=,0.72,nM,CHEMBL854558,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cells,CHEMBL1146036,KI,Cc1ccccc1/C=C/C(=O)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL611402,CHEMBL233,Mu opioid receptor,Ki,=,0.71,nM,CHEMBL854558,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cells,CHEMBL1146036,KI,O=C(/C=C/c1ccccc1Cl)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL607127,CHEMBL233,Mu opioid receptor,Ki,=,0.49,nM,CHEMBL854558,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cells,CHEMBL1146036,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccc(C)cc5)[C@@H](C2)N(C)CC[C@]314
CHEMBL607017,CHEMBL233,Mu opioid receptor,Ki,=,0.4,nM,CHEMBL854558,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cells,CHEMBL1146036,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccccc5C)[C@@H](C2)N(C)CC[C@]314
CHEMBL607016,CHEMBL233,Mu opioid receptor,Ki,=,0.68,nM,CHEMBL854558,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cells,CHEMBL1146036,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccccc5Cl)[C@@H](C2)N(C)CC[C@]314
CHEMBL607068,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL854558,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cells,CHEMBL1146036,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(NC(=O)/C=C/c2ccc([N+](=O)[O-])cc2)[C@H]1C5
CHEMBL607018,CHEMBL233,Mu opioid receptor,Ki,=,0.34,nM,CHEMBL854558,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cells,CHEMBL1146036,KI,Cc1ccc(/C=C/C(=O)N[C@@]23CCC(=O)[C@@H]4Oc5c(O)ccc6c5[C@@]42CCN(C)[C@@H]3C6)cc1
CHEMBL607125,CHEMBL233,Mu opioid receptor,Ki,=,0.21,nM,CHEMBL854558,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cells,CHEMBL1146036,KI,Cc1ccccc1/C=C/C(=O)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL2113666,CHEMBL233,Mu opioid receptor,Ki,=,0.15,nM,CHEMBL854558,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cells,CHEMBL1146036,KI,CN1CC[C@]23c4c5cccc4O[C@H]2C(=O)CC[C@@]3(NC(=O)/C=C/c2ccccc2Cl)[C@H]1C5
CHEMBL386492,CHEMBL233,Mu opioid receptor,Ki,=,2.98,nM,CHEMBL854558,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cells,CHEMBL1146036,KI,O=C(/C=C/c1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL386272,CHEMBL233,Mu opioid receptor,Ki,=,4.78,nM,CHEMBL854558,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cells,CHEMBL1146036,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL607126,CHEMBL233,Mu opioid receptor,Ki,=,0.35,nM,CHEMBL854558,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cells,CHEMBL1146036,KI,Cc1ccc(CCC(=O)N[C@@]23CCC(=O)[C@@H]4Oc5c(O)ccc6c5[C@@]42CCN(C)[C@@H]3C6)cc1
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL854558,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cells,CHEMBL1146036,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL854558,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cells,CHEMBL1146036,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL373984,CHEMBL233,Mu opioid receptor,Ki,=,0.69,nM,CHEMBL870428,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1146900,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C(=O)NCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL384915,CHEMBL233,Mu opioid receptor,Ki,=,1100.0,nM,CHEMBL870428,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1146900,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C(=O)NCCC(=O)O
CHEMBL58646,CHEMBL233,Mu opioid receptor,Ki,=,0.31,nM,CHEMBL870415,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(N)=O)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL214104,CHEMBL233,Mu opioid receptor,Ki,=,3.1,nM,CHEMBL870415,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1146899,KI,CC[C@@]12CCN(CC3CC3)C(C(=O)c3ccc(C(=O)NCCc4ccc(-c5ccccc5)cc4)cc31)[C@@H]2C
CHEMBL60869,CHEMBL233,Mu opioid receptor,Ki,=,2.1,nM,CHEMBL870415,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1146899,KI,CC[C@@]12CCN(CC3CC3)C(C(=O)c3ccc(C(N)=O)cc31)[C@@H]2C
CHEMBL215594,CHEMBL233,Mu opioid receptor,Ki,=,6.7,nM,CHEMBL870415,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)N(C)CCc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL212434,CHEMBL233,Mu opioid receptor,Ki,=,5.8,nM,CHEMBL870415,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)NCCCc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL378355,CHEMBL233,Mu opioid receptor,Ki,=,6.4,nM,CHEMBL870415,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@@H]1[C@@H]2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)cc4)cc3[C@]1(C)CCN2CC1CC1
CHEMBL210005,CHEMBL233,Mu opioid receptor,Ki,=,0.25,nM,CHEMBL870415,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1[C@H]2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)cc4)cc3[C@]1(C)CCN2CC1CC1
CHEMBL377789,CHEMBL233,Mu opioid receptor,Ki,=,0.3,nM,CHEMBL870415,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL1162933,CHEMBL233,Mu opioid receptor,Ki,=,11.0,nM,CHEMBL870415,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)NCc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL215760,CHEMBL233,Mu opioid receptor,Ki,=,18.0,nM,CHEMBL870415,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)Nc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL213291,CHEMBL233,Mu opioid receptor,Ki,=,2.5,nM,CHEMBL870415,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)NCCCc4ccccc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL209550,CHEMBL233,Mu opioid receptor,Ki,=,3.5,nM,CHEMBL870415,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccccc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL213880,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL870415,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)NCc4ccccc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL293103,CHEMBL233,Mu opioid receptor,Ki,=,840.0,nM,CHEMBL870415,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)Nc4ccccc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL386272,CHEMBL233,Mu opioid receptor,Ki,=,4.78,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL387016,CHEMBL233,Mu opioid receptor,Ki,=,85.6,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL217658,CHEMBL233,Mu opioid receptor,Ki,=,0.86,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C1CC[C@@]2(NCCc3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL448428,CHEMBL233,Mu opioid receptor,Ki,=,0.73,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C(Cc1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL217102,CHEMBL233,Mu opioid receptor,Ki,=,0.96,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C1CC[C@@]2(NCCCCc3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL383896,CHEMBL233,Mu opioid receptor,Ki,=,1.0,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C1CC[C@@]2(NCC/C=C/c3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL216558,CHEMBL233,Mu opioid receptor,Ki,=,1.89,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C1CC[C@@]2(NC/C=C/Cc3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL217479,CHEMBL233,Mu opioid receptor,Ki,=,1.34,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C(CCCc1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL217710,CHEMBL233,Mu opioid receptor,Ki,=,1.87,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C(C/C=C/c1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL386492,CHEMBL233,Mu opioid receptor,Ki,=,2.98,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C(/C=C/c1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL387101,CHEMBL233,Mu opioid receptor,Ki,=,1.33,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NCCc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL277530,CHEMBL233,Mu opioid receptor,Ki,=,2.64,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)Cc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL215926,CHEMBL233,Mu opioid receptor,Ki,=,2.23,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NCCCCc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL411089,CHEMBL233,Mu opioid receptor,Ki,=,1.15,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NCC/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL384118,CHEMBL233,Mu opioid receptor,Ki,=,6.76,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC/C=C/Cc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL263482,CHEMBL233,Mu opioid receptor,Ki,=,3.88,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)CCCc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL216365,CHEMBL233,Mu opioid receptor,Ki,=,8.19,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)C/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL217790,CHEMBL233,Mu opioid receptor,Ki,=,8.07,nM,CHEMBL907785,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/Cc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL385482,CHEMBL233,Mu opioid receptor,Ki,=,0.32,nM,CHEMBL907184,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in C6 cells,CHEMBL1137387,KI,O=C1CC[C@@]2(NC/C=C/c3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL376413,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(CC3CCCCC3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL373925,CHEMBL233,Mu opioid receptor,Ki,=,17.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@H](c3ccccc3)N(Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL373707,CHEMBL233,Mu opioid receptor,Ki,=,1.8,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@H](c3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL425112,CHEMBL233,Mu opioid receptor,Ki,=,1600.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@H](c3ccccc3)N(Cc3ccccc3)C[C@H]2C[C@@]1(C)c1ccccc1
CHEMBL412996,CHEMBL233,Mu opioid receptor,Ki,=,4.7,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@H](c3ccccc3)N(Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218520,CHEMBL233,Mu opioid receptor,Ki,=,3.3,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@H](c3ccccc3)N(C)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218706,CHEMBL233,Mu opioid receptor,Ki,=,94.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,CC(=O)N1C[C@H]2C[C@@](C)(c3cccc(O)c3)[C@@H](C)CN2C[C@@H]1c1ccccc1
CHEMBL219319,CHEMBL233,Mu opioid receptor,Ki,=,3.6,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@H](c3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL426523,CHEMBL233,Mu opioid receptor,Ki,=,0.62,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@H](c3ccccc3)CC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL319536,CHEMBL233,Mu opioid receptor,Ki,=,1.8,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,1.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,3.7,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL219097,CHEMBL233,Mu opioid receptor,Ki,=,380.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,CC(C)[C@H]1CN2C[C@H](C)[C@](C)(c3cccc(O)c3)C[C@@H]2CN1
CHEMBL375119,CHEMBL233,Mu opioid receptor,Ki,=,2.7,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@H](C3CCCCC3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218980,CHEMBL233,Mu opioid receptor,Ki,=,25.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@@H](Cc3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL435746,CHEMBL233,Mu opioid receptor,Ki,=,8.9,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@H](Cc3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218506,CHEMBL233,Mu opioid receptor,Ki,=,180.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@@H](c3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219317,CHEMBL233,Mu opioid receptor,Ki,=,31.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(C(=O)Nc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL374324,CHEMBL233,Mu opioid receptor,Ki,=,210.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(S(=O)(=O)c3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL374678,CHEMBL233,Mu opioid receptor,Ki,=,160.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCCN(Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL375165,CHEMBL233,Mu opioid receptor,Ki,=,36.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(CCCc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219495,CHEMBL233,Mu opioid receptor,Ki,=,5.5,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(CCc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL376690,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL220248,CHEMBL233,Mu opioid receptor,Ki,=,220.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(c3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL384336,CHEMBL233,Mu opioid receptor,Ki,=,160.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(C(=O)CCc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218135,CHEMBL233,Mu opioid receptor,Ki,=,17.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(C(=O)Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218404,CHEMBL233,Mu opioid receptor,Ki,=,2.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(C(=O)c3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL426173,CHEMBL233,Mu opioid receptor,Ki,=,520.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,CC(=O)N1CCN2C[C@H](C)[C@](C)(c3cccc(O)c3)C[C@@H]2C1
CHEMBL219044,CHEMBL233,Mu opioid receptor,Ki,=,11.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,COC(=O)c1cccc(CN2CCN3C[C@H](C)[C@](C)(c4cccc(O)c4)C[C@@H]3C2)c1
CHEMBL219337,CHEMBL233,Mu opioid receptor,Ki,=,750.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccc(N(C)C)cc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL375803,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccc(O)cc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218909,CHEMBL233,Mu opioid receptor,Ki,=,4.3,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3cccc(O)c3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218242,CHEMBL233,Mu opioid receptor,Ki,=,1.8,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccccc3O)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218705,CHEMBL233,Mu opioid receptor,Ki,=,17.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccc(Cl)cc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL373641,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3cccc(Cl)c3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219318,CHEMBL233,Mu opioid receptor,Ki,=,0.47,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccccc3Cl)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL217999,CHEMBL233,Mu opioid receptor,Ki,=,14.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,Cc1ccc(CN2CCN3C[C@H](C)[C@](C)(c4cccc(O)c4)C[C@@H]3C2)cc1
CHEMBL217998,CHEMBL233,Mu opioid receptor,Ki,=,1.3,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,Cc1cccc(CN2CCN3C[C@H](C)[C@](C)(c4cccc(O)c4)C[C@@H]3C2)c1
CHEMBL219599,CHEMBL233,Mu opioid receptor,Ki,=,0.98,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,Cc1ccccc1CN1CCN2C[C@H](C)[C@](C)(c3cccc(O)c3)C[C@@H]2C1
CHEMBL219554,CHEMBL233,Mu opioid receptor,Ki,=,3.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccsc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL373446,CHEMBL233,Mu opioid receptor,Ki,=,1.4,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3cccs3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL217950,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccoc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL374455,CHEMBL233,Mu opioid receptor,Ki,=,7.4,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccco3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219152,CHEMBL233,Mu opioid receptor,Ki,=,15.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccncc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219099,CHEMBL233,Mu opioid receptor,Ki,=,13.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3cccnc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219466,CHEMBL233,Mu opioid receptor,Ki,=,20.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccccn3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL373709,CHEMBL233,Mu opioid receptor,Ki,=,88.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccnc4ccccc34)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL375633,CHEMBL233,Mu opioid receptor,Ki,=,3.5,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3cccc4ccccc34)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218136,CHEMBL233,Mu opioid receptor,Ki,=,90.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccc4ccccc4c3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL384895,CHEMBL233,Mu opioid receptor,Ki,=,13.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3cccc(OCc4ccccc4)c3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219154,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL909851,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3cccc(Oc4ccccc4)c3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,3.7,nM,CHEMBL909312,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL219012,CHEMBL233,Mu opioid receptor,Ki,=,120.0,nM,CHEMBL909312,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1[C@@H]2CCCCN2CC[C@@]1(C)c1cccc(O)c1
CHEMBL373398,CHEMBL233,Mu opioid receptor,Ki,=,940.0,nM,CHEMBL909312,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1CN2CCCC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219011,CHEMBL233,Mu opioid receptor,Ki,=,710.0,nM,CHEMBL909312,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1CN2CCCC[C@@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL262420,CHEMBL233,Mu opioid receptor,Ki,=,37.0,nM,CHEMBL909312,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1[C@H]2CC[C@@H](c3ccccc3)CN2CC[C@@]1(C)c1cccc(O)c1
CHEMBL385280,CHEMBL233,Mu opioid receptor,Ki,=,26.0,nM,CHEMBL909312,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1[C@H]2CC[C@H](c3ccccc3)CN2CC[C@@]1(C)c1cccc(O)c1
CHEMBL438821,CHEMBL233,Mu opioid receptor,Ki,=,0.9,nM,CHEMBL909312,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1[C@@H]2CC[C@@H](c3ccccc3)CN2CC[C@@]1(C)c1cccc(O)c1
CHEMBL385392,CHEMBL233,Mu opioid receptor,Ki,=,73.0,nM,CHEMBL909312,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1[C@@H]2CC[C@H](c3ccccc3)CN2CC[C@@]1(C)c1cccc(O)c1
CHEMBL374559,CHEMBL233,Mu opioid receptor,Ki,=,110.0,nM,CHEMBL909312,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1CN2C[C@@H](c3ccccc3)CC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219079,CHEMBL233,Mu opioid receptor,Ki,=,430.0,nM,CHEMBL909312,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1CN2C[C@@H](c3ccccc3)CC[C@@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL426523,CHEMBL233,Mu opioid receptor,Ki,=,0.62,nM,CHEMBL909312,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1CN2C[C@H](c3ccccc3)CC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL387248,CHEMBL233,Mu opioid receptor,Ki,=,110.0,nM,CHEMBL909312,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1CN2C[C@H](c3ccccc3)CC[C@@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL319536,CHEMBL233,Mu opioid receptor,Ki,=,1.8,nM,CHEMBL909312,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,1.0,nM,CHEMBL909312,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells,CHEMBL1137299,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL346879,CHEMBL233,Mu opioid receptor,Ki,=,16.8,nM,CHEMBL919062,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1149288,KI,Oc1ccc2c3c1O[C@H]1c4c(c(-c5ccccc5)cn4Cc4ccccc4)C[C@@]4(O)C(C2)N(CC2CC2)CC[C@]314
CHEMBL567175,CHEMBL233,Mu opioid receptor,Ki,=,6.3,nM,CHEMBL919062,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1149288,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL222814,CHEMBL233,Mu opioid receptor,Ki,=,15.4,nM,CHEMBL919062,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1149288,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2c(c4c(n2CCc2ccccc2)CCCC4)C[C@@]3(O)C1C5
CHEMBL222579,CHEMBL233,Mu opioid receptor,Ki,=,17.9,nM,CHEMBL919062,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1149288,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2c(c4c(n2CC2CCCCC2)CCCC4)C[C@@]3(O)C1C5
CHEMBL221421,CHEMBL233,Mu opioid receptor,Ki,=,88.9,nM,CHEMBL919062,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1149288,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2c(c4c(n2Cc2ccccc2)CCCC4)C[C@@]3(O)C1C5
CHEMBL222704,CHEMBL233,Mu opioid receptor,Ki,=,25.8,nM,CHEMBL919062,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1149288,KI,CCn1c2c(c3c1[C@@H]1Oc4c(O)ccc5c4[C@@]14CCN(C)C(C5)[C@]4(O)C3)CCCC2
CHEMBL374228,CHEMBL233,Mu opioid receptor,Ki,=,25.2,nM,CHEMBL919062,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1149288,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2c(c4c(n2C)CCCC4)C[C@@]3(O)C1C5
CHEMBL222762,CHEMBL233,Mu opioid receptor,Ki,=,7.46,nM,CHEMBL919062,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1149288,KI,Oc1ccc2c3c1O[C@H]1c4c(c5c(n4CCc4ccccc4)CCCC5)C[C@@]4(O)C(C2)N(CC2CC2)CC[C@]314
CHEMBL385316,CHEMBL233,Mu opioid receptor,Ki,=,18.5,nM,CHEMBL919062,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1149288,KI,Oc1ccc2c3c1O[C@H]1c4c(c5c(n4CC4CCCCC4)CCCC5)C[C@@]4(O)C(C2)N(CC2CC2)CC[C@]314
CHEMBL222647,CHEMBL233,Mu opioid receptor,Ki,=,5.39,nM,CHEMBL919062,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1149288,KI,Oc1ccc2c3c1O[C@H]1c4c(c5c(n4Cc4ccccc4)CCCC5)C[C@@]4(O)C(C2)N(CC2CC2)CC[C@]314
CHEMBL222597,CHEMBL233,Mu opioid receptor,Ki,=,2.52,nM,CHEMBL919062,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1149288,KI,Oc1ccc2c3c1O[C@H]1c4c(c5c(n4CC4CC4)CCCC5)C[C@@]4(O)C(C2)N(CC2CC2)CC[C@]314
CHEMBL222486,CHEMBL233,Mu opioid receptor,Ki,=,5.06,nM,CHEMBL919062,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1149288,KI,CCn1c2c(c3c1[C@@H]1Oc4c(O)ccc5c4[C@@]14CCN(CC1CC1)C(C5)[C@]4(O)C3)CCCC2
CHEMBL610534,CHEMBL233,Mu opioid receptor,Ki,=,5.76,nM,CHEMBL919062,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1149288,KI,Cn1c2c(c3c1[C@@H]1Oc4c(O)ccc5c4[C@@]14CCN(CC1CC1)[C@H](C5)[C@]4(O)C3)CCCC2
CHEMBL373910,CHEMBL233,Mu opioid receptor,Ki,=,8.75,nM,CHEMBL919062,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1149288,KI,CCn1cc(-c2ccccc2)c2c1[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)C(C4)[C@]3(O)C2
CHEMBL221419,CHEMBL233,Mu opioid receptor,Ki,=,7.6,nM,CHEMBL919062,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1149288,KI,Cn1cc(-c2ccccc2)c2c1[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)C(C4)[C@]3(O)C2
CHEMBL301160,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL917909,B,Displacement of [3H]DAMGO from human opioid gamma receptor expressed in CHO cells,CHEMBL1147138,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL2113275,CHEMBL233,Mu opioid receptor,Ki,=,0.43,nM,CHEMBL917909,B,Displacement of [3H]DAMGO from human opioid gamma receptor expressed in CHO cells,CHEMBL1147138,KI,C=CCN1CC[C@]23c4c5ccc(OC(=O)CCCCCCCCC(=O)Oc6ccc7c(c6)[C@@]68CCCCC6[C@@H](C7)N(CC6CCC6)CC8)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL224014,CHEMBL233,Mu opioid receptor,Ki,=,0.29,nM,CHEMBL917909,B,Displacement of [3H]DAMGO from human opioid gamma receptor expressed in CHO cells,CHEMBL1147138,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL224671,CHEMBL233,Mu opioid receptor,Ki,=,0.46,nM,CHEMBL917909,B,Displacement of [3H]DAMGO from human opioid gamma receptor expressed in CHO cells,CHEMBL1147138,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c3c1O[C@H]1[C@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,0.79,nM,CHEMBL917909,B,Displacement of [3H]DAMGO from human opioid gamma receptor expressed in CHO cells,CHEMBL1147138,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL917909,B,Displacement of [3H]DAMGO from human opioid gamma receptor expressed in CHO cells,CHEMBL1147138,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL895,CHEMBL233,Mu opioid receptor,Ki,=,0.89,nM,CHEMBL917909,B,Displacement of [3H]DAMGO from human opioid gamma receptor expressed in CHO cells,CHEMBL1147138,KI,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL389072,CHEMBL233,Mu opioid receptor,Ki,=,340.0,nM,CHEMBL904883,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,COc1ccc2c(c1)[C@]13CCN(C)[C@H](C2)[C@@H]1Cc1c([nH]c2ccccc12)C3
CHEMBL376355,CHEMBL233,Mu opioid receptor,Ki,=,0.37,nM,CHEMBL904883,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,Nc1nc2c(s1)C[C@H]1[C@H]3Cc4ccc(O)cc4[C@@]1(CCN3CC1CCC1)C2
CHEMBL226217,CHEMBL233,Mu opioid receptor,Ki,=,0.12,nM,CHEMBL904883,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,Nc1nc2c(s1)C[C@H]1[C@H]3Cc4ccc(O)cc4[C@@]1(CCN3CC1CC1)C2
CHEMBL226167,CHEMBL233,Mu opioid receptor,Ki,=,0.49,nM,CHEMBL904883,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,CN1CC[C@]23Cc4nc(N)sc4C[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL375504,CHEMBL233,Mu opioid receptor,Ki,=,3.9,nM,CHEMBL904883,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,Oc1ccc2c(c1)[C@]13CCN(CC4CCC4)[C@H](C2)[C@@H]1Cc1c([nH]c2ccccc12)C3
CHEMBL226166,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL904883,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1Cc1c([nH]c2ccccc12)C3
CHEMBL226114,CHEMBL233,Mu opioid receptor,Ki,=,22.0,nM,CHEMBL904883,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,CN1CC[C@]23Cc4[nH]c5ccccc5c4C[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL375503,CHEMBL233,Mu opioid receptor,Ki,=,330.0,nM,CHEMBL904883,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,COc1ccc2c(c1)[C@]13CCN(CC4CCC4)[C@H](C2)[C@@H]1Cc1c([nH]c2ccccc12)C3
CHEMBL226113,CHEMBL233,Mu opioid receptor,Ki,=,5.9,nM,CHEMBL904883,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1Cc1c([nH]c2ccccc12)C3
CHEMBL592,CHEMBL233,Mu opioid receptor,Ki,=,0.21,nM,CHEMBL887388,B,Displacement of [3H]DAMGO from human mu opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL394624,CHEMBL233,Mu opioid receptor,Ki,=,0.7,nM,CHEMBL887388,B,Displacement of [3H]DAMGO from human mu opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,O=C(NCc1ccccc1)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CCC1)CC3
CHEMBL242048,CHEMBL233,Mu opioid receptor,Ki,=,0.12,nM,CHEMBL887388,B,Displacement of [3H]DAMGO from human mu opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,O=C(Nc1ccccc1)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CCC1)CC3
CHEMBL242047,CHEMBL233,Mu opioid receptor,Ki,=,3.7,nM,CHEMBL887388,B,Displacement of [3H]DAMGO from human mu opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,CCNC(=O)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CCC1)CC3
CHEMBL242046,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL887388,B,Displacement of [3H]DAMGO from human mu opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,CNC(=O)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CCC1)CC3
CHEMBL301160,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL887388,B,Displacement of [3H]DAMGO from human mu opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL263096,CHEMBL233,Mu opioid receptor,Ki,=,0.3,nM,CHEMBL887388,B,Displacement of [3H]DAMGO from human mu opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,O=C(NCc1ccccc1)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CC1)CC3
CHEMBL397035,CHEMBL233,Mu opioid receptor,Ki,=,0.11,nM,CHEMBL887388,B,Displacement of [3H]DAMGO from human mu opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,O=C(Nc1ccccc1)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CC1)CC3
CHEMBL427862,CHEMBL233,Mu opioid receptor,Ki,=,0.29,nM,CHEMBL887388,B,Displacement of [3H]DAMGO from human mu opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,CCNC(=O)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CC1)CC3
CHEMBL241824,CHEMBL233,Mu opioid receptor,Ki,=,5.3,nM,CHEMBL887388,B,Displacement of [3H]DAMGO from human mu opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,CNC(=O)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CC1)CC3
CHEMBL49269,CHEMBL233,Mu opioid receptor,Ki,=,0.062,nM,CHEMBL887388,B,Displacement of [3H]DAMGO from human mu opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL245049,CHEMBL233,Mu opioid receptor,Ki,=,1.4,nM,CHEMBL887388,B,Displacement of [3H]DAMGO from human mu opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,CNC(=O)Oc1ccc2c(c1)C13CCCCC1C(C2)N(C)CC3
CHEMBL241823,CHEMBL233,Mu opioid receptor,Ki,=,4.8,nM,CHEMBL887388,B,Displacement of [3H]DAMGO from human mu opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,CCNC(=O)Oc1ccc2c(c1)C13CCCCC1C(C2)N(C)CC3
CHEMBL230249,CHEMBL233,Mu opioid receptor,Ki,=,6265.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL388123,CHEMBL233,Mu opioid receptor,Ki,=,246.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,Cc1ccccc1C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL229018,CHEMBL233,Mu opioid receptor,Ki,=,21455.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,c1ccc(COC2(c3ccccc3)CCN(C(c3ccccc3)c3ccccc3)CC2)cc1
CHEMBL229017,CHEMBL233,Mu opioid receptor,Ki,=,1649.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCCOC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL229016,CHEMBL233,Mu opioid receptor,Ki,=,377.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCOC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL228965,CHEMBL233,Mu opioid receptor,Ki,=,412.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,COC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL388122,CHEMBL233,Mu opioid receptor,Ki,=,843.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,COc1ccc(C(c2ccc(OC)cc2)N2CCC(O)(c3ccccc3)CC2)cc1
CHEMBL228964,CHEMBL233,Mu opioid receptor,Ki,=,843.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,COc1ccccc1C(c1ccccc1OC)N1CCC(O)(c2ccccc2)CC1
CHEMBL228913,CHEMBL233,Mu opioid receptor,Ki,=,183.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL228912,CHEMBL233,Mu opioid receptor,Ki,=,148.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2F)c2ccccc2F)CC1
CHEMBL228911,CHEMBL233,Mu opioid receptor,Ki,=,256.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL389665,CHEMBL233,Mu opioid receptor,Ki,=,2147.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,Cc1ccccc1C(c1ccccc1C)N1CCC(O)(c2ccccc2)CC1
CHEMBL437742,CHEMBL233,Mu opioid receptor,Ki,=,2864.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,O=C(O)c1ccccc1C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL228858,CHEMBL233,Mu opioid receptor,Ki,=,120.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OCc1ccccc1C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL228857,CHEMBL233,Mu opioid receptor,Ki,=,28.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,COc1ccccc1C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL228856,CHEMBL233,Mu opioid receptor,Ki,=,2449.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccc(Br)cc2)CC1
CHEMBL388314,CHEMBL233,Mu opioid receptor,Ki,=,170.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2Br)CC1
CHEMBL228802,CHEMBL233,Mu opioid receptor,Ki,=,177.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2F)CC1
CHEMBL228850,CHEMBL233,Mu opioid receptor,Ki,=,793.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
CHEMBL390498,CHEMBL233,Mu opioid receptor,Ki,=,201.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2cccc(Cl)c2)CC1
CHEMBL228849,CHEMBL233,Mu opioid receptor,Ki,=,609.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2Cl)CC1
CHEMBL228848,CHEMBL233,Mu opioid receptor,Ki,=,9.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCc1ccccc1C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL228795,CHEMBL233,Mu opioid receptor,Ki,=,1207.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccc(C(F)(F)F)cc2)CC1
CHEMBL390280,CHEMBL233,Mu opioid receptor,Ki,=,714.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2cccc(C(F)(F)F)c2)CC1
CHEMBL228794,CHEMBL233,Mu opioid receptor,Ki,=,127.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2C(F)(F)F)CC1
CHEMBL228793,CHEMBL233,Mu opioid receptor,Ki,=,3728.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,Cc1ccc(C(c2ccccc2)N2CCC(O)(c3ccccc3)CC2)cc1
CHEMBL390279,CHEMBL233,Mu opioid receptor,Ki,=,147.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,Cc1cccc(C(c2ccccc2)N2CCC(O)(c3ccccc3)CC2)c1
CHEMBL541636,CHEMBL233,Mu opioid receptor,Ki,=,361.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,Br.Cc1ccccc1C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL535844,CHEMBL233,Mu opioid receptor,Ki,=,35.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,Cc1ccccc1C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1.Cl
CHEMBL228740,CHEMBL233,Mu opioid receptor,Ki,=,405.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2cccs2)CC1
CHEMBL374603,CHEMBL233,Mu opioid receptor,Ki,=,819.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2cccnc2)CC1
CHEMBL374602,CHEMBL233,Mu opioid receptor,Ki,=,9324.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccn2)CC1
CHEMBL228690,CHEMBL233,Mu opioid receptor,Ki,=,233.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL228738,CHEMBL233,Mu opioid receptor,Ki,=,3736.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,O=C(Nc1c(F)cccc1F)C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL228736,CHEMBL233,Mu opioid receptor,Ki,=,59810.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,COC(=O)C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL228687,CHEMBL233,Mu opioid receptor,Ki,=,451.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCOCC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL228686,CHEMBL233,Mu opioid receptor,Ki,=,780.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,COCC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL397945,CHEMBL233,Mu opioid receptor,Ki,=,24.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(Cc2ccccc2)c2ccccc2)CC1
CHEMBL231608,CHEMBL233,Mu opioid receptor,Ki,=,787.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)C2CCCC2)CC1
CHEMBL231607,CHEMBL233,Mu opioid receptor,Ki,=,144.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCCCCCC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL413791,CHEMBL233,Mu opioid receptor,Ki,=,125.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CC(C)CCC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL230253,CHEMBL233,Mu opioid receptor,Ki,=,37.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCCCCC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL390882,CHEMBL233,Mu opioid receptor,Ki,=,29.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCCCC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL230145,CHEMBL233,Mu opioid receptor,Ki,=,341.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCCC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL433814,CHEMBL233,Mu opioid receptor,Ki,=,2298.0,nM,CHEMBL888956,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL2113281,CHEMBL233,Mu opioid receptor,Ki,=,144.0,nM,CHEMBL887338,B,Displacement of [3H]diprenorphine from mu opioid receptor expressed in human HEK293 cells,CHEMBL1145404,KI,O=Cc1cc2ccc(C(=O)Nc3cccc4c5c([nH]c34)[C@@H]3Oc4c(O)ccc6c4[C@@]34CCN(CC3CC3)[C@H](C6)[C@]4(O)C5)cc2cc1C=O
CHEMBL434746,CHEMBL233,Mu opioid receptor,Ki,=,3740.0,nM,CHEMBL890201,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C3=C[C@@H](OC)O[C@H]3OC)C[C@]21C
CHEMBL226732,CHEMBL233,Mu opioid receptor,Ki,=,3190.0,nM,CHEMBL890201,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C3=C[C@@H](OC)O[C@@H]3OC)C[C@]21C
CHEMBL427280,CHEMBL233,Mu opioid receptor,Ki,=,9790.0,nM,CHEMBL890201,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H]([C@@H]3CCOC3)C[C@]21C
CHEMBL364058,CHEMBL233,Mu opioid receptor,Ki,=,7240.0,nM,CHEMBL890201,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C3CCOC3)C[C@]21C
CHEMBL2113278,CHEMBL233,Mu opioid receptor,Ki,=,4810.0,nM,CHEMBL890201,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C3CC(OC)OC3OC)C[C@]21C
CHEMBL390935,CHEMBL233,Mu opioid receptor,Ki,=,1450.0,nM,CHEMBL890201,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3Br)C[C@]21C
CHEMBL2113282,CHEMBL233,Mu opioid receptor,Ki,=,400.0,nM,CHEMBL895003,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells,CHEMBL1148706,KI,O=C1[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCc1ccccc1
CHEMBL334898,CHEMBL233,Mu opioid receptor,Ki,=,3.1,nM,CHEMBL895003,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells,CHEMBL1148706,KI,C[C@H]1C2CCCC1(c1cccc(O)c1)CCN2CCc1ccccc1
CHEMBL397276,CHEMBL233,Mu opioid receptor,Ki,=,0.6,nM,CHEMBL895003,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells,CHEMBL1148706,KI,C[C@H]1[C@H]2CCC[C@]1(c1cccc(O)c1)CCN2CCc1ccccc1
CHEMBL414889,CHEMBL233,Mu opioid receptor,Ki,=,8.0,nM,CHEMBL895003,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells,CHEMBL1148706,KI,C[C@@H]1[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCc1ccccc1
CHEMBL242226,CHEMBL233,Mu opioid receptor,Ki,=,0.19,nM,CHEMBL895003,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells,CHEMBL1148706,KI,C=C1[C@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCc1ccccc1
CHEMBL437949,CHEMBL233,Mu opioid receptor,Ki,=,7.0,nM,CHEMBL895003,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells,CHEMBL1148706,KI,C=C1[C@@H]2CCC[C@]1(c1cccc(O)c1)CCN2CCc1ccccc1
CHEMBL243301,CHEMBL233,Mu opioid receptor,Ki,=,54.0,nM,CHEMBL895003,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells,CHEMBL1148706,KI,Oc1cccc([C@@]23CCC[C@@H]([C@@H]2O)N(CCc2ccccc2)CC3)c1
CHEMBL388873,CHEMBL233,Mu opioid receptor,Ki,=,0.19,nM,CHEMBL895003,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells,CHEMBL1148706,KI,Oc1cccc([C@]23CCC[C@H]([C@H]2O)N(CCc2ccccc2)CC3)c1
CHEMBL243300,CHEMBL233,Mu opioid receptor,Ki,=,59.0,nM,CHEMBL895003,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells,CHEMBL1148706,KI,Oc1cccc([C@]23CCC[C@H]([C@@H]2O)N(CCc2ccccc2)CC3)c1
CHEMBL243092,CHEMBL233,Mu opioid receptor,Ki,=,45.0,nM,CHEMBL895003,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells,CHEMBL1148706,KI,Oc1cccc([C@@]23CCC[C@@H]([C@H]2O)N(CCc2ccccc2)CC3)c1
CHEMBL243091,CHEMBL233,Mu opioid receptor,Ki,=,33.0,nM,CHEMBL895003,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells,CHEMBL1148706,KI,O=C1[C@H]2CCC[C@]1(c1cccc(O)c1)CCN2CCc1ccccc1
CHEMBL2113294,CHEMBL233,Mu opioid receptor,Ki,=,1.69,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccccc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL511142,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2113666,CHEMBL233,Mu opioid receptor,Ki,=,0.15,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,CN1CC[C@]23c4c5cccc4O[C@H]2C(=O)CC[C@@]3(NC(=O)/C=C/c2ccccc2Cl)[C@H]1C5
CHEMBL2113314,CHEMBL233,Mu opioid receptor,Ki,=,0.48,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,CO[C@@]12C=C[C@@]3([C@@H]4CN(C(=O)/C=C/c5ccc(C)cc5)C[C@@H]41)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113313,CHEMBL233,Mu opioid receptor,Ki,=,0.22,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,CO[C@@]12C=C[C@@]3([C@@H]4CN(C(=O)/C=C/c5ccccc5C)C[C@@H]41)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113312,CHEMBL233,Mu opioid receptor,Ki,=,0.68,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1CNC/C=C/c1ccc(Cl)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113311,CHEMBL233,Mu opioid receptor,Ki,=,0.39,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1CNC/C=C/c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113310,CHEMBL233,Mu opioid receptor,Ki,=,34.2,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC/C=C/c4ccc(Cl)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL2113309,CHEMBL233,Mu opioid receptor,Ki,=,11.3,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC/C=C/c4ccccc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL2113308,CHEMBL233,Mu opioid receptor,Ki,=,0.19,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccc([N+](=O)[O-])cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113307,CHEMBL233,Mu opioid receptor,Ki,=,0.18,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccc(Cl)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113306,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccc(C)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113305,CHEMBL233,Mu opioid receptor,Ki,=,0.25,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccccc1Cl)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113304,CHEMBL233,Mu opioid receptor,Ki,=,0.14,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccccc1C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113303,CHEMBL233,Mu opioid receptor,Ki,=,0.25,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113302,CHEMBL233,Mu opioid receptor,Ki,=,12.8,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,COc1ccc(/C=C/C(=O)NC[C@H]2C[C@@]34CC[C@@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(C)[C@@H]4C6)cc1
CHEMBL2113301,CHEMBL233,Mu opioid receptor,Ki,=,1.98,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,COc1ccccc1/C=C/C(=O)NC[C@H]1C[C@@]23CC[C@@]1(OC)[C@@H]1Oc4c(OC)ccc5c4[C@@]12CCN(C)[C@@H]3C5
CHEMBL2113300,CHEMBL233,Mu opioid receptor,Ki,=,2.96,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccccc4[N+](=O)[O-])[C@@H](C2)N(C)CC[C@]315
CHEMBL2113299,CHEMBL233,Mu opioid receptor,Ki,=,0.87,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccc([N+](=O)[O-])cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL2113298,CHEMBL233,Mu opioid receptor,Ki,=,2.61,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccc(Cl)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL2113297,CHEMBL233,Mu opioid receptor,Ki,=,11.8,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccc(C)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL2113296,CHEMBL233,Mu opioid receptor,Ki,=,0.63,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccccc4Cl)[C@@H](C2)N(C)CC[C@]315
CHEMBL2113295,CHEMBL233,Mu opioid receptor,Ki,=,0.74,nM,CHEMBL896952,B,Displacement of [3H]DAMGO from human cloned mu opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccccc4C)[C@@H](C2)N(C)CC[C@]315
CHEMBL49269,CHEMBL233,Mu opioid receptor,Ki,=,0.062,nM,CHEMBL893242,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1147995,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL243195,CHEMBL233,Mu opioid receptor,Ki,=,22.0,nM,CHEMBL893242,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1147995,KI,CNC(=O)Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL428038,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL893242,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1147995,KI,CNC(=O)Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL394573,CHEMBL233,Mu opioid receptor,Ki,=,3.2,nM,CHEMBL893242,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1147995,KI,NC(=O)Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL242968,CHEMBL233,Mu opioid receptor,Ki,=,1.4,nM,CHEMBL893242,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1147995,KI,NC(=O)Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL390912,CHEMBL233,Mu opioid receptor,Ki,=,5.8,nM,CHEMBL893242,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1147995,KI,O=c1[nH]c2cc3c(cc2o1)[C@@]12CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC2
CHEMBL242967,CHEMBL233,Mu opioid receptor,Ki,=,160.0,nM,CHEMBL893242,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1147995,KI,O=c1[nH]c2cc3c(cc2o1)[C@@]12CCCC[C@H]1[C@@H](C3)N(CC1CC1)CC2
CHEMBL242757,CHEMBL233,Mu opioid receptor,Ki,=,40.0,nM,CHEMBL893242,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1147995,KI,Nc1nc2cc3c(cc2o1)[C@@]12CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC2
CHEMBL390911,CHEMBL233,Mu opioid receptor,Ki,=,150.0,nM,CHEMBL893242,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1147995,KI,Nc1nc2cc3c(cc2o1)[C@@]12CCCC[C@H]1[C@@H](C3)N(CC1CC1)CC2
CHEMBL390866,CHEMBL233,Mu opioid receptor,Ki,=,7.1,nM,CHEMBL893242,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1147995,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CCC1
CHEMBL242756,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL893242,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1147995,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL49143,CHEMBL233,Mu opioid receptor,Ki,=,3.7,nM,CHEMBL893242,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1147995,KI,Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL299220,CHEMBL233,Mu opioid receptor,Ki,=,1.3,nM,CHEMBL893242,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1147995,KI,Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL301160,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL893242,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane,CHEMBL1147995,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL228690,CHEMBL233,Mu opioid receptor,Ki,=,207.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL232286,CHEMBL233,Mu opioid receptor,Ki,=,353.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CC(C)S(=O)(=O)N1CCN(Cc2ccccc2C2(O)CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)CC1
CHEMBL232285,CHEMBL233,Mu opioid receptor,Ki,=,351.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCS(=O)(=O)N1CCN(Cc2ccccc2C2(O)CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)CC1
CHEMBL232076,CHEMBL233,Mu opioid receptor,Ki,=,190.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CN1CCN(Cc2ccccc2C2(O)CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)CC1
CHEMBL232075,CHEMBL233,Mu opioid receptor,Ki,=,145.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccccc2CN2CCNCC2)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL394222,CHEMBL233,Mu opioid receptor,Ki,=,120.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccccc2CN2CCOCC2)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL232074,CHEMBL233,Mu opioid receptor,Ki,=,304.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCNC(=O)NCc1ccccc1C1(O)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL231866,CHEMBL233,Mu opioid receptor,Ki,=,198.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CNC(=O)NCc1ccccc1C1(O)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL437177,CHEMBL233,Mu opioid receptor,Ki,=,163.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CC(C)S(=O)(=O)NCc1ccccc1C1(O)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL232478,CHEMBL233,Mu opioid receptor,Ki,=,271.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCCS(=O)(=O)NCc1ccccc1C1(O)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL232477,CHEMBL233,Mu opioid receptor,Ki,=,167.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CNCc1ccccc1C1(O)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL233957,CHEMBL233,Mu opioid receptor,Ki,=,181.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CC1(C)CCC(N2CCC(O)(c3ccccc3CN)CC2)c2ccccc21
CHEMBL233535,CHEMBL233,Mu opioid receptor,Ki,=,452.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(CC2CCCCCC2)CC1
CHEMBL233956,CHEMBL233,Mu opioid receptor,Ki,=,616.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2ccccc2Br)c2ccccc2Br)CC1
CHEMBL400036,CHEMBL233,Mu opioid receptor,Ki,=,616.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2cccc(F)c2)c2cccc(F)c2)CC1
CHEMBL233955,CHEMBL233,Mu opioid receptor,Ki,=,37.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2ccccc2F)c2ccccc2F)CC1
CHEMBL233750,CHEMBL233,Mu opioid receptor,Ki,=,249.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL233749,CHEMBL233,Mu opioid receptor,Ki,=,3085.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2ccc(Cl)cc2)c2ccc(Cl)cc2)CC1
CHEMBL233748,CHEMBL233,Mu opioid receptor,Ki,=,502.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,Cc1ccc(C(c2ccc(C)cc2)N2CCC(O)(c3ccccc3CN)CC2)cc1
CHEMBL400035,CHEMBL233,Mu opioid receptor,Ki,=,190.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,Cc1ccccc1C(c1ccccc1C)N1CCC(O)(c2ccccc2CN)CC1
CHEMBL233536,CHEMBL233,Mu opioid receptor,Ki,=,72.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2ccccc2)c2ccccc2Br)CC1
CHEMBL398794,CHEMBL233,Mu opioid receptor,Ki,=,72.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2ccccc2)c2ccccc2Cl)CC1
CHEMBL233327,CHEMBL233,Mu opioid receptor,Ki,=,28.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,Cc1ccccc1C(c1ccccc1)N1CCC(O)(c2ccccc2CN)CC1
CHEMBL233503,CHEMBL233,Mu opioid receptor,Ki,=,125.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL441914,CHEMBL233,Mu opioid receptor,Ki,=,2.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCCCCC(c1ccccc1)N1CCC(O)(c2ccccc2CN)CC1
CHEMBL233326,CHEMBL233,Mu opioid receptor,Ki,=,2.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCCCC(c1ccccc1)N1CCC(O)(c2ccccc2CN)CC1
CHEMBL393971,CHEMBL233,Mu opioid receptor,Ki,=,11540.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccccn2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL393356,CHEMBL233,Mu opioid receptor,Ki,=,756.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,Cc1ccsc1C1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL233323,CHEMBL233,Mu opioid receptor,Ki,=,1734.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2cccs2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL231874,CHEMBL233,Mu opioid receptor,Ki,=,4554.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccco2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL231664,CHEMBL233,Mu opioid receptor,Ki,=,3364.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(CCCc2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL231661,CHEMBL233,Mu opioid receptor,Ki,=,10390.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(Cc2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL394695,CHEMBL233,Mu opioid receptor,Ki,=,407.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(C2CCCCC2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL234773,CHEMBL233,Mu opioid receptor,Ki,=,8899.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCCCCCC1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL234771,CHEMBL233,Mu opioid receptor,Ki,=,3599.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CC(C)(C)C1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL397761,CHEMBL233,Mu opioid receptor,Ki,=,272.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCCCC1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL233721,CHEMBL233,Mu opioid receptor,Ki,=,13230.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CC(C)C1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL398039,CHEMBL233,Mu opioid receptor,Ki,=,18365.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(C2CC2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL233503,CHEMBL233,Mu opioid receptor,Ki,=,125.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL233502,CHEMBL233,Mu opioid receptor,Ki,=,186.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OCc1ccccc1C1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL233501,CHEMBL233,Mu opioid receptor,Ki,=,8382.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,N#Cc1ccc(C2(O)CCN(C(c3ccccc3)c3ccccc3)CC2)cc1
CHEMBL401234,CHEMBL233,Mu opioid receptor,Ki,=,11050.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,COc1ccc(C2(O)CCN(C(c3ccccc3)c3ccccc3)CC2)cc1
CHEMBL233494,CHEMBL233,Mu opioid receptor,Ki,=,2988.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,COc1cccc(C2(O)CCN(C(c3ccccc3)c3ccccc3)CC2)c1
CHEMBL233493,CHEMBL233,Mu opioid receptor,Ki,=,983.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,COc1ccccc1C1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL393675,CHEMBL233,Mu opioid receptor,Ki,=,11430.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCCc1ccc(C2(O)CCN(C(c3ccccc3)c3ccccc3)CC2)cc1
CHEMBL234543,CHEMBL233,Mu opioid receptor,Ki,=,3433.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCc1ccc(C2(O)CCN(C(c3ccccc3)c3ccccc3)CC2)cc1
CHEMBL393985,CHEMBL233,Mu opioid receptor,Ki,=,940.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,Cc1ccc(C2(O)CCN(C(c3ccccc3)c3ccccc3)CC2)cc1
CHEMBL437380,CHEMBL233,Mu opioid receptor,Ki,=,273.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,Cc1cccc(C2(O)CCN(C(c3ccccc3)c3ccccc3)CC2)c1
CHEMBL232273,CHEMBL233,Mu opioid receptor,Ki,=,74.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,Cc1ccccc1C1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL232067,CHEMBL233,Mu opioid receptor,Ki,=,1057.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccc(Br)cc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL392753,CHEMBL233,Mu opioid receptor,Ki,=,936.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccc(Cl)cc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL232066,CHEMBL233,Mu opioid receptor,Ki,=,771.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccc(F)cc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL395838,CHEMBL233,Mu opioid receptor,Ki,=,705.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2cccc(F)c2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL232476,CHEMBL233,Mu opioid receptor,Ki,=,589.0,nM,CHEMBL892114,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccccc2F)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,3.715,nM,CHEMBL894812,B,Displacement of [3H]diprenorphine from human recombinant mu opioid receptor expressed in in CHO cells,CHEMBL1148695,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL2372052,CHEMBL233,Mu opioid receptor,Ki,=,354.81,nM,CHEMBL894812,B,Displacement of [3H]diprenorphine from human recombinant mu opioid receptor expressed in in CHO cells,CHEMBL1148695,KI,C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)C(C)(C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)CNC(=O)[C@H](CN)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O
CHEMBL409969,CHEMBL233,Mu opioid receptor,Ki,=,74.13,nM,CHEMBL894812,B,Displacement of [3H]diprenorphine from human recombinant mu opioid receptor expressed in in CHO cells,CHEMBL1148695,KI,C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)C(C)(C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O
CHEMBL232740,CHEMBL233,Mu opioid receptor,Ki,=,2763.0,nM,CHEMBL896480,B,Displacement of [3H]DAMGO from cloned human mu opioid receptor,CHEMBL1149528,KI,CCOC(=O)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL401245,CHEMBL233,Mu opioid receptor,Ki,=,20.0,nM,CHEMBL896539,B,Displacement of [3H]DAMGO from cloned mu opioid receptor expressed in CHO cell membrane,CHEMBL1149641,KI,CO[C@]12C(O)C[C@@]3(C[C@@H]1[C@@H](C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL235239,CHEMBL233,Mu opioid receptor,Ki,=,4.3,nM,CHEMBL896539,B,Displacement of [3H]DAMGO from cloned mu opioid receptor expressed in CHO cell membrane,CHEMBL1149641,KI,CO[C@]12CC(O)[C@@]3(C[C@@H]1[C@@H](C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL392269,CHEMBL233,Mu opioid receptor,Ki,=,34.0,nM,CHEMBL896539,B,Displacement of [3H]DAMGO from cloned mu opioid receptor expressed in CHO cell membrane,CHEMBL1149641,KI,CO[C@]12CC(O)[C@@]3(C[C@@H]1[C@H](C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL238017,CHEMBL233,Mu opioid receptor,Ki,=,13.0,nM,CHEMBL896539,B,Displacement of [3H]DAMGO from cloned mu opioid receptor expressed in CHO cell membrane,CHEMBL1149641,KI,CO[C@]12C(O)C[C@@]3(C[C@@H]1[C@H](C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL235560,CHEMBL233,Mu opioid receptor,Ki,=,643.47,nM,CHEMBL899318,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,NC(=O)c1cccc(Oc2ccc(CCNCc3ccccc3)cc2)n1
CHEMBL399814,CHEMBL233,Mu opioid receptor,Ki,=,389.49,nM,CHEMBL899318,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,O=C(c1ccc(Oc2ccc(CNCCc3ccccc3)cc2)nc1)N1CCCCC1
CHEMBL238305,CHEMBL233,Mu opioid receptor,Ki,=,52.27,nM,CHEMBL899318,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,CC(C)NC(=O)c1ccc(Oc2ccc(CNCCc3ccccc3)cc2)nc1
CHEMBL238283,CHEMBL233,Mu opioid receptor,Ki,=,57.15,nM,CHEMBL899318,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,CCNC(=O)c1ccc(Oc2ccc(CNCCc3ccccc3)cc2)nc1
CHEMBL396392,CHEMBL233,Mu opioid receptor,Ki,=,52.29,nM,CHEMBL899318,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,CNC(=O)c1ccc(Oc2ccc(CNCCc3ccccc3)cc2)nc1
CHEMBL238282,CHEMBL233,Mu opioid receptor,Ki,=,234.53,nM,CHEMBL899318,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,CNC(=N)c1ccc(Oc2ccc(CNCCc3ccccc3)cc2)nc1
CHEMBL238280,CHEMBL233,Mu opioid receptor,Ki,=,20.55,nM,CHEMBL899318,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,N=C(N)c1ccc(Oc2ccc(CNCCc3ccccc3)cc2)nc1
CHEMBL238361,CHEMBL233,Mu opioid receptor,Ki,=,0.17,nM,CHEMBL899318,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,NC(=O)c1ccc(Oc2ccc(CNCCc3ccccc3)cc2)nc1
CHEMBL236393,CHEMBL233,Mu opioid receptor,Ki,=,1076.86,nM,CHEMBL899318,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,N#Cc1ccc(Oc2ccc(CCNCc3ccccc3)cc2)nc1
CHEMBL237066,CHEMBL233,Mu opioid receptor,Ki,=,7.44,nM,CHEMBL899318,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,NC(=O)c1ccc(Oc2ccc(CCNCc3ccccc3)cc2)nc1
CHEMBL238317,CHEMBL233,Mu opioid receptor,Ki,=,0.29,nM,CHEMBL899318,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,NC(=O)c1ccc(Oc2ccc(CNCCc3ccccc3)cc2)cc1
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.87,nM,CHEMBL899318,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL300662,CHEMBL233,Mu opioid receptor,Ki,=,0.15,nM,CHEMBL899318,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,C[C@H]1CN(CC[C@H](O)C2CCCCC2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL236376,CHEMBL233,Mu opioid receptor,Ki,=,1.77,nM,CHEMBL899318,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,NC(=O)c1ccc(Oc2ccc(CNCCc3ccccc3)cc2)cn1
CHEMBL392828,CHEMBL233,Mu opioid receptor,Ki,=,0.62,nM,CHEMBL898721,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1137484,KI,Cc1c[nH]c(=O)c(CCCCNC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)n1
CHEMBL237074,CHEMBL233,Mu opioid receptor,Ki,=,15.4,nM,CHEMBL898721,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1137484,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCCCCc1[nH]c(=O)c(C)nc1C
CHEMBL413703,CHEMBL233,Mu opioid receptor,Ki,=,4.23,nM,CHEMBL898721,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1137484,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCCCCc1nc(C)c(C)[nH]c1=O
CHEMBL236868,CHEMBL233,Mu opioid receptor,Ki,=,56.9,nM,CHEMBL898721,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1137484,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCCCCc1[nH]c(=O)cnc1C
CHEMBL236663,CHEMBL233,Mu opioid receptor,Ki,=,0.66,nM,CHEMBL898721,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1137484,KI,Cc1cccc(C)c1Cc1[nH]c(=O)c(CCCCNC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)nc1C
CHEMBL236662,CHEMBL233,Mu opioid receptor,Ki,=,0.125,nM,CHEMBL898721,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1137484,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCCCCc1nc(C)c(CCc2ccccc2)[nH]c1=O
CHEMBL236462,CHEMBL233,Mu opioid receptor,Ki,=,0.55,nM,CHEMBL898721,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1137484,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCCCc1nc(C)c(CCc2ccccc2)[nH]c1=O
CHEMBL392057,CHEMBL233,Mu opioid receptor,Ki,=,0.42,nM,CHEMBL898721,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1137484,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCCCCc1nc(C)c(Cc2ccccc2)[nH]c1=O
CHEMBL236461,CHEMBL233,Mu opioid receptor,Ki,=,1.0,nM,CHEMBL898721,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1137484,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCCCc1nc(C)c(Cc2ccccc2)[nH]c1=O
CHEMBL236460,CHEMBL233,Mu opioid receptor,Ki,=,129.1,nM,CHEMBL898721,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1137484,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCc1nc(C)c(C)[nH]c1=O
CHEMBL236253,CHEMBL233,Mu opioid receptor,Ki,=,76.5,nM,CHEMBL898721,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1137484,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCCc1nc(C)c(C)[nH]c1=O
CHEMBL437372,CHEMBL233,Mu opioid receptor,Ki,=,8.88,nM,CHEMBL898721,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1137484,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCCCc1nc(C)c(C)[nH]c1=O
CHEMBL237066,CHEMBL233,Mu opioid receptor,Ki,=,7.44,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc(CCNCc3ccccc3)cc2)nc1
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.87,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL300662,CHEMBL233,Mu opioid receptor,Ki,=,0.15,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,C[C@H]1CN(CC[C@H](O)C2CCCCC2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL238361,CHEMBL233,Mu opioid receptor,Ki,=,0.17,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc(CNCCc3ccccc3)cc2)nc1
CHEMBL238364,CHEMBL233,Mu opioid receptor,Ki,=,215.87,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCCN(CCCN2CCOCC2)C3)nc1
CHEMBL238363,CHEMBL233,Mu opioid receptor,Ki,=,128.7,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCCN(CCN2CCOCC2)C3)nc1
CHEMBL238157,CHEMBL233,Mu opioid receptor,Ki,=,41.67,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCCN(CCCC2CCCCC2)C3)nc1
CHEMBL439038,CHEMBL233,Mu opioid receptor,Ki,=,24.42,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCCN(CCCC(F)(F)F)C3)nc1
CHEMBL238156,CHEMBL233,Mu opioid receptor,Ki,=,42.03,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,CCC(CC)CN1CCCc2cc(Oc3ccc(C(N)=O)cn3)ccc2C1
CHEMBL396637,CHEMBL233,Mu opioid receptor,Ki,=,18.33,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,CC(C)(C)CCN1CCCc2cc(Oc3ccc(C(N)=O)cn3)ccc2C1
CHEMBL237934,CHEMBL233,Mu opioid receptor,Ki,=,11.93,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,CC(C)CCCCN1CCCc2cc(Oc3ccc(C(N)=O)cn3)ccc2C1
CHEMBL396636,CHEMBL233,Mu opioid receptor,Ki,=,7.55,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,CC(C)CCCN1CCCc2cc(Oc3ccc(C(N)=O)cn3)ccc2C1
CHEMBL237718,CHEMBL233,Mu opioid receptor,Ki,=,11.14,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,CC(C)CCN1CCCc2cc(Oc3ccc(C(N)=O)cn3)ccc2C1
CHEMBL237716,CHEMBL233,Mu opioid receptor,Ki,=,12.03,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,CCCCCCN1CCCc2cc(Oc3ccc(C(N)=O)cn3)ccc2C1
CHEMBL237506,CHEMBL233,Mu opioid receptor,Ki,=,11.86,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,CCCCCN1CCCc2cc(Oc3ccc(C(N)=O)cn3)ccc2C1
CHEMBL237505,CHEMBL233,Mu opioid receptor,Ki,=,20.81,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,CCCCN1CCCc2cc(Oc3ccc(C(N)=O)cn3)ccc2C1
CHEMBL237295,CHEMBL233,Mu opioid receptor,Ki,=,5.05,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc(CCN3CCc4ccccc4C3)cc2)nc1
CHEMBL237294,CHEMBL233,Mu opioid receptor,Ki,=,91.49,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCN(CCc2ccccc2)CC3)nc1
CHEMBL237293,CHEMBL233,Mu opioid receptor,Ki,=,405.8,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCN(Cc2ccccc2)CC3)nc1
CHEMBL237073,CHEMBL233,Mu opioid receptor,Ki,=,10.09,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCCN(CCc2ccccc2)C3)nc1
CHEMBL398089,CHEMBL233,Mu opioid receptor,Ki,=,231.59,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CN(Cc2ccccc2)CC3)nc1
CHEMBL237071,CHEMBL233,Mu opioid receptor,Ki,=,185.0,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCN(CCCc2ccccc2)C3)nc1
CHEMBL397148,CHEMBL233,Mu opioid receptor,Ki,=,15.95,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCN(CCc2ccccc2)C3)nc1
CHEMBL235155,CHEMBL233,Mu opioid receptor,Ki,=,179.0,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCN(Cc2ccccc2)C3)nc1
CHEMBL235154,CHEMBL233,Mu opioid receptor,Ki,=,658.8,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CN(CCc2ccccc2)C3)nc1
CHEMBL238362,CHEMBL233,Mu opioid receptor,Ki,=,1008.0,nM,CHEMBL901089,B,Displacement of [3H]diprenorphine from cloned human mu opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CN(Cc2ccccc2)C3)nc1
CHEMBL427683,CHEMBL233,Mu opioid receptor,Ki,=,34.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)[nH]c4ccccc43)CC2)C(C)C)c1
CHEMBL391631,CHEMBL233,Mu opioid receptor,Ki,=,16.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,CNC(=O)CN1CN(c2ccccc2)C2(CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)C1=O
CHEMBL391650,CHEMBL233,Mu opioid receptor,Ki,=,34.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC3(CC2)C(=O)NCN3c2ccccc2)C(C)C)c1
CHEMBL238819,CHEMBL233,Mu opioid receptor,Ki,=,108.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(CC(=O)NC4CCC4)c4ccccc43)CC2)C(C)C)c1
CHEMBL238818,CHEMBL233,Mu opioid receptor,Ki,=,119.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(CC(=O)NC4CC4)c4ccccc43)CC2)C(C)C)c1
CHEMBL393138,CHEMBL233,Mu opioid receptor,Ki,=,100.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(CC(=O)NCC4CC4)c4ccccc43)CC2)C(C)C)c1
CHEMBL238600,CHEMBL233,Mu opioid receptor,Ki,=,432.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(CC(=O)NCc4ccccc4)c4ccccc43)CC2)C(C)C)c1
CHEMBL238602,CHEMBL233,Mu opioid receptor,Ki,=,199.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,C=CCNC(=O)Cn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL241157,CHEMBL233,Mu opioid receptor,Ki,=,180.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COCCNC(=O)Cn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL241155,CHEMBL233,Mu opioid receptor,Ki,=,75.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(CC(=O)NCCO)c4ccccc43)CC2)C(C)C)c1
CHEMBL399393,CHEMBL233,Mu opioid receptor,Ki,=,245.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(CC(=O)NC(C)(C)C)c4ccccc43)CC2)C(C)C)c1
CHEMBL240941,CHEMBL233,Mu opioid receptor,Ki,=,238.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(CC(=O)NC(C)C)c4ccccc43)CC2)C(C)C)c1
CHEMBL240298,CHEMBL233,Mu opioid receptor,Ki,=,161.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,CCCCNC(=O)Cn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL240086,CHEMBL233,Mu opioid receptor,Ki,=,272.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,CCCNC(=O)Cn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL240085,CHEMBL233,Mu opioid receptor,Ki,=,289.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,CCNC(=O)Cn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL240084,CHEMBL233,Mu opioid receptor,Ki,=,46.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,CNCCn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL241357,CHEMBL233,Mu opioid receptor,Ki,=,70.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(CS(C)(=O)=O)c4ccccc43)CC2)C(C)C)c1
CHEMBL391422,CHEMBL233,Mu opioid receptor,Ki,=,125.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(C[S+](C)[O-])c4ccccc43)CC2)C(C)C)c1
CHEMBL391518,CHEMBL233,Mu opioid receptor,Ki,=,62.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(CCO)c4ccccc43)CC2)C(C)C)c1
CHEMBL238796,CHEMBL233,Mu opioid receptor,Ki,=,1701.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(CC(=O)O)c4ccccc43)CC2)C(C)C)c1
CHEMBL445154,CHEMBL233,Mu opioid receptor,Ki,=,122.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,CNC(=O)CCn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL439035,CHEMBL233,Mu opioid receptor,Ki,=,172.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(CCN(C)Cc4ccccc4)c4ccccc43)CC2)C(C)C)c1
CHEMBL238795,CHEMBL233,Mu opioid receptor,Ki,=,106.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(CCN(C)C)c4ccccc43)CC2)C(C)C)c1
CHEMBL393960,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(CCSC)c4ccccc43)CC2)C(C)C)c1
CHEMBL391234,CHEMBL233,Mu opioid receptor,Ki,=,271.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COC(=O)CCn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL240074,CHEMBL233,Mu opioid receptor,Ki,=,23.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(CSC)c4ccccc43)CC2)C(C)C)c1
CHEMBL401248,CHEMBL233,Mu opioid receptor,Ki,=,103.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(CCOC(C)=O)c4ccccc43)CC2)C(C)C)c1
CHEMBL238637,CHEMBL233,Mu opioid receptor,Ki,=,271.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COC(=O)Cn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL392548,CHEMBL233,Mu opioid receptor,Ki,=,188.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(CC(=O)N(C)C)c4ccccc43)CC2)C(C)C)c1
CHEMBL391487,CHEMBL233,Mu opioid receptor,Ki,=,449.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,CNC(=O)Cn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL391487,CHEMBL233,Mu opioid receptor,Ki,=,54.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,CNC(=O)Cn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL391487,CHEMBL233,Mu opioid receptor,Ki,=,164.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,CNC(=O)Cn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL391486,CHEMBL233,Mu opioid receptor,Ki,=,138.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(CC(N)=O)c4ccccc43)CC2)C(C)C)c1
CHEMBL239260,CHEMBL233,Mu opioid receptor,Ki,=,113.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,CCC(=O)Cn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL239045,CHEMBL233,Mu opioid receptor,Ki,=,9.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,CCOCn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL239043,CHEMBL233,Mu opioid receptor,Ki,=,273.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COCCn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL239043,CHEMBL233,Mu opioid receptor,Ki,=,60.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COCCn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL239043,CHEMBL233,Mu opioid receptor,Ki,=,184.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COCCn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL238833,CHEMBL233,Mu opioid receptor,Ki,=,195.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COCn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL238833,CHEMBL233,Mu opioid receptor,Ki,=,70.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COCn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL427683,CHEMBL233,Mu opioid receptor,Ki,=,59.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)[nH]c4ccccc43)CC2)C(C)C)c1
CHEMBL238833,CHEMBL233,Mu opioid receptor,Ki,=,57.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COCn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL427683,CHEMBL233,Mu opioid receptor,Ki,=,109.0,nM,CHEMBL885747,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1139059,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)[nH]c4ccccc43)CC2)C(C)C)c1
CHEMBL203356,CHEMBL233,Mu opioid receptor,Ki,=,500.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(Cc1ccccc1)CC2
CHEMBL393980,CHEMBL233,Mu opioid receptor,Ki,=,977.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)NCN3c2ccccc2)c2cc(Cl)c(Cl)cc21
CHEMBL241087,CHEMBL233,Mu opioid receptor,Ki,=,59.1,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)NCN3c2ccccc2)c2ccc(F)cc21
CHEMBL393807,CHEMBL233,Mu opioid receptor,Ki,=,49.1,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)NCN3c2ccccc2)c2ccc(Cl)cc21
CHEMBL241086,CHEMBL233,Mu opioid receptor,Ki,=,130.5,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCc3c(Cl)cccc31)CC2
CHEMBL241085,CHEMBL233,Mu opioid receptor,Ki,=,162.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCc3ccc(Cl)cc31)CC2
CHEMBL393781,CHEMBL233,Mu opioid receptor,Ki,=,11.1,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCc3cccc(Cl)c31)CC2
CHEMBL240005,CHEMBL233,Mu opioid receptor,Ki,=,72.3,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCc3c(F)cccc31)CC2
CHEMBL239824,CHEMBL233,Mu opioid receptor,Ki,=,133.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCc3ccc(F)cc31)CC2
CHEMBL392798,CHEMBL233,Mu opioid receptor,Ki,=,5.1,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCc3cccc(F)c31)CC2
CHEMBL239822,CHEMBL233,Mu opioid receptor,Ki,=,48.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)NCN3c2ccccc2)c2ccccc21
CHEMBL442090,CHEMBL233,Mu opioid receptor,Ki,=,673.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCCc3ccccc31)CC2
CHEMBL27460,CHEMBL233,Mu opioid receptor,Ki,=,346.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCc3ccccc31)CC2
CHEMBL284414,CHEMBL233,Mu opioid receptor,Ki,=,19.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCc3ccccc31)CC2
CHEMBL391703,CHEMBL233,Mu opioid receptor,Ki,=,787.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccc(F)cc1)c1ccc(F)cc1)CC2
CHEMBL239821,CHEMBL233,Mu opioid receptor,Ki,=,3187.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1cccc(F)c1)c1cccc(F)c1)CC2
CHEMBL239820,CHEMBL233,Mu opioid receptor,Ki,=,567.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1F)c1ccccc1F)CC2
CHEMBL239819,CHEMBL233,Mu opioid receptor,Ki,=,1616.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1cccc(Cl)c1)c1cccc(Cl)c1)CC2
CHEMBL241272,CHEMBL233,Mu opioid receptor,Ki,=,595.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL439212,CHEMBL233,Mu opioid receptor,Ki,=,346.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,Cc1ccccc1C(c1ccccc1C)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL241080,CHEMBL233,Mu opioid receptor,Ki,=,5081.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1)c1ccc(Cl)cc1)CC2
CHEMBL241079,CHEMBL233,Mu opioid receptor,Ki,=,1109.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,Cc1ccccc1C(c1ccccc1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL428563,CHEMBL233,Mu opioid receptor,Ki,=,778.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1)c1ccccc1Cl)CC2
CHEMBL392969,CHEMBL233,Mu opioid receptor,Ki,=,818.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1)c1ccccc1F)CC2
CHEMBL241067,CHEMBL233,Mu opioid receptor,Ki,=,475.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1c3ccccc3C=Cc3ccccc31)CC2
CHEMBL240870,CHEMBL233,Mu opioid receptor,Ki,=,2454.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1c3ccccc3CCc3ccccc31)CC2
CHEMBL240657,CHEMBL233,Mu opioid receptor,Ki,=,486.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1)c1ccccc1)CC2
CHEMBL391083,CHEMBL233,Mu opioid receptor,Ki,=,398.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1)C1CCCC1)CC2
CHEMBL428033,CHEMBL233,Mu opioid receptor,Ki,=,30.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CC(C)CCC(c1ccccc1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL391082,CHEMBL233,Mu opioid receptor,Ki,=,22.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CCCCC(c1ccccc1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL241112,CHEMBL233,Mu opioid receptor,Ki,=,244.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CCCC(c1ccccc1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL240216,CHEMBL233,Mu opioid receptor,Ki,=,355.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CCC(c1ccccc1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL392893,CHEMBL233,Mu opioid receptor,Ki,=,74.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CC(c1ccccc1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL240215,CHEMBL233,Mu opioid receptor,Ki,=,29.5,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(Cc1c(Cl)cccc1Cl)CC2
CHEMBL401451,CHEMBL233,Mu opioid receptor,Ki,=,37.4,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(Cc1ccccc1Cl)CC2
CHEMBL240033,CHEMBL233,Mu opioid receptor,Ki,=,133.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(Cc1ccsc1)CC2
CHEMBL240896,CHEMBL233,Mu opioid receptor,Ki,=,233.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(Cc1cccnc1)CC2
CHEMBL240895,CHEMBL233,Mu opioid receptor,Ki,=,1761.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(Cc1ccccn1)CC2
CHEMBL240001,CHEMBL233,Mu opioid receptor,Ki,=,887.0,nM,CHEMBL886505,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(CC1CCCCC1)CC2
CHEMBL13786,CHEMBL233,Mu opioid receptor,Ki,=,19.0,nM,CHEMBL887068,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1139195,KI,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL246572,CHEMBL233,Mu opioid receptor,Ki,=,100.0,nM,CHEMBL887068,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1139195,KI,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc2nc(N)sc2c1)C(=O)O
CHEMBL246479,CHEMBL233,Mu opioid receptor,Ki,=,640.0,nM,CHEMBL887068,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1139195,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1ccc2nc(N)sc2c1)C(=O)N[C@H](C(=O)O)[C@@H](C)O
CHEMBL247760,CHEMBL233,Mu opioid receptor,Ki,=,19.0,nM,CHEMBL887068,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1139195,KI,Cc1cc(C(N)=O)cc(C)c1C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)O)[C@@H](C)O
CHEMBL393867,CHEMBL233,Mu opioid receptor,Ki,=,1100.0,nM,CHEMBL887068,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1139195,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cccc(C(N)=O)c1)C(=O)N[C@H](C(=O)O)[C@@H](C)O
CHEMBL247759,CHEMBL233,Mu opioid receptor,Ki,=,1200.0,nM,CHEMBL887068,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1139195,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc2nc(N)sc2c1)C(=O)O
CHEMBL246739,CHEMBL233,Mu opioid receptor,Ki,=,9.8,nM,CHEMBL887068,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1139195,KI,Cc1cc(C(N)=O)cc(C)c1C[C@H](N)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)O
CHEMBL247064,CHEMBL233,Mu opioid receptor,Ki,=,1200.0,nM,CHEMBL887068,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1139195,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc2nc(N)sc2c1)C(=O)O
CHEMBL247758,CHEMBL233,Mu opioid receptor,Ki,=,9.8,nM,CHEMBL887068,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1139195,KI,Cc1cc(C(N)=O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)O
CHEMBL246682,CHEMBL233,Mu opioid receptor,Ki,=,560.0,nM,CHEMBL887068,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1139195,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cccc(C(N)=O)c1)C(=O)O
CHEMBL247363,CHEMBL233,Mu opioid receptor,Ki,=,1400.0,nM,CHEMBL887068,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1139195,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(N)cc1)C(=O)O
CHEMBL246956,CHEMBL233,Mu opioid receptor,Ki,=,18.0,nM,CHEMBL887068,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1139195,KI,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(C(N)=O)cc1)C(N)=O
CHEMBL247368,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL887068,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1139195,KI,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL391580,CHEMBL233,Mu opioid receptor,Ki,=,28.0,nM,CHEMBL887068,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1139195,KI,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(C(N)=O)cc1)C(=O)O
CHEMBL401093,CHEMBL233,Mu opioid receptor,Ki,=,105.0,nM,CHEMBL922767,B,Displacement of [3H]DAMGO from mu opioid receptor,CHEMBL1140452,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(O)[C@H]1C5
CHEMBL427706,CHEMBL233,Mu opioid receptor,Ki,=,66.0,nM,CHEMBL922767,B,Displacement of [3H]DAMGO from mu opioid receptor,CHEMBL1140452,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccc(I)cc4c2C[C@@]3(O)[C@H]1C5
CHEMBL401094,CHEMBL233,Mu opioid receptor,Ki,=,71.0,nM,CHEMBL922767,B,Displacement of [3H]DAMGO from mu opioid receptor,CHEMBL1140452,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccc(Br)cc4c2C[C@@]3(O)[C@H]1C5
CHEMBL248840,CHEMBL233,Mu opioid receptor,Ki,=,47.0,nM,CHEMBL922767,B,Displacement of [3H]DAMGO from mu opioid receptor,CHEMBL1140452,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccc(Cl)cc4c2C[C@@]3(O)[C@H]1C5
CHEMBL248839,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL922767,B,Displacement of [3H]DAMGO from mu opioid receptor,CHEMBL1140452,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccc(F)cc4c2C[C@@]3(O)[C@H]1C5
CHEMBL377789,CHEMBL233,Mu opioid receptor,Ki,=,0.3,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL428055,CHEMBL233,Mu opioid receptor,Ki,=,2.4,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCCc4cccc5ccccc45)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL251161,CHEMBL233,Mu opioid receptor,Ki,=,4.2,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4cccc5ccccc45)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL251160,CHEMBL233,Mu opioid receptor,Ki,=,2.5,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCc4cccc5ccccc45)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL430397,CHEMBL233,Mu opioid receptor,Ki,=,1.9,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCCc4ccc5ccccc5c4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL399344,CHEMBL233,Mu opioid receptor,Ki,=,0.18,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc5ccccc5c4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL250388,CHEMBL233,Mu opioid receptor,Ki,=,1.3,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCc4ccc5ccccc5c4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL250387,CHEMBL233,Mu opioid receptor,Ki,=,0.29,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,Cc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)[C@@]3(C)CCN(CC5CC5)C(C4)[C@@H]3C)cc2)cc1
CHEMBL250186,CHEMBL233,Mu opioid receptor,Ki,=,0.98,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccc(Cl)c(Cl)c5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL438871,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccc(Cl)cc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL249985,CHEMBL233,Mu opioid receptor,Ki,=,0.084,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,COc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)[C@@]3(C)CCN(CC5CC5)C(C4)[C@@H]3C)cc2)cc1
CHEMBL398294,CHEMBL233,Mu opioid receptor,Ki,=,4.0,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccccc4Br)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL250993,CHEMBL233,Mu opioid receptor,Ki,=,0.35,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4cccc(Br)c4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL249567,CHEMBL233,Mu opioid receptor,Ki,=,2.4,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(Br)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL399465,CHEMBL233,Mu opioid receptor,Ki,=,6.7,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccccc4-c4ccccc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL401278,CHEMBL233,Mu opioid receptor,Ki,=,0.95,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4cccc(-c5ccccc5)c4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL3085528,CHEMBL233,Mu opioid receptor,Ki,=,0.16,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL58646,CHEMBL233,Mu opioid receptor,Ki,=,0.31,nM,CHEMBL941712,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(N)=O)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL396460,CHEMBL233,Mu opioid receptor,Ki,=,3030.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O
CHEMBL449966,CHEMBL233,Mu opioid receptor,Ki,=,2600.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CC(C)C1CCC(N2CCC(C(=O)NCc3ccccc3)(c3ccccc3)CC2)CC1
CHEMBL272592,CHEMBL233,Mu opioid receptor,Ki,=,5155.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CC(C)(C)C1CCC(N2CCC3(CC2)C(=O)NCc2cc(F)ccc23)CC1
CHEMBL272640,CHEMBL233,Mu opioid receptor,Ki,=,6139.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CC(C)(C)C1CCC(N2CCC3(CC2)C(=O)NCc2ccccc23)CC1
CHEMBL407846,CHEMBL233,Mu opioid receptor,Ki,=,6755.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CC(C)C1CCC(N2CCC3(CC2)C(=O)NCc2cc(F)ccc23)CC1
CHEMBL271590,CHEMBL233,Mu opioid receptor,Ki,=,5406.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CC(C)C1CCC(N2CCC3(CC2)C(=O)NCc2ccccc23)CC1
CHEMBL259681,CHEMBL233,Mu opioid receptor,Ki,=,1582.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CC(C)(C)C1CCC(N2CCC3(CC2)C(=O)N(Cc2ccccc2)Cc2cc(F)ccc23)CC1
CHEMBL259473,CHEMBL233,Mu opioid receptor,Ki,=,247.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CC(C)(C)C1CCC(N2CCC3(CC2)C(=O)N(Cc2ccccc2)Cc2cccc(F)c23)CC1
CHEMBL272805,CHEMBL233,Mu opioid receptor,Ki,=,215.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CC(C)(C)C1CCC(N2CCC3(CC2)C(=O)N(Cc2ccccc2)Cc2ccccc23)CC1
CHEMBL412290,CHEMBL233,Mu opioid receptor,Ki,=,1875.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CC(C)C1CCC(N2CCC3(CC2)C(=O)N(Cc2ccccc2)Cc2cc(F)ccc23)CC1
CHEMBL270756,CHEMBL233,Mu opioid receptor,Ki,=,6500.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CC(C)C1CCC(N2CCC3(CC2)C(=O)N(Cc2ccccc2)Cc2cccc(F)c23)CC1
CHEMBL409621,CHEMBL233,Mu opioid receptor,Ki,=,1340.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CC(C)C1CCC(N2CCC3(CC2)C(=O)N(Cc2ccccc2)Cc2ccccc23)CC1
CHEMBL407275,CHEMBL233,Mu opioid receptor,Ki,=,3503.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CN1Cc2cc(F)ccc2C2(CCN(C3CCC(C(C)(C)C)CC3)CC2)C1=O
CHEMBL272600,CHEMBL233,Mu opioid receptor,Ki,=,7800.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CN1Cc2cccc(F)c2C2(CCN(C3CCC(C(C)(C)C)CC3)CC2)C1=O
CHEMBL272390,CHEMBL233,Mu opioid receptor,Ki,=,1005.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CN1Cc2ccccc2C2(CCN(C3CCC(C(C)(C)C)CC3)CC2)C1=O
CHEMBL272601,CHEMBL233,Mu opioid receptor,Ki,=,540.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CC(C)C1CCC(N2CCC3(CC2)C(=O)N(C)Cc2cc(F)ccc23)CC1
CHEMBL270133,CHEMBL233,Mu opioid receptor,Ki,=,2075.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CC(C)C1CCC(N2CCC3(CC2)C(=O)N(C)Cc2cccc(F)c23)CC1
CHEMBL272852,CHEMBL233,Mu opioid receptor,Ki,=,476.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,CC(C)C1CCC(N2CCC3(CC2)C(=O)N(C)Cc2ccccc23)CC1
CHEMBL412098,CHEMBL233,Mu opioid receptor,Ki,=,47.0,nM,CHEMBL930990,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1141567,KI,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CC[C@H]3CCCc4cccc1c43)CC2
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.3,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL429588,CHEMBL233,Mu opioid receptor,Ki,=,0.38,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(Cc1cccs1)N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL443326,CHEMBL233,Mu opioid receptor,Ki,=,0.43,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(Cc1cccs1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL270918,CHEMBL233,Mu opioid receptor,Ki,=,0.27,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,COc1ccc(CC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1
CHEMBL411927,CHEMBL233,Mu opioid receptor,Ki,=,0.16,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(Cc1ccccc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL273105,CHEMBL233,Mu opioid receptor,Ki,=,0.13,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,COc1cccc(CC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)c1
CHEMBL412050,CHEMBL233,Mu opioid receptor,Ki,=,0.12,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(CCc1ccccc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL438413,CHEMBL233,Mu opioid receptor,Ki,=,0.06,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(/C=C/Cc1ccccc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL272021,CHEMBL233,Mu opioid receptor,Ki,=,10.08,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(O)c1ccc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1
CHEMBL411916,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,CN(C)c1cccc(C(=O)NC2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)c1
CHEMBL271755,CHEMBL233,Mu opioid receptor,Ki,=,0.92,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,CC(C)(C)OC(=O)Nc1ccc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1
CHEMBL410526,CHEMBL233,Mu opioid receptor,Ki,=,0.12,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,COc1cccc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)c1
CHEMBL272051,CHEMBL233,Mu opioid receptor,Ki,=,0.43,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,Nc1ccc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1
CHEMBL260528,CHEMBL233,Mu opioid receptor,Ki,=,0.31,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccccn1
CHEMBL271811,CHEMBL233,Mu opioid receptor,Ki,=,0.26,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,COc1cc(OC)cc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)c1
CHEMBL410884,CHEMBL233,Mu opioid receptor,Ki,=,0.21,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,COC(=O)c1ccc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1
CHEMBL271797,CHEMBL233,Mu opioid receptor,Ki,=,0.21,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccccc1
CHEMBL411738,CHEMBL233,Mu opioid receptor,Ki,=,0.19,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,COc1cc(OC)cc(C(=O)N[C@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)c1
CHEMBL407466,CHEMBL233,Mu opioid receptor,Ki,=,0.19,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cccc([N+](=O)[O-])c1
CHEMBL271815,CHEMBL233,Mu opioid receptor,Ki,=,0.18,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccccc1
CHEMBL429929,CHEMBL233,Mu opioid receptor,Ki,=,0.16,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,COc1cccc(C(=O)N[C@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)c1
CHEMBL410122,CHEMBL233,Mu opioid receptor,Ki,=,0.13,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cccc(O)c1
CHEMBL272215,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(Cl)c(Cl)c1
CHEMBL409458,CHEMBL233,Mu opioid receptor,Ki,=,0.05,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(Cl)cc1
CHEMBL409036,CHEMBL233,Mu opioid receptor,Ki,=,0.64,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(C[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL272181,CHEMBL233,Mu opioid receptor,Ki,=,0.67,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(C[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL406116,CHEMBL233,Mu opioid receptor,Ki,=,1.49,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(C[C@@H]1O[C@H](COCc2ccccc2)[C@@H](OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1OCc1ccccc1)N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL982,CHEMBL233,Mu opioid receptor,Ki,=,0.91,nM,CHEMBL950282,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1142345,KI,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL2364732,CHEMBL233,Mu opioid receptor,Ki,=,39.2,nM,CHEMBL950325,B,Binding affinity to mu opioid receptor,CHEMBL1144030,KI,[11CH3]n1c2c(c3ccccc31)C[C@@]1(O)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,3.7,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL401615,CHEMBL233,Mu opioid receptor,Ki,=,0.5,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](CCCCN)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL437983,CHEMBL233,Mu opioid receptor,Ki,=,0.41,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](CCCN)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL257895,CHEMBL233,Mu opioid receptor,Ki,=,11.0,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(=O)O)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL401789,CHEMBL233,Mu opioid receptor,Ki,=,7.3,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](CC(=O)O)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL256010,CHEMBL233,Mu opioid receptor,Ki,=,4.7,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](CCc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL270401,CHEMBL233,Mu opioid receptor,Ki,=,11.0,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](CC2CCCCC2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL270187,CHEMBL233,Mu opioid receptor,Ki,=,2.0,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL404303,CHEMBL233,Mu opioid receptor,Ki,=,2.7,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL402964,CHEMBL233,Mu opioid receptor,Ki,=,1.9,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(-c3ccccc3)cc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL403190,CHEMBL233,Mu opioid receptor,Ki,=,1.7,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL255354,CHEMBL233,Mu opioid receptor,Ki,=,2.9,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@@H](NC(=O)[C@@H](Cc1ccccc1)CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)C(=O)O
CHEMBL403633,CHEMBL233,Mu opioid receptor,Ki,=,0.63,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H](NC(=O)[C@@H](Cc1ccccc1)CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)C(=O)O
CHEMBL271662,CHEMBL233,Mu opioid receptor,Ki,=,15.0,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N(Cc2cccc(Cl)c2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL270833,CHEMBL233,Mu opioid receptor,Ki,=,74.0,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N(Cc2ccc(-c3ccccc3)cc2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL403191,CHEMBL233,Mu opioid receptor,Ki,=,66.0,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N(CCc2ccccc2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL255555,CHEMBL233,Mu opioid receptor,Ki,=,23.0,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N(Cc2ccccc2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL404583,CHEMBL233,Mu opioid receptor,Ki,=,32.0,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N(c2ccccc2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL258294,CHEMBL233,Mu opioid receptor,Ki,=,22.0,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N(CC2CC2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL258115,CHEMBL233,Mu opioid receptor,Ki,=,28.0,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,CC(C)CN(C(=O)CCN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)[C@@H](Cc1ccccc1)C(=O)O
CHEMBL403324,CHEMBL233,Mu opioid receptor,Ki,=,19.0,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,CCN(C(=O)CCN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)[C@@H](Cc1ccccc1)C(=O)O
CHEMBL256834,CHEMBL233,Mu opioid receptor,Ki,=,66.0,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N(C)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL403325,CHEMBL233,Mu opioid receptor,Ki,=,58.0,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N[C@@H](CCc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL441899,CHEMBL233,Mu opioid receptor,Ki,=,80.0,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N[C@@H](Cc2ccc(-c3ccccc3)cc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL401508,CHEMBL233,Mu opioid receptor,Ki,=,20.0,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N[C@@H](CC2CCCCC2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL401716,CHEMBL233,Mu opioid receptor,Ki,=,36.0,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL270190,CHEMBL233,Mu opioid receptor,Ki,=,0.47,nM,CHEMBL933964,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL260521,CHEMBL233,Mu opioid receptor,Ki,=,6800.0,nM,CHEMBL940228,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143969,KI,C=CCN1C[C@@H]2C(c3ccccc3)=CC[C@H]1CN2Cc1ccc(C(=O)N(CC)CC)cc1
CHEMBL260519,CHEMBL233,Mu opioid receptor,Ki,=,250.0,nM,CHEMBL940228,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143969,KI,C=CCN1C[C@H]2C(c3ccccc3)=CC[C@@H]1CN2Cc1ccc(C(=O)N(CC)CC)cc1
CHEMBL409266,CHEMBL233,Mu opioid receptor,Ki,=,5700.0,nM,CHEMBL940228,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143969,KI,CCCN1C[C@@H]2[C@H](c3ccccc3)CC[C@H]1CN2Cc1ccc(C(=O)N(CC)CC)cc1
CHEMBL258791,CHEMBL233,Mu opioid receptor,Ki,=,7300.0,nM,CHEMBL940228,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143969,KI,C=CCN1C[C@@H]2[C@H](c3ccccc3)CC[C@H]1CN2Cc1ccc(C(=O)N(CC)CC)cc1
CHEMBL407728,CHEMBL233,Mu opioid receptor,Ki,=,6320.0,nM,CHEMBL940228,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143969,KI,C=CCN1C[C@@H]2[C@@H](c3ccccc3)CC[C@H]1CN2Cc1ccc(C(=O)N(CC)CC)cc1
CHEMBL260767,CHEMBL233,Mu opioid receptor,Ki,=,53.7,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,CNC(=O)Cn1c(=O)n(C2CCN(CC[C@H](Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL428253,CHEMBL233,Mu opioid receptor,Ki,=,223.87,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cn4cccn4)c4ccccc43)CC2)C(C)C)c1
CHEMBL260784,CHEMBL233,Mu opioid receptor,Ki,=,120.23,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cn4ccnc4)c4ccccc43)CC2)C(C)C)c1
CHEMBL410257,CHEMBL233,Mu opioid receptor,Ki,=,213.8,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4c[nH]cn4)c4ccccc43)CC2)C(C)C)c1
CHEMBL259964,CHEMBL233,Mu opioid receptor,Ki,=,75.86,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4cnccn4)c4ccccc43)CC2)C(C)C)c1
CHEMBL258781,CHEMBL233,Mu opioid receptor,Ki,=,47.86,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4cccnc4)c4ccccc43)CC2)C(C)C)c1
CHEMBL260169,CHEMBL233,Mu opioid receptor,Ki,=,44.67,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4cccs4)c4ccccc43)CC2)C(C)C)c1
CHEMBL259120,CHEMBL233,Mu opioid receptor,Ki,=,56.23,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4c(C)noc4C)c4ccccc43)CC2)C(C)C)c1
CHEMBL410706,CHEMBL233,Mu opioid receptor,Ki,=,144.54,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4cc(C)on4)c4ccccc43)CC2)C(C)C)c1
CHEMBL262062,CHEMBL233,Mu opioid receptor,Ki,=,83.18,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4ncco4)c4ccccc43)CC2)C(C)C)c1
CHEMBL262064,CHEMBL233,Mu opioid receptor,Ki,=,104.71,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4cocn4)c4ccccc43)CC2)C(C)C)c1
CHEMBL442469,CHEMBL233,Mu opioid receptor,Ki,=,524.81,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4noc(C(C)(C)C)n4)c4ccccc43)CC2)C(C)C)c1
CHEMBL409351,CHEMBL233,Mu opioid receptor,Ki,=,42.66,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4ccncc4)c4ccccc43)CC2)C(C)C)c1
CHEMBL406926,CHEMBL233,Mu opioid receptor,Ki,=,38.9,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4csc(C)n4)c4ccccc43)CC2)C(C)C)c1
CHEMBL408909,CHEMBL233,Mu opioid receptor,Ki,=,52.48,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4ccccn4)c4ccccc43)CC2)C(C)C)c1
CHEMBL259511,CHEMBL233,Mu opioid receptor,Ki,=,38.9,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4ccsc4)c4ccccc43)CC2)C(C)C)c1
CHEMBL259263,CHEMBL233,Mu opioid receptor,Ki,=,42.66,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4cscn4)c4ccccc43)CC2)C(C)C)c1
CHEMBL239043,CHEMBL233,Mu opioid receptor,Ki,=,186.21,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COCCn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL391487,CHEMBL233,Mu opioid receptor,Ki,=,165.96,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,CNC(=O)Cn1c(=O)n(C2CCN(CCC(Oc3cc(OC)ccc3C)C(C)C)CC2)c2ccccc21
CHEMBL261839,CHEMBL233,Mu opioid receptor,Ki,=,100.0,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4ncsn4)c4ccccc43)CC2)C(C)C)c1
CHEMBL259291,CHEMBL233,Mu opioid receptor,Ki,=,25.12,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4n[nH]c(=O)[nH]4)c4ccccc43)CC2)C(C)C)c1
CHEMBL259292,CHEMBL233,Mu opioid receptor,Ki,=,181.97,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4cnn[nH]4)c4ccccc43)CC2)C(C)C)c1
CHEMBL259048,CHEMBL233,Mu opioid receptor,Ki,=,77.62,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4ncon4)c4ccccc43)CC2)C(C)C)c1
CHEMBL259262,CHEMBL233,Mu opioid receptor,Ki,=,1023.29,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4nnn[nH]4)c4ccccc43)CC2)C(C)C)c1
CHEMBL406409,CHEMBL233,Mu opioid receptor,Ki,=,100.0,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4ncn(C)n4)c4ccccc43)CC2)C(C)C)c1
CHEMBL260555,CHEMBL233,Mu opioid receptor,Ki,=,47.86,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4ncnn4C)c4ccccc43)CC2)C(C)C)c1
CHEMBL260556,CHEMBL233,Mu opioid receptor,Ki,=,36.31,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4ncn[nH]4)c4ccccc43)CC2)C(C)C)c1
CHEMBL260556,CHEMBL233,Mu opioid receptor,Ki,=,138.04,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4ncn[nH]4)c4ccccc43)CC2)C(C)C)c1
CHEMBL438919,CHEMBL233,Mu opioid receptor,Ki,=,204.17,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4noc(C)n4)c4ccccc43)CC2)C(C)C)c1
CHEMBL259157,CHEMBL233,Mu opioid receptor,Ki,=,95.5,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4nc(C)no4)c4ccccc43)CC2)C(C)C)c1
CHEMBL258897,CHEMBL233,Mu opioid receptor,Ki,=,120.23,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cc4nnc(C)[nH]4)c4ccccc43)CC2)C(C)C)c1
CHEMBL411643,CHEMBL233,Mu opioid receptor,Ki,=,38.9,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cn4cncn4)c4ccccc43)CC2)C(C)C)c1
CHEMBL406647,CHEMBL233,Mu opioid receptor,Ki,=,123.03,nM,CHEMBL940231,B,Displacement of [3H]Diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1143970,KI,COc1ccc(C)c(OC(CCN2CCC(n3c(=O)n(Cn4ccnc4C)c4ccccc43)CC2)C(C)C)c1
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,4.0,nM,CHEMBL925796,B,Displacement of [3H]naloxone from human mu poioid receptor expressed in HEK293 cells,CHEMBL1147037,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL404097,CHEMBL233,Mu opioid receptor,Ki,=,34600.0,nM,CHEMBL925796,B,Displacement of [3H]naloxone from human mu poioid receptor expressed in HEK293 cells,CHEMBL1147037,KI,COC1=C[C@]23CCN(C)[C@H](Cc4ccc(OC)c(O)c42)C3=CC1=O
CHEMBL403893,CHEMBL233,Mu opioid receptor,Ki,=,7400.0,nM,CHEMBL925796,B,Displacement of [3H]naloxone from human mu poioid receptor expressed in HEK293 cells,CHEMBL1147037,KI,COC1=CC=C2[C@H]3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL485,CHEMBL233,Mu opioid receptor,Ki,=,6300.0,nM,CHEMBL925796,B,Displacement of [3H]naloxone from human mu poioid receptor expressed in HEK293 cells,CHEMBL1147037,KI,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
CHEMBL257627,CHEMBL233,Mu opioid receptor,Ki,=,459.0,nM,CHEMBL925796,B,Displacement of [3H]naloxone from human mu poioid receptor expressed in HEK293 cells,CHEMBL1147037,KI,COc1ccc2c3c1O[C@H]1C(=O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314
CHEMBL437602,CHEMBL233,Mu opioid receptor,Ki,=,286.0,nM,CHEMBL925796,B,Displacement of [3H]naloxone from human mu poioid receptor expressed in HEK293 cells,CHEMBL1147037,KI,COC1=CC=C2[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL255467,CHEMBL233,Mu opioid receptor,Ki,=,146.0,nM,CHEMBL925796,B,Displacement of [3H]naloxone from human mu poioid receptor expressed in HEK293 cells,CHEMBL1147037,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)C=C[C@H]3[C@H]1C5
CHEMBL408422,CHEMBL233,Mu opioid receptor,Ki,=,305.0,nM,CHEMBL922696,B,Displacement of [3H]diprenorphine from recombinant mu opioid receptor expressed in C6 cells,CHEMBL1144851,KI,COc1ccc2c3c1O[C@H]1CC=C[C@H]4[C@@H](C2)N(C)CC[C@]314
CHEMBL410907,CHEMBL233,Mu opioid receptor,Ki,=,2.1,nM,CHEMBL922696,B,Displacement of [3H]diprenorphine from recombinant mu opioid receptor expressed in C6 cells,CHEMBL1144851,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2CC=C[C@H]3[C@H]1C5
CHEMBL409743,CHEMBL233,Mu opioid receptor,Ki,=,524.0,nM,CHEMBL922696,B,Displacement of [3H]diprenorphine from recombinant mu opioid receptor expressed in C6 cells,CHEMBL1144851,KI,CO[C@H]1CC[C@H]2[C@H]3Cc4cccc5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL412301,CHEMBL233,Mu opioid receptor,Ki,=,1910.0,nM,CHEMBL922696,B,Displacement of [3H]diprenorphine from recombinant mu opioid receptor expressed in C6 cells,CHEMBL1144851,KI,COc1ccc2c3c1O[C@H]1[C@@H](OC)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
CHEMBL358043,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL922696,B,Displacement of [3H]diprenorphine from recombinant mu opioid receptor expressed in C6 cells,CHEMBL1144851,KI,CO[C@H]1C=C[C@H]2[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL258669,CHEMBL233,Mu opioid receptor,Ki,=,122.0,nM,CHEMBL922696,B,Displacement of [3H]diprenorphine from recombinant mu opioid receptor expressed in C6 cells,CHEMBL1144851,KI,CN1CC[C@]23c4c5cccc4O[C@H]2[C@@H](O)CC[C@H]3[C@H]1C5
CHEMBL485,CHEMBL233,Mu opioid receptor,Ki,=,727.0,nM,CHEMBL922696,B,Displacement of [3H]diprenorphine from recombinant mu opioid receptor expressed in C6 cells,CHEMBL1144851,KI,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,1.7,nM,CHEMBL922696,B,Displacement of [3H]diprenorphine from recombinant mu opioid receptor expressed in C6 cells,CHEMBL1144851,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL261048,CHEMBL233,Mu opioid receptor,Ki,=,22.9,nM,CHEMBL922696,B,Displacement of [3H]diprenorphine from recombinant mu opioid receptor expressed in C6 cells,CHEMBL1144851,KI,CN1CC[C@]23c4c5cccc4O[C@H]2CCC[C@H]3[C@H]1C5
CHEMBL262346,CHEMBL233,Mu opioid receptor,Ki,=,290.0,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](SC(=O)c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL445332,CHEMBL233,Mu opioid receptor,Ki,=,4370.0,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL259658,CHEMBL233,Mu opioid receptor,Ki,=,3.1,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](NC(=O)c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL213155,CHEMBL233,Mu opioid receptor,Ki,=,4180.0,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](NC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL258754,CHEMBL233,Mu opioid receptor,Ki,=,1030.0,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)C2CCCCC2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL410436,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccsc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL264967,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2cccs2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL260121,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2cc3ccccc3o2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL261807,CHEMBL233,Mu opioid receptor,Ki,=,180.0,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccc3ccccc3c2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL265195,CHEMBL233,Mu opioid receptor,Ki,=,260.0,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccc([N+](=O)[O-])cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL408775,CHEMBL233,Mu opioid receptor,Ki,=,7550.0,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccccc2[N+](=O)[O-])C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL260286,CHEMBL233,Mu opioid receptor,Ki,=,70.0,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccc(OC)cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL260485,CHEMBL233,Mu opioid receptor,Ki,=,30.0,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2cccc(OC)c2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL429685,CHEMBL233,Mu opioid receptor,Ki,=,1640.0,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccccc2OC)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL259299,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccc(Br)cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL261024,CHEMBL233,Mu opioid receptor,Ki,=,110.0,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2cccc(Br)c2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL407155,CHEMBL233,Mu opioid receptor,Ki,=,110.0,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccccc2Br)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL363324,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL923550,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL38576,CHEMBL233,Mu opioid receptor,Ki,=,53.0,nM,CHEMBL927003,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL257140,CHEMBL233,Mu opioid receptor,Ki,=,6.5,nM,CHEMBL927003,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,CN(C(=O)Cc1cc2c(cc1S(=O)(=O)N(C)Cc1ccccc1)OCO2)[C@H](CN1CCCC1)c1ccccc1
CHEMBL257139,CHEMBL233,Mu opioid receptor,Ki,=,34.0,nM,CHEMBL927003,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,CN(C(=O)Cc1cc2c(cc1S(=O)(=O)N(C)C)OCO2)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL402135,CHEMBL233,Mu opioid receptor,Ki,=,47.0,nM,CHEMBL927003,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,CN(C(=O)Cc1cc2c(cc1S(=O)(=O)N(C)C)OCO2)[C@H](CN1CCCC1)c1ccccc1
CHEMBL403273,CHEMBL233,Mu opioid receptor,Ki,=,450.0,nM,CHEMBL927003,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,CN(C(=O)Cc1ccc2c(c1)OCO2)[C@H](CN1CCCC1)c1ccccc1
CHEMBL429677,CHEMBL233,Mu opioid receptor,Ki,=,9.0,nM,CHEMBL927003,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CC[C@H](O)C2)c2ccccc2)c(S(=O)(=O)N2CCOCC2)cc1OC
CHEMBL402189,CHEMBL233,Mu opioid receptor,Ki,=,15.0,nM,CHEMBL927003,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CCCC2)c2ccccc2)c(S(=O)(=O)N2CCOCC2)cc1OC
CHEMBL254754,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL927003,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CC[C@H](O)C2)c2ccccc2)c(S(=O)(=O)N2CCN(C)CC2)cc1OC
CHEMBL437784,CHEMBL233,Mu opioid receptor,Ki,=,52.0,nM,CHEMBL927003,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CCCC2)c2ccccc2)c(S(=O)(=O)N2CCN(C)CC2)cc1OC
CHEMBL257355,CHEMBL233,Mu opioid receptor,Ki,=,5.9,nM,CHEMBL927003,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CC[C@H](O)C2)c2ccccc2)c(S(=O)(=O)N2CCCC2)cc1OC
CHEMBL402820,CHEMBL233,Mu opioid receptor,Ki,=,14.0,nM,CHEMBL927003,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CCCC2)c2ccccc2)c(S(=O)(=O)N2CCCC2)cc1OC
CHEMBL401594,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL927003,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CCCC2)c2ccccc2)c(S(=O)(=O)N(C)Cc2ccccc2)cc1OC
CHEMBL254960,CHEMBL233,Mu opioid receptor,Ki,=,25.0,nM,CHEMBL927003,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CC[C@H](O)C2)c2ccccc2)c(S(=O)(=O)N(C)C)cc1OC
CHEMBL254959,CHEMBL233,Mu opioid receptor,Ki,=,42.0,nM,CHEMBL927003,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CCCC2)c2ccccc2)c(S(=O)(=O)N(C)C)cc1OC
CHEMBL411557,CHEMBL233,Mu opioid receptor,Ki,=,9.4,nM,CHEMBL927003,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O
CHEMBL316446,CHEMBL233,Mu opioid receptor,Ki,=,1.45,nM,CHEMBL969336,B,Displacement of [3H]DAMGO from mu opioid receptor in human SH-SY5Y cells,CHEMBL1149874,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL455502,CHEMBL233,Mu opioid receptor,Ki,=,112.5,nM,CHEMBL969336,B,Displacement of [3H]DAMGO from mu opioid receptor in human SH-SY5Y cells,CHEMBL1149874,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL500212,CHEMBL233,Mu opioid receptor,Ki,=,37.3,nM,CHEMBL969336,B,Displacement of [3H]DAMGO from mu opioid receptor in human SH-SY5Y cells,CHEMBL1149874,KI,CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(N)=O
CHEMBL504973,CHEMBL233,Mu opioid receptor,Ki,=,12.1,nM,CHEMBL969336,B,Displacement of [3H]DAMGO from mu opioid receptor in human SH-SY5Y cells,CHEMBL1149874,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL35838,CHEMBL233,Mu opioid receptor,Ki,=,11.4,nM,CHEMBL969336,B,Displacement of [3H]DAMGO from mu opioid receptor in human SH-SY5Y cells,CHEMBL1149874,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL466147,CHEMBL233,Mu opioid receptor,Ki,=,705.0,nM,CHEMBL969336,B,Displacement of [3H]DAMGO from mu opioid receptor in human SH-SY5Y cells,CHEMBL1149874,KI,C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL445690,CHEMBL233,Mu opioid receptor,Ki,=,3190.0,nM,CHEMBL969336,B,Displacement of [3H]DAMGO from mu opioid receptor in human SH-SY5Y cells,CHEMBL1149874,KI,C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL387816,CHEMBL233,Mu opioid receptor,Ki,=,225.9,nM,CHEMBL969336,B,Displacement of [3H]DAMGO from mu opioid receptor in human SH-SY5Y cells,CHEMBL1149874,KI,C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL512955,CHEMBL233,Mu opioid receptor,Ki,=,72.7,nM,CHEMBL969336,B,Displacement of [3H]DAMGO from mu opioid receptor in human SH-SY5Y cells,CHEMBL1149874,KI,C[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL592,CHEMBL233,Mu opioid receptor,Ki,=,0.21,nM,CHEMBL1005603,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL499868,CHEMBL233,Mu opioid receptor,Ki,=,3.9,nM,CHEMBL1005603,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.Nc1ccc(Oc2ccc3c(c2)[C@@]24CCCC[C@@]2(O)[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL526362,CHEMBL233,Mu opioid receptor,Ki,=,16.0,nM,CHEMBL1005603,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.O=[N+]([O-])c1ccc(Oc2ccc3c(c2)[C@@]24CCCC[C@@]2(O)[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL501447,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL1005603,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.O[C@@]12CCCC[C@@]13CCN(CC1CCC1)[C@@H]2Cc1ccc(OCCc2ccccc2)cc13
CHEMBL524505,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL1005603,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.O[C@@]12CCCC[C@@]13CCN(CC1CCC1)[C@@H]2Cc1ccc(OCc2ccccc2)cc13
CHEMBL500123,CHEMBL233,Mu opioid receptor,Ki,=,18.0,nM,CHEMBL1005603,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.OCCCOc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL497108,CHEMBL233,Mu opioid receptor,Ki,=,55.0,nM,CHEMBL1005603,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.NC(=O)COc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL521543,CHEMBL233,Mu opioid receptor,Ki,=,0.22,nM,CHEMBL1005603,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,COc1ccc(CC(=O)Oc2ccc3c(c2)[C@@]24CCCC[C@@]2(O)[C@@H](C3)N(CC2CCC2)CC4)cc1.Cl
CHEMBL451320,CHEMBL233,Mu opioid receptor,Ki,=,15.0,nM,CHEMBL1005603,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.O=C(Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3)c1ccc(-c2ccccc2)cc1
CHEMBL500419,CHEMBL233,Mu opioid receptor,Ki,=,0.061,nM,CHEMBL1005603,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.O=C(COc1ccccc1)Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL500154,CHEMBL233,Mu opioid receptor,Ki,=,2.3,nM,CHEMBL1005603,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cc1ccc(C(C)C(=O)Oc2ccc3c(c2)[C@@]24CCCC[C@@]2(O)[C@@H](C3)N(CC2CCC2)CC4)cc1.Cl
CHEMBL501739,CHEMBL233,Mu opioid receptor,Ki,=,0.32,nM,CHEMBL1005603,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.O=C(Cc1ccccc1)Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL503457,CHEMBL233,Mu opioid receptor,Ki,=,2.7,nM,CHEMBL1005603,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.O=C(Cc1ccc(-c2ccccc2)cc1)Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL33986,CHEMBL233,Mu opioid receptor,Ki,=,0.22,nM,CHEMBL1005603,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL301160,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL1005603,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL499884,CHEMBL233,Mu opioid receptor,Ki,=,6.7,nM,CHEMBL1005603,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,C[C@H]1[C@H]2Cc3ccc(C(=O)N(C)CCc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL3216439,CHEMBL233,Mu opioid receptor,Ki,=,310.0,nM,CHEMBL1018970,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1139314,KI,Cc1ccc2nc(NC(=O)c3ccc(Cl)cc3)nc(NC3CCCCC3NC(=N)N)c2c1.Cl.Cl.Cl
CHEMBL3216666,CHEMBL233,Mu opioid receptor,Ki,=,330.0,nM,CHEMBL1018970,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1139314,KI,Cc1ccc2nc(NC(=O)c3ccc(Cl)cc3)nc(N[C@H]3CCCC[C@H]3NC(=N)N)c2c1.Cl.Cl.Cl
CHEMBL3216904,CHEMBL233,Mu opioid receptor,Ki,=,270.0,nM,CHEMBL1018970,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells,CHEMBL1139314,KI,Cc1ccc2nc(NC(=O)c3ccc(Cl)cc3)nc(N[C@@H]3CCCC[C@@H]3NC(=N)N)c2c1.Cl.Cl.Cl
CHEMBL501238,CHEMBL233,Mu opioid receptor,Ki,=,8.3,nM,CHEMBL1021530,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1139377,KI,CN1C(=O)[C@H](NC(=O)Nc2cccc(OCCNC(=O)COCC(=O)NNC(=O)COCC(=O)N[C@H]3CC[C@@]4(O)[C@H]5Cc6cc(O)cc7c6[C@@]4(CCN5C)[C@H]3O7)c2)N=C(c2ccccc2)c2ccccc21
CHEMBL509792,CHEMBL233,Mu opioid receptor,Ki,=,5.7,nM,CHEMBL1021530,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1139377,KI,CN1C(=O)[C@H](NC(=O)Nc2cccc(OCCNC(=O)COCC(=O)NCCNC(=O)COCC(=O)N[C@H]3CC[C@@]4(O)[C@H]5Cc6cc(O)cc7c6[C@@]4(CCN5C)[C@H]3O7)c2)N=C(c2ccccc2)c2ccccc21
CHEMBL502398,CHEMBL233,Mu opioid receptor,Ki,=,29.4,nM,CHEMBL1021530,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1139377,KI,CN1C(=O)[C@H](NC(=O)Nc2cccc(OCCNC(=O)COCC(=O)NCCCCCCNC(=O)COCC(=O)N[C@H]3CC[C@@]4(O)[C@H]5Cc6cc(O)cc7c6[C@@]4(CCN5C)[C@H]3O7)c2)N=C(c2ccccc2)c2ccccc21
CHEMBL442943,CHEMBL233,Mu opioid receptor,Ki,=,24.1,nM,CHEMBL1021530,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1139377,KI,CN1C(=O)[C@H](NC(=O)Nc2cccc(OCCNC(=O)COCC(=O)N[C@H]3CC[C@@]4(O)[C@H]5Cc6cc(O)cc7c6[C@@]4(CCN5C)[C@H]3O7)c2)N=C(c2ccccc2)c2ccccc21
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,6.7,nM,CHEMBL1021530,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1139377,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL452991,CHEMBL233,Mu opioid receptor,Ki,=,0.0298,nM,CHEMBL1021530,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1139377,KI,CNC(=O)COCC(=O)NCCCCNC(=O)COCC(=O)N[C@H]1CC[C@@]2(O)[C@H]3Cc4cc(O)cc5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL495760,CHEMBL233,Mu opioid receptor,Ki,=,9800.0,nM,CHEMBL995853,B,Binding affinity to mu opioid receptor,CHEMBL1141669,KI,N#CC1(c2ccccc2)CCN(CCCCc2ccccc2)CC1
CHEMBL495549,CHEMBL233,Mu opioid receptor,Ki,=,5900.0,nM,CHEMBL995853,B,Binding affinity to mu opioid receptor,CHEMBL1141669,KI,N#CC1(c2ccccc2)CCN(Cc2ccccc2)CC1
CHEMBL1237044,CHEMBL233,Mu opioid receptor,Ki,=,1600.0,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,COc1cccc(C2(O)CCCCC2CN(C)C)c1
CHEMBL443601,CHEMBL233,Mu opioid receptor,Ki,=,9.5,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CN(C)C[C@H]1CCCC[C@]1(O)c1cccc(C(N)=O)c1
CHEMBL1400,CHEMBL233,Mu opioid receptor,Ki,=,8.6,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CN(C)C[C@H]1CCCC[C@]1(O)c1cccc(O)c1
CHEMBL506457,CHEMBL233,Mu opioid receptor,Ki,=,400.0,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,NC(=O)c1ccc2c3c1O[C@H]1C4NC5C(C[C@@]6(O)[C@H]7Cc8ccc(C(N)=O)c9c8[C@@]6(CCN7CC6CC6)[C@H]5O9)C4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL573214,CHEMBL233,Mu opioid receptor,Ki,=,2.7,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL517567,CHEMBL233,Mu opioid receptor,Ki,=,0.77,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(C(N)=O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL511142,CHEMBL233,Mu opioid receptor,Ki,=,0.21,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL516552,CHEMBL233,Mu opioid receptor,Ki,=,18.0,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C=CCN1CC[C@]23c4c5ccc(C(N)=O)c4O[C@@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL415284,CHEMBL233,Mu opioid receptor,Ki,=,0.19,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL56585,CHEMBL233,Mu opioid receptor,Ki,=,0.16,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CC1CC1
CHEMBL297428,CHEMBL233,Mu opioid receptor,Ki,=,0.31,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CC1C2Cc3ccc(C(N)=O)cc3C1(C)CCN2CC1CC1
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.11,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL56695,CHEMBL233,Mu opioid receptor,Ki,=,0.71,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,NC(=O)c1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL397705,CHEMBL233,Mu opioid receptor,Ki,=,6.9,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CC(C)=CCN1CC[C@@]2(C)c3cc(O)ccc3C[C@@H]1[C@H]2C
CHEMBL461227,CHEMBL233,Mu opioid receptor,Ki,=,5.2,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CC(C)=CCN1CC[C@@]2(C)c3cc(C(N)=O)ccc3C[C@@H]1[C@@H]2C
CHEMBL257661,CHEMBL233,Mu opioid receptor,Ki,=,3.8,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C[C@H]1[C@@H]2Cc3ccc(O)cc3[C@]1(C)CCN2C
CHEMBL511884,CHEMBL233,Mu opioid receptor,Ki,=,1.6,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CC1C2Cc3ccc(C(N)=O)cc3C1(C)CCN2C
CHEMBL3275494,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C[C@H]1C2Cc3ccc(O)cc3[C@@]1(C)CCN2CCc1ccccc1
CHEMBL464230,CHEMBL233,Mu opioid receptor,Ki,=,0.015,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CC1C2Cc3ccc(C(N)=O)cc3C1(C)CCN2CCc1ccccc1
CHEMBL33986,CHEMBL233,Mu opioid receptor,Ki,=,0.12,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL517779,CHEMBL233,Mu opioid receptor,Ki,=,0.15,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,NC(=O)c1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,0.66,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL464250,CHEMBL233,Mu opioid receptor,Ki,=,4.5,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C=CCN1CC[C@]23c4c5ccc(C(N)=O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL140278,CHEMBL233,Mu opioid receptor,Ki,=,0.19,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,Oc1ccc2c3c1O[C@H]1[C@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL442719,CHEMBL233,Mu opioid receptor,Ki,=,2.5,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,NC(=O)c1ccc2c3c1O[C@H]1[C@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL468469,CHEMBL233,Mu opioid receptor,Ki,=,0.21,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL511588,CHEMBL233,Mu opioid receptor,Ki,=,7.1,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,NC(=O)c1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL982,CHEMBL233,Mu opioid receptor,Ki,=,0.44,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL518083,CHEMBL233,Mu opioid receptor,Ki,=,2.6,nM,CHEMBL1019876,B,Displacement of [3H]DAMGO form human mu opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(C(N)=O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL316446,CHEMBL233,Mu opioid receptor,Ki,=,1.11,nM,CHEMBL955666,B,Displacement of [3H]DAMGO from mu opioid receptor in human SHSY5Y cells,CHEMBL1150362,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL509528,CHEMBL233,Mu opioid receptor,Ki,=,0.081,nM,CHEMBL955666,B,Displacement of [3H]DAMGO from mu opioid receptor in human SHSY5Y cells,CHEMBL1150362,KI,CCCCCCC(N)C(=O)N[C@@H](Cc1c(C)cc(O)cc1C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL412923,CHEMBL233,Mu opioid receptor,Ki,=,0.059,nM,CHEMBL955666,B,Displacement of [3H]DAMGO from mu opioid receptor in human SHSY5Y cells,CHEMBL1150362,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL526349,CHEMBL233,Mu opioid receptor,Ki,=,266.0,nM,CHEMBL955666,B,Displacement of [3H]DAMGO from mu opioid receptor in human SHSY5Y cells,CHEMBL1150362,KI,CCCCCCC(NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CCC(=O)N[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(N)=O
CHEMBL446814,CHEMBL233,Mu opioid receptor,Ki,=,148.0,nM,CHEMBL955666,B,Displacement of [3H]DAMGO from mu opioid receptor in human SHSY5Y cells,CHEMBL1150362,KI,CCCCCCC(N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]1O[C@H](C(N)=O)[C@@H](O)[C@H](O)[C@H]1O
CHEMBL451830,CHEMBL233,Mu opioid receptor,Ki,=,151.0,nM,CHEMBL955666,B,Displacement of [3H]DAMGO from mu opioid receptor in human SHSY5Y cells,CHEMBL1150362,KI,NC(=O)[C@H]1O[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](N)Cc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O
CHEMBL503367,CHEMBL233,Mu opioid receptor,Ki,=,121.0,nM,CHEMBL955666,B,Displacement of [3H]DAMGO from mu opioid receptor in human SHSY5Y cells,CHEMBL1150362,KI,CCCCCCC(NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL499141,CHEMBL233,Mu opioid receptor,Ki,=,115.0,nM,CHEMBL955666,B,Displacement of [3H]DAMGO from mu opioid receptor in human SHSY5Y cells,CHEMBL1150362,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CCC(=O)N[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
CHEMBL505960,CHEMBL233,Mu opioid receptor,Ki,=,15.4,nM,CHEMBL955666,B,Displacement of [3H]DAMGO from mu opioid receptor in human SHSY5Y cells,CHEMBL1150362,KI,CCCCCCCCCCC(N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL500704,CHEMBL233,Mu opioid receptor,Ki,=,3.02,nM,CHEMBL955666,B,Displacement of [3H]DAMGO from mu opioid receptor in human SHSY5Y cells,CHEMBL1150362,KI,CCCCCC[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL510939,CHEMBL233,Mu opioid receptor,Ki,=,2.92,nM,CHEMBL955666,B,Displacement of [3H]DAMGO from mu opioid receptor in human SHSY5Y cells,CHEMBL1150362,KI,CCCCCC[C@@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL471806,CHEMBL233,Mu opioid receptor,Ki,=,2.15,nM,CHEMBL955666,B,Displacement of [3H]DAMGO from mu opioid receptor in human SHSY5Y cells,CHEMBL1150362,KI,CCCCCCC(N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL482496,CHEMBL233,Mu opioid receptor,Ki,=,82.0,nM,CHEMBL959798,B,Binding affinity to mu opioid receptor,CHEMBL1150367,KI,[3H]C([3H])([3H])Oc1cc(I)c(OC)cc1CCNCc1ccccc1OC([3H])([3H])[3H]
CHEMBL58646,CHEMBL233,Mu opioid receptor,Ki,=,0.31,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3ccc(C(N)=O)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL213880,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3ccc(C(=O)NCc4ccccc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL377789,CHEMBL233,Mu opioid receptor,Ki,=,0.3,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL493621,CHEMBL233,Mu opioid receptor,Ki,=,5.5,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3cc4cc[nH]c(=O)c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL495462,CHEMBL233,Mu opioid receptor,Ki,=,88.0,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3cc(N)c(C(N)=O)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL522375,CHEMBL233,Mu opioid receptor,Ki,=,0.55,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3ccc(C(N)=O)c(N)c3[C@@]1(C)CCN2CC1CC1
CHEMBL495461,CHEMBL233,Mu opioid receptor,Ki,=,630.0,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3cc([N+](=O)[O-])c(C(N)=O)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL494614,CHEMBL233,Mu opioid receptor,Ki,=,20.0,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3ccc(C(N)=O)c([N+](=O)[O-])c3[C@@]1(C)CCN2CC1CC1
CHEMBL494613,CHEMBL233,Mu opioid receptor,Ki,=,3800.0,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3cc([N+](=O)[O-])c(O)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL509054,CHEMBL233,Mu opioid receptor,Ki,=,32.0,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3ccc(O)c([N+](=O)[O-])c3[C@@]1(C)CCN2CC1CC1
CHEMBL468182,CHEMBL233,Mu opioid receptor,Ki,=,88.0,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3cc4ncnc(NCc5ccccc5)c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL463518,CHEMBL233,Mu opioid receptor,Ki,=,28.0,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3cc4ncnc(NCCc5ccc(-c6ccccc6)cc5)c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL511243,CHEMBL233,Mu opioid receptor,Ki,=,44.0,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3ccc4c(NCc5ccccc5)ncnc4c3[C@@]1(C)CCN2CC1CC1
CHEMBL468857,CHEMBL233,Mu opioid receptor,Ki,=,6.9,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3ccc4c(NCCc5ccc(-c6ccccc6)cc5)ncnc4c3[C@@]1(C)CCN2CC1CC1
CHEMBL502583,CHEMBL233,Mu opioid receptor,Ki,=,890.0,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3cc4ncnc(N)c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL469189,CHEMBL233,Mu opioid receptor,Ki,=,0.55,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3ccc4c(N)ncnc4c3[C@@]1(C)CCN2CC1CC1
CHEMBL512474,CHEMBL233,Mu opioid receptor,Ki,=,270.0,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3ccc4c(=O)[nH]cnc4c3[C@@]1(C)CCN2CC1CC1
CHEMBL469188,CHEMBL233,Mu opioid receptor,Ki,=,170.0,nM,CHEMBL973302,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1150274,KI,C[C@H]1C2Cc3cc4nc[nH]c(=O)c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL1627,CHEMBL233,Mu opioid receptor,Ki,=,0.6,nM,CHEMBL1025637,B,Displacement of [3H]DAMGO from mu opioid receptor,CHEMBL1140103,KI,CNC(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
CHEMBL25230,CHEMBL233,Mu opioid receptor,Ki,=,260.0,nM,CHEMBL993334,B,Displacement of [3H]diprenorphine from human mu opioid receptor in CHO cells,CHEMBL1140111,KI,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(O)c2)C[C@H]1C
CHEMBL493846,CHEMBL233,Mu opioid receptor,Ki,=,55.6,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc2ccccc2c1
CHEMBL495058,CHEMBL233,Mu opioid receptor,Ki,=,8.36,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc2ccccc2c1
CHEMBL495057,CHEMBL233,Mu opioid receptor,Ki,=,0.07,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cnc2ccccc2c1
CHEMBL523382,CHEMBL233,Mu opioid receptor,Ki,=,0.12,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cnc2ccccc2c1
CHEMBL494854,CHEMBL233,Mu opioid receptor,Ki,=,0.11,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc2ccccc2n1
CHEMBL494853,CHEMBL233,Mu opioid receptor,Ki,=,0.21,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc2ccccc2n1
CHEMBL521854,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cc2ccccc2cn1
CHEMBL522201,CHEMBL233,Mu opioid receptor,Ki,=,0.55,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cc2ccccc2cn1
CHEMBL271815,CHEMBL233,Mu opioid receptor,Ki,=,0.92,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccccc1
CHEMBL271797,CHEMBL233,Mu opioid receptor,Ki,=,1.41,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccccc1
CHEMBL522143,CHEMBL233,Mu opioid receptor,Ki,=,0.37,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1
CHEMBL515864,CHEMBL233,Mu opioid receptor,Ki,=,0.48,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1
CHEMBL472937,CHEMBL233,Mu opioid receptor,Ki,=,0.14,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cccnc1
CHEMBL514769,CHEMBL233,Mu opioid receptor,Ki,=,0.15,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cccnc1
CHEMBL260528,CHEMBL233,Mu opioid receptor,Ki,=,5.85,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccccn1
CHEMBL514781,CHEMBL233,Mu opioid receptor,Ki,=,2.65,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccccn1
CHEMBL525046,CHEMBL233,Mu opioid receptor,Ki,=,2.02,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,C[C@@H](O)[C@H](NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H]2Cc3ccccc3CN2)CSSC1(C)C)C(N)=O
CHEMBL473136,CHEMBL233,Mu opioid receptor,Ki,=,0.41,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,COC(=O)/C=C/C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.26,nM,CHEMBL1006330,B,Displacement of [3H]naloxone from monocloned mu opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.11,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL567175,CHEMBL233,Mu opioid receptor,Ki,=,5.3,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL511795,CHEMBL233,Mu opioid receptor,Ki,=,46.0,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,NC(=O)c1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL469815,CHEMBL233,Mu opioid receptor,Ki,=,0.51,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)Cc1c([nH]c2ccccc12)C3
CHEMBL398707,CHEMBL233,Mu opioid receptor,Ki,=,0.28,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5
CHEMBL471049,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,CN1CC[C@]23c4c5ccc(C(N)=O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5
CHEMBL471048,CHEMBL233,Mu opioid receptor,Ki,=,0.3,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,CN1CC[C@]23CC(=O)CC[C@H]2[C@H]1Cc1ccc(C(N)=O)c(O)c13
CHEMBL511816,CHEMBL233,Mu opioid receptor,Ki,=,0.24,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,Oc1ccc2c3c1O[C@H]1CCC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL511621,CHEMBL233,Mu opioid receptor,Ki,=,2.5,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,NC(=O)c1ccc2c3c1O[C@H]1CCC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL470005,CHEMBL233,Mu opioid receptor,Ki,=,0.16,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,NC(=O)c1ccc2c(c1O)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CC1)CC3
CHEMBL470617,CHEMBL233,Mu opioid receptor,Ki,=,2.0,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[I-]
CHEMBL511461,CHEMBL233,Mu opioid receptor,Ki,=,37.0,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(C(N)=O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[I-]
CHEMBL511302,CHEMBL233,Mu opioid receptor,Ki,=,1.3,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,C[N+]1(CC2CC2)CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13.[I-]
CHEMBL511645,CHEMBL233,Mu opioid receptor,Ki,=,0.072,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@]1(O)CC[C@@H](O)C3
CHEMBL895,CHEMBL233,Mu opioid receptor,Ki,=,1.6,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL513762,CHEMBL233,Mu opioid receptor,Ki,=,3.8,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,NC(=O)c1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL512150,CHEMBL233,Mu opioid receptor,Ki,=,0.52,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@]1(O)CC[C@H](O)C3
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.26,nM,CHEMBL993513,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1153911,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL473136,CHEMBL233,Mu opioid receptor,Ki,=,0.41,nM,CHEMBL993513,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1153911,KI,COC(=O)/C=C/C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL500766,CHEMBL233,Mu opioid receptor,Ki,=,2.02,nM,CHEMBL993513,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1153911,KI,C[C@@H](O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](Cc1ccc(O)cc1)NC(=O)[C@H](CS)NC(=O)[C@H](N)Cc1ccccc1)[C@@H](C)O)C(C)(C)S)C(=O)O
CHEMBL476600,CHEMBL233,Mu opioid receptor,Ki,=,0.14,nM,CHEMBL993513,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1153911,KI,O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccn1
CHEMBL476603,CHEMBL233,Mu opioid receptor,Ki,=,1.59,nM,CHEMBL993513,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1153911,KI,O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cccnc1
CHEMBL515621,CHEMBL233,Mu opioid receptor,Ki,=,5.58,nM,CHEMBL993513,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1153911,KI,O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccncc1
CHEMBL516263,CHEMBL233,Mu opioid receptor,Ki,=,123.23,nM,CHEMBL993513,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1153911,KI,O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccc1
CHEMBL516085,CHEMBL233,Mu opioid receptor,Ki,=,68.4,nM,CHEMBL993513,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1153911,KI,O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cc2ccccc2cn1
CHEMBL472843,CHEMBL233,Mu opioid receptor,Ki,=,1.44,nM,CHEMBL993513,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1153911,KI,O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2n1
CHEMBL473253,CHEMBL233,Mu opioid receptor,Ki,=,2.69,nM,CHEMBL993513,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1153911,KI,O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cnc2ccccc2c1
CHEMBL513990,CHEMBL233,Mu opioid receptor,Ki,=,225.27,nM,CHEMBL993513,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1153911,KI,O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2c1
CHEMBL56695,CHEMBL233,Mu opioid receptor,Ki,=,0.71,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,NC(=O)c1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL471243,CHEMBL233,Mu opioid receptor,Ki,=,0.052,nM,CHEMBL955069,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1153960,KI,Cl.NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3
CHEMBL490632,CHEMBL233,Mu opioid receptor,Ki,=,2009.0,nM,CHEMBL961055,B,Inhibition of human cloned mu opioid receptor by competitive binding experiment,CHEMBL1153452,KI,COc1c(OCCF)cccc1C(=O)C1CCN(CCc2ccc(C)cc2)CC1
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,1.6,nM,CHEMBL1013976,B,Displacement of [3H]DAGO from mu opioid receptor,CHEMBL1147348,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL481512,CHEMBL233,Mu opioid receptor,Ki,=,1.052,nM,CHEMBL993917,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143349,KI,CC1(N2CCC(n3c([C@@H]4CCCNC4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL518950,CHEMBL233,Mu opioid receptor,Ki,=,3.7,nM,CHEMBL993917,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143349,KI,CN1CCC[C@@H](c2nc3ccccc3n2C2CCN(C3(C)CCCCCCC3)CC2)C1
CHEMBL481366,CHEMBL233,Mu opioid receptor,Ki,=,0.59,nM,CHEMBL993917,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143349,KI,CC1(N2CCC(n3c([C@H]4CCCNC4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL501331,CHEMBL233,Mu opioid receptor,Ki,=,11.0,nM,CHEMBL993917,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143349,KI,CN1CCC[C@H](c2nc3ccccc3n2C2CCN(C3(C)CCCCCCC3)CC2)C1
CHEMBL481367,CHEMBL233,Mu opioid receptor,Ki,=,6.3,nM,CHEMBL993917,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143349,KI,CC1(N2CCC(n3c(-c4cccc(S(C)(=O)=O)c4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL481547,CHEMBL233,Mu opioid receptor,Ki,=,45.0,nM,CHEMBL993917,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143349,KI,CC1(N2CCC(n3c(-c4ccc(F)c(Cl)c4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL481548,CHEMBL233,Mu opioid receptor,Ki,=,151.0,nM,CHEMBL993917,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143349,KI,CC1(N2CCC(n3c(-c4ccc5cc[nH]c5c4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL481707,CHEMBL233,Mu opioid receptor,Ki,=,102.0,nM,CHEMBL993917,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143349,KI,CC1(N2CCC(n3c(-c4cc5ccccc5o4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL519100,CHEMBL233,Mu opioid receptor,Ki,=,65.0,nM,CHEMBL993917,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143349,KI,CC1(N2CCC(n3c(-c4cccc(C(F)(F)F)c4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL480425,CHEMBL233,Mu opioid receptor,Ki,=,11.0,nM,CHEMBL993917,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143349,KI,CC1(N2CCC(n3c(-c4cccc(OCCO)c4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL480426,CHEMBL233,Mu opioid receptor,Ki,=,20.0,nM,CHEMBL993917,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143349,KI,CC1(N2CCC(n3c(-c4cccc(CN)c4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL519925,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL993917,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143349,KI,CC1CN(c2nc3ccccc3n2C2CCN(C3(C)CCCCCCC3)CC2)CC(C)N1
CHEMBL480619,CHEMBL233,Mu opioid receptor,Ki,=,11.0,nM,CHEMBL993917,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1143349,KI,CC1(N2CCC(n3cnc4ccccc43)CC2)CCCCCCC1
CHEMBL3084538,CHEMBL233,Mu opioid receptor,Ki,=,1315.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)c1ccc([C@@]2(C(N)=O)C[C@H]3CC[C@@H](C2)N3C(c2ccccc2Cl)c2ccccc2Cl)nc1
CHEMBL3084540,CHEMBL233,Mu opioid receptor,Ki,=,348.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)[C@]1(c2cccc(F)n2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084541,CHEMBL233,Mu opioid receptor,Ki,=,468.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)[C@]1(c2cc(F)cc(F)n2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084544,CHEMBL233,Mu opioid receptor,Ki,=,74.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)[C@]1(c2cc(F)c(F)cn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084545,CHEMBL233,Mu opioid receptor,Ki,=,367.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)[C@]1(c2cc(CF)c(F)cn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084547,CHEMBL233,Mu opioid receptor,Ki,=,343.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,N[C@]1(c2ccccn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084548,CHEMBL233,Mu opioid receptor,Ki,=,209.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,N[C@]1(c2ccc(F)cn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084549,CHEMBL233,Mu opioid receptor,Ki,=,312.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,CC(=O)N[C@]1(c2ccccn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084550,CHEMBL233,Mu opioid receptor,Ki,=,601.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,CC(=O)N[C@]1(c2ccc(F)cn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084551,CHEMBL233,Mu opioid receptor,Ki,=,741.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,COC(=O)N[C@]1(c2ccccn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL511232,CHEMBL233,Mu opioid receptor,Ki,=,887.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,COC(=O)NC1(c2ccc(F)cn2)C[C@H]2CC[C@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084552,CHEMBL233,Mu opioid receptor,Ki,=,961.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,COC(=O)N[C@]1(c2ccc(Cl)cn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084553,CHEMBL233,Mu opioid receptor,Ki,=,840.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,CN(C)[C@]1(c2ccccn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084526,CHEMBL233,Mu opioid receptor,Ki,=,85.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)[C@@]1(Cc2ccc(F)cc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084554,CHEMBL233,Mu opioid receptor,Ki,=,284.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)[C@]1(Cc2ccc(Cl)cc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084555,CHEMBL233,Mu opioid receptor,Ki,=,190.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)C[C@]1(Cc2ccc(F)cc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084557,CHEMBL233,Mu opioid receptor,Ki,=,447.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,N[C@]1(Cc2ccc(Cl)cc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084559,CHEMBL233,Mu opioid receptor,Ki,=,71.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)[C@]1(c2cccnc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084560,CHEMBL233,Mu opioid receptor,Ki,=,265.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)[C@]1(c2ccncc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084561,CHEMBL233,Mu opioid receptor,Ki,=,46.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)[C@]1(c2ccc(Br)nc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL512962,CHEMBL233,Mu opioid receptor,Ki,=,474.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)C1(C2CCCCN2)C[C@H]2CC[C@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL228690,CHEMBL233,Mu opioid receptor,Ki,=,233.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL467933,CHEMBL233,Mu opioid receptor,Ki,=,738.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,C[C@@H]1CN(C(c2ccccc2)c2ccccc2)CC[C@@]1(O)c1ccccc1
CHEMBL511920,CHEMBL233,Mu opioid receptor,Ki,=,94.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,OC1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1)c1ccccc1
CHEMBL466846,CHEMBL233,Mu opioid receptor,Ki,=,514.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,OC1(c2ccccc2)CC2CCCC(C1)N2C(c1ccccc1)c1ccccc1
CHEMBL513136,CHEMBL233,Mu opioid receptor,Ki,=,65.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,Cc1ccccc1C(c1ccccc1C)N1C2CCC1CC(O)(c1ccccc1)C2
CHEMBL466847,CHEMBL233,Mu opioid receptor,Ki,=,22.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,OC1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL511373,CHEMBL233,Mu opioid receptor,Ki,=,1487.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,OC1(c2cncs2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL513171,CHEMBL233,Mu opioid receptor,Ki,=,470.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,OC1(c2cccnn2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL511374,CHEMBL233,Mu opioid receptor,Ki,=,42.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,OC1(c2cccnc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL466126,CHEMBL233,Mu opioid receptor,Ki,=,708.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,Cc1ccnc(C2(O)CC3CCC(C2)N3C(c2ccccc2Cl)c2ccc(C)cc2Cl)c1
CHEMBL467488,CHEMBL233,Mu opioid receptor,Ki,=,57.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,Cc1ccc(C(c2ccccc2Cl)N2C3CCC2CC(O)(c2cccc(F)c2)C3)c(Cl)c1
CHEMBL512411,CHEMBL233,Mu opioid receptor,Ki,=,535.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,Cc1ccc(C(c2ccccc2Cl)N2C3CCC2CC(O)(c2ccncn2)C3)c(Cl)c1
CHEMBL466066,CHEMBL233,Mu opioid receptor,Ki,=,384.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,COc1ccc(CC2(O)CC3CCC(C2)N3C(c2ccccc2Cl)c2ccc(C)cc2Cl)nc1
CHEMBL466067,CHEMBL233,Mu opioid receptor,Ki,=,104.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,Cc1ccc(C(c2ccccc2Cl)N2C3CCC2CC(O)(C2CCCC2)C3)c(Cl)c1
CHEMBL506634,CHEMBL233,Mu opioid receptor,Ki,=,781.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,Cc1ccc(C(c2ccccc2Cl)N2C3CCC2CC(O)(C2CCNC2=O)C3)c(Cl)c1
CHEMBL513303,CHEMBL233,Mu opioid receptor,Ki,=,1553.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,Cc1ccc(C(c2ccccc2Cl)N2C3CCC2CC(O)(C2CCCN2Cc2ccccc2)C3)c(Cl)c1
CHEMBL466679,CHEMBL233,Mu opioid receptor,Ki,=,622.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,Cc1ccc(C(c2ccccc2Cl)N2C3CCC2CC(O)(C2=NCCCN2)C3)c(Cl)c1
CHEMBL512247,CHEMBL233,Mu opioid receptor,Ki,=,306.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,Cc1ccc(C(c2ccccc2Cl)N2C3CCC2CC(O)(CCCO)C3)c(Cl)c1
CHEMBL512982,CHEMBL233,Mu opioid receptor,Ki,=,7255.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,OC1(c2cccnc2)C2CCC1CN(C(c1ccccc1Cl)c1ccccc1Cl)C2
CHEMBL466082,CHEMBL233,Mu opioid receptor,Ki,=,3586.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,Cc1ccnc(C2(O)C3CCC2CN(C(c2ccccc2Cl)c2ccccc2Cl)C3)c1
CHEMBL512950,CHEMBL233,Mu opioid receptor,Ki,=,636.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,COC1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL468952,CHEMBL233,Mu opioid receptor,Ki,=,627.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,OCC1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL513471,CHEMBL233,Mu opioid receptor,Ki,=,123.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,O=C(O)C1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL512414,CHEMBL233,Mu opioid receptor,Ki,=,38.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,NC(=O)C1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL467313,CHEMBL233,Mu opioid receptor,Ki,=,576.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,COC(=O)NC1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL512258,CHEMBL233,Mu opioid receptor,Ki,=,458.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,NC1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL467314,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,CNC(=O)NC1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL466919,CHEMBL233,Mu opioid receptor,Ki,=,996.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,O=C(NC1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl)C1CC1
CHEMBL513660,CHEMBL233,Mu opioid receptor,Ki,=,100.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,Clc1ccccc1C(c1ccccc1Cl)N1C2CCC1CC(c1ccccc1)(c1nc[nH]n1)C2
CHEMBL467119,CHEMBL233,Mu opioid receptor,Ki,=,601.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,O/N=C/C1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL466921,CHEMBL233,Mu opioid receptor,Ki,=,126.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,NC(=O)C1(c2ccc(F)cc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL467131,CHEMBL233,Mu opioid receptor,Ki,=,55.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,NC(=O)C1(c2ccc(Cl)cc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL512612,CHEMBL233,Mu opioid receptor,Ki,=,59.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,COc1ccc(C2(C(N)=O)CC3CCC(C2)N3C(c2ccccc2Cl)c2ccccc2Cl)cc1
CHEMBL467497,CHEMBL233,Mu opioid receptor,Ki,=,50.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,CNC(=O)C1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL513667,CHEMBL233,Mu opioid receptor,Ki,=,215.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,CCNC(=O)C1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL467699,CHEMBL233,Mu opioid receptor,Ki,=,333.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,CC(C)NC(=O)C1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL466693,CHEMBL233,Mu opioid receptor,Ki,=,60.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,COCCNC(=O)C1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL466694,CHEMBL233,Mu opioid receptor,Ki,=,57.0,nM,CHEMBL966891,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138606,KI,CC(O)CNC(=O)C1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084528,CHEMBL233,Mu opioid receptor,Ki,=,52.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)[C@]1(c2ccccn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084529,CHEMBL233,Mu opioid receptor,Ki,=,123.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)[C@]1(c2ccc(F)cn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084530,CHEMBL233,Mu opioid receptor,Ki,=,143.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)[C@]1(c2ccc(Cl)cn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084531,CHEMBL233,Mu opioid receptor,Ki,=,153.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)[C@]1(c2ccc(Br)cn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084532,CHEMBL233,Mu opioid receptor,Ki,=,26.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,Cc1ccc([C@@]2(C(N)=O)C[C@H]3CC[C@@H](C2)N3C(c2ccccc2Cl)c2ccccc2Cl)nc1
CHEMBL3084533,CHEMBL233,Mu opioid receptor,Ki,=,133.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,COc1ccc([C@@]2(C(N)=O)C[C@H]3CC[C@@H](C2)N3C(c2ccccc2Cl)c2ccccc2Cl)nc1
CHEMBL3084534,CHEMBL233,Mu opioid receptor,Ki,=,205.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)[C@]1(c2ccc(N)cn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084536,CHEMBL233,Mu opioid receptor,Ki,=,481.0,nM,CHEMBL1009677,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1138605,KI,N#Cc1ccc([C@@]2(C(N)=O)C[C@H]3CC[C@@H](C2)N3C(c2ccccc2Cl)c2ccccc2Cl)nc1
CHEMBL500122,CHEMBL233,Mu opioid receptor,Ki,=,220.0,nM,CHEMBL968093,B,Displacement of [125]OXY from mu opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OS(=O)(=O)c2ccc(C)cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL264967,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL968093,B,Displacement of [125]OXY from mu opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2cccs2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL259299,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL968093,B,Displacement of [125]OXY from mu opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccc(Br)cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL261024,CHEMBL233,Mu opioid receptor,Ki,=,110.0,nM,CHEMBL968093,B,Displacement of [125]OXY from mu opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2cccc(Br)c2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL407155,CHEMBL233,Mu opioid receptor,Ki,=,110.0,nM,CHEMBL968093,B,Displacement of [125]OXY from mu opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccccc2Br)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL526686,CHEMBL233,Mu opioid receptor,Ki,=,280.0,nM,CHEMBL968093,B,Displacement of [125]OXY from mu opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OC(=O)CCc2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL499315,CHEMBL233,Mu opioid receptor,Ki,=,1090.0,nM,CHEMBL968093,B,Displacement of [125]OXY from mu opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OC(=O)Cc2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL524522,CHEMBL233,Mu opioid receptor,Ki,=,5660.0,nM,CHEMBL968093,B,Displacement of [125]OXY from mu opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OC(=O)CNC(=O)OC(C)(C)C)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL498116,CHEMBL233,Mu opioid receptor,Ki,=,520.0,nM,CHEMBL968093,B,Displacement of [125]OXY from mu opioid receptor,CHEMBL1157966,KI,CCCCCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL498442,CHEMBL233,Mu opioid receptor,Ki,=,310.0,nM,CHEMBL968093,B,Displacement of [125]OXY from mu opioid receptor,CHEMBL1157966,KI,CCCCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL379138,CHEMBL233,Mu opioid receptor,Ki,=,520.0,nM,CHEMBL968093,B,Displacement of [125]OXY from mu opioid receptor,CHEMBL1157966,KI,CCCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL365216,CHEMBL233,Mu opioid receptor,Ki,=,6820.0,nM,CHEMBL968093,B,Displacement of [125]OXY from mu opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OS(C)(=O)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL363324,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL968093,B,Displacement of [125]OXY from mu opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3349273,CHEMBL233,Mu opioid receptor,Ki,=,674.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,NC[C@@]1(c2ccccc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349274,CHEMBL233,Mu opioid receptor,Ki,=,566.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,CNC[C@@]1(c2ccccc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349275,CHEMBL233,Mu opioid receptor,Ki,=,1486.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,CN(C)C[C@@]1(c2ccccc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349276,CHEMBL233,Mu opioid receptor,Ki,=,777.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,CC(=O)NC[C@@]1(c2ccccc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349277,CHEMBL233,Mu opioid receptor,Ki,=,905.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,COC(=O)NC[C@@]1(c2ccccc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349278,CHEMBL233,Mu opioid receptor,Ki,=,2620.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,CC(=O)N(C)C[C@@]1(c2ccccc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349279,CHEMBL233,Mu opioid receptor,Ki,=,4169.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,Clc1ccccc1C(c1ccccc1Cl)N1[C@@H]2CC[C@H]1C[C@](CN1CCCC1)(c1ccccc1)C2
CHEMBL3349281,CHEMBL233,Mu opioid receptor,Ki,=,2106.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,CC(=O)NC[C@@]1(c2ccc(F)cc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349282,CHEMBL233,Mu opioid receptor,Ki,=,2407.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,COc1ccc([C@]2(CNC(C)=O)C[C@H]3CC[C@@H](C2)N3C(c2ccccc2Cl)c2ccccc2Cl)cc1
CHEMBL3349283,CHEMBL233,Mu opioid receptor,Ki,=,1204.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,Clc1ccccc1C(c1ccccc1Cl)N1[C@@H]2CC[C@H]1C[C@@]1(CNc3ccccc31)C2
CHEMBL3349284,CHEMBL233,Mu opioid receptor,Ki,=,1706.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,Fc1ccc2c(c1)[C@]1(CN2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349285,CHEMBL233,Mu opioid receptor,Ki,=,998.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,Cc1ccc2c(c1)[C@]1(CN2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349286,CHEMBL233,Mu opioid receptor,Ki,=,1336.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,NC[C@@]1(Cc2ccccc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349287,CHEMBL233,Mu opioid receptor,Ki,=,458.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,CC(=O)NC[C@@]1(Cc2ccccc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349260,CHEMBL233,Mu opioid receptor,Ki,=,1414.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,NC[C@@]1(Cc2ccc(F)cc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349261,CHEMBL233,Mu opioid receptor,Ki,=,782.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,CC(=O)NC[C@@]1(Cc2ccc(F)cc2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349263,CHEMBL233,Mu opioid receptor,Ki,=,617.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,NC[C@@]1(c2ccccn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349248,CHEMBL233,Mu opioid receptor,Ki,=,374.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,CC(=O)NC[C@@]1(c2ccccn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349249,CHEMBL233,Mu opioid receptor,Ki,=,743.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,CCNC[C@@]1(c2ccccn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349250,CHEMBL233,Mu opioid receptor,Ki,=,785.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,CN(C)C[C@@]1(c2ccccn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349256,CHEMBL233,Mu opioid receptor,Ki,=,1284.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,CC(=O)NC[C@@]1(c2cccc(F)n2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349257,CHEMBL233,Mu opioid receptor,Ki,=,3976.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,CN(C)C[C@@]1(c2cccc(F)n2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349272,CHEMBL233,Mu opioid receptor,Ki,=,123.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,COc1cccc([C@]2(CN)C[C@H]3CC[C@@H](C2)N3C(c2ccccc2Cl)c2ccccc2Cl)n1
CHEMBL3349258,CHEMBL233,Mu opioid receptor,Ki,=,251.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,COc1cccc([C@]2(CNC(C)=O)C[C@H]3CC[C@@H](C2)N3C(c2ccccc2Cl)c2ccccc2Cl)n1
CHEMBL3349264,CHEMBL233,Mu opioid receptor,Ki,=,442.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,CCNC[C@@]1(c2cccc(OC)n2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349268,CHEMBL233,Mu opioid receptor,Ki,=,758.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,CC(=O)NC[C@@]1(c2ncccc2CN2CCCCC2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3349269,CHEMBL233,Mu opioid receptor,Ki,=,3447.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,COc1ccc([C@]2(CNC(C)=O)C[C@H]3CC[C@@H](C2)N3C(c2ccccc2Cl)c2ccccc2Cl)nc1
CHEMBL3349270,CHEMBL233,Mu opioid receptor,Ki,=,752.0,nM,CHEMBL1012095,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1152183,KI,CC(=O)NC[C@@]1(c2ccc(Br)cn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL455906,CHEMBL233,Mu opioid receptor,Ki,=,1220.0,nM,CHEMBL1021465,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1151739,KI,Oc1ccc2c(c1)[C@]13CCC[C@H](C1)N(CCc1ccccc1)C[C@@H]3O2
CHEMBL455905,CHEMBL233,Mu opioid receptor,Ki,=,560.0,nM,CHEMBL1021465,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1151739,KI,Oc1cccc2c1O[C@H]1CN(CCc3ccccc3)[C@@H]3CCC[C@]21C3
CHEMBL515842,CHEMBL233,Mu opioid receptor,Ki,=,190.0,nM,CHEMBL1021465,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1151739,KI,Oc1cccc2c1O[C@@H]1CC[C@H]3C[C@@]21CCN3CCc1ccccc1
CHEMBL515681,CHEMBL233,Mu opioid receptor,Ki,=,740.0,nM,CHEMBL1021465,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1151739,KI,Oc1ccc2c(c1)[C@@]13CCN(CCc4ccccc4)[C@@H](CC[C@H]1O2)C3
CHEMBL450850,CHEMBL233,Mu opioid receptor,Ki,=,3210.0,nM,CHEMBL1021465,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1151739,KI,CN1CC[C@@]23C[C@@H]1CC[C@H]2Oc1c(O)cccc13
CHEMBL514724,CHEMBL233,Mu opioid receptor,Ki,=,7.0,nM,CHEMBL1010016,B,Binding affinity to mu opioid receptor,CHEMBL1151739,KI,Oc1cccc2c1O[C@@H]1[C@@H]3CCC[C@]21CCN3CCc1ccccc1
CHEMBL475108,CHEMBL233,Mu opioid receptor,Ki,=,1.4,nM,CHEMBL1030604,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1136834,KI,C[C@H]1C2Cc3ccc4[nH]nnc4c3[C@@]1(C)CCN2CC1CC1
CHEMBL506290,CHEMBL233,Mu opioid receptor,Ki,=,2.5,nM,CHEMBL1030604,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1136834,KI,Cc1nc2c3c(ccc2[nH]1)CC1[C@H](C)[C@]3(C)CCN1CC1CC1
CHEMBL475107,CHEMBL233,Mu opioid receptor,Ki,=,9.5,nM,CHEMBL1030604,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1136834,KI,C[C@H]1C2Cc3ccc4[nH]cnc4c3[C@@]1(C)CCN2CC1CC1
CHEMBL515593,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL1030604,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1136834,KI,C[C@H]1C2Cc3cc4nn[nH]c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL515257,CHEMBL233,Mu opioid receptor,Ki,=,60.0,nM,CHEMBL1030604,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1136834,KI,C[C@H]1C2Cc3cc4nc(O)[nH]c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL473699,CHEMBL233,Mu opioid receptor,Ki,=,0.77,nM,CHEMBL1030604,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1136834,KI,Cc1nc2cc3c(cc2[nH]1)[C@@]1(C)CCN(CC2CC2)C(C3)[C@@H]1C
CHEMBL518712,CHEMBL233,Mu opioid receptor,Ki,=,0.31,nM,CHEMBL1030604,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1136834,KI,C[C@H]1C2Cc3cc4nc[nH]c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL170384,CHEMBL233,Mu opioid receptor,Ki,=,18.0,nM,CHEMBL1030604,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1136834,KI,C[C@H]1C2Cc3cc4cc[nH]c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL56585,CHEMBL233,Mu opioid receptor,Ki,=,0.16,nM,CHEMBL1030604,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1136834,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CC1CC1
CHEMBL240657,CHEMBL233,Mu opioid receptor,Ki,=,489.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1)c1ccccc1)CC2
CHEMBL510201,CHEMBL233,Mu opioid receptor,Ki,=,692.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CN1CN(c2ccccc2)C2(CCN(C(c3ccccc3)c3ccccc3)CC2)C1=O
CHEMBL474091,CHEMBL233,Mu opioid receptor,Ki,=,2283.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3)c3ccccc3)CC2)C1=O
CHEMBL475308,CHEMBL233,Mu opioid receptor,Ki,=,11755.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3)c3ccccc3)CC2)C1=O
CHEMBL514606,CHEMBL233,Mu opioid receptor,Ki,=,8438.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3)c3ccccc3)CC2)C1=O
CHEMBL472676,CHEMBL233,Mu opioid receptor,Ki,=,4042.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)N1CN(c2ccccc2)C2(CCN(C(c3ccccc3)c3ccccc3)CC2)C1=O
CHEMBL472677,CHEMBL233,Mu opioid receptor,Ki,=,5279.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CC2CC2)CN(c2ccccc2)C12CCN(C(c1ccccc1)c1ccccc1)CC2
CHEMBL474708,CHEMBL233,Mu opioid receptor,Ki,=,4314.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,C#CCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3)c3ccccc3)CC2)C1=O
CHEMBL514965,CHEMBL233,Mu opioid receptor,Ki,=,63020.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,C=CCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3)c3ccccc3)CC2)C1=O
CHEMBL241272,CHEMBL233,Mu opioid receptor,Ki,=,5945.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL475496,CHEMBL233,Mu opioid receptor,Ki,=,33120.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL516077,CHEMBL233,Mu opioid receptor,Ki,=,683.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,COC(=O)CN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL473884,CHEMBL233,Mu opioid receptor,Ki,=,483.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCO)CN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL516024,CHEMBL233,Mu opioid receptor,Ki,=,726.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,COCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL472867,CHEMBL233,Mu opioid receptor,Ki,=,886.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,NCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL473068,CHEMBL233,Mu opioid receptor,Ki,=,1069.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CNCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL475096,CHEMBL233,Mu opioid receptor,Ki,=,776.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCNCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL518325,CHEMBL233,Mu opioid receptor,Ki,=,745.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)NCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL456225,CHEMBL233,Mu opioid receptor,Ki,=,625.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCNC2CCCC2)CN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL510745,CHEMBL233,Mu opioid receptor,Ki,=,400.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCNC2CCCCC2)CN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL460636,CHEMBL233,Mu opioid receptor,Ki,=,421.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CN(C)CCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL517265,CHEMBL233,Mu opioid receptor,Ki,=,978.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCNC2CC2)CN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL499169,CHEMBL233,Mu opioid receptor,Ki,=,1921.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)N(CCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O)C(C)C
CHEMBL515829,CHEMBL233,Mu opioid receptor,Ki,=,2546.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCCCNCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL457244,CHEMBL233,Mu opioid receptor,Ki,=,1376.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)CNCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL501088,CHEMBL233,Mu opioid receptor,Ki,=,1800.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCNCC2CCCCC2)CN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL457451,CHEMBL233,Mu opioid receptor,Ki,=,436.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCN2CCCC2)CN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL464191,CHEMBL233,Mu opioid receptor,Ki,=,436.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCCN2CCCC2)CN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL464192,CHEMBL233,Mu opioid receptor,Ki,=,683.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCN2CCCCC2)CN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL240215,CHEMBL233,Mu opioid receptor,Ki,=,29.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,O=C1NCN(c2ccccc2)C12CCN(Cc1c(Cl)cccc1Cl)CC2
CHEMBL517167,CHEMBL233,Mu opioid receptor,Ki,=,146.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CNCCN1CN(c2ccccc2)C2(CCN(Cc3c(Cl)cccc3Cl)CC2)C1=O
CHEMBL515142,CHEMBL233,Mu opioid receptor,Ki,=,167.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCNCCN1CN(c2ccccc2)C2(CCN(Cc3c(Cl)cccc3Cl)CC2)C1=O
CHEMBL475707,CHEMBL233,Mu opioid receptor,Ki,=,136.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)NCCN1CN(c2ccccc2)C2(CCN(Cc3c(Cl)cccc3Cl)CC2)C1=O
CHEMBL472669,CHEMBL233,Mu opioid receptor,Ki,=,89.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCNCC2CC2)CN(c2ccccc2)C12CCN(Cc1c(Cl)cccc1Cl)CC2
CHEMBL516389,CHEMBL233,Mu opioid receptor,Ki,=,112.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCNC2CCC2)CN(c2ccccc2)C12CCN(Cc1c(Cl)cccc1Cl)CC2
CHEMBL514662,CHEMBL233,Mu opioid receptor,Ki,=,28.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCCNCCN1CN(c2ccccc2)C2(CCN(Cc3c(Cl)cccc3Cl)CC2)C1=O
CHEMBL475310,CHEMBL233,Mu opioid receptor,Ki,=,26.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)CNCCN1CN(c2ccccc2)C2(CCN(Cc3c(Cl)cccc3Cl)CC2)C1=O
CHEMBL473700,CHEMBL233,Mu opioid receptor,Ki,=,36.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCCCNCCN1CN(c2ccccc2)C2(CCN(Cc3c(Cl)cccc3Cl)CC2)C1=O
CHEMBL473701,CHEMBL233,Mu opioid receptor,Ki,=,122.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCN(CC)CCN1CN(c2ccccc2)C2(CCN(Cc3c(Cl)cccc3Cl)CC2)C1=O
CHEMBL473904,CHEMBL233,Mu opioid receptor,Ki,=,37.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCN2CCCC2)CN(c2ccccc2)C12CCN(Cc1c(Cl)cccc1Cl)CC2
CHEMBL239822,CHEMBL233,Mu opioid receptor,Ki,=,48.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)NCN3c2ccccc2)c2ccccc21
CHEMBL471262,CHEMBL233,Mu opioid receptor,Ki,=,142.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL511649,CHEMBL233,Mu opioid receptor,Ki,=,14.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC(=O)CN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL474283,CHEMBL233,Mu opioid receptor,Ki,=,59.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)N(CCO)CN3c2ccccc2)c2ccccc21
CHEMBL474485,CHEMBL233,Mu opioid receptor,Ki,=,35.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL474687,CHEMBL233,Mu opioid receptor,Ki,=,37.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL514489,CHEMBL233,Mu opioid receptor,Ki,=,69.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)NCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL515091,CHEMBL233,Mu opioid receptor,Ki,=,96.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)N(CCNC2CCCC2)CN3c2ccccc2)c2ccccc21
CHEMBL514463,CHEMBL233,Mu opioid receptor,Ki,=,120.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)N(CCNC2CCCCC2)CN3c2ccccc2)c2ccccc21
CHEMBL473272,CHEMBL233,Mu opioid receptor,Ki,=,43.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCCNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL475094,CHEMBL233,Mu opioid receptor,Ki,=,198.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,C=CCNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL474092,CHEMBL233,Mu opioid receptor,Ki,=,64.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)N(CCNC2CCC2)CN3c2ccccc2)c2ccccc21
CHEMBL473278,CHEMBL233,Mu opioid receptor,Ki,=,239.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)N(CCNCC2CC2)CN3c2ccccc2)c2ccccc21
CHEMBL473279,CHEMBL233,Mu opioid receptor,Ki,=,61.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)CNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL473280,CHEMBL233,Mu opioid receptor,Ki,=,82.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)N(CCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O)C(C)C
CHEMBL473898,CHEMBL233,Mu opioid receptor,Ki,=,69.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)N(CCN2CCCC2)CN3c2ccccc2)c2ccccc21
CHEMBL474096,CHEMBL233,Mu opioid receptor,Ki,=,66.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCCCNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL515575,CHEMBL233,Mu opioid receptor,Ki,=,204.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)CCNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL471882,CHEMBL233,Mu opioid receptor,Ki,=,102.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)N(CCNCC2CCCCC2)CN3c2ccccc2)c2ccccc21
CHEMBL511162,CHEMBL233,Mu opioid receptor,Ki,=,139.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)N(CCNCc2ccccc2)CN3c2ccccc2)c2ccccc21
CHEMBL516187,CHEMBL233,Mu opioid receptor,Ki,=,297.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCCCNCCN1CN(c2ccccc2)C2(CCN(C3CCCc4ccc(Cl)cc43)CC2)C1=O
CHEMBL511161,CHEMBL233,Mu opioid receptor,Ki,=,141.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCCCNCCN1CN(c2ccccc2)C2(CCN(C3CCCc4c(Cl)cccc43)CC2)C1=O
CHEMBL471880,CHEMBL233,Mu opioid receptor,Ki,=,50.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCCCNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4cc(Cl)ccc43)CC2)C1=O
CHEMBL472086,CHEMBL233,Mu opioid receptor,Ki,=,306.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CCCCNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4cc(Cl)c(Cl)cc43)CC2)C1=O
CHEMBL475497,CHEMBL233,Mu opioid receptor,Ki,=,13000.0,nM,CHEMBL1030625,B,Displacement of [125I]diprenorphine from human MOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)CCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL474755,CHEMBL233,Mu opioid receptor,Ki,=,2.5,nM,CHEMBL1022992,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1152801,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(OC(=O)/C=C/c5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL514774,CHEMBL233,Mu opioid receptor,Ki,=,0.34,nM,CHEMBL1022992,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1152801,KI,O=C1CC[C@@]2(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL386492,CHEMBL233,Mu opioid receptor,Ki,=,3.0,nM,CHEMBL1022992,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1152801,KI,O=C(/C=C/c1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL386272,CHEMBL233,Mu opioid receptor,Ki,=,4.8,nM,CHEMBL1022992,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1152801,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL1022992,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1152801,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL471543,CHEMBL233,Mu opioid receptor,Ki,=,4.2,nM,CHEMBL1022992,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1152801,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(OC(=O)/C=C/c5ccc(C)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL512526,CHEMBL233,Mu opioid receptor,Ki,=,3.5,nM,CHEMBL1022992,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1152801,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(OC(=O)/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL470585,CHEMBL233,Mu opioid receptor,Ki,=,7000.0,nM,CHEMBL1010736,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells by scintillation counting,CHEMBL1152790,KI,CC(C)N[C@H]1CCn2c(=O)[nH]c3cccc(c32)[C@@H]1O.Cl
CHEMBL513390,CHEMBL233,Mu opioid receptor,Ki,=,130000.0,nM,CHEMBL1010736,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells by scintillation counting,CHEMBL1152790,KI,CC(C)N[C@@H]1CCn2c(=O)[nH]c3cccc(c32)[C@H]1O.Cl
CHEMBL513390,CHEMBL233,Mu opioid receptor,Ki,=,13000.0,nM,CHEMBL1010736,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells by scintillation counting,CHEMBL1152790,KI,CC(C)N[C@@H]1CCn2c(=O)[nH]c3cccc(c32)[C@H]1O.Cl
CHEMBL506616,CHEMBL233,Mu opioid receptor,Ki,=,130.0,nM,CHEMBL1000645,B,Displacement of [3H]diprenorphine from human cloned mu receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H]1Cc1c[nH]c2ccccc12
CHEMBL502411,CHEMBL233,Mu opioid receptor,Ki,=,30.0,nM,CHEMBL1000645,B,Displacement of [3H]diprenorphine from human cloned mu receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@H]1Cc1ccccc1
CHEMBL506217,CHEMBL233,Mu opioid receptor,Ki,=,670.0,nM,CHEMBL1000645,B,Displacement of [3H]diprenorphine from human cloned mu receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N2CCC[C@@H]2C(=O)N[C@H]1Cc1ccccc1
CHEMBL486388,CHEMBL233,Mu opioid receptor,Ki,=,120.0,nM,CHEMBL1000645,B,Displacement of [3H]diprenorphine from human cloned mu receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@H]1Cc1ccc(O)cc1
CHEMBL510506,CHEMBL233,Mu opioid receptor,Ki,=,37.0,nM,CHEMBL1000645,B,Displacement of [3H]diprenorphine from human cloned mu receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2cccc(O)c2)C(=O)N2CCC[C@@H]2C(=O)N[C@H]1Cc1ccccc1
CHEMBL509201,CHEMBL233,Mu opioid receptor,Ki,=,40.0,nM,CHEMBL1000645,B,Displacement of [3H]diprenorphine from human cloned mu receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@H]1Cc1cccc(O)c1
CHEMBL507127,CHEMBL233,Mu opioid receptor,Ki,=,170.0,nM,CHEMBL1000645,B,Displacement of [3H]diprenorphine from human cloned mu receptor by cell based assay,CHEMBL1136971,KI,COc1ccc(C[C@@H]2NC(=O)[C@@H](Cc3c[nH]c4ccccc34)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H]3CCCN3C2=O)cc1
CHEMBL506211,CHEMBL233,Mu opioid receptor,Ki,=,43.0,nM,CHEMBL1000645,B,Displacement of [3H]diprenorphine from human cloned mu receptor by cell based assay,CHEMBL1136971,KI,COc1ccc(C[C@@H]2NC(=O)[C@H]3CCCN3C(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](Cc3c[nH]c4ccccc34)NC2=O)cc1
CHEMBL446754,CHEMBL233,Mu opioid receptor,Ki,=,210.0,nM,CHEMBL1000645,B,Displacement of [3H]diprenorphine from human cloned mu receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N2CCC[C@@H]2C(=O)N[C@H]1Cc1ccccc1
CHEMBL501888,CHEMBL233,Mu opioid receptor,Ki,=,48.0,nM,CHEMBL1000645,B,Displacement of [3H]diprenorphine from human cloned mu receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@H]1Cc1ccc(F)cc1
CHEMBL525580,CHEMBL233,Mu opioid receptor,Ki,=,2200.0,nM,CHEMBL1000645,B,Displacement of [3H]diprenorphine from human cloned mu receptor by cell based assay,CHEMBL1136971,KI,C[C@@H]1NC(=O)[C@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC1=O
CHEMBL499595,CHEMBL233,Mu opioid receptor,Ki,=,22.0,nM,CHEMBL1000645,B,Displacement of [3H]diprenorphine from human cloned mu receptor by cell based assay,CHEMBL1136971,KI,C[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]2CCCN2C1=O
CHEMBL522071,CHEMBL233,Mu opioid receptor,Ki,=,770.0,nM,CHEMBL1000645,B,Displacement of [3H]diprenorphine from human cloned mu receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)NCC(=O)N2CCC[C@@H]2C(=O)N[C@H]1Cc1ccccc1
CHEMBL450818,CHEMBL233,Mu opioid receptor,Ki,=,340.0,nM,CHEMBL1000645,B,Displacement of [3H]diprenorphine from human cloned mu receptor by cell based assay,CHEMBL1136971,KI,CC(=O)N1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL442612,CHEMBL233,Mu opioid receptor,Ki,=,360.0,nM,CHEMBL1000645,B,Displacement of [3H]diprenorphine from human cloned mu receptor by cell based assay,CHEMBL1136971,KI,CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@@H]1C(N)=O
CHEMBL3084634,CHEMBL233,Mu opioid receptor,Ki,=,1073.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,Clc1ccccc1C(c1ccccc1Cl)N1[C@@H]2CC[C@H]1C[C@@H](c1ccccn1)C2
CHEMBL3084673,CHEMBL233,Mu opioid receptor,Ki,=,1136.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,Fc1ccc([C@H]2C[C@H]3CC[C@@H](C2)N3C(c2ccccc2Cl)c2ccccc2Cl)nc1
CHEMBL3084656,CHEMBL233,Mu opioid receptor,Ki,=,894.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,Clc1ccccc1C(c1ccccc1Cl)N1[C@@H]2CC[C@H]1C[C@@H](c1ccc(Br)cn1)C2
CHEMBL3084648,CHEMBL233,Mu opioid receptor,Ki,=,661.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,Cc1ccc([C@H]2C[C@H]3CC[C@@H](C2)N3C(c2ccccc2Cl)c2ccccc2Cl)nc1
CHEMBL3084655,CHEMBL233,Mu opioid receptor,Ki,=,234.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,Oc1ccc([C@H]2C[C@H]3CC[C@@H](C2)N3C(c2ccccc2Cl)c2ccccc2Cl)nc1
CHEMBL3084666,CHEMBL233,Mu opioid receptor,Ki,=,584.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,CSc1ccc([C@H]2C[C@H]3CC[C@@H](C2)N3C(c2ccccc2Cl)c2ccccc2Cl)nc1
CHEMBL3084672,CHEMBL233,Mu opioid receptor,Ki,=,1684.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,Cc1cccnc1[C@H]1C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL3084660,CHEMBL233,Mu opioid receptor,Ki,=,8382.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,Clc1ccccc1C(c1ccccc1Cl)N1[C@@H]2CC[C@H]1C[C@@H](c1ncccc1Br)C2
CHEMBL3084669,CHEMBL233,Mu opioid receptor,Ki,=,918.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,Clc1ccccc1C(c1ccccc1Cl)N1[C@@H]2CC[C@H]1C[C@@H](c1ncccc1CN1CCCCC1)C2
CHEMBL3084635,CHEMBL233,Mu opioid receptor,Ki,=,891.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,Cc1ccnc([C@H]2C[C@H]3CC[C@@H](C2)N3C(c2ccccc2Cl)c2ccccc2Cl)c1
CHEMBL3084661,CHEMBL233,Mu opioid receptor,Ki,=,5420.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,Fc1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3C(c2ccccc2Cl)c2ccccc2Cl)n1
CHEMBL3084667,CHEMBL233,Mu opioid receptor,Ki,=,276.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,Cc1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3C(c2ccccc2Cl)c2ccccc2Cl)n1
CHEMBL3084636,CHEMBL233,Mu opioid receptor,Ki,=,421.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,COc1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3C(c2ccccc2Cl)c2ccccc2Cl)n1
CHEMBL3084668,CHEMBL233,Mu opioid receptor,Ki,=,330.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,Clc1ccccc1C(c1ccccc1Cl)N1[C@@H]2CC[C@H]1C[C@@H](c1ccccc1)C2
CHEMBL3084637,CHEMBL233,Mu opioid receptor,Ki,=,286.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,Clc1ccccc1C(c1ccccc1Cl)N1[C@@H]2CC[C@H]1C[C@@H](c1cccnc1)C2
CHEMBL3084642,CHEMBL233,Mu opioid receptor,Ki,=,791.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,Clc1ccccc1C(c1ccccc1Cl)N1[C@@H]2CC[C@H]1C[C@@H](c1ccncc1)C2
CHEMBL3084649,CHEMBL233,Mu opioid receptor,Ki,=,1175.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,Clc1ccccc1C(c1ccccc1Cl)N1[C@@H]2CC[C@H]1C[C@@H](c1ncccn1)C2
CHEMBL561373,CHEMBL233,Mu opioid receptor,Ki,=,412.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,Clc1ccccc1C(c1ccccc1Cl)N1[C@H]2CC[C@H]1CC(C1CCCCN1)C2
CHEMBL3084677,CHEMBL233,Mu opioid receptor,Ki,=,596.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,CN1CCCCC1[C@H]1C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL561115,CHEMBL233,Mu opioid receptor,Ki,=,309.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,N#CCN1CCCCC1C1C[C@@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL551111,CHEMBL233,Mu opioid receptor,Ki,=,325.0,nM,CHEMBL1063067,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,OCCN1CCCCC1C1C[C@@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL550063,CHEMBL233,Mu opioid receptor,Ki,=,2700.0,nM,CHEMBL1056545,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1153522,KI,NC(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1
CHEMBL551613,CHEMBL233,Mu opioid receptor,Ki,=,450.0,nM,CHEMBL1056545,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1153522,KI,O=C(c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1)N1Cc2ccccc2C1
CHEMBL551536,CHEMBL233,Mu opioid receptor,Ki,=,1800.0,nM,CHEMBL1056545,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1153522,KI,CN(Cc1ccccc1)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1
CHEMBL550669,CHEMBL233,Mu opioid receptor,Ki,=,3400.0,nM,CHEMBL1056545,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1153522,KI,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)o1
CHEMBL562898,CHEMBL233,Mu opioid receptor,Ki,=,220.0,nM,CHEMBL1056545,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1153522,KI,CCN(CC)C(=O)c1cc(C2=CC3(CCNCC3)Oc3ccccc32)cs1
CHEMBL562478,CHEMBL233,Mu opioid receptor,Ki,=,3400.0,nM,CHEMBL1056545,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells,CHEMBL1153522,KI,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)c(C)c1
CHEMBL567175,CHEMBL233,Mu opioid receptor,Ki,=,151.0,nM,CHEMBL1052524,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1153456,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL416647,CHEMBL233,Mu opioid receptor,Ki,=,1850.0,nM,CHEMBL1052524,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1153456,KI,COc1ccc2c(c1O)[C@]13CCN(C)[C@H](C2)[C@]1(O)Cc1c([nH]c2ccccc12)C3
CHEMBL246003,CHEMBL233,Mu opioid receptor,Ki,=,474.0,nM,CHEMBL1052524,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1153456,KI,COc1c(O)ccc2c1[C@]13CCN(C)[C@H](C2)[C@]1(O)Cc1c([nH]c2ccccc12)C3
CHEMBL551072,CHEMBL233,Mu opioid receptor,Ki,=,1820.0,nM,CHEMBL1052524,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1153456,KI,COc1ccc2c(c1)[C@]13CCN(C)C[C@@]1(C2)Cc1c([nH]c2ccccc12)C3
CHEMBL557252,CHEMBL233,Mu opioid receptor,Ki,=,713.0,nM,CHEMBL1052524,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1153456,KI,COc1ccc2c(c1)[C@]13CCN(C)C[C@@]1(C2)Cc1c(n(C)c2ccccc12)C3
CHEMBL554292,CHEMBL233,Mu opioid receptor,Ki,=,1420.0,nM,CHEMBL1052524,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1153456,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)C[C@@]1(C2)Cc1c([nH]c2ccccc12)C3
CHEMBL562139,CHEMBL233,Mu opioid receptor,Ki,=,104.0,nM,CHEMBL1052524,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1153456,KI,CN1CC[C@]23Cc4[nH]c5ccccc5c4C[C@]2(Cc2ccc(O)cc23)C1
CHEMBL557937,CHEMBL233,Mu opioid receptor,Ki,=,40.2,nM,CHEMBL1052524,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1153456,KI,CN1CC[C@]23Cc4c(c5ccccc5n4C)C[C@]2(Cc2ccc(O)cc23)C1
CHEMBL562340,CHEMBL233,Mu opioid receptor,Ki,=,523.0,nM,CHEMBL1052524,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1153456,KI,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)C[C@@]1(C2)Cc1c([nH]c2ccccc12)C3
CHEMBL558135,CHEMBL233,Mu opioid receptor,Ki,=,469.0,nM,CHEMBL1052524,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1153456,KI,Cn1c2c(c3ccccc31)C[C@@]13Cc4ccc(O)cc4[C@@]1(CCN(CC1CC1)C3)C2
CHEMBL554617,CHEMBL233,Mu opioid receptor,Ki,=,0.56,nM,CHEMBL1063595,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153596,KI,O=C(O[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)N(c1ccccc1)c1ccccc1
CHEMBL560200,CHEMBL233,Mu opioid receptor,Ki,=,1.85,nM,CHEMBL1063595,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153596,KI,CN(C)C(=O)O[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL563988,CHEMBL233,Mu opioid receptor,Ki,=,0.79,nM,CHEMBL1063595,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153596,KI,Cc1ccc(S(=O)(=O)O[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1
CHEMBL551074,CHEMBL233,Mu opioid receptor,Ki,=,1.11,nM,CHEMBL1063595,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153596,KI,CS(=O)(=O)O[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL558140,CHEMBL233,Mu opioid receptor,Ki,=,2.12,nM,CHEMBL1063595,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153596,KI,Cl.Oc1ccc2c3c1O[C@H]1[C@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL578629,CHEMBL233,Mu opioid receptor,Ki,=,0.18,nM,CHEMBL1047527,B,Displacement of [3H]diprenorphine from human cloned mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL1155180,KI,CO[C@]12C=C[C@@]3(C[C@@H]1[C@@](C)(O)CCc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL575994,CHEMBL233,Mu opioid receptor,Ki,=,201.0,nM,CHEMBL1051417,B,Binding affinity to mu opioid receptor,CHEMBL1154191,KI,FCCCC1OC2(CCN(Cc3ccccc3)CC2)c2ccccc21
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,2.55,nM,CHEMBL1056132,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL566557,CHEMBL233,Mu opioid receptor,Ki,=,1330.0,nM,CHEMBL1056132,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CC[C@]12CCN(C[C@H](O)c3ccccc3)C[C@H]1Oc1ccc(O)cc12
CHEMBL567213,CHEMBL233,Mu opioid receptor,Ki,=,600.0,nM,CHEMBL1056132,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CC[C@]12CCN(C[C@@H](O)c3ccccc3)C[C@H]1Oc1ccc(O)cc12
CHEMBL568076,CHEMBL233,Mu opioid receptor,Ki,=,200.0,nM,CHEMBL1056132,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CC[C@]12CCN(CCc3ccccc3)C[C@H]1Oc1ccc(O)cc12
CHEMBL582929,CHEMBL233,Mu opioid receptor,Ki,=,1330.0,nM,CHEMBL1056132,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CC[C@]12CCN(C)C[C@H]1Oc1ccc(O)cc12
CHEMBL566749,CHEMBL233,Mu opioid receptor,Ki,=,3500.0,nM,CHEMBL1056132,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CC[C@]12CCNC[C@H]1Oc1ccc(O)cc12
CHEMBL566527,CHEMBL233,Mu opioid receptor,Ki,=,80.0,nM,CHEMBL1056132,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CC[C@@]12CCN(C[C@H](O)c3ccccc3)C[C@@H]1Oc1ccc(O)cc12
CHEMBL568309,CHEMBL233,Mu opioid receptor,Ki,=,9.3,nM,CHEMBL1056132,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CC[C@@]12CCN(C[C@@H](O)c3ccccc3)C[C@@H]1Oc1ccc(O)cc12
CHEMBL72180,CHEMBL233,Mu opioid receptor,Ki,=,0.7,nM,CHEMBL1056132,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CC[C@@]12CCN(CCc3ccccc3)C[C@@H]1Oc1ccc(O)cc12
CHEMBL430441,CHEMBL233,Mu opioid receptor,Ki,=,15.9,nM,CHEMBL1056132,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CC[C@@]12CCN(C)C[C@@H]1Oc1ccc(O)cc12
CHEMBL567855,CHEMBL233,Mu opioid receptor,Ki,=,48.0,nM,CHEMBL1056132,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CC[C@@]12CCNC[C@@H]1Oc1ccc(O)cc12
CHEMBL301160,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL1056140,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL566346,CHEMBL233,Mu opioid receptor,Ki,=,0.71,nM,CHEMBL1056140,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,O=C(O)CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL565679,CHEMBL233,Mu opioid receptor,Ki,=,0.46,nM,CHEMBL1056140,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,CC(CCCCCCC(C)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)C(=O)O
CHEMBL566762,CHEMBL233,Mu opioid receptor,Ki,=,1.7,nM,CHEMBL1056140,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,COC(=O)C(C)CCCCCCC(C)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL573918,CHEMBL233,Mu opioid receptor,Ki,=,47.0,nM,CHEMBL1056140,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,CC(C)(CCCCCCC(C)(C)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)C(=O)O
CHEMBL575647,CHEMBL233,Mu opioid receptor,Ki,=,8.6,nM,CHEMBL1056140,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,CC(C)(CCCCCCC(C)(C)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)C(=O)OCc1ccccc1
CHEMBL147511,CHEMBL233,Mu opioid receptor,Ki,=,0.09,nM,CHEMBL1056140,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL582930,CHEMBL233,Mu opioid receptor,Ki,=,0.95,nM,CHEMBL1056140,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,CC(CCCCCCC(C)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL584790,CHEMBL233,Mu opioid receptor,Ki,=,0.47,nM,CHEMBL1056140,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,CC(C)(CCCCCCC(C)(C)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL575031,CHEMBL233,Mu opioid receptor,Ki,=,2.9,nM,CHEMBL1056140,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,CC(CCCCC(C)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL584791,CHEMBL233,Mu opioid receptor,Ki,=,0.43,nM,CHEMBL1056140,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,C=CCN1CC[C@]23c4c5ccc(OC(=O)CCCCCCCCC(=O)Oc6ccc7c(c6)[C@@]68CCCC[C@H]6C(C7)N(CC6CCC6)CC8)c4O[C@H]2CCC[C@H]3[C@H]1C5
CHEMBL584792,CHEMBL233,Mu opioid receptor,Ki,=,3.7,nM,CHEMBL1056140,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,C=CCN1CC[C@]23c4c5ccc(OC(=O)C(C)CCCCCCC(C)C(=O)Oc6ccc7c(c6)[C@@]68CCCC[C@H]6C(C7)N(CC6CCC6)CC8)c4O[C@H]2CCC[C@H]3C1C5
CHEMBL572393,CHEMBL233,Mu opioid receptor,Ki,=,728.0,nM,CHEMBL1056073,B,Binding affinity to mu opioid receptor,CHEMBL1154631,KI,CCC(=O)N(c1ccc(C(C)NC(=O)[C@H]2O[C@@H](c3nc4c(NC5CCCC5)ncnc4[nH]3)[C@H](O)[C@@H]2O)cc1)C1CCN(CCc2ccccc2)CC1
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL1056073,B,Binding affinity to mu opioid receptor,CHEMBL1154631,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,3.8,nM,CHEMBL1056073,B,Binding affinity to mu opioid receptor,CHEMBL1154631,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL385482,CHEMBL233,Mu opioid receptor,Ki,=,0.32,nM,CHEMBL1061220,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,O=C1CC[C@@]2(NC/C=C/c3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL216251,CHEMBL233,Mu opioid receptor,Ki,=,0.7,nM,CHEMBL1061220,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL574175,CHEMBL233,Mu opioid receptor,Ki,=,0.97,nM,CHEMBL1061220,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,O=C1CC[C@@]2(NCC#Cc3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL575682,CHEMBL233,Mu opioid receptor,Ki,=,1.31,nM,CHEMBL1061220,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,O=C(C#Cc1ccccc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL575451,CHEMBL233,Mu opioid receptor,Ki,=,1.46,nM,CHEMBL1061220,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)C#Cc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL386492,CHEMBL233,Mu opioid receptor,Ki,=,2.98,nM,CHEMBL1061220,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,O=C(/C=C/c1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL574397,CHEMBL233,Mu opioid receptor,Ki,=,3.75,nM,CHEMBL1061220,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,O=C(C#Cc1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL386272,CHEMBL233,Mu opioid receptor,Ki,=,4.78,nM,CHEMBL1061220,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL578422,CHEMBL233,Mu opioid receptor,Ki,=,7.43,nM,CHEMBL1061220,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)C#Cc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL577168,CHEMBL233,Mu opioid receptor,Ki,=,9.68,nM,CHEMBL1061220,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NCC#Cc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL577786,CHEMBL233,Mu opioid receptor,Ki,=,486.0,nM,CHEMBL1058547,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2ccc(C(N)=O)cc2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL573517,CHEMBL233,Mu opioid receptor,Ki,=,5036.0,nM,CHEMBL1058547,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2ccccc2C(N)=O)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL573775,CHEMBL233,Mu opioid receptor,Ki,=,1017.0,nM,CHEMBL1058547,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(NC(C)=O)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL583331,CHEMBL233,Mu opioid receptor,Ki,=,462.0,nM,CHEMBL1058547,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(NS(C)(=O)=O)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL574640,CHEMBL233,Mu opioid receptor,Ki,=,75.0,nM,CHEMBL1058547,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(NC(=O)OC)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL573757,CHEMBL233,Mu opioid receptor,Ki,=,2879.0,nM,CHEMBL1058547,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(N)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL573739,CHEMBL233,Mu opioid receptor,Ki,=,4711.0,nM,CHEMBL1058547,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(C(=O)NC)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL577615,CHEMBL233,Mu opioid receptor,Ki,=,282.0,nM,CHEMBL1058547,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(C(N)=O)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL575926,CHEMBL233,Mu opioid receptor,Ki,=,7104.0,nM,CHEMBL1058547,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(C(=O)OC)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL577359,CHEMBL233,Mu opioid receptor,Ki,=,4162.0,nM,CHEMBL1058547,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(CN(C)C)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL577394,CHEMBL233,Mu opioid receptor,Ki,=,3809.0,nM,CHEMBL1058547,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(CO)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL577356,CHEMBL233,Mu opioid receptor,Ki,=,831.0,nM,CHEMBL1058547,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(CN)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL576740,CHEMBL233,Mu opioid receptor,Ki,=,1541.0,nM,CHEMBL1058547,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(C(C)=O)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL572669,CHEMBL233,Mu opioid receptor,Ki,=,3750.0,nM,CHEMBL1058547,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(C(C)O)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL567818,CHEMBL233,Mu opioid receptor,Ki,=,1188.0,nM,CHEMBL1058547,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(C=O)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL567604,CHEMBL233,Mu opioid receptor,Ki,=,88.0,nM,CHEMBL1058547,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL301160,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL49269,CHEMBL233,Mu opioid receptor,Ki,=,0.062,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL568876,CHEMBL233,Mu opioid receptor,Ki,=,0.71,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Ic1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL576273,CHEMBL233,Mu opioid receptor,Ki,=,5.4,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Ic1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL568877,CHEMBL233,Mu opioid receptor,Ki,=,0.31,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,COc1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL568988,CHEMBL233,Mu opioid receptor,Ki,=,2.5,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,COc1ccc(CN(Cc2ccc(OC)cc2)c2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL568813,CHEMBL233,Mu opioid receptor,Ki,=,16.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Ic1ccc(CN(Cc2ccc(I)cc2)c2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL571998,CHEMBL233,Mu opioid receptor,Ki,=,0.26,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,c1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL571767,CHEMBL233,Mu opioid receptor,Ki,=,0.026,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,COc1ccc(Nc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL568757,CHEMBL233,Mu opioid receptor,Ki,=,0.08,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,c1ccc(Nc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL571560,CHEMBL233,Mu opioid receptor,Ki,=,1.7,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,c1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL571990,CHEMBL233,Mu opioid receptor,Ki,=,0.61,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,COc1ccc(Nc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL570225,CHEMBL233,Mu opioid receptor,Ki,=,1.7,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,c1ccc(Nc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL568989,CHEMBL233,Mu opioid receptor,Ki,=,0.34,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(OC(=O)Nc2ccc(I)cc2)cc13
CHEMBL570429,CHEMBL233,Mu opioid receptor,Ki,=,0.58,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,O=C(Nc1ccc(I)cc1)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL570654,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,O=C(Nc1ccc(I)cc1)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL568829,CHEMBL233,Mu opioid receptor,Ki,=,11.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(NC(=O)Nc2ccccc2)cc13
CHEMBL571561,CHEMBL233,Mu opioid receptor,Ki,=,3.9,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,O=C(Nc1ccccc1)Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL569724,CHEMBL233,Mu opioid receptor,Ki,=,17.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(NC(=O)Nc2ccc(I)cc2)cc13
CHEMBL569725,CHEMBL233,Mu opioid receptor,Ki,=,23.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,O=C(Nc1ccc(I)cc1)Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL572216,CHEMBL233,Mu opioid receptor,Ki,=,24.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,O=C(Nc1ccc(I)cc1)Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL570449,CHEMBL233,Mu opioid receptor,Ki,=,15.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1cc(CO)c(O)cc13
CHEMBL568878,CHEMBL233,Mu opioid receptor,Ki,=,360.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,OCc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL578173,CHEMBL233,Mu opioid receptor,Ki,=,190.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1cc(CNCc2ccccc2)c(O)cc13
CHEMBL576065,CHEMBL233,Mu opioid receptor,Ki,=,110.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1cc2c(cc13)OCN(Cc1ccccc1)C2
CHEMBL585901,CHEMBL233,Mu opioid receptor,Ki,=,3.8,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,O/N=C\c1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL568830,CHEMBL233,Mu opioid receptor,Ki,=,290.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,NCc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL583265,CHEMBL233,Mu opioid receptor,Ki,=,330.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CCCNCc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL569215,CHEMBL233,Mu opioid receptor,Ki,=,6.8,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Oc1cc2c(cc1CNCCCCNCc1cc3c(cc1O)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)C[C@@H]1[C@@H]3CCCC[C@]23CCN1CC1CCC1
CHEMBL569313,CHEMBL233,Mu opioid receptor,Ki,=,76.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Oc1cc2c(cc1CNCCCCCCNCc1cc3c(cc1O)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)C[C@@H]1[C@@H]3CCCC[C@]23CCN1CC1CCC1
CHEMBL569448,CHEMBL233,Mu opioid receptor,Ki,=,24.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Oc1cc2c(cc1CNCCCCCCCCNCc1cc3c(cc1O)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)C[C@@H]1[C@@H]3CCCC[C@]23CCN1CC1CCC1
CHEMBL568071,CHEMBL233,Mu opioid receptor,Ki,=,160.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CCN(CCCCN(CC)Cc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Cc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL566128,CHEMBL233,Mu opioid receptor,Ki,=,64.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CCN(CCCCCCN(CC)Cc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Cc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL584530,CHEMBL233,Mu opioid receptor,Ki,=,180.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CCC(O)c1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL567170,CHEMBL233,Mu opioid receptor,Ki,=,74.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Oc1cc2c(cc1C(O)CCCCC(O)c1cc3c(cc1O)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)C[C@@H]1[C@@H]3CCCC[C@]23CCN1CC1CCC1
CHEMBL568758,CHEMBL233,Mu opioid receptor,Ki,=,35.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Oc1cc2c(cc1C(O)CCCCCCCCCCC(O)c1cc3c(cc1O)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)C[C@@H]1[C@@H]3CCCC[C@]23CCN1CC1CCC1
CHEMBL571322,CHEMBL233,Mu opioid receptor,Ki,=,17.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CCCCC(O)c1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL570428,CHEMBL233,Mu opioid receptor,Ki,=,36.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CCCCCCCCCC(O)c1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL572217,CHEMBL233,Mu opioid receptor,Ki,=,36.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,OCCCCCCCCCCC(O)c1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL569009,CHEMBL233,Mu opioid receptor,Ki,=,36.0,nM,CHEMBL1050689,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL1156775,KI,O=C(CCCCC(=O)NCc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)NCc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL570516,CHEMBL233,Mu opioid receptor,Ki,=,6543.0,nM,CHEMBL1041659,B,Binding affinity to mu opioid receptor,CHEMBL1156813,KI,CCC(=O)N(CCCCCCCNC(=O)c1nn(-c2ccc(Cl)cc2Cl)c(-c2ccc(Cl)cc2)c1C)C1CCN(CCc2ccccc2)CC1
CHEMBL585721,CHEMBL233,Mu opioid receptor,Ki,=,0.3,nM,CHEMBL1038966,B,Displacement of [125I]OXY from human mu opioid receptor expressed in CHO cells,CHEMBL1156815,KI,Oc1cccc2c1O[C@H]1CCC[C@H]3CN(CCc4ccccc4)CC[C@@]231
CHEMBL104042,CHEMBL233,Mu opioid receptor,Ki,=,0.08,nM,CHEMBL1038966,B,Displacement of [125I]OXY from human mu opioid receptor expressed in CHO cells,CHEMBL1156815,KI,Oc1cccc2c1O[C@H]1CCC[C@H]3CN(CC4CC4)CC[C@@]231
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,0.98,nM,CHEMBL1038966,B,Displacement of [125I]OXY from human mu opioid receptor expressed in CHO cells,CHEMBL1156815,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL571843,CHEMBL233,Mu opioid receptor,Ki,=,0.65,nM,CHEMBL1038966,B,Displacement of [125I]OXY from human mu opioid receptor expressed in CHO cells,CHEMBL1156815,KI,CN1CC[C@]23c4cccc(O)c4O[C@H]2CCC[C@H]3C1
CHEMBL397705,CHEMBL233,Mu opioid receptor,Ki,=,3.9,nM,CHEMBL1038966,B,Displacement of [125I]OXY from human mu opioid receptor expressed in CHO cells,CHEMBL1156815,KI,CC(C)=CCN1CC[C@@]2(C)c3cc(O)ccc3C[C@@H]1[C@H]2C
CHEMBL571862,CHEMBL233,Mu opioid receptor,Ki,=,24.0,nM,CHEMBL1038966,B,Displacement of [125I]OXY from human mu opioid receptor expressed in CHO cells,CHEMBL1156815,KI,COc1cccc2c1O[C@H]1CCC[C@H]3CN(CCc4ccccc4)CC[C@@]231
CHEMBL585536,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL1038966,B,Displacement of [125I]OXY from human mu opioid receptor expressed in CHO cells,CHEMBL1156815,KI,COc1cccc2c1O[C@H]1CCC[C@@H]3CN(C)CC[C@@]231
CHEMBL583881,CHEMBL233,Mu opioid receptor,Ki,=,30.0,nM,CHEMBL1038966,B,Displacement of [125I]OXY from human mu opioid receptor expressed in CHO cells,CHEMBL1156815,KI,COc1cccc2c1O[C@H]1CCC[C@H]3CN(CC4CC4)CC[C@@]231
CHEMBL571862,CHEMBL233,Mu opioid receptor,Ki,=,145.0,nM,CHEMBL1038966,B,Displacement of [125I]OXY from human mu opioid receptor expressed in CHO cells,CHEMBL1156815,KI,COc1cccc2c1O[C@H]1CCC[C@H]3CN(CCc4ccccc4)CC[C@@]231
CHEMBL585721,CHEMBL233,Mu opioid receptor,Ki,=,275.0,nM,CHEMBL1038966,B,Displacement of [125I]OXY from human mu opioid receptor expressed in CHO cells,CHEMBL1156815,KI,Oc1cccc2c1O[C@H]1CCC[C@H]3CN(CCc4ccccc4)CC[C@@]231
CHEMBL571610,CHEMBL233,Mu opioid receptor,Ki,=,236.0,nM,CHEMBL1038966,B,Displacement of [125I]OXY from human mu opioid receptor expressed in CHO cells,CHEMBL1156815,KI,COc1cccc2c1O[C@H]1CCC[C@H]3CN(C)CC[C@@]231
CHEMBL104042,CHEMBL233,Mu opioid receptor,Ki,=,1330.0,nM,CHEMBL1038966,B,Displacement of [125I]OXY from human mu opioid receptor expressed in CHO cells,CHEMBL1156815,KI,Oc1cccc2c1O[C@H]1CCC[C@H]3CN(CC4CC4)CC[C@@]231
CHEMBL571610,CHEMBL233,Mu opioid receptor,Ki,=,7610.0,nM,CHEMBL1038966,B,Displacement of [125I]OXY from human mu opioid receptor expressed in CHO cells,CHEMBL1156815,KI,COc1cccc2c1O[C@H]1CCC[C@H]3CN(C)CC[C@@]231
CHEMBL584725,CHEMBL233,Mu opioid receptor,Ki,=,8840.0,nM,CHEMBL1038966,B,Displacement of [125I]OXY from human mu opioid receptor expressed in CHO cells,CHEMBL1156815,KI,CN1CC[C@]23c4cccc(O)c4O[C@H]2CCC[C@@H]3C1
CHEMBL571843,CHEMBL233,Mu opioid receptor,Ki,=,8000.0,nM,CHEMBL1038966,B,Displacement of [125I]OXY from human mu opioid receptor expressed in CHO cells,CHEMBL1156815,KI,CN1CC[C@]23c4cccc(O)c4O[C@H]2CCC[C@H]3C1
CHEMBL569316,CHEMBL233,Mu opioid receptor,Ki,=,205.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ccccn3)CC2)cc1
CHEMBL569956,CHEMBL233,Mu opioid receptor,Ki,=,1251.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ncc[nH]3)CC2)cc1
CHEMBL568803,CHEMBL233,Mu opioid receptor,Ki,=,181.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3cccs3)CC2)cc1
CHEMBL570000,CHEMBL233,Mu opioid receptor,Ki,=,115.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ccco3)CC2)cc1
CHEMBL584941,CHEMBL233,Mu opioid receptor,Ki,=,127.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ccsc3)CC2)cc1
CHEMBL568818,CHEMBL233,Mu opioid receptor,Ki,=,177.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ccoc3)CC2)cc1
CHEMBL569006,CHEMBL233,Mu opioid receptor,Ki,=,472.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3cccc(F)c3)CC2)cc1
CHEMBL576267,CHEMBL233,Mu opioid receptor,Ki,=,162.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ccccc3F)CC2)cc1
CHEMBL569728,CHEMBL233,Mu opioid receptor,Ki,=,62.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ccc(C)cc3)CC2)cc1
CHEMBL568865,CHEMBL233,Mu opioid receptor,Ki,=,648.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CC(C)c3ccccc3)CC2)cc1
CHEMBL569755,CHEMBL233,Mu opioid receptor,Ki,=,88.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ccccc3)CC2)cc1
CHEMBL585900,CHEMBL233,Mu opioid receptor,Ki,=,126.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCC3CC3)CC2)cc1
CHEMBL570233,CHEMBL233,Mu opioid receptor,Ki,=,289.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCC3CCCCC3)CC2)cc1
CHEMBL570232,CHEMBL233,Mu opioid receptor,Ki,=,130.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,C=CCCN1CCC(N(c2ccc(C(=O)N(CC)CC)cc2)c2cccc(O)c2)CC1
CHEMBL571324,CHEMBL233,Mu opioid receptor,Ki,=,87.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(C)CC2)cc1
CHEMBL570181,CHEMBL233,Mu opioid receptor,Ki,=,4445.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(OC)c2)C2CCN(CCc3ncc[nH]3)CC2)cc1
CHEMBL569704,CHEMBL233,Mu opioid receptor,Ki,=,1299.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(OC)c2)C2CCN(CCc3ccoc3)CC2)cc1
CHEMBL570446,CHEMBL233,Mu opioid receptor,Ki,=,2533.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(OC)c2)C2CCN(CCc3ccco3)CC2)cc1
CHEMBL570645,CHEMBL233,Mu opioid receptor,Ki,=,1963.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(OC)c2)C2CCN(CCc3cccs3)CC2)cc1
CHEMBL569945,CHEMBL233,Mu opioid receptor,Ki,=,1596.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(OC)c2)C2CCN(CCc3ccsc3)CC2)cc1
CHEMBL569084,CHEMBL233,Mu opioid receptor,Ki,=,2106.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(OC)c2)C2CCN(CCc3ccccc3)CC2)cc1
CHEMBL13470,CHEMBL233,Mu opioid receptor,Ki,=,352.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL584727,CHEMBL233,Mu opioid receptor,Ki,=,309.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3c[nH]cn3)CC2)cc1
CHEMBL569529,CHEMBL233,Mu opioid receptor,Ki,=,1549.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ccncc3)CC2)cc1
CHEMBL570448,CHEMBL233,Mu opioid receptor,Ki,=,772.0,nM,CHEMBL1043619,B,Displacement of [125I]FK33824 from human cloned mu opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3nccn3C)CC2)cc1
CHEMBL316446,CHEMBL233,Mu opioid receptor,Ki,=,4.55,nM,CHEMBL1037472,B,Binding affinity to human mu opioid receptor,CHEMBL1155981,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL333357,CHEMBL233,Mu opioid receptor,Ki,=,8.23,nM,CHEMBL1037472,B,Binding affinity to human mu opioid receptor,CHEMBL1155981,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL577745,CHEMBL233,Mu opioid receptor,Ki,=,2.32,nM,CHEMBL1037472,B,Binding affinity to human mu opioid receptor,CHEMBL1155981,KI,CC(C)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCc1ccccc1
CHEMBL577746,CHEMBL233,Mu opioid receptor,Ki,=,4.97,nM,CHEMBL1037472,B,Binding affinity to human mu opioid receptor,CHEMBL1155981,KI,CC(C)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCc1ccccc1
CHEMBL577747,CHEMBL233,Mu opioid receptor,Ki,=,4.56,nM,CHEMBL1037472,B,Binding affinity to human mu opioid receptor,CHEMBL1155981,KI,C[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCc1ccccc1
CHEMBL577748,CHEMBL233,Mu opioid receptor,Ki,=,8.67,nM,CHEMBL1037472,B,Binding affinity to human mu opioid receptor,CHEMBL1155981,KI,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCc1ccccc1
CHEMBL570634,CHEMBL233,Mu opioid receptor,Ki,=,56.23,nM,CHEMBL1037472,B,Binding affinity to human mu opioid receptor,CHEMBL1155981,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)NCc1ccccc1
CHEMBL577749,CHEMBL233,Mu opioid receptor,Ki,=,122.0,nM,CHEMBL1037472,B,Binding affinity to human mu opioid receptor,CHEMBL1155981,KI,C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCc1ccccc1
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.3,nM,CHEMBL1071833,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL982,CHEMBL233,Mu opioid receptor,Ki,=,0.91,nM,CHEMBL1071833,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL593214,CHEMBL233,Mu opioid receptor,Ki,=,0.34,nM,CHEMBL1071833,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,Cc1ccc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1.O=C(O)C(=O)O
CHEMBL611929,CHEMBL233,Mu opioid receptor,Ki,=,0.47,nM,CHEMBL1071833,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(C(F)(F)F)cc1.O=C(O)C(=O)O
CHEMBL611930,CHEMBL233,Mu opioid receptor,Ki,=,0.88,nM,CHEMBL1071833,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(Br)cc1.O=C(O)C(=O)O
CHEMBL611931,CHEMBL233,Mu opioid receptor,Ki,=,0.82,nM,CHEMBL1071833,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(I)cc1.O=C(O)C(=O)O
CHEMBL611932,CHEMBL233,Mu opioid receptor,Ki,=,1.09,nM,CHEMBL1071833,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,CC(C)(C)c1ccc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1.O=C(O)C(=O)O
CHEMBL593215,CHEMBL233,Mu opioid receptor,Ki,=,0.48,nM,CHEMBL1071833,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(Cl)c(Cl)c1.O=C(O)C(=O)O
CHEMBL611933,CHEMBL233,Mu opioid receptor,Ki,=,0.61,nM,CHEMBL1071833,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(Cl)cc1.O=C(O)C(=O)O
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,0.9,nM,CHEMBL1071833,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL467094,CHEMBL233,Mu opioid receptor,Ki,=,7265.0,nM,CHEMBL1066752,B,Displacement of [3H]DAMGO from human MOR,CHEMBL1153197,KI,COc1cc2c3c(c1OC)-c1cc4c(cc1CC3N(C)CC2)OCO4
CHEMBL595472,CHEMBL233,Mu opioid receptor,Ki,=,66.5,nM,CHEMBL1074666,B,Displacement of [125I]diprenorphine from human mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153251,KI,CCN(CC)C(=O)c1ccc(C2(c3cccc(O)c3)CCN(CCc3ccccc3)CC2)cc1
CHEMBL593824,CHEMBL233,Mu opioid receptor,Ki,=,380.0,nM,CHEMBL1074666,B,Displacement of [125I]diprenorphine from human mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153251,KI,CCCC(C)CN1CCC(c2ccc(C(O)(CC)CC)cc2)(c2cccc(C(N)=O)c2)CC1
CHEMBL605293,CHEMBL233,Mu opioid receptor,Ki,=,35.0,nM,CHEMBL1074666,B,Displacement of [125I]diprenorphine from human mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153251,KI,CCN(CC)C(=O)c1ccc(C2(c3cccc(O)c3)CCCN(CC3CC3)C2)cc1
CHEMBL592908,CHEMBL233,Mu opioid receptor,Ki,=,52.0,nM,CHEMBL1074666,B,Displacement of [125I]diprenorphine from human mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153251,KI,CCN(C)C(=O)c1ccc(C2(c3cccc(O)c3)CCCN(CC3CC3)C2)cc1
CHEMBL595233,CHEMBL233,Mu opioid receptor,Ki,=,110.0,nM,CHEMBL1074666,B,Displacement of [125I]diprenorphine from human mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153251,KI,CC(C)(O)c1ccc(C2(c3cccc(O)c3)CCCN(CC3CC3)C2)cc1
CHEMBL72180,CHEMBL233,Mu opioid receptor,Ki,=,0.7,nM,CHEMBL1074338,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1157715,KI,CC[C@@]12CCN(CCc3ccccc3)C[C@@H]1Oc1ccc(O)cc12
CHEMBL592302,CHEMBL233,Mu opioid receptor,Ki,=,354.0,nM,CHEMBL1074338,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1157715,KI,CC[C@@]12CCN(CCc3ccc(F)cc3)C[C@@H]1Oc1c(O)cccc12
CHEMBL592300,CHEMBL233,Mu opioid receptor,Ki,=,670.0,nM,CHEMBL1074338,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1157715,KI,CC[C@@]12CCN(CCc3ccc([N+](=O)[O-])cc3)C[C@@H]1Oc1c(O)cccc12
CHEMBL599174,CHEMBL233,Mu opioid receptor,Ki,=,795.0,nM,CHEMBL1074338,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1157715,KI,CC[C@@]12CCN(C)C[C@@H]1Oc1c(O)cccc12
CHEMBL598977,CHEMBL233,Mu opioid receptor,Ki,=,740.0,nM,CHEMBL1074338,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1157715,KI,CN1CC[C@@]2(CCc3ccccc3)c3cccc(O)c3O[C@H]2C1
CHEMBL599175,CHEMBL233,Mu opioid receptor,Ki,=,1630.0,nM,CHEMBL1074338,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1157715,KI,CC[C@@]12CCN(CCc3ccccc3)C[C@@H]1Oc1c(O)cccc12
CHEMBL589260,CHEMBL233,Mu opioid receptor,Ki,=,4670.0,nM,CHEMBL1074338,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1157715,KI,CC[C@@]12CCN(CC3CC3)C[C@@H]1Oc1c(O)cccc12
CHEMBL592627,CHEMBL233,Mu opioid receptor,Ki,=,0.9,nM,CHEMBL1074338,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1157715,KI,Oc1ccc2c(c1)C1CCN(CCc3ccccc3)CC1O2
CHEMBL589587,CHEMBL233,Mu opioid receptor,Ki,=,4.0,nM,CHEMBL1074338,B,Displacement of [3H]DAMGO from mu opioid receptor expressed in CHO cells,CHEMBL1157715,KI,Oc1ccc2c(c1)C1CCN(CC3CC3)CC1O2
CHEMBL301160,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL1100233,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL1154976,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL151872,CHEMBL233,Mu opioid receptor,Ki,=,66.0,nM,CHEMBL1100233,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL1154976,KI,c1cc2c(cc1OCCCCCCCCCCOc1ccc3c(c1)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL348023,CHEMBL233,Mu opioid receptor,Ki,=,29.0,nM,CHEMBL1100233,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL1154976,KI,c1cc2c(cc1OCCCCOc1ccc3c(c1)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1075629,CHEMBL233,Mu opioid receptor,Ki,=,7.1,nM,CHEMBL1100233,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL1154976,KI,c1cc2c(cc1OCCCOc1ccc3c(c1)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1076572,CHEMBL233,Mu opioid receptor,Ki,=,0.95,nM,CHEMBL1100233,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL1154976,KI,OC(COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1076573,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL1100233,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL1154976,KI,OC(COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)CC(O)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1076574,CHEMBL233,Mu opioid receptor,Ki,=,17.0,nM,CHEMBL1100233,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL1154976,KI,OC(CCC(O)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1076575,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL1100233,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL1154976,KI,OC(CCCC(O)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1076576,CHEMBL233,Mu opioid receptor,Ki,=,3.2,nM,CHEMBL1100233,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL1154976,KI,OC(CCCCC(O)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1076577,CHEMBL233,Mu opioid receptor,Ki,=,4.8,nM,CHEMBL1100233,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL1154976,KI,OC(CCCCCC(O)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1076578,CHEMBL233,Mu opioid receptor,Ki,=,2.4,nM,CHEMBL1100233,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL1154976,KI,OC(CCCCCCC(O)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1076579,CHEMBL233,Mu opioid receptor,Ki,=,0.24,nM,CHEMBL1100233,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL1154976,KI,OC(COc1ccc(Cc2ccc(OCC(O)COc3ccc4c(c3)[C@@]35CCCC[C@H]3[C@@H](C4)N(CC3CCC3)CC5)cc2)cc1)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1081084,CHEMBL233,Mu opioid receptor,Ki,=,7.3,nM,CHEMBL1100233,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL1154976,KI,c1cc2c(cc1OCC1CO1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1081250,CHEMBL233,Mu opioid receptor,Ki,=,7.4,nM,CHEMBL1100233,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL1154976,KI,CCCCCCCCC(O)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1080925,CHEMBL233,Mu opioid receptor,Ki,=,0.21,nM,CHEMBL1100233,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL1154976,KI,CCCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1081093,CHEMBL233,Mu opioid receptor,Ki,=,70.0,nM,CHEMBL1100233,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL1154976,KI,CCCCCCCCCCOc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1081608,CHEMBL233,Mu opioid receptor,Ki,=,6.5,nM,CHEMBL1100233,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL1154976,KI,OC(COc1ccccc1)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1076554,CHEMBL233,Mu opioid receptor,Ki,=,45000.0,nM,CHEMBL1103137,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cells,CHEMBL1154971,KI,Cc1cccc(O)c1C(=O)C1=CCCN2CCC[C@@H]12
CHEMBL1080153,CHEMBL233,Mu opioid receptor,Ki,=,49000.0,nM,CHEMBL1103137,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cells,CHEMBL1154971,KI,O=C(C1=CCCN2CCC[C@@H]12)c1ccccc1O
CHEMBL608815,CHEMBL233,Mu opioid receptor,Ki,=,18000.0,nM,CHEMBL1103137,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cells,CHEMBL1154971,KI,Cc1cccc(O)c1C(=O)C1=CCCN2CCC[C@H]12
CHEMBL1082013,CHEMBL233,Mu opioid receptor,Ki,=,3200.0,nM,CHEMBL1103137,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cells,CHEMBL1154971,KI,Cc1cccc(O)c1C(=O)C1=CCN2CCC[C@@H]12
CHEMBL1080674,CHEMBL233,Mu opioid receptor,Ki,=,13000.0,nM,CHEMBL1103137,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cells,CHEMBL1154971,KI,Cc1cccc(O)c1C(=O)C1=CCCCN2CCC[C@@H]12
CHEMBL1080485,CHEMBL233,Mu opioid receptor,Ki,=,69.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN([C@H]3CC[C@@H](C(C)C)CC3)CC2)c2ccccc21
CHEMBL1080484,CHEMBL233,Mu opioid receptor,Ki,=,30.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN([C@H]3CC[C@H](C(C)C)CC3)CC2)c2ccccc21
CHEMBL1080483,CHEMBL233,Mu opioid receptor,Ki,=,268.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)CN1c2ccccc2N(C2CCN(C3CCC4CCCCC4C3)CC2)S1(=O)=O
CHEMBL1079943,CHEMBL233,Mu opioid receptor,Ki,=,14.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)CN1Cc2ccccc2N(C2CCN(C3CCC4CCCCC4C3)CC2)S1(=O)=O
CHEMBL1079942,CHEMBL233,Mu opioid receptor,Ki,=,5.8,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)CN1N=C(c2ccccc2)C2(CCN(C3CCC4CCCCC4C3)CC2)C1=O
CHEMBL1079941,CHEMBL233,Mu opioid receptor,Ki,=,19.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)CN1Cc2ccccc2N(C2CCN(Cc3ccc(C)c4ccccc34)CC2)C1=O
CHEMBL1079940,CHEMBL233,Mu opioid receptor,Ki,=,7.3,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)CN1N=C(c2ccccc2)C2(CCN(C3CCC(C(C)(C)C)CC3)CC2)C1=O
CHEMBL1079418,CHEMBL233,Mu opioid receptor,Ki,=,113.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)CN1C(=O)OC2(CCN(C3CCC(C(C)(C)C)CC3)CC2)c2ccccc21
CHEMBL1079417,CHEMBL233,Mu opioid receptor,Ki,=,3177.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)CN1c2ccccc2N(C2CCN(C3CCCCCC3)CC2)S1(=O)=O
CHEMBL1081741,CHEMBL233,Mu opioid receptor,Ki,=,527.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)CN1C(=O)OC2(CCN(C3CCCCCC3)CC2)c2ccccc21
CHEMBL1079571,CHEMBL233,Mu opioid receptor,Ki,=,107.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)CN1c2ccccc2N(C2CCN(C3CCCCCCCCC3)CC2)S1(=O)=O
CHEMBL1079400,CHEMBL233,Mu opioid receptor,Ki,=,2.2,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)CN1Cc2ccccc2N(C2CCN(C3CCCCCCCCC3)CC2)S1(=O)=O
CHEMBL1080464,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)CN1N=C(c2ccccc2)C2(CCN(C3CCCCCCCCC3)CC2)C1=O
CHEMBL1080463,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)CN1C(=O)OC2(CCN(C3CCCCCCCCC3)CC2)c2ccccc21
CHEMBL1076242,CHEMBL233,Mu opioid receptor,Ki,=,346.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)CN1c2ccccc2N(C2CCN(C3CCC(C(C)C)CC3)CC2)S1(=O)=O
CHEMBL1081192,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)CN1Cc2ccccc2N(C2CCN(C3CCC(C(C)C)CC3)CC2)S1(=O)=O
CHEMBL1081191,CHEMBL233,Mu opioid receptor,Ki,=,5.2,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)CN1N=C(c2ccccc2)C2(CCN(C3CCC(C(C)C)CC3)CC2)C1=O
CHEMBL1082092,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)CN1Cc2ccccc2N(C2CCN(C3CCC(C(C)C)CC3)CC2)C1=O
CHEMBL1076208,CHEMBL233,Mu opioid receptor,Ki,=,108.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)CN1C(=O)OC2(CCN(C3CCC(C(C)C)CC3)CC2)c2ccccc21
CHEMBL1079562,CHEMBL233,Mu opioid receptor,Ki,=,3.7,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN(Cc3ccccc3-c3ccccc3)CC2)c2ccccc21
CHEMBL1080520,CHEMBL233,Mu opioid receptor,Ki,=,120.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN(Cc3ccc(OC)c4ccccc34)CC2)c2ccccc21
CHEMBL1080508,CHEMBL233,Mu opioid receptor,Ki,=,138.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN(Cc3ccc(C)c4ccccc34)CC2)c2ccccc21
CHEMBL1080507,CHEMBL233,Mu opioid receptor,Ki,=,67.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN(Cc3cccc4ccccc34)CC2)c2ccccc21
CHEMBL1088569,CHEMBL233,Mu opioid receptor,Ki,=,2707.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN(CCC(C)(C)C)CC2)c2ccccc21
CHEMBL1087370,CHEMBL233,Mu opioid receptor,Ki,=,1883.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN(CC3CCCCC3)CC2)c2ccccc21
CHEMBL1087278,CHEMBL233,Mu opioid receptor,Ki,=,127.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN(C3CCC4CCCCC4C3)CC2)c2ccccc21
CHEMBL1087276,CHEMBL233,Mu opioid receptor,Ki,=,47.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN(C3CCC(C)(C)CC3(C)C)CC2)c2ccccc21
CHEMBL1087658,CHEMBL233,Mu opioid receptor,Ki,=,77.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN(C3CCC(C(C)(C)C)CC3)CC2)c2ccccc21
CHEMBL1087657,CHEMBL233,Mu opioid receptor,Ki,=,201.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN(C3CCC(C(C)C)CC3)CC2)c2ccccc21
CHEMBL1087532,CHEMBL233,Mu opioid receptor,Ki,=,282.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN(C3CCC(C)(C)CC3)CC2)c2ccccc21
CHEMBL1087531,CHEMBL233,Mu opioid receptor,Ki,=,350.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN(C3CCCC3(C)C)CC2)c2ccccc21
CHEMBL1088171,CHEMBL233,Mu opioid receptor,Ki,=,34.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN(C3CCCC4(CCCCC4)C3)CC2)c2ccccc21
CHEMBL1088036,CHEMBL233,Mu opioid receptor,Ki,=,11.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN(C3CCCCCCCCC3)CC2)c2ccccc21
CHEMBL1086749,CHEMBL233,Mu opioid receptor,Ki,=,608.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN(C3CCCCCCC3)CC2)c2ccccc21
CHEMBL1086622,CHEMBL233,Mu opioid receptor,Ki,=,1794.0,nM,CHEMBL1112210,B,Displacement of [3H]diprenorphine from human MOP receptor expressed in CHOK1 cells,CHEMBL1154346,KI,CNC(=O)Cn1c(=O)n(C2CCN(C3CCCCCC3)CC2)c2ccccc21
CHEMBL1079079,CHEMBL233,Mu opioid receptor,Ki,=,1496.0,nM,CHEMBL1111404,B,Displacement of [3H]DAMGO from mu opioid at 10 uM by scintillation counting,CHEMBL1154290,KI,COc1ccc(-c2c(C#N)c(C(=O)NN3CCCCC3)nn2-c2ccccc2[125I])cc1
CHEMBL1091995,CHEMBL233,Mu opioid receptor,Ki,=,420.0,nM,CHEMBL1112644,B,Binding affinity to mu opioid receptor,CHEMBL1156939,KI,O=CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL1094237,CHEMBL233,Mu opioid receptor,Ki,=,650.0,nM,CHEMBL1104717,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1157818,KI,CCC(=O)N1C[C@H]2[C@H](N3CCCC3)CC[C@@H]1CN2C(=O)Cc1ccc(Cl)c(Cl)c1
CHEMBL1096475,CHEMBL233,Mu opioid receptor,Ki,=,6120.0,nM,CHEMBL1104717,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1157818,KI,COC(=O)N1C[C@H]2[C@@H](N3CCCC3)CC[C@@H]1CN2C(=O)Cc1ccc(Cl)c(Cl)c1
CHEMBL1094880,CHEMBL233,Mu opioid receptor,Ki,=,140.0,nM,CHEMBL1104717,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1157818,KI,COC(=O)N1C[C@H]2[C@H](N3CCCC3)CC[C@@H]1CN2C(=O)Cc1ccc(Cl)c(Cl)c1
CHEMBL1096474,CHEMBL233,Mu opioid receptor,Ki,=,180.0,nM,CHEMBL1104717,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1157818,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1C[C@H]2CC[C@H](N3CCCC3)[C@@H]1CN2Cc1ccccc1
CHEMBL1096473,CHEMBL233,Mu opioid receptor,Ki,=,1150.0,nM,CHEMBL1104717,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1157818,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1C[C@@H]2CC[C@@H](N3CCCC3)[C@H]1CN2Cc1ccccc1
CHEMBL1095521,CHEMBL233,Mu opioid receptor,Ki,=,470.0,nM,CHEMBL1104717,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in CHOK1 cells,CHEMBL1157818,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1C[C@H]2CC[C@@H](N3CCCC3)[C@@H]1CN2Cc1ccccc1
CHEMBL603370,CHEMBL233,Mu opioid receptor,Ki,=,0.36,nM,CHEMBL1107425,B,Displacement of [(3)H]U69593 from mu opioid receptor,CHEMBL1157818,KI,COC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C(CN2CCCC2)C1
CHEMBL1241328,CHEMBL233,Mu opioid receptor,Ki,=,8900.0,nM,CHEMBL1247783,B,Binding affinity to mu opioid receptor,CHEMBL1240486,KI,Cl.Cn1c(=O)[nH]c2c([nH]c(=O)n2C)c1=N
CHEMBL1701,CHEMBL233,Mu opioid receptor,Ki,=,920.0,nM,CHEMBL1291966,B,Binding affinity at mu-opioid receptor,CHEMBL1287706,KI,CCOC(=O)C1(c2ccccc2)CCN(C)CC1.Cl
CHEMBL1645202,CHEMBL233,Mu opioid receptor,Ki,=,456.0,nM,CHEMBL1646514,B,Displacement of radioligand from mu opioid receptor,CHEMBL1641560,KI,FCCC1OC2(CCN(Cc3ccccc3)CC2)c2ccccc21
CHEMBL1650844,CHEMBL233,Mu opioid receptor,Ki,=,201.0,nM,CHEMBL1659154,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO-K1 cells after 45 mins,CHEMBL1649335,KI,OCC1(N2CCC(n3c(N4CC5CNCC5C4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL1650845,CHEMBL233,Mu opioid receptor,Ki,=,128.0,nM,CHEMBL1659154,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO-K1 cells after 45 mins,CHEMBL1649335,KI,OCC1(N2CCC(n3c(N4CC5CN(Cc6ccccc6)CC5C4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL1650847,CHEMBL233,Mu opioid receptor,Ki,=,229.0,nM,CHEMBL1659154,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO-K1 cells after 45 mins,CHEMBL1649335,KI,CN1CCN(c2nc3ccccc3n2C2CCN(C3(CO)CCCCCCC3)CC2)CC1
CHEMBL1650843,CHEMBL233,Mu opioid receptor,Ki,=,178.0,nM,CHEMBL1659154,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO-K1 cells after 45 mins,CHEMBL1649335,KI,OCC1(N2CCC(n3c(-c4ccc(Cl)cc4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL1650842,CHEMBL233,Mu opioid receptor,Ki,=,302.0,nM,CHEMBL1659154,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO-K1 cells after 45 mins,CHEMBL1649335,KI,OCC1(N2CCC(n3c(-c4ccc(F)c(Cl)c4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL1650851,CHEMBL233,Mu opioid receptor,Ki,=,16.0,nM,CHEMBL1659154,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO-K1 cells after 45 mins,CHEMBL1649335,KI,O=c1[nH]c2ccccc2n1C1CCN(C2(CO)CCCCCCC2)CC1
CHEMBL1743603,CHEMBL233,Mu opioid receptor,Ki,=,4500.0,nM,CHEMBL1670099,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1667791,KI,Cc1cc(O)cc(C)c1C[C@@H](C(=O)N1Cc2ccccc2C[C@H]1C(=O)NCCC(=O)O)N(C)C.O=C(O)C(F)(F)F
CHEMBL1214049,CHEMBL233,Mu opioid receptor,Ki,=,2300.0,nM,CHEMBL1670099,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1667791,KI,Cc1cc(O)cc(C)c1C[C@@H](C(=O)N1Cc2ccccc2C[C@H]1C(=O)O)N(C)C
CHEMBL1743605,CHEMBL233,Mu opioid receptor,Ki,=,3.5,nM,CHEMBL1670099,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1667791,KI,Cc1cc(O)cc(C)c1C[C@@H](C(=O)N1Cc2ccccc2C[C@H]1C(=O)NCCC(=O)OC1=C2O[C@H]3[C@@H](O)C=C[C@H]4[C@H]5CC(C=C1)C2[C@]43CCN5C)N(C)C.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL1743604,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL1670099,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1667791,KI,Cc1cc(O)cc(C)c1C[C@@H](C(=O)N1Cc2ccccc2C[C@H]1C(=O)OC1=C2O[C@H]3[C@@H](O)C=C[C@H]4[C@H]5CC(C=C1)C2[C@]43CCN5C)N(C)C.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL1672177,CHEMBL233,Mu opioid receptor,Ki,=,2.0,nM,CHEMBL1678426,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@]23CCC[C@H](C2)N(C/C=C/c2ccccc2)CC3)c1
CHEMBL1672178,CHEMBL233,Mu opioid receptor,Ki,=,6.0,nM,CHEMBL1678426,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@@]23CCC[C@@H](C2)N(C/C=C/c2ccccc2)CC3)c1
CHEMBL1672179,CHEMBL233,Mu opioid receptor,Ki,=,26.0,nM,CHEMBL1678426,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@]23CCC[C@H](C2)N(C/C=C\c2ccccc2)CC3)c1
CHEMBL1672180,CHEMBL233,Mu opioid receptor,Ki,=,14.0,nM,CHEMBL1678426,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@@]23CCC[C@@H](C2)N(C/C=C\c2ccccc2)CC3)c1
CHEMBL1672181,CHEMBL233,Mu opioid receptor,Ki,=,47.0,nM,CHEMBL1678426,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@]23CCC[C@H](C2)N(C[C@@H]2C[C@H]2c2ccccc2)CC3)c1
CHEMBL1672182,CHEMBL233,Mu opioid receptor,Ki,=,3.0,nM,CHEMBL1678426,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@@]23CCC[C@@H](C2)N(C[C@H]2C[C@@H]2c2ccccc2)CC3)c1
CHEMBL1672183,CHEMBL233,Mu opioid receptor,Ki,=,16.0,nM,CHEMBL1678426,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@]23CCC[C@H](C2)N(C[C@H]2C[C@@H]2c2ccccc2)CC3)c1
CHEMBL1672184,CHEMBL233,Mu opioid receptor,Ki,=,4.0,nM,CHEMBL1678426,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@@]23CCC[C@@H](C2)N(C[C@@H]2C[C@H]2c2ccccc2)CC3)c1
CHEMBL1672185,CHEMBL233,Mu opioid receptor,Ki,=,265.0,nM,CHEMBL1678426,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@]23CCC[C@H](C2)N(C[C@@H]2C[C@@H]2c2ccccc2)CC3)c1
CHEMBL1672186,CHEMBL233,Mu opioid receptor,Ki,=,459.0,nM,CHEMBL1678426,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@@]23CCC[C@@H](C2)N(C[C@H]2C[C@H]2c2ccccc2)CC3)c1
CHEMBL1672187,CHEMBL233,Mu opioid receptor,Ki,=,76.0,nM,CHEMBL1678426,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@]23CCC[C@H](C2)N(C[C@H]2C[C@H]2c2ccccc2)CC3)c1
CHEMBL1672188,CHEMBL233,Mu opioid receptor,Ki,=,11.0,nM,CHEMBL1678426,B,Displacement of [125I]IOXY from human recombinant mu opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@@]23CCC[C@@H](C2)N(C[C@@H]2C[C@@H]2c2ccccc2)CC3)c1
CHEMBL1672190,CHEMBL233,Mu opioid receptor,Ki,=,1.75,nM,CHEMBL1678430,B,Binding affinity to mu opioid receptor,CHEMBL1671786,KI,C[C@H]1CN(CC2CC2c2ccccc2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL301160,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL49269,CHEMBL233,Mu opioid receptor,Ki,=,0.062,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL299220,CHEMBL233,Mu opioid receptor,Ki,=,1.3,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL242756,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL390911,CHEMBL233,Mu opioid receptor,Ki,=,150.0,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Nc1nc2cc3c(cc2o1)[C@@]12CCCC[C@H]1[C@@H](C3)N(CC1CC1)CC2
CHEMBL1766021,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1cc2sc(N)nc2cc13
CHEMBL390866,CHEMBL233,Mu opioid receptor,Ki,=,7.1,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CCC1
CHEMBL1766022,CHEMBL233,Mu opioid receptor,Ki,=,2.7,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CCCF
CHEMBL1766023,CHEMBL233,Mu opioid receptor,Ki,=,2.4,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1C[C@@H]1CCCO1
CHEMBL1766024,CHEMBL233,Mu opioid receptor,Ki,=,3.0,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766025,CHEMBL233,Mu opioid receptor,Ki,=,4.7,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CCNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766026,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,FC(F)(F)CNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766027,CHEMBL233,Mu opioid receptor,Ki,=,17.0,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CCCNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766028,CHEMBL233,Mu opioid receptor,Ki,=,57.0,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CC(=O)Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766029,CHEMBL233,Mu opioid receptor,Ki,=,180.0,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,c1ccc(Nc2nc3cc4c(cc3s2)C[C@@H]2[C@@H]3CCCC[C@]43CCN2CC2CC2)cc1
CHEMBL1766030,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,c1ccc(CNc2nc3cc4c(cc3s2)C[C@@H]2[C@@H]3CCCC[C@]43CCN2CC2CC2)cc1
CHEMBL1766031,CHEMBL233,Mu opioid receptor,Ki,=,9.1,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,COc1cccc(CNc2nc3cc4c(cc3s2)C[C@@H]2[C@@H]3CCCC[C@]43CCN2CC2CC2)c1
CHEMBL1766032,CHEMBL233,Mu opioid receptor,Ki,=,9.9,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Oc1cccc(CNc2nc3cc4c(cc3s2)C[C@@H]2[C@@H]3CCCC[C@]43CCN2CC2CC2)c1
CHEMBL1766033,CHEMBL233,Mu opioid receptor,Ki,=,130.0,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CCNC(=S)Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766034,CHEMBL233,Mu opioid receptor,Ki,=,610.0,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,c1ccc(Nc2nc3cc4c(cc3s2)C[C@@H]2[C@@H]3CCCC[C@]43CCN2CC2CC2)nc1
CHEMBL1766035,CHEMBL233,Mu opioid receptor,Ki,=,2700.0,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,c1c2c(cc3sc(NN4CCNCC4)nc13)C[C@@H]1[C@@H]3CCCC[C@]23CCN1CC1CC1
CHEMBL1766036,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CN(C)c1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766037,CHEMBL233,Mu opioid receptor,Ki,=,110.0,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CC(=O)N(C)c1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766038,CHEMBL233,Mu opioid receptor,Ki,=,86.0,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CCN(C(C)=O)c1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766039,CHEMBL233,Mu opioid receptor,Ki,=,1.8,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CCC1
CHEMBL1766040,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CCNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CCC1
CHEMBL1766041,CHEMBL233,Mu opioid receptor,Ki,=,7.4,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CCCF
CHEMBL1766042,CHEMBL233,Mu opioid receptor,Ki,=,15.0,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CC(=O)Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CCCF
CHEMBL1766043,CHEMBL233,Mu opioid receptor,Ki,=,4.0,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CCNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CCCF
CHEMBL1766044,CHEMBL233,Mu opioid receptor,Ki,=,24.0,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CCCNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CCCF
CHEMBL1766045,CHEMBL233,Mu opioid receptor,Ki,=,76.0,nM,CHEMBL1769429,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CN(C)c1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CCCF
CHEMBL1774952,CHEMBL233,Mu opioid receptor,Ki,=,2.5,nM,CHEMBL1776827,B,Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,c1c2c(cc3sc(NCCCCCCCCCCNc4nc5cc6c(cc5s4)C[C@@H]4[C@@H]5CCCC[C@]65CCN4CC4CC4)nc13)C[C@@H]1[C@@H]3CCCC[C@]23CCN1CC1CC1
CHEMBL1774951,CHEMBL233,Mu opioid receptor,Ki,=,8.8,nM,CHEMBL1776827,B,Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,O=C(CCCCCCCCC(=O)Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1)Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL242756,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL1776827,B,Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1774950,CHEMBL233,Mu opioid receptor,Ki,=,0.82,nM,CHEMBL1776827,B,Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,C=CCN1CC[C@]23c4c5ccc(OC(=O)CCCCCCCCC(=O)Oc6ccc7c(c6)[C@@]68CCCC[C@@]6(O)[C@@H](C7)N(CC6CCC6)CC8)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL1774949,CHEMBL233,Mu opioid receptor,Ki,=,0.089,nM,CHEMBL1776827,B,Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1774948,CHEMBL233,Mu opioid receptor,Ki,=,0.55,nM,CHEMBL1776827,B,Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,C=CCN1CC[C@]23c4c5ccc(OC(=O)CCCCCCCCC(=O)Oc6ccc7c(c6)[C@@]68CCCC[C@@]6(OC)[C@@H](C7)N(CC6CCC6)CC8)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL1773091,CHEMBL233,Mu opioid receptor,Ki,=,0.15,nM,CHEMBL1776827,B,Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,CO[C@@]12CCCC[C@@]13CCN(CC1CCC1)[C@@H]2Cc1ccc(OC(=O)CCCCCCCCC(=O)OCc2ccccc2)cc13
CHEMBL1774947,CHEMBL233,Mu opioid receptor,Ki,=,0.26,nM,CHEMBL1776827,B,Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,CO[C@@]12CCCC[C@@]13CCN(CC1CCC1)[C@@H]2Cc1ccc(OC(=O)CCCCCCCCC(=O)Oc2ccc4c(c2)[C@@]25CCCC[C@@]2(OC)[C@@H](C4)N(CC2CCC2)CC5)cc13
CHEMBL146756,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL1776827,B,Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,O=C(/C=C/C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL147511,CHEMBL233,Mu opioid receptor,Ki,=,0.09,nM,CHEMBL1776827,B,Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1774946,CHEMBL233,Mu opioid receptor,Ki,=,0.14,nM,CHEMBL1776827,B,Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,CO[C@@]12CCCC[C@@]13CCN(CC1CCC1)[C@@H]2Cc1ccc(O)cc13
CHEMBL33986,CHEMBL233,Mu opioid receptor,Ki,=,0.22,nM,CHEMBL1776827,B,Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL301160,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL1776827,B,Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL1776827,B,Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,0.5623,nM,CHEMBL1786446,B,Displacement of [3H]DPN from human recombinant mu-type opioid receptor expressed in CHO cell membranes,CHEMBL1781947,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL1783826,CHEMBL233,Mu opioid receptor,Ki,=,190.55,nM,CHEMBL1786446,B,Displacement of [3H]DPN from human recombinant mu-type opioid receptor expressed in CHO cell membranes,CHEMBL1781947,KI,O=C(NCCCN1CCC(c2c(Cl)cccc2Cl)CC1)[C@H]1CCCN1Cc1ccccc1
CHEMBL1795711,CHEMBL233,Mu opioid receptor,Ki,=,2.5,nM,CHEMBL1799266,B,Displacement of [3H]-DAMGO from MOR-1 expressed in CHO cells after 150 mins,CHEMBL1795226,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cccc(I)c1
CHEMBL1795712,CHEMBL233,Mu opioid receptor,Ki,=,0.7,nM,CHEMBL1799266,B,Displacement of [3H]-DAMGO from MOR-1 expressed in CHO cells after 150 mins,CHEMBL1795226,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@H](NC(=O)c2cccc(I)c2)CC[C@@]3(O)[C@H]1C5
CHEMBL1795713,CHEMBL233,Mu opioid receptor,Ki,=,1.75,nM,CHEMBL1799266,B,Displacement of [3H]-DAMGO from MOR-1 expressed in CHO cells after 150 mins,CHEMBL1795226,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@H](NC(=O)c2cccc(I)c2)CC[C@@]3(O)[C@H]1C5
CHEMBL1795717,CHEMBL233,Mu opioid receptor,Ki,=,2.33,nM,CHEMBL1799272,B,Displacement of [125I]-IBNtxA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,C[C@@H](O)[C@H](NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC1(C)C)C(N)=O
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,4.23,nM,CHEMBL1799272,B,Displacement of [125I]-IBNtxA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL1254682,CHEMBL233,Mu opioid receptor,Ki,=,1.29,nM,CHEMBL1799272,B,Displacement of [125I]-IBNtxA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,C=CCN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,1.15,nM,CHEMBL1799272,B,Displacement of [125I]-IBNtxA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,3.34,nM,CHEMBL1799272,B,Displacement of [125I]-IBNtxA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,4.6,nM,CHEMBL1799272,B,Displacement of [125I]-IBNtxA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL1795717,CHEMBL233,Mu opioid receptor,Ki,=,2.96,nM,CHEMBL1799273,B,Displacement of [125I]-IBNalA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,C[C@@H](O)[C@H](NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC1(C)C)C(N)=O
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,2.27,nM,CHEMBL1799273,B,Displacement of [125I]-IBNalA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL1254682,CHEMBL233,Mu opioid receptor,Ki,=,1.69,nM,CHEMBL1799273,B,Displacement of [125I]-IBNalA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,C=CCN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,2.71,nM,CHEMBL1799273,B,Displacement of [125I]-IBNalA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,0.45,nM,CHEMBL1799273,B,Displacement of [125I]-IBNalA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,2.52,nM,CHEMBL1799273,B,Displacement of [125I]-IBNalA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL1795717,CHEMBL233,Mu opioid receptor,Ki,=,1.06,nM,CHEMBL1799274,B,Displacement of [125I]-IBOxyA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,C[C@@H](O)[C@H](NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC1(C)C)C(N)=O
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,0.57,nM,CHEMBL1799274,B,Displacement of [125I]-IBOxyA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL1254682,CHEMBL233,Mu opioid receptor,Ki,=,0.48,nM,CHEMBL1799274,B,Displacement of [125I]-IBOxyA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,C=CCN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.07,nM,CHEMBL1799274,B,Displacement of [125I]-IBOxyA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,1.55,nM,CHEMBL1799274,B,Displacement of [125I]-IBOxyA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,1.92,nM,CHEMBL1799274,B,Displacement of [125I]-IBOxyA from MOR-1 expressed in CHO cells,CHEMBL1795226,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL1808383,CHEMBL233,Mu opioid receptor,Ki,=,168.0,nM,CHEMBL1811688,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1806441,KI,CS(=O)(=O)Nc1cccc([C@H]2[C@@H]3CN(CCCc4ccccc4)C[C@@H]32)c1
CHEMBL1808384,CHEMBL233,Mu opioid receptor,Ki,=,4.79,nM,CHEMBL1811688,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1806441,KI,C[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CCCc3ccccc3)C[C@@H]21
CHEMBL1808300,CHEMBL233,Mu opioid receptor,Ki,=,167.0,nM,CHEMBL1809749,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells coexpressing human recombinant MOR after 2 hrs by liquid scintillation counting,CHEMBL1806350,KI,Oc1cccc2c1O[C@@H]1CC[C@@H]3C[C@]21CCN3CCc1ccccc1
CHEMBL1808302,CHEMBL233,Mu opioid receptor,Ki,=,486.0,nM,CHEMBL1809749,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells coexpressing human recombinant MOR after 2 hrs by liquid scintillation counting,CHEMBL1806350,KI,Oc1ccc2c(c1)[C@]13CCN(CCc4ccccc4)[C@H](CC[C@H]1O2)C3
CHEMBL1808303,CHEMBL233,Mu opioid receptor,Ki,=,250.0,nM,CHEMBL1809749,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells coexpressing human recombinant MOR after 2 hrs by liquid scintillation counting,CHEMBL1806350,KI,Oc1ccc2c(c1)[C@]13CCN(CCc4ccccc4)[C@H](CC[C@@H]1O2)C3
CHEMBL515681,CHEMBL233,Mu opioid receptor,Ki,=,352.0,nM,CHEMBL1809749,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells coexpressing human recombinant MOR after 2 hrs by liquid scintillation counting,CHEMBL1806350,KI,Oc1ccc2c(c1)[C@@]13CCN(CCc4ccccc4)[C@@H](CC[C@H]1O2)C3
CHEMBL1808304,CHEMBL233,Mu opioid receptor,Ki,=,384.0,nM,CHEMBL1809749,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells coexpressing human recombinant MOR after 2 hrs by liquid scintillation counting,CHEMBL1806350,KI,Oc1cccc2c1O[C@H]1CC[C@@H]3C[C@]21CCN3CCc1ccccc1
CHEMBL515842,CHEMBL233,Mu opioid receptor,Ki,=,49.0,nM,CHEMBL1809749,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells coexpressing human recombinant MOR after 2 hrs by liquid scintillation counting,CHEMBL1806350,KI,Oc1cccc2c1O[C@@H]1CC[C@H]3C[C@@]21CCN3CCc1ccccc1
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,2.55,nM,CHEMBL1809749,B,Displacement of [125I]IOXY from human mu opioid receptor expressed in CHO cells coexpressing human recombinant MOR after 2 hrs by liquid scintillation counting,CHEMBL1806350,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL1814702,CHEMBL233,Mu opioid receptor,Ki,=,619.0,nM,CHEMBL1816052,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL1811836,KI,CN1C[C@H]2Oc3c(O)cccc3[C@@]23CCC[C@@H]1C3
CHEMBL1814703,CHEMBL233,Mu opioid receptor,Ki,=,1500.0,nM,CHEMBL1816052,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL1811836,KI,CN1C[C@H]2Oc3ccc(O)cc3[C@@]23CCC[C@@H]1C3
CHEMBL1814704,CHEMBL233,Mu opioid receptor,Ki,=,67.0,nM,CHEMBL1816052,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL1811836,KI,Oc1ccc2c(c1)[C@]13CCC[C@H](C1)N(CCc1ccccc1)C[C@H]3O2
CHEMBL1814705,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL1816052,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL1811836,KI,Oc1cccc2c1O[C@@H]1CN(CCc3ccccc3)[C@@H]3CCC[C@]21C3
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,2.6,nM,CHEMBL1816052,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL1811836,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL573214,CHEMBL233,Mu opioid receptor,Ki,=,79.9,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL1818336,CHEMBL233,Mu opioid receptor,Ki,=,109.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CO[C@@H]1CCCN1S(=O)(=O)c1ccccc1-c1ccc(CNCC(C)C)cc1
CHEMBL1818337,CHEMBL233,Mu opioid receptor,Ki,=,198.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)N2CCOC[C@H]2C)cc1
CHEMBL1818338,CHEMBL233,Mu opioid receptor,Ki,=,508.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)NC(C)C)cc1
CHEMBL1818339,CHEMBL233,Mu opioid receptor,Ki,=,391.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)N(C)S(=O)(=O)c1ccccc1-c1ccc(CNC2CCCC2)cc1
CHEMBL1818340,CHEMBL233,Mu opioid receptor,Ki,=,1260.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)N(C)S(=O)(=O)c1ccccc1-c1ccc(CN2CCCCC2)cc1
CHEMBL1818341,CHEMBL233,Mu opioid receptor,Ki,=,64.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)N2CCCC2)cc1
CHEMBL1818342,CHEMBL233,Mu opioid receptor,Ki,=,751.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)N2CCC(F)(F)C2)cc1
CHEMBL1818222,CHEMBL233,Mu opioid receptor,Ki,=,684.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CN(C)Cc1ccc(-c2ccccc2S(=O)(=O)N2CCCC2)cc1
CHEMBL1818326,CHEMBL233,Mu opioid receptor,Ki,=,1007.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,O=S(=O)(c1ccccc1-c1ccc(CNC2CCOCC2)cc1)N1CCC(F)(F)C1
CHEMBL1818327,CHEMBL233,Mu opioid receptor,Ki,=,740.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,C[C@@H]1COCCN1S(=O)(=O)c1ccccc1-c1ccc(CNC2CCOCC2)cc1
CHEMBL1818328,CHEMBL233,Mu opioid receptor,Ki,=,70.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,O=S(=O)(c1ccccc1-c1ccc(CNC2CCOCC2)cc1)N1CCCC1
CHEMBL1818329,CHEMBL233,Mu opioid receptor,Ki,=,433.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,COC[C@H](C)NCc1ccc(-c2ccccc2S(=O)(=O)N2CCCC2)cc1
CHEMBL1818330,CHEMBL233,Mu opioid receptor,Ki,=,89.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,COC1CCN(Cc2ccc(-c3ccccc3S(=O)(=O)N3CCCC3)cc2)CC1
CHEMBL1818331,CHEMBL233,Mu opioid receptor,Ki,=,101.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CN(C)CCNCc1ccc(-c2ccccc2S(=O)(=O)N2CCCC2)cc1
CHEMBL1818332,CHEMBL233,Mu opioid receptor,Ki,=,193.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC1(CNCc2ccc(-c3ccccc3S(=O)(=O)N3CCCC3)cc2)COC1
CHEMBL1818233,CHEMBL233,Mu opioid receptor,Ki,=,94.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC1(O)CCN(Cc2ccc(-c3ccccc3S(=O)(=O)N3CCCC3)cc2)CC1
CHEMBL1818234,CHEMBL233,Mu opioid receptor,Ki,=,66.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,O=S(=O)(c1ccccc1-c1ccc(CN2C[C@@H]3CCC[C@H]2C3)cc1)N1CCCC1
CHEMBL1818235,CHEMBL233,Mu opioid receptor,Ki,=,207.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,COC[C@@H]1CCCN1S(=O)(=O)c1ccccc1-c1ccc(CN2C[C@@H]3CCC[C@H]2C3)cc1
CHEMBL1818236,CHEMBL233,Mu opioid receptor,Ki,=,32.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,O=S(=O)(c1ccccc1-c1ccc(CN2CCC(CCO)CC2)cc1)N1CCCC[C@H]1CO
CHEMBL1818237,CHEMBL233,Mu opioid receptor,Ki,=,932.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)N2CCCC2)cn1
CHEMBL1818324,CHEMBL233,Mu opioid receptor,Ki,=,378.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)N2CCOC[C@H]2C)cc1F
CHEMBL1818325,CHEMBL233,Mu opioid receptor,Ki,=,112.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,O=S(=O)(c1ccccc1-c1ccc(CN2CCC(CCO)CC2)c(F)c1)N1CCCCC1
CHEMBL1818223,CHEMBL233,Mu opioid receptor,Ki,=,763.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)N2CCCC2)nc1
CHEMBL1818228,CHEMBL233,Mu opioid receptor,Ki,=,1327.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)(C)CCNCc1ccc(-c2cnccc2S(=O)(=O)N2CCCC2)cc1
CHEMBL1818230,CHEMBL233,Mu opioid receptor,Ki,=,163.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2cccnc2S(=O)(=O)N2CCCC2)cc1
CHEMBL1818231,CHEMBL233,Mu opioid receptor,Ki,=,735.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,O=S(=O)(c1ncccc1-c1ccc(CN2C[C@@H]3CCC[C@H]2C3)cc1)N1CCCC1
CHEMBL1818232,CHEMBL233,Mu opioid receptor,Ki,=,39.0,nM,CHEMBL1820179,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)(C)CCNCc1ccc(-c2cccnc2S(=O)(=O)N2CCCC2)cc1
CHEMBL1818334,CHEMBL233,Mu opioid receptor,Ki,=,1.69,nM,CHEMBL1820307,B,Agonist activity at human mu opioid receptor by GTPgamma S binding assay,CHEMBL1817540,KI,CC(C)C[C@]1(c2cccc(O)c2)CCN(CC2CC2)C1
CHEMBL1818335,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL1820307,B,Agonist activity at human mu opioid receptor by GTPgamma S binding assay,CHEMBL1817540,KI,O=S(=O)(c1ccccc1-c1ccc(CN[C@H]2c3ccccc3C[C@H]2O)cc1)N1CCCCC1
CHEMBL1824509,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL1828461,B,Displacement of [3H]naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cl.O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccnc(Cl)c1
CHEMBL1824510,CHEMBL233,Mu opioid receptor,Ki,=,0.63,nM,CHEMBL1828461,B,Displacement of [3H]naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cl.O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccnc(Br)c1
CHEMBL1824512,CHEMBL233,Mu opioid receptor,Ki,=,0.39,nM,CHEMBL1828461,B,Displacement of [3H]naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cc1cc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)ccn1.Cl
CHEMBL1824514,CHEMBL233,Mu opioid receptor,Ki,=,0.67,nM,CHEMBL1828461,B,Displacement of [3H]naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cl.O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1Cl
CHEMBL1824513,CHEMBL233,Mu opioid receptor,Ki,=,0.45,nM,CHEMBL1828461,B,Displacement of [3H]naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cl.O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1Br
CHEMBL1824515,CHEMBL233,Mu opioid receptor,Ki,=,0.58,nM,CHEMBL1828461,B,Displacement of [3H]naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cc1cnccc1C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5.Cl
CHEMBL1824516,CHEMBL233,Mu opioid receptor,Ki,=,0.85,nM,CHEMBL1828461,B,Displacement of [3H]naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cl.O=C(Cc1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1824511,CHEMBL233,Mu opioid receptor,Ki,=,0.57,nM,CHEMBL1828461,B,Displacement of [3H]naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cl.O=C(CCc1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1824517,CHEMBL233,Mu opioid receptor,Ki,=,0.73,nM,CHEMBL1828461,B,Displacement of [3H]naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cl.O=C(CNC(=O)c1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1824518,CHEMBL233,Mu opioid receptor,Ki,=,0.87,nM,CHEMBL1828461,B,Displacement of [3H]naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,CN1CCC(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)CC1.Cl
CHEMBL511142,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL1838909,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL1834409,CHEMBL233,Mu opioid receptor,Ki,=,2.14,nM,CHEMBL1838909,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CCC(C)(C)[C@](C)(O)[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL1834410,CHEMBL233,Mu opioid receptor,Ki,=,2.95,nM,CHEMBL1838909,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)CC(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL1834411,CHEMBL233,Mu opioid receptor,Ki,=,2.19,nM,CHEMBL1838909,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)CC(C)(C)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL1834412,CHEMBL233,Mu opioid receptor,Ki,=,5.56,nM,CHEMBL1838909,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@](C)(O)c1ccc(C(C)(C)C)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL1834413,CHEMBL233,Mu opioid receptor,Ki,=,11.4,nM,CHEMBL1838909,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)CC1CC4CCC1C4)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL1834414,CHEMBL233,Mu opioid receptor,Ki,=,14.3,nM,CHEMBL1838909,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@](C)(O)C(C)(C)C)[C@H]1Cc4c(Br)cc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL1834415,CHEMBL233,Mu opioid receptor,Ki,=,13.2,nM,CHEMBL1838909,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@](C)(O)C(C)(C)C)[C@H]1Cc4c(Cl)cc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL1834416,CHEMBL233,Mu opioid receptor,Ki,=,10.5,nM,CHEMBL1838909,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@](C)(O)C(C)(C)C)[C@H]1Cc4cc(Br)c(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL396460,CHEMBL233,Mu opioid receptor,Ki,=,437.0,nM,CHEMBL1838909,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,1.59,nM,CHEMBL1838909,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL294616,CHEMBL233,Mu opioid receptor,Ki,=,504.0,nM,CHEMBL1838909,B,Displacement of [3H]DAMGO from human MOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CC1(C)SSC(C)(C)[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H]1C(=O)O
CHEMBL508112,CHEMBL233,Mu opioid receptor,Ki,=,1264.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,c1ccc2sc(SSc3nc4ccccc4s3)nc2c1
CHEMBL290106,CHEMBL233,Mu opioid receptor,Ki,=,2236.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O
CHEMBL296419,CHEMBL233,Mu opioid receptor,Ki,=,606.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
CHEMBL633,CHEMBL233,Mu opioid receptor,Ki,=,7728.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1
CHEMBL1403281,CHEMBL233,Mu opioid receptor,Ki,=,985.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
CHEMBL64894,CHEMBL233,Mu opioid receptor,Ki,=,871.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1.[Cl-]
CHEMBL808,CHEMBL233,Mu opioid receptor,Ki,=,2311.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
CHEMBL30008,CHEMBL233,Mu opioid receptor,Ki,=,2125.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1
CHEMBL726,CHEMBL233,Mu opioid receptor,Ki,=,8421.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
CHEMBL691,CHEMBL233,Mu opioid receptor,Ki,=,10867.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C
CHEMBL54,CHEMBL233,Mu opioid receptor,Ki,=,992.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
CHEMBL139835,CHEMBL233,Mu opioid receptor,Ki,=,886.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
CHEMBL1255837,CHEMBL233,Mu opioid receptor,Ki,=,345.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CS(=O)(=O)O
CHEMBL104,CHEMBL233,Mu opioid receptor,Ki,=,731.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
CHEMBL964,CHEMBL233,Mu opioid receptor,Ki,=,1425.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CCN(CC)C(=S)SSC(=S)N(CC)CC
CHEMBL411,CHEMBL233,Mu opioid receptor,Ki,=,2345.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1
CHEMBL71,CHEMBL233,Mu opioid receptor,Ki,=,5844.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
CHEMBL43064,CHEMBL233,Mu opioid receptor,Ki,=,922.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL219916,CHEMBL233,Mu opioid receptor,Ki,=,1712.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1
CHEMBL1479,CHEMBL233,Mu opioid receptor,Ki,=,5715.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C
CHEMBL584,CHEMBL233,Mu opioid receptor,Ki,=,5859.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,1.657,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1618305,CHEMBL233,Mu opioid receptor,Ki,=,2.921,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2/C(=N/N=C2\CC[C@@]4(O)[C@H]6Cc7ccc(O)c8c7[C@@]4(CCN6CC=C)[C@H]2O8)CC[C@@]3(O)[C@H]1C5
CHEMBL91,CHEMBL233,Mu opioid receptor,Ki,=,2460.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,8.063,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL1276308,CHEMBL233,Mu opioid receptor,Ki,=,997.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
CHEMBL841,CHEMBL233,Mu opioid receptor,Ki,=,0.586,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
CHEMBL895,CHEMBL233,Mu opioid receptor,Ki,=,9.925,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL141343,CHEMBL233,Mu opioid receptor,Ki,=,4363.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,Cc1c(C)c2c(c(C)c1O)CCC(C)(CN1CCN(c3cc(N4CCCC4)nc(N4CCCC4)n3)CC1)O2
CHEMBL772,CHEMBL233,Mu opioid receptor,Ki,=,1686.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC
CHEMBL18797,CHEMBL233,Mu opioid receptor,Ki,=,13667.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CSc1ccc(/C=C2/C(C)=C(CC(=O)O)c3cc(F)ccc32)cc1
CHEMBL83,CHEMBL233,Mu opioid receptor,Ki,=,7142.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
CHEMBL163,CHEMBL233,Mu opioid receptor,Ki,=,26606.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
CHEMBL114,CHEMBL233,Mu opioid receptor,Ki,=,3907.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1
CHEMBL81,CHEMBL233,Mu opioid receptor,Ki,=,477.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12
CHEMBL118865,CHEMBL233,Mu opioid receptor,Ki,=,95.0,nM,CHEMBL1909182,B,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)C1CCC2(CCCO2)CC1N1CCCC1
CHEMBL573214,CHEMBL233,Mu opioid receptor,Ki,=,32.4,nM,CHEMBL1924793,B,Displacement of [3H]diprenorphine from human opioid mu receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL415247,CHEMBL233,Mu opioid receptor,Ki,=,11.5,nM,CHEMBL1924793,B,Displacement of [3H]diprenorphine from human opioid mu receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1
CHEMBL575508,CHEMBL233,Mu opioid receptor,Ki,=,30.8,nM,CHEMBL1924793,B,Displacement of [3H]diprenorphine from human opioid mu receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1C
CHEMBL277863,CHEMBL233,Mu opioid receptor,Ki,=,34.7,nM,CHEMBL1924793,B,Displacement of [3H]diprenorphine from human opioid mu receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,COC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)[C@H](CN2CCCC2)C1
CHEMBL238316,CHEMBL233,Mu opioid receptor,Ki,=,2.43,nM,CHEMBL1924793,B,Displacement of [3H]diprenorphine from human opioid mu receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,NC(=O)c1ccc(Oc2ccc(CNCc3ccccc3)cc2)nc1
CHEMBL1921839,CHEMBL233,Mu opioid receptor,Ki,=,232.0,nM,CHEMBL1924793,B,Displacement of [3H]diprenorphine from human opioid mu receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,NC(=O)c1ccc(Oc2ccc(CN3CCCC3c3ccccc3)cc2)nc1
CHEMBL1921840,CHEMBL233,Mu opioid receptor,Ki,=,39.6,nM,CHEMBL1924793,B,Displacement of [3H]diprenorphine from human opioid mu receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,NC(=O)c1ccc(Oc2ccc(CN3CCCC3c3cccnc3)cc2)nc1
CHEMBL1921841,CHEMBL233,Mu opioid receptor,Ki,=,31.5,nM,CHEMBL1924793,B,Displacement of [3H]diprenorphine from human opioid mu receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,NC(=O)c1ccc(Oc2ccc(CN3CCCC3c3cccnc3)cc2)c(Cl)c1
CHEMBL1921842,CHEMBL233,Mu opioid receptor,Ki,=,25.8,nM,CHEMBL1924793,B,Displacement of [3H]diprenorphine from human opioid mu receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,NC(=O)c1ccc(Oc2ccc(CN3CCC[C@H]3c3cccnc3)cc2)c(Cl)c1
CHEMBL1921844,CHEMBL233,Mu opioid receptor,Ki,=,41.1,nM,CHEMBL1924793,B,Displacement of [3H]diprenorphine from human opioid mu receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,NC(=O)c1ccc(Oc2ccc(CN3CCCC3c3cccc(F)c3)cc2)c(F)c1
CHEMBL1921845,CHEMBL233,Mu opioid receptor,Ki,=,35.8,nM,CHEMBL1924793,B,Displacement of [3H]diprenorphine from human opioid mu receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,NC(=O)c1ccc(Oc2ccc(CN3CCC[C@H]3c3cccc(F)c3)cc2)c(F)c1
CHEMBL1921847,CHEMBL233,Mu opioid receptor,Ki,=,22.7,nM,CHEMBL1924793,B,Displacement of [3H]diprenorphine from human opioid mu receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,Cc1cc(C)cc([C@@H]2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1
CHEMBL1921848,CHEMBL233,Mu opioid receptor,Ki,=,101.0,nM,CHEMBL1924793,B,Displacement of [3H]diprenorphine from human opioid mu receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,Cc1cc(C)cc([C@H]2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1
CHEMBL1921849,CHEMBL233,Mu opioid receptor,Ki,=,52.7,nM,CHEMBL1924793,B,Displacement of [3H]diprenorphine from human opioid mu receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,CC1(C)CN(Cc2ccc(Oc3ccc(C(N)=O)cn3)cc2)C1c1ccccc1
CHEMBL1921850,CHEMBL233,Mu opioid receptor,Ki,=,43.1,nM,CHEMBL1924793,B,Displacement of [3H]diprenorphine from human opioid mu receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,CC1(C)CN(Cc2ccc(Oc3ccc(C(N)=O)cn3)cc2)[C@@H]1c1ccccc1
CHEMBL1921851,CHEMBL233,Mu opioid receptor,Ki,=,107.0,nM,CHEMBL1924793,B,Displacement of [3H]diprenorphine from human opioid mu receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,CC1(C)CN(Cc2ccc(Oc3ccc(C(N)=O)cn3)cc2)[C@H]1c1ccccc1
CHEMBL1939698,CHEMBL233,Mu opioid receptor,Ki,=,481.0,nM,CHEMBL1941653,B,Binding affinity to mu opioid receptor,CHEMBL1938297,KI,FCC1OC2(CCN(Cc3ccccc3)CC2)c2ccccc21
CHEMBL1645202,CHEMBL233,Mu opioid receptor,Ki,=,456.0,nM,CHEMBL1941653,B,Binding affinity to mu opioid receptor,CHEMBL1938297,KI,FCCC1OC2(CCN(Cc3ccccc3)CC2)c2ccccc21
CHEMBL575994,CHEMBL233,Mu opioid receptor,Ki,=,246.0,nM,CHEMBL1941653,B,Binding affinity to mu opioid receptor,CHEMBL1938297,KI,FCCCC1OC2(CCN(Cc3ccccc3)CC2)c2ccccc21
CHEMBL1939699,CHEMBL233,Mu opioid receptor,Ki,=,605.0,nM,CHEMBL1941653,B,Binding affinity to mu opioid receptor,CHEMBL1938297,KI,FCCCCC1OC2(CCN(Cc3ccccc3)CC2)c2ccccc21
CHEMBL1951699,CHEMBL233,Mu opioid receptor,Ki,=,138.0,nM,CHEMBL1955135,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting,CHEMBL1949670,KI,CN1C[C@H](O)[C@]2(c3cccc(O)c3)CCC[C@H]1C2
CHEMBL1951701,CHEMBL233,Mu opioid receptor,Ki,=,74.0,nM,CHEMBL1955135,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting,CHEMBL1949670,KI,Oc1cccc([C@@]23CCC[C@@H](C2)N(CCc2ccccc2)C[C@@H]3O)c1
CHEMBL1951700,CHEMBL233,Mu opioid receptor,Ki,=,346.0,nM,CHEMBL1955135,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting,CHEMBL1949670,KI,CN1C[C@@H](O)[C@]2(c3cccc(O)c3)CCC[C@H]1C2
CHEMBL1951702,CHEMBL233,Mu opioid receptor,Ki,=,4.6,nM,CHEMBL1955135,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting,CHEMBL1949670,KI,Oc1cccc([C@@]23CCC[C@@H](C2)N(CCc2ccccc2)C[C@H]3O)c1
CHEMBL1951704,CHEMBL233,Mu opioid receptor,Ki,=,315.0,nM,CHEMBL1955135,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting,CHEMBL1949670,KI,CN1C2CCC[C@@](c3cccc(O)c3)(C2)[C@@H]1CO
CHEMBL1951705,CHEMBL233,Mu opioid receptor,Ki,=,22.0,nM,CHEMBL1955135,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting,CHEMBL1949670,KI,CN1CC2(OCCO2)[C@]2(c3cccc(O)c3)CCC[C@H]1C2
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,2.6,nM,CHEMBL1955135,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting,CHEMBL1949670,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL1955135,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting,CHEMBL1949670,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL440765,CHEMBL233,Mu opioid receptor,Ki,=,2370.0,nM,CHEMBL1955135,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting,CHEMBL1949670,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL1808384,CHEMBL233,Mu opioid receptor,Ki,=,4.8,nM,CHEMBL1958666,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1955785,KI,C[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CCCc3ccccc3)C[C@@H]21
CHEMBL1808384,CHEMBL233,Mu opioid receptor,Ki,=,3.5,nM,CHEMBL1958664,B,Antagonist activity at human mu opioid receptor by GTP-gamma S binding assay,CHEMBL1955785,KI,C[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CCCc3ccccc3)C[C@@H]21
CHEMBL1957717,CHEMBL233,Mu opioid receptor,Ki,=,0.81,nM,CHEMBL1958666,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1955785,KI,C[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC3Cc4ccccc4C3)C[C@@H]21
CHEMBL1957717,CHEMBL233,Mu opioid receptor,Ki,=,0.3,nM,CHEMBL1958664,B,Antagonist activity at human mu opioid receptor by GTP-gamma S binding assay,CHEMBL1955785,KI,C[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC3Cc4ccccc4C3)C[C@@H]21
CHEMBL1957842,CHEMBL233,Mu opioid receptor,Ki,=,6.6,nM,CHEMBL1958666,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1955785,KI,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC(O)Cc3ccccc3)C[C@@H]21
CHEMBL1957842,CHEMBL233,Mu opioid receptor,Ki,=,2.5,nM,CHEMBL1958664,B,Antagonist activity at human mu opioid receptor by GTP-gamma S binding assay,CHEMBL1955785,KI,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC(O)Cc3ccccc3)C[C@@H]21
CHEMBL1957843,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL1958666,B,Displacement of [3H]DAMGO from human mu opioid receptor,CHEMBL1955785,KI,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC3Cc4ccccc4C3O)C[C@@H]21
CHEMBL1957843,CHEMBL233,Mu opioid receptor,Ki,=,0.08,nM,CHEMBL1958664,B,Antagonist activity at human mu opioid receptor by GTP-gamma S binding assay,CHEMBL1955785,KI,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC3Cc4ccccc4C3O)C[C@@H]21
CHEMBL445332,CHEMBL233,Mu opioid receptor,Ki,=,1370.0,nM,CHEMBL2026565,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL2022018,CHEMBL233,Mu opioid receptor,Ki,=,2600.0,nM,CHEMBL2026565,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](/C=C\c3ccoc3)C[C@]21C
CHEMBL2022019,CHEMBL233,Mu opioid receptor,Ki,=,1490.0,nM,CHEMBL2026565,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3ccccc3)C[C@]21C
CHEMBL2022021,CHEMBL233,Mu opioid receptor,Ki,=,3090.0,nM,CHEMBL2026565,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3cccc(OC)c3)C[C@]21C
CHEMBL2022293,CHEMBL233,Mu opioid receptor,Ki,=,3600.0,nM,CHEMBL2026565,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3ccccc3O)C[C@]21C
CHEMBL2022298,CHEMBL233,Mu opioid receptor,Ki,=,4800.0,nM,CHEMBL2026565,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3cccc(OC(F)(F)F)c3)C[C@]21C
CHEMBL2022299,CHEMBL233,Mu opioid receptor,Ki,=,3400.0,nM,CHEMBL2026565,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3cccc(C(F)(F)F)c3)C[C@]21C
CHEMBL2022300,CHEMBL233,Mu opioid receptor,Ki,=,9800.0,nM,CHEMBL2026565,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3ccco3)C[C@]21C
CHEMBL2022302,CHEMBL233,Mu opioid receptor,Ki,=,2530.0,nM,CHEMBL2026565,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3ccsc3)C[C@]21C
CHEMBL3215669,CHEMBL233,Mu opioid receptor,Ki,=,0.43,nM,CHEMBL2051428,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK-293 cells by scintillation counting,CHEMBL2046316,KI,CCOc1ccc(Cc2nc3cc([N+](=O)[O-])ccc3n2CCC2CCCN2C)cc1.Cl.Cl
CHEMBL3216999,CHEMBL233,Mu opioid receptor,Ki,=,5.41,nM,CHEMBL2051428,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK-293 cells by scintillation counting,CHEMBL2046316,KI,CCOc1ccc(Cc2nc3cc(NC(=N)c4cccs4)ccc3n2CCN(CC)CC)cc1.Cl.Cl
CHEMBL3217000,CHEMBL233,Mu opioid receptor,Ki,=,110.0,nM,CHEMBL2051428,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK-293 cells by scintillation counting,CHEMBL2046316,KI,CCOc1ccc(Cc2nc3cc(NC(=N)c4cccs4)ccc3n2CCN(C)C)cc1.Cl.Cl
CHEMBL3216780,CHEMBL233,Mu opioid receptor,Ki,=,170.0,nM,CHEMBL2051428,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK-293 cells by scintillation counting,CHEMBL2046316,KI,CCOc1ccc(Cc2nc3cc(NC(=N)c4cccs4)ccc3n2CCC2CCCN2C)cc1.Cl.Cl
CHEMBL3215885,CHEMBL233,Mu opioid receptor,Ki,=,2900.0,nM,CHEMBL2051428,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK-293 cells by scintillation counting,CHEMBL2046316,KI,CCOc1ccc(Cc2nc3cc(NC(=N)c4cccs4)ccc3n2C2CCN(C)CC2)cc1.Cl.Cl
CHEMBL3215667,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL2051428,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK-293 cells by scintillation counting,CHEMBL2046316,KI,CCOc1ccc(Cc2nc3cc(NC(=N)c4ccco4)ccc3n2CCN(CC)CC)cc1.Cl.Cl
CHEMBL3217210,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL2051428,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK-293 cells by scintillation counting,CHEMBL2046316,KI,CCOc1ccc(Cc2nc3cc(NC(=N)c4ccsc4)ccc3n2CCN(CC)CC)cc1.Cl.Cl
CHEMBL3216560,CHEMBL233,Mu opioid receptor,Ki,=,42.0,nM,CHEMBL2051428,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK-293 cells by scintillation counting,CHEMBL2046316,KI,CCOc1ccc(Cc2nc3cc(NC(=N)c4ccoc4)ccc3n2CCN(CC)CC)cc1.Cl.Cl
CHEMBL3217211,CHEMBL233,Mu opioid receptor,Ki,=,48.0,nM,CHEMBL2051428,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK-293 cells by scintillation counting,CHEMBL2046316,KI,CCOc1ccc(Cc2nc3cc(NC(C)=N)ccc3n2CCN(CC)CC)cc1.Cl.Cl
CHEMBL3215668,CHEMBL233,Mu opioid receptor,Ki,=,7.5,nM,CHEMBL2051428,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK-293 cells by scintillation counting,CHEMBL2046316,KI,CCOc1ccc(Cc2nc3cc(NC(=N)N[N+](=O)[O-])ccc3n2CCN(CC)CC)cc1.Cl.Cl
CHEMBL3217001,CHEMBL233,Mu opioid receptor,Ki,=,7.8,nM,CHEMBL2051428,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK-293 cells by scintillation counting,CHEMBL2046316,KI,CCOc1ccc(Cc2nc3ccc(NC(=N)c4cccs4)cc3n2CCN(CC)CC)cc1.Cl.Cl
CHEMBL1201776,CHEMBL233,Mu opioid receptor,Ki,=,160.0,nM,CHEMBL2051428,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK-293 cells by scintillation counting,CHEMBL2046316,KI,CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,2.2,nM,CHEMBL2051428,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK-293 cells by scintillation counting,CHEMBL2046316,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL2048787,CHEMBL233,Mu opioid receptor,Ki,=,44.0,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,CN1CC[C@]23c4c5ccc(NCc6ccc(O)cc6)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL2048786,CHEMBL233,Mu opioid receptor,Ki,=,7.0,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,CN1CC[C@]23c4c5ccc(NCc6cccc(O)c6)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL2048785,CHEMBL233,Mu opioid receptor,Ki,=,13.0,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,CN1CC[C@]23c4c5ccc(NCc6ccccc6O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL2048784,CHEMBL233,Mu opioid receptor,Ki,=,60.0,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,COc1ccc(CNc2ccc3c4c2O[C@H]2[C@@H](O)C=C[C@H]5[C@@H](C3)N(C)CC[C@@]452)cc1
CHEMBL2048783,CHEMBL233,Mu opioid receptor,Ki,=,45.0,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,COc1cccc(CNc2ccc3c4c2O[C@H]2[C@@H](O)C=C[C@H]5[C@@H](C3)N(C)CC[C@@]452)c1
CHEMBL2048782,CHEMBL233,Mu opioid receptor,Ki,=,8.5,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,COc1ccccc1CNc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
CHEMBL1457,CHEMBL233,Mu opioid receptor,Ki,=,9.5,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,0.88,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL2048781,CHEMBL233,Mu opioid receptor,Ki,=,150.0,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,Oc1cccc(CNc2ccc3c(c2)C[C@@H]2[C@@H]4CCCC[C@]34CCN2CC2CC2)c1
CHEMBL2048780,CHEMBL233,Mu opioid receptor,Ki,=,3.2,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,CN(Cc1ccc(O)cc1)c1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL2048779,CHEMBL233,Mu opioid receptor,Ki,=,17.0,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,CN(Cc1cccc(O)c1)c1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL2048778,CHEMBL233,Mu opioid receptor,Ki,=,26.0,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,CN(Cc1ccc(Cl)cc1)c1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL2048777,CHEMBL233,Mu opioid receptor,Ki,=,9.5,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,COc1ccc(CN(C)c2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL2048776,CHEMBL233,Mu opioid receptor,Ki,=,13.0,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,COc1cccc(CN(C)c2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)c1
CHEMBL2048775,CHEMBL233,Mu opioid receptor,Ki,=,14.0,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,COc1ccccc1CN(C)c1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL2048774,CHEMBL233,Mu opioid receptor,Ki,=,0.42,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(NCc2cccc(O)c2)cc13
CHEMBL2048773,CHEMBL233,Mu opioid receptor,Ki,=,0.28,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,Oc1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL2048772,CHEMBL233,Mu opioid receptor,Ki,=,0.16,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,Oc1cccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)c1
CHEMBL2048771,CHEMBL233,Mu opioid receptor,Ki,=,1.9,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,Oc1ccccc1CNc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL2048770,CHEMBL233,Mu opioid receptor,Ki,=,0.35,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,Oc1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL2048769,CHEMBL233,Mu opioid receptor,Ki,=,0.32,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,Oc1cccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)c1
CHEMBL2048768,CHEMBL233,Mu opioid receptor,Ki,=,1.7,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,Oc1ccccc1CNc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL2048767,CHEMBL233,Mu opioid receptor,Ki,=,0.43,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,O=[N+]([O-])c1cccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)c1
CHEMBL2048766,CHEMBL233,Mu opioid receptor,Ki,=,0.17,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,c1cc2c(cc1CNc1ccc3c(c1)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CC1)CC4)OCO2
CHEMBL568877,CHEMBL233,Mu opioid receptor,Ki,=,0.31,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,COc1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL2048765,CHEMBL233,Mu opioid receptor,Ki,=,0.51,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,COc1cccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)c1
CHEMBL2046467,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,COc1ccccc1CNc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL2048764,CHEMBL233,Mu opioid receptor,Ki,=,0.34,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,c1cc2c(cc1CNc1ccc3c(c1)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)OCO2
CHEMBL2048763,CHEMBL233,Mu opioid receptor,Ki,=,1.7,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,Clc1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL2048762,CHEMBL233,Mu opioid receptor,Ki,=,0.86,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,COc1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL2048761,CHEMBL233,Mu opioid receptor,Ki,=,0.69,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,COc1cccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)c1
CHEMBL2048760,CHEMBL233,Mu opioid receptor,Ki,=,2.7,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,COc1ccccc1CNc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL571560,CHEMBL233,Mu opioid receptor,Ki,=,1.7,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,c1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL571998,CHEMBL233,Mu opioid receptor,Ki,=,0.26,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,c1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL299220,CHEMBL233,Mu opioid receptor,Ki,=,1.3,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL49143,CHEMBL233,Mu opioid receptor,Ki,=,3.7,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL48420,CHEMBL233,Mu opioid receptor,Ki,=,7.9,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(N)cc13
CHEMBL49269,CHEMBL233,Mu opioid receptor,Ki,=,0.062,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL301160,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL592,CHEMBL233,Mu opioid receptor,Ki,=,0.21,nM,CHEMBL2050632,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2046406,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL2064130,CHEMBL233,Mu opioid receptor,Ki,=,138.0,nM,CHEMBL2067842,B,Displacement of [3H]DAMGO from human recombinant MOP receptor expressed in CHO-K1 cells after 45 mins by scintillation proximity assay,CHEMBL2062521,KI,Cc1ccccc1C1CCN(CCC(=O)N2c3ccccc3CC2C(=O)N(C)C)CC1
CHEMBL2064132,CHEMBL233,Mu opioid receptor,Ki,=,29.8,nM,CHEMBL2067842,B,Displacement of [3H]DAMGO from human recombinant MOP receptor expressed in CHO-K1 cells after 45 mins by scintillation proximity assay,CHEMBL2062521,KI,CCOc1ccccc1N1CCN(CCC(=O)N2c3ccccc3CC2C(=O)N(C)C)CC1
CHEMBL2064133,CHEMBL233,Mu opioid receptor,Ki,=,397.0,nM,CHEMBL2067842,B,Displacement of [3H]DAMGO from human recombinant MOP receptor expressed in CHO-K1 cells after 45 mins by scintillation proximity assay,CHEMBL2062521,KI,CN(C)C(=O)C1Cc2ccccc2N1C(=O)CCN1CCN(c2ccccc2)CC1
CHEMBL2064134,CHEMBL233,Mu opioid receptor,Ki,=,235.0,nM,CHEMBL2067842,B,Displacement of [3H]DAMGO from human recombinant MOP receptor expressed in CHO-K1 cells after 45 mins by scintillation proximity assay,CHEMBL2062521,KI,CN(C)C(=O)C1Cc2ccccc2N1C(=O)CCN1CCN(c2cnccn2)CC1
CHEMBL2064139,CHEMBL233,Mu opioid receptor,Ki,=,502.0,nM,CHEMBL2067842,B,Displacement of [3H]DAMGO from human recombinant MOP receptor expressed in CHO-K1 cells after 45 mins by scintillation proximity assay,CHEMBL2062521,KI,CN(C)C(=O)C1Cc2ccccc2N1C(=O)CCN1CCC(c2ccccc2)CC1
CHEMBL2064145,CHEMBL233,Mu opioid receptor,Ki,=,318.0,nM,CHEMBL2067842,B,Displacement of [3H]DAMGO from human recombinant MOP receptor expressed in CHO-K1 cells after 45 mins by scintillation proximity assay,CHEMBL2062521,KI,Cc1ccccc1N1CCN(CCC(=O)N2c3ccccc3CC2C(=O)N(C)C)CC1
CHEMBL2064156,CHEMBL233,Mu opioid receptor,Ki,=,67.2,nM,CHEMBL2067842,B,Displacement of [3H]DAMGO from human recombinant MOP receptor expressed in CHO-K1 cells after 45 mins by scintillation proximity assay,CHEMBL2062521,KI,Cc1ccccc1C1CCN(CCC(=O)N2c3ccccc3C[C@H]2C(=O)N(C)C)CC1
CHEMBL2064157,CHEMBL233,Mu opioid receptor,Ki,=,80.7,nM,CHEMBL2067842,B,Displacement of [3H]DAMGO from human recombinant MOP receptor expressed in CHO-K1 cells after 45 mins by scintillation proximity assay,CHEMBL2062521,KI,CN(C)C(=O)[C@@H]1Cc2ccccc2N1C(=O)CCN1CCC(c2ccccc2)CC1
CHEMBL2064158,CHEMBL233,Mu opioid receptor,Ki,=,238.0,nM,CHEMBL2067842,B,Displacement of [3H]DAMGO from human recombinant MOP receptor expressed in CHO-K1 cells after 45 mins by scintillation proximity assay,CHEMBL2062521,KI,CN(C)C(=O)[C@@H]1Cc2ccccc2N1C(=O)CCN1CCC(c2ccc(F)cc2)CC1
CHEMBL2064159,CHEMBL233,Mu opioid receptor,Ki,=,139.0,nM,CHEMBL2067842,B,Displacement of [3H]DAMGO from human recombinant MOP receptor expressed in CHO-K1 cells after 45 mins by scintillation proximity assay,CHEMBL2062521,KI,Cc1cc(F)ccc1C1CCN(CCC(=O)N2c3ccccc3C[C@H]2C(=O)N(C)C)CC1
CHEMBL2064160,CHEMBL233,Mu opioid receptor,Ki,=,82.1,nM,CHEMBL2067842,B,Displacement of [3H]DAMGO from human recombinant MOP receptor expressed in CHO-K1 cells after 45 mins by scintillation proximity assay,CHEMBL2062521,KI,Cc1cccc(C)c1C1CCN(CCC(=O)N2c3ccccc3C[C@H]2C(=O)N(C)C)CC1
CHEMBL2064161,CHEMBL233,Mu opioid receptor,Ki,=,28.4,nM,CHEMBL2067842,B,Displacement of [3H]DAMGO from human recombinant MOP receptor expressed in CHO-K1 cells after 45 mins by scintillation proximity assay,CHEMBL2062521,KI,CN(C)C(=O)[C@@H]1Cc2ccccc2N1C(=O)CCN1CC2CCC(C1)C2c1ccccc1
CHEMBL2151735,CHEMBL233,Mu opioid receptor,Ki,=,14.8,nM,CHEMBL2156213,B,Displacement of [3H]diprenorphine from human MOR expressed in HEK293 cell membrane by liquid scintillation counting,CHEMBL2150869,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N(C)[C@H](C)C(=O)N[C@H]1Cc2ccccc2CN(CC(N)=O)C1=O
CHEMBL2151734,CHEMBL233,Mu opioid receptor,Ki,=,60.0,nM,CHEMBL2156213,B,Displacement of [3H]diprenorphine from human MOR expressed in HEK293 cell membrane by liquid scintillation counting,CHEMBL2150869,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N(C)[C@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N(C)CC(N)=O
CHEMBL1834247,CHEMBL233,Mu opioid receptor,Ki,=,170.0,nM,CHEMBL2156213,B,Displacement of [3H]diprenorphine from human MOR expressed in HEK293 cell membrane by liquid scintillation counting,CHEMBL2150869,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](C)C(=O)N[C@H]1Cc2ccccc2CN(CC(N)=O)C1=O
CHEMBL260120,CHEMBL233,Mu opioid receptor,Ki,=,1100.0,nM,CHEMBL2156213,B,Displacement of [3H]diprenorphine from human MOR expressed in HEK293 cell membrane by liquid scintillation counting,CHEMBL2150869,KI,C[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N(C)CC(N)=O)N(C)C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL409225,CHEMBL233,Mu opioid receptor,Ki,=,2700.0,nM,CHEMBL2156213,B,Displacement of [3H]diprenorphine from human MOR expressed in HEK293 cell membrane by liquid scintillation counting,CHEMBL2150869,KI,C[C@H](C(=O)N[C@H]1Cc2ccccc2CN(CC(N)=O)C1=O)N1Cc2cc(O)ccc2C[C@H](N)C1=O
CHEMBL551074,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL2161468,B,Binding affinity to mu opioid receptor,CHEMBL2157973,KI,CS(=O)(=O)O[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL316446,CHEMBL233,Mu opioid receptor,Ki,=,0.29,nM,CHEMBL2161187,B,Displacement of [3H]DAMGO from mu-opioid receptor expressed in CHOK1 cells after overnight incubation by scintillation proximity assay,CHEMBL2157939,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL2158990,CHEMBL233,Mu opioid receptor,Ki,=,14.9,nM,CHEMBL2161187,B,Displacement of [3H]DAMGO from mu-opioid receptor expressed in CHOK1 cells after overnight incubation by scintillation proximity assay,CHEMBL2157939,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CCC(=O)N[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,0.14,nM,CHEMBL2161187,B,Displacement of [3H]DAMGO from mu-opioid receptor expressed in CHOK1 cells after overnight incubation by scintillation proximity assay,CHEMBL2157939,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL4299173,CHEMBL233,Mu opioid receptor,Ki,=,1.7,nM,CHEMBL2163107,B,Binding affinity to human mu opioid receptor,CHEMBL2157906,KI,COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@H](C)c2nc(-c3ccccc3)c[nH]2)cc1C(=O)O.Cl.Cl
CHEMBL2158541,CHEMBL233,Mu opioid receptor,Ki,=,400.0,nM,CHEMBL2162310,B,Displacement of [3H]DAMGO from human recombinant mu-opioid receptor expressed in CHO cells after 60 mins by liquid scintillation assay,CHEMBL2157908,KI,CC(C)C[C@H](CN(C=O)[C@H](Cc1ccccc1)CN(C=O)CCN(C=O)CCN(C=O)[C@@H](CN)Cc1ccc(O)cc1)NS(C)(=O)=O
CHEMBL2158958,CHEMBL233,Mu opioid receptor,Ki,=,3.87,nM,CHEMBL2162349,B,Displacement of [3H]DAMGO from MOP receptor expressed in CHO-K1 cells after overnight incubation by beta counting method,CHEMBL2157899,KI,CCCCCCCCC(N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O
CHEMBL2158957,CHEMBL233,Mu opioid receptor,Ki,=,0.73,nM,CHEMBL2162349,B,Displacement of [3H]DAMGO from MOP receptor expressed in CHO-K1 cells after overnight incubation by beta counting method,CHEMBL2157899,KI,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL2158956,CHEMBL233,Mu opioid receptor,Ki,=,132.0,nM,CHEMBL2162349,B,Displacement of [3H]DAMGO from MOP receptor expressed in CHO-K1 cells after overnight incubation by beta counting method,CHEMBL2157899,KI,CCCCCCCCC(N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O
CHEMBL2158955,CHEMBL233,Mu opioid receptor,Ki,=,1.6,nM,CHEMBL2162349,B,Displacement of [3H]DAMGO from MOP receptor expressed in CHO-K1 cells after overnight incubation by beta counting method,CHEMBL2157899,KI,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL316446,CHEMBL233,Mu opioid receptor,Ki,=,0.76,nM,CHEMBL2162349,B,Displacement of [3H]DAMGO from MOP receptor expressed in CHO-K1 cells after overnight incubation by beta counting method,CHEMBL2157899,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL2163919,CHEMBL233,Mu opioid receptor,Ki,=,27.4,nM,CHEMBL2166336,B,Displacement of [3H]DAMGO from FLAG-tagged mu opioid receptor expressed in HEK293 cells after 60 mins by liquid scintillation counter,CHEMBL2163332,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccc2ccccc2c1
CHEMBL2163918,CHEMBL233,Mu opioid receptor,Ki,=,26.0,nM,CHEMBL2166336,B,Displacement of [3H]DAMGO from FLAG-tagged mu opioid receptor expressed in HEK293 cells after 60 mins by liquid scintillation counter,CHEMBL2163332,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1cccc2ccccc12
CHEMBL2163917,CHEMBL233,Mu opioid receptor,Ki,=,0.274,nM,CHEMBL2166336,B,Displacement of [3H]DAMGO from FLAG-tagged mu opioid receptor expressed in HEK293 cells after 60 mins by liquid scintillation counter,CHEMBL2163332,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccoc1
CHEMBL2163916,CHEMBL233,Mu opioid receptor,Ki,=,0.221,nM,CHEMBL2166336,B,Displacement of [3H]DAMGO from FLAG-tagged mu opioid receptor expressed in HEK293 cells after 60 mins by liquid scintillation counter,CHEMBL2163332,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1
CHEMBL2163915,CHEMBL233,Mu opioid receptor,Ki,=,7.73,nM,CHEMBL2166336,B,Displacement of [3H]DAMGO from FLAG-tagged mu opioid receptor expressed in HEK293 cells after 60 mins by liquid scintillation counter,CHEMBL2163332,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccc2c(c1)OCO2
CHEMBL2163914,CHEMBL233,Mu opioid receptor,Ki,=,4.83,nM,CHEMBL2166336,B,Displacement of [3H]DAMGO from FLAG-tagged mu opioid receptor expressed in HEK293 cells after 60 mins by liquid scintillation counter,CHEMBL2163332,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccc(OC)cc1
CHEMBL2163913,CHEMBL233,Mu opioid receptor,Ki,=,5.48,nM,CHEMBL2166336,B,Displacement of [3H]DAMGO from FLAG-tagged mu opioid receptor expressed in HEK293 cells after 60 mins by liquid scintillation counter,CHEMBL2163332,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccccc1Cl
CHEMBL2163912,CHEMBL233,Mu opioid receptor,Ki,=,3.49,nM,CHEMBL2166336,B,Displacement of [3H]DAMGO from FLAG-tagged mu opioid receptor expressed in HEK293 cells after 60 mins by liquid scintillation counter,CHEMBL2163332,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1cccc(Cl)c1
CHEMBL2163911,CHEMBL233,Mu opioid receptor,Ki,=,7.12,nM,CHEMBL2166336,B,Displacement of [3H]DAMGO from FLAG-tagged mu opioid receptor expressed in HEK293 cells after 60 mins by liquid scintillation counter,CHEMBL2163332,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccc(Cl)cc1
CHEMBL2163910,CHEMBL233,Mu opioid receptor,Ki,=,13.7,nM,CHEMBL2166336,B,Displacement of [3H]DAMGO from FLAG-tagged mu opioid receptor expressed in HEK293 cells after 60 mins by liquid scintillation counter,CHEMBL2163332,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccc(F)cc1
CHEMBL2163922,CHEMBL233,Mu opioid receptor,Ki,=,15.7,nM,CHEMBL2166336,B,Displacement of [3H]DAMGO from FLAG-tagged mu opioid receptor expressed in HEK293 cells after 60 mins by liquid scintillation counter,CHEMBL2163332,KI,C=C(C(N)=O)[C@@H](NC(=O)C(=C)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccccc1)c1ccccc1
CHEMBL2163921,CHEMBL233,Mu opioid receptor,Ki,=,0.535,nM,CHEMBL2166336,B,Displacement of [3H]DAMGO from FLAG-tagged mu opioid receptor expressed in HEK293 cells after 60 mins by liquid scintillation counter,CHEMBL2163332,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccccc1
CHEMBL2163920,CHEMBL233,Mu opioid receptor,Ki,=,103.0,nM,CHEMBL2166336,B,Displacement of [3H]DAMGO from FLAG-tagged mu opioid receptor expressed in HEK293 cells after 60 mins by liquid scintillation counter,CHEMBL2163332,KI,C=C(C(=O)N[C@@H](Cc1ccccc1)C(N)=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccccc1
CHEMBL333357,CHEMBL233,Mu opioid receptor,Ki,=,3.2,nM,CHEMBL2166336,B,Displacement of [3H]DAMGO from FLAG-tagged mu opioid receptor expressed in HEK293 cells after 60 mins by liquid scintillation counter,CHEMBL2163332,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL316446,CHEMBL233,Mu opioid receptor,Ki,=,2.6,nM,CHEMBL2166336,B,Displacement of [3H]DAMGO from FLAG-tagged mu opioid receptor expressed in HEK293 cells after 60 mins by liquid scintillation counter,CHEMBL2163332,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL2171852,CHEMBL233,Mu opioid receptor,Ki,=,760.0,nM,CHEMBL2176093,B,Displacement of [3H]DAMGO from mu opioid receptor transfected in human HN9.10 cells after 3 hrs by liquid scintillation counter,CHEMBL2169823,KI,Br.NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H]1C[C@H](N)CN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL2171851,CHEMBL233,Mu opioid receptor,Ki,=,3700.0,nM,CHEMBL2176093,B,Displacement of [3H]DAMGO from mu opioid receptor transfected in human HN9.10 cells after 3 hrs by liquid scintillation counter,CHEMBL2169823,KI,Br.NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H]1C[C@H](N)CN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL2171850,CHEMBL233,Mu opioid receptor,Ki,=,760.0,nM,CHEMBL2176093,B,Displacement of [3H]DAMGO from mu opioid receptor transfected in human HN9.10 cells after 3 hrs by liquid scintillation counter,CHEMBL2169823,KI,Br.N[C@H]1C[C@@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2ccccc2)C(=O)O)N(C(=O)[C@@H](N)Cc2ccc(O)cc2)C1
CHEMBL2171849,CHEMBL233,Mu opioid receptor,Ki,=,1010.0,nM,CHEMBL2176093,B,Displacement of [3H]DAMGO from mu opioid receptor transfected in human HN9.10 cells after 3 hrs by liquid scintillation counter,CHEMBL2169823,KI,Br.N[C@H]1C[C@@H](C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)O)N(C(=O)[C@@H](N)Cc2ccc(O)cc2)C1
CHEMBL2171847,CHEMBL233,Mu opioid receptor,Ki,=,38.0,nM,CHEMBL2176093,B,Displacement of [3H]DAMGO from mu opioid receptor transfected in human HN9.10 cells after 3 hrs by liquid scintillation counter,CHEMBL2169823,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N1C[C@@H]2C[C@H]1C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N2.O=C(O)C(F)(F)F
CHEMBL2171846,CHEMBL233,Mu opioid receptor,Ki,=,63.0,nM,CHEMBL2176093,B,Displacement of [3H]DAMGO from mu opioid receptor transfected in human HN9.10 cells after 3 hrs by liquid scintillation counter,CHEMBL2169823,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N1C[C@@H]2C[C@H]1C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@H](Cc1ccccc1)C(=O)N2.O=C(O)C(F)(F)F
CHEMBL2178724,CHEMBL233,Mu opioid receptor,Ki,=,74000.0,nM,CHEMBL2183873,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cells after 2 hrs by liquid scintillation counting,CHEMBL2177066,KI,CC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(N)=O
CHEMBL2178733,CHEMBL233,Mu opioid receptor,Ki,=,5.6,nM,CHEMBL2183873,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cells after 2 hrs by liquid scintillation counting,CHEMBL2177066,KI,CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(N)=O
CHEMBL2178732,CHEMBL233,Mu opioid receptor,Ki,=,15.5,nM,CHEMBL2183873,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cells after 2 hrs by liquid scintillation counting,CHEMBL2177066,KI,CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL2178731,CHEMBL233,Mu opioid receptor,Ki,=,5.9,nM,CHEMBL2183873,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cells after 2 hrs by liquid scintillation counting,CHEMBL2177066,KI,NC(=O)[C@H]1CC(=O)NCCC(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL2183873,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cells after 2 hrs by liquid scintillation counting,CHEMBL2177066,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL2181202,CHEMBL233,Mu opioid receptor,Ki,=,0.143,nM,CHEMBL2182467,B,Binding affinity to mu opioid receptor,CHEMBL2177074,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL611438,CHEMBL233,Mu opioid receptor,Ki,=,230.0,nM,CHEMBL2187197,B,Binding affinity to mu opioid receptor by radioligand binding assay,CHEMBL2177065,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(O)[C@H]1C5
CHEMBL610261,CHEMBL233,Mu opioid receptor,Ki,=,51.0,nM,CHEMBL2187197,B,Binding affinity to mu opioid receptor by radioligand binding assay,CHEMBL2177065,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL2179663,CHEMBL233,Mu opioid receptor,Ki,=,13.0,nM,CHEMBL2187202,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by scintillation counting analysis,CHEMBL2177065,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C=C4[C@@H](C2)N(CC2CC2)CC[C@]431
CHEMBL2179662,CHEMBL233,Mu opioid receptor,Ki,=,0.94,nM,CHEMBL2187202,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by scintillation counting analysis,CHEMBL2177065,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OC(=O)CCc2ccccc2)[C@H]1C5
CHEMBL2179661,CHEMBL233,Mu opioid receptor,Ki,=,1.43,nM,CHEMBL2187202,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by scintillation counting analysis,CHEMBL2177065,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OC(=O)Cc2ccccc2)[C@H]1C5
CHEMBL2179660,CHEMBL233,Mu opioid receptor,Ki,=,84.0,nM,CHEMBL2187202,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by scintillation counting analysis,CHEMBL2177065,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OC(=O)c2ccccc2)[C@H]1C5
CHEMBL2179659,CHEMBL233,Mu opioid receptor,Ki,=,2.58,nM,CHEMBL2187202,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by scintillation counting analysis,CHEMBL2177065,KI,O=C(CCc1ccccc1)O[C@@]12Cc3cc(-c4ccc(Cl)cc4)cnc3[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL2179658,CHEMBL233,Mu opioid receptor,Ki,=,1.04,nM,CHEMBL2187202,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by scintillation counting analysis,CHEMBL2177065,KI,O=C(Cc1ccccc1)O[C@@]12Cc3cc(-c4ccc(Cl)cc4)cnc3[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL2179657,CHEMBL233,Mu opioid receptor,Ki,=,192.0,nM,CHEMBL2187202,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by scintillation counting analysis,CHEMBL2177065,KI,O=C(O[C@@]12Cc3cc(-c4ccc(Cl)cc4)cnc3[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccc1
CHEMBL2179656,CHEMBL233,Mu opioid receptor,Ki,=,0.54,nM,CHEMBL2187202,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by scintillation counting analysis,CHEMBL2177065,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OCCCc2ccccc2)[C@H]1C5
CHEMBL2179655,CHEMBL233,Mu opioid receptor,Ki,=,0.41,nM,CHEMBL2187202,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by scintillation counting analysis,CHEMBL2177065,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OC/C=C/c2ccccc2)[C@H]1C5
CHEMBL2179654,CHEMBL233,Mu opioid receptor,Ki,=,4.69,nM,CHEMBL2187202,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by scintillation counting analysis,CHEMBL2177065,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OCc2ccccc2)[C@H]1C5
CHEMBL2179653,CHEMBL233,Mu opioid receptor,Ki,=,7.89,nM,CHEMBL2187202,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by scintillation counting analysis,CHEMBL2177065,KI,CO[C@@]12Cc3cc(-c4ccc(Cl)cc4)cnc3[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL2179652,CHEMBL233,Mu opioid receptor,Ki,=,0.66,nM,CHEMBL2187202,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by scintillation counting analysis,CHEMBL2177065,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL2179651,CHEMBL233,Mu opioid receptor,Ki,=,3.03,nM,CHEMBL2187202,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by scintillation counting analysis,CHEMBL2177065,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C[C@@]4(OC/C=C/c5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL2179650,CHEMBL233,Mu opioid receptor,Ki,=,8.42,nM,CHEMBL2187202,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by scintillation counting analysis,CHEMBL2177065,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C[C@@]4(OCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL2179649,CHEMBL233,Mu opioid receptor,Ki,=,41.9,nM,CHEMBL2187202,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells by scintillation counting analysis,CHEMBL2177065,KI,CO[C@@]12Cc3cc(-c4ccc(Cl)cc4)cnc3[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL1852475,CHEMBL233,Mu opioid receptor,Ki,=,0.87,nM,CHEMBL2184596,B,Displacement of [3H]Naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,CN1CCC(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)CC1
CHEMBL2178341,CHEMBL233,Mu opioid receptor,Ki,=,2.13,nM,CHEMBL2184596,B,Displacement of [3H]Naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncn1
CHEMBL2178340,CHEMBL233,Mu opioid receptor,Ki,=,2.07,nM,CHEMBL2184596,B,Displacement of [3H]Naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccnnc1
CHEMBL1852458,CHEMBL233,Mu opioid receptor,Ki,=,0.73,nM,CHEMBL2184596,B,Displacement of [3H]Naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(CNC(=O)c1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1852555,CHEMBL233,Mu opioid receptor,Ki,=,0.57,nM,CHEMBL2184596,B,Displacement of [3H]Naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(CCc1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1852814,CHEMBL233,Mu opioid receptor,Ki,=,0.85,nM,CHEMBL2184596,B,Displacement of [3H]Naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(Cc1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL2178339,CHEMBL233,Mu opioid receptor,Ki,=,0.43,nM,CHEMBL2184596,B,Displacement of [3H]Naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,COc1cnccc1C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1852393,CHEMBL233,Mu opioid receptor,Ki,=,0.58,nM,CHEMBL2184596,B,Displacement of [3H]Naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,Cc1cnccc1C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1852602,CHEMBL233,Mu opioid receptor,Ki,=,0.45,nM,CHEMBL2184596,B,Displacement of [3H]Naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1Br
CHEMBL1852672,CHEMBL233,Mu opioid receptor,Ki,=,0.67,nM,CHEMBL2184596,B,Displacement of [3H]Naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1Cl
CHEMBL2178338,CHEMBL233,Mu opioid receptor,Ki,=,0.6,nM,CHEMBL2184596,B,Displacement of [3H]Naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,COc1cc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)ccn1
CHEMBL1852558,CHEMBL233,Mu opioid receptor,Ki,=,0.39,nM,CHEMBL2184596,B,Displacement of [3H]Naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,Cc1cc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)ccn1
CHEMBL2177697,CHEMBL233,Mu opioid receptor,Ki,=,1.25,nM,CHEMBL2184596,B,Displacement of [3H]Naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,N#Cc1cc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)ccn1
CHEMBL1852385,CHEMBL233,Mu opioid receptor,Ki,=,0.63,nM,CHEMBL2184596,B,Displacement of [3H]Naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccnc(Br)c1
CHEMBL1852788,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL2184596,B,Displacement of [3H]Naloxone from mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccnc(Cl)c1
CHEMBL440765,CHEMBL233,Mu opioid receptor,Ki,=,1145.0,nM,CHEMBL2182840,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting,CHEMBL2177058,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL441765,CHEMBL233,Mu opioid receptor,Ki,=,290.0,nM,CHEMBL2182840,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting,CHEMBL2177058,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL2180641,CHEMBL233,Mu opioid receptor,Ki,=,788.0,nM,CHEMBL2182840,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting,CHEMBL2177058,KI,CCCCCCN(CCc1ccccc1)CCc1cccc(O)c1
CHEMBL2180640,CHEMBL233,Mu opioid receptor,Ki,=,412.0,nM,CHEMBL2182840,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting,CHEMBL2177058,KI,CCCCN(CCc1ccccc1)CCc1cccc(O)c1
CHEMBL2180639,CHEMBL233,Mu opioid receptor,Ki,=,542.0,nM,CHEMBL2182840,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting,CHEMBL2177058,KI,Oc1cccc(CCN(CCc2ccccc2)CC2CCC2)c1
CHEMBL2180638,CHEMBL233,Mu opioid receptor,Ki,=,826.0,nM,CHEMBL2182840,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting,CHEMBL2177058,KI,Oc1cccc(CCN(CCc2ccccc2)CC2CC2)c1
CHEMBL2180637,CHEMBL233,Mu opioid receptor,Ki,=,325.0,nM,CHEMBL2182840,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting,CHEMBL2177058,KI,CCCCCN(CCc1ccccc1)CCc1cccc(O)c1
CHEMBL1188090,CHEMBL233,Mu opioid receptor,Ki,=,594.0,nM,CHEMBL2182840,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting,CHEMBL2177058,KI,CCCN(CCc1ccccc1)CCc1cccc(O)c1
CHEMBL2205811,CHEMBL233,Mu opioid receptor,Ki,=,5392.0,nM,CHEMBL2215556,B,Binding affinity to mu opioid receptor,CHEMBL2203059,KI,COc1cccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)c1
CHEMBL2205836,CHEMBL233,Mu opioid receptor,Ki,=,5325.0,nM,CHEMBL2215556,B,Binding affinity to mu opioid receptor,CHEMBL2203059,KI,COc1ccccc1CCN1C2C3C4CC5C6C4C2C6C1(O)C53
CHEMBL2205832,CHEMBL233,Mu opioid receptor,Ki,=,3415.0,nM,CHEMBL2215556,B,Binding affinity to mu opioid receptor,CHEMBL2203059,KI,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccccn1
CHEMBL2205829,CHEMBL233,Mu opioid receptor,Ki,=,4780.0,nM,CHEMBL2215556,B,Binding affinity to mu opioid receptor,CHEMBL2203059,KI,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccc2c(c1)OCO2
CHEMBL2205827,CHEMBL233,Mu opioid receptor,Ki,=,1269.0,nM,CHEMBL2215556,B,Binding affinity to mu opioid receptor,CHEMBL2203059,KI,COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC
CHEMBL2205825,CHEMBL233,Mu opioid receptor,Ki,=,2137.0,nM,CHEMBL2215556,B,Binding affinity to mu opioid receptor,CHEMBL2203059,KI,COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1
CHEMBL2205824,CHEMBL233,Mu opioid receptor,Ki,=,2330.0,nM,CHEMBL2215556,B,Binding affinity to mu opioid receptor,CHEMBL2203059,KI,COc1cccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)c1
CHEMBL2205823,CHEMBL233,Mu opioid receptor,Ki,=,7474.0,nM,CHEMBL2215556,B,Binding affinity to mu opioid receptor,CHEMBL2203059,KI,COc1ccccc1CN1C2C3C4CC5C6C4C2C6C1(O)C53
CHEMBL2208355,CHEMBL233,Mu opioid receptor,Ki,=,0.18,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,CC1C2Cc3ccc(C(=O)NCCc4ccc5ccccc5c4)cc3C1(C)CCN2CC1CC1
CHEMBL2208354,CHEMBL233,Mu opioid receptor,Ki,=,0.064,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,COc1ccc2cc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)ccc2c1
CHEMBL2208353,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,COc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)c(C)c1
CHEMBL2208352,CHEMBL233,Mu opioid receptor,Ki,=,0.059,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,COc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)cc1C
CHEMBL2208351,CHEMBL233,Mu opioid receptor,Ki,=,0.0016,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,CC1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccc6c(c5)OCO6)cc4)cc3C1(C)CCN2CC1CC1
CHEMBL2208350,CHEMBL233,Mu opioid receptor,Ki,=,0.0071,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,COc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)cc1OC
CHEMBL2208349,CHEMBL233,Mu opioid receptor,Ki,=,0.0056,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,CC1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5O)cc4)cc3C1(C)CCN2CC1CC1
CHEMBL2208348,CHEMBL233,Mu opioid receptor,Ki,=,0.021,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,CC1C2Cc3ccc(C(=O)NCCc4ccc(-c5cccc(O)c5)cc4)cc3C1(C)CCN2CC1CC1
CHEMBL2208347,CHEMBL233,Mu opioid receptor,Ki,=,0.0049,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,C[C@H]1[C@H]2Cc3ccc(C(=O)NCCc4ccc(-c5ccc(O)cc5)cc4)cc3[C@]1(C)CCN2CC1CC1
CHEMBL2203338,CHEMBL233,Mu opioid receptor,Ki,=,0.0056,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,CC1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccc(O)cc5)cc4)cc3C1(C)CCN2CC1CC1
CHEMBL2208346,CHEMBL233,Mu opioid receptor,Ki,=,0.3,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,CC1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccc(OC(F)F)cc5)cc4)cc3C1(C)CCN2CC1CC1
CHEMBL2208345,CHEMBL233,Mu opioid receptor,Ki,=,1.8,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,CC1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccc(OC(F)(F)F)cc5)cc4)cc3C1(C)CCN2CC1CC1
CHEMBL2208363,CHEMBL233,Mu opioid receptor,Ki,=,0.12,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,CC(C)Oc1ccccc1-c1ccc(CCNC(=O)c2ccc3c(c2)C2(C)CCN(CC4CC4)C(C3)C2C)cc1
CHEMBL2208362,CHEMBL233,Mu opioid receptor,Ki,=,0.43,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,CC(C)Oc1cccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)c1
CHEMBL2208361,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,CC(C)Oc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)cc1
CHEMBL2208360,CHEMBL233,Mu opioid receptor,Ki,=,0.64,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,CCOc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)cc1
CHEMBL2208359,CHEMBL233,Mu opioid receptor,Ki,=,0.12,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,COc1ccccc1-c1ccc(CCNC(=O)c2ccc3c(c2)C2(C)CCN(CC4CC4)C(C3)C2C)cc1
CHEMBL2208358,CHEMBL233,Mu opioid receptor,Ki,=,0.018,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,COc1cccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)c1
CHEMBL377789,CHEMBL233,Mu opioid receptor,Ki,=,0.3,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL289683,CHEMBL233,Mu opioid receptor,Ki,=,0.16,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,CC1C2Cc3ccc(O)cc3C1(C)CCN2CC1CC1
CHEMBL297428,CHEMBL233,Mu opioid receptor,Ki,=,0.31,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,CC1C2Cc3ccc(C(N)=O)cc3C1(C)CCN2CC1CC1
CHEMBL2208356,CHEMBL233,Mu opioid receptor,Ki,=,0.084,nM,CHEMBL2215304,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL2203245,KI,COc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)cc1
CHEMBL2313631,CHEMBL233,Mu opioid receptor,Ki,=,3.0,nM,CHEMBL2319307,B,Binding affinity to MOR (unknown origin),CHEMBL2311398,KI,CCOC(=O)N(c1ccccc1)C1CCN(CCn2c(=O)n(C3CC3)c3ccccc32)CC1
CHEMBL2313630,CHEMBL233,Mu opioid receptor,Ki,=,540.0,nM,CHEMBL2319307,B,Binding affinity to MOR (unknown origin),CHEMBL2311398,KI,C=C(C)n1c(=O)n(CCN2CCC(N(C(=O)OCC)c3ccc(Cl)c(Cl)c3)CC2)c2ccccc21
CHEMBL2313629,CHEMBL233,Mu opioid receptor,Ki,=,19.0,nM,CHEMBL2319307,B,Binding affinity to MOR (unknown origin),CHEMBL2311398,KI,C=C(C)n1c(=O)n(CCN2CCC(N(C(=O)CC)c3cc(Cl)ccc3Cl)CC2)c2ccccc21
CHEMBL2313628,CHEMBL233,Mu opioid receptor,Ki,=,37.0,nM,CHEMBL2319307,B,Binding affinity to MOR (unknown origin),CHEMBL2311398,KI,C=C(C)n1c(=O)n(CCN2CCC(N(C(=O)CC)c3cccc(Cl)c3)CC2)c2ccccc21
CHEMBL1921847,CHEMBL233,Mu opioid receptor,Ki,=,16.4,nM,CHEMBL2327122,B,Binding affinity to human cloned MOR in presence of Na+/GDP,CHEMBL2321730,KI,Cc1cc(C)cc([C@@H]2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1
CHEMBL2372399,CHEMBL233,Mu opioid receptor,Ki,=,5880.0,nM,CHEMBL2327851,B,Displacement of [3H]DAMGO from MOR (unknown origin) expressed in CHO cells,CHEMBL2321730,KI,CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccc(O)cc2)NCc2ccccc2)CC(=O)NC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL2334769,CHEMBL233,Mu opioid receptor,Ki,=,0.758,nM,CHEMBL2341882,B,Displacement of [3H]DAMGO from FLAG-tagged mu-type opioid receptor (unknown origin) expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis,CHEMBL2331515,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H]1CCN(C(=O)[C@@H](N)Cc2ccc(O)cc2)C1)c1ccco1
CHEMBL2334768,CHEMBL233,Mu opioid receptor,Ki,=,0.574,nM,CHEMBL2341882,B,Displacement of [3H]DAMGO from FLAG-tagged mu-type opioid receptor (unknown origin) expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis,CHEMBL2331515,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H]1CCN(C(=O)[C@@H](N)Cc2ccc(O)cc2)C1)c1ccccc1
CHEMBL2334770,CHEMBL233,Mu opioid receptor,Ki,=,0.296,nM,CHEMBL2341882,B,Displacement of [3H]DAMGO from FLAG-tagged mu-type opioid receptor (unknown origin) expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis,CHEMBL2331515,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCN(C(=O)[C@@H](N)Cc2ccc(O)cc2)C1)c1ccccc1
CHEMBL2334771,CHEMBL233,Mu opioid receptor,Ki,=,0.165,nM,CHEMBL2341882,B,Displacement of [3H]DAMGO from FLAG-tagged mu-type opioid receptor (unknown origin) expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis,CHEMBL2331515,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCN(C(=O)[C@@H](N)Cc2ccc(O)cc2)C1)c1ccco1
CHEMBL2334773,CHEMBL233,Mu opioid receptor,Ki,=,0.0405,nM,CHEMBL2341882,B,Displacement of [3H]DAMGO from FLAG-tagged mu-type opioid receptor (unknown origin) expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis,CHEMBL2331515,KI,C=C(C(=O)O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)c1ccco1
CHEMBL2334772,CHEMBL233,Mu opioid receptor,Ki,=,0.0322,nM,CHEMBL2341882,B,Displacement of [3H]DAMGO from FLAG-tagged mu-type opioid receptor (unknown origin) expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis,CHEMBL2331515,KI,C=C(C(=O)O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)c1ccccc1
CHEMBL2334774,CHEMBL233,Mu opioid receptor,Ki,=,0.0137,nM,CHEMBL2341882,B,Displacement of [3H]DAMGO from FLAG-tagged mu-type opioid receptor (unknown origin) expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis,CHEMBL2331515,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H]1CCN(C(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1)c1ccccc1
CHEMBL2334775,CHEMBL233,Mu opioid receptor,Ki,=,0.0128,nM,CHEMBL2341882,B,Displacement of [3H]DAMGO from FLAG-tagged mu-type opioid receptor (unknown origin) expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis,CHEMBL2331515,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H]1CCN(C(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1)c1ccco1
CHEMBL2334776,CHEMBL233,Mu opioid receptor,Ki,=,0.00986,nM,CHEMBL2341882,B,Displacement of [3H]DAMGO from FLAG-tagged mu-type opioid receptor (unknown origin) expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis,CHEMBL2331515,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCN(C(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1)c1ccccc1
CHEMBL2335120,CHEMBL233,Mu opioid receptor,Ki,=,0.00372,nM,CHEMBL2341882,B,Displacement of [3H]DAMGO from FLAG-tagged mu-type opioid receptor (unknown origin) expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis,CHEMBL2331515,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCN(C(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1)c1ccco1
CHEMBL2347239,CHEMBL233,Mu opioid receptor,Ki,=,0.82,nM,CHEMBL2353047,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting,CHEMBL2346652,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)cn4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL2347238,CHEMBL233,Mu opioid receptor,Ki,=,0.61,nM,CHEMBL2353047,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting,CHEMBL2346652,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)nc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL2347237,CHEMBL233,Mu opioid receptor,Ki,=,0.33,nM,CHEMBL2353047,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting,CHEMBL2346652,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccn5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL2347236,CHEMBL233,Mu opioid receptor,Ki,=,0.064,nM,CHEMBL2353047,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting,CHEMBL2346652,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5cccnc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL2347235,CHEMBL233,Mu opioid receptor,Ki,=,0.065,nM,CHEMBL2353047,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting,CHEMBL2346652,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccncc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL2381589,CHEMBL233,Mu opioid receptor,Ki,=,5012.0,nM,CHEMBL2383891,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin),CHEMBL2380279,KI,COC(=O)CCCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL2381591,CHEMBL233,Mu opioid receptor,Ki,=,4570.0,nM,CHEMBL2383891,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin),CHEMBL2380279,KI,COC(=O)[C@@H]1C[C@H](OC(=O)CCCC(=O)O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL2381594,CHEMBL233,Mu opioid receptor,Ki,=,724.0,nM,CHEMBL2383891,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin),CHEMBL2380279,KI,CCOC(=O)/C=C/C(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL2381593,CHEMBL233,Mu opioid receptor,Ki,=,711.0,nM,CHEMBL2383891,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin),CHEMBL2380279,KI,COC(=O)/C=C/C(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,0.9,nM,CHEMBL2383891,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin),CHEMBL2380279,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,2.6,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL2386904,CHEMBL233,Mu opioid receptor,Ki,=,16.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,Oc1ccc2c(c1)[C@]1(CCc3ccccc3)CCN(CCc3cccc(C(F)(F)F)c3)C[C@@H]1O2
CHEMBL2386903,CHEMBL233,Mu opioid receptor,Ki,=,174.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,Oc1ccc2c(c1)[C@]1(CCc3ccccc3)CCN(CCc3ccccc3C(F)(F)F)C[C@@H]1O2
CHEMBL2386902,CHEMBL233,Mu opioid receptor,Ki,=,23.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,C=CCN1CC[C@@]2(CCc3ccccc3)c3cc(O)ccc3O[C@H]2C1
CHEMBL2386901,CHEMBL233,Mu opioid receptor,Ki,=,5.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,Oc1ccc2c(c1)[C@]1(CCc3ccccc3)CCN(CC3CC3)C[C@@H]1O2
CHEMBL2386900,CHEMBL233,Mu opioid receptor,Ki,=,8.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,Oc1ccc2c(c1)[C@]1(CCc3ccccc3)CCN(CCc3ccc(C(F)(F)F)cc3)C[C@@H]1O2
CHEMBL2386899,CHEMBL233,Mu opioid receptor,Ki,=,7.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,Oc1ccc2c(c1)[C@]1(CCc3ccccc3)CCN(CCc3ccccc3F)C[C@@H]1O2
CHEMBL2386898,CHEMBL233,Mu opioid receptor,Ki,=,22.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,Oc1ccc2c(c1)[C@]1(CCc3ccccc3)CCN(CCc3ccc(F)cc3)C[C@@H]1O2
CHEMBL2386897,CHEMBL233,Mu opioid receptor,Ki,=,49.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,Oc1ccc2c(c1)[C@]1(CCc3ccccc3)CCN(CCCc3ccccc3)C[C@@H]1O2
CHEMBL2386896,CHEMBL233,Mu opioid receptor,Ki,=,9.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,Oc1ccc2c(c1)[C@]1(CCc3ccccc3)CCN(CCc3ccccc3)C[C@@H]1O2
CHEMBL2386895,CHEMBL233,Mu opioid receptor,Ki,=,96.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,CN1CC[C@@]2(CCc3ccccc3F)c3cc(O)ccc3O[C@H]2C1
CHEMBL2386894,CHEMBL233,Mu opioid receptor,Ki,=,166.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,CN1CC[C@@]2(CCc3ccc(F)cc3)c3cc(O)ccc3O[C@H]2C1
CHEMBL2386893,CHEMBL233,Mu opioid receptor,Ki,=,91.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,CCCCC[C@@]12CCN(C)C[C@@H]1Oc1ccc(O)cc12
CHEMBL2386892,CHEMBL233,Mu opioid receptor,Ki,=,97.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,CCCC[C@@]12CCN(C)C[C@@H]1Oc1ccc(O)cc12
CHEMBL2386891,CHEMBL233,Mu opioid receptor,Ki,=,84.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,CCC[C@@]12CCN(C)C[C@@H]1Oc1ccc(O)cc12
CHEMBL430441,CHEMBL233,Mu opioid receptor,Ki,=,19.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,CC[C@@]12CCN(C)C[C@@H]1Oc1ccc(O)cc12
CHEMBL2386824,CHEMBL233,Mu opioid receptor,Ki,=,425.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,CN1CC[C@@]2(C)c3cc(O)ccc3O[C@H]2C1
CHEMBL2386823,CHEMBL233,Mu opioid receptor,Ki,=,28.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,CN1CC[C@@]2(CCCCCc3ccccc3)c3cc(O)ccc3O[C@H]2C1
CHEMBL2386822,CHEMBL233,Mu opioid receptor,Ki,=,45.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,CN1CC[C@@]2(CCCCc3ccccc3)c3cc(O)ccc3O[C@H]2C1
CHEMBL2386821,CHEMBL233,Mu opioid receptor,Ki,=,165.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,CN1CC[C@@]2(CCCc3ccccc3)c3cc(O)ccc3O[C@H]2C1
CHEMBL2386820,CHEMBL233,Mu opioid receptor,Ki,=,66.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,CN1CC[C@@]2(CCc3ccccc3)c3cc(O)ccc3O[C@H]2C1
CHEMBL2386819,CHEMBL233,Mu opioid receptor,Ki,=,60.0,nM,CHEMBL2390779,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis,CHEMBL2384966,KI,CN1CC[C@@]2(Cc3ccccc3)c3cc(O)ccc3O[C@H]2C1
CHEMBL1196093,CHEMBL233,Mu opioid receptor,Ki,=,4.0,nM,CHEMBL2390780,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL2384966,KI,CC[C@@]12CCN(CC3CC3)C[C@@H]1Oc1ccc(O)cc12
CHEMBL72180,CHEMBL233,Mu opioid receptor,Ki,=,0.9,nM,CHEMBL2390780,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL2384966,KI,CC[C@@]12CCN(CCc3ccccc3)C[C@@H]1Oc1ccc(O)cc12
CHEMBL2387190,CHEMBL233,Mu opioid receptor,Ki,=,533.0,nM,CHEMBL2389093,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells,CHEMBL2385080,KI,O=C1Cc2ccccc2N1C1CCN(CC2CCCCC2)CC1
CHEMBL320874,CHEMBL233,Mu opioid receptor,Ki,=,91.1,nM,CHEMBL2389093,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells,CHEMBL2385080,KI,O=C1Cc2ccccc2N1C1CCN(Cc2ccccc2)CC1
CHEMBL2387193,CHEMBL233,Mu opioid receptor,Ki,=,79.9,nM,CHEMBL2389093,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells,CHEMBL2385080,KI,O=C1Cc2ccccc2N1C1CCN(C2CC[C@H]3CCCc4cccc2c43)CC1
CHEMBL2387199,CHEMBL233,Mu opioid receptor,Ki,=,46.97,nM,CHEMBL2389093,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells,CHEMBL2385080,KI,O=C1CCc2ccccc2N1C1CCN(C2CCCCCCC2)CC1
CHEMBL101454,CHEMBL233,Mu opioid receptor,Ki,=,29.9,nM,CHEMBL2389093,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells,CHEMBL2385080,KI,O=C1Cc2ccccc2N1C1CCN(C2CCCCCCC2)CC1
CHEMBL2387200,CHEMBL233,Mu opioid receptor,Ki,=,23.27,nM,CHEMBL2389093,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CC1CC(=O)N(C2CCN(C3CCCCCCC3)CC2)c2ccccc21
CHEMBL2387197,CHEMBL233,Mu opioid receptor,Ki,=,16.26,nM,CHEMBL2389093,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CCC1C(=O)N(C2CCN(C3CCCCCCC3)CC2)c2ccccc21
CHEMBL2387189,CHEMBL233,Mu opioid receptor,Ki,=,16.13,nM,CHEMBL2389093,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CCC(C)(C)[C@H]1CC[C@@H](N2CCC(N3C(=O)Cc4ccccc43)CC2)CC1
CHEMBL2387195,CHEMBL233,Mu opioid receptor,Ki,=,10.49,nM,CHEMBL2389093,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CC1C(=O)N(C2CCN(C3CCCCCCC3)CC2)c2ccccc21
CHEMBL2387187,CHEMBL233,Mu opioid receptor,Ki,=,8.0,nM,CHEMBL2389093,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CC(C)C1CCC(N2CCC(N3C(=O)Cc4ccccc43)CC2)CC1
CHEMBL2387198,CHEMBL233,Mu opioid receptor,Ki,=,7.62,nM,CHEMBL2389093,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CC(C)C1CCC(N2CCC(N3C(=O)CCc4ccccc43)CC2)CC1
CHEMBL2387188,CHEMBL233,Mu opioid receptor,Ki,=,5.39,nM,CHEMBL2389093,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CCC[C@H]1CC[C@@H](N2CCC(N3C(=O)Cc4ccccc43)CC2)CC1
CHEMBL2387194,CHEMBL233,Mu opioid receptor,Ki,=,3.62,nM,CHEMBL2389093,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CC1C(=O)N(C2CCN([C@H]3CC[C@@H](C(C)C)CC3)CC2)c2ccccc21
CHEMBL2387191,CHEMBL233,Mu opioid receptor,Ki,=,3.44,nM,CHEMBL2389093,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CC(C1CCCCC1)N1CCC(N2C(=O)Cc3ccccc32)CC1
CHEMBL102900,CHEMBL233,Mu opioid receptor,Ki,=,2.7,nM,CHEMBL2389093,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells,CHEMBL2385080,KI,O=C1Cc2ccccc2N1C1CCN(C2C3CCCC2CCC3)CC1
CHEMBL2387192,CHEMBL233,Mu opioid receptor,Ki,=,2.34,nM,CHEMBL2389093,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CC(c1ccccc1)N1CCC(N2C(=O)Cc3ccccc32)CC1
CHEMBL2387196,CHEMBL233,Mu opioid receptor,Ki,=,1.07,nM,CHEMBL2389093,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CCC1C(=O)N(C2CCN([C@H]3CC[C@@H](C(C)C)CC3)CC2)c2ccccc21
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,8.1,nM,CHEMBL2395088,B,Displacement of [3H]Diprenorphine from human recombinant mu opioid receptor expressed in CHOK1 cells after 60 mins,CHEMBL2390918,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,0.28,nM,CHEMBL2394939,B,Binding affinity to human mu-type opioid receptor by radioligand displacement assay,CHEMBL2390830,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL58362,CHEMBL233,Mu opioid receptor,Ki,=,0.01,nM,CHEMBL2399175,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL2396537,KI,CC[C@@H]1CN2CC[C@]3(Nc4cccc(OC)c4C3=O)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL2396991,CHEMBL233,Mu opioid receptor,Ki,=,7.0,nM,CHEMBL2399175,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL2396537,KI,CC[C@@H]1CN2CC[C@@]34OCCO[C@@]3(Nc3ccc(F)c(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL2397019,CHEMBL233,Mu opioid receptor,Ki,=,6.22,nM,CHEMBL2399076,B,Displacement of [3H]naloxone from mu opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2c1
CHEMBL2397018,CHEMBL233,Mu opioid receptor,Ki,=,1.13,nM,CHEMBL2399076,B,Displacement of [3H]naloxone from mu opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cnc2ccccc2c1
CHEMBL2397017,CHEMBL233,Mu opioid receptor,Ki,=,9.09,nM,CHEMBL2399076,B,Displacement of [3H]naloxone from mu opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2n1
CHEMBL2397016,CHEMBL233,Mu opioid receptor,Ki,=,3.5,nM,CHEMBL2399076,B,Displacement of [3H]naloxone from mu opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cc2ccccc2cn1
CHEMBL2397015,CHEMBL233,Mu opioid receptor,Ki,=,4.34,nM,CHEMBL2399076,B,Displacement of [3H]naloxone from mu opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccc1
CHEMBL2397022,CHEMBL233,Mu opioid receptor,Ki,=,0.82,nM,CHEMBL2399076,B,Displacement of [3H]naloxone from mu opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccncc1
CHEMBL2397021,CHEMBL233,Mu opioid receptor,Ki,=,0.75,nM,CHEMBL2399076,B,Displacement of [3H]naloxone from mu opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cccnc1
CHEMBL2397020,CHEMBL233,Mu opioid receptor,Ki,=,1.51,nM,CHEMBL2399076,B,Displacement of [3H]naloxone from mu opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccn1
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.34,nM,CHEMBL2399076,B,Displacement of [3H]naloxone from mu opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL2409225,CHEMBL233,Mu opioid receptor,Ki,=,6.6,nM,CHEMBL2410569,B,Displacement of [125]IBNtxA from MOR-1 (unknown origin) transfected in CHO cells after 90 mins by competitive binding assay,CHEMBL2407029,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(I)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL2409224,CHEMBL233,Mu opioid receptor,Ki,=,9.3,nM,CHEMBL2410569,B,Displacement of [125]IBNtxA from MOR-1 (unknown origin) transfected in CHO cells after 90 mins by competitive binding assay,CHEMBL2407029,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL2409223,CHEMBL233,Mu opioid receptor,Ki,=,13.0,nM,CHEMBL2410569,B,Displacement of [125]IBNtxA from MOR-1 (unknown origin) transfected in CHO cells after 90 mins by competitive binding assay,CHEMBL2407029,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(I)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL2409222,CHEMBL233,Mu opioid receptor,Ki,=,7.3,nM,CHEMBL2410569,B,Displacement of [125]IBNtxA from MOR-1 (unknown origin) transfected in CHO cells after 90 mins by competitive binding assay,CHEMBL2407029,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL2409172,CHEMBL233,Mu opioid receptor,Ki,=,101.0,nM,CHEMBL2410920,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells after 90 mins by liquid scintillation counting,CHEMBL2407012,KI,NC(=O)[C@H](CNC(=O)[C@H](CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)Cc1ccccc1)Cc1ccccc1.O=C(O)C(F)(F)F
CHEMBL2409171,CHEMBL233,Mu opioid receptor,Ki,=,19.0,nM,CHEMBL2410920,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells after 90 mins by liquid scintillation counting,CHEMBL2407012,KI,NC(=O)C[C@H](Cc1ccccc1)NC(=O)C[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1.O=C(O)C(F)(F)F
CHEMBL2409170,CHEMBL233,Mu opioid receptor,Ki,=,20.0,nM,CHEMBL2410920,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells after 90 mins by liquid scintillation counting,CHEMBL2407012,KI,NC(=O)C[C@@H]1Cc2ccccc2CN1C(=O)C[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1.O=C(O)C(F)(F)F
CHEMBL2409169,CHEMBL233,Mu opioid receptor,Ki,=,3.3,nM,CHEMBL2410920,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells after 90 mins by liquid scintillation counting,CHEMBL2407012,KI,NC(=O)[C@H](CNC(=O)C[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)Cc1ccccc1.O=C(O)C(F)(F)F
CHEMBL2409168,CHEMBL233,Mu opioid receptor,Ki,=,5.5,nM,CHEMBL2410920,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells after 90 mins by liquid scintillation counting,CHEMBL2407012,KI,NC(=O)[C@@H](CNC(=O)C[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)Cc1ccccc1.O=C(O)C(F)(F)F
CHEMBL2409034,CHEMBL233,Mu opioid receptor,Ki,=,14.0,nM,CHEMBL2410920,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells after 90 mins by liquid scintillation counting,CHEMBL2407012,KI,NC(=O)[C@H]1Cc2ccccc2CN(C(=O)C[C@H](Cc2ccccc2)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](N)Cc2ccc(O)cc2)C1.O=C(O)C(F)(F)F
CHEMBL333357,CHEMBL233,Mu opioid receptor,Ki,=,5.3,nM,CHEMBL2410920,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells after 90 mins by liquid scintillation counting,CHEMBL2407012,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL2409033,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL2410920,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells after 90 mins by liquid scintillation counting,CHEMBL2407012,KI,NC(=O)[C@@H]1Cc2ccccc2CN(C(=O)C[C@H](Cc2ccccc2)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](N)Cc2ccc(O)cc2)C1.O=C(O)C(F)(F)F
CHEMBL2413879,CHEMBL233,Mu opioid receptor,Ki,=,3100.0,nM,CHEMBL2416895,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 120 mins by liquid scintillation counting,CHEMBL2412978,KI,CN(CCCc1ccccc1)[C@H]1CCCC[C@@H]1OCCCc1ccccc1
CHEMBL2413877,CHEMBL233,Mu opioid receptor,Ki,=,1600.0,nM,CHEMBL2416895,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 120 mins by liquid scintillation counting,CHEMBL2412978,KI,CN(CCc1ccccc1)[C@H]1CCCC[C@@H]1OCCCc1ccccc1
CHEMBL2413796,CHEMBL233,Mu opioid receptor,Ki,=,4200.0,nM,CHEMBL2416895,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 120 mins by liquid scintillation counting,CHEMBL2412978,KI,CN(C)[C@H]1CCCC[C@@H]1OC/C=C/c1ccccc1
CHEMBL2413795,CHEMBL233,Mu opioid receptor,Ki,=,2300.0,nM,CHEMBL2416895,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 120 mins by liquid scintillation counting,CHEMBL2412978,KI,CN(C)[C@H]1CCCC[C@@H]1OCCCc1ccccc1
CHEMBL440765,CHEMBL233,Mu opioid receptor,Ki,=,2370.0,nM,CHEMBL2423614,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2417511,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL2418732,CHEMBL233,Mu opioid receptor,Ki,=,52.0,nM,CHEMBL2423614,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2417511,KI,Oc1cccc([C@@]23CCN(CCc4ccccc4)[C@@H](C[C@H](c4ccccc4)C2)C3)c1
CHEMBL2418735,CHEMBL233,Mu opioid receptor,Ki,=,40.0,nM,CHEMBL2423614,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2417511,KI,O=C1C[C@H]2C[C@](c3cccc(O)c3)(CCN2CCc2ccccc2)C1
CHEMBL2418731,CHEMBL233,Mu opioid receptor,Ki,=,23.0,nM,CHEMBL2423614,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2417511,KI,CN1CC[C@]2(c3cccc(O)c3)C[C@@H](c3ccccc3)C[C@H]1C2
CHEMBL2418736,CHEMBL233,Mu opioid receptor,Ki,=,22.0,nM,CHEMBL2423614,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2417511,KI,CN1CC[C@]2(c3cccc(O)c3)C[C@H](O)C[C@@H]1C2
CHEMBL2418737,CHEMBL233,Mu opioid receptor,Ki,=,10.4,nM,CHEMBL2423614,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2417511,KI,Oc1cccc([C@@]23CCN(CCc4ccccc4)[C@H](C[C@@H](O)C2)C3)c1
CHEMBL2418730,CHEMBL233,Mu opioid receptor,Ki,=,7.2,nM,CHEMBL2423614,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2417511,KI,C[C@H]1C[C@H]2C[C@](c3cccc(O)c3)(CCN2CCc2ccccc2)C1
CHEMBL2418729,CHEMBL233,Mu opioid receptor,Ki,=,4.92,nM,CHEMBL2423614,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2417511,KI,C[C@H]1C[C@H]2C[C@](c3cccc(O)c3)(CCN2C)C1
CHEMBL2418734,CHEMBL233,Mu opioid receptor,Ki,=,4.0,nM,CHEMBL2423614,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2417511,KI,Oc1cccc([C@]23CCN(CCc4ccccc4)[C@H](C2)[C@H]2CCCC[C@@H]2C3)c1
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,2.6,nM,CHEMBL2423614,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2417511,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL2418572,CHEMBL233,Mu opioid receptor,Ki,=,2.23,nM,CHEMBL2423614,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2417511,KI,C[C@H]1CC[C@@]2(c3cccc(O)c3)CCN(CCc3ccccc3)[C@@H]1C2
CHEMBL2418571,CHEMBL233,Mu opioid receptor,Ki,=,1.49,nM,CHEMBL2423614,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2417511,KI,C[C@H]1CC[C@@]2(c3cccc(O)c3)CCN(C)[C@@H]1C2
CHEMBL2418733,CHEMBL233,Mu opioid receptor,Ki,=,0.9,nM,CHEMBL2423614,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2417511,KI,CN1CC[C@]2(c3cccc(O)c3)C[C@H]3CCCC[C@@H]3[C@H]1C2
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL2423614,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2417511,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL2431120,CHEMBL233,Mu opioid receptor,Ki,=,1540.0,nM,CHEMBL2433830,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL2429761,KI,COc1cc2nc(C3CC3)nc(N3CCN(c4ccccc4OC)CC3)c2cc1OC
CHEMBL2205829,CHEMBL233,Mu opioid receptor,Ki,=,4780.0,nM,CHEMBL2432432,B,Inhibition of mu opioid receptor (unknown origin) by PDSP assay,CHEMBL2429832,KI,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccc2c(c1)OCO2
CHEMBL2205827,CHEMBL233,Mu opioid receptor,Ki,=,1269.0,nM,CHEMBL2432432,B,Inhibition of mu opioid receptor (unknown origin) by PDSP assay,CHEMBL2429832,KI,COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC
CHEMBL2432059,CHEMBL233,Mu opioid receptor,Ki,=,2125.0,nM,CHEMBL2432432,B,Inhibition of mu opioid receptor (unknown origin) by PDSP assay,CHEMBL2429832,KI,CN(CCc1ccccn1)[C@H]1C2C3CC4C5C3CC2C5C41
CHEMBL522201,CHEMBL233,Mu opioid receptor,Ki,=,2.57,nM,CHEMBL2444609,B,Binding affinity to wild type MOR (unknown origin) expressed in CHO cells after 15 mins by Ca2+ mobilization assay,CHEMBL2440098,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cc2ccccc2cn1
CHEMBL522143,CHEMBL233,Mu opioid receptor,Ki,=,1.09,nM,CHEMBL2444609,B,Binding affinity to wild type MOR (unknown origin) expressed in CHO cells after 15 mins by Ca2+ mobilization assay,CHEMBL2440098,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,1.85,nM,CHEMBL2444609,B,Binding affinity to wild type MOR (unknown origin) expressed in CHO cells after 15 mins by Ca2+ mobilization assay,CHEMBL2440098,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL2443262,CHEMBL233,Mu opioid receptor,Ki,=,6.0,nM,CHEMBL2445974,B,Binding affinity to human mu opioid receptor by radio-ligand binding assay,CHEMBL2440083,KI,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1
CHEMBL322796,CHEMBL233,Mu opioid receptor,Ki,=,10.6,nM,CHEMBL3089516,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3085727,KI,COc1cccc2c1[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(OC)CCC(=O)C3
CHEMBL3086756,CHEMBL233,Mu opioid receptor,Ki,=,0.3,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(CNC(=O)c1ccccn1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL3086755,CHEMBL233,Mu opioid receptor,Ki,=,0.32,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(CCc1ccccn1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL3086754,CHEMBL233,Mu opioid receptor,Ki,=,0.29,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(Cc1ccccn1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL3086753,CHEMBL233,Mu opioid receptor,Ki,=,6.22,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2c1
CHEMBL3086752,CHEMBL233,Mu opioid receptor,Ki,=,1.13,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cnc2ccccc2c1
CHEMBL3086751,CHEMBL233,Mu opioid receptor,Ki,=,9.09,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2n1
CHEMBL3086750,CHEMBL233,Mu opioid receptor,Ki,=,3.5,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cc2ccccc2cn1
CHEMBL3086749,CHEMBL233,Mu opioid receptor,Ki,=,4.34,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccc1
CHEMBL3086748,CHEMBL233,Mu opioid receptor,Ki,=,0.82,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccncc1
CHEMBL3086747,CHEMBL233,Mu opioid receptor,Ki,=,0.75,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cccnc1
CHEMBL3086746,CHEMBL233,Mu opioid receptor,Ki,=,1.51,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccn1
CHEMBL3086745,CHEMBL233,Mu opioid receptor,Ki,=,225.3,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2c1
CHEMBL3086744,CHEMBL233,Mu opioid receptor,Ki,=,2.69,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cnc2ccccc2c1
CHEMBL3086762,CHEMBL233,Mu opioid receptor,Ki,=,1.44,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2n1
CHEMBL3086761,CHEMBL233,Mu opioid receptor,Ki,=,68.4,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cc2ccccc2cn1
CHEMBL3086760,CHEMBL233,Mu opioid receptor,Ki,=,123.2,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccc1
CHEMBL3086759,CHEMBL233,Mu opioid receptor,Ki,=,5.58,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccncc1
CHEMBL3086758,CHEMBL233,Mu opioid receptor,Ki,=,1.59,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cccnc1
CHEMBL3086757,CHEMBL233,Mu opioid receptor,Ki,=,0.14,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccn1
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.26,nM,CHEMBL3089529,B,Displacement of [3H]NLX from mu opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL3217271,CHEMBL233,Mu opioid receptor,Ki,=,0.43,nM,CHEMBL3088919,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL3085655,KI,C[C@@H]1CN(CCCc2ccccc2)[C@H]2C[C@H](N(C)CC3CC3)C[C@]1(c1cccc(O)c1)C2.Cl.Cl
CHEMBL3216613,CHEMBL233,Mu opioid receptor,Ki,=,0.28,nM,CHEMBL3088919,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL3085655,KI,C[C@@H]1CN(CCCc2ccccc2)[C@H]2C[C@H](N(C)C)C[C@]1(c1cccc(O)c1)C2.Cl.Cl
CHEMBL3217273,CHEMBL233,Mu opioid receptor,Ki,=,7.55,nM,CHEMBL3088919,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL3085655,KI,C[C@@H]1CN(CCCc2ccccc2)[C@H]2C[C@H](NCC3CC3)C[C@]1(c1cccc(O)c1)C2.Cl.Cl
CHEMBL3215960,CHEMBL233,Mu opioid receptor,Ki,=,1.66,nM,CHEMBL3088919,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL3085655,KI,CCCN[C@H]1C[C@H]2C[C@@](c3cccc(O)c3)(C1)[C@H](C)CN2CCCc1ccccc1.Cl.Cl
CHEMBL3217051,CHEMBL233,Mu opioid receptor,Ki,=,3.35,nM,CHEMBL3088919,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL3085655,KI,CCN[C@H]1C[C@H]2C[C@@](c3cccc(O)c3)(C1)[C@H](C)CN2CCCc1ccccc1.Cl.Cl
CHEMBL3217272,CHEMBL233,Mu opioid receptor,Ki,=,0.371,nM,CHEMBL3088919,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL3085655,KI,CN[C@H]1C[C@H]2C[C@@](c3cccc(O)c3)(C1)[C@H](C)CN2CCCc1ccccc1.Cl.Cl
CHEMBL3086466,CHEMBL233,Mu opioid receptor,Ki,=,1.61,nM,CHEMBL3088919,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL3085655,KI,C[C@@H]1CN(CCCc2ccccc2)[C@@H]2CCC[C@]1(c1cccc(O)c1)C2.Cl
CHEMBL3086308,CHEMBL233,Mu opioid receptor,Ki,=,0.14,nM,CHEMBL3090463,B,Displacement of [3H]-DAMGO from human mu opioid receptor transfected in CHO cells after 60 mins,CHEMBL3085732,KI,Br.CNc1nc2c(s1)C[C@H]1[C@H]3Cc4ccc(O)cc4[C@@]1(CCN3CC1CC1)C2
CHEMBL3086307,CHEMBL233,Mu opioid receptor,Ki,=,9.6,nM,CHEMBL3090463,B,Displacement of [3H]-DAMGO from human mu opioid receptor transfected in CHO cells after 60 mins,CHEMBL3085732,KI,CNc1nc2c(s1)C[C@H]1[C@H]3Cc4ccc(OC)cc4[C@@]1(CCN3CC1CC1)C2
CHEMBL3086306,CHEMBL233,Mu opioid receptor,Ki,=,6.6,nM,CHEMBL3090463,B,Displacement of [3H]-DAMGO from human mu opioid receptor transfected in CHO cells after 60 mins,CHEMBL3085732,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1Cc1sc(NC(C)=O)nc1C3
CHEMBL3086305,CHEMBL233,Mu opioid receptor,Ki,=,0.085,nM,CHEMBL3090463,B,Displacement of [3H]-DAMGO from human mu opioid receptor transfected in CHO cells after 60 mins,CHEMBL3085732,KI,CC(=O)Nc1nc2c(s1)C[C@H]1[C@H]3Cc4ccc(O)cc4[C@@]1(CCN3CC1CC1)C2
CHEMBL3086303,CHEMBL233,Mu opioid receptor,Ki,=,6.7,nM,CHEMBL3090463,B,Displacement of [3H]-DAMGO from human mu opioid receptor transfected in CHO cells after 60 mins,CHEMBL3085732,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1Cc1sc(N)nc1C3
CHEMBL301160,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL3090463,B,Displacement of [3H]-DAMGO from human mu opioid receptor transfected in CHO cells after 60 mins,CHEMBL3085732,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL508044,CHEMBL233,Mu opioid receptor,Ki,=,3400.0,nM,CHEMBL3101317,B,Inhibition of MOR (unknown origin),CHEMBL3098058,KI,COc1cccc(OC)c1-c1cc(C(=O)N[C@@H](CC(C)C)C(=O)O)nn1-c1ccnc2cc(Cl)ccc12
CHEMBL3099899,CHEMBL233,Mu opioid receptor,Ki,=,2040.0,nM,CHEMBL3102176,B,Inhibition of human mu opioid receptor,CHEMBL3098111,KI,COc1ccc(CNC(=O)c2cc(-c3cc(Cl)cc(Cl)c3)cnc2-c2cccnc2)cc1OC
CHEMBL3104104,CHEMBL233,Mu opioid receptor,Ki,=,25.8,nM,CHEMBL3106324,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3102699,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCCc2ccccc21
CHEMBL2307889,CHEMBL233,Mu opioid receptor,Ki,=,323.0,nM,CHEMBL3107080,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3102719,KI,N=C(N)NCCC[C@@H](NC(=O)CC1(CC(=O)N2CCN(C3c4ccccc4NC(=O)c4ccccc43)CC2)CCCC1)C(=O)NCCn1c(=O)n(-c2ccccc2)n(-c2ccccc2)c1=O
CHEMBL3220706,CHEMBL233,Mu opioid receptor,Ki,=,830.0,nM,CHEMBL3223625,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cells by liquid scintillation counting analysis,CHEMBL3217747,KI,CCC[C@@H](C)CN1CCC(c2cccc(O)c2)(c2ncc(C(=O)N(CC)CC)cn2)CC1
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.7,nM,CHEMBL3227799,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL3217593,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL3219777,CHEMBL233,Mu opioid receptor,Ki,=,51.8,nM,CHEMBL3227799,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL3217593,KI,Cc1nnc(C(C)C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccc(NC(=O)COCC(=O)NCCCCCCCNC(=O)COCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1
CHEMBL3219778,CHEMBL233,Mu opioid receptor,Ki,=,9.2,nM,CHEMBL3227799,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO cells after 1 hr,CHEMBL3217593,KI,CNC(=O)COCC(=O)NCCCCCCCNC(=O)COCC(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL3219614,CHEMBL233,Mu opioid receptor,Ki,=,2.0,nM,CHEMBL3225963,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in cells after 1 hr by liquid scintillation counting analysis,CHEMBL3217574,KI,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CCCC3(O)CCCCC3)C[C@@H]21
CHEMBL3219615,CHEMBL233,Mu opioid receptor,Ki,=,3.5,nM,CHEMBL3225963,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in cells after 1 hr by liquid scintillation counting analysis,CHEMBL3217574,KI,CC[C@]1(c2cccc(C(N)=O)c2)[C@@H]2CN(CC3(O)Cc4ccccc4C3)C[C@@H]21
CHEMBL3219616,CHEMBL233,Mu opioid receptor,Ki,=,1.0,nM,CHEMBL3225963,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in cells after 1 hr by liquid scintillation counting analysis,CHEMBL3217574,KI,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC3(O)Cc4ccccc4C3)C[C@@H]21
CHEMBL258098,CHEMBL233,Mu opioid receptor,Ki,=,390.0,nM,CHEMBL3224073,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane after 2 hrs by liquid scintillation counting analysis,CHEMBL3217531,KI,COCO[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL272939,CHEMBL233,Mu opioid receptor,Ki,=,41.0,nM,CHEMBL3224073,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane after 2 hrs by liquid scintillation counting analysis,CHEMBL3217531,KI,CCOCO[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3219937,CHEMBL233,Mu opioid receptor,Ki,=,777.0,nM,CHEMBL3224073,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane after 2 hrs by liquid scintillation counting analysis,CHEMBL3217531,KI,CCO[C@@H](C)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3219940,CHEMBL233,Mu opioid receptor,Ki,=,3523.0,nM,CHEMBL3224073,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane after 2 hrs by liquid scintillation counting analysis,CHEMBL3217531,KI,CCO[C@H](CBr)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3219942,CHEMBL233,Mu opioid receptor,Ki,=,1540.0,nM,CHEMBL3224073,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane after 2 hrs by liquid scintillation counting analysis,CHEMBL3217531,KI,CCNC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL120758,CHEMBL233,Mu opioid receptor,Ki,=,0.12,nM,CHEMBL3239389,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin),CHEMBL3232856,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL333357,CHEMBL233,Mu opioid receptor,Ki,=,1.33,nM,CHEMBL3239386,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3232856,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL1818341,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3268181,B,Antagonist activity at human cloned mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]-GTP[gammaS] binding,CHEMBL3259577,KI,CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)N2CCCC2)cc1
CHEMBL3264439,CHEMBL233,Mu opioid receptor,Ki,=,186.0,nM,CHEMBL3268184,B,Displacement of [3H]diprenorphine from mu opioid receptor (unknown origin) expressed in CHO cells membranes,CHEMBL3259577,KI,C[C@H]1CN(CCOC(=O)[C@H]2Cc3ccc(O)cc3CN2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL3264440,CHEMBL233,Mu opioid receptor,Ki,=,6.55,nM,CHEMBL3268184,B,Displacement of [3H]diprenorphine from mu opioid receptor (unknown origin) expressed in CHO cells membranes,CHEMBL3259577,KI,C[C@H]1CN(CCCOC(=O)[C@H]2Cc3ccc(O)cc3CN2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL3264441,CHEMBL233,Mu opioid receptor,Ki,=,26.5,nM,CHEMBL3268184,B,Displacement of [3H]diprenorphine from mu opioid receptor (unknown origin) expressed in CHO cells membranes,CHEMBL3259577,KI,CCOC(=O)C(CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)OC(=O)[C@H]1Cc2ccc(O)cc2CN1
CHEMBL3262542,CHEMBL233,Mu opioid receptor,Ki,=,41.5,nM,CHEMBL3270912,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cell membranes after 60 mins,CHEMBL3259735,KI,O=C1Cc2ccccc2N1C1CCN([C@H]2CC[C@@H]3CCCc4cccc2c43)CC1
CHEMBL3262543,CHEMBL233,Mu opioid receptor,Ki,=,30.3,nM,CHEMBL3270912,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cell membranes after 60 mins,CHEMBL3259735,KI,O=C1Cc2ccccc2N1C1CCN([C@@H]2CC[C@@H]3CCCc4cccc2c43)CC1
CHEMBL3262544,CHEMBL233,Mu opioid receptor,Ki,=,8.19,nM,CHEMBL3270912,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cell membranes after 60 mins,CHEMBL3259735,KI,CCC1C(=O)N(C2CCN([C@H]3CC[C@@H]4CCCc5cccc3c54)CC2)c2ccccc21
CHEMBL3262545,CHEMBL233,Mu opioid receptor,Ki,=,1.46,nM,CHEMBL3270912,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cell membranes after 60 mins,CHEMBL3259735,KI,CCC1C(=O)N(C2CCN([C@@H]3CC[C@@H]4CCCc5cccc3c54)CC2)c2ccccc21
CHEMBL3262546,CHEMBL233,Mu opioid receptor,Ki,=,1.05,nM,CHEMBL3270912,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cell membranes after 60 mins,CHEMBL3259735,KI,CCC1C(=O)N(C2CCN(C3CCCc4ccccc43)CC2)c2ccccc21
CHEMBL3262547,CHEMBL233,Mu opioid receptor,Ki,=,10.2,nM,CHEMBL3270912,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cell membranes after 60 mins,CHEMBL3259735,KI,CCC1C(=O)N(C2CCN(C3CCc4ccccc4C3)CC2)c2ccccc21
CHEMBL3262548,CHEMBL233,Mu opioid receptor,Ki,=,10.6,nM,CHEMBL3270912,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cell membranes after 60 mins,CHEMBL3259735,KI,CCC1C(=O)N(C2CCN(Cc3cccc4[nH]ccc34)CC2)c2ccccc21
CHEMBL3262549,CHEMBL233,Mu opioid receptor,Ki,=,1.97,nM,CHEMBL3270912,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cell membranes after 60 mins,CHEMBL3259735,KI,CCC1C(=O)N(C2CCN(CCC(c3ccccc3)c3ccccc3)CC2)c2ccccc21
CHEMBL3262550,CHEMBL233,Mu opioid receptor,Ki,=,100.0,nM,CHEMBL3270912,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cell membranes after 60 mins,CHEMBL3259735,KI,CCC1C(=O)N(C2CCN(C(C)CC(c3ccccc3)c3ccccc3)CC2)c2ccccc21
CHEMBL3262551,CHEMBL233,Mu opioid receptor,Ki,=,10.2,nM,CHEMBL3270912,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cell membranes after 60 mins,CHEMBL3259735,KI,CCC1C(=O)N(C2CCN(CCCc3ccccc3)CC2)c2ccccc21
CHEMBL3262552,CHEMBL233,Mu opioid receptor,Ki,=,33.4,nM,CHEMBL3270912,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cell membranes after 60 mins,CHEMBL3259735,KI,CCC1C(=O)N(C2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21
CHEMBL3262553,CHEMBL233,Mu opioid receptor,Ki,=,167.8,nM,CHEMBL3270912,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cell membranes after 60 mins,CHEMBL3259735,KI,CCC1C(=O)N(C2CCN(CCCCc3ccc(-c4ccccc4)cc3)CC2)c2ccccc21
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,2.96,nM,CHEMBL3270912,B,Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cell membranes after 60 mins,CHEMBL3259735,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL3262091,CHEMBL233,Mu opioid receptor,Ki,=,1.0,nM,CHEMBL3267129,B,Displacement of [3H]-DAMGO from human mu opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis,CHEMBL3259633,KI,CC[C@@](O)(c1ccccc1)[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL3262089,CHEMBL233,Mu opioid receptor,Ki,=,0.71,nM,CHEMBL3267129,B,Displacement of [3H]-DAMGO from human mu opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis,CHEMBL3259633,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262092,CHEMBL233,Mu opioid receptor,Ki,=,0.82,nM,CHEMBL3267129,B,Displacement of [3H]-DAMGO from human mu opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis,CHEMBL3259633,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262361,CHEMBL233,Mu opioid receptor,Ki,=,3.2,nM,CHEMBL3267129,B,Displacement of [3H]-DAMGO from human mu opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis,CHEMBL3259633,KI,CC[C@@](O)(c1ccccc1)[C@H]1C[C@@]23C=C[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL3262090,CHEMBL233,Mu opioid receptor,Ki,=,1.3,nM,CHEMBL3267129,B,Displacement of [3H]-DAMGO from human mu opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis,CHEMBL3259633,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262088,CHEMBL233,Mu opioid receptor,Ki,=,4.0,nM,CHEMBL3267129,B,Displacement of [3H]-DAMGO from human mu opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis,CHEMBL3259633,KI,CC[C@](O)([C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5)C(C)(C)C
CHEMBL3262362,CHEMBL233,Mu opioid receptor,Ki,=,4.2,nM,CHEMBL3267129,B,Displacement of [3H]-DAMGO from human mu opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis,CHEMBL3259633,KI,CC[C@](O)([C@H]1C[C@@]23C=C[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5)C(C)(C)C
CHEMBL3262093,CHEMBL233,Mu opioid receptor,Ki,=,4.0,nM,CHEMBL3267129,B,Displacement of [3H]-DAMGO from human mu opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis,CHEMBL3259633,KI,CO[C@]12C=C[C@@]3(C[C@@H]1[C@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL511142,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL3267129,B,Displacement of [3H]-DAMGO from human mu opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis,CHEMBL3259633,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL281786,CHEMBL233,Mu opioid receptor,Ki,=,0.07,nM,CHEMBL3293115,B,Binding affinity to human cloned mu opioid receptor expressed in CHO cells by radioligand displacement assay,CHEMBL3286325,KI,CO[C@]12CC[C@@]3(C[C@@H]1C(C)(C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL511142,CHEMBL233,Mu opioid receptor,Ki,=,0.09,nM,CHEMBL3293115,B,Binding affinity to human cloned mu opioid receptor expressed in CHO cells by radioligand displacement assay,CHEMBL3286325,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3291215,CHEMBL233,Mu opioid receptor,Ki,=,0.24,nM,CHEMBL3293115,B,Binding affinity to human cloned mu opioid receptor expressed in CHO cells by radioligand displacement assay,CHEMBL3286325,KI,CC(C)(C)[C@@](C)(O)[C@H]1C[C@@]23CC[C@]1(OCCF)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL3291216,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL3293115,B,Binding affinity to human cloned mu opioid receptor expressed in CHO cells by radioligand displacement assay,CHEMBL3286325,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@]2(OCCF)C=C[C@@]3(C[C@@H]2[C@@](C)(O)CCc2ccccc2)[C@H]1C5
CHEMBL3291214,CHEMBL233,Mu opioid receptor,Ki,=,0.24,nM,CHEMBL3293115,B,Binding affinity to human cloned mu opioid receptor expressed in CHO cells by radioligand displacement assay,CHEMBL3286325,KI,CC(C)(O)[C@H]1C[C@@]23CC[C@@]1(OCCF)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL3287466,CHEMBL233,Mu opioid receptor,Ki,=,58.2,nM,CHEMBL3292383,B,Displacement of [3H]DAMGO from mu-opioid receptor (unknown origin),CHEMBL3286318,KI,O=C1CC[C@@]23Cc4ccc(O)cc4[C@@]2(CCN(CC2CC2)C3)C1
CHEMBL3287467,CHEMBL233,Mu opioid receptor,Ki,=,112.0,nM,CHEMBL3292383,B,Displacement of [3H]DAMGO from mu-opioid receptor (unknown origin),CHEMBL3286318,KI,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)C[C@@]1(C2)Cc1cc2ccccc2nc1C3
CHEMBL3287468,CHEMBL233,Mu opioid receptor,Ki,=,415.0,nM,CHEMBL3292383,B,Displacement of [3H]DAMGO from mu-opioid receptor (unknown origin),CHEMBL3286318,KI,Oc1ccc2c(c1)[C@]13CCN(CC4(O)CC4)C[C@@]1(C2)Cc1cc2ccccc2nc1C3
CHEMBL3287469,CHEMBL233,Mu opioid receptor,Ki,=,76.3,nM,CHEMBL3292383,B,Displacement of [3H]DAMGO from mu-opioid receptor (unknown origin),CHEMBL3286318,KI,Oc1ccc2c(c1)[C@]13CCN(Cc4ccccc4)C[C@@]1(C2)Cc1cc2ccccc2nc1C3
CHEMBL3287470,CHEMBL233,Mu opioid receptor,Ki,=,3.06,nM,CHEMBL3292383,B,Displacement of [3H]DAMGO from mu-opioid receptor (unknown origin),CHEMBL3286318,KI,CN1CC[C@]23Cc4nc5ccccc5cc4C[C@]2(Cc2ccc(O)cc23)C1
CHEMBL3309506,CHEMBL233,Mu opioid receptor,Ki,=,1.23,nM,CHEMBL3361831,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,CN1C(=O)CCC2=C1[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(C)[C@H](C4)[C@]3(O)C2
CHEMBL3309507,CHEMBL233,Mu opioid receptor,Ki,=,0.29,nM,CHEMBL3361831,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C2=C(CCC(=O)N2Cc2ccccc2)C[C@@]3(O)[C@H]1C5
CHEMBL3309508,CHEMBL233,Mu opioid receptor,Ki,=,2.37,nM,CHEMBL3361831,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,CN1C(=O)[C@H](CCO)CC2=C1[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(C)[C@H](C4)[C@]3(O)C2
CHEMBL3309509,CHEMBL233,Mu opioid receptor,Ki,=,12.8,nM,CHEMBL3361831,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,CN1C(=O)[C@@H](CCO)CC2=C1[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(C)[C@H](C4)[C@]3(O)C2
CHEMBL3309264,CHEMBL233,Mu opioid receptor,Ki,=,2.03,nM,CHEMBL3361831,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C2=C(C[C@@H](CCO)C(=O)N2Cc2ccccc2)C[C@@]3(O)[C@H]1C5
CHEMBL3309510,CHEMBL233,Mu opioid receptor,Ki,=,3.0,nM,CHEMBL3361831,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C2=C(C[C@H](CCO)C(=O)N2Cc2ccccc2)C[C@@]3(O)[C@H]1C5
CHEMBL3309511,CHEMBL233,Mu opioid receptor,Ki,=,0.56,nM,CHEMBL3361831,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,C[C@@H]1CC2=C([C@@H]3Oc4c(O)ccc5c4[C@@]34CCN(CC3CC3)[C@H](C5)[C@]4(O)C2)N(Cc2ccccc2)C1=O
CHEMBL3309512,CHEMBL233,Mu opioid receptor,Ki,=,0.42,nM,CHEMBL3361831,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,C[C@H]1CC2=C([C@@H]3Oc4c(O)ccc5c4[C@@]34CCN(CC3CC3)[C@H](C5)[C@]4(O)C2)N(Cc2ccccc2)C1=O
CHEMBL3309513,CHEMBL233,Mu opioid receptor,Ki,=,0.43,nM,CHEMBL3361831,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,O=C1[C@H](CCO)CC2=C([C@@H]3Oc4c(O)ccc5c4[C@@]34CCN(CC3CC3)[C@H](C5)[C@]4(O)C2)N1Cc1ccccc1
CHEMBL3309514,CHEMBL233,Mu opioid receptor,Ki,=,1.54,nM,CHEMBL3361831,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,O=C1[C@@H](CCO)CC2=C([C@@H]3Oc4c(O)ccc5c4[C@@]34CCN(CC3CC3)[C@H](C5)[C@]4(O)C2)N1Cc1ccccc1
CHEMBL3309515,CHEMBL233,Mu opioid receptor,Ki,=,0.18,nM,CHEMBL3361831,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,O=C1CCC2=C([C@@H]3Oc4c(O)ccc5c4[C@@]34CCN(CC3CC3)[C@H](C5)[C@]4(O)C2)N1Cc1ccccc1
CHEMBL3309518,CHEMBL233,Mu opioid receptor,Ki,=,0.11,nM,CHEMBL3361831,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,O=C1CCC2=C([C@@H]3Oc4c(O)ccc5c4[C@@]34CCN(CC3CC3)[C@H](C5)[C@]4(O)C2)N1CC1CCCCC1
CHEMBL3357966,CHEMBL233,Mu opioid receptor,Ki,=,13.2,nM,CHEMBL3361831,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,CCOC(=O)Cc1c2c(n(Cc3ccccc3)c1O)[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(C)[C@H](C4)[C@]3(O)C2
CHEMBL3357967,CHEMBL233,Mu opioid receptor,Ki,=,8.65,nM,CHEMBL3361831,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,CCOC(=O)Cc1c2c(n(Cc3ccccc3)c1O)[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@H](C4)[C@]3(O)C2
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL3361831,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL567175,CHEMBL233,Mu opioid receptor,Ki,=,6.3,nM,CHEMBL3361831,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL573214,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL3361831,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL3299002,CHEMBL233,Mu opioid receptor,Ki,=,3900.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(Cc2ccccc2)[C@@H]2CCC[C@H](N3CCCC3)[C@H]21
CHEMBL3323508,CHEMBL233,Mu opioid receptor,Ki,=,4300.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(Cc2ccccc2)C2CCCC(N3CCC(O)C3)C21
CHEMBL3323509,CHEMBL233,Mu opioid receptor,Ki,=,2800.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCNC2CCCC(N3CCCC3)C21
CHEMBL3323510,CHEMBL233,Mu opioid receptor,Ki,=,4900.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCNC2CCCC(N3CCC(O)C3)C21
CHEMBL3323511,CHEMBL233,Mu opioid receptor,Ki,=,5100.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,CN1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C2C1CCCC2N1CCCC1
CHEMBL3323512,CHEMBL233,Mu opioid receptor,Ki,=,6000.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,CN1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C2C1CCCC2N1CCC(O)C1
CHEMBL3323513,CHEMBL233,Mu opioid receptor,Ki,=,2300.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,CCCCN1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C2C(N3CCCC3)CCCC21
CHEMBL3323514,CHEMBL233,Mu opioid receptor,Ki,=,740.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,COc1ccc(CN2CCN(C(=O)Cc3ccc(Cl)c(Cl)c3)C3C(N4CCCC4)CCCC32)cc1
CHEMBL3323515,CHEMBL233,Mu opioid receptor,Ki,=,2260.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(Cc2ccccn2)C2CCCC(N3CCCC3)C21
CHEMBL3323516,CHEMBL233,Mu opioid receptor,Ki,=,4690.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(Cc2cnc[nH]2)C2CCCC(N3CCCC3)C21
CHEMBL3323517,CHEMBL233,Mu opioid receptor,Ki,=,4400.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(Cc2cnc[nH]2)C2CCCC(N3CCC(O)C3)C21
CHEMBL3323518,CHEMBL233,Mu opioid receptor,Ki,=,1300.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,O=C(c1ccccc1)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C2C(N3CCCC3)CCCC21
CHEMBL3323519,CHEMBL233,Mu opioid receptor,Ki,=,3620.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,O=C(c1ccccc1)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C2C(N3CCC(O)C3)CCCC21
CHEMBL3323520,CHEMBL233,Mu opioid receptor,Ki,=,2800.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,CC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C2C(N3CCCC3)CCCC21
CHEMBL3323521,CHEMBL233,Mu opioid receptor,Ki,=,3335.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,CCC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C2C(N3CCCC3)CCCC21
CHEMBL3299005,CHEMBL233,Mu opioid receptor,Ki,=,2355.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,COC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)[C@H]2[C@H]1CCC[C@@H]2N1CCCC1
CHEMBL3323522,CHEMBL233,Mu opioid receptor,Ki,=,4450.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,COC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C2C(N3CCC(O)C3)CCCC21
CHEMBL3323523,CHEMBL233,Mu opioid receptor,Ki,=,1775.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,CCOC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C2C(N3CCCC3)CCCC21
CHEMBL3323526,CHEMBL233,Mu opioid receptor,Ki,=,2200.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,COC(=O)CC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C2C(N3CCCC3)CCCC21
CHEMBL3323527,CHEMBL233,Mu opioid receptor,Ki,=,6000.0,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,COC(=O)CC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C2C(N3CCC(O)C3)CCCC21
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,2.3,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,5.2,nM,CHEMBL3379233,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in CHO-K1 cells by scintillation counting analysis,CHEMBL3352357,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL3366385,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cells by scintillation counting,CHEMBL3351525,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL3319079,CHEMBL233,Mu opioid receptor,Ki,=,3.6,nM,CHEMBL3366385,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cells by scintillation counting,CHEMBL3351525,KI,O=C1CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)CNC(=O)[C@H](Cc2ccc(O)cc2)N1
CHEMBL3319080,CHEMBL233,Mu opioid receptor,Ki,=,314.0,nM,CHEMBL3366385,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cells by scintillation counting,CHEMBL3351525,KI,CC(=O)N[C@H](Cc1c(C)[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(N)=O
CHEMBL3319081,CHEMBL233,Mu opioid receptor,Ki,=,426.0,nM,CHEMBL3366385,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cells by scintillation counting,CHEMBL3351525,KI,CC(=O)N[C@H](Cc1c[nH]c2ccc(C)cc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(N)=O
CHEMBL3319084,CHEMBL233,Mu opioid receptor,Ki,=,5.7,nM,CHEMBL3366385,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cells by scintillation counting,CHEMBL3351525,KI,CC(=O)N[C@H](Cc1c[nH]c2cc(F)ccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(N)=O
CHEMBL3319085,CHEMBL233,Mu opioid receptor,Ki,=,20.8,nM,CHEMBL3366385,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cells by scintillation counting,CHEMBL3351525,KI,CC(=O)N[C@H](Cc1c[nH]c2ccc(Cl)cc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(N)=O
CHEMBL3319087,CHEMBL233,Mu opioid receptor,Ki,=,114.0,nM,CHEMBL3366385,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cells by scintillation counting,CHEMBL3351525,KI,CC(=O)N[C@H](Cc1c[nH]c2ccc(Br)cc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(N)=O
CHEMBL3319088,CHEMBL233,Mu opioid receptor,Ki,=,190.0,nM,CHEMBL3366385,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cells by scintillation counting,CHEMBL3351525,KI,CC(=O)N[C@H](Cc1c[nH]c2c(Br)cccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(N)=O
CHEMBL3319089,CHEMBL233,Mu opioid receptor,Ki,=,51.9,nM,CHEMBL3366385,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cells by scintillation counting,CHEMBL3351525,KI,CC(=O)N[C@H](Cc1c[nH]c2ccc([N+](=O)[O-])cc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(N)=O
CHEMBL3319091,CHEMBL233,Mu opioid receptor,Ki,=,4.03,nM,CHEMBL3366385,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cells by scintillation counting,CHEMBL3351525,KI,CC(=O)N[C@H](Cc1c(C)[nH]c2c(Br)cccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(N)=O
CHEMBL3330683,CHEMBL233,Mu opioid receptor,Ki,=,18.0,nM,CHEMBL3385053,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,COC(=O)[C@@H]1C[C@H](OC(=O)/C=C/c2ccsc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3330682,CHEMBL233,Mu opioid receptor,Ki,=,334.0,nM,CHEMBL3385053,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,COC(=O)[C@@H]1C[C@H](OC(=O)/C=C/c2cccnc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3330676,CHEMBL233,Mu opioid receptor,Ki,=,2820.0,nM,CHEMBL3385053,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,COC(=O)[C@@H]1C[C@H](OC(=O)/C=C/c2ccc3c(c2)OCO3)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3330670,CHEMBL233,Mu opioid receptor,Ki,=,52.0,nM,CHEMBL3385053,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,COC(=O)[C@@H]1C[C@H](OC(=O)/C=C/c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3330669,CHEMBL233,Mu opioid receptor,Ki,=,439.0,nM,CHEMBL3385053,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,C=CC(C)C(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3330667,CHEMBL233,Mu opioid receptor,Ki,=,1441.0,nM,CHEMBL3385053,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,C=CCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3330666,CHEMBL233,Mu opioid receptor,Ki,=,540.0,nM,CHEMBL3385053,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,C/C=C/C(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3330665,CHEMBL233,Mu opioid receptor,Ki,=,362.0,nM,CHEMBL3385053,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,C=C(C)CC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3330664,CHEMBL233,Mu opioid receptor,Ki,=,284.0,nM,CHEMBL3385053,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,COC(=O)[C@@H]1C[C@H](OC(=O)C=C(C)C)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3330663,CHEMBL233,Mu opioid receptor,Ki,=,979.0,nM,CHEMBL3385053,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,C=CC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,2.3,nM,CHEMBL3385053,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL3325745,CHEMBL233,Mu opioid receptor,Ki,=,44.5,nM,CHEMBL3362475,B,Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 mins,CHEMBL3351750,KI,CN(C)[C@]1(c2ccccc2)CC[C@@](O)(c2ccccc2)CC1
CHEMBL3325747,CHEMBL233,Mu opioid receptor,Ki,=,1.9,nM,CHEMBL3362475,B,Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 mins,CHEMBL3351750,KI,CN(C)[C@]1(c2ccccc2)CC[C@@](O)(CCc2ccccc2)CC1.Cl
CHEMBL3325748,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL3362475,B,Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 mins,CHEMBL3351750,KI,CN(C)[C@]1(c2ccccc2)CC[C@@H](OCc2ccccc2)CC1.Cl
CHEMBL3325749,CHEMBL233,Mu opioid receptor,Ki,=,830.0,nM,CHEMBL3362475,B,Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 mins,CHEMBL3351750,KI,CN(C)[C@]1(c2ccccc2)CC[C@H](OCc2ccccc2)CC1.Cl
CHEMBL3325751,CHEMBL233,Mu opioid receptor,Ki,=,3.0,nM,CHEMBL3362475,B,Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 mins,CHEMBL3351750,KI,CN(C)[C@]1(c2ccccc2)CC[C@@H](NCc2ccccc2)CC1.Cl.Cl
CHEMBL3325878,CHEMBL233,Mu opioid receptor,Ki,=,11.0,nM,CHEMBL3362475,B,Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 mins,CHEMBL3351750,KI,CN(C)[C@]1(c2ccccc2)CC[C@@H](NCCc2ccccc2)CC1.Cl.Cl
CHEMBL3325879,CHEMBL233,Mu opioid receptor,Ki,=,22.0,nM,CHEMBL3362475,B,Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 mins,CHEMBL3351750,KI,CN(C)[C@]1(c2ccccc2)CC[C@@H](NCCCc2ccccc2)CC1.Cl.Cl
CHEMBL3325880,CHEMBL233,Mu opioid receptor,Ki,=,2.1,nM,CHEMBL3362475,B,Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 mins,CHEMBL3351750,KI,CN(C)C1(c2ccccc2)CCC(NC(=O)Cc2ccccc2)CC1.Cl
CHEMBL3325881,CHEMBL233,Mu opioid receptor,Ki,=,0.7,nM,CHEMBL3362475,B,Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 mins,CHEMBL3351750,KI,CN(C)[C@]1(c2ccccc2)CC[C@@H](NC(=O)NCCCc2ccccc2)CC1.Cl
CHEMBL3326220,CHEMBL233,Mu opioid receptor,Ki,=,0.3,nM,CHEMBL3362475,B,Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 mins,CHEMBL3351750,KI,CN(C)[C@]1(c2ccccc2)CC[C@@H](NC(=O)CCC2CCCC2)CC1.Cl
CHEMBL3326221,CHEMBL233,Mu opioid receptor,Ki,=,6.4,nM,CHEMBL3362475,B,Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 mins,CHEMBL3351750,KI,CN(C)C1(c2ccccc2)CCC(NCc2c[nH]c3ccccc23)CC1
CHEMBL3326222,CHEMBL233,Mu opioid receptor,Ki,=,9.5,nM,CHEMBL3362475,B,Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 mins,CHEMBL3351750,KI,CN(C)[C@]1(c2ccccc2)CC[C@@H](NCCc2c[nH]c3ccccc23)CC1.Cl.Cl
CHEMBL3326223,CHEMBL233,Mu opioid receptor,Ki,=,9.0,nM,CHEMBL3362475,B,Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 mins,CHEMBL3351750,KI,CN(C)[C@]1(c2ccccc2)CC[C@@H](NCCc2c[nH]c3ccc(F)cc23)CC1.Cl.Cl
CHEMBL3326224,CHEMBL233,Mu opioid receptor,Ki,=,0.6,nM,CHEMBL3362475,B,Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 mins,CHEMBL3351750,KI,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3ccccc3[nH]c12.Cl
CHEMBL3326227,CHEMBL233,Mu opioid receptor,Ki,=,310.0,nM,CHEMBL3362475,B,Displacement of [3H]Naloxone from human mu opioid receptor receptor expressed in CHO-K1 cells after 90 mins,CHEMBL3351750,KI,CN(C)[C@]1(c2ccccc2)CC[C@@]2(CC1)OCCc1c3ccccc3[nH]c12.Cl
CHEMBL300662,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL3369356,B,Binding affinity to human mu opioid receptor expressed in CHO cells,CHEMBL3352410,KI,C[C@H]1CN(CC[C@H](O)C2CCCCC2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL3326796,CHEMBL233,Mu opioid receptor,Ki,=,7.7,nM,CHEMBL3369356,B,Binding affinity to human mu opioid receptor expressed in CHO cells,CHEMBL3352410,KI,C[C@H]1CN(CC[C@H](O)C2CCCCC2)CC[C@@]1(C)c1ccccc1
CHEMBL3325962,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL3366609,B,Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assay,CHEMBL3352090,KI,COc1ccc2[nH]c3c(c2c1)CCO[C@]31CC[C@](c2ccccc2)(N(C)C)CC1.Cl
CHEMBL3325961,CHEMBL233,Mu opioid receptor,Ki,=,0.4,nM,CHEMBL3366609,B,Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assay,CHEMBL3352090,KI,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(O)ccc3[nH]c12.O=C(O)CC(O)(CC(=O)O)C(=O)O
CHEMBL3325960,CHEMBL233,Mu opioid receptor,Ki,=,2.7,nM,CHEMBL3366609,B,Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assay,CHEMBL3352090,KI,Cc1ccc2[nH]c3c(c2c1)CCO[C@]31CC[C@](c2ccccc2)(N(C)C)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O
CHEMBL3325959,CHEMBL233,Mu opioid receptor,Ki,=,2.0,nM,CHEMBL3366609,B,Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assay,CHEMBL3352090,KI,CN[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12.O=C(O)CC(O)(CC(=O)O)C(=O)O
CHEMBL3325958,CHEMBL233,Mu opioid receptor,Ki,=,46.0,nM,CHEMBL3366609,B,Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assay,CHEMBL3352090,KI,CN(C)[C@]1(c2ccccc2)CC[C@@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12.O=C(O)CC(O)(CC(=O)O)C(=O)O
CHEMBL3325957,CHEMBL233,Mu opioid receptor,Ki,=,0.7,nM,CHEMBL3366609,B,Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assay,CHEMBL3352090,KI,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12.O=C(O)CC(O)(CC(=O)O)C(=O)O
CHEMBL3326232,CHEMBL233,Mu opioid receptor,Ki,=,0.36,nM,CHEMBL3366609,B,Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assay,CHEMBL3352090,KI,CN[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3ccccc3[nH]c12.O=C(O)CC(O)(CC(=O)O)C(=O)O
CHEMBL3326231,CHEMBL233,Mu opioid receptor,Ki,=,1.95,nM,CHEMBL3366609,B,Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assay,CHEMBL3352090,KI,CN(C)[C@]1(c2ccccc2)CC[C@@]2(CCCc3c4ccccc4[nH]c32)CC1
CHEMBL3326230,CHEMBL233,Mu opioid receptor,Ki,=,3.1,nM,CHEMBL3366609,B,Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assay,CHEMBL3352090,KI,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)SCCc1c3ccccc3[nH]c12.O=C(O)CC(O)(CC(=O)O)C(=O)O
CHEMBL3326229,CHEMBL233,Mu opioid receptor,Ki,=,0.24,nM,CHEMBL3366609,B,Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assay,CHEMBL3352090,KI,CN(C)[C@]1(c2ccccc2)CC[C@@]2(CC1)c1[nH]c3ccccc3c1CCN2C.Cl
CHEMBL3326228,CHEMBL233,Mu opioid receptor,Ki,=,0.39,nM,CHEMBL3366609,B,Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assay,CHEMBL3352090,KI,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)NCCc1c3ccccc3[nH]c12.Cl
CHEMBL3326227,CHEMBL233,Mu opioid receptor,Ki,=,310.0,nM,CHEMBL3366609,B,Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assay,CHEMBL3352090,KI,CN(C)[C@]1(c2ccccc2)CC[C@@]2(CC1)OCCc1c3ccccc3[nH]c12.Cl
CHEMBL3326224,CHEMBL233,Mu opioid receptor,Ki,=,0.26,nM,CHEMBL3366609,B,Displacement of [3H]naloxone from human MOP receptor expressed in CHO-K1 cells by scintillation proximity assay,CHEMBL3352090,KI,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3ccccc3[nH]c12.Cl
CHEMBL3360832,CHEMBL233,Mu opioid receptor,Ki,=,3.39,nM,CHEMBL3387189,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cells after 60 mins by scintillation counting analysis,CHEMBL3351542,KI,N=C(N)NCCC[C@H](N)C(=O)NCC1(Nc2ccccc2)CCN(Cc2ccccc2)CC1
CHEMBL3361418,CHEMBL233,Mu opioid receptor,Ki,=,2022.0,nM,CHEMBL3387189,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cells after 60 mins by scintillation counting analysis,CHEMBL3351542,KI,N=C(N)NCC(=O)NCC1(Nc2cccc3ccccc23)CCN(Cc2ccccc2)CC1
CHEMBL3361419,CHEMBL233,Mu opioid receptor,Ki,=,688.0,nM,CHEMBL3387189,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cells after 60 mins by scintillation counting analysis,CHEMBL3351542,KI,COc1cc(NC2(CNC(=O)CNC(=N)N)CCN(Cc3ccccc3)CC2)cc(OC)c1
CHEMBL3361425,CHEMBL233,Mu opioid receptor,Ki,=,201.0,nM,CHEMBL3387189,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cells after 60 mins by scintillation counting analysis,CHEMBL3351542,KI,N=C(N)NCCNC(=O)C1(Nc2ccccc2)CCN(Cc2ccccc2)CC1
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,354.0,nM,CHEMBL3387189,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cells after 60 mins by scintillation counting analysis,CHEMBL3351542,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL415247,CHEMBL233,Mu opioid receptor,Ki,=,4.0,nM,CHEMBL3399797,B,Displacement of [3H]diprenorphine from human recombinant mu opioid receptor expressed in HEK cells after 60 mins,CHEMBL3396991,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1
CHEMBL3397593,CHEMBL233,Mu opioid receptor,Ki,=,13.23,nM,CHEMBL3399797,B,Displacement of [3H]diprenorphine from human recombinant mu opioid receptor expressed in HEK cells after 60 mins,CHEMBL3396991,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1CCF
CHEMBL3397594,CHEMBL233,Mu opioid receptor,Ki,=,19.61,nM,CHEMBL3399797,B,Displacement of [3H]diprenorphine from human recombinant mu opioid receptor expressed in HEK cells after 60 mins,CHEMBL3396991,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1CCCF
CHEMBL3397595,CHEMBL233,Mu opioid receptor,Ki,=,63.08,nM,CHEMBL3399797,B,Displacement of [3H]diprenorphine from human recombinant mu opioid receptor expressed in HEK cells after 60 mins,CHEMBL3396991,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(OCCF)cc2CN1
CHEMBL3397596,CHEMBL233,Mu opioid receptor,Ki,=,57.52,nM,CHEMBL3399797,B,Displacement of [3H]diprenorphine from human recombinant mu opioid receptor expressed in HEK cells after 60 mins,CHEMBL3396991,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(OCCCF)cc2CN1
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.45,nM,CHEMBL3399797,B,Displacement of [3H]diprenorphine from human recombinant mu opioid receptor expressed in HEK cells after 60 mins,CHEMBL3396991,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,2.6,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL3409123,CHEMBL233,Mu opioid receptor,Ki,=,159.0,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCCc3ccccc3)CCN(CCc3ccccc3C(F)(F)F)C[C@@H]1O2
CHEMBL3409122,CHEMBL233,Mu opioid receptor,Ki,=,3.9,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCCc3ccccc3)CCN(CC3CC3)C[C@@H]1O2
CHEMBL3409121,CHEMBL233,Mu opioid receptor,Ki,=,3.1,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCCc3ccccc3)CCN(CCc3ccc(C(F)(F)F)cc3)C[C@@H]1O2
CHEMBL3409120,CHEMBL233,Mu opioid receptor,Ki,=,5.8,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCCc3ccccc3)CCN(CCc3ccccc3F)C[C@@H]1O2
CHEMBL3409119,CHEMBL233,Mu opioid receptor,Ki,=,4.2,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCCc3ccccc3)CCN(CCc3ccc(F)cc3)C[C@@H]1O2
CHEMBL3409118,CHEMBL233,Mu opioid receptor,Ki,=,5.6,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCCc3ccccc3)CCN(CCc3ccccc3)C[C@@H]1O2
CHEMBL3409117,CHEMBL233,Mu opioid receptor,Ki,=,38.0,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCc3ccccc3)CCN(CCc3cccc(C(F)(F)F)c3)C[C@@H]1O2
CHEMBL3409115,CHEMBL233,Mu opioid receptor,Ki,=,294.0,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCc3ccccc3)CCN(CCc3ccccc3C(F)(F)F)C[C@@H]1O2
CHEMBL3409114,CHEMBL233,Mu opioid receptor,Ki,=,14.0,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCc3ccccc3)CCN(CC3CC3)C[C@@H]1O2
CHEMBL3409113,CHEMBL233,Mu opioid receptor,Ki,=,3.8,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCc3ccccc3)CCN(CCc3ccc(C(F)(F)F)cc3)C[C@@H]1O2
CHEMBL3409112,CHEMBL233,Mu opioid receptor,Ki,=,80.0,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCc3ccccc3)CCN(CCCc3ccccc3)C[C@@H]1O2
CHEMBL3409111,CHEMBL233,Mu opioid receptor,Ki,=,10.1,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCc3ccccc3)CCN(CCc3ccccc3F)C[C@@H]1O2
CHEMBL3409110,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCc3ccccc3)CCN(CCc3ccc(F)cc3)C[C@@H]1O2
CHEMBL3409109,CHEMBL233,Mu opioid receptor,Ki,=,7.7,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCc3ccccc3)CCN(CCc3ccccc3)C[C@@H]1O2
CHEMBL3409108,CHEMBL233,Mu opioid receptor,Ki,=,93.0,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCc3ccccc3)CCN(CCc3cccc(C(F)(F)F)c3)C[C@@H]1O2
CHEMBL3409107,CHEMBL233,Mu opioid receptor,Ki,=,351.0,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCc3ccccc3)CCN(CCc3ccccc3C(F)(F)F)C[C@@H]1O2
CHEMBL3409106,CHEMBL233,Mu opioid receptor,Ki,=,13.0,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCc3ccccc3)CCN(CC3CC3)C[C@@H]1O2
CHEMBL3409105,CHEMBL233,Mu opioid receptor,Ki,=,53.0,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,C=CCN1CC[C@@]2(CCCc3ccccc3)c3cc(O)ccc3O[C@H]2C1
CHEMBL3409104,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCc3ccccc3)CCN(CCc3ccc(C(F)(F)F)cc3)C[C@@H]1O2
CHEMBL3409103,CHEMBL233,Mu opioid receptor,Ki,=,73.0,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCc3ccccc3)CCN(CCCc3ccccc3)C[C@@H]1O2
CHEMBL3409102,CHEMBL233,Mu opioid receptor,Ki,=,17.0,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCc3ccccc3)CCN(CCc3ccccc3F)C[C@@H]1O2
CHEMBL3409101,CHEMBL233,Mu opioid receptor,Ki,=,47.0,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCc3ccccc3)CCN(CCc3ccc(F)cc3)C[C@@H]1O2
CHEMBL3409100,CHEMBL233,Mu opioid receptor,Ki,=,14.0,nM,CHEMBL3412858,B,Displacement of [3H]DAMGO from human recombinant opioid mu receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method,CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCc3ccccc3)CCN(CCc3ccccc3)C[C@@H]1O2
CHEMBL1330,CHEMBL233,Mu opioid receptor,Ki,=,63.0,nM,CHEMBL3423922,B,Displacement of [3H]naloxone from MOR (unknown origin) expressed in human 293T cells,CHEMBL3421561,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)C=C[C@H]3[C@H]1C5
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,22.0,nM,CHEMBL3423922,B,Displacement of [3H]naloxone from MOR (unknown origin) expressed in human 293T cells,CHEMBL3421561,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL1455766,CHEMBL233,Mu opioid receptor,Ki,=,306.0,nM,CHEMBL3590960,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3588796,KI,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C(C)C)cc2)cc1
CHEMBL3590193,CHEMBL233,Mu opioid receptor,Ki,=,8170.0,nM,CHEMBL3590960,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3588796,KI,Cc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(Br)cc4)C(C)C)ccc3C2)cc1
CHEMBL3590195,CHEMBL233,Mu opioid receptor,Ki,=,1749.0,nM,CHEMBL3590960,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3588796,KI,Cc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccccc4)C(C)(C)C)ccc3C2)cc1
CHEMBL3596370,CHEMBL233,Mu opioid receptor,Ki,=,422.0,nM,CHEMBL3598350,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cells,CHEMBL3596130,KI,Cl.Oc1ccc2c3c1O[C@H]1c4nc5ccccc5cc4C[C@@]4(O)[C@@H](C2)N(CCF)CC[C@]314
CHEMBL3596369,CHEMBL233,Mu opioid receptor,Ki,=,123.0,nM,CHEMBL3598350,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cells,CHEMBL3596130,KI,CCCN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2nc4ccccc4cc2C[C@@]3(O)[C@H]1C5.Cl
CHEMBL3596368,CHEMBL233,Mu opioid receptor,Ki,=,670.0,nM,CHEMBL3598350,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cells,CHEMBL3596130,KI,CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2nc4ccccc4cc2C[C@@]3(O)[C@H]1C5.Cl
CHEMBL610012,CHEMBL233,Mu opioid receptor,Ki,=,20.8,nM,CHEMBL3598350,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cells,CHEMBL3596130,KI,Oc1ccc2c3c1O[C@H]1c4nc5ccccc5cc4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL3596365,CHEMBL233,Mu opioid receptor,Ki,=,675.0,nM,CHEMBL3598350,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cells,CHEMBL3596130,KI,Cl.Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CCF)CC[C@]314
CHEMBL3596364,CHEMBL233,Mu opioid receptor,Ki,=,133.0,nM,CHEMBL3598350,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cells,CHEMBL3596130,KI,CCCN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(O)[C@H]1C5.Cl
CHEMBL3596363,CHEMBL233,Mu opioid receptor,Ki,=,788.0,nM,CHEMBL3598350,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cells,CHEMBL3596130,KI,CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(O)[C@H]1C5.Cl
CHEMBL567175,CHEMBL233,Mu opioid receptor,Ki,=,30.7,nM,CHEMBL3598350,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cells,CHEMBL3596130,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL3597153,CHEMBL233,Mu opioid receptor,Ki,=,1.4,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CCCCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597152,CHEMBL233,Mu opioid receptor,Ki,=,13.0,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CCCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597151,CHEMBL233,Mu opioid receptor,Ki,=,4.3,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CCCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597150,CHEMBL233,Mu opioid receptor,Ki,=,6.6,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)CCCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597088,CHEMBL233,Mu opioid receptor,Ki,=,3.8,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)CCCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597087,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597086,CHEMBL233,Mu opioid receptor,Ki,=,39.0,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597085,CHEMBL233,Mu opioid receptor,Ki,=,26.0,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597084,CHEMBL233,Mu opioid receptor,Ki,=,2.6,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597083,CHEMBL233,Mu opioid receptor,Ki,=,5.0,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)C(N)=O
CHEMBL3597082,CHEMBL233,Mu opioid receptor,Ki,=,5.2,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597080,CHEMBL233,Mu opioid receptor,Ki,=,1200.0,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597079,CHEMBL233,Mu opioid receptor,Ki,=,120.0,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597078,CHEMBL233,Mu opioid receptor,Ki,=,0.24,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597077,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597076,CHEMBL233,Mu opioid receptor,Ki,=,2.8,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597075,CHEMBL233,Mu opioid receptor,Ki,=,15.0,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597074,CHEMBL233,Mu opioid receptor,Ki,=,5.6,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)CCNC(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597073,CHEMBL233,Mu opioid receptor,Ki,=,3.2,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597072,CHEMBL233,Mu opioid receptor,Ki,=,8.8,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597071,CHEMBL233,Mu opioid receptor,Ki,=,4.8,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CCNC(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,0.56,nM,CHEMBL3599488,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL316446,CHEMBL233,Mu opioid receptor,Ki,=,2.6,nM,CHEMBL3630375,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) transfected in HEK293 cells,CHEMBL3627650,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL3629337,CHEMBL233,Mu opioid receptor,Ki,=,0.565,nM,CHEMBL3630375,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) transfected in HEK293 cells,CHEMBL3627650,KI,C=C(C(N)=O)[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1cccs1
CHEMBL3627737,CHEMBL233,Mu opioid receptor,Ki,=,0.515,nM,CHEMBL3630375,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) transfected in HEK293 cells,CHEMBL3627650,KI,C=C(C(N)=O)[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccsc1
CHEMBL3695669,CHEMBL233,Mu opioid receptor,Ki,=,22.75,nM,CHEMBL3705537,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)C3=CN1Cc1ccc(O)cc1
CHEMBL3908275,CHEMBL233,Mu opioid receptor,Ki,=,89.96,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCC4CCCCC4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3664526,CHEMBL233,Mu opioid receptor,Ki,=,0.21,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1cccc(COC[C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(C)[C@@H]4C6)c1
CHEMBL3659473,CHEMBL233,Mu opioid receptor,Ki,=,19.17,nM,CHEMBL3705265,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μl/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3638883,KI,CCC(=O)N(c1ccccc1)C1CCN(CCC(C(=O)N2CCCC2)(c2ccccc2)c2ccccc2)CC1
CHEMBL3667194,CHEMBL233,Mu opioid receptor,Ki,=,1.7,nM,CHEMBL3705859,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(=O)NCCc2ccc(-c4cnc(O)nc4O)cc2)c(O)c13
CHEMBL3664526,CHEMBL233,Mu opioid receptor,Ki,=,6.37,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1cccc(COC[C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(C)[C@@H]4C6)c1
CHEMBL3695671,CHEMBL233,Mu opioid receptor,Ki,=,21.18,nM,CHEMBL3705537,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,O=C(O)CN1C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3947184,CHEMBL233,Mu opioid receptor,Ki,=,0.43,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,C=CCOC[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(OC)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL3667190,CHEMBL233,Mu opioid receptor,Ki,=,0.39,nM,CHEMBL3705859,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(=O)NCCc2ccc(-c4ccccc4)cc2)c(O)c13
CHEMBL3647961,CHEMBL233,Mu opioid receptor,Ki,=,4032.0,nM,CHEMBL3707517,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25° C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. Fifty μL/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C23CCCC(CCC2)C3)c1=O
CHEMBL3647962,CHEMBL233,Mu opioid receptor,Ki,=,61.6,nM,CHEMBL3707517,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25° C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. Fifty μL/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,C[C@@H]1C[C@@H]2C[C@H](C1)C[C@@H](N1[C@@H]3CCC[C@H]1C[C@@H](n1c(=O)c(C(=O)O)nc4ccccc41)C3)C2
CHEMBL3907149,CHEMBL233,Mu opioid receptor,Ki,=,164.67,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(Cl)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3951177,CHEMBL233,Mu opioid receptor,Ki,=,29.57,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCC4CCC4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3912511,CHEMBL233,Mu opioid receptor,Ki,=,25.58,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCC4CCCCC4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3647958,CHEMBL233,Mu opioid receptor,Ki,=,1631.0,nM,CHEMBL3707517,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25° C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. Fifty μL/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL3667196,CHEMBL233,Mu opioid receptor,Ki,=,0.52,nM,CHEMBL3705859,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CO[C@@]12CCC(=O)C[C@@]13CCN(C)[C@@H]2Cc1ccc(C(=O)NCCc2ccc(-c4c[nH]c(=O)[nH]c4=O)cc2)c(O)c13
CHEMBL3667197,CHEMBL233,Mu opioid receptor,Ki,=,0.15,nM,CHEMBL3705859,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(=O)NCCc2ccc(-c4cn[nH]c4)cc2)c(O)c13
CHEMBL3907149,CHEMBL233,Mu opioid receptor,Ki,=,0.12,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(Cl)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL376690,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL3705131,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,KI,C[C@H]1CN2CCN(Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL3955920,CHEMBL233,Mu opioid receptor,Ki,=,306.06,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COc4ccccc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3892737,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cccc(C)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3951177,CHEMBL233,Mu opioid receptor,Ki,=,0.15,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCC4CCC4)[C@@H](C2)N(C)CC[C@]315
CHEMBL426523,CHEMBL233,Mu opioid receptor,Ki,=,0.57,nM,CHEMBL3705131,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,KI,C[C@H]1CN2C[C@H](c3ccccc3)CC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL3919397,CHEMBL233,Mu opioid receptor,Ki,=,36.08,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(Cl)c(Cl)c4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3923372,CHEMBL233,Mu opioid receptor,Ki,=,1.0,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(Cl)c(Cl)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3948231,CHEMBL233,Mu opioid receptor,Ki,=,4.38,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(F)(F)F)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3916122,CHEMBL233,Mu opioid receptor,Ki,=,2.0,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3667198,CHEMBL233,Mu opioid receptor,Ki,=,1.7,nM,CHEMBL3705859,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23CC(=O)CCC2[C@H]1Cc1ccc(C(=O)NCCc2nc4ccccc4[nH]2)c(O)c13
CHEMBL3947184,CHEMBL233,Mu opioid receptor,Ki,=,36.0,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,C=CCOC[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(OC)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL3892737,CHEMBL233,Mu opioid receptor,Ki,=,0.15,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cccc(C)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3944046,CHEMBL233,Mu opioid receptor,Ki,=,0.07,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4C)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3667195,CHEMBL233,Mu opioid receptor,Ki,=,3.5,nM,CHEMBL3705859,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(C(=O)NCCc5ccc(-c6c[nH]c(=O)[nH]c6=O)cc5)c(O)c4[C@@]2(CCN3C)C1
CHEMBL3695670,CHEMBL233,Mu opioid receptor,Ki,=,5.61,nM,CHEMBL3705537,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@@H]3CN1
CHEMBL3916122,CHEMBL233,Mu opioid receptor,Ki,=,0.12,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3952829,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4C)[C@@H](C2)N(C)CC[C@]315
CHEMBL3907149,CHEMBL233,Mu opioid receptor,Ki,=,1.47,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(Cl)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3948231,CHEMBL233,Mu opioid receptor,Ki,=,0.35,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(F)(F)F)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL218404,CHEMBL233,Mu opioid receptor,Ki,=,2.0,nM,CHEMBL3705131,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,KI,C[C@H]1CN2CCN(C(=O)c3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL409938,CHEMBL233,Mu opioid receptor,Ki,=,0.32,nM,CHEMBL3705859,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=CC3C1C5
CHEMBL3647959,CHEMBL233,Mu opioid receptor,Ki,=,4450.0,nM,CHEMBL3707517,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25° C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. Fifty μL/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL3948231,CHEMBL233,Mu opioid receptor,Ki,=,241.2,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(F)(F)F)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3959791,CHEMBL233,Mu opioid receptor,Ki,=,162.95,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccncc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3912511,CHEMBL233,Mu opioid receptor,Ki,=,1.6,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCC4CCCCC4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3952829,CHEMBL233,Mu opioid receptor,Ki,=,1.76,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4C)[C@@H](C2)N(C)CC[C@]315
CHEMBL3982823,CHEMBL233,Mu opioid receptor,Ki,=,0.53,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COC/C=C/c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3667199,CHEMBL233,Mu opioid receptor,Ki,=,0.43,nM,CHEMBL3705859,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(=O)NCCc2ccc(-c4cc[nH]c(=O)c4)cc2)c(O)c13
CHEMBL3911769,CHEMBL233,Mu opioid receptor,Ki,=,0.08,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cccc6ccccc46)[C@@H](C2)N(C)CC[C@]315
CHEMBL3664525,CHEMBL233,Mu opioid receptor,Ki,=,0.17,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1OC1C4(OC)CCC5(CC4COCc4ccccc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3664542,CHEMBL233,Mu opioid receptor,Ki,=,59.0,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@@H]2C[C@H]2c2ccccc2)C3(C)C)c2sccc2n1
CHEMBL3947184,CHEMBL233,Mu opioid receptor,Ki,=,127.0,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,C=CCOC[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(OC)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL3904663,CHEMBL233,Mu opioid receptor,Ki,=,0.4,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(F)(F)F)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3919397,CHEMBL233,Mu opioid receptor,Ki,=,1.22,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(Cl)c(Cl)c4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3695668,CHEMBL233,Mu opioid receptor,Ki,=,12.77,nM,CHEMBL3705537,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@@H]3CN1Cc1ccc(O)cc1
CHEMBL3664540,CHEMBL233,Mu opioid receptor,Ki,=,42.0,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,C#CCOCC1CC23CCC1(OC)C1Oc4c(OC)ccc5c4[C@@]12CCN(C)[C@@H]3C5
CHEMBL3664541,CHEMBL233,Mu opioid receptor,Ki,=,1264.0,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,C=CCOCC1CC23CCC1(OC)C1Oc4c(OC)ccc5c4[C@@]12CCN(C)[C@@H]3C5
CHEMBL219495,CHEMBL233,Mu opioid receptor,Ki,=,5.5,nM,CHEMBL3705131,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,KI,C[C@H]1CN2CCN(CCc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL3915488,CHEMBL233,Mu opioid receptor,Ki,=,0.74,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc6ccccc6c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3900482,CHEMBL233,Mu opioid receptor,Ki,=,7.99,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(C)(C)C)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL435746,CHEMBL233,Mu opioid receptor,Ki,=,8.9,nM,CHEMBL3705131,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,KI,C[C@H]1CN2C[C@H](Cc3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL3919397,CHEMBL233,Mu opioid receptor,Ki,=,0.04,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(Cl)c(Cl)c4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3946351,CHEMBL233,Mu opioid receptor,Ki,=,5.71,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(OC(F)(F)F)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3695667,CHEMBL233,Mu opioid receptor,Ki,=,24.41,nM,CHEMBL3705537,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,NC(=O)CN1C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3912511,CHEMBL233,Mu opioid receptor,Ki,=,0.15,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCC4CCCCC4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3647960,CHEMBL233,Mu opioid receptor,Ki,=,1600.0,nM,CHEMBL3707517,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25° C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. Fifty μL/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCCC2)c1=O
CHEMBL3667194,CHEMBL233,Mu opioid receptor,Ki,=,1.3,nM,CHEMBL3705859,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(=O)NCCc2ccc(-c4cnc(O)nc4O)cc2)c(O)c13
CHEMBL3904663,CHEMBL233,Mu opioid receptor,Ki,=,96.35,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(F)(F)F)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3901699,CHEMBL233,Mu opioid receptor,Ki,=,0.15,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3667193,CHEMBL233,Mu opioid receptor,Ki,=,0.63,nM,CHEMBL3705859,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(=O)NCCc2ccc(-c4ccc(=O)[nH]c4)cc2)c(O)c13
CHEMBL3915488,CHEMBL233,Mu opioid receptor,Ki,=,1.87,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc6ccccc6c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3948400,CHEMBL233,Mu opioid receptor,Ki,=,324.75,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc6ccccc6c4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3901699,CHEMBL233,Mu opioid receptor,Ki,=,89.26,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3904663,CHEMBL233,Mu opioid receptor,Ki,=,2.2,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(F)(F)F)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3664540,CHEMBL233,Mu opioid receptor,Ki,=,5.9,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,C#CCOCC1CC23CCC1(OC)C1Oc4c(OC)ccc5c4[C@@]12CCN(C)[C@@H]3C5
CHEMBL3954498,CHEMBL233,Mu opioid receptor,Ki,=,1752.98,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(-c6ccccc6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3893577,CHEMBL233,Mu opioid receptor,Ki,=,2.58,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cccc(C)c4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3954498,CHEMBL233,Mu opioid receptor,Ki,=,25.78,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(-c6ccccc6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3695665,CHEMBL233,Mu opioid receptor,Ki,=,218.1,nM,CHEMBL3705537,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,COc1ccc(CN2C=C3[C@H]4Cc5ccc(OC)cc5[C@@]3(CCN4CC3CC3)CC2=O)cc1
CHEMBL3647963,CHEMBL233,Mu opioid receptor,Ki,=,1436.0,nM,CHEMBL3707517,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25° C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. Fifty μL/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCCCC2)c1=O
CHEMBL3659471,CHEMBL233,Mu opioid receptor,Ki,=,330.6,nM,CHEMBL3705265,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μl/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3638883,KI,CCC(=O)N(c1ccccc1)C1CCN(CCC(c2ccccc2)c2ccccc2)CC1
CHEMBL219319,CHEMBL233,Mu opioid receptor,Ki,=,3.6,nM,CHEMBL3705131,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,KI,C[C@H]1CN2C[C@H](c3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL3664525,CHEMBL233,Mu opioid receptor,Ki,=,1.12,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1OC1C4(OC)CCC5(CC4COCc4ccccc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3664540,CHEMBL233,Mu opioid receptor,Ki,=,1043.0,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,C#CCOCC1CC23CCC1(OC)C1Oc4c(OC)ccc5c4[C@@]12CCN(C)[C@@H]3C5
CHEMBL3647959,CHEMBL233,Mu opioid receptor,Ki,=,3825.0,nM,CHEMBL3707517,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25° C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. Fifty μL/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL3893577,CHEMBL233,Mu opioid receptor,Ki,=,0.05,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cccc(C)c4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3955920,CHEMBL233,Mu opioid receptor,Ki,=,2.95,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COc4ccccc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3900482,CHEMBL233,Mu opioid receptor,Ki,=,3.58,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(C)(C)C)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3948400,CHEMBL233,Mu opioid receptor,Ki,=,22.53,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc6ccccc6c4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3923372,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(Cl)c(Cl)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3893577,CHEMBL233,Mu opioid receptor,Ki,=,23.97,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cccc(C)c4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3955920,CHEMBL233,Mu opioid receptor,Ki,=,16.19,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COc4ccccc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3982823,CHEMBL233,Mu opioid receptor,Ki,=,4.35,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COC/C=C/c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3911529,CHEMBL233,Mu opioid receptor,Ki,=,355.34,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(C)(C)C)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3923372,CHEMBL233,Mu opioid receptor,Ki,=,21.06,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(Cl)c(Cl)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL218520,CHEMBL233,Mu opioid receptor,Ki,=,3.3,nM,CHEMBL3705131,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,KI,C[C@H]1CN2C[C@H](c3ccccc3)N(C)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL3944046,CHEMBL233,Mu opioid receptor,Ki,=,1.55,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4C)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3954498,CHEMBL233,Mu opioid receptor,Ki,=,1.91,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(-c6ccccc6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3916122,CHEMBL233,Mu opioid receptor,Ki,=,9.2,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3911529,CHEMBL233,Mu opioid receptor,Ki,=,2.7,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(C)(C)C)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3664541,CHEMBL233,Mu opioid receptor,Ki,=,6.5,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,C=CCOCC1CC23CCC1(OC)C1Oc4c(OC)ccc5c4[C@@]12CCN(C)[C@@H]3C5
CHEMBL3659474,CHEMBL233,Mu opioid receptor,Ki,=,82.83,nM,CHEMBL3705265,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μl/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3638883,KI,CCC(=O)N(c1ccccc1)C1CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1
CHEMBL3667191,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL3705859,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(=O)NCCc2nc4ccccc4[nH]2)c(O)c13
CHEMBL3908275,CHEMBL233,Mu opioid receptor,Ki,=,0.05,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCC4CCCCC4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3946351,CHEMBL233,Mu opioid receptor,Ki,=,4.4,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(OC(F)(F)F)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3908275,CHEMBL233,Mu opioid receptor,Ki,=,0.69,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCC4CCCCC4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3659472,CHEMBL233,Mu opioid receptor,Ki,=,36.1,nM,CHEMBL3705265,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μl/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3638883,KI,CCC(=O)N(c1ccccc1)C1CCN(CCC(C(=O)N(C)C)(c2ccccc2)c2ccccc2)CC1
CHEMBL3948400,CHEMBL233,Mu opioid receptor,Ki,=,2.6,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc6ccccc6c4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3667200,CHEMBL233,Mu opioid receptor,Ki,=,1.6,nM,CHEMBL3705859,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(=O)NCCc2ccc(-c4cnc(=O)[nH]c4)cc2)c(O)c13
CHEMBL3901699,CHEMBL233,Mu opioid receptor,Ki,=,14.44,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3911769,CHEMBL233,Mu opioid receptor,Ki,=,0.59,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cccc6ccccc46)[C@@H](C2)N(C)CC[C@]315
CHEMBL3664512,CHEMBL233,Mu opioid receptor,Ki,=,58.0,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,CC1(C)c2[nH]nc(Nc3ncnc4ccoc34)c2CN1C(=O)N[C@H]1C[C@@H]1c1ccccc1
CHEMBL3695676,CHEMBL233,Mu opioid receptor,Ki,=,50.42,nM,CHEMBL3705537,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,Oc1ccc2c(c1)[C@@]13CCNC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL3959791,CHEMBL233,Mu opioid receptor,Ki,=,2.3,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccncc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3911529,CHEMBL233,Mu opioid receptor,Ki,=,12.13,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(C)(C)C)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL3667192,CHEMBL233,Mu opioid receptor,Ki,=,0.66,nM,CHEMBL3705859,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(C(=O)NCCc5ccc(-c6c[nH]c(=O)[nH]c6=O)cc5)c(O)c4[C@@]2(CCN3CCc2ccccc2)C1
CHEMBL3735756,CHEMBL233,Mu opioid receptor,Ki,=,341.0,nM,CHEMBL3736711,B,Displacement of [3H]DAMGO from human mu-opioid receptor stably expressed in HEK cell membrane after 90 mins by scintillation counting method,CHEMBL3734659,KI,COc1ccc(CCN(CCCc2ccccc2)CCc2ccc3c(c2)OCO3)cc1OC
CHEMBL438389,CHEMBL233,Mu opioid receptor,Ki,=,9.5,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,KI,CC(C)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299402,CHEMBL233,Mu opioid receptor,Ki,=,6.0,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccc(I)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299466,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,KI,CC(C)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299371,CHEMBL233,Mu opioid receptor,Ki,=,1.0,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299390,CHEMBL233,Mu opioid receptor,Ki,=,3.0,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299423,CHEMBL233,Mu opioid receptor,Ki,=,1.0,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299415,CHEMBL233,Mu opioid receptor,Ki,=,0.4,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N(C)[C@@H](Cc1ccc(F)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299479,CHEMBL233,Mu opioid receptor,Ki,=,4.0,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,KI,CC(C)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccc(F)cc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299483,CHEMBL233,Mu opioid receptor,Ki,=,4.0,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccc(Cl)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4299476,CHEMBL233,Mu opioid receptor,Ki,=,4.0,nM,CHEMBL3738443,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL3734657,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccc(Br)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL3746843,CHEMBL233,Mu opioid receptor,Ki,=,2041.74,nM,CHEMBL3748891,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO-FlpIn cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3745681,KI,CO[C@]12C=C[C@@]3([C@@H]4C(=O)N(CCCCCCN)C(=O)[C@@H]41)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5.Cl.Cl
CHEMBL3746274,CHEMBL233,Mu opioid receptor,Ki,=,263.03,nM,CHEMBL3748891,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO-FlpIn cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3745681,KI,CO[C@]12C=C[C@@]3([C@@H]4C(=O)N(CCCCCCNC(=O)OC(C)(C)C)C(=O)[C@@H]41)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL3746149,CHEMBL233,Mu opioid receptor,Ki,=,107.15,nM,CHEMBL3748891,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO-FlpIn cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3745681,KI,CO[C@]12CC[C@@]3(C[C@@H]1C(=O)NCCCCCCN)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5.Cl.Cl
CHEMBL3746697,CHEMBL233,Mu opioid receptor,Ki,=,2.188,nM,CHEMBL3748891,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO-FlpIn cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3745681,KI,CO[C@]12CC[C@@]3(C[C@@H]1C(=O)NCCCCCCNC(=O)OC(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL3747317,CHEMBL233,Mu opioid receptor,Ki,=,194.98,nM,CHEMBL3748891,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO-FlpIn cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3745681,KI,CO[C@]12C=C[C@@]3(C[C@@H]1C(=O)NCCCCCCN)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5.Cl.Cl
CHEMBL3747778,CHEMBL233,Mu opioid receptor,Ki,=,7.413,nM,CHEMBL3748891,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO-FlpIn cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3745681,KI,CO[C@]12C=C[C@@]3(C[C@@H]1C(=O)NCCCCCCNC(=O)OC(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL511142,CHEMBL233,Mu opioid receptor,Ki,=,1.585,nM,CHEMBL3748891,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO-FlpIn cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3745681,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,2187.76,nM,CHEMBL3748891,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO-FlpIn cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3745681,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,87.1,nM,CHEMBL3748890,B,"Displacement of 2-((1E,3E,5E)-5-(1-Ethyl-3,3-dimethyl-5-sulfoindolin-2-ylidene)-penta-1,3-dien-1-yl)-1-(6-((6-((6S,7R,7aR,12bS)-9-hydroxy-7-methoxy-3-methyl-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamido)hexyl)-amino)-6-oxohexyl)-3,3-dimethyl-3H-indol-1-ium-5-sulfonate,2,2,2-Trifluoroacetate Salt from human MOR expressed in HEK293 cells by Cheng-Prusoff analysis",CHEMBL3745681,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL278789,CHEMBL233,Mu opioid receptor,Ki,=,19.5,nM,CHEMBL3748890,B,"Displacement of 2-((1E,3E,5E)-5-(1-Ethyl-3,3-dimethyl-5-sulfoindolin-2-ylidene)-penta-1,3-dien-1-yl)-1-(6-((6-((6S,7R,7aR,12bS)-9-hydroxy-7-methoxy-3-methyl-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamido)hexyl)-amino)-6-oxohexyl)-3,3-dimethyl-3H-indol-1-ium-5-sulfonate,2,2,2-Trifluoroacetate Salt from human MOR expressed in HEK293 cells by Cheng-Prusoff analysis",CHEMBL3745681,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
CHEMBL281786,CHEMBL233,Mu opioid receptor,Ki,=,0.123,nM,CHEMBL3748890,B,"Displacement of 2-((1E,3E,5E)-5-(1-Ethyl-3,3-dimethyl-5-sulfoindolin-2-ylidene)-penta-1,3-dien-1-yl)-1-(6-((6-((6S,7R,7aR,12bS)-9-hydroxy-7-methoxy-3-methyl-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamido)hexyl)-amino)-6-oxohexyl)-3,3-dimethyl-3H-indol-1-ium-5-sulfonate,2,2,2-Trifluoroacetate Salt from human MOR expressed in HEK293 cells by Cheng-Prusoff analysis",CHEMBL3745681,KI,CO[C@]12CC[C@@]3(C[C@@H]1C(C)(C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL1618305,CHEMBL233,Mu opioid receptor,Ki,=,1.445,nM,CHEMBL3748890,B,"Displacement of 2-((1E,3E,5E)-5-(1-Ethyl-3,3-dimethyl-5-sulfoindolin-2-ylidene)-penta-1,3-dien-1-yl)-1-(6-((6-((6S,7R,7aR,12bS)-9-hydroxy-7-methoxy-3-methyl-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamido)hexyl)-amino)-6-oxohexyl)-3,3-dimethyl-3H-indol-1-ium-5-sulfonate,2,2,2-Trifluoroacetate Salt from human MOR expressed in HEK293 cells by Cheng-Prusoff analysis",CHEMBL3745681,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2/C(=N/N=C2\CC[C@@]4(O)[C@H]6Cc7ccc(O)c8c7[C@@]4(CCN6CC=C)[C@H]2O8)CC[C@@]3(O)[C@H]1C5
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,1.148,nM,CHEMBL3748890,B,"Displacement of 2-((1E,3E,5E)-5-(1-Ethyl-3,3-dimethyl-5-sulfoindolin-2-ylidene)-penta-1,3-dien-1-yl)-1-(6-((6-((6S,7R,7aR,12bS)-9-hydroxy-7-methoxy-3-methyl-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamido)hexyl)-amino)-6-oxohexyl)-3,3-dimethyl-3H-indol-1-ium-5-sulfonate,2,2,2-Trifluoroacetate Salt from human MOR expressed in HEK293 cells by Cheng-Prusoff analysis",CHEMBL3745681,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.2754,nM,CHEMBL3748890,B,"Displacement of 2-((1E,3E,5E)-5-(1-Ethyl-3,3-dimethyl-5-sulfoindolin-2-ylidene)-penta-1,3-dien-1-yl)-1-(6-((6-((6S,7R,7aR,12bS)-9-hydroxy-7-methoxy-3-methyl-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamido)hexyl)-amino)-6-oxohexyl)-3,3-dimethyl-3H-indol-1-ium-5-sulfonate,2,2,2-Trifluoroacetate Salt from human MOR expressed in HEK293 cells by Cheng-Prusoff analysis",CHEMBL3745681,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,1.259,nM,CHEMBL3748906,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cells preincubated for 1 hr followed by radioligand addition measured after 1 hr by liquid scintillation counting analysis,CHEMBL3745681,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL278789,CHEMBL233,Mu opioid receptor,Ki,=,1.585,nM,CHEMBL3748906,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cells preincubated for 1 hr followed by radioligand addition measured after 1 hr by liquid scintillation counting analysis,CHEMBL3745681,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
CHEMBL281786,CHEMBL233,Mu opioid receptor,Ki,=,0.1995,nM,CHEMBL3748906,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cells preincubated for 1 hr followed by radioligand addition measured after 1 hr by liquid scintillation counting analysis,CHEMBL3745681,KI,CO[C@]12CC[C@@]3(C[C@@H]1C(C)(C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL1618305,CHEMBL233,Mu opioid receptor,Ki,=,3.162,nM,CHEMBL3748906,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cells preincubated for 1 hr followed by radioligand addition measured after 1 hr by liquid scintillation counting analysis,CHEMBL3745681,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2/C(=N/N=C2\CC[C@@]4(O)[C@H]6Cc7ccc(O)c8c7[C@@]4(CCN6CC=C)[C@H]2O8)CC[C@@]3(O)[C@H]1C5
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,1.259,nM,CHEMBL3748906,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cells preincubated for 1 hr followed by radioligand addition measured after 1 hr by liquid scintillation counting analysis,CHEMBL3745681,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.1995,nM,CHEMBL3748906,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cells preincubated for 1 hr followed by radioligand addition measured after 1 hr by liquid scintillation counting analysis,CHEMBL3745681,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL3752900,CHEMBL233,Mu opioid receptor,Ki,=,2818.38,nM,CHEMBL3756495,B,Binding affinity to mu type opioid receptor (unknown origin) by competition binding assay,CHEMBL3751848,KI,C=CCN(CC=C)CCc1c[nH]c2ccc(Cl)cc12
CHEMBL3754166,CHEMBL233,Mu opioid receptor,Ki,=,1737.8,nM,CHEMBL3756495,B,Binding affinity to mu type opioid receptor (unknown origin) by competition binding assay,CHEMBL3751848,KI,C=CCN(CC=C)CCc1c[nH]c2ccc(Br)cc12
CHEMBL3758231,CHEMBL233,Mu opioid receptor,Ki,=,14.0,nM,CHEMBL3762577,B,Binding affinity at mu opioid receptor (unknown origin),CHEMBL3758122,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCCN(CC1Cc2ccccc2CN1C(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](Cc1ccccc1)C(=O)NC(CC1CCCCC1)C(=O)O
CHEMBL3758257,CHEMBL233,Mu opioid receptor,Ki,=,1050.0,nM,CHEMBL3762577,B,Binding affinity at mu opioid receptor (unknown origin),CHEMBL3758122,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N1Cc2ccccc2CC1CN[C@@H](Cc1ccccc1)C(=O)NC(CC1CCCCC1)C(=O)O
CHEMBL2181202,CHEMBL233,Mu opioid receptor,Ki,=,0.143,nM,CHEMBL3762577,B,Binding affinity at mu opioid receptor (unknown origin),CHEMBL3758122,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL538700,CHEMBL233,Mu opioid receptor,Ki,=,1.19,nM,CHEMBL3762577,B,Binding affinity at mu opioid receptor (unknown origin),CHEMBL3758122,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL3759383,CHEMBL233,Mu opioid receptor,Ki,=,0.94,nM,CHEMBL3762577,B,Binding affinity at mu opioid receptor (unknown origin),CHEMBL3758122,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CN[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL3758712,CHEMBL233,Mu opioid receptor,Ki,=,0.042,nM,CHEMBL3762577,B,Binding affinity at mu opioid receptor (unknown origin),CHEMBL3758122,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)NCC(=O)Nc1ccccc1
CHEMBL3759292,CHEMBL233,Mu opioid receptor,Ki,=,0.031,nM,CHEMBL3762577,B,Binding affinity at mu opioid receptor (unknown origin),CHEMBL3758122,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)NCC(=O)NCc1ccccc1
CHEMBL3758292,CHEMBL233,Mu opioid receptor,Ki,=,0.5,nM,CHEMBL3762577,B,Binding affinity at mu opioid receptor (unknown origin),CHEMBL3758122,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)NCc1nc2ccccc2[nH]1
CHEMBL3758259,CHEMBL233,Mu opioid receptor,Ki,=,0.47,nM,CHEMBL3762577,B,Binding affinity at mu opioid receptor (unknown origin),CHEMBL3758122,KI,NC(=O)[C@H]1CSCSC[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N1
CHEMBL326684,CHEMBL233,Mu opioid receptor,Ki,=,0.01,nM,CHEMBL3762577,B,Binding affinity at mu opioid receptor (unknown origin),CHEMBL3758122,KI,CO[C@@]12CCC(=O)[C@]3(C)Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL3759489,CHEMBL233,Mu opioid receptor,Ki,=,10.2,nM,CHEMBL3762577,B,Binding affinity at mu opioid receptor (unknown origin),CHEMBL3758122,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@@]2(C)c2[nH]c4ccccc4c2C[C@@]3(CCCc2ccccc2)[C@H]1C5
CHEMBL3759292,CHEMBL233,Mu opioid receptor,Ki,=,16.22,nM,CHEMBL3762576,B,Displacement of [3H]DPN from human mu opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL3758122,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)NCC(=O)NCc1ccccc1
CHEMBL3759541,CHEMBL233,Mu opioid receptor,Ki,=,1.71,nM,CHEMBL3762581,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL3758122,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)NCC(=O)N(c1ccccc1)c1ccccc1
CHEMBL3758563,CHEMBL233,Mu opioid receptor,Ki,=,3.3,nM,CHEMBL3762581,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL3758122,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)NCC(=O)N1CCc2ccccc2C1
CHEMBL147511,CHEMBL233,Mu opioid receptor,Ki,=,0.09,nM,CHEMBL3762581,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL3758122,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL146756,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL3762581,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL3758122,KI,O=C(/C=C/C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL3759092,CHEMBL233,Mu opioid receptor,Ki,=,0.83,nM,CHEMBL3762577,B,Binding affinity at mu opioid receptor (unknown origin),CHEMBL3758122,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCC(=O)Nc1ccccc1
CHEMBL301160,CHEMBL233,Mu opioid receptor,Ki,=,0.12,nM,CHEMBL3762577,B,Binding affinity at mu opioid receptor (unknown origin),CHEMBL3758122,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL3759238,CHEMBL233,Mu opioid receptor,Ki,=,0.38,nM,CHEMBL3762577,B,Binding affinity at mu opioid receptor (unknown origin),CHEMBL3758122,KI,O=C1c2ccc(O)cc2[C@@]23CCCC[C@H]2[C@@H]1N(CC1CCCO1)CC3
CHEMBL3758348,CHEMBL233,Mu opioid receptor,Ki,=,3.2,nM,CHEMBL3762581,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane,CHEMBL3758122,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@@]2(CO)C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL3759660,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL3762763,B,"Displacement of [3H]D-Ala2,N-Me-Phe4,Gly5-ol]-Enkephalin from human mu opioid receptor expressed in CHO cell membrane",CHEMBL3758122,KI,Nc1nc2cc3c(cc2s1)C[C@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL583066,CHEMBL233,Mu opioid receptor,Ki,=,0.016,nM,CHEMBL3762577,B,Binding affinity at mu opioid receptor (unknown origin),CHEMBL3758122,KI,NC(=O)[C@@H]1CSCSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL415284,CHEMBL233,Mu opioid receptor,Ki,=,0.36,nM,CHEMBL3777304,B,Binding affinity to human mu opioid receptor,CHEMBL3774335,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,0.53,nM,CHEMBL3777304,B,Binding affinity to human mu opioid receptor,CHEMBL3774335,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL3785955,CHEMBL233,Mu opioid receptor,Ki,=,2460.0,nM,CHEMBL3790690,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in CHO-K1 cells after 150 mins by liquid scintillation counting method,CHEMBL3785048,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(Cc2cccnc2)C2CCCC(N3CCCC3)C21
CHEMBL3786545,CHEMBL233,Mu opioid receptor,Ki,=,3480.0,nM,CHEMBL3790690,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in CHO-K1 cells after 150 mins by liquid scintillation counting method,CHEMBL3785048,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(Cc2cccnc2)C2CCCC(N3CCC(O)C3)C21
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,5.2,nM,CHEMBL3790690,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in CHO-K1 cells after 150 mins by liquid scintillation counting method,CHEMBL3785048,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,2.3,nM,CHEMBL3790690,B,Displacement of [3H]naloxone from human mu opioid receptor expressed in CHO-K1 cells after 150 mins by liquid scintillation counting method,CHEMBL3785048,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL3786469,CHEMBL233,Mu opioid receptor,Ki,=,342.0,nM,CHEMBL3789771,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells after 45 mins by scintillation proximity assay,CHEMBL3785031,KI,Cc1cc(F)ccc1C1CCN(CC2Cc3ccccc3CN2)CC1
CHEMBL3786899,CHEMBL233,Mu opioid receptor,Ki,=,225.0,nM,CHEMBL3789771,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells after 45 mins by scintillation proximity assay,CHEMBL3785031,KI,c1ccc2c(c1)CNC(CN1CCC3(CCc4ccccc43)CC1)C2
CHEMBL3786338,CHEMBL233,Mu opioid receptor,Ki,=,58.2,nM,CHEMBL3789771,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells after 45 mins by scintillation proximity assay,CHEMBL3785031,KI,CN1Cc2ccccc2CC1CN1CCC2(CCc3ccccc32)CC1
CHEMBL3786486,CHEMBL233,Mu opioid receptor,Ki,=,231.0,nM,CHEMBL3789771,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells after 45 mins by scintillation proximity assay,CHEMBL3785031,KI,CN1C(=O)c2ccccc2CC1CN1CCC2(CCc3ccccc32)CC1
CHEMBL3787051,CHEMBL233,Mu opioid receptor,Ki,=,74.4,nM,CHEMBL3789771,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells after 45 mins by scintillation proximity assay,CHEMBL3785031,KI,CC(=O)N1Cc2ccccc2CC1CN1CCC2(CCc3ccccc32)CC1
CHEMBL3785560,CHEMBL233,Mu opioid receptor,Ki,=,68.8,nM,CHEMBL3789771,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells after 45 mins by scintillation proximity assay,CHEMBL3785031,KI,Oc1ccc(Cl)c2c1CNC(CN1CCC3(CCc4ccccc43)CC1)C2
CHEMBL3785095,CHEMBL233,Mu opioid receptor,Ki,=,139.0,nM,CHEMBL3789771,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells after 45 mins by scintillation proximity assay,CHEMBL3785031,KI,Oc1ccc(Br)c2c1CNC(CN1CCC3(CCc4ccccc43)CC1)C2
CHEMBL3785718,CHEMBL233,Mu opioid receptor,Ki,=,288.0,nM,CHEMBL3789771,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells after 45 mins by scintillation proximity assay,CHEMBL3785031,KI,Oc1cccc2c1CNC(CN1CCC3(CCc4ccccc43)CC1)C2
CHEMBL3785728,CHEMBL233,Mu opioid receptor,Ki,=,392.0,nM,CHEMBL3789771,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells after 45 mins by scintillation proximity assay,CHEMBL3785031,KI,Oc1ccc2c(c1)CC(CN1CCC3(CCc4ccccc43)CC1)NC2
CHEMBL3785605,CHEMBL233,Mu opioid receptor,Ki,=,49.1,nM,CHEMBL3789771,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells after 45 mins by scintillation proximity assay,CHEMBL3785031,KI,c1ccc2c(c1)CC(CN1CCC3(CCc4ccccc43)CC1)CO2
CHEMBL3787174,CHEMBL233,Mu opioid receptor,Ki,=,289.0,nM,CHEMBL3789771,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells after 45 mins by scintillation proximity assay,CHEMBL3785031,KI,c1ccc2c(c1)CCC(CN1CCC3(CCc4ccccc43)CC1)C2
CHEMBL3785839,CHEMBL233,Mu opioid receptor,Ki,=,108.0,nM,CHEMBL3789771,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHOK1 cells after 45 mins by scintillation proximity assay,CHEMBL3785031,KI,NC(=O)N1Cc2ccccc2CC1CN1CCC2(CCc3ccccc32)CC1
CHEMBL1797689,CHEMBL233,Mu opioid receptor,Ki,=,0.769,nM,CHEMBL3787926,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes,CHEMBL3785070,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)C1
CHEMBL3786675,CHEMBL233,Mu opioid receptor,Ki,=,0.692,nM,CHEMBL3787926,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes,CHEMBL3785070,KI,O=C1CCC[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)C1
CHEMBL3785854,CHEMBL233,Mu opioid receptor,Ki,=,24.7,nM,CHEMBL3787926,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes,CHEMBL3785070,KI,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@@H](C2)[C@]1(O)Cc1c([nH]c2ccccc12)C3
CHEMBL3787016,CHEMBL233,Mu opioid receptor,Ki,=,5.75,nM,CHEMBL3787926,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes,CHEMBL3785070,KI,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCc1c([nH]c2ccccc12)C3
CHEMBL3787263,CHEMBL233,Mu opioid receptor,Ki,=,7.2,nM,CHEMBL3787926,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes,CHEMBL3785070,KI,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@@H](C2)[C@]1(O)Cc1cc2ccccc2nc1C3
CHEMBL3787663,CHEMBL233,Mu opioid receptor,Ki,=,17.6,nM,CHEMBL3787926,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes,CHEMBL3785070,KI,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCc1cc2ccccc2nc1C3
CHEMBL3786970,CHEMBL233,Mu opioid receptor,Ki,=,22.0,nM,CHEMBL3787926,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes,CHEMBL3785070,KI,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)C/C1=C\c1ccccc1
CHEMBL3786218,CHEMBL233,Mu opioid receptor,Ki,=,5.81,nM,CHEMBL3787926,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes,CHEMBL3785070,KI,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)CC/C1=C\c1ccccc1
CHEMBL3785265,CHEMBL233,Mu opioid receptor,Ki,=,4.61,nM,CHEMBL3787926,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes,CHEMBL3785070,KI,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)C/C1=C/c1ccccc1
CHEMBL3786083,CHEMBL233,Mu opioid receptor,Ki,=,52.2,nM,CHEMBL3787926,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes,CHEMBL3785070,KI,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)CC/C1=C/c1ccccc1
CHEMBL252172,CHEMBL233,Mu opioid receptor,Ki,=,10.5,nM,CHEMBL3787926,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes,CHEMBL3785070,KI,O=C1/C(=C/c2ccccc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1400,CHEMBL233,Mu opioid receptor,Ki,=,11.0,nM,CHEMBL3812012,B,Displacement of [3H]naloxone from human MOR expressed in CHO-K1 cell membranes after 60 mins by microbeta scintillation counting method,CHEMBL3808393,KI,CN(C)C[C@H]1CCCC[C@]1(O)c1cccc(O)c1
CHEMBL1066,CHEMBL233,Mu opioid receptor,Ki,=,2400.0,nM,CHEMBL3812012,B,Displacement of [3H]naloxone from human MOR expressed in CHO-K1 cell membranes after 60 mins by microbeta scintillation counting method,CHEMBL3808393,KI,COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1
CHEMBL1400,CHEMBL233,Mu opioid receptor,Ki,=,13.0,nM,CHEMBL3812001,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 60 mins,CHEMBL3808393,KI,CN(C)C[C@H]1CCCC[C@]1(O)c1cccc(O)c1
CHEMBL3408737,CHEMBL233,Mu opioid receptor,Ki,=,0.11,nM,CHEMBL3810903,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in HEK293 cell membrane incubated for 1 hr by TopCount scintillation counting method,CHEMBL3808291,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(N)=O)C1=O
CHEMBL3809510,CHEMBL233,Mu opioid receptor,Ki,=,321.0,nM,CHEMBL3810903,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in HEK293 cell membrane incubated for 1 hr by TopCount scintillation counting method,CHEMBL3808291,KI,CC[C@H](C)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL3808415,CHEMBL233,Mu opioid receptor,Ki,=,5.0,nM,CHEMBL3810903,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in HEK293 cell membrane incubated for 1 hr by TopCount scintillation counting method,CHEMBL3808291,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CCN1Cc2ccccc2C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1=O)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL3808398,CHEMBL233,Mu opioid receptor,Ki,=,15.0,nM,CHEMBL3810903,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in HEK293 cell membrane incubated for 1 hr by TopCount scintillation counting method,CHEMBL3808291,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C1=O
CHEMBL3810104,CHEMBL233,Mu opioid receptor,Ki,=,15.0,nM,CHEMBL3810903,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in HEK293 cell membrane incubated for 1 hr by TopCount scintillation counting method,CHEMBL3808291,KI,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CCN1Cc2ccccc2C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O
CHEMBL3808523,CHEMBL233,Mu opioid receptor,Ki,=,9.6,nM,CHEMBL3810903,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in HEK293 cell membrane incubated for 1 hr by TopCount scintillation counting method,CHEMBL3808291,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C1=O
CHEMBL3810101,CHEMBL233,Mu opioid receptor,Ki,=,3150.0,nM,CHEMBL3810903,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in HEK293 cell membrane incubated for 1 hr by TopCount scintillation counting method,CHEMBL3808291,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL982,CHEMBL233,Mu opioid receptor,Ki,=,0.24,nM,CHEMBL3857935,B,Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting,CHEMBL3856219,KI,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL3890511,CHEMBL233,Mu opioid receptor,Ki,=,731.0,nM,CHEMBL3858679,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL3856240,KI,Oc1ccc(CCN(CCc2ccccc2)CC2CCC2)cc1
CHEMBL3950863,CHEMBL233,Mu opioid receptor,Ki,=,1750.0,nM,CHEMBL3858679,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL3856240,KI,Oc1ccc(CCN(CCc2ccccc2)CC2CC2)cc1
CHEMBL3897499,CHEMBL233,Mu opioid receptor,Ki,=,2357.0,nM,CHEMBL3869796,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cells after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,CCCN1CC[C@H]2c3cc4ccc(C(F)(F)F)cc4nc3[C@H](CC)[C@H]3CCC[C@@H]1[C@@H]32
CHEMBL3946273,CHEMBL233,Mu opioid receptor,Ki,=,892.0,nM,CHEMBL3869796,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cells after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,CC[C@H]1C(=O)C[C@@H]2CCN(Cc3cccs3)[C@@H]3CCC[C@H]1[C@@H]23
CHEMBL3890935,CHEMBL233,Mu opioid receptor,Ki,=,1902.0,nM,CHEMBL3869796,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cells after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,CC[C@H]1C(=O)C[C@@H]2CCN(CC3CCCCC3)[C@@H]3CCC[C@H]1[C@@H]23
CHEMBL3958393,CHEMBL233,Mu opioid receptor,Ki,=,632.0,nM,CHEMBL3869796,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cells after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,CCCCCCCN1CC[C@H]2CC(=O)[C@H](CC)[C@H]3CCC[C@@H]1[C@H]23
CHEMBL3930104,CHEMBL233,Mu opioid receptor,Ki,=,0.07943,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(CO)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1ccccc1
CHEMBL3890980,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1ccccc1
CHEMBL3975037,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(C1CCCC1)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1ccccc1
CHEMBL3911562,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CCC(CC)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1ccccc1
CHEMBL3914215,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,COC(=O)CCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1ccccc1
CHEMBL3949382,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(O)CCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1ccccc1
CHEMBL3958806,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3897058,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3899784,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(C1CCCC1)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3935092,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(C1CCCCC1)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3937881,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(CCC1CCCC1)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3983714,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3914068,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(CO)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3915013,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(Cc1ccccc1)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3912364,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(O)CC1(CC(=O)N(CCN2[C@@H]3CC[C@H]2C[C@@H](c2cccc(O)c2)C3)CC2CCCCC2)CCCCC1
CHEMBL3919593,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(O)CC1(CC(=O)N(CCN2[C@@H]3CC[C@H]2C[C@@H](c2cccc(O)c2)C3)CC2CCCCC2)CCCC1
CHEMBL3955687,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(O)C1CCCCC1C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3911517,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(O)CCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3954518,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)(CC(=O)O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3938671,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(O)CS(=O)(=O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3930987,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3981775,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CCC(C)NC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3973947,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(NCc1ccccc1)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3931758,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(Nc1ccc2c(c1)OCO2)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3934448,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(Nc1cccc(F)c1)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3977132,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CCCCCNC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3929945,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(NCc1ccc(F)cc1)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3930802,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(C[C@H]2CC[C@@H](O)CC2)C(=O)[C@@H](O)CO)c1
CHEMBL3895484,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(C[C@H]2CC[C@H](O)CC2)C(=O)[C@@H](O)CO)c1
CHEMBL3892763,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC1(C)C(CN(CCN2[C@@H]3CC[C@H]2C[C@@H](c2cccc(C(N)=O)c2)C3)C(=O)CO)C1(C)C
CHEMBL3954621,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)[C@H](O)CO)c1
CHEMBL3911639,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCC(C(F)(F)F)CC2)C(=O)[C@@H](O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3909993,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCC(C(F)(F)F)CC1.O=C(O)C(F)(F)F
CHEMBL3907179,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCC(C(F)(F)F)CC2)C(=O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3971000,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC1CCC(CN(CCN2[C@@H]3CC[C@H]2C[C@@H](c2cccc(C(N)=O)c2)C3)C(=O)[C@@H](O)CO)CC1.O=C(O)C(F)(F)F
CHEMBL3968243,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC1CCC(CN(CCN2[C@@H]3CC[C@H]2C[C@@H](c2cccc(C(N)=O)c2)C3)C(=O)CS(C)(=O)=O)CC1.O=C(O)C(F)(F)F
CHEMBL3949956,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC(F)(F)c2ccccc2)C(=O)[C@@H](O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3952629,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1cccc(F)c1.O=C(O)C(F)(F)F
CHEMBL3954319,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(Cc2cccc(F)c2)C(=O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3966240,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCc1ccc(O)cc1)CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2.O=C(O)C(F)(F)F
CHEMBL3963911,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CCc2ccc(O)cc2)C(=O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3904914,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCc1ccc(F)cc1)CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2.O=C(O)C(F)(F)F
CHEMBL3921767,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CCc2ccc(F)cc2)C(=O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3979596,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CCc2cccc(F)c2)C(=O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3954546,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CN(C)S(=O)(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccc(CF)cc1.O=C(O)C(F)(F)F
CHEMBL3936633,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(Cc2ccc(F)cc2)C(=O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3981656,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccc(F)cc1.O=C(O)C(F)(F)F
CHEMBL3979255,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccc(C(F)(F)F)cc1.O=C(O)C(F)(F)F
CHEMBL3920969,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CN(C)S(=O)(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccc(C(F)(F)F)cc1.O=C(O)C(F)(F)F
CHEMBL3911241,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(Cc2ccc(C(F)(F)F)cc2)C(=O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3958491,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCC1.O=C(O)C(F)(F)F
CHEMBL3955853,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)(C)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCC1.O=C(O)C(F)(F)F
CHEMBL3898530,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCC2)C(=O)[C@H]2CC[C@H](O)CC2)c1.O=C(O)C(F)(F)F
CHEMBL3964639,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)(CO)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCC1.O=C(O)C(F)(F)F
CHEMBL3974741,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCC2)C(=O)CCO)c1.O=C(O)C(F)(F)F
CHEMBL3965191,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(Cc2ccccc2)C(=O)[C@H](O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3919667,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,C[C@@H](O)[C@H](O)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccccc1.O=C(O)C(F)(F)F
CHEMBL3929334,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,N#CCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccccc1.O=C(O)C(F)(F)F
CHEMBL3972887,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(Cc2ccccc2)C(=O)C2(O)CC2)c1.O=C(O)C(F)(F)F
CHEMBL3975358,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)(CO)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccccc1.O=C(O)C(F)(F)F
CHEMBL3963804,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,COCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccccc1.O=C(O)C(F)(F)F
CHEMBL3907942,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccccc1.O=C(O)C(F)(F)F
CHEMBL3956478,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)(C)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccccc1.O=C(O)C(F)(F)F
CHEMBL3959139,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(O)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccccc1.O=C(O)C(F)(F)F
CHEMBL3911926,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)(O)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccccc1.O=C(O)C(F)(F)F
CHEMBL3921673,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccccc1.O=C(O)C(F)(F)F
CHEMBL3896588,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,C[C@H](O)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCC1.O=C(O)C(F)(F)F
CHEMBL3984601,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCC2)C(=O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3956373,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)(C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCC1)S(C)(=O)=O.O=C(O)C(F)(F)F
CHEMBL3953788,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCC1.O=C(O)C(F)(F)F
CHEMBL3918827,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCC2)C(=O)[C@H](O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3916056,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCC2)C(=O)[C@@H](O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3942380,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(CO)(CO)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCC1.O=C(O)C(F)(F)F
CHEMBL3939720,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCC2)C(=O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3904332,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCC1.O=C(O)C(F)(F)F
CHEMBL3894611,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCC2)C(=O)[C@H](O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3941359,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCC2)C(=O)[C@@H](O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3944063,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(CO)(CO)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCC1.O=C(O)C(F)(F)F
CHEMBL3910717,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCC(F)CC2)C(=O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3928220,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCC(F)CC2)C(=O)[C@@H](O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3962974,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,C[C@H](O)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCC(F)(F)CC1.O=C(O)C(F)(F)F
CHEMBL3967870,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CN(C)CC[C@H](O)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCC(F)(F)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL3904035,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCC(F)(F)CC1.O=C(O)C(F)(F)F
CHEMBL3913816,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCC(F)(F)CC2)C(=O)[C@H](O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3948980,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCC(F)(F)CC2)C(=O)[C@@H](O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3951589,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(CO)(CO)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCC(F)(F)CC1.O=C(O)C(F)(F)F
CHEMBL3951192,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)(C)C(=O)N(CCCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccccc1.O=C(O)C(F)(F)F
CHEMBL3948566,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)(O)C(=O)N(CCCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccccc1.O=C(O)C(F)(F)F
CHEMBL3891950,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccccc1.O=C(O)C(F)(F)F
CHEMBL3986988,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(O)C(O)C(=O)N(CCCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccccc1.O=C(O)C(F)(F)F
CHEMBL3929973,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCCN(Cc2ccccc2)C(=O)[C@H](O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3927259,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCCN(Cc2ccccc2)C(=O)[C@@H](O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3964093,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(Cc2ccccc2)C(=O)[C@@H](O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3967052,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(=O)OCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1ccccc1.O=C(O)C(F)(F)F
CHEMBL3915579,CHEMBL233,Mu opioid receptor,Ki,=,0.1585,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCc1ccccc1)CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2.O=C(O)C(F)(F)F
CHEMBL3912877,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CCc2ccccc2)C(=O)[C@@H](O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3972035,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,C[C@H](O)C(=O)N(CCCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1ccccc1
CHEMBL3974531,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCCN(Cc2ccccc2)C(=O)CO)c1
CHEMBL3932397,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3935106,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(=O)N(CCCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3985084,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCCN(CC2CCCCC2)C(=O)CO)c1
CHEMBL3897075,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(Cc2c(F)cccc2F)C(=O)[C@H]2CC[C@H](O)CC2)c1.O=C(O)C(F)(F)F
CHEMBL3946714,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)(C)OCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1c(F)cccc1F.O=C(O)C(F)(F)F
CHEMBL3949391,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(Cc2c(F)cccc2F)C(=O)C2(O)CC2)c1.O=C(O)C(F)(F)F
CHEMBL3908840,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,N#CCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1c(F)cccc1F.O=C(O)C(F)(F)F
CHEMBL3911576,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)(CO)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1c(F)cccc1F.O=C(O)C(F)(F)F
CHEMBL3904165,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,C[C@H](O)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1c(F)cccc1F.O=C(O)C(F)(F)F
CHEMBL3901466,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(Cc2c(F)cccc2F)C(=O)[C@@H](O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3960780,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(Cc2c(F)cccc2F)C(=O)[C@H](O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3958117,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)C[C@H](O)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1c(F)cccc1F.O=C(O)C(F)(F)F
CHEMBL3923303,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(Cc2c(F)cccc2F)C(=O)[C@@H](O)Cc2ccccc2)c1.O=C(O)C(F)(F)F
CHEMBL3913557,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1c(F)cccc1F
CHEMBL3976888,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1c(F)cccc1F.O=C(O)C(F)(F)F
CHEMBL3974425,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)(C)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1c(F)cccc1F.O=C(O)C(F)(F)F
CHEMBL3937755,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,COCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1c(F)cccc1F.O=C(O)C(F)(F)F
CHEMBL3934968,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)(O)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1c(F)cccc1F.O=C(O)C(F)(F)F
CHEMBL3948803,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CN(C)S(=O)(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)Cc1c(F)cccc1F.O=C(O)C(F)(F)F
CHEMBL3951426,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(O)CCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1c(F)cccc1F
CHEMBL3923014,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(O)C(F)(F)F.O=C(O)CCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1c(F)cccc1F
CHEMBL3932748,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC12CC3CC(CC(C3)C1)C2.O=C(O)C(F)(F)F
CHEMBL3969678,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC23CC4CC(CC(C4)C2)C3)C(=O)CCC(=O)O)c1.O=C(O)C(F)(F)F
CHEMBL3972380,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC23CC4CC(CC(C4)C2)C3)C(=O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3944414,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(O)C(F)(F)F.O=C(O)CCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC12CC3CC(CC(C3)C1)C2
CHEMBL3947039,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC12CC3CC(CC(C3)C1)C2.O=C(O)C(F)(F)F
CHEMBL3959422,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(CO)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC12CC3CC(CC(C3)C1)C2.O=C(O)C(F)(F)F
CHEMBL3985420,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC23CC4CC(CC(O)(C4)C2)C3)C(=O)CO)c1
CHEMBL3953728,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC23CC4CC(CC(O)(C4)C2)C3)C(=O)[C@@H](O)CO)c1
CHEMBL3965695,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,COCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1.O=C(O)C(F)(F)F
CHEMBL3908268,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CN(C)S(=O)(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1.O=C(O)C(F)(F)F
CHEMBL3920943,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CN(C)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3973434,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)C[C@H](O)CO)c1.O=C(O)C(F)(F)F
CHEMBL3975896,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)[C@@H](O)CCO)c1.O=C(O)C(F)(F)F
CHEMBL3970586,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)CCCO)c1
CHEMBL3958731,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CN(C)CC(O)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3956988,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CCN(CC)CC[C@H](O)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3954387,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)(C)NCC[C@H](O)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3947390,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CN(C)CC[C@H](O)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3944763,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(CO)(CO)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3942979,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CN[C@@H](CO)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL3940352,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)C2(O)CC2)c1.O=C(O)C(F)(F)F
CHEMBL3904974,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CN(C)CCCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3924084,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)(CO)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3952624,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CN(C)[C@@H](Cc1ccccc1)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3938376,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)C2(O)CC2)c1
CHEMBL3979589,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)C[C@H](O)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3982022,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)[C@@H](O)Cc2ccccc2)c1
CHEMBL3940842,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C([C@@H](O)C1CCCCC1)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3912914,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C([C@H](O)C1CCCCC1)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3936278,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C([C@H](O)CCc1ccccc1)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3939047,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CN(C)[C@@H](Cc1ccccc1)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3899996,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)C[C@H](O)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3929089,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1)C1(O)CC1
CHEMBL3983741,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(C(O)CCc1ccccc1)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3981257,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C([C@@H](O)Cc1ccccc1)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3897435,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C([C@@H](O)c1ccccc1)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3905164,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)Nc1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)CO)c1
CHEMBL3907395,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(=O)N(Cc1ccccc1)[C@H](C)CN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2
CHEMBL3904639,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,C[C@H](CN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)N(Cc1ccccc1)C(=O)C1CCCC1
CHEMBL3965427,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,C[C@H](CN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)N(Cc1ccccc1)C(=O)CCC(=O)O
CHEMBL3909222,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CCC(CC)C(=O)N(Cc1ccccc1)[C@H](C)CN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2
CHEMBL3949757,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,C[C@H](CN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)N(Cc1ccccc1)C(=O)C1CCCCC1
CHEMBL3947053,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,C[C@H](CN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)N(Cc1ccccc1)C(=O)CC1CCCC1
CHEMBL3900924,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)CC(=O)N(Cc1ccccc1)[C@H](C)CN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2
CHEMBL3898149,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,C[C@H](CN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)N(Cc1ccccc1)C(=O)Cc1ccccc1
CHEMBL3893866,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,C[C@H](CN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)N(Cc1ccccc1)C(=O)CCC1CCCC1
CHEMBL3936213,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,C[C@H](CN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)N(Cc1ccccc1)C(=O)C1CC1
CHEMBL3978023,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(=O)NOP(=O)(O)O)c1)C2)CC1CCC(F)(F)CC1
CHEMBL3910689,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCC(F)(F)CC2)C(=O)CO)c1
CHEMBL3924562,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CCCC2CCCCC2)C(=O)CO)c1
CHEMBL3914747,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CCC2CCCCC2)C(=O)CO)c1
CHEMBL3962054,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CCCc2ccccc2)C(=O)CO)c1
CHEMBL3959336,CHEMBL233,Mu opioid receptor,Ki,=,0.631,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CCc2ccccc2)C(=O)CO)c1
CHEMBL3895543,CHEMBL233,Mu opioid receptor,Ki,=,0.1259,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)[C@@H](O)CO)c1.O=C(O)C(=O)O
CHEMBL3898217,CHEMBL233,Mu opioid receptor,Ki,=,0.1259,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(CO)ONC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)[C@@H](O)CO)c1
CHEMBL3137319,CHEMBL233,Mu opioid receptor,Ki,=,0.1259,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)[C@@H](O)CO)c1.O=S(=O)(O)O
CHEMBL3137313,CHEMBL233,Mu opioid receptor,Ki,=,0.1259,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)[C@@H](O)CO)c1
CHEMBL3952923,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3919761,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3971059,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)NC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3973639,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)Nc2ccc3c(c2)OCO3)c1
CHEMBL3931401,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)NCc2ccc(F)cc2)c1
CHEMBL3934103,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CCCCCNC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3930269,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CCC(C)NC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3978967,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,COC(=O)CCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3918766,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)Cc2ccccc2)c1
CHEMBL3954068,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)CO)c1
CHEMBL3908846,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)CCC(=O)O)c1
CHEMBL3906031,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(Cc2ccccc2)C(=O)CO)c1
CHEMBL3904261,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(CO)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1ccc(C(F)(F)F)cc1
CHEMBL3901553,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(CO)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1ccc(Cl)cc1
CHEMBL3965686,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(CO)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1ccc(F)cc1
CHEMBL3953716,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1c(F)cccc1F
CHEMBL3949332,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1c(F)cccc1F
CHEMBL3951949,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1cccc(F)c1
CHEMBL3889993,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1cccc(F)c1
CHEMBL3892743,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1c(F)cccc1F
CHEMBL3899890,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1c(F)cccc1F
CHEMBL3964041,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(CO)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1c(F)cccc1F
CHEMBL3937988,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CC(C)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1cccc(F)c1
CHEMBL3947549,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(O)C(O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1cccc(F)c1
CHEMBL3983302,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(CO)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)Cc1cccc(F)c1
CHEMBL3980164,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,COc1ccc(NC(=O)N(CCN2[C@@H]3CC[C@H]2C[C@@H](c2cccc(O)c2)C3)CC2CCCCC2)cc1OC
CHEMBL3908565,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,NC(=O)CCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3905743,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,CS(=O)(=O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3915012,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,COC(=O)CCC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL3980392,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3880325,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL3879907,KI,O=C(Nc1ccc(OC(F)F)cc1)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(O)c1)C2)CC1CCCCC1
CHEMBL210665,CHEMBL233,Mu opioid receptor,Ki,=,13470.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,N#C[C@@H]1CCCN1C(=O)[C@@H]1CC[C@@H](CO)N1
CHEMBL3695216,CHEMBL233,Mu opioid receptor,Ki,=,3869.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)(C)OC(=O)N1CC2CN(c3nc4ccccc4n(C4CCN(C5CCCCCCC5)CC4)c3=O)CC2C1
CHEMBL3695217,CHEMBL233,Mu opioid receptor,Ki,=,394.3,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NCC(O)CO)nc2ccccc2n1[C@H]1C[C@H]2CC[C@@H](C1)N2C1CCCCCCC1
CHEMBL3695218,CHEMBL233,Mu opioid receptor,Ki,=,819.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695219,CHEMBL233,Mu opioid receptor,Ki,=,1670.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)C1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1
CHEMBL3695221,CHEMBL233,Mu opioid receptor,Ki,=,590.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,N[C@@H]1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C1
CHEMBL3695222,CHEMBL233,Mu opioid receptor,Ki,=,12100.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)[C@H](CO)Nc1nc2ccccc2n([C@@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695224,CHEMBL233,Mu opioid receptor,Ki,=,1172.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CNc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695228,CHEMBL233,Mu opioid receptor,Ki,=,12825.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)Cc1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695229,CHEMBL233,Mu opioid receptor,Ki,=,2510.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CC1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C1
CHEMBL3695230,CHEMBL233,Mu opioid receptor,Ki,=,770.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)[C@@H](CO)Nc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695234,CHEMBL233,Mu opioid receptor,Ki,=,3330.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)N1
CHEMBL3695235,CHEMBL233,Mu opioid receptor,Ki,=,210.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COc1ccc(NC(=O)c2nc3ccccc3n([C@@]3(C)C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)cn1
CHEMBL3695236,CHEMBL233,Mu opioid receptor,Ki,=,743.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CONC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695237,CHEMBL233,Mu opioid receptor,Ki,=,373.7,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(Nc1ccc(=O)[nH]c1)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695238,CHEMBL233,Mu opioid receptor,Ki,=,2700.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COc1ccc(NC(=O)c2nc3ccccc3n([C@@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)cn1
CHEMBL3695239,CHEMBL233,Mu opioid receptor,Ki,=,9840.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(Nc1ccc(=O)[nH]c1)c1nc2ccccc2n([C@@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695240,CHEMBL233,Mu opioid receptor,Ki,=,391.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NCC(O)CO)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3898898,CHEMBL233,Mu opioid receptor,Ki,=,422.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,C[C@]12CC[C@H](C[C@H](N3C(=O)C(N[C@@H](CO)C(=O)O)Nc4ccccc43)C1)N2C1CCCCCCC1
CHEMBL3695242,CHEMBL233,Mu opioid receptor,Ki,=,188.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NO)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695243,CHEMBL233,Mu opioid receptor,Ki,=,488.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,C[C@@]12CC[C@@H](C[C@@H](n3c(=O)c(C(=O)NCC(=O)O)nc4ccccc43)C1)N2C1CCCCCCC1
CHEMBL3695244,CHEMBL233,Mu opioid receptor,Ki,=,462.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NC(CO)C(=O)O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695245,CHEMBL233,Mu opioid receptor,Ki,=,1320.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C23CC4CC(CC(C4)C2)C3)c1=O
CHEMBL3639941,CHEMBL233,Mu opioid receptor,Ki,=,3200.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CNCCNc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695249,CHEMBL233,Mu opioid receptor,Ki,=,1083.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CN(CCNc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)CC(=O)O
CHEMBL3695251,CHEMBL233,Mu opioid receptor,Ki,=,1300.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)[C@@H](Nc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)c1ccccc1
CHEMBL3695252,CHEMBL233,Mu opioid receptor,Ki,=,377.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)[C@H](Cc1ccccc1)Nc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695253,CHEMBL233,Mu opioid receptor,Ki,=,723.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)C1(O)CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1
CHEMBL3695254,CHEMBL233,Mu opioid receptor,Ki,=,644.2,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C1NC(=O)C2(CCN(c3nc4ccccc4n([C@H]4C[C@H]5CC[C@@H](C4)N5C4CCCCCCC4)c3=O)CC2)N1
CHEMBL3939135,CHEMBL233,Mu opioid receptor,Ki,=,713.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)C1CCN(CCNc2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1
CHEMBL3695255,CHEMBL233,Mu opioid receptor,Ki,=,1990.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CNC(=O)CNc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695256,CHEMBL233,Mu opioid receptor,Ki,=,6100.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC1(C(=O)O)CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1
CHEMBL3698861,CHEMBL233,Mu opioid receptor,Ki,=,1140.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C1CN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CCN1
CHEMBL3698862,CHEMBL233,Mu opioid receptor,Ki,=,2530.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)C(CO)NCCNc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698863,CHEMBL233,Mu opioid receptor,Ki,=,3920.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(=O)NC1(C(=O)O)CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1
CHEMBL3698864,CHEMBL233,Mu opioid receptor,Ki,=,5200.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)C1(O)CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C1
CHEMBL3698865,CHEMBL233,Mu opioid receptor,Ki,=,10900.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)CN(CCNc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)CC(=O)O
CHEMBL3698866,CHEMBL233,Mu opioid receptor,Ki,=,8900.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)(Nc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)C(=O)O
CHEMBL3698868,CHEMBL233,Mu opioid receptor,Ki,=,1600.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)N1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1=O
CHEMBL3698869,CHEMBL233,Mu opioid receptor,Ki,=,2250.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CN1CC2CN(c3nc4ccccc4n([C@H]4C[C@H]5CC[C@@H](C4)N5C4CCCCCCC4)c3=O)CC2C1
CHEMBL3698870,CHEMBL233,Mu opioid receptor,Ki,=,1470.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)C1CCCN1C(=O)CNc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698872,CHEMBL233,Mu opioid receptor,Ki,=,2918.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)C(=O)N1CC2CN(c3nc4ccccc4n(C4CCN(C5CCCCCCC5)CC4)c3=O)CC2C1
CHEMBL3698873,CHEMBL233,Mu opioid receptor,Ki,=,4700.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CC1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1
CHEMBL3698874,CHEMBL233,Mu opioid receptor,Ki,=,2807.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC1(C(=O)O)CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C1
CHEMBL3698876,CHEMBL233,Mu opioid receptor,Ki,=,11942.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CN(CCO)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698877,CHEMBL233,Mu opioid receptor,Ki,=,480.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698878,CHEMBL233,Mu opioid receptor,Ki,=,679.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698879,CHEMBL233,Mu opioid receptor,Ki,=,5300.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)C1CCC(N2[C@@H]3CC[C@H]2C[C@@H](n2c(=O)c(C(=O)O)nc4ccccc42)C3)CC1
CHEMBL3698882,CHEMBL233,Mu opioid receptor,Ki,=,46010.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3COC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698884,CHEMBL233,Mu opioid receptor,Ki,=,459.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695245,CHEMBL233,Mu opioid receptor,Ki,=,10970.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C23CC4CC(CC(C4)C2)C3)c1=O
CHEMBL3698889,CHEMBL233,Mu opioid receptor,Ki,=,2660.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2Cc3cccc4cccc2c34)c1=O
CHEMBL3698890,CHEMBL233,Mu opioid receptor,Ki,=,14300.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC1(N2CCC(n3c(=O)c(C(=O)O)nc4ccccc43)CC2)CCCCCCC1
CHEMBL3698892,CHEMBL233,Mu opioid receptor,Ki,=,679.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC12CC3CC(C)(C1)CC(N1[C@@H]4CC[C@H]1C[C@@H](n1c(=O)c(C(=O)O)nc5ccccc51)C4)(C3)C2
CHEMBL3698893,CHEMBL233,Mu opioid receptor,Ki,=,39554.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C23CC4CC(CC(C4)C2)C3)c1=O
CHEMBL3889570,CHEMBL233,Mu opioid receptor,Ki,=,16252.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCC1(N2CCC(n3c(=O)c(C(=O)O)nc4ccccc43)CC2)CCCCCCC1
CHEMBL3698894,CHEMBL233,Mu opioid receptor,Ki,=,57791.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCCC1(N2CCC(n3c(=O)c(C(=O)O)nc4ccccc43)CC2)CCCCCCC1
CHEMBL3698895,CHEMBL233,Mu opioid receptor,Ki,=,16913.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)N[C@@H]1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C1
CHEMBL3698896,CHEMBL233,Mu opioid receptor,Ki,=,1445.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1ccncc1Nc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698897,CHEMBL233,Mu opioid receptor,Ki,=,8927.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CN(C(=O)O)[C@@H]1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C1
CHEMBL3698893,CHEMBL233,Mu opioid receptor,Ki,=,17180.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C23CC4CC(CC(C4)C2)C3)c1=O
CHEMBL3698892,CHEMBL233,Mu opioid receptor,Ki,=,4750.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC12CC3CC(C)(C1)CC(N1[C@@H]4CC[C@H]1C[C@@H](n1c(=O)c(C(=O)O)nc5ccccc51)C4)(C3)C2
CHEMBL3698899,CHEMBL233,Mu opioid receptor,Ki,=,2060.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CCCCCCCCC2)c1=O
CHEMBL3698900,CHEMBL233,Mu opioid receptor,Ki,=,699.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CCCCCCCC2)c1=O
CHEMBL3698901,CHEMBL233,Mu opioid receptor,Ki,=,3429.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2C3CCCC2CCC3)c1=O
CHEMBL3698902,CHEMBL233,Mu opioid receptor,Ki,=,709.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCC2)c1=O
CHEMBL3698903,CHEMBL233,Mu opioid receptor,Ki,=,1029.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2C3CCCC2CCC3)c1=O
CHEMBL3698904,CHEMBL233,Mu opioid receptor,Ki,=,396.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCC2)c1=O
CHEMBL3698906,CHEMBL233,Mu opioid receptor,Ki,=,368.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NC(Cc1c[nH]cn1)C(=O)O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698907,CHEMBL233,Mu opioid receptor,Ki,=,307.1,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NC(Cc1ccccc1)C(=O)O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3647963,CHEMBL233,Mu opioid receptor,Ki,=,1436.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCCCC2)c1=O
CHEMBL3647958,CHEMBL233,Mu opioid receptor,Ki,=,1631.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL3647958,CHEMBL233,Mu opioid receptor,Ki,=,4032.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL4107573,CHEMBL233,Mu opioid receptor,Ki,=,43.0,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1C4(OC)CC[C@@]5(C[C@@H]4COCC#N)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4107573,CHEMBL233,Mu opioid receptor,Ki,=,1.3,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1C4(OC)CC[C@@]5(C[C@@H]4COCC#N)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4107573,CHEMBL233,Mu opioid receptor,Ki,=,221.0,nM,CHEMBL3707592,B,Binding Assay: Binding assay of certain compounds of this invention to the opioid receptor was determine using radioligand binding assay (screening and dose-displacement).,CHEMBL3638745,KI,COc1ccc2c3c1O[C@H]1C4(OC)CC[C@@]5(C[C@@H]4COCC#N)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3665429,CHEMBL233,Mu opioid receptor,Ki,=,2950.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,CC(C)C1CCC(N2CCC(N3C(=O)CC(=O)Nc4ccccc43)CC2)CC1
CHEMBL3665430,CHEMBL233,Mu opioid receptor,Ki,=,5000.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,CCC1(CC)C(=O)Nc2ccccc2N(C2CCN(C3CCC(C(C)C)CC3)CC2)C1=O
CHEMBL3665423,CHEMBL233,Mu opioid receptor,Ki,=,1300.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,O=c1[nH]c2ccccc2n(C2CCN(C3Cc4cccc5cccc3c45)CC2)c1=O
CHEMBL3665427,CHEMBL233,Mu opioid receptor,Ki,=,3800.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,O=C1CC(=O)N(C2CCN(C3CCCCCCC3)CC2)c2cc(F)ccc2N1
CHEMBL3665421,CHEMBL233,Mu opioid receptor,Ki,=,2500.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,O=c1[nH]c2ccc(F)cc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3665424,CHEMBL233,Mu opioid receptor,Ki,=,3300.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,NC(=O)Cn1c(=O)c(=O)n(C2CCN(C3Cc4cccc5cccc3c45)CC2)c2ccccc21
CHEMBL3665433,CHEMBL233,Mu opioid receptor,Ki,=,9540.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,N#CCn1c(=O)c(=O)n(C2CCN(C3CCCCCCC3)CC2)c2ccccc21
CHEMBL3665436,CHEMBL233,Mu opioid receptor,Ki,=,28200.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,O=c1[nH]c2ccc(N3CCOCC3)cc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3665439,CHEMBL233,Mu opioid receptor,Ki,=,529.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,O=c1[nH]c2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3665440,CHEMBL233,Mu opioid receptor,Ki,=,769.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,O=c1[nH]c2ccccc2n([C@@H]2C[C@H]3CCC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3670294,CHEMBL233,Mu opioid receptor,Ki,=,11930.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,O=C1CC(=O)N([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CCCCCCC2)c2ccccc2N1
CHEMBL3665443,CHEMBL233,Mu opioid receptor,Ki,=,1380.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,O=c1[nH]c2ccccc2n([C@H]2C[C@H]3C=C[C@@H](C2)N3C2/C=C\CCCCC2)c1=O
CHEMBL3665444,CHEMBL233,Mu opioid receptor,Ki,=,15750.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,O=c1[nH]c2ccccc2n([C@@H]2C[C@H]3C=C[C@@H](C2)N3C2/C=C\CCCCC2)c1=O
CHEMBL3665435,CHEMBL233,Mu opioid receptor,Ki,=,17385.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,O=c1[nH]c2ncccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3665441,CHEMBL233,Mu opioid receptor,Ki,=,12380.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,O=C1CC(=O)N(C2CCN(C3CCCCCCC3)CC2)c2cccnc2N1
CHEMBL3670297,CHEMBL233,Mu opioid receptor,Ki,=,11670.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,COC(=O)C1(N2CCC(N3C(=O)CC(=O)Nc4ccc(F)cc43)CC2)CCCCCCC1
CHEMBL3665425,CHEMBL233,Mu opioid receptor,Ki,=,13700.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,O=C1CC(=O)N(C2CCN(C3CCCCCCC3)CC2)c2ccccc2N1
CHEMBL3665419,CHEMBL233,Mu opioid receptor,Ki,=,2200.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,O=c1[nH]c2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3665428,CHEMBL233,Mu opioid receptor,Ki,=,6200.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,CCC1(CC)C(=O)Nc2ccccc2N(C2CCN(C3CCCCCCC3)CC2)C1=O
CHEMBL3665422,CHEMBL233,Mu opioid receptor,Ki,=,825.0,nM,CHEMBL3706265,B,"μ-Opioid Receptor Binding Assays: μ-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 h at about 25° C.",CHEMBL3638667,KI,CC(C)C1CCC(N2CCC(n3c(=O)c(=O)[nH]c4ccccc43)CC2)CC1
CHEMBL3698834,CHEMBL233,Mu opioid receptor,Ki,=,2053.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CN(C)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698835,CHEMBL233,Mu opioid receptor,Ki,=,17060.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NCCO)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698836,CHEMBL233,Mu opioid receptor,Ki,=,4340.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2CC3CNCC3C2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698837,CHEMBL233,Mu opioid receptor,Ki,=,1145.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NCc2ccccc2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698838,CHEMBL233,Mu opioid receptor,Ki,=,1074.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)(C)OC(=O)NCCNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698839,CHEMBL233,Mu opioid receptor,Ki,=,1634.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)(C)OC(=O)N1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CC1
CHEMBL3698840,CHEMBL233,Mu opioid receptor,Ki,=,1397.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NCCNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698841,CHEMBL233,Mu opioid receptor,Ki,=,1480.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2CCNCC2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698842,CHEMBL233,Mu opioid receptor,Ki,=,1530.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CS(=O)(=O)NCCNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698843,CHEMBL233,Mu opioid receptor,Ki,=,2391.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CN1CC2CN(c3nc4ccccc4n(C4CCN(C5CCCCCCC5)CC4)c3=O)CC2C1
CHEMBL3698844,CHEMBL233,Mu opioid receptor,Ki,=,3278.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(=O)N1CC2CN(c3nc4ccccc4n(C4CCN(C5CCCCCCC5)CC4)c3=O)CC2C1
CHEMBL3698845,CHEMBL233,Mu opioid receptor,Ki,=,3157.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)(C)OC(=O)Nc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698846,CHEMBL233,Mu opioid receptor,Ki,=,1199.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,Nc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695257,CHEMBL233,Mu opioid receptor,Ki,=,2313.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COC(=O)C1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CC1
CHEMBL3698847,CHEMBL233,Mu opioid receptor,Ki,=,5254.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(=O)Nc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698848,CHEMBL233,Mu opioid receptor,Ki,=,2078.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C1CN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CCN1
CHEMBL3698849,CHEMBL233,Mu opioid receptor,Ki,=,26627.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2Cc3ccccc3C2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3695259,CHEMBL233,Mu opioid receptor,Ki,=,3396.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)(C)OC(=O)NC1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CC1
CHEMBL3695260,CHEMBL233,Mu opioid receptor,Ki,=,3037.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CC1
CHEMBL3695261,CHEMBL233,Mu opioid receptor,Ki,=,3942.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(=O)NC1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CC1
CHEMBL3698850,CHEMBL233,Mu opioid receptor,Ki,=,5281.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,C=CCNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698851,CHEMBL233,Mu opioid receptor,Ki,=,5979.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NCC(O)CO)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3695262,CHEMBL233,Mu opioid receptor,Ki,=,629.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,N=C(N)NCCNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695263,CHEMBL233,Mu opioid receptor,Ki,=,2438.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COC(=O)[C@@H]1CCCN1c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695264,CHEMBL233,Mu opioid receptor,Ki,=,5244.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COC(=O)[C@@H]1C[C@@H](O)CN1c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695265,CHEMBL233,Mu opioid receptor,Ki,=,3780.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)C1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CC1
CHEMBL3695266,CHEMBL233,Mu opioid receptor,Ki,=,1895.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CS(=O)(=O)NC1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CC1
CHEMBL3695267,CHEMBL233,Mu opioid receptor,Ki,=,1488.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NC2CCNCC2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3695268,CHEMBL233,Mu opioid receptor,Ki,=,6403.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)CNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695269,CHEMBL233,Mu opioid receptor,Ki,=,3341.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)[C@H](CO)Nc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695270,CHEMBL233,Mu opioid receptor,Ki,=,627.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COc1ccc(Nc2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)cn1
CHEMBL3695271,CHEMBL233,Mu opioid receptor,Ki,=,2064.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(=O)N[C@@H]1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)C1
CHEMBL3695272,CHEMBL233,Mu opioid receptor,Ki,=,1451.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2CCc3ccccc32)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3695273,CHEMBL233,Mu opioid receptor,Ki,=,624.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,N[C@H]1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)C1
CHEMBL3695276,CHEMBL233,Mu opioid receptor,Ki,=,1866.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)[C@@H]1CCCN1c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695277,CHEMBL233,Mu opioid receptor,Ki,=,809.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2CCc3ccccc3C2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3695278,CHEMBL233,Mu opioid receptor,Ki,=,513.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COC(=O)c1ccc2c(c1)CN(c1nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c1=O)CC2
CHEMBL3695279,CHEMBL233,Mu opioid receptor,Ki,=,3986.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1ccc(Nc2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)c[nH]1
CHEMBL3695280,CHEMBL233,Mu opioid receptor,Ki,=,1414.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COC(=O)C(CO)Nc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695281,CHEMBL233,Mu opioid receptor,Ki,=,2368.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)CCNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695283,CHEMBL233,Mu opioid receptor,Ki,=,1345.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(=O)N1CCC(Nc2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CC1
CHEMBL3695284,CHEMBL233,Mu opioid receptor,Ki,=,634.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CS(=O)(=O)N1CCC(Nc2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CC1
CHEMBL3695285,CHEMBL233,Mu opioid receptor,Ki,=,512.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,N[C@@H]1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)C1
CHEMBL3695286,CHEMBL233,Mu opioid receptor,Ki,=,3557.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2CCC(O)CC2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3695288,CHEMBL233,Mu opioid receptor,Ki,=,5414.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NC[C@@H](O)CO)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698750,CHEMBL233,Mu opioid receptor,Ki,=,2109.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NC[C@H](O)CO)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698751,CHEMBL233,Mu opioid receptor,Ki,=,5056.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)[C@H](CO)Nc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698752,CHEMBL233,Mu opioid receptor,Ki,=,1360.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)CNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698753,CHEMBL233,Mu opioid receptor,Ki,=,524.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NCC(O)CNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698754,CHEMBL233,Mu opioid receptor,Ki,=,3183.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(=O)N[C@H]1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)C1
CHEMBL3698755,CHEMBL233,Mu opioid receptor,Ki,=,6657.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)C1CCCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)C1
CHEMBL3698756,CHEMBL233,Mu opioid receptor,Ki,=,4412.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)CN(C)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698759,CHEMBL233,Mu opioid receptor,Ki,=,9284.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)CNc1nc2ccccc2n(C2CCN(C34CC5CC(CC(C5)C3)C4)CC2)c1=O
CHEMBL3698760,CHEMBL233,Mu opioid receptor,Ki,=,3642.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CN(CC(O)CO)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698761,CHEMBL233,Mu opioid receptor,Ki,=,1523.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CS(=O)(=O)N[C@@H]1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)C1
CHEMBL3698762,CHEMBL233,Mu opioid receptor,Ki,=,3296.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NC(CO)CO)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698763,CHEMBL233,Mu opioid receptor,Ki,=,6155.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2CC[C@H](O)C2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698764,CHEMBL233,Mu opioid receptor,Ki,=,248.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698852,CHEMBL233,Mu opioid receptor,Ki,=,2511.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698853,CHEMBL233,Mu opioid receptor,Ki,=,7426.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698854,CHEMBL233,Mu opioid receptor,Ki,=,887.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)(C)OC(=O)N1CC2CN(C(=O)c3nc4ccccc4n(C4CCN(C5CCCCCCC5)CC4)c3=O)CC2C1
CHEMBL3698765,CHEMBL233,Mu opioid receptor,Ki,=,678.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698768,CHEMBL233,Mu opioid receptor,Ki,=,1239.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698769,CHEMBL233,Mu opioid receptor,Ki,=,1723.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CNC(=O)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698770,CHEMBL233,Mu opioid receptor,Ki,=,2727.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NCC(O)CO)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698771,CHEMBL233,Mu opioid receptor,Ki,=,871.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COc1ccc(NC(=O)c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)cn1
CHEMBL3698772,CHEMBL233,Mu opioid receptor,Ki,=,2787.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CN(C)C(=O)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698773,CHEMBL233,Mu opioid receptor,Ki,=,2144.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(Nc1ccc(=O)[nH]c1)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698774,CHEMBL233,Mu opioid receptor,Ki,=,1918.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CONC(=O)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698775,CHEMBL233,Mu opioid receptor,Ki,=,1914.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NOCc1ccccc1)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698856,CHEMBL233,Mu opioid receptor,Ki,=,4089.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C1CNc2ccccc2N1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698857,CHEMBL233,Mu opioid receptor,Ki,=,6758.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C1CN(C2CCN(C3CCCCCCC3)CC2)c2ccccc2N1
CHEMBL3698776,CHEMBL233,Mu opioid receptor,Ki,=,1663.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,N#Cc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698777,CHEMBL233,Mu opioid receptor,Ki,=,10180.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NC[C@@H](O)CO)nc2ccccc2n1C1CCN(C23CC4CC(CC(C4)C2)C3)CC1
CHEMBL3698778,CHEMBL233,Mu opioid receptor,Ki,=,459.3,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)CNc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695217,CHEMBL233,Mu opioid receptor,Ki,=,394.3,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NCC(O)CO)nc2ccccc2n1[C@H]1C[C@H]2CC[C@@H](C1)N2C1CCCCCCC1
CHEMBL3698779,CHEMBL233,Mu opioid receptor,Ki,=,4650.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2CC[C@@H](O)C2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3695218,CHEMBL233,Mu opioid receptor,Ki,=,819.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698781,CHEMBL233,Mu opioid receptor,Ki,=,5570.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NO)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698858,CHEMBL233,Mu opioid receptor,Ki,=,196.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2CC3CNCC3C2)nc2ncccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698782,CHEMBL233,Mu opioid receptor,Ki,=,576.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NC[C@@H](O)CO)nc2ccccc2n1[C@H]1C[C@H]2CC[C@@H](C1)N2C1CCCCCCC1
CHEMBL3698783,CHEMBL233,Mu opioid receptor,Ki,=,6700.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)CNc1nc2ccccc2n([C@@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698785,CHEMBL233,Mu opioid receptor,Ki,=,1217.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccc(F)cc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698786,CHEMBL233,Mu opioid receptor,Ki,=,706.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CN1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1
CHEMBL3698787,CHEMBL233,Mu opioid receptor,Ki,=,4420.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1cccc(CNc2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)c1
CHEMBL3698788,CHEMBL233,Mu opioid receptor,Ki,=,1458.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)C1CCCN1C(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698789,CHEMBL233,Mu opioid receptor,Ki,=,1375.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CN(CC(=O)O)C(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698790,CHEMBL233,Mu opioid receptor,Ki,=,60.2,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)(NC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)C(=O)O
CHEMBL3698791,CHEMBL233,Mu opioid receptor,Ki,=,784.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CSCCC(NC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)C(=O)O
CHEMBL3698792,CHEMBL233,Mu opioid receptor,Ki,=,770.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CC(NC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)C(=O)O
CHEMBL3698793,CHEMBL233,Mu opioid receptor,Ki,=,400.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(N[C@H](C(=O)O)c1ccccc1)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698794,CHEMBL233,Mu opioid receptor,Ki,=,263.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(NC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)C(=O)O
CHEMBL3698795,CHEMBL233,Mu opioid receptor,Ki,=,452.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)CC(NC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)C(=O)O
CHEMBL3698796,CHEMBL233,Mu opioid receptor,Ki,=,1792.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1ccc(CNC(=O)c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)cc1
CHEMBL3698798,CHEMBL233,Mu opioid receptor,Ki,=,1160.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NCc1nn[nH]n1)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698799,CHEMBL233,Mu opioid receptor,Ki,=,1930.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1ccc(CNC(=O)c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)nc1
CHEMBL3698801,CHEMBL233,Mu opioid receptor,Ki,=,1865.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C23CC4CC(CC2C4)C3)c1=O
CHEMBL3698804,CHEMBL233,Mu opioid receptor,Ki,=,2800.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCC(C#CC(C)(C)C)N1[C@@H]2CC[C@H]1C[C@@H](n1c(=O)c(C(=O)O)nc3ccccc31)C2
CHEMBL3698807,CHEMBL233,Mu opioid receptor,Ki,=,10098.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)[C@@H]1CN(CCNc2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C[C@H]1C(=O)OCC
CHEMBL3698808,CHEMBL233,Mu opioid receptor,Ki,=,37211.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)[C@@H]1CN(CCNc2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C[C@H]1C(=O)O
CHEMBL3698809,CHEMBL233,Mu opioid receptor,Ki,=,3877.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CN(C)C1(C(=O)O)CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1
CHEMBL3698810,CHEMBL233,Mu opioid receptor,Ki,=,7122.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)C1CN(CCNc2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C[C@H]1C(=O)OCC
CHEMBL3698814,CHEMBL233,Mu opioid receptor,Ki,=,3291.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2/C=C\CCCCC2)c1=O
CHEMBL3698816,CHEMBL233,Mu opioid receptor,Ki,=,443.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(N[C@H](C(=O)O)c1ccccc1)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698817,CHEMBL233,Mu opioid receptor,Ki,=,487.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C(C)CCC(C)C)c1=O
CHEMBL3698818,CHEMBL233,Mu opioid receptor,Ki,=,160.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C(C)CC(C)C)c1=O
CHEMBL3698819,CHEMBL233,Mu opioid receptor,Ki,=,664.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)CCC(C)N1[C@@H]2CCC[C@H]1C[C@@H](n1c(=O)c(C(=O)O)nc3ccccc31)C2
CHEMBL3698820,CHEMBL233,Mu opioid receptor,Ki,=,397.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)CC(C)N1[C@@H]2CCC[C@H]1C[C@@H](n1c(=O)c(C(=O)O)nc3ccccc31)C2
CHEMBL3647961,CHEMBL233,Mu opioid receptor,Ki,=,1862.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C23CCCC(CCC2)C3)c1=O
CHEMBL3698821,CHEMBL233,Mu opioid receptor,Ki,=,689.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CN(CC(=O)O)[C@H]1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CCC[C@@H](C3)N4C3CCCCCCC3)c2=O)C1
CHEMBL3984664,CHEMBL233,Mu opioid receptor,Ki,=,292.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)c1nc2ccccc2n([C@@H]2C[C@H]3CCC[C@@H](C2)N3C/C=C2\CCC3CC2C3(C)C)c1=O
CHEMBL3698823,CHEMBL233,Mu opioid receptor,Ki,=,5490.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C23CCC(CC2)C3)c1=O
CHEMBL3647963,CHEMBL233,Mu opioid receptor,Ki,=,1436.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCCCC2)c1=O
CHEMBL3647960,CHEMBL233,Mu opioid receptor,Ki,=,1600.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCCC2)c1=O
CHEMBL3698825,CHEMBL233,Mu opioid receptor,Ki,=,407.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCCC[C@@H](C2)N3C2/C=C\CCCCC2)c1=O
CHEMBL3647959,CHEMBL233,Mu opioid receptor,Ki,=,3825.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL3647959,CHEMBL233,Mu opioid receptor,Ki,=,4450.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL3698826,CHEMBL233,Mu opioid receptor,Ki,=,14374.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2C3CC4CC(C3)CC2C4)c1=O
CHEMBL3698827,CHEMBL233,Mu opioid receptor,Ki,=,670.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC1(C)[C@H]2CC[C@@H](CCN3[C@@H]4CC[C@H]3C[C@@H](n3c(=O)c(C(=O)O)nc5ccccc53)C4)[C@@H]1C2
CHEMBL3698828,CHEMBL233,Mu opioid receptor,Ki,=,1759.0,nM,CHEMBL3887030,B,"Radioligand Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.2nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20mg membrane protein/well in a final volume of 500 uL binding buffer (10mM MgCl2, 1mM EDTA, 5% DMSO, 50mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylemimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500uL of ice-cold binding buffer. Filter plates were subsequently dried at 50C for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50uL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)CC(C)N1[C@@H]2CC[C@H]1C[C@@H](n1c(=O)c(C(=O)O)nc3ccccc31)C2
CHEMBL3965826,CHEMBL233,Mu opioid receptor,Ki,=,189.66,nM,CHEMBL3705375,B,"Binding Assay: u-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3639331,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)[C@H](C)N)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3691854,CHEMBL233,Mu opioid receptor,Ki,=,3.66,nM,CHEMBL3705375,B,"Binding Assay: u-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@@H](N)Cc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691860,CHEMBL233,Mu opioid receptor,Ki,=,0.77,nM,CHEMBL3705375,B,"Binding Assay: u-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691861,CHEMBL233,Mu opioid receptor,Ki,=,4.89,nM,CHEMBL3705375,B,"Binding Assay: u-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@@H](N)CC(=O)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691862,CHEMBL233,Mu opioid receptor,Ki,=,3.18,nM,CHEMBL3705375,B,"Binding Assay: u-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691864,CHEMBL233,Mu opioid receptor,Ki,=,0.36,nM,CHEMBL3705375,B,"Binding Assay: u-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@H](Cc1ccccc1)NC(C)=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691865,CHEMBL233,Mu opioid receptor,Ki,=,0.53,nM,CHEMBL3705375,B,"Binding Assay: u-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)CN)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691875,CHEMBL233,Mu opioid receptor,Ki,=,5.83,nM,CHEMBL3705375,B,"Binding Assay: u-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@H](CO)NC(C)=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691886,CHEMBL233,Mu opioid receptor,Ki,=,1.51,nM,CHEMBL3705375,B,"Binding Assay: u-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3639331,KI,COC12CC[C@@]3(C[C@@H]1CNC(=O)c1ccccc1C(=O)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4115704,CHEMBL233,Mu opioid receptor,Ki,=,112.19,nM,CHEMBL3705915,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638713,KI,
CHEMBL4115706,CHEMBL233,Mu opioid receptor,Ki,=,30.0,nM,CHEMBL3705915,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638713,KI,
CHEMBL4115707,CHEMBL233,Mu opioid receptor,Ki,=,141.5,nM,CHEMBL3705915,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638713,KI,
CHEMBL4115708,CHEMBL233,Mu opioid receptor,Ki,=,241.8,nM,CHEMBL3705915,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638713,KI,
CHEMBL4115773,CHEMBL233,Mu opioid receptor,Ki,=,448.7,nM,CHEMBL3706236,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638455,KI,
CHEMBL4115775,CHEMBL233,Mu opioid receptor,Ki,=,6.55,nM,CHEMBL3706236,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638455,KI,
CHEMBL4115777,CHEMBL233,Mu opioid receptor,Ki,=,4.55,nM,CHEMBL3706236,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638455,KI,
CHEMBL4115749,CHEMBL233,Mu opioid receptor,Ki,=,3.11,nM,CHEMBL3706236,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638455,KI,
CHEMBL4115751,CHEMBL233,Mu opioid receptor,Ki,=,0.52,nM,CHEMBL3706236,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638455,KI,
CHEMBL4115760,CHEMBL233,Mu opioid receptor,Ki,=,0.59,nM,CHEMBL3706236,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638455,KI,
CHEMBL4115767,CHEMBL233,Mu opioid receptor,Ki,=,0.56,nM,CHEMBL3706236,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638455,KI,
CHEMBL4115768,CHEMBL233,Mu opioid receptor,Ki,=,1.86,nM,CHEMBL3706236,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638455,KI,
CHEMBL4115769,CHEMBL233,Mu opioid receptor,Ki,=,3.95,nM,CHEMBL3706236,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638455,KI,
CHEMBL4115770,CHEMBL233,Mu opioid receptor,Ki,=,0.41,nM,CHEMBL3706236,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638455,KI,
CHEMBL4115771,CHEMBL233,Mu opioid receptor,Ki,=,0.71,nM,CHEMBL3706236,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638455,KI,
CHEMBL4115779,CHEMBL233,Mu opioid receptor,Ki,=,14367.18,nM,CHEMBL3706236,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638455,KI,
CHEMBL4115780,CHEMBL233,Mu opioid receptor,Ki,=,651.45,nM,CHEMBL3706236,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638455,KI,
CHEMBL4115781,CHEMBL233,Mu opioid receptor,Ki,=,3938.0,nM,CHEMBL3706236,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638455,KI,
CHEMBL4115782,CHEMBL233,Mu opioid receptor,Ki,=,5593.0,nM,CHEMBL3706236,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3638455,KI,
CHEMBL4115784,CHEMBL233,Mu opioid receptor,Ki,=,9047.92,nM,CHEMBL3706241,B,"Radioligand Dose-Displacement Binding Assay: mu-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3638576,KI,
CHEMBL4115785,CHEMBL233,Mu opioid receptor,Ki,=,15.91,nM,CHEMBL3706241,B,"Radioligand Dose-Displacement Binding Assay: mu-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3638576,KI,
CHEMBL4115710,CHEMBL233,Mu opioid receptor,Ki,=,3.55,nM,CHEMBL3706241,B,"Radioligand Dose-Displacement Binding Assay: mu-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3638576,KI,
CHEMBL4115712,CHEMBL233,Mu opioid receptor,Ki,=,8.39,nM,CHEMBL3706241,B,"Radioligand Dose-Displacement Binding Assay: mu-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3638576,KI,
CHEMBL4115713,CHEMBL233,Mu opioid receptor,Ki,=,3876.11,nM,CHEMBL3706241,B,"Radioligand Dose-Displacement Binding Assay: mu-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3638576,KI,
CHEMBL4115714,CHEMBL233,Mu opioid receptor,Ki,=,26.99,nM,CHEMBL3706241,B,"Radioligand Dose-Displacement Binding Assay: mu-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3638576,KI,
CHEMBL4115734,CHEMBL233,Mu opioid receptor,Ki,=,14884.0,nM,CHEMBL3706241,B,"Radioligand Dose-Displacement Binding Assay: mu-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3638576,KI,
CHEMBL4115735,CHEMBL233,Mu opioid receptor,Ki,=,2.28,nM,CHEMBL3706241,B,"Radioligand Dose-Displacement Binding Assay: mu-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3638576,KI,
CHEMBL4115736,CHEMBL233,Mu opioid receptor,Ki,=,0.86,nM,CHEMBL3706241,B,"Radioligand Dose-Displacement Binding Assay: mu-Opioid Receptor Binding Assay Procedures: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well).",CHEMBL3638576,KI,
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.7,nM,CHEMBL3706102,B,"Radioligand Binding Assay: A bivalent ligand 1 (FIG. 14) that combines the pharmacophores of naltrexone (a MOR antagonist) and maraviroc (a CCR5 antagonist) into one molecule was designed and synthesized. Herein is reported the characterization of this novel molecular probe in for its binding affinity, Ca2− flux functional activity, and HIV-1 inhibition potency. Bivalent ligand 1 was first characterized in hMOR-expressed CHO cells in the competitive radioligand binding assay as described previously.",CHEMBL3638635,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL3219777,CHEMBL233,Mu opioid receptor,Ki,=,51.8,nM,CHEMBL3706102,B,"Radioligand Binding Assay: A bivalent ligand 1 (FIG. 14) that combines the pharmacophores of naltrexone (a MOR antagonist) and maraviroc (a CCR5 antagonist) into one molecule was designed and synthesized. Herein is reported the characterization of this novel molecular probe in for its binding affinity, Ca2− flux functional activity, and HIV-1 inhibition potency. Bivalent ligand 1 was first characterized in hMOR-expressed CHO cells in the competitive radioligand binding assay as described previously.",CHEMBL3638635,KI,Cc1nnc(C(C)C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccc(NC(=O)COCC(=O)NCCCCCCCNC(=O)COCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1
CHEMBL3697625,CHEMBL233,Mu opioid receptor,Ki,=,9.2,nM,CHEMBL3706102,B,"Radioligand Binding Assay: A bivalent ligand 1 (FIG. 14) that combines the pharmacophores of naltrexone (a MOR antagonist) and maraviroc (a CCR5 antagonist) into one molecule was designed and synthesized. Herein is reported the characterization of this novel molecular probe in for its binding affinity, Ca2− flux functional activity, and HIV-1 inhibition potency. Bivalent ligand 1 was first characterized in hMOR-expressed CHO cells in the competitive radioligand binding assay as described previously.",CHEMBL3638635,KI,Cc1nnc(C(C)C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1cccc(NC(=O)COCC(=O)NCCCCCCCNC(=O)COCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)c1
CHEMBL3688135,CHEMBL233,Mu opioid receptor,Ki,=,977.19,nM,CHEMBL3705876,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638511,KI,O=C(O)CCC[C@]12CCN(CC3CC3)[C@H](Cc3ccc(O)cc31)[C@@H]2CC(=O)O
CHEMBL4114012,CHEMBL233,Mu opioid receptor,Ki,=,621.4,nM,CHEMBL3705876,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638511,KI,O=C(O)/C=C1\[C@H]2Cc3ccc(O)cc3[C@]1(CCCC(=O)O)CCN2CC1CC1
CHEMBL4106660,CHEMBL233,Mu opioid receptor,Ki,=,853.3,nM,CHEMBL3705876,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638511,KI,CN(C)C(=O)CCC[C@]12CCN(CC3CC3)[C@H](Cc3ccc(O)cc31)/C2=C\C(=O)O
CHEMBL4114012,CHEMBL233,Mu opioid receptor,Ki,=,1343.0,nM,CHEMBL3705876,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638511,KI,O=C(O)/C=C1\[C@H]2Cc3ccc(O)cc3[C@]1(CCCC(=O)O)CCN2CC1CC1
CHEMBL3704583,CHEMBL233,Mu opioid receptor,Ki,=,3560.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,O=C(O)CN1CCC[C@H]1c1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704584,CHEMBL233,Mu opioid receptor,Ki,=,1112.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,O=C(O)CN1CCC[C@@H]1c1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704586,CHEMBL233,Mu opioid receptor,Ki,=,5540.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,O=C(O)CCN1CCC[C@@H]1c1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704588,CHEMBL233,Mu opioid receptor,Ki,=,1670.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,NC(=O)CN1CCC[C@H]1c1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704589,CHEMBL233,Mu opioid receptor,Ki,=,4640.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,O=C(O)CN1CCCC[C@H]1c1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704590,CHEMBL233,Mu opioid receptor,Ki,=,11320.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,O=C(O)CN1CCCC[C@@H]1c1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704591,CHEMBL233,Mu opioid receptor,Ki,=,7450.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,O=C(O)CN1CCC[C@H](c2nc3ccccc3n2[C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)C1
CHEMBL3704594,CHEMBL233,Mu opioid receptor,Ki,=,11770.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,O=C(O)CN1CCC/C(=C2/N(CC(=O)O)c3ccccc3N2[C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)C1
CHEMBL3704607,CHEMBL233,Mu opioid receptor,Ki,=,511.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,CCOC(=N)/N=c1\[nH]c2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3704608,CHEMBL233,Mu opioid receptor,Ki,=,339.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,NC(=O)/N=c1\[nH]c2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3704609,CHEMBL233,Mu opioid receptor,Ki,=,2473.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,CONC(=N)/N=c1\[nH]c2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3704610,CHEMBL233,Mu opioid receptor,Ki,=,2771.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,COC(=O)/N=c1\n(CC(N)=O)c2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3704612,CHEMBL233,Mu opioid receptor,Ki,=,1183.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,O=C(O)CNc1nc2ccccc2n1C1C[C@H]2CCC[C@@H](C1)N2C1CCCCCCCCC1
CHEMBL3704613,CHEMBL233,Mu opioid receptor,Ki,=,1577.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,OCc1nc2ccccc2n1C1C[C@H]2CCC[C@@H](C1)N2[C@H]1C[C@@H]2CCC[C@@H](C2)C1
CHEMBL3704614,CHEMBL233,Mu opioid receptor,Ki,=,1497.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,O=C(O)CO/N=C/c1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@H]1C[C@@H]2CCC[C@@H](C2)C1
CHEMBL3704620,CHEMBL233,Mu opioid receptor,Ki,=,1837.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,CS(=O)(=O)NCCN1CCC[C@H]1Cc1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704623,CHEMBL233,Mu opioid receptor,Ki,=,4006.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,O=C(O)CN1CCC[C@H]1Cc1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704625,CHEMBL233,Mu opioid receptor,Ki,=,4497.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,O=C(O)CCN1CC[C@@H](Cc2nc3ccccc3n2[C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)C1
CHEMBL3704627,CHEMBL233,Mu opioid receptor,Ki,=,1879.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,CS(=O)(=O)NCCN1CC[C@@H](Cc2nc3ccccc3n2[C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)C1
CHEMBL3704629,CHEMBL233,Mu opioid receptor,Ki,=,3007.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,CCN(CC)C(=O)CN1CC[C@@H](Cc2nc3ccccc3n2[C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)C1
CHEMBL3704623,CHEMBL233,Mu opioid receptor,Ki,=,2846.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,O=C(O)CN1CCC[C@H]1Cc1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704631,CHEMBL233,Mu opioid receptor,Ki,=,1914.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,c1ccc2c(c1)nc(C[C@H]1COCCN1)n2[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704632,CHEMBL233,Mu opioid receptor,Ki,=,1669.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,c1ccc2c(c1)nc(C[C@@H]1COCCN1)n2[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704634,CHEMBL233,Mu opioid receptor,Ki,=,4335.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,O=C(O)CCN1CCC[C@H]1Cc1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704635,CHEMBL233,Mu opioid receptor,Ki,=,3003.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,O=C(O)CN1CCCC[C@H]1Cc1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704644,CHEMBL233,Mu opioid receptor,Ki,=,520.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,c1ccc2c(c1)nc(-c1c[nH]cn1)n2[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704645,CHEMBL233,Mu opioid receptor,Ki,=,529.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,c1ccc2c(c1)nc(-c1cc[nH]n1)n2[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704646,CHEMBL233,Mu opioid receptor,Ki,=,952.0,nM,CHEMBL3706380,B,"Radioligand Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human mu-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hrs at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 uL of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hrs.",CHEMBL3639368,KI,Cn1cc(Cl)c(-c2nc3ccccc3n2[C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)n1
CHEMBL4112289,CHEMBL233,Mu opioid receptor,Ki,=,67.22,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(Cl)c(Cl)c4)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL4106939,CHEMBL233,Mu opioid receptor,Ki,=,162.64,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cc6c(cc4Cl)OCO6)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL4108501,CHEMBL233,Mu opioid receptor,Ki,=,242.28,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C)cc4)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL3678964,CHEMBL233,Mu opioid receptor,Ki,=,9.55,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccc(F)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678965,CHEMBL233,Mu opioid receptor,Ki,=,2.29,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1cc4ccccc4s1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678966,CHEMBL233,Mu opioid receptor,Ki,=,1.36,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccc(C)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678967,CHEMBL233,Mu opioid receptor,Ki,=,2.11,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678968,CHEMBL233,Mu opioid receptor,Ki,=,544.34,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,COc1ccc(COC[C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CC[N+](C)(CC2CC2)[C@@H]4C6)cc1
CHEMBL4111313,CHEMBL233,Mu opioid receptor,Ki,=,1489.98,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COc4ccccc4)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL4108857,CHEMBL233,Mu opioid receptor,Ki,=,5811.0,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccoc4)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL3678971,CHEMBL233,Mu opioid receptor,Ki,=,47.12,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccoc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL4108315,CHEMBL233,Mu opioid receptor,Ki,=,275.25,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cc6ccccc6o4)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL4106588,CHEMBL233,Mu opioid receptor,Ki,=,182.47,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc6ccccc6c4)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL3678975,CHEMBL233,Mu opioid receptor,Ki,=,24.29,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccsc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678976,CHEMBL233,Mu opioid receptor,Ki,=,4.51,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1F)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678977,CHEMBL233,Mu opioid receptor,Ki,=,4.3,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1cccc(C)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678979,CHEMBL233,Mu opioid receptor,Ki,=,5.35,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1cccc(F)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678980,CHEMBL233,Mu opioid receptor,Ki,=,6.26,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1cccc(Cl)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL4108094,CHEMBL233,Mu opioid receptor,Ki,=,261.93,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(C)(F)F)cc4)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL4113404,CHEMBL233,Mu opioid receptor,Ki,=,570.67,nM,CHEMBL3705573,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for -opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccco4)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL3959398,CHEMBL233,Mu opioid receptor,Ki,=,0.6,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CN(C)C1(c2ccccc2)CCC2(CC1)OCCc1c2[nH]c2ccccc12
CHEMBL3959398,CHEMBL233,Mu opioid receptor,Ki,=,310.0,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CN(C)C1(c2ccccc2)CCC2(CC1)OCCc1c2[nH]c2ccccc12
CHEMBL3959398,CHEMBL233,Mu opioid receptor,Ki,=,1.3,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CN(C)C1(c2ccccc2)CCC2(CC1)OCCc1c2[nH]c2ccccc12
CHEMBL3980449,CHEMBL233,Mu opioid receptor,Ki,=,3.1,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CN(C)C1(c2ccccc2)CCC2(CC1)SCCc1c2[nH]c2ccccc12
CHEMBL3894898,CHEMBL233,Mu opioid receptor,Ki,=,0.36,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CN(C)C1(c2ccccc2)CCC2(CC1)NCCc1c2[nH]c2ccccc12
CHEMBL3894898,CHEMBL233,Mu opioid receptor,Ki,=,4.5,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CN(C)C1(c2ccccc2)CCC2(CC1)NCCc1c2[nH]c2ccccc12
CHEMBL3919062,CHEMBL233,Mu opioid receptor,Ki,=,4.4,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CC(=O)N1CCc2c([nH]c3ccccc23)C12CCC(c1ccccc1)(N(C)C)CC2
CHEMBL3919062,CHEMBL233,Mu opioid receptor,Ki,=,2.2,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CC(=O)N1CCc2c([nH]c3ccccc23)C12CCC(c1ccccc1)(N(C)C)CC2
CHEMBL3924497,CHEMBL233,Mu opioid receptor,Ki,=,2.0,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,COc1ccc2[nH]c3c(c2c1)CCOC31CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3909041,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CC1Cc2c([nH]c3ccccc23)C2(CCC(c3ccccc3)(N(C)C)CC2)O1
CHEMBL3909041,CHEMBL233,Mu opioid receptor,Ki,=,58.0,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CC1Cc2c([nH]c3ccccc23)C2(CCC(c3ccccc3)(N(C)C)CC2)O1
CHEMBL3973336,CHEMBL233,Mu opioid receptor,Ki,=,14.0,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CC1Cc2c([nH]c3ccc(Br)cc23)C2(CCC(c3ccccc3)(N(C)C)CC2)O1
CHEMBL3942233,CHEMBL233,Mu opioid receptor,Ki,=,6.6,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CC1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)C2(CCC(c3ccccc3)(N(C)C)CC2)O1
CHEMBL3942233,CHEMBL233,Mu opioid receptor,Ki,=,25.0,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CC1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)C2(CCC(c3ccccc3)(N(C)C)CC2)O1
CHEMBL3909755,CHEMBL233,Mu opioid receptor,Ki,=,7.2,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CN(C)C1(c2ccc(F)cc2)CCC2(CC1)OCCc1c2[nH]c2ccccc12
CHEMBL3961861,CHEMBL233,Mu opioid receptor,Ki,=,2.1,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CN(C)C1(c2cccc(F)c2)CCC2(CC1)OCCc1c2[nH]c2ccccc12
CHEMBL3962932,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CN(C)C1(c2ccccc2)CCC2(CC1)OCCc1c2[nH]c2ccc(F)cc12
CHEMBL3962932,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CN(C)C1(c2ccccc2)CCC2(CC1)OCCc1c2[nH]c2ccc(F)cc12
CHEMBL3914982,CHEMBL233,Mu opioid receptor,Ki,=,2.7,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,Cc1ccc2[nH]c3c(c2c1)CCOC31CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3953613,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CNC1(c2ccccc2)CCC2(CC1)OCCc1c2[nH]c2ccccc12
CHEMBL3979202,CHEMBL233,Mu opioid receptor,Ki,=,15.0,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,Cc1ccc2[nH]c3c(c2c1)CCNC31CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3899983,CHEMBL233,Mu opioid receptor,Ki,=,17.0,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CN(C)C1(c2ccccc2)CCC2(CC1)NCCc1c2[nH]c2cc(F)ccc12
CHEMBL3890825,CHEMBL233,Mu opioid receptor,Ki,=,1.7,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CC(=O)N1CCc2c([nH]c3cc(F)ccc23)C12CCC(c1ccccc1)(N(C)C)CC2
CHEMBL3894557,CHEMBL233,Mu opioid receptor,Ki,=,0.5,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CC1Cc2c([nH]c3ccccc23)C2(CCC(c3ccccc3)(N(C)C)CC2)N1
CHEMBL3954763,CHEMBL233,Mu opioid receptor,Ki,=,0.7,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CN(C)C1(c2ccccc2)CCC2(CC1)NCCc1c2[nH]c2ccc(F)cc12
CHEMBL3983394,CHEMBL233,Mu opioid receptor,Ki,=,61.0,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CC1Cc2c([nH]c3ccc(F)cc23)C2(CCC(c3ccccc3)(N(C)C)CC2)O1
CHEMBL3892273,CHEMBL233,Mu opioid receptor,Ki,=,14.0,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,Cc1ccc2[nH]c3c(c2c1)CC(C)OC31CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3895920,CHEMBL233,Mu opioid receptor,Ki,=,19.0,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CN(C)C1(c2ccccc2)CCC2(CC1)OCCc1c2[nH]c2ccc(Br)cc12
CHEMBL3959597,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CN(C)C1(c2ccccc2)CCC2(CC1)OCCc1c2[nH]c2ccc(O)cc12
CHEMBL3892859,CHEMBL233,Mu opioid receptor,Ki,=,2.3,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,COC(=O)C1Cc2c([nH]c3ccccc23)C2(CCC(c3ccccc3)(N(C)C)CC2)N1
CHEMBL3958404,CHEMBL233,Mu opioid receptor,Ki,=,2.7,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CN(C)C1(c2ccccc2)CCC2(CC1)NC(CO)Cc1c2[nH]c2ccccc12
CHEMBL3909973,CHEMBL233,Mu opioid receptor,Ki,=,6.8,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CNC1(c2ccccc2)CCC2(CC1)OCCc1c2[nH]c2ccc(F)cc12
CHEMBL3936891,CHEMBL233,Mu opioid receptor,Ki,=,58.0,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CN(C)C1(c2ccc(F)cc2)CCC2(CC1)c1sc3ccccc3c1CC[S+]2[O-]
CHEMBL3966641,CHEMBL233,Mu opioid receptor,Ki,=,0.6,nM,CHEMBL3887216,B,"Binding Assay: The receptor affinity for the human mu-opiate receptor was determined in a homogeneous batch in microtitre plates. For this, dilution series of the particular spirocyclic cyclohexane derivative to be tested were incubated in a total volume of 250 ul for 90 minutes at room temperature with a receptor membrane preparation (15-40 ug protein per 250 ul incubation batch) of CHO-K1 cells, which express the human mu-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H]-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany). 50 mmoles/l Tris-HCl supplemented with 0.05 wt. % sodium azide and with 0.06 wt. % bovine serum albumin was used as the incubation buffer. 25 umoles/l naloxone was additionally added for determination of the non-specific binding.",CHEMBL3886217,KI,CN(C)C1(Cc2ccccc2)CCC2(CC1)NCCc1c2[nH]c2ccccc12
CHEMBL4115660,CHEMBL233,Mu opioid receptor,Ki,=,0.28,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,NC(=O)c1ccc2c(c1O)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL4108846,CHEMBL233,Mu opioid receptor,Ki,=,0.11,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(C(N)=O)c(O)c4[C@@]2(CCN3CC2CCC2)C1
CHEMBL3948892,CHEMBL233,Mu opioid receptor,Ki,=,0.097,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,C=C1CC[C@H]2[C@H]3Cc4ccc(C(N)=O)c(O)c4[C@@]2(CCN3CC2CCC2)C1
CHEMBL3986245,CHEMBL233,Mu opioid receptor,Ki,=,0.22,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@@H]1CC[C@H](O)C3
CHEMBL3954177,CHEMBL233,Mu opioid receptor,Ki,=,0.097,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@@H]1CCC(=O)C3
CHEMBL3983967,CHEMBL233,Mu opioid receptor,Ki,=,0.12,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,NC(=O)c1ccc2c(c1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL4114524,CHEMBL233,Mu opioid receptor,Ki,=,0.13,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@@H]1CC[C@@H](O)C3
CHEMBL4114677,CHEMBL233,Mu opioid receptor,Ki,=,0.56,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,CC(C)=CCN1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13
CHEMBL4114707,CHEMBL233,Mu opioid receptor,Ki,=,0.5,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(C(N)=O)c(O)c4[C@@]2(CCN3CC=C(C)C)C1
CHEMBL3903900,CHEMBL233,Mu opioid receptor,Ki,=,0.19,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,C[C@H]1[C@H]2Cc3ccc(C(N)=O)cc3[C@]1(C)CCN2CC1CCC1
CHEMBL461227,CHEMBL233,Mu opioid receptor,Ki,=,2.1,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,CC(C)=CCN1CC[C@@]2(C)c3cc(C(N)=O)ccc3C[C@@H]1[C@@H]2C
CHEMBL370029,CHEMBL233,Mu opioid receptor,Ki,=,0.16,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@]1(O)CCC(=O)C3
CHEMBL512150,CHEMBL233,Mu opioid receptor,Ki,=,0.59,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@]1(O)CC[C@H](O)C3
CHEMBL511645,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@]1(O)CC[C@@H](O)C3
CHEMBL4110274,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,CC1[C@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2[C@H](C)C1CC1
CHEMBL3971916,CHEMBL233,Mu opioid receptor,Ki,=,22.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,CC1[C@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2[C@@H](C)C1CC1
CHEMBL4109400,CHEMBL233,Mu opioid receptor,Ki,=,0.82,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,CC1C2Cc3ccc(O)cc3[C@]1(C)CCN2CC1(C)CC1
CHEMBL4113472,CHEMBL233,Mu opioid receptor,Ki,=,4.6,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,CC1C2Cc3ccc(O)cc3[C@]1(C)CCN2CC(C)(C)O
CHEMBL3958318,CHEMBL233,Mu opioid receptor,Ki,=,0.11,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,COCCN1CC[C@@]2(C)c3cc(O)ccc3C[C@@H]1[C@@H]2C
CHEMBL4108042,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,CC1C2Cc3ccc(C(N)=O)cc3[C@]1(C)CCN2CC1(C)CC1
CHEMBL3977887,CHEMBL233,Mu opioid receptor,Ki,=,0.68,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,C[C@H]1[C@H]2Cc3ccc(C(=O)NCCc4ccc(-c5ccc(O)nc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL3928839,CHEMBL233,Mu opioid receptor,Ki,=,0.27,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,C[C@H]1[C@H]2Cc3ccc(C(=O)NCCc4ccc(-c5cn[nH]c5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL4106879,CHEMBL233,Mu opioid receptor,Ki,=,0.37,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(C(=O)NCCc5ccc(-c6cccnc6)cc5)c(O)c4[C@@]2(CCN3CC2CC2)C1
CHEMBL3919938,CHEMBL233,Mu opioid receptor,Ki,=,2.3,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,C[C@@]12CCCCC[C@@H](Cc3ccc(C(N)=O)cc31)[C@@H]2N
CHEMBL3919938,CHEMBL233,Mu opioid receptor,Ki,=,3.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,C[C@@]12CCCCC[C@@H](Cc3ccc(C(N)=O)cc31)[C@@H]2N
CHEMBL3972934,CHEMBL233,Mu opioid receptor,Ki,=,23.0,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,CN1CC[C@]23c4cccc(C(N)=O)c4O[C@H]2CCC[C@H]3C1
CHEMBL3946804,CHEMBL233,Mu opioid receptor,Ki,=,4.4,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,CCCCCCN1CCC(C(=O)N(C)CC)(c2cccc(O)c2)CC1
CHEMBL4108042,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,CC1C2Cc3ccc(C(N)=O)cc3[C@]1(C)CCN2CC1(C)CC1
CHEMBL4114285,CHEMBL233,Mu opioid receptor,Ki,=,0.083,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,C[C@H](C1CC1)N1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(C(N)=O)cc13
CHEMBL3895359,CHEMBL233,Mu opioid receptor,Ki,=,0.14,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,C[C@@H](C1CC1)N1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13
CHEMBL4108566,CHEMBL233,Mu opioid receptor,Ki,=,5.8,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,C[C@H](C1CC1)N1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13
CHEMBL4115016,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,C[C@H](C1CCC1)N1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13
CHEMBL3911427,CHEMBL233,Mu opioid receptor,Ki,=,0.12,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,COCCN1CC[C@@]2(C)c3cc(C(N)=O)ccc3C[C@@H]1[C@@H]2C
CHEMBL4114055,CHEMBL233,Mu opioid receptor,Ki,=,0.098,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,NC(=O)c1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL4108288,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,NC(=O)c1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CC1)CC3
CHEMBL3939227,CHEMBL233,Mu opioid receptor,Ki,=,0.05,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,C[C@H]1[C@H]2Cc3ccc(C(N)=O)cc3[C@@]1(C)CCN2C[C@H]1CCCO1
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,0.32,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL3039334,CHEMBL233,Mu opioid receptor,Ki,=,1.3,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,Oc1ccc2c3c1OC1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL3917891,CHEMBL233,Mu opioid receptor,Ki,=,0.41,nM,CHEMBL3887250,B,"null: The Ki (binding affinity) for u opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of Med. Chem. 2012, p 3878), which is incorporated herein in its entirety. Briefly, membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed the cloned human u opioid receptor were incubated with 12 different concentrations of the compound set forth herein in the presence of 0.25 nM [3H]DAMGO (see Tiberi et al., Can. J. Physiol. Pharmacol. 1988, Vol. 66, p 1368, which is incorporated by reference herein in its entirety) in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25° C. Incubation times of 60 min were used for [3H]DAMGO (see Gulati et al., Life Sci. 1990, Vol. 47, p 159, which is incorporated by reference herein in its entirety). Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass fiber.",CHEMBL3886239,KI,CO[C@@H]1C([C@](C)(O)C(C)(C)C)[C@H]2CC[C@@]13Oc1c(O)ccc4c1[C@@]31CCN(CC3CC3)[C@H](C4)C21
CHEMBL3647963,CHEMBL233,Mu opioid receptor,Ki,=,1436.0,nM,CHEMBL3887299,B,"mu-Opioid Receptor Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 5004, of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 uL/well).",CHEMBL3886266,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCCCC2)c1=O
CHEMBL3647960,CHEMBL233,Mu opioid receptor,Ki,=,1600.0,nM,CHEMBL3887299,B,"mu-Opioid Receptor Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 5004, of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 uL/well).",CHEMBL3886266,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCCC2)c1=O
CHEMBL3906430,CHEMBL233,Mu opioid receptor,Ki,=,3825.0,nM,CHEMBL3887299,B,"mu-Opioid Receptor Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 5004, of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 uL/well).",CHEMBL3886266,KI,O=C(O)c1nc2ccccc2n(C2CC3CCC(C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL3647959,CHEMBL233,Mu opioid receptor,Ki,=,4450.0,nM,CHEMBL3887299,B,"mu-Opioid Receptor Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 5004, of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 uL/well).",CHEMBL3886266,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL3647958,CHEMBL233,Mu opioid receptor,Ki,=,1631.0,nM,CHEMBL3887299,B,"mu-Opioid Receptor Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 5004, of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 uL/well).",CHEMBL3886266,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL4114883,CHEMBL233,Mu opioid receptor,Ki,=,4032.0,nM,CHEMBL3887299,B,"mu-Opioid Receptor Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 5004, of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 uL/well).",CHEMBL3886266,KI,N[C@]12CCC[C@H](C[C@H](n3c(=O)c(C(=O)O)nc4ccccc43)C1)N2C1CC2CCCC(C2)C1
CHEMBL3647962,CHEMBL233,Mu opioid receptor,Ki,=,61.6,nM,CHEMBL3887299,B,"mu-Opioid Receptor Binding Assay: Radioligand dose-displacement binding assays for mu-opioid receptors used 0.2 nM[3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 uL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 5004, of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 uL/well).",CHEMBL3886266,KI,C[C@@H]1C[C@@H]2C[C@H](C1)C[C@@H](N1[C@@H]3CCC[C@H]1C[C@@H](n1c(=O)c(C(=O)O)nc4ccccc41)C3)C2
CHEMBL4107541,CHEMBL233,Mu opioid receptor,Ki,=,49.88,nM,CHEMBL3887472,B,"Radioligand Dose-Displacement Binding Assays (mu): Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2,1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886333,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4[C@](O)(CC(O)CO)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4111934,CHEMBL233,Mu opioid receptor,Ki,=,77.05,nM,CHEMBL3887472,B,"Radioligand Dose-Displacement Binding Assays (mu): Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2,1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886333,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4C(NC(C)C(N)=O)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4108359,CHEMBL233,Mu opioid receptor,Ki,=,278.49,nM,CHEMBL3887472,B,"Radioligand Dose-Displacement Binding Assays (mu): Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2,1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886333,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4C(NC(C(=O)O)c4ccccc4)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4107606,CHEMBL233,Mu opioid receptor,Ki,=,122.72,nM,CHEMBL3887472,B,"Radioligand Dose-Displacement Binding Assays (mu): Radioligand dose-displacement binding assays for mu-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2,1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886333,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4C(N[C@@H](C(N)=O)c4ccccc4)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4111224,CHEMBL233,Mu opioid receptor,Ki,=,4.16,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1C)[C@H]1Cc4ccc(OCCO)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4107680,CHEMBL233,Mu opioid receptor,Ki,=,2.05,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(N)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4115338,CHEMBL233,Mu opioid receptor,Ki,=,16.36,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,C=Cc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL4107906,CHEMBL233,Mu opioid receptor,Ki,=,4.41,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(F)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4113804,CHEMBL233,Mu opioid receptor,Ki,=,15.83,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COc4ccc(-n6ccnc6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4107470,CHEMBL233,Mu opioid receptor,Ki,=,148.85,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CSc4nc6ccccc6s4)[C@@H](C2)N(C)CC[C@]315
CHEMBL4106544,CHEMBL233,Mu opioid receptor,Ki,=,49.98,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CSc4nc6ccccc6s4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4115091,CHEMBL233,Mu opioid receptor,Ki,=,36.46,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COc1ccc(-n4ccnc4)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4111378,CHEMBL233,Mu opioid receptor,Ki,=,116.06,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CSc4nc(C)ns4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3916122,CHEMBL233,Mu opioid receptor,Ki,=,1.52,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4110639,CHEMBL233,Mu opioid receptor,Ki,=,0.93,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COc1ccc(-n4ccnc4)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4110417,CHEMBL233,Mu opioid receptor,Ki,=,1544.07,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CSc4nc(C)ns4)[C@@H](C2)N(C)CC[C@]315
CHEMBL4113984,CHEMBL233,Mu opioid receptor,Ki,=,3386.17,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CSc4nncs4)[C@@H](C2)N(C)CC[C@]315
CHEMBL4108301,CHEMBL233,Mu opioid receptor,Ki,=,188.28,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CSc4nncs4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4108017,CHEMBL233,Mu opioid receptor,Ki,=,17.42,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(F)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4111233,CHEMBL233,Mu opioid receptor,Ki,=,20.74,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(NS(C)(=O)=O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4110440,CHEMBL233,Mu opioid receptor,Ki,=,132.97,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(NC(C)=O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4112656,CHEMBL233,Mu opioid receptor,Ki,=,20.7,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)NCC[C@]315
CHEMBL4109652,CHEMBL233,Mu opioid receptor,Ki,=,49.26,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(Br)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4107210,CHEMBL233,Mu opioid receptor,Ki,=,146.95,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(C#N)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4114477,CHEMBL233,Mu opioid receptor,Ki,=,17.25,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(C(N)=O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4111231,CHEMBL233,Mu opioid receptor,Ki,=,1.33,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1)[C@H]2O5
CHEMBL4109258,CHEMBL233,Mu opioid receptor,Ki,=,54.23,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(C(=O)O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4114002,CHEMBL233,Mu opioid receptor,Ki,=,304.17,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4c(C)noc4C)[C@@H](C2)N(C)CC[C@]315
CHEMBL4106985,CHEMBL233,Mu opioid receptor,Ki,=,6.29,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1cc4ccccc4s1)[C@H]1Cc4ccc(OCCO)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4112472,CHEMBL233,Mu opioid receptor,Ki,=,92.69,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4c(C)noc4C)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4112358,CHEMBL233,Mu opioid receptor,Ki,=,37.54,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNCc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4113058,CHEMBL233,Mu opioid receptor,Ki,=,9.01,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CNCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4112051,CHEMBL233,Mu opioid receptor,Ki,=,19.39,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CN(Cc4ccccc4)S(C)(=O)=O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4112771,CHEMBL233,Mu opioid receptor,Ki,=,11.79,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CN(Cc4ccccc4)C(C)=O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4107918,CHEMBL233,Mu opioid receptor,Ki,=,4.69,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CSCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4108066,CHEMBL233,Mu opioid receptor,Ki,=,14.02,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4C[S+]([O-])Cc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4113830,CHEMBL233,Mu opioid receptor,Ki,=,51.1,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COCCOCCOCCOC[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(OC)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL4106700,CHEMBL233,Mu opioid receptor,Ki,=,215.94,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COCCOCCOCCOCCOCCOC[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(OC)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL4111124,CHEMBL233,Mu opioid receptor,Ki,=,6.72,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COCCOCCOCCOc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4110312,CHEMBL233,Mu opioid receptor,Ki,=,26.92,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COCCOCCOCCOCCOCCOc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4109389,CHEMBL233,Mu opioid receptor,Ki,=,87.86,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COCCOCCOCCOc1ccc(COC[C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)cc1
CHEMBL4115652,CHEMBL233,Mu opioid receptor,Ki,=,135.49,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COCCOCCOCCOCCOCCOc1ccc(COC[C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)cc1
CHEMBL4111803,CHEMBL233,Mu opioid receptor,Ki,=,19.04,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COC(=O)COc1ccc(COC[C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)cc1
CHEMBL4111244,CHEMBL233,Mu opioid receptor,Ki,=,544.71,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(OCC(=O)O)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4112155,CHEMBL233,Mu opioid receptor,Ki,=,383.41,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CCC(N)=O)CC[C@]315
CHEMBL4111763,CHEMBL233,Mu opioid receptor,Ki,=,349.03,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CNCC(=O)O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4106505,CHEMBL233,Mu opioid receptor,Ki,=,308.21,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(=O)NCC(=O)O)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4114486,CHEMBL233,Mu opioid receptor,Ki,=,55.53,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CNCC(N)=O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4115536,CHEMBL233,Mu opioid receptor,Ki,=,210.34,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCC(N)=O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4115119,CHEMBL233,Mu opioid receptor,Ki,=,1005.26,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(CC(=O)O)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4109818,CHEMBL233,Mu opioid receptor,Ki,=,154.5,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(C(O)CO)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4111717,CHEMBL233,Mu opioid receptor,Ki,=,29.33,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cccc(NC(N)=O)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4107627,CHEMBL233,Mu opioid receptor,Ki,=,14.29,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COC(=O)[C@@H](N)Cc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4107681,CHEMBL233,Mu opioid receptor,Ki,=,83.27,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cccc(NCC(=O)O)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4110146,CHEMBL233,Mu opioid receptor,Ki,=,13.09,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(c5ccccc5)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4109267,CHEMBL233,Mu opioid receptor,Ki,=,14.98,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COCCOCCOCCOCCOCCO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(OC)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4109653,CHEMBL233,Mu opioid receptor,Ki,=,7.79,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COCCOCCOCCO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(OC)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4111263,CHEMBL233,Mu opioid receptor,Ki,=,1774.64,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(Cc6nn[nH]n6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4107537,CHEMBL233,Mu opioid receptor,Ki,=,32.04,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CCCc1cc(COC[C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(C)[C@@H]4C6)on1
CHEMBL4114011,CHEMBL233,Mu opioid receptor,Ki,=,849.99,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CCC(=O)O)CC[C@]315
CHEMBL4114882,CHEMBL233,Mu opioid receptor,Ki,=,312.15,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC(=O)O)CC[C@]315
CHEMBL4106487,CHEMBL233,Mu opioid receptor,Ki,=,176.92,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC(N)=O)CC[C@]315
CHEMBL4109778,CHEMBL233,Mu opioid receptor,Ki,=,163.53,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(OCC(=O)O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4109142,CHEMBL233,Mu opioid receptor,Ki,=,20.39,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(OCc5nn[nH]n5)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4109061,CHEMBL233,Mu opioid receptor,Ki,=,8.69,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(OCC(N)=O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4114584,CHEMBL233,Mu opioid receptor,Ki,=,261.23,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(CC(O)CO)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4112287,CHEMBL233,Mu opioid receptor,Ki,=,1.76,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4C(C)(C)OCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4110056,CHEMBL233,Mu opioid receptor,Ki,=,35.79,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cccc(C(=N)N)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4111594,CHEMBL233,Mu opioid receptor,Ki,=,7.29,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CS(=O)(=O)Cc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4113221,CHEMBL233,Mu opioid receptor,Ki,=,341.38,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCC(O)CO)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4109954,CHEMBL233,Mu opioid receptor,Ki,=,82.53,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(C#N)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4108808,CHEMBL233,Mu opioid receptor,Ki,=,338.89,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(-c5nn[nH]n5)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4114523,CHEMBL233,Mu opioid receptor,Ki,=,1102.05,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(C(=O)O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4115153,CHEMBL233,Mu opioid receptor,Ki,=,1.17,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1cccc(NC(=O)c4ccccc4)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4106746,CHEMBL233,Mu opioid receptor,Ki,=,0.34,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(C(N)=O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3930597,CHEMBL233,Mu opioid receptor,Ki,=,147.99,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COC(=O)[C@H](C)N)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4110981,CHEMBL233,Mu opioid receptor,Ki,=,361.75,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COC(=O)[C@@H](N)CO)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4108290,CHEMBL233,Mu opioid receptor,Ki,=,60.13,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COC(=O)[C@@H](N)C(C)O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3908063,CHEMBL233,Mu opioid receptor,Ki,=,5.42,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CC[C@H](C)[C@H](N)C(=O)OC[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(OC)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL3965826,CHEMBL233,Mu opioid receptor,Ki,=,189.66,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)[C@H](C)N)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4107821,CHEMBL233,Mu opioid receptor,Ki,=,7.65,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COC(=O)[C@@H](N)CC(C)C)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4113588,CHEMBL233,Mu opioid receptor,Ki,=,169.53,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COC(=O)[C@@H](N)CCC(N)=O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4115222,CHEMBL233,Mu opioid receptor,Ki,=,0.19,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COC(=O)[C@@H](N)Cc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3927136,CHEMBL233,Mu opioid receptor,Ki,=,0.15,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CC[C@H](C)[C@H](N)C(=O)OC[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL3939745,CHEMBL233,Mu opioid receptor,Ki,=,1.4,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COC(=O)[C@H](C)N)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3969293,CHEMBL233,Mu opioid receptor,Ki,=,15.09,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CCOC(=O)CC[C@H]1[C@H](COCc2ccccc2)[C@]2(OC)CC[C@]13[C@H]1Cc4ccc(OC)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4114384,CHEMBL233,Mu opioid receptor,Ki,=,60.54,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5([C@@H](CC#N)[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3956140,CHEMBL233,Mu opioid receptor,Ki,=,926.92,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5([C@@H](CCC(=O)O)[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3930729,CHEMBL233,Mu opioid receptor,Ki,=,24.41,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,CCOC(=O)CC[C@H]1[C@H](COCc2ccccc2)[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(OC)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL4106722,CHEMBL233,Mu opioid receptor,Ki,=,3.32,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(O)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4106647,CHEMBL233,Mu opioid receptor,Ki,=,155.62,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(NC(C)=O)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4113890,CHEMBL233,Mu opioid receptor,Ki,=,985.95,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(Cc2nn[nH]n2)CC[C@]315
CHEMBL4112393,CHEMBL233,Mu opioid receptor,Ki,=,497.73,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cccc(CC(=O)O)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4109220,CHEMBL233,Mu opioid receptor,Ki,=,54.83,nM,CHEMBL3887789,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for t-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hr at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Count.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(O)CO)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3923831,CHEMBL233,Mu opioid receptor,Ki,=,8.44,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,CO[C@H]1C=CC2C3Cc4ccc(O)c5c4[C@@]2(CCN3C)C1O5
CHEMBL4110373,CHEMBL233,Mu opioid receptor,Ki,=,15.72,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4107642,CHEMBL233,Mu opioid receptor,Ki,=,21.97,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4112562,CHEMBL233,Mu opioid receptor,Ki,=,50.66,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4106506,CHEMBL233,Mu opioid receptor,Ki,=,23.11,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4108649,CHEMBL233,Mu opioid receptor,Ki,=,39.4,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4112722,CHEMBL233,Mu opioid receptor,Ki,=,72.98,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4110642,CHEMBL233,Mu opioid receptor,Ki,=,56.86,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4108525,CHEMBL233,Mu opioid receptor,Ki,=,111.05,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL656,CHEMBL233,Mu opioid receptor,Ki,=,133.48,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314
CHEMBL4110656,CHEMBL233,Mu opioid receptor,Ki,=,653.9,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4112234,CHEMBL233,Mu opioid receptor,Ki,=,631.76,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4111500,CHEMBL233,Mu opioid receptor,Ki,=,775.19,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4112727,CHEMBL233,Mu opioid receptor,Ki,=,892.7,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4108425,CHEMBL233,Mu opioid receptor,Ki,=,1862.14,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4109078,CHEMBL233,Mu opioid receptor,Ki,=,1898.3,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4114370,CHEMBL233,Mu opioid receptor,Ki,=,1607.19,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4108254,CHEMBL233,Mu opioid receptor,Ki,=,3616.6,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL2448883,CHEMBL233,Mu opioid receptor,Ki,=,1953.0,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COc1ccc2c3c1O[C@H]1[C@@H](O)C=CC4[C@@H](C2)N(C)CC[C@@]341
CHEMBL3895828,CHEMBL233,Mu opioid receptor,Ki,=,1821.51,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCO[C@H]1C=CC2C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)C1O5
CHEMBL3937789,CHEMBL233,Mu opioid receptor,Ki,=,1383.07,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCO[C@H]1C=CC2C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)C1O5
CHEMBL3934684,CHEMBL233,Mu opioid receptor,Ki,=,4260.21,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCO[C@H]1C=CC2C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)C1O5
CHEMBL3967811,CHEMBL233,Mu opioid receptor,Ki,=,2891.36,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCO[C@H]1C=CC2C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)C1O5
CHEMBL3933053,CHEMBL233,Mu opioid receptor,Ki,=,2427.13,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCO[C@H]1C=CC2C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)C1O5
CHEMBL3956767,CHEMBL233,Mu opioid receptor,Ki,=,14202.77,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCO[C@H]1C=CC2C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)C1O5
CHEMBL3984515,CHEMBL233,Mu opioid receptor,Ki,=,9963.93,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCOCCO[C@H]1C=CC2C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)C1O5
CHEMBL3911284,CHEMBL233,Mu opioid receptor,Ki,=,9975.84,nM,CHEMBL3888044,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCOCCOCCOCCO[C@H]1C=CC2C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)C1O5
CHEMBL895,CHEMBL233,Mu opioid receptor,Ki,=,14.31,nM,CHEMBL3888049,B,Binding of PEG-Nalbuphine assays: Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed using GraphPad Prism 4.0 and IC50 is generated by non-linear regression from dose-response curves. Ki values were calculated using the Cheng Prusoff equation using the Kd values from saturation isotherms as follows: Ki=IC50/(1+[Ligand]/Kd).,CHEMBL3886551,KI,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL3954154,CHEMBL233,Mu opioid receptor,Ki,=,27.41,nM,CHEMBL3888049,B,Binding of PEG-Nalbuphine assays: Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed using GraphPad Prism 4.0 and IC50 is generated by non-linear regression from dose-response curves. Ki values were calculated using the Cheng Prusoff equation using the Kd values from saturation isotherms as follows: Ki=IC50/(1+[Ligand]/Kd).,CHEMBL3886551,KI,COCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL3973162,CHEMBL233,Mu opioid receptor,Ki,=,17.54,nM,CHEMBL3888049,B,Binding of PEG-Nalbuphine assays: Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed using GraphPad Prism 4.0 and IC50 is generated by non-linear regression from dose-response curves. Ki values were calculated using the Cheng Prusoff equation using the Kd values from saturation isotherms as follows: Ki=IC50/(1+[Ligand]/Kd).,CHEMBL3886551,KI,COCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL3901176,CHEMBL233,Mu opioid receptor,Ki,=,35.09,nM,CHEMBL3888049,B,Binding of PEG-Nalbuphine assays: Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed using GraphPad Prism 4.0 and IC50 is generated by non-linear regression from dose-response curves. Ki values were calculated using the Cheng Prusoff equation using the Kd values from saturation isotherms as follows: Ki=IC50/(1+[Ligand]/Kd).,CHEMBL3886551,KI,COCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL3947626,CHEMBL233,Mu opioid receptor,Ki,=,44.28,nM,CHEMBL3888049,B,Binding of PEG-Nalbuphine assays: Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed using GraphPad Prism 4.0 and IC50 is generated by non-linear regression from dose-response curves. Ki values were calculated using the Cheng Prusoff equation using the Kd values from saturation isotherms as follows: Ki=IC50/(1+[Ligand]/Kd).,CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL3966308,CHEMBL233,Mu opioid receptor,Ki,=,77.94,nM,CHEMBL3888049,B,Binding of PEG-Nalbuphine assays: Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed using GraphPad Prism 4.0 and IC50 is generated by non-linear regression from dose-response curves. Ki values were calculated using the Cheng Prusoff equation using the Kd values from saturation isotherms as follows: Ki=IC50/(1+[Ligand]/Kd).,CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL3953339,CHEMBL233,Mu opioid receptor,Ki,=,79.55,nM,CHEMBL3888049,B,Binding of PEG-Nalbuphine assays: Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed using GraphPad Prism 4.0 and IC50 is generated by non-linear regression from dose-response curves. Ki values were calculated using the Cheng Prusoff equation using the Kd values from saturation isotherms as follows: Ki=IC50/(1+[Ligand]/Kd).,CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL3919846,CHEMBL233,Mu opioid receptor,Ki,=,122.3,nM,CHEMBL3888049,B,Binding of PEG-Nalbuphine assays: Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed using GraphPad Prism 4.0 and IC50 is generated by non-linear regression from dose-response curves. Ki values were calculated using the Cheng Prusoff equation using the Kd values from saturation isotherms as follows: Ki=IC50/(1+[Ligand]/Kd).,CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL4111642,CHEMBL233,Mu opioid receptor,Ki,=,502.0,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,C[C@@H]1C[C@@H]2C[C@H](C1)C[C@@H](N1[C@@H]3CC[C@H]1C[C@@H](n1c(=O)c(N4CC[C@@H]4C(=O)O)nc4ccccc41)C3)C2
CHEMBL3942346,CHEMBL233,Mu opioid receptor,Ki,=,219.0,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,C[C@@H]1C[C@@H]2C[C@H](C1)C[C@@H](N1[C@@H]3CC[C@H]1C[C@@H](n1c(=O)c(N4CC[C@H]4C(=O)O)nc4ccccc41)C3)C2
CHEMBL3970857,CHEMBL233,Mu opioid receptor,Ki,=,500.0,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,O=C(O)[C@@H]1CCN1c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3[C@H]2C[C@@H]3CCC[C@@H](C3)C2)c1=O
CHEMBL3894621,CHEMBL233,Mu opioid receptor,Ki,=,48.9,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,C[C@@H]1C[C@@H]2C[C@H](C1)C[C@@H](N1[C@@H]3CCC[C@H]1C[C@@H](n1c(=O)c(N4CC[C@H]4C(=O)O)nc4ccccc41)C3)C2
CHEMBL3986914,CHEMBL233,Mu opioid receptor,Ki,=,29.1,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,C[C@@H]1C[C@@H]2C[C@H](C1)C[C@@H](N1[C@@H]3CCC[C@H]1C[C@@H](n1c(=O)c(N4CC(C(=O)O)C4)nc4ccccc41)C3)C2
CHEMBL4115318,CHEMBL233,Mu opioid receptor,Ki,=,38.9,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,CC12C[C@H]3C[C@@H](N4[C@@H]5CCC[C@H]4C[C@@H](n4c(=O)c(N6CC[C@@H]6C(=O)O)nc6ccccc64)C5)C[C@@H]1C[C@@H]2C3
CHEMBL4114020,CHEMBL233,Mu opioid receptor,Ki,=,154.0,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,CC12C[C@H]3C[C@@H](N4[C@@H]5CCC[C@H]4C[C@@H](n4c(=O)c(N6CC[C@H]6C(=O)O)nc6ccccc64)C5)C[C@@H]1C[C@@H]2C3
CHEMBL4113014,CHEMBL233,Mu opioid receptor,Ki,=,54.1,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,CC12C[C@H]3C[C@@H](N4[C@@H]5CCC[C@H]4C[C@@H](n4c(=O)c(N6CC(C(=O)O)C6)nc6ccccc64)C5)C[C@@H]1C[C@@H]2C3
CHEMBL3903565,CHEMBL233,Mu opioid receptor,Ki,=,43.4,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,C[C@@H]1C[C@@H]2C[C@H](C1)C[C@@H](N1[C@@H]3CCC[C@H]1C[C@@H](n1c(=O)c(N4CC(CC(=O)O)C4)nc4ccccc41)C3)C2
CHEMBL4112220,CHEMBL233,Mu opioid receptor,Ki,=,2830.0,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,CC12C[C@H]3C[C@@H](N4[C@@H]5COC[C@H]4C[C@@H](n4c(=O)c(N6CC[C@H]6C(=O)O)nc6ccccc64)C5)C[C@@H]1C[C@@H]2C3
CHEMBL3920823,CHEMBL233,Mu opioid receptor,Ki,=,3420.0,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,CC1(C)[C@H]2CC[C@@H](CCN3[C@@H]4CCC[C@H]3C[C@@H](n3c(=O)c(N5CC[C@@H]5C(=O)O)nc5ccccc53)C4)[C@@H]1C2
CHEMBL3926298,CHEMBL233,Mu opioid receptor,Ki,=,744.0,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,CC1(C)[C@H]2CC[C@@H](CCN3[C@@H]4CCC[C@H]3C[C@@H](n3c(=O)c(N5CC(C(=O)O)C5)nc5ccccc53)C4)[C@@H]1C2
CHEMBL3935191,CHEMBL233,Mu opioid receptor,Ki,=,259.0,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,O=C(O)[C@@H]1CCN1c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)c1=O
CHEMBL3973642,CHEMBL233,Mu opioid receptor,Ki,=,494.0,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,O=C(O)CC1CN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4[C@@H]3C[C@@H]4CCCC[C@@H](C4)C3)c2=O)C1
CHEMBL4107594,CHEMBL233,Mu opioid receptor,Ki,=,136.0,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,O=C(O)[C@H]1CCN1c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)c1=O
CHEMBL3941054,CHEMBL233,Mu opioid receptor,Ki,=,128.0,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,O=C(O)[C@@H]1CCN1c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)c1=O
CHEMBL4107295,CHEMBL233,Mu opioid receptor,Ki,=,83.0,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,N[C@@H]1CN(c2nc3ccccc3n([C@H]3C[C@H]4CCC[C@@H](C3)N4[C@@H]3C[C@@H]4CCCC[C@@H](C4)C3)c2=O)[C@@H]1C(=O)O
CHEMBL4110144,CHEMBL233,Mu opioid receptor,Ki,=,57.0,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,CN(C)[C@@H]1CN(c2nc3ccccc3n([C@H]3C[C@H]4CCC[C@@H](C3)N4[C@@H]3C[C@@H]4CCCC[C@@H](C4)C3)c2=O)[C@@H]1C(=O)O
CHEMBL3895142,CHEMBL233,Mu opioid receptor,Ki,=,919.0,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,O=C(O)[C@@H]1CCCN1c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3[C@H]2C[C@@H]3CCC[C@@H](C3)C2)c1=O
CHEMBL4112615,CHEMBL233,Mu opioid receptor,Ki,=,86.0,nM,CHEMBL3888260,B,"In Vitro Mu-Opioid Receptor Binding Assay: Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand dose-displacement binding assays for human μ-opioid receptors used 0.2 nM [3H]-diprenorphine (NEN, Boston, Mass.), with 5-20 mg membrane protein/well in a final volume of 500 μL binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 1-2 hr at about 25 °C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard, Meriden, Conn.) presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by performing three filtration washes with 500 μL of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Wallac, Turku, Finland) was added (50 μL/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,CC12C[C@H]3C[C@@H](N4[C@@H]5CCC[C@H]4C[C@@H](n4c(=O)c(N6CCC[C@H]6C(=O)O)nc6ccccc64)C5)C[C@@H]1C[C@@H]2C3
CHEMBL511142,CHEMBL233,Mu opioid receptor,Ki,=,0.3,nM,CHEMBL3888317,B,"μ-Opioid Receptor Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886656,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4107585,CHEMBL233,Mu opioid receptor,Ki,=,0.45,nM,CHEMBL3888317,B,"μ-Opioid Receptor Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886656,KI,CC(C)(C)[C@@]1(C)OCO[C@]23CC[C@@]4(C[C@@H]21)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4113162,CHEMBL233,Mu opioid receptor,Ki,=,0.35,nM,CHEMBL3888317,B,"μ-Opioid Receptor Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886656,KI,CCC1O[C@]23CC[C@@]4(C[C@@H]2[C@@](C)(C(C)(C)C)O1)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4111049,CHEMBL233,Mu opioid receptor,Ki,=,0.54,nM,CHEMBL3888317,B,"μ-Opioid Receptor Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886656,KI,CCCC1O[C@]23CC[C@@]4(C[C@@H]2[C@@](C)(C(C)(C)C)O1)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4113900,CHEMBL233,Mu opioid receptor,Ki,=,2.26,nM,CHEMBL3888317,B,"μ-Opioid Receptor Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886656,KI,CC(C)(C)[C@@]1(C)OC(c2ccccc2)O[C@]23CC[C@@]4(C[C@@H]21)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL3944286,CHEMBL233,Mu opioid receptor,Ki,=,6252.0,nM,CHEMBL3888406,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours.",CHEMBL3886698,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)C[C@]1(CC[C@@]1(C3)NC(=O)NC1=O)C2
CHEMBL4113236,CHEMBL233,Mu opioid receptor,Ki,=,9550.0,nM,CHEMBL3888406,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours.",CHEMBL3886698,KI,COC(=O)c1cc2c([nH]c1=O)C[C@@]13CCN(CC4CC4)C[C@@]1(Cc1ccc(OC)cc13)C2
CHEMBL4113521,CHEMBL233,Mu opioid receptor,Ki,=,15592.0,nM,CHEMBL3888406,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours.",CHEMBL3886698,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)C[C@@]1(C2)Cc1cc(C(N)=O)c(=O)[nH]c1C3
CHEMBL4108929,CHEMBL233,Mu opioid receptor,Ki,=,770.1,nM,CHEMBL3888406,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours.",CHEMBL3886698,KI,NC(=O)c1cc2c([nH]c1=O)C[C@@]13CCN(CC4CC4)C[C@@]1(Cc1ccc(O)cc13)C2
CHEMBL3916263,CHEMBL233,Mu opioid receptor,Ki,=,472.5,nM,CHEMBL3888406,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours.",CHEMBL3886698,KI,O=C1NC(=O)[C@@]2(CC[C@@]34Cc5ccc(O)cc5[C@@]3(CCN(CC3CC3)C4)C2)N1
CHEMBL3981333,CHEMBL233,Mu opioid receptor,Ki,=,676.0,nM,CHEMBL3888406,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours.",CHEMBL3886698,KI,O=C1NC(=O)[C@]2(CC[C@@]34Cc5ccc(O)cc5[C@@]3(CCN(CC3CC3)C4)C2)N1
CHEMBL3890527,CHEMBL233,Mu opioid receptor,Ki,=,6.18,nM,CHEMBL3888719,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,O=C(O)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4115581,CHEMBL233,Mu opioid receptor,Ki,=,668.0,nM,CHEMBL3888719,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)C1[C@@H](O)[C@H](OCc1ccccc1)C(=O)C3
CHEMBL3922780,CHEMBL233,Mu opioid receptor,Ki,=,591.0,nM,CHEMBL3888719,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](CCO)C(=O)C3
CHEMBL4106563,CHEMBL233,Mu opioid receptor,Ki,=,222.8,nM,CHEMBL3888719,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](CCOCc1ccccc1)C(=O)C3
CHEMBL3932459,CHEMBL233,Mu opioid receptor,Ki,=,1959.0,nM,CHEMBL3888719,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,COCC[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(OC)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3976681,CHEMBL233,Mu opioid receptor,Ki,=,476.0,nM,CHEMBL3888719,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1C[C@@H](C(C)C)C(=O)C3
CHEMBL3948713,CHEMBL233,Mu opioid receptor,Ki,=,1.98,nM,CHEMBL3888719,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,CC(C)[C@@H]1C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4111936,CHEMBL233,Mu opioid receptor,Ki,=,7.42,nM,CHEMBL3888719,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for μ-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 μl binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 μl of ice-cold binding buffer. Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well), and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,CC(C)[C@H]1C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3943372,CHEMBL233,Mu opioid receptor,Ki,=,70.5,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(C(=O)c2cc3ccccc3n2C)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3960085,CHEMBL233,Mu opioid receptor,Ki,=,49.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(C(=N)c2cc3ccccc3n2C)(N2CCCC2)CC1
CHEMBL3975775,CHEMBL233,Mu opioid receptor,Ki,=,1160.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(C(=O)c2cc3ccccc3n2C)(N2CCCC2)CC1
CHEMBL3959941,CHEMBL233,Mu opioid receptor,Ki,=,640.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CNC1(c2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3935944,CHEMBL233,Mu opioid receptor,Ki,=,600.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3951213,CHEMBL233,Mu opioid receptor,Ki,=,80.5,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(Cc2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3951213,CHEMBL233,Mu opioid receptor,Ki,=,155.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(Cc2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3945941,CHEMBL233,Mu opioid receptor,Ki,=,140.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CC(=O)NCC1(C)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3942616,CHEMBL233,Mu opioid receptor,Ki,=,1.25,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(C)(CNS(=O)(=O)c2ccc(Cl)cc2)CC1
CHEMBL3966922,CHEMBL233,Mu opioid receptor,Ki,=,47.5,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CCCCC1(CNS(=O)(=O)c2ccc(Cl)cc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3937167,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(CO)(CCCCc2ccccc2)CC1
CHEMBL3937167,CHEMBL233,Mu opioid receptor,Ki,=,783.33,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(CO)(CCCCc2ccccc2)CC1
CHEMBL3928190,CHEMBL233,Mu opioid receptor,Ki,=,14.25,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C(=O)/C=C/c2ccccc2)CC1
CHEMBL3969636,CHEMBL233,Mu opioid receptor,Ki,=,15.4,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CC(=O)N(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3928190,CHEMBL233,Mu opioid receptor,Ki,=,8.05,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C(=O)/C=C/c2ccccc2)CC1
CHEMBL3969636,CHEMBL233,Mu opioid receptor,Ki,=,895.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CC(=O)N(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3977883,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C(=O)NCc2ccccc2)CC1
CHEMBL3977883,CHEMBL233,Mu opioid receptor,Ki,=,2.2,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C(=O)NCc2ccccc2)CC1
CHEMBL3982674,CHEMBL233,Mu opioid receptor,Ki,=,22.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CCNC(=O)N(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3982674,CHEMBL233,Mu opioid receptor,Ki,=,52.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CCNC(=O)N(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3893777,CHEMBL233,Mu opioid receptor,Ki,=,1110.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CNC1(c2ccccc2)CCC(Cc2ccccc2)(CN(C)C)CC1
CHEMBL3932117,CHEMBL233,Mu opioid receptor,Ki,=,215.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)CC1(Cc2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3959625,CHEMBL233,Mu opioid receptor,Ki,=,410.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,Cc1c(C2(N(C)C)CCC(c3ccccc3)(N(C)C)CC2)[nH]c2ccccc12
CHEMBL3974883,CHEMBL233,Mu opioid receptor,Ki,=,2455.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)CC1(c2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3945501,CHEMBL233,Mu opioid receptor,Ki,=,555.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CNC1(c2ccccc2)CCC(c2cccs2)(N(C)C)CC1
CHEMBL3982887,CHEMBL233,Mu opioid receptor,Ki,=,445.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2cccs2)(N(C)C)CC1
CHEMBL3982887,CHEMBL233,Mu opioid receptor,Ki,=,4110.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2cccs2)(N(C)C)CC1
CHEMBL3890424,CHEMBL233,Mu opioid receptor,Ki,=,1.8,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2cccc(F)c2)CCC(C)(CNC(=O)/C=C/c2ccccc2)CC1
CHEMBL3959501,CHEMBL233,Mu opioid receptor,Ki,=,130.5,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CC(NC(=O)/C=C/c1ccccc1)C1CCC(c2cccc(F)c2)(N(C)C)CC1
CHEMBL3899387,CHEMBL233,Mu opioid receptor,Ki,=,13.35,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2cccc(F)c2)CCC(C)(CNS(=O)(=O)/C=C/c2ccccc2)CC1
CHEMBL3899387,CHEMBL233,Mu opioid receptor,Ki,=,1.24,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2cccc(F)c2)CCC(C)(CNS(=O)(=O)/C=C/c2ccccc2)CC1
CHEMBL3911970,CHEMBL233,Mu opioid receptor,Ki,=,188.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CCCCC1(N(C)C)CCC(NC)(c2ccccc2)CC1
CHEMBL3911970,CHEMBL233,Mu opioid receptor,Ki,=,755.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CCCCC1(N(C)C)CCC(NC)(c2ccccc2)CC1
CHEMBL3898034,CHEMBL233,Mu opioid receptor,Ki,=,900.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CCCCN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3898034,CHEMBL233,Mu opioid receptor,Ki,=,61.5,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CCCCN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3934183,CHEMBL233,Mu opioid receptor,Ki,=,120.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)Cc2ccccc2)CC1
CHEMBL3934183,CHEMBL233,Mu opioid receptor,Ki,=,44.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)Cc2ccccc2)CC1
CHEMBL3960588,CHEMBL233,Mu opioid receptor,Ki,=,18.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C(=O)C(c2ccccc2)c2ccccc2)CC1
CHEMBL3985824,CHEMBL233,Mu opioid receptor,Ki,=,115.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CCCCC1(N(C)C)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3985824,CHEMBL233,Mu opioid receptor,Ki,=,34.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CCCCC1(N(C)C)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3977691,CHEMBL233,Mu opioid receptor,Ki,=,107.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CNC1(c2ccccc2)CCC(CC2CCCC2)(N(C)C)CC1
CHEMBL3977691,CHEMBL233,Mu opioid receptor,Ki,=,32.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CNC1(c2ccccc2)CCC(CC2CCCC2)(N(C)C)CC1
CHEMBL3909426,CHEMBL233,Mu opioid receptor,Ki,=,47.5,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(CC2CCCC2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3909426,CHEMBL233,Mu opioid receptor,Ki,=,6.6,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(CC2CCCC2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3965425,CHEMBL233,Mu opioid receptor,Ki,=,5.3,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(CC2CCCC2)CCC(c2ccccc2)(N(C)C(=O)/C=C/c2ccccc2)CC1
CHEMBL3965425,CHEMBL233,Mu opioid receptor,Ki,=,92.5,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(CC2CCCC2)CCC(c2ccccc2)(N(C)C(=O)/C=C/c2ccccc2)CC1
CHEMBL3920864,CHEMBL233,Mu opioid receptor,Ki,=,10230.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)CC(=O)O)CC1
CHEMBL3920864,CHEMBL233,Mu opioid receptor,Ki,=,5205.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)CC(=O)O)CC1
CHEMBL3926333,CHEMBL233,Mu opioid receptor,Ki,=,650.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CNC1(c2ccccc2)CCC(c2ccc(OC)cc2)(N(C)C)CC1
CHEMBL3946074,CHEMBL233,Mu opioid receptor,Ki,=,1190.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CNC1(c2ccccc2)CCC(c2ccc(C(F)(F)F)cc2)(N(C)C)CC1
CHEMBL3907138,CHEMBL233,Mu opioid receptor,Ki,=,1695.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccc(C(F)(F)F)cc2)(N(C)C)CC1
CHEMBL3907138,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccc(C(F)(F)F)cc2)(N(C)C)CC1
CHEMBL3919659,CHEMBL233,Mu opioid receptor,Ki,=,660.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,COc1ccc(C2(N(C)C)CCC(c3ccccc3)(N(C)C)CC2)cc1
CHEMBL3919659,CHEMBL233,Mu opioid receptor,Ki,=,670.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,COc1ccc(C2(N(C)C)CCC(c3ccccc3)(N(C)C)CC2)cc1
CHEMBL3921976,CHEMBL233,Mu opioid receptor,Ki,=,180.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(CC1(C)CCC(c2ccccc2)(N(C)C)CC1)c1c[nH]c2ccccc12
CHEMBL3921976,CHEMBL233,Mu opioid receptor,Ki,=,0.4,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(CC1(C)CCC(c2ccccc2)(N(C)C)CC1)c1c[nH]c2ccccc12
CHEMBL3937593,CHEMBL233,Mu opioid receptor,Ki,=,385.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(Cc1c[nH]c2ccccc12)CC1(C)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3929120,CHEMBL233,Mu opioid receptor,Ki,=,115.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)Cc2cccnc2)CC1
CHEMBL3929120,CHEMBL233,Mu opioid receptor,Ki,=,325.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)Cc2cccnc2)CC1
CHEMBL3950879,CHEMBL233,Mu opioid receptor,Ki,=,1055.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CNc1nc(NC)nc(N(C)C2(c3ccccc3)CCC(c3ccccc3)(N(C)C)CC2)n1
CHEMBL3896402,CHEMBL233,Mu opioid receptor,Ki,=,740.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CNc1nc(Oc2ccc(OC)cc2)nc(N(C)C2(c3ccccc3)CCC(c3ccccc3)(N(C)C)CC2)n1
CHEMBL3982651,CHEMBL233,Mu opioid receptor,Ki,=,6.35,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C(=O)c2ccn(C)n2)CC1
CHEMBL3982651,CHEMBL233,Mu opioid receptor,Ki,=,45.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C(=O)c2ccn(C)n2)CC1
CHEMBL3955335,CHEMBL233,Mu opioid receptor,Ki,=,235.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CCCC(=O)OC1(c2[nH]c3ccccc3c2C)CCC(c2cccc(F)c2)(N(C)C)CC1
CHEMBL3980782,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C(=O)c2cccc(C(F)(F)F)c2)CC1
CHEMBL3943194,CHEMBL233,Mu opioid receptor,Ki,=,2400.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,COc1ccc(Oc2nc(Oc3ccc(OC)cc3)nc(N(C)C3(c4ccccc4)CCC(c4ccccc4)(N(C)C)CC3)n2)cc1
CHEMBL3972755,CHEMBL233,Mu opioid receptor,Ki,=,63.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)Cc2ccn(C)n2)CC1
CHEMBL3972755,CHEMBL233,Mu opioid receptor,Ki,=,3730.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)Cc2ccn(C)n2)CC1
CHEMBL3967435,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,COc1ccc(C(=O)N(C)C2(c3ccccc3)CCC(c3ccccc3)(N(C)C)CC2)cc1
CHEMBL3967435,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,COc1ccc(C(=O)N(C)C2(c3ccccc3)CCC(c3ccccc3)(N(C)C)CC2)cc1
CHEMBL3928651,CHEMBL233,Mu opioid receptor,Ki,=,435.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,COc1ccc(CN(C)C2(c3ccccc3)CCC(c3ccccc3)(N(C)C)CC2)cc1
CHEMBL3928651,CHEMBL233,Mu opioid receptor,Ki,=,1995.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,COc1ccc(CN(C)C2(c3ccccc3)CCC(c3ccccc3)(N(C)C)CC2)cc1
CHEMBL3916201,CHEMBL233,Mu opioid receptor,Ki,=,155.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CNC1(c2[nH]c3ccccc3c2C)CCC(c2cccc(F)c2)(N(C)C)CC1
CHEMBL3939293,CHEMBL233,Mu opioid receptor,Ki,=,420.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,Cc1c(C2(N3CCCCC3)CCC(c3ccccc3)(N(C)C)CC2)[nH]c2ccccc12
CHEMBL3914240,CHEMBL233,Mu opioid receptor,Ki,=,130.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)Cc2cccc(C(F)(F)F)c2)CC1
CHEMBL3914240,CHEMBL233,Mu opioid receptor,Ki,=,1666.67,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)Cc2cccc(C(F)(F)F)c2)CC1
CHEMBL3889835,CHEMBL233,Mu opioid receptor,Ki,=,14.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C(=O)c2cccc(F)c2)CC1
CHEMBL3889835,CHEMBL233,Mu opioid receptor,Ki,=,0.35,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C(=O)c2cccc(F)c2)CC1
CHEMBL3951319,CHEMBL233,Mu opioid receptor,Ki,=,39.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)Cc2cccc(F)c2)CC1
CHEMBL3899856,CHEMBL233,Mu opioid receptor,Ki,=,2900.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)CCO)CC1
CHEMBL3937815,CHEMBL233,Mu opioid receptor,Ki,=,1425.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C(=O)CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3906866,CHEMBL233,Mu opioid receptor,Ki,=,176.67,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CNC(=O)CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3937815,CHEMBL233,Mu opioid receptor,Ki,=,2595.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C(=O)CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3906866,CHEMBL233,Mu opioid receptor,Ki,=,735.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CNC(=O)CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3961206,CHEMBL233,Mu opioid receptor,Ki,=,255.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,Cc1c(C2(N(C)C)CCC(c3ccccc3)(N(C)C)CC2)[nH]c2ccc(F)cc12
CHEMBL3946171,CHEMBL233,Mu opioid receptor,Ki,=,255.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)c1nc(N(C)C)nc(N(C)C2(c3ccccc3)CCC(c3ccccc3)(N(C)C)CC2)n1
CHEMBL3972320,CHEMBL233,Mu opioid receptor,Ki,=,415.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)CCCCO)CC1
CHEMBL3919376,CHEMBL233,Mu opioid receptor,Ki,=,9020.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C(=O)CCC(=O)O)CC1
CHEMBL3943962,CHEMBL233,Mu opioid receptor,Ki,=,1580.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,Cc1c(C2(N3CCCC3)CCC(c3ccccc3)(N(C)C)CC2)[nH]c2ccc(F)cc12
CHEMBL3924824,CHEMBL233,Mu opioid receptor,Ki,=,1890.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(O)(c2ccccc2)CC1
CHEMBL3900292,CHEMBL233,Mu opioid receptor,Ki,=,3.0,nM,CHEMBL3888831,B,"Binding Assay: The affinity to the human μ-opiate receptor was determined in a homogeneous preparation in microtiter plates. For this, dilution series of the respective compound to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 mg of protein per 250 μl of incubation batch) of CHO-K 1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation of NEN, Zaventem, Belgium), in the presence of 1 nmol/l of the radioactive ligand [3H'-naloxone (NET719, NEN, Zaventem, Belgium) and of 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 25 μmol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 1000 g and the radioactivity measured in a β-counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,Cc1ccc(C2(N(C)C)CCC(O)(c3ccccc3)CC2)cc1
CHEMBL4070750,CHEMBL233,Mu opioid receptor,Ki,=,6.47,nM,CHEMBL3992794,B,Displacement of [3H]naloxone from recombinant human MOR expressed in HEK cell membranes incubated for 60 mins,CHEMBL3992491,KI,Cc1ccc(C(=O)NCC2NCCc3ccccc32)cc1
CHEMBL4097865,CHEMBL233,Mu opioid receptor,Ki,=,4.65,nM,CHEMBL3992794,B,Displacement of [3H]naloxone from recombinant human MOR expressed in HEK cell membranes incubated for 60 mins,CHEMBL3992491,KI,CCc1ccc(C(=O)NCC2NCCc3ccccc32)cc1
CHEMBL4105599,CHEMBL233,Mu opioid receptor,Ki,=,36.4,nM,CHEMBL3992794,B,Displacement of [3H]naloxone from recombinant human MOR expressed in HEK cell membranes incubated for 60 mins,CHEMBL3992491,KI,Cc1ccc(C(=O)NCC2NCCc3ccccc32)cc1C
CHEMBL4065924,CHEMBL233,Mu opioid receptor,Ki,=,54.3,nM,CHEMBL3992794,B,Displacement of [3H]naloxone from recombinant human MOR expressed in HEK cell membranes incubated for 60 mins,CHEMBL3992491,KI,O=C(NCC1NCCc2ccccc21)c1ccc(Cl)c(Cl)c1
CHEMBL4097466,CHEMBL233,Mu opioid receptor,Ki,=,5.28,nM,CHEMBL3992794,B,Displacement of [3H]naloxone from recombinant human MOR expressed in HEK cell membranes incubated for 60 mins,CHEMBL3992491,KI,Cc1ccc(C(=O)NCC2c3ccccc3CCN2C)cc1
CHEMBL4070288,CHEMBL233,Mu opioid receptor,Ki,=,2.27,nM,CHEMBL3992794,B,Displacement of [3H]naloxone from recombinant human MOR expressed in HEK cell membranes incubated for 60 mins,CHEMBL3992491,KI,CCc1ccc(C(=O)NCC2c3ccccc3CCN2C)cc1
CHEMBL4071332,CHEMBL233,Mu opioid receptor,Ki,=,30.8,nM,CHEMBL3992794,B,Displacement of [3H]naloxone from recombinant human MOR expressed in HEK cell membranes incubated for 60 mins,CHEMBL3992491,KI,Cc1ccc(C(=O)NCC2c3ccccc3CCN2C)cc1C
CHEMBL4092125,CHEMBL233,Mu opioid receptor,Ki,=,6.91,nM,CHEMBL3992794,B,Displacement of [3H]naloxone from recombinant human MOR expressed in HEK cell membranes incubated for 60 mins,CHEMBL3992491,KI,CN1CCc2ccccc2C1CNC(=O)c1ccc(Cl)c(Cl)c1
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL4001471,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cells,CHEMBL4000201,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL4073537,CHEMBL233,Mu opioid receptor,Ki,=,313.0,nM,CHEMBL4001471,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cells,CHEMBL4000201,KI,O=C1/C(=C/c2ccccc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CCCc2ccccc2)[C@H]1O5
CHEMBL4094170,CHEMBL233,Mu opioid receptor,Ki,=,56.0,nM,CHEMBL4001471,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cells,CHEMBL4000201,KI,O=C1/C(=C/c2ccccc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CCc2ccccc2)[C@H]1O5
CHEMBL4083911,CHEMBL233,Mu opioid receptor,Ki,=,17.5,nM,CHEMBL4001471,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cells,CHEMBL4000201,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)/C(=C/c2ccccc2)C[C@@]3(O)[C@H]1C5
CHEMBL4071862,CHEMBL233,Mu opioid receptor,Ki,=,274.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2ccccc2)CC2CCCC2)c1
CHEMBL4092640,CHEMBL233,Mu opioid receptor,Ki,=,537.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2ccccc2)CC2CCCCC2)c1
CHEMBL4063231,CHEMBL233,Mu opioid receptor,Ki,=,463.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2ccccc2)Cc2ccccc2)c1
CHEMBL4084881,CHEMBL233,Mu opioid receptor,Ki,=,670.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2ccccc2)C2CCC2)c1
CHEMBL4078954,CHEMBL233,Mu opioid receptor,Ki,=,259.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,CC(C)CCN(CCc1ccccc1)CCc1cccc(O)c1.Cl
CHEMBL4096973,CHEMBL233,Mu opioid receptor,Ki,=,230.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2cccc(O)c2)CC2CCC2)c1
CHEMBL4103205,CHEMBL233,Mu opioid receptor,Ki,=,631.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2cccc(O)c2)CC2CC2)c1
CHEMBL4078930,CHEMBL233,Mu opioid receptor,Ki,=,358.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,C=CCN(CCc1cccc(O)c1)CCc1cccc(O)c1.Cl
CHEMBL4065350,CHEMBL233,Mu opioid receptor,Ki,=,167.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2cccc(O)c2)CC2CCCCC2)c1
CHEMBL4086783,CHEMBL233,Mu opioid receptor,Ki,=,584.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2cccc(O)c2)CC2CCCC2)c1
CHEMBL4073963,CHEMBL233,Mu opioid receptor,Ki,=,211.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,CC(C)CCN(CCc1cccc(O)c1)CCc1cccc(O)c1.Cl
CHEMBL4094512,CHEMBL233,Mu opioid receptor,Ki,=,16.1,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,Cl.Oc1ccc(CCN(CCc2cccc(O)c2)CC2CCC2)cc1
CHEMBL4084291,CHEMBL233,Mu opioid receptor,Ki,=,234.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,Cl.Oc1ccc(CCN(CCc2cccc(O)c2)CC2CCCCC2)cc1
CHEMBL4102256,CHEMBL233,Mu opioid receptor,Ki,=,192.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,C=CCN(CCc1ccc(O)cc1)CCc1cccc(O)c1.Cl
CHEMBL4069115,CHEMBL233,Mu opioid receptor,Ki,=,460.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,Cl.Oc1ccc(CCN(CCc2cccc(O)c2)CC2CC2)cc1
CHEMBL4090181,CHEMBL233,Mu opioid receptor,Ki,=,398.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2ccccc2)CC2CCC2)c1F
CHEMBL4101576,CHEMBL233,Mu opioid receptor,Ki,=,851.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2ccccc2)CC2CCCCC2)c1F
CHEMBL4083571,CHEMBL233,Mu opioid receptor,Ki,=,557.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2cccc(O)c2F)CC2CCC2)c1
CHEMBL4093848,CHEMBL233,Mu opioid receptor,Ki,=,523.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,Cl.Oc1ccc(CCN(CCc2cccc(O)c2F)CC2CCC2)cc1
CHEMBL4073160,CHEMBL233,Mu opioid receptor,Ki,=,1065.0,nM,CHEMBL4019245,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4017505,KI,c1ccc(CCN(CCc2ccccc2)CC2CCC2)cc1
CHEMBL270190,CHEMBL233,Mu opioid receptor,Ki,=,0.3162,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL1186579,CHEMBL233,Mu opioid receptor,Ki,=,7.943,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL4071225,CHEMBL233,Mu opioid receptor,Ki,=,0.1585,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,Oc1cccc(C2CC3CCC(C2)N3CCCc2ccccc2)c1
CHEMBL4092037,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,Oc1cccc(C2C[C@H]3CC[C@H](C2)N3CCCc2ccccc2)c1
CHEMBL4092037,CHEMBL233,Mu opioid receptor,Ki,=,5.012,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,Oc1cccc(C2C[C@H]3CC[C@H](C2)N3CCCc2ccccc2)c1
CHEMBL4059786,CHEMBL233,Mu opioid receptor,Ki,=,0.1259,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,NC(=O)c1cccc(C2C[C@H]3CC[C@H](C2)N3CCCc2ccccc2)c1
CHEMBL4059786,CHEMBL233,Mu opioid receptor,Ki,=,15.85,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,NC(=O)c1cccc(C2C[C@H]3CC[C@H](C2)N3CCCc2ccccc2)c1
CHEMBL4082678,CHEMBL233,Mu opioid receptor,Ki,=,0.2512,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,CCCCCCCN1[C@@H]2CC[C@@H]1CC(c1cccc(O)c1)C2
CHEMBL4082678,CHEMBL233,Mu opioid receptor,Ki,=,19.95,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,CCCCCCCN1[C@@H]2CC[C@@H]1CC(c1cccc(O)c1)C2
CHEMBL4060795,CHEMBL233,Mu opioid receptor,Ki,=,0.3981,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,CCCCCCCN1[C@@H]2CC[C@@H]1CC(c1cccc(C(N)=O)c1)C2
CHEMBL4060795,CHEMBL233,Mu opioid receptor,Ki,=,31.62,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,CCCCCCCN1[C@@H]2CC[C@@H]1CC(c1cccc(C(N)=O)c1)C2
CHEMBL4069480,CHEMBL233,Mu opioid receptor,Ki,=,15.85,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,Oc1cccc(C2C[C@H]3CC[C@H](C2)N3Cc2c(F)cccc2F)c1
CHEMBL4069480,CHEMBL233,Mu opioid receptor,Ki,=,630.96,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,Oc1cccc(C2C[C@H]3CC[C@H](C2)N3Cc2c(F)cccc2F)c1
CHEMBL4065740,CHEMBL233,Mu opioid receptor,Ki,=,31.62,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,NC(=O)c1cccc(C2C[C@H]3CC[C@H](C2)N3Cc2c(F)cccc2F)c1
CHEMBL4065740,CHEMBL233,Mu opioid receptor,Ki,=,1258.93,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,NC(=O)c1cccc(C2C[C@H]3CC[C@H](C2)N3Cc2c(F)cccc2F)c1
CHEMBL4071120,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,Oc1cccc(C2C[C@H]3CC[C@H](C2)N3CCCOc2ccccc2)c1
CHEMBL4071120,CHEMBL233,Mu opioid receptor,Ki,=,3.162,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,Oc1cccc(C2C[C@H]3CC[C@H](C2)N3CCCOc2ccccc2)c1
CHEMBL4062483,CHEMBL233,Mu opioid receptor,Ki,=,0.1995,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,NC(=O)c1cccc(C2C[C@H]3CC[C@H](C2)N3CCCOc2ccccc2)c1
CHEMBL4062483,CHEMBL233,Mu opioid receptor,Ki,=,6.31,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,NC(=O)c1cccc(C2C[C@H]3CC[C@H](C2)N3CCCOc2ccccc2)c1
CHEMBL4084184,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,CC(C)(C)c1ccc(CN2[C@@H]3CC[C@@H]2CC(c2cccc(O)c2)C3)cc1
CHEMBL4084184,CHEMBL233,Mu opioid receptor,Ki,=,1.995,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,CC(C)(C)c1ccc(CN2[C@@H]3CC[C@@H]2CC(c2cccc(O)c2)C3)cc1
CHEMBL4067358,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,CC(C)(C)c1ccc(CN2[C@@H]3CC[C@@H]2CC(c2cccc(C(N)=O)c2)C3)cc1
CHEMBL4067358,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,CC(C)(C)c1ccc(CN2[C@@H]3CC[C@@H]2CC(c2cccc(C(N)=O)c2)C3)cc1
CHEMBL4088609,CHEMBL233,Mu opioid receptor,Ki,=,0.7943,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,O=C1c2ccccc2C(=O)N1CCCCN1[C@@H]2CC[C@@H]1CC(c1cccc(O)c1)C2
CHEMBL4088609,CHEMBL233,Mu opioid receptor,Ki,=,39.81,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,O=C1c2ccccc2C(=O)N1CCCCN1[C@@H]2CC[C@@H]1CC(c1cccc(O)c1)C2
CHEMBL4082129,CHEMBL233,Mu opioid receptor,Ki,=,1.585,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,NC(=O)c1cccc(C2C[C@H]3CC[C@H](C2)N3CCCCN2C(=O)c3ccccc3C2=O)c1
CHEMBL4082129,CHEMBL233,Mu opioid receptor,Ki,=,31.62,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,NC(=O)c1cccc(C2C[C@H]3CC[C@H](C2)N3CCCCN2C(=O)c3ccccc3C2=O)c1
CHEMBL4077003,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,O=C(CN1[C@@H]2CC[C@@H]1CC(c1cccc(O)c1)C2)C1CCCCC1
CHEMBL4077003,CHEMBL233,Mu opioid receptor,Ki,=,1.995,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,O=C(CN1[C@@H]2CC[C@@H]1CC(c1cccc(O)c1)C2)C1CCCCC1
CHEMBL4062974,CHEMBL233,Mu opioid receptor,Ki,=,0.1585,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,NC(=O)c1cccc(C2C[C@H]3CC[C@H](C2)N3CC(=O)C2CCCCC2)c1
CHEMBL4062974,CHEMBL233,Mu opioid receptor,Ki,=,15.85,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,NC(=O)c1cccc(C2C[C@H]3CC[C@H](C2)N3CC(=O)C2CCCCC2)c1
CHEMBL4065743,CHEMBL233,Mu opioid receptor,Ki,=,0.2512,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,Oc1cccc(C2C[C@H]3CC[C@H](C2)N3CC(O)Cc2ccccc2)c1
CHEMBL4065743,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,Oc1cccc(C2C[C@H]3CC[C@H](C2)N3CC(O)Cc2ccccc2)c1
CHEMBL4069933,CHEMBL233,Mu opioid receptor,Ki,=,0.2512,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,NC(=O)c1cccc(C2C[C@H]3CC[C@H](C2)N3CC(O)Cc2ccccc2)c1
CHEMBL4069933,CHEMBL233,Mu opioid receptor,Ki,=,31.62,nM,CHEMBL4022084,B,Displacement of [3H]DPN from recombinant human mu opioid receptor expressed in CHOK1 cell membranes,CHEMBL4020770,KI,NC(=O)c1cccc(C2C[C@H]3CC[C@H](C2)N3CC(O)Cc2ccccc2)c1
CHEMBL471980,CHEMBL233,Mu opioid receptor,Ki,=,6700.0,nM,CHEMBL4023582,B,Displacement of [3H]-Diprenorphine from human mu opioid receptor expressed in HEK293-TSA cell membranes after 4 hrs by scintillation counting method,CHEMBL4020829,KI,CCOc1ccc(Cc2nc3cc(C(=O)N(CC)CC)ccc3n2CCC(C)C)cc1
CHEMBL4079520,CHEMBL233,Mu opioid receptor,Ki,=,53600.0,nM,CHEMBL4023582,B,Displacement of [3H]-Diprenorphine from human mu opioid receptor expressed in HEK293-TSA cell membranes after 4 hrs by scintillation counting method,CHEMBL4020829,KI,CCOc1ccc(Nc2nc3cc(C(=O)N(CC)CC)ccc3n2CCC(C)C)cc1
CHEMBL4082936,CHEMBL233,Mu opioid receptor,Ki,=,556.0,nM,CHEMBL4023582,B,Displacement of [3H]-Diprenorphine from human mu opioid receptor expressed in HEK293-TSA cell membranes after 4 hrs by scintillation counting method,CHEMBL4020829,KI,CCOc1ccc(Cc2nc3cc(C(=O)N(CC)CC)ccc3n2CCN2CCCCC2)cc1
CHEMBL312040,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL4023582,B,Displacement of [3H]-Diprenorphine from human mu opioid receptor expressed in HEK293-TSA cell membranes after 4 hrs by scintillation counting method,CHEMBL4020829,KI,CCOc1ccc(Cc2nc3cc([N+](=O)[O-])ccc3n2CCN(CC)CC)cc1
CHEMBL471980,CHEMBL233,Mu opioid receptor,Ki,=,6309.57,nM,CHEMBL4023582,B,Displacement of [3H]-Diprenorphine from human mu opioid receptor expressed in HEK293-TSA cell membranes after 4 hrs by scintillation counting method,CHEMBL4020829,KI,CCOc1ccc(Cc2nc3cc(C(=O)N(CC)CC)ccc3n2CCC(C)C)cc1
CHEMBL4079520,CHEMBL233,Mu opioid receptor,Ki,=,50118.72,nM,CHEMBL4023582,B,Displacement of [3H]-Diprenorphine from human mu opioid receptor expressed in HEK293-TSA cell membranes after 4 hrs by scintillation counting method,CHEMBL4020829,KI,CCOc1ccc(Nc2nc3cc(C(=O)N(CC)CC)ccc3n2CCC(C)C)cc1
CHEMBL4082936,CHEMBL233,Mu opioid receptor,Ki,=,501.19,nM,CHEMBL4023582,B,Displacement of [3H]-Diprenorphine from human mu opioid receptor expressed in HEK293-TSA cell membranes after 4 hrs by scintillation counting method,CHEMBL4020829,KI,CCOc1ccc(Cc2nc3cc(C(=O)N(CC)CC)ccc3n2CCN2CCCCC2)cc1
CHEMBL493846,CHEMBL233,Mu opioid receptor,Ki,=,0.0013,nM,CHEMBL4029367,B,Displacement of [3H]-DAMGO from human HA-tagged mu-opioid receptor expressed in HEK293 cells after 90 mins by liquid scintillation counting analysis,CHEMBL4028804,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc2ccccc2c1
CHEMBL963,CHEMBL233,Mu opioid receptor,Ki,=,1.79,nM,CHEMBL4031999,B,Displacement of [3H]-DAMGO from recombinant human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4028881,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL4074110,CHEMBL233,Mu opioid receptor,Ki,=,1.65,nM,CHEMBL4031999,B,Displacement of [3H]-DAMGO from recombinant human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4028881,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2CCC[C@@]3(O)[C@H]1C5
CHEMBL607405,CHEMBL233,Mu opioid receptor,Ki,=,0.32,nM,CHEMBL4031999,B,Displacement of [3H]-DAMGO from recombinant human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4028881,KI,CO[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4065490,CHEMBL233,Mu opioid receptor,Ki,=,0.24,nM,CHEMBL4031999,B,Displacement of [3H]-DAMGO from recombinant human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4028881,KI,CO[C@@]12CCC[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL607351,CHEMBL233,Mu opioid receptor,Ki,=,0.45,nM,CHEMBL4031999,B,Displacement of [3H]-DAMGO from recombinant human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4028881,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(OCc2ccccc2)[C@H]1C5
CHEMBL4103328,CHEMBL233,Mu opioid receptor,Ki,=,0.048,nM,CHEMBL4031999,B,Displacement of [3H]-DAMGO from recombinant human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4028881,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2CCC[C@@]3(OCc2ccccc2)[C@H]1C5
CHEMBL326684,CHEMBL233,Mu opioid receptor,Ki,=,0.25,nM,CHEMBL4031999,B,Displacement of [3H]-DAMGO from recombinant human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4028881,KI,CO[C@@]12CCC(=O)[C@]3(C)Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4088589,CHEMBL233,Mu opioid receptor,Ki,=,0.34,nM,CHEMBL4031999,B,Displacement of [3H]-DAMGO from recombinant human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4028881,KI,CO[C@@]12CCC[C@]3(C)Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4066752,CHEMBL233,Mu opioid receptor,Ki,=,0.627,nM,CHEMBL4035922,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL4033703,KI,O=C(c1ccccc1)N1C[C@H]2OC34CCC1C2C31CCN(CC2CC2)C4Cc2ccc(O)cc21
CHEMBL4081856,CHEMBL233,Mu opioid receptor,Ki,=,0.308,nM,CHEMBL4035922,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL4033703,KI,O=S(=O)(c1ccccc1)N1C[C@H]2OC34CCC1C2C31CCN(CC2CC2)C4Cc2ccc(O)cc21
CHEMBL4100943,CHEMBL233,Mu opioid receptor,Ki,=,1.56,nM,CHEMBL4035922,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL4033703,KI,Oc1ccc2c(c1)C13CCN(CC4CC4)C(C2)C12CCC1C3[C@@H](CN1Cc1ccccc1)O2
CHEMBL4067629,CHEMBL233,Mu opioid receptor,Ki,=,0.953,nM,CHEMBL4036553,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cell membranes,CHEMBL4033739,KI,Oc1ccc2c(c1)C13CCN(CC4CC4)C(C2)C12CCC1C3[C@@H](CN1c1ccccc1)C2
CHEMBL4076681,CHEMBL233,Mu opioid receptor,Ki,=,0.826,nM,CHEMBL4036553,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cell membranes,CHEMBL4033739,KI,O=C(Oc1ccccc1)N1C[C@H]2CC34CCC1C2C31CCN(CC2CC2)C4Cc2ccc(O)cc21
CHEMBL4076632,CHEMBL233,Mu opioid receptor,Ki,=,0.545,nM,CHEMBL4036553,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cell membranes,CHEMBL4033739,KI,O=C(Nc1ccccc1)N1C[C@H]2CC34CCC1C2C31CCN(CC2CC2)C4Cc2ccc(O)cc21
CHEMBL4098662,CHEMBL233,Mu opioid receptor,Ki,=,2.5,nM,CHEMBL4036553,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cell membranes,CHEMBL4033739,KI,Oc1ccc2c(c1)C13CCN(CC4CC4)C(C2)C12CCC1C3[C@@H](CN1CC1CCCCC1)C2
CHEMBL4068691,CHEMBL233,Mu opioid receptor,Ki,=,0.726,nM,CHEMBL4036553,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cell membranes,CHEMBL4033739,KI,O=C(c1ccccn1)N1C[C@H]2CC34CCC1C2C31CCN(CC2CC2)C4Cc2ccc(O)cc21
CHEMBL4103044,CHEMBL233,Mu opioid receptor,Ki,=,0.455,nM,CHEMBL4036553,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cell membranes,CHEMBL4033739,KI,O=C(c1ccoc1)N1C[C@H]2CC34CCC1C2C31CCN(CC2CC2)C4Cc2ccc(O)cc21
CHEMBL4083940,CHEMBL233,Mu opioid receptor,Ki,=,0.578,nM,CHEMBL4036553,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cell membranes,CHEMBL4033739,KI,O=C(c1ccccc1)N1C[C@H]2CC34CCC1C2C31CCN(CC2CC2)C4Cc2ccc(O)cc21
CHEMBL4061334,CHEMBL233,Mu opioid receptor,Ki,=,3.44,nM,CHEMBL4036553,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cell membranes,CHEMBL4033739,KI,Oc1ccc2c(c1)C13CCN(CC4CC4)C(C2)C12CCC1C3[C@@H](CN1Cc1ccccc1)C2
CHEMBL4094845,CHEMBL233,Mu opioid receptor,Ki,=,0.813,nM,CHEMBL4036553,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cell membranes,CHEMBL4033739,KI,Oc1ccc2c(c1)C13CCN(CC4CC4)C(C2)C12CCC1C3[C@@H](CN1c1cnccn1)C2
CHEMBL4085033,CHEMBL233,Mu opioid receptor,Ki,=,1.15,nM,CHEMBL4038746,B,Displacement of [3H]DAMGO from recombinant human mu opioid receptor expressed in CHO cell membranes after 120 mins by liquid scintillation counter analysis,CHEMBL4038279,KI,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC(CC2)C(=O)N1
CHEMBL4095366,CHEMBL233,Mu opioid receptor,Ki,=,0.9,nM,CHEMBL4038746,B,Displacement of [3H]DAMGO from recombinant human mu opioid receptor expressed in CHO cell membranes after 120 mins by liquid scintillation counter analysis,CHEMBL4038279,KI,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@H](C2)C(=O)N1
CHEMBL4074931,CHEMBL233,Mu opioid receptor,Ki,=,3.16,nM,CHEMBL4038746,B,Displacement of [3H]DAMGO from recombinant human mu opioid receptor expressed in CHO cell membranes after 120 mins by liquid scintillation counter analysis,CHEMBL4038279,KI,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCCC[C@H]2C(=O)N1
CHEMBL4083221,CHEMBL233,Mu opioid receptor,Ki,=,0.46,nM,CHEMBL4038746,B,Displacement of [3H]DAMGO from recombinant human mu opioid receptor expressed in CHO cell membranes after 120 mins by liquid scintillation counter analysis,CHEMBL4038279,KI,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@H]2C(=O)N1
CHEMBL1927270,CHEMBL233,Mu opioid receptor,Ki,=,0.56,nM,CHEMBL4038746,B,Displacement of [3H]DAMGO from recombinant human mu opioid receptor expressed in CHO cell membranes after 120 mins by liquid scintillation counter analysis,CHEMBL4038279,KI,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL4071324,CHEMBL233,Mu opioid receptor,Ki,=,5.04,nM,CHEMBL4044348,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis,CHEMBL4043100,KI,O=C1/C(=C/c2ccc(Br)cc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL4070277,CHEMBL233,Mu opioid receptor,Ki,=,6.13,nM,CHEMBL4044348,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis,CHEMBL4043100,KI,O=C1/C(=C/c2ccc(Cl)cc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL3632690,CHEMBL233,Mu opioid receptor,Ki,=,17.2,nM,CHEMBL4044348,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis,CHEMBL4043100,KI,CN(C)c1ccc(/C=C2\C[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@@H](O6)C2=O)cc1
CHEMBL2059381,CHEMBL233,Mu opioid receptor,Ki,=,20.9,nM,CHEMBL4044348,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis,CHEMBL4043100,KI,O=C1/C(=C/c2ccc(F)cc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL2059382,CHEMBL233,Mu opioid receptor,Ki,=,5.16,nM,CHEMBL4044348,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis,CHEMBL4043100,KI,COc1ccc(/C=C2\C[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@@H](O6)C2=O)cc1
CHEMBL252172,CHEMBL233,Mu opioid receptor,Ki,=,11.0,nM,CHEMBL4044348,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis,CHEMBL4043100,KI,O=C1/C(=C/c2ccccc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL4092119,CHEMBL233,Mu opioid receptor,Ki,=,19.9,nM,CHEMBL4044348,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis,CHEMBL4043100,KI,O=C1/C(=C/c2ccc(I)cc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL4081053,CHEMBL233,Mu opioid receptor,Ki,=,10.7,nM,CHEMBL4044348,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis,CHEMBL4043100,KI,O=C1/C(=C/c2cccc(F)c2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL4105306,CHEMBL233,Mu opioid receptor,Ki,=,12.8,nM,CHEMBL4044348,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis,CHEMBL4043100,KI,O=C1/C(=C/c2ccccc2F)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL4089193,CHEMBL233,Mu opioid receptor,Ki,=,32.7,nM,CHEMBL4044348,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis,CHEMBL4043100,KI,N#Cc1ccc(/C=C2\C[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@@H](O6)C2=O)cc1
CHEMBL4061882,CHEMBL233,Mu opioid receptor,Ki,=,192.0,nM,CHEMBL4044348,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis,CHEMBL4043100,KI,O=C1/C(=C/c2ccc(C(F)(F)F)cc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL4090365,CHEMBL233,Mu opioid receptor,Ki,=,499.0,nM,CHEMBL4044348,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis,CHEMBL4043100,KI,COc1ccc2c3c1O[C@H]1C(=O)/C(=C/c4ccccc4)C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4082214,CHEMBL233,Mu opioid receptor,Ki,=,32.3,nM,CHEMBL4049835,B,Displacement of [3H]DAMGO from recombinant human mu-opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4049389,KI,Cc1cc(C)cc(C2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3)c(Cl)c2)c1
CHEMBL4069892,CHEMBL233,Mu opioid receptor,Ki,=,62.8,nM,CHEMBL4049835,B,Displacement of [3H]DAMGO from recombinant human mu-opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4049389,KI,Cc1cc(C)cc(C2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3)c(F)c2)c1
CHEMBL4090064,CHEMBL233,Mu opioid receptor,Ki,=,220.0,nM,CHEMBL4049835,B,Displacement of [3H]DAMGO from recombinant human mu-opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4049389,KI,Cc1cc(C)cc(C2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)c(Cl)c2)c1
CHEMBL4062024,CHEMBL233,Mu opioid receptor,Ki,=,27.9,nM,CHEMBL4049835,B,Displacement of [3H]DAMGO from recombinant human mu-opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4049389,KI,Cc1cc(C)cc(C2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)c(F)c2)c1
CHEMBL4063074,CHEMBL233,Mu opioid receptor,Ki,=,90.9,nM,CHEMBL4049835,B,Displacement of [3H]DAMGO from recombinant human mu-opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4049389,KI,Cc1cc(C)cc(C2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1
CHEMBL4130069,CHEMBL233,Mu opioid receptor,Ki,=,8.913,nM,CHEMBL4124509,B,Displacement of [3H]DAMGO from MOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL4126803,CHEMBL233,Mu opioid receptor,Ki,=,2.512,nM,CHEMBL4124509,B,Displacement of [3H]DAMGO from MOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL4128853,CHEMBL233,Mu opioid receptor,Ki,=,2.884,nM,CHEMBL4124509,B,Displacement of [3H]DAMGO from MOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,CC1(C)SSC(C)(C)[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H]1NC(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL4129668,CHEMBL233,Mu opioid receptor,Ki,=,2.344,nM,CHEMBL4124509,B,Displacement of [3H]DAMGO from MOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NCCSSCCNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL4130303,CHEMBL233,Mu opioid receptor,Ki,=,0.2692,nM,CHEMBL4124509,B,Displacement of [3H]DAMGO from MOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NCCSSCCNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL200199,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL4124518,B,Binding affinity to MOR (unknown origin),CHEMBL4118237,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NNC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL4130069,CHEMBL233,Mu opioid receptor,Ki,=,8.9,nM,CHEMBL4124509,B,Displacement of [3H]DAMGO from MOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL4126803,CHEMBL233,Mu opioid receptor,Ki,=,2.5,nM,CHEMBL4124509,B,Displacement of [3H]DAMGO from MOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL4128853,CHEMBL233,Mu opioid receptor,Ki,=,2.9,nM,CHEMBL4124509,B,Displacement of [3H]DAMGO from MOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,CC1(C)SSC(C)(C)[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H]1NC(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL4129668,CHEMBL233,Mu opioid receptor,Ki,=,2.4,nM,CHEMBL4124509,B,Displacement of [3H]DAMGO from MOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NCCSSCCNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL4130303,CHEMBL233,Mu opioid receptor,Ki,=,0.27,nM,CHEMBL4124509,B,Displacement of [3H]DAMGO from MOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NCCSSCCNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL1782140,CHEMBL233,Mu opioid receptor,Ki,=,0.15,nM,CHEMBL4136384,B,Binding affinity to Mu-type opioid receptor (unknown origin),CHEMBL4130566,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CC(N)=O)C1=O
CHEMBL4160669,CHEMBL233,Mu opioid receptor,Ki,=,3040.0,nM,CHEMBL4137921,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cell membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,CN(Cc1cnn(C)c1)C(=O)NCCN1Cc2ccccc2C1
CHEMBL4171269,CHEMBL233,Mu opioid receptor,Ki,=,10200.0,nM,CHEMBL4137921,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cell membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,Nc1nc(Cl)cc(NC[C@@H](O)CN2CCc3ccccc3C2)n1
CHEMBL4165704,CHEMBL233,Mu opioid receptor,Ki,=,478.0,nM,CHEMBL4137921,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cell membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,CN(C)[C@H](CNC(=O)Nc1ccc(C(N)=O)cc1)c1cccs1
CHEMBL4172930,CHEMBL233,Mu opioid receptor,Ki,=,1290.0,nM,CHEMBL4137921,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cell membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,O=C(NCCN1CCc2ccccc2C1)c1ccc(O)c(Cl)c1
CHEMBL4160217,CHEMBL233,Mu opioid receptor,Ki,=,2470.0,nM,CHEMBL4137921,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cell membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,CN(C)[C@H](CNC(=O)c1c[nH]nc1-c1ccccc1)c1cccs1
CHEMBL4164624,CHEMBL233,Mu opioid receptor,Ki,=,8690.0,nM,CHEMBL4137921,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cell membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,Cc1ccc2nc(CNCc3nnc4n3CCCCC4)[nH]c2c1C
CHEMBL4172508,CHEMBL233,Mu opioid receptor,Ki,=,6920.0,nM,CHEMBL4137921,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cell membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,C[C@H](c1ccco1)N(C)CC(=O)N1CCC(C(N)=O)CC1
CHEMBL4161204,CHEMBL233,Mu opioid receptor,Ki,=,2430.0,nM,CHEMBL4137921,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cell membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,CN(C)[C@H](CNC(=O)C1CCN(C(N)=O)CC1)c1cccs1
CHEMBL4169128,CHEMBL233,Mu opioid receptor,Ki,=,45700.0,nM,CHEMBL4137921,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cell membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,NC(=O)[C@H](NC1CCN(Cc2ccccn2)CC1)c1ccc(F)cc1
CHEMBL4162636,CHEMBL233,Mu opioid receptor,Ki,=,5700.0,nM,CHEMBL4137921,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cell membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,NC(=O)c1ccc(N2CCCN(Cc3ccc(F)cc3)CC2)nc1
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL4150315,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membranes after 2 hrs by liquid scintillation spectrometry,CHEMBL4145618,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL4169199,CHEMBL233,Mu opioid receptor,Ki,=,240.0,nM,CHEMBL4150315,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membranes after 2 hrs by liquid scintillation spectrometry,CHEMBL4145618,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)N1C(=O)O[C@H](CNC(=O)[C@@H](N)Cc2ccc(O)cc2)C1=O
CHEMBL4177061,CHEMBL233,Mu opioid receptor,Ki,=,0.36,nM,CHEMBL4150328,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin),CHEMBL4145618,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)O
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,4.0,nM,CHEMBL4153254,B,Displacement of [3H]diprenorphine from human MOR expressed in African green monkey COS1 cell membranes incubated for 1 hr by scintillation counting method,CHEMBL4152209,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL4168822,CHEMBL233,Mu opioid receptor,Ki,=,814.0,nM,CHEMBL4153254,B,Displacement of [3H]diprenorphine from human MOR expressed in African green monkey COS1 cell membranes incubated for 1 hr by scintillation counting method,CHEMBL4152209,KI,COC(=O)N1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL4168247,CHEMBL233,Mu opioid receptor,Ki,=,1080.0,nM,CHEMBL4153254,B,Displacement of [3H]diprenorphine from human MOR expressed in African green monkey COS1 cell membranes incubated for 1 hr by scintillation counting method,CHEMBL4152209,KI,COC(=O)N1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)[C@H](O)C(=O)[C@H]3[C@H]1C5
CHEMBL4203753,CHEMBL233,Mu opioid receptor,Ki,=,48.0,nM,CHEMBL4197659,B,Displacement of [3H]DAMGO from MOR (unknown origin) expressed in CHO cell membranes,CHEMBL4196036,KI,C[C@H]1[C@H]2Cc3cc4sc(N)nc4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL4211113,CHEMBL233,Mu opioid receptor,Ki,=,8.3,nM,CHEMBL4197659,B,Displacement of [3H]DAMGO from MOR (unknown origin) expressed in CHO cell membranes,CHEMBL4196036,KI,C[C@H]1[C@H]2Cc3cc4sc(N)nc4cc3[C@@]1(C)CCN2CC1CCC1
CHEMBL4210181,CHEMBL233,Mu opioid receptor,Ki,=,23.03,nM,CHEMBL4197669,B,Displacement of [3H]-diprenorphine from MOR (unknown origin) after 1 to 2 hrs by scintillation counting method,CHEMBL4196036,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@@]1(C)CC[N+]2(C)CC1CC1
CHEMBL4213336,CHEMBL233,Mu opioid receptor,Ki,=,56.45,nM,CHEMBL4197669,B,Displacement of [3H]-diprenorphine from MOR (unknown origin) after 1 to 2 hrs by scintillation counting method,CHEMBL4196036,KI,C=CC[N+]1(C)CC[C@]2(C)c3cc(O)ccc3C[C@@H]1[C@@H]2C
CHEMBL55033,CHEMBL233,Mu opioid receptor,Ki,=,0.78,nM,CHEMBL4197677,B,Binding affinity to MOR (unknown origin),CHEMBL4196036,KI,CCC12CCN(CC3CC3)C(C(=O)c3ccc(O)cc31)C2C
CHEMBL4218284,CHEMBL233,Mu opioid receptor,Ki,=,45.0,nM,CHEMBL4197677,B,Binding affinity to MOR (unknown origin),CHEMBL4196036,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2C[C@@H]1C[C@@]1(CN1CCCCC1)c1ccccc1
CHEMBL4213351,CHEMBL233,Mu opioid receptor,Ki,=,2900.0,nM,CHEMBL4197677,B,Binding affinity to MOR (unknown origin),CHEMBL4196036,KI,C[C@H]1[C@H]2C(=O)c3ccc(O)cc3[C@@]1(C)CCN2CC1CCCO1
CHEMBL4245818,CHEMBL233,Mu opioid receptor,Ki,=,30.3,nM,CHEMBL4234963,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)CO)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4241031,CHEMBL233,Mu opioid receptor,Ki,=,7.2,nM,CHEMBL4234963,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)OC(C)=O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4237854,CHEMBL233,Mu opioid receptor,Ki,=,34.1,nM,CHEMBL4234963,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)OC(=O)C(C)C)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4243112,CHEMBL233,Mu opioid receptor,Ki,=,73.9,nM,CHEMBL4234963,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)OC(=O)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4238309,CHEMBL233,Mu opioid receptor,Ki,=,7.1,nM,CHEMBL4234963,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)OC(=O)c4ccc(C(F)(F)F)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4248801,CHEMBL233,Mu opioid receptor,Ki,=,49.3,nM,CHEMBL4234963,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)C=O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4237758,CHEMBL233,Mu opioid receptor,Ki,=,782.9,nM,CHEMBL4234963,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)C(O)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4242847,CHEMBL233,Mu opioid receptor,Ki,=,6.3,nM,CHEMBL4234963,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL4229484,KI,COc1cccc(C(O)[C@@]2(C)C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)c1
CHEMBL4246433,CHEMBL233,Mu opioid receptor,Ki,=,0.4,nM,CHEMBL4234963,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL4229484,KI,COc1ccc(C(O)[C@@]2(C)C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)cc1
CHEMBL4243463,CHEMBL233,Mu opioid receptor,Ki,=,17.0,nM,CHEMBL4234963,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)C(O)c4ccc(-c6ccccc6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4239240,CHEMBL233,Mu opioid receptor,Ki,=,12.7,nM,CHEMBL4234963,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)C(O)c4ccc(C(F)(F)F)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4240426,CHEMBL233,Mu opioid receptor,Ki,=,303.5,nM,CHEMBL4234963,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)C(=O)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4243649,CHEMBL233,Mu opioid receptor,Ki,=,4.3,nM,CHEMBL4234963,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL4229484,KI,COc1cccc(C(=O)[C@@]2(C)C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)c1
CHEMBL4238289,CHEMBL233,Mu opioid receptor,Ki,=,39.3,nM,CHEMBL4234963,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL4229484,KI,COc1ccc(C(=O)[C@@]2(C)C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)cc1
CHEMBL4245987,CHEMBL233,Mu opioid receptor,Ki,=,485.1,nM,CHEMBL4234963,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)C(=O)c4ccc(-c6ccccc6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4241369,CHEMBL233,Mu opioid receptor,Ki,=,81.1,nM,CHEMBL4234963,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)C(=O)c4ccc(C(F)(F)F)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4249256,CHEMBL233,Mu opioid receptor,Ki,=,129.5,nM,CHEMBL4234963,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)C=C[C@@]5(C[C@@H]4C(=O)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4287623,CHEMBL233,Mu opioid receptor,Ki,=,328.0,nM,CHEMBL4260828,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cells by radioligand binding assay,CHEMBL4257579,KI,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL4282702,CHEMBL233,Mu opioid receptor,Ki,=,536.0,nM,CHEMBL4260828,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cells by radioligand binding assay,CHEMBL4257579,KI,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCCCc2ccc(F)cc2)CC1
CHEMBL4291048,CHEMBL233,Mu opioid receptor,Ki,=,902.0,nM,CHEMBL4260828,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cells by radioligand binding assay,CHEMBL4257579,KI,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCN(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL4278465,CHEMBL233,Mu opioid receptor,Ki,=,10000.0,nM,CHEMBL4260828,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cells by radioligand binding assay,CHEMBL4257579,KI,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCCN(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL1644978,CHEMBL233,Mu opioid receptor,Ki,=,356.0,nM,CHEMBL4260828,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cells by radioligand binding assay,CHEMBL4257579,KI,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL1644980,CHEMBL233,Mu opioid receptor,Ki,=,70.0,nM,CHEMBL4260828,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cells by radioligand binding assay,CHEMBL4257579,KI,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccccc2)c2ccccc2)CC1
CHEMBL4293307,CHEMBL233,Mu opioid receptor,Ki,=,8253.0,nM,CHEMBL4260828,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cells by radioligand binding assay,CHEMBL4257579,KI,COc1ccc(N(CCCCN2CCC(O)(c3ccc(Cl)c(C(F)(F)F)c3)CC2)c2ccc(OC)cc2)cc1
CHEMBL47050,CHEMBL233,Mu opioid receptor,Ki,=,867.0,nM,CHEMBL4260828,B,Displacement of [3H]DAMGO from human MOR expressed in HEK cells by radioligand binding assay,CHEMBL4257579,KI,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL4276875,CHEMBL233,Mu opioid receptor,Ki,=,0.037,nM,CHEMBL4276376,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4270665,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL4284374,CHEMBL233,Mu opioid receptor,Ki,=,7.51,nM,CHEMBL4276376,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4270665,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4277122,CHEMBL233,Mu opioid receptor,Ki,=,5.0,nM,CHEMBL4276376,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4270665,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O)Cc1ccccc1
CHEMBL4287777,CHEMBL233,Mu opioid receptor,Ki,=,5.0,nM,CHEMBL4276376,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4270665,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4280549,CHEMBL233,Mu opioid receptor,Ki,=,5.0,nM,CHEMBL4276376,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4270665,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4291181,CHEMBL233,Mu opioid receptor,Ki,=,5.0,nM,CHEMBL4276376,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4270665,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCCN)C(N)=O)C1=O
CHEMBL4283991,CHEMBL233,Mu opioid receptor,Ki,=,5.0,nM,CHEMBL4276376,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4270665,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4294583,CHEMBL233,Mu opioid receptor,Ki,=,5.0,nM,CHEMBL4276376,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4270665,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4278603,CHEMBL233,Mu opioid receptor,Ki,=,5.0,nM,CHEMBL4276376,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4270665,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4280750,CHEMBL233,Mu opioid receptor,Ki,=,6.16,nM,CHEMBL4276376,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4270665,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)O
CHEMBL4288649,CHEMBL233,Mu opioid receptor,Ki,=,0.34,nM,CHEMBL4276376,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4270665,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)O
CHEMBL4290989,CHEMBL233,Mu opioid receptor,Ki,=,0.52,nM,CHEMBL4276376,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes after 60 mins by liquid scintillation counting,CHEMBL4270665,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)O
CHEMBL4472703,CHEMBL233,Mu opioid receptor,Ki,=,1995.26,nM,CHEMBL4308644,B,Displacement of [3H]-DAMGO from human recombinant MOR receptor expressed in stable HEK cells after 90 mins by microbeta scintillation counting method,CHEMBL4304834,KI,CC[C@H]1c2cc(OC)ccc2CC[C@@]1(C)N
CHEMBL4462756,CHEMBL233,Mu opioid receptor,Ki,=,18.0,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,O=C(O)c1ccc2c3c([nH]c2c1)[C@@H]1Oc2c(O)ccc4c2[C@@]12CCN(CC1CC1)[C@H](C4)[C@]2(O)C3
CHEMBL4468216,CHEMBL233,Mu opioid receptor,Ki,=,19.0,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,O=C(O)c1ccc2c3c([nH]c2c1Cl)[C@@H]1Oc2c(O)ccc4c2[C@@]12CCN(CC1CC1)[C@H](C4)[C@]2(O)C3
CHEMBL4534307,CHEMBL233,Mu opioid receptor,Ki,=,0.95,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,CC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1
CHEMBL4551066,CHEMBL233,Mu opioid receptor,Ki,=,1.4,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,CCC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1
CHEMBL4439770,CHEMBL233,Mu opioid receptor,Ki,=,24.0,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,Cc1n[nH]c2c1C[C@@]1(O)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4516674,CHEMBL233,Mu opioid receptor,Ki,=,8.6,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,Cc1nc(N)nc2c1C[C@@]1(O)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4542825,CHEMBL233,Mu opioid receptor,Ki,=,3.4,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,CC(C)NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1
CHEMBL4529950,CHEMBL233,Mu opioid receptor,Ki,=,1.0,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,O=C(Nc1ccccc1)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1
CHEMBL4561876,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,O=C(NCc1ccccc1)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1
CHEMBL4452187,CHEMBL233,Mu opioid receptor,Ki,=,4.0,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,O=C(C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)N1CCCC1
CHEMBL4459343,CHEMBL233,Mu opioid receptor,Ki,=,16.5,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,COC(=O)C(C)(C)NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1
CHEMBL4435773,CHEMBL233,Mu opioid receptor,Ki,=,46.1,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)C(=O)O
CHEMBL3679612,CHEMBL233,Mu opioid receptor,Ki,=,1.6,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,COC(=O)C1(NC(=O)C2=C(O)[C@@H]3Oc4c(O)ccc5c4[C@@]34CCN(CC3CC3)[C@H](C5)[C@]4(O)C2)CC1
CHEMBL4472077,CHEMBL233,Mu opioid receptor,Ki,=,93.6,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)C(=O)NS(C)(=O)=O
CHEMBL4521187,CHEMBL233,Mu opioid receptor,Ki,=,19.4,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,C[C@H](CO)NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1
CHEMBL4445736,CHEMBL233,Mu opioid receptor,Ki,=,7.3,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,Cc1noc(C(C)(C)NC(=O)C2=C(O)[C@@H]3Oc4c(O)ccc5c4[C@@]34CCN(CC3CC3)[C@H](C5)[C@]4(O)C2)n1
CHEMBL2105755,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1
CHEMBL4457877,CHEMBL233,Mu opioid receptor,Ki,=,5.1,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,N#Cc1ccc(NC(=O)C2=C(O)[C@@H]3Oc4c(O)ccc5c4[C@@]34CCN(CC3CC3)[C@H](C5)[C@]4(O)C2)cc1
CHEMBL4543425,CHEMBL233,Mu opioid receptor,Ki,=,9.8,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,O=C(Nc1ccccn1)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1
CHEMBL4574150,CHEMBL233,Mu opioid receptor,Ki,=,2.4,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,O=C(Nc1ccc2cc[nH]c2c1)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1
CHEMBL1201770,CHEMBL233,Mu opioid receptor,Ki,=,5.48,nM,CHEMBL4310614,B,Displacement of [3H]-DAMGO from recombinant human mu-opioid receptor expressed in CHOK1 cells,CHEMBL4308867,KI,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[Br-]
CHEMBL4442460,CHEMBL233,Mu opioid receptor,Ki,=,2000.0,nM,CHEMBL4323493,B,Displacement of [3H] diprenorphine from mu opioid receptor (unknown origin),CHEMBL4321823,KI,COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2)c2ccccc2)CC1
CHEMBL4544086,CHEMBL233,Mu opioid receptor,Ki,=,2300.0,nM,CHEMBL4323493,B,Displacement of [3H] diprenorphine from mu opioid receptor (unknown origin),CHEMBL4321823,KI,COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccc(F)cc2)c2ccccc2)CC1
CHEMBL4459592,CHEMBL233,Mu opioid receptor,Ki,=,380.0,nM,CHEMBL4344750,B,Displacement of [3H]-diprenorphine from recombinant human MOR transiently expressed in HEK293 cell membranes measured after 60 mins,CHEMBL4342472,KI,CN1/C(=C/C=C/C2=[N+](CCCCCC(=O)NCCCNC(=N)Nc3ccc4[nH]c5c(c4c3)C[C@@]3(O)[C@H]4Cc6ccc(O)c7c6[C@@]3(CCN4CC3CC3)[C@H]5O7)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C(C)(C)c2cc(S(=O)(=O)O)ccc21
CHEMBL4463414,CHEMBL233,Mu opioid receptor,Ki,=,40.0,nM,CHEMBL4344750,B,Displacement of [3H]-diprenorphine from recombinant human MOR transiently expressed in HEK293 cell membranes measured after 60 mins,CHEMBL4342472,KI,CN1/C(=C/C=C/C=C/C2=[N+](CCCCCC(=O)NCCCNC(=N)Nc3ccc4[nH]c5c(c4c3)C[C@@]3(O)[C@H]4Cc6ccc(O)c7c6[C@@]3(CCN4CC3CC3)[C@H]5O7)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C(C)(C)c2cc(S(=O)(=O)O)ccc21
CHEMBL4438046,CHEMBL233,Mu opioid receptor,Ki,=,100.0,nM,CHEMBL4344750,B,Displacement of [3H]-diprenorphine from recombinant human MOR transiently expressed in HEK293 cell membranes measured after 60 mins,CHEMBL4342472,KI,CN1/C(=C/C=C/C=C/C2=[N+](CCCCCC(=O)NCC(=O)NCC(=O)NCCCNC(=N)Nc3ccc4[nH]c5c(c4c3)C[C@@]3(O)[C@H]4Cc6ccc(O)c7c6[C@@]3(CCN4CC3CC3)[C@H]5O7)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C(C)(C)c2cc(S(=O)(=O)O)ccc21
CHEMBL4577693,CHEMBL233,Mu opioid receptor,Ki,=,133.0,nM,CHEMBL4344750,B,Displacement of [3H]-diprenorphine from recombinant human MOR transiently expressed in HEK293 cell membranes measured after 60 mins,CHEMBL4342472,KI,CN1/C(=C/C=C/C=C/C2=[N+](CCCCCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCCCNC(=N)Nc3ccc4[nH]c5c(c4c3)C[C@@]3(O)[C@H]4Cc6ccc(O)c7c6[C@@]3(CCN4CC3CC3)[C@H]5O7)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C(C)(C)c2cc(S(=O)(=O)O)ccc21
CHEMBL4514226,CHEMBL233,Mu opioid receptor,Ki,=,110.0,nM,CHEMBL4344750,B,Displacement of [3H]-diprenorphine from recombinant human MOR transiently expressed in HEK293 cell membranes measured after 60 mins,CHEMBL4342472,KI,CN1/C(=C/C=C/C2=[N+](CCCCCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCCCNC(=N)Nc3ccc4[nH]c5c(c4c3)C[C@@]3(O)[C@H]4Cc6ccc(O)c7c6[C@@]3(CCN4CC3CC3)[C@H]5O7)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C(C)(C)c2cc(S(=O)(=O)O)ccc21
CHEMBL656,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314
CHEMBL4446292,CHEMBL233,Mu opioid receptor,Ki,=,534.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,O=C1COC2(CCN(Cc3ccccc3)CC2)CN1c1ccccc1
CHEMBL4439908,CHEMBL233,Mu opioid receptor,Ki,=,437.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
CHEMBL4461864,CHEMBL233,Mu opioid receptor,Ki,=,401.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,O=C1OC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
CHEMBL4541206,CHEMBL233,Mu opioid receptor,Ki,=,7.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O
CHEMBL4467749,CHEMBL233,Mu opioid receptor,Ki,=,69.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,C[C@@H]1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O
CHEMBL4450665,CHEMBL233,Mu opioid receptor,Ki,=,8.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,C[C@H]1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O
CHEMBL4515812,CHEMBL233,Mu opioid receptor,Ki,=,3.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CCC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O
CHEMBL4436170,CHEMBL233,Mu opioid receptor,Ki,=,1.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC(C)C1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O
CHEMBL4439285,CHEMBL233,Mu opioid receptor,Ki,=,13.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,COCC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O
CHEMBL4459117,CHEMBL233,Mu opioid receptor,Ki,=,46.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,O=C1C(CO)OC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
CHEMBL4528962,CHEMBL233,Mu opioid receptor,Ki,=,40.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,O=C1C(COCc2ccccc2)OC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
CHEMBL4446209,CHEMBL233,Mu opioid receptor,Ki,=,92.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,COC(=O)CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O
CHEMBL4458456,CHEMBL233,Mu opioid receptor,Ki,=,636.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CN(C)C(=O)CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O
CHEMBL4516327,CHEMBL233,Mu opioid receptor,Ki,=,3.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1(C)OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O
CHEMBL4438550,CHEMBL233,Mu opioid receptor,Ki,=,15.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,O=C1N(c2ccccc2)CC2(CCN(CCc3ccccc3)CC2)OC12CC2
CHEMBL4452042,CHEMBL233,Mu opioid receptor,Ki,=,3.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2Cl)C1=O
CHEMBL4584335,CHEMBL233,Mu opioid receptor,Ki,=,8.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2F)C1=O
CHEMBL4526087,CHEMBL233,Mu opioid receptor,Ki,=,57.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,COc1ccccc1N1CC2(CCN(CCc3ccccc3)CC2)OC(C)C1=O
CHEMBL4592081,CHEMBL233,Mu opioid receptor,Ki,=,535.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2O)C1=O
CHEMBL4550656,CHEMBL233,Mu opioid receptor,Ki,=,126.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,COc1cccc(N2CC3(CCN(CCc4ccccc4)CC3)OC(C)C2=O)c1
CHEMBL4471711,CHEMBL233,Mu opioid receptor,Ki,=,727.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cccc(O)c2)C1=O
CHEMBL4513933,CHEMBL233,Mu opioid receptor,Ki,=,606.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccc(O)cc2)C1=O
CHEMBL4578955,CHEMBL233,Mu opioid receptor,Ki,=,930.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccn2)C1=O
CHEMBL4440055,CHEMBL233,Mu opioid receptor,Ki,=,304.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cccnc2)C1=O
CHEMBL4439718,CHEMBL233,Mu opioid receptor,Ki,=,304.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cnccn2)C1=O
CHEMBL4538620,CHEMBL233,Mu opioid receptor,Ki,=,90.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cccc(C(F)(F)F)n2)C1=O
CHEMBL4483643,CHEMBL233,Mu opioid receptor,Ki,=,93.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ncccc2F)C1=O
CHEMBL4448670,CHEMBL233,Mu opioid receptor,Ki,=,262.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ncccc2C(F)(F)F)C1=O
CHEMBL4470425,CHEMBL233,Mu opioid receptor,Ki,=,204.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cncc(F)c2)C1=O
CHEMBL4460762,CHEMBL233,Mu opioid receptor,Ki,=,28.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cnccc2C(F)(F)F)C1=O
CHEMBL4535897,CHEMBL233,Mu opioid receptor,Ki,=,123.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cccnc2C(F)(F)F)C1=O
CHEMBL4593220,CHEMBL233,Mu opioid receptor,Ki,=,261.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2cncc(C(F)(F)F)c2)C1=O
CHEMBL4536259,CHEMBL233,Mu opioid receptor,Ki,=,6.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccc3F)CC2)CN(c2ccccc2)C1=O
CHEMBL4534193,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3cccc(F)c3)CC2)CN(c2ccccc2)C1=O
CHEMBL4544352,CHEMBL233,Mu opioid receptor,Ki,=,19.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccc(F)cc3)CC2)CN(c2ccccc2)C1=O
CHEMBL4451838,CHEMBL233,Mu opioid receptor,Ki,=,190.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC(=O)Nc1ccccc1CCN1CCC2(CC1)CN(c1ccccc1)C(=O)C(C)O2
CHEMBL4573960,CHEMBL233,Mu opioid receptor,Ki,=,144.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC(=O)Nc1cccc(CCN2CCC3(CC2)CN(c2ccccc2)C(=O)C(C)O3)c1
CHEMBL4463621,CHEMBL233,Mu opioid receptor,Ki,=,49.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3cccc(C#N)c3)CC2)CN(c2ccccc2)C1=O
CHEMBL4473746,CHEMBL233,Mu opioid receptor,Ki,=,90.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccn3)CC2)CN(c2ccccc2)C1=O
CHEMBL4571738,CHEMBL233,Mu opioid receptor,Ki,=,117.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3cccnc3)CC2)CN(c2ccccc2)C1=O
CHEMBL4445578,CHEMBL233,Mu opioid receptor,Ki,=,516.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccncc3)CC2)CN(c2ccccc2)C1=O
CHEMBL4540888,CHEMBL233,Mu opioid receptor,Ki,=,127.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC1OC2(CCN(CCc3ccccn3)CC2)CN(c2cnccc2C(F)(F)F)C1=O
CHEMBL4576031,CHEMBL233,Mu opioid receptor,Ki,=,11.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,C[C@H]1OC2(CCN(CCc3ccccc3F)CC2)CN(c2cnccc2C(F)(F)F)C1=O
CHEMBL4522004,CHEMBL233,Mu opioid receptor,Ki,=,34.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,C[C@H]1OC2(CCN(CCc3ccccc3F)CC2)CN(c2ncccc2C(F)(F)F)C1=O
CHEMBL4525653,CHEMBL233,Mu opioid receptor,Ki,=,46.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,CC(=O)Nc1cccc(CCN2CCC3(CC2)CN(c2ccccc2)C(=O)[C@@H](C)O3)c1
CHEMBL4461774,CHEMBL233,Mu opioid receptor,Ki,=,175.0,nM,CHEMBL4356647,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4354824,KI,O=C1N(c2cccnc2C(F)(F)F)CC2(CCN(CCc3ccccc3F)CC2)OC12CC2
CHEMBL4570328,CHEMBL233,Mu opioid receptor,Ki,=,604.0,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(N3CCc4ccccc43)CC2)CC1
CHEMBL4435280,CHEMBL233,Mu opioid receptor,Ki,=,376.0,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3ccc4ccccc43)CC2)CC1
CHEMBL4548515,CHEMBL233,Mu opioid receptor,Ki,=,2.4,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CN)c4ccccc43)CC2)CC1
CHEMBL4439997,CHEMBL233,Mu opioid receptor,Ki,=,716.0,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CO)c4ccccc43)CC2)CC1
CHEMBL4457077,CHEMBL233,Mu opioid receptor,Ki,=,504.0,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CN(C)C)c4ccccc43)CC2)CC1
CHEMBL4465668,CHEMBL233,Mu opioid receptor,Ki,=,437.0,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CCN)c4ccccc43)CC2)CC1.Cl.Cl
CHEMBL4451073,CHEMBL233,Mu opioid receptor,Ki,=,46.2,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CCCN)c4ccccc43)CC2)CC1.Cl.Cl
CHEMBL4541337,CHEMBL233,Mu opioid receptor,Ki,=,453.0,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CN4CCCC4)c4ccccc43)CC2)CC1
CHEMBL4590786,CHEMBL233,Mu opioid receptor,Ki,=,1308.0,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CN4CCC(N)CC4)c4ccccc43)CC2)CC1
CHEMBL4473045,CHEMBL233,Mu opioid receptor,Ki,=,306.0,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CN4CC[C@@H](O)C4)c4ccccc43)CC2)CC1
CHEMBL4518220,CHEMBL233,Mu opioid receptor,Ki,=,973.0,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CNCCO)c4ccccc43)CC2)CC1
CHEMBL4460695,CHEMBL233,Mu opioid receptor,Ki,=,71.3,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CNC(N)=S)c4ccccc43)CC2)CC1
CHEMBL4467156,CHEMBL233,Mu opioid receptor,Ki,=,227.0,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CCNC(N)=S)c4ccccc43)CC2)CC1
CHEMBL4591048,CHEMBL233,Mu opioid receptor,Ki,=,382.0,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CCCNC(N)=S)c4ccccc43)CC2)CC1
CHEMBL4594096,CHEMBL233,Mu opioid receptor,Ki,=,857.0,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CNC(=O)[C@@H](N)CCCNC(=N)N)c4ccccc43)CC2)CC1
CHEMBL4521436,CHEMBL233,Mu opioid receptor,Ki,=,949.0,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CNC(=O)CCCCCN)c4ccccc43)CC2)CC1
CHEMBL4519453,CHEMBL233,Mu opioid receptor,Ki,=,269.0,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CCNCC(=O)NCc1cn(C2CCN([C@H]3CC[C@@H](C(C)C)CC3)CC2)c2ccccc12
CHEMBL4473383,CHEMBL233,Mu opioid receptor,Ki,=,453.0,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(C(N)=O)c4ccccc43)CC2)CC1
CHEMBL4439811,CHEMBL233,Mu opioid receptor,Ki,=,56.4,nM,CHEMBL4358237,B,Displacement of [3H]DAMGO from human MOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(/C=N/O)c4ccccc43)CC2)CC1
CHEMBL4471584,CHEMBL233,Mu opioid receptor,Ki,=,3.7,nM,CHEMBL4371115,B,Binding affinity to mu opioid receptor (unknown origin) expressed in HEK cells at pH 6.5,CHEMBL4371002,KI,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1F
CHEMBL4471584,CHEMBL233,Mu opioid receptor,Ki,=,7.3,nM,CHEMBL4371114,B,Binding affinity to mu opioid receptor (unknown origin) expressed in HEK cells at pH 5.5,CHEMBL4371002,KI,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1F
CHEMBL4471584,CHEMBL233,Mu opioid receptor,Ki,=,17.9,nM,CHEMBL4371113,B,Binding affinity to mu opioid receptor (unknown origin) expressed in HEK cells at pH 7.4,CHEMBL4371002,KI,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1F
CHEMBL596,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL4371113,B,Binding affinity to mu opioid receptor (unknown origin) expressed in HEK cells at pH 7.4,CHEMBL4371002,KI,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL4467777,CHEMBL233,Mu opioid receptor,Ki,=,1.1,nM,CHEMBL4371520,B,Displacement of [3H]-Diprenorphine from mu opioid receptor (unknown origin) expressed in sf9 insect cell membranes after 1 hr by liquid scintillation counting method,CHEMBL4371007,KI,C[C@@H](Cc1ccsc1)NC(=O)NC[C@H](Cc1ccc(O)cc1)N(C)C
CHEMBL4449152,CHEMBL233,Mu opioid receptor,Ki,=,42.0,nM,CHEMBL4371520,B,Displacement of [3H]-Diprenorphine from mu opioid receptor (unknown origin) expressed in sf9 insect cell membranes after 1 hr by liquid scintillation counting method,CHEMBL4371007,KI,CC(Cc1ccsc1)NC(=O)NCC(Cc1ccccc1)N(C)C
CHEMBL4463417,CHEMBL233,Mu opioid receptor,Ki,=,2500.0,nM,CHEMBL4371520,B,Displacement of [3H]-Diprenorphine from mu opioid receptor (unknown origin) expressed in sf9 insect cell membranes after 1 hr by liquid scintillation counting method,CHEMBL4371007,KI,CN(C)[C@H](CNC(=O)Nc1cccnc1Cl)Cc1ccccc1
CHEMBL60533,CHEMBL233,Mu opioid receptor,Ki,=,118.0,nM,CHEMBL4380084,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cell membranes incubated for 60 mins,CHEMBL4376854,KI,CC[C@@H]1CN2CCc3c([nH]c4ccccc34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL292521,CHEMBL233,Mu opioid receptor,Ki,=,105.0,nM,CHEMBL4380084,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cell membranes incubated for 60 mins,CHEMBL4376854,KI,CC[C@@H]1CN2CCc3c([nH]c4cccc(O)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL299031,CHEMBL233,Mu opioid receptor,Ki,=,161.0,nM,CHEMBL4380084,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cell membranes incubated for 60 mins,CHEMBL4376854,KI,CC[C@@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL61630,CHEMBL233,Mu opioid receptor,Ki,=,7.16,nM,CHEMBL4380084,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cell membranes incubated for 60 mins,CHEMBL4376854,KI,CC[C@@H]1CN2CC[C@@]3(O)C(=Nc4cccc(OC)c43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4546925,CHEMBL233,Mu opioid receptor,Ki,=,54.5,nM,CHEMBL4380084,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cell membranes incubated for 60 mins,CHEMBL4376854,KI,CC[C@@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,0.41,nM,CHEMBL4380084,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cell membranes incubated for 60 mins,CHEMBL4376854,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL4443759,CHEMBL233,Mu opioid receptor,Ki,=,0.29,nM,CHEMBL4381834,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(C(=O)N2Cc3ccccc3C2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4443773,CHEMBL233,Mu opioid receptor,Ki,=,33.0,nM,CHEMBL4381834,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(C(=O)N2CCCC2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4587201,CHEMBL233,Mu opioid receptor,Ki,=,0.48,nM,CHEMBL4381834,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(CN(C)Cc2ccccc2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4592669,CHEMBL233,Mu opioid receptor,Ki,=,0.45,nM,CHEMBL4381834,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(CNCc2ccccc2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4440537,CHEMBL233,Mu opioid receptor,Ki,=,0.23,nM,CHEMBL4381834,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(CN2CCc3ccccc3C2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4443716,CHEMBL233,Mu opioid receptor,Ki,=,0.8,nM,CHEMBL4381834,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(CN2Cc3ccccc3C2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4557264,CHEMBL233,Mu opioid receptor,Ki,=,38.0,nM,CHEMBL4381834,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(CN2CCOCC2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4437661,CHEMBL233,Mu opioid receptor,Ki,=,19.6,nM,CHEMBL4381834,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(CN2CC3CC3C2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4482942,CHEMBL233,Mu opioid receptor,Ki,=,5.0,nM,CHEMBL4381834,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(CN2CCCCC2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4564309,CHEMBL233,Mu opioid receptor,Ki,=,15.0,nM,CHEMBL4381834,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(CN2CCCC2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4453368,CHEMBL233,Mu opioid receptor,Ki,=,3.6,nM,CHEMBL4381834,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(Cc2ccccc2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,4.2,nM,CHEMBL4381834,B,Displacement of [3H]diprenorphine from human MOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL1779999,CHEMBL233,Mu opioid receptor,Ki,=,18.0,nM,CHEMBL4386122,B,Binding affinity to human mu opioid receptor by cell based assay,CHEMBL4385605,KI,COC1Cc2ccccc2[C@]2(CC[C@@H](N(C)Cc3ccccc3)CC2)O1
CHEMBL4277264,CHEMBL233,Mu opioid receptor,Ki,=,8200.0,nM,CHEMBL4392151,B,Displacement of [3H]-DAMGO from recombinant human MOR stably expressed in HEK cells measured after 90 mins by microbeta scintillation counting method,CHEMBL4390674,KI,Cc1cc(Oc2nccc3occc23)ccc1-c1c(C)ncc2nccn12
CHEMBL4572614,CHEMBL233,Mu opioid receptor,Ki,=,9400.0,nM,CHEMBL4392151,B,Displacement of [3H]-DAMGO from recombinant human MOR stably expressed in HEK cells measured after 90 mins by microbeta scintillation counting method,CHEMBL4390674,KI,Cc1ncc2nccn2c1-c1ccc(Oc2nccc3occc23)cc1C(F)(F)F
CHEMBL4469848,CHEMBL233,Mu opioid receptor,Ki,=,4400.0,nM,CHEMBL4392151,B,Displacement of [3H]-DAMGO from recombinant human MOR stably expressed in HEK cells measured after 90 mins by microbeta scintillation counting method,CHEMBL4390674,KI,FC(F)(F)c1cc(Oc2nccc3occc23)ccc1-c1cccc2nccn12
CHEMBL4466483,CHEMBL233,Mu opioid receptor,Ki,=,2100.0,nM,CHEMBL4392151,B,Displacement of [3H]-DAMGO from recombinant human MOR stably expressed in HEK cells measured after 90 mins by microbeta scintillation counting method,CHEMBL4390674,KI,FC(F)(F)c1cc(Oc2nccc3ccsc23)ccc1-c1cccc2nccn12
CHEMBL4575948,CHEMBL233,Mu opioid receptor,Ki,=,406.0,nM,CHEMBL4396287,B,Displacement of [3H]DAMGO from human MOR expressed in CHO-K1 cells membranes after 60 mins by micro beta scintillation counting method,CHEMBL4393719,KI,FC(CCN1CCc2ccccc2CC1)Cc1ccccc1
CHEMBL333357,CHEMBL233,Mu opioid receptor,Ki,=,2.95,nM,CHEMBL4399057,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cell membranes incubated for 2 hrs by liquid scintillation counting method,CHEMBL4396910,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL4527584,CHEMBL233,Mu opioid receptor,Ki,=,18.91,nM,CHEMBL4399057,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cell membranes incubated for 2 hrs by liquid scintillation counting method,CHEMBL4396910,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1cccc(O)c1
CHEMBL331325,CHEMBL233,Mu opioid receptor,Ki,=,0.81,nM,CHEMBL4399057,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cell membranes incubated for 2 hrs by liquid scintillation counting method,CHEMBL4396910,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL4514319,CHEMBL233,Mu opioid receptor,Ki,=,0.26,nM,CHEMBL4399057,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cell membranes incubated for 2 hrs by liquid scintillation counting method,CHEMBL4396910,KI,Cc1cc(O)c(Cl)c(C)c1C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL4466953,CHEMBL233,Mu opioid receptor,Ki,=,4.98,nM,CHEMBL4399057,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cell membranes incubated for 2 hrs by liquid scintillation counting method,CHEMBL4396910,KI,Cc1cc(C[C@H](N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)cc(C)c1O
CHEMBL4475274,CHEMBL233,Mu opioid receptor,Ki,=,4.38,nM,CHEMBL4399057,B,Displacement of [3H]DAMGO from human recombinant MOR expressed in CHO cell membranes incubated for 2 hrs by liquid scintillation counting method,CHEMBL4396910,KI,COc1cc(C[C@H](N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)cc(OC)c1O
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,51.0,nM,CHEMBL4403880,B,Displacement of [3H]-diprenorphine from human MOR expressed in CHO cell membranes incubated for 1 hr by scintillation counting method,CHEMBL4402550,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL4473632,CHEMBL233,Mu opioid receptor,Ki,=,22.8,nM,CHEMBL4403880,B,Displacement of [3H]-diprenorphine from human MOR expressed in CHO cell membranes incubated for 1 hr by scintillation counting method,CHEMBL4402550,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSCc2ccccc2CSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccc(F)cc2)NC(=O)CNC1=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL4551481,CHEMBL233,Mu opioid receptor,Ki,=,83.7,nM,CHEMBL4403880,B,Displacement of [3H]-diprenorphine from human MOR expressed in CHO cell membranes incubated for 1 hr by scintillation counting method,CHEMBL4402550,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccc(F)cc2)NC(=O)CNC1=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL4539430,CHEMBL233,Mu opioid receptor,Ki,=,13.8,nM,CHEMBL4403880,B,Displacement of [3H]-diprenorphine from human MOR expressed in CHO cell membranes incubated for 1 hr by scintillation counting method,CHEMBL4402550,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CSCc2ccccc2CSC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C(=O)NCC(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)NNC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)CNC1=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL4586954,CHEMBL233,Mu opioid receptor,Ki,=,15.9,nM,CHEMBL4403880,B,Displacement of [3H]-diprenorphine from human MOR expressed in CHO cell membranes incubated for 1 hr by scintillation counting method,CHEMBL4402550,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSCc2ccccc2CSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)NNC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)CNC1=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,6.08,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL4586277,CHEMBL233,Mu opioid receptor,Ki,=,428.0,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CC(C(=O)NCc1ccc(C(F)(F)F)cc1N1CCC(Cc2ccccc2)(N(C)C)CC1)c1ccc(NS(C)(=O)=O)c(F)c1
CHEMBL4483060,CHEMBL233,Mu opioid receptor,Ki,=,368.0,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CN(C)C1(Cc2ccccc2)CCN(c2cc(C(F)(F)F)ccc2CNC(=O)Nc2ccc(NS(C)(=O)=O)c(F)c2)CC1
CHEMBL4571845,CHEMBL233,Mu opioid receptor,Ki,=,322.0,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CN(C)C1(Cc2ccccc2)CCN(c2cc(C(F)(F)F)ccc2CNC(=O)Nc2ccc(CNS(C)(=O)=O)c(F)c2)CC1
CHEMBL4476530,CHEMBL233,Mu opioid receptor,Ki,=,76.2,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CN(C)C1(Cc2ccccc2)CCN(c2cc(C(F)(F)F)ccc2CNC(=O)NCc2ccc(NS(C)(=O)=O)c(F)c2)CC1
CHEMBL4536869,CHEMBL233,Mu opioid receptor,Ki,=,72.4,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CN(C)C1(Cc2ccccc2)CCN(c2cc(C(F)(F)F)ccc2CNC(=O)Nc2ccc(CNS(N)(=O)=O)c(F)c2)CC1
CHEMBL4555508,CHEMBL233,Mu opioid receptor,Ki,=,240.0,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CN(C)C1(Cc2ccccc2)CCN(c2cc(C(F)(F)F)ccc2CNC(=O)Nc2ccc(CO)c(F)c2)CC1
CHEMBL4471708,CHEMBL233,Mu opioid receptor,Ki,=,137.0,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CN(C)C1(Cc2ccccc2)CCN(c2cc(C(F)(F)F)ccc2CNC(=O)Nc2cccc3ccc(O)cc23)CC1
CHEMBL4438643,CHEMBL233,Mu opioid receptor,Ki,=,261.0,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CN(C)C1(Cc2ccccc2)CCN(c2cc(C(F)(F)F)ccc2CNC(=O)Nc2cccc3c2CC(O)CC3)CC1
CHEMBL4457595,CHEMBL233,Mu opioid receptor,Ki,=,225.0,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CN(C)C1(Cc2ccccc2)CCN(c2cc(C(F)(F)F)ccc2CNC(=O)Nc2ccc3c(c2)OCC3)CC1
CHEMBL4562769,CHEMBL233,Mu opioid receptor,Ki,=,240.0,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CN(C)C1(Cc2ccccc2)CCN(c2cc(C(F)(F)F)ccc2CNC(=O)Nc2cccc3[nH]c(=O)ccc23)CC1
CHEMBL4448866,CHEMBL233,Mu opioid receptor,Ki,=,105.0,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CN(C)C1(Cc2ccccc2)CCN(c2cc(C(F)(F)F)ccc2CNC(=O)Nc2cccc3c(=O)[nH]ccc23)CC1
CHEMBL4459611,CHEMBL233,Mu opioid receptor,Ki,=,166.0,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CN(C)C1(Cc2ccccc2)CCN(c2cc(C(F)(F)F)ccc2CNC(=O)Nc2ccc3cccnc3c2)CC1
CHEMBL4453980,CHEMBL233,Mu opioid receptor,Ki,=,177.0,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CN(C)C1(Cc2ccccc2)CCN(c2cc(C(F)(F)F)ccc2CNC(=O)Nc2ccc3ccncc3c2)CC1
CHEMBL4457304,CHEMBL233,Mu opioid receptor,Ki,=,17.0,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CN(C)C1(Cc2ccccc2)CCN(c2cc(C(F)(F)F)ccc2CNC(=O)Nc2ccc3cnccc3c2)CC1
CHEMBL4442473,CHEMBL233,Mu opioid receptor,Ki,=,205.0,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CN(C)C1(Cc2ccccc2)CCN(c2cc(C(F)(F)F)ccc2CNC(=O)Nc2cccc3ccncc23)CC1
CHEMBL4553702,CHEMBL233,Mu opioid receptor,Ki,=,507.0,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CN(C)C1(Cc2ccccc2)CCN(c2cc(C(F)(F)F)ccc2CNC(=O)Nc2cccc3cnccc23)CC1
CHEMBL4438974,CHEMBL233,Mu opioid receptor,Ki,=,29.0,nM,CHEMBL4408647,B,Displacement of [3H]-DAMGO from full length human MOR expressed in chem5 cells incubated for 60 mins by liquid scintillation counter,CHEMBL4406835,KI,CN(C)C1(Cc2ccccc2)CCN(c2cc(C(F)(F)F)ccc2CNC(=O)Nc2cccc3ncccc23)CC1
CHEMBL4550234,CHEMBL233,Mu opioid receptor,Ki,=,0.0109,nM,CHEMBL4409275,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting,CHEMBL4406853,KI,C=C(C(N)=O)C(NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)N(C)C(=O)C(N)Cc1c(C)cc(O)cc1C)c1ccco1
CHEMBL4521879,CHEMBL233,Mu opioid receptor,Ki,=,0.0109,nM,CHEMBL4409275,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting,CHEMBL4406853,KI,C=C(C(N)=O)C(NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)N(C)C(=O)C(N)Cc1c(C)cc(O)cc1C)c1ccccc1
CHEMBL4439415,CHEMBL233,Mu opioid receptor,Ki,=,0.0109,nM,CHEMBL4409275,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting,CHEMBL4406853,KI,C=C(C(N)=O)C(NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](C)N(C)C(=O)C(N)Cc1c(C)cc(O)cc1C)c1ccco1
CHEMBL4450250,CHEMBL233,Mu opioid receptor,Ki,=,0.0109,nM,CHEMBL4409275,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting,CHEMBL4406853,KI,C=C(C(N)=O)C(NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](C)N(C)C(=O)C(N)Cc1c(C)cc(O)cc1C)c1ccccc1
CHEMBL4476487,CHEMBL233,Mu opioid receptor,Ki,=,1.0,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,CCC(CC)CN(CCCCCCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)C(=O)CO
CHEMBL4519976,CHEMBL233,Mu opioid receptor,Ki,=,0.631,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,CCC(CC)CN(CCCCCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)C(=O)CO
CHEMBL4541806,CHEMBL233,Mu opioid receptor,Ki,=,0.631,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,CCC(CC)CN(CCCCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)C(=O)CO
CHEMBL4463675,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,CCC(CC)CN(CCCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)C(=O)CO
CHEMBL4468796,CHEMBL233,Mu opioid receptor,Ki,=,0.1585,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,CCC(CC)CN(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)C(=O)CO
CHEMBL4591528,CHEMBL233,Mu opioid receptor,Ki,=,12.59,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCOCC2)C(=O)CO)c1
CHEMBL3910689,CHEMBL233,Mu opioid receptor,Ki,=,0.1259,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCC(F)(F)CC2)C(=O)CO)c1
CHEMBL4569252,CHEMBL233,Mu opioid receptor,Ki,=,0.7943,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,CCCCCCN(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)C(=O)CO
CHEMBL3990727,CHEMBL233,Mu opioid receptor,Ki,=,1.585,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCC2)C(=O)CO)c1
CHEMBL3990213,CHEMBL233,Mu opioid receptor,Ki,=,0.2512,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCC2)C(=O)CO)c1
CHEMBL3962054,CHEMBL233,Mu opioid receptor,Ki,=,0.7943,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CCCc2ccccc2)C(=O)CO)c1
CHEMBL3959336,CHEMBL233,Mu opioid receptor,Ki,=,0.631,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CCc2ccccc2)C(=O)CO)c1
CHEMBL3906031,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(Cc2ccccc2)C(=O)CO)c1
CHEMBL4471516,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)c2ccco2)c1
CHEMBL4460387,CHEMBL233,Mu opioid receptor,Ki,=,0.3981,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)Cc2nnn[nH]2)c1
CHEMBL3919761,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,CS(=O)(=O)CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3137319,CHEMBL233,Mu opioid receptor,Ki,=,0.1585,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)[C@@H](O)CO)c1.O=S(=O)(O)O
CHEMBL3954068,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)CO)c1
CHEMBL3990868,CHEMBL233,Mu opioid receptor,Ki,=,0.1995,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,CN(C)S(=O)(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL4475360,CHEMBL233,Mu opioid receptor,Ki,=,0.2512,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,CS(=O)(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL3971059,CHEMBL233,Mu opioid receptor,Ki,=,0.1995,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,CC(C)NC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL4520212,CHEMBL233,Mu opioid receptor,Ki,=,0.1259,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,COC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL4544814,CHEMBL233,Mu opioid receptor,Ki,=,0.7943,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)C(F)(F)F)c1
CHEMBL4567073,CHEMBL233,Mu opioid receptor,Ki,=,0.1259,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,CC(C)(C)C(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL4467513,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,CC(=O)N(CCN1[C@@H]2CC[C@H]1C[C@@H](c1cccc(C(N)=O)c1)C2)CC1CCCCC1
CHEMBL4474822,CHEMBL233,Mu opioid receptor,Ki,=,0.2512,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCNCC2CCCCC2)c1
CHEMBL4465208,CHEMBL233,Mu opioid receptor,Ki,=,630.96,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,C[C@H]1CN(CCC(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL320218,CHEMBL233,Mu opioid receptor,Ki,=,0.1,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,C[C@H]1CN(CCCc2ccccc2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL4441036,CHEMBL233,Mu opioid receptor,Ki,=,0.3162,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL4577852,CHEMBL233,Mu opioid receptor,Ki,=,0.3162,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@H]1c1cccc(O)c1
CHEMBL1201770,CHEMBL233,Mu opioid receptor,Ki,=,7.943,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[Br-]
CHEMBL19019,CHEMBL233,Mu opioid receptor,Ki,=,0.1585,nM,CHEMBL4411118,B,Displacement of [3H]-DPN from recombinant human mu opioid receptor expressed in CHO-K1 cell membranes by radioligand binding assay,CHEMBL4406921,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL4562437,CHEMBL233,Mu opioid receptor,Ki,=,993.0,nM,CHEMBL4423343,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK cells by radioligand binding assay,CHEMBL4422623,KI,Cc1cccc(C)c1N1C(=O)[C@H](CC2CNc3ccccc32)NC2(CCN(C)CC2)C1=O
CHEMBL4472251,CHEMBL233,Mu opioid receptor,Ki,=,10000.0,nM,CHEMBL4423343,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK cells by radioligand binding assay,CHEMBL4422623,KI,Cc1cccc(C)c1N1C(=O)CNC2(CCN(C)CC2)C1=O
CHEMBL4552298,CHEMBL233,Mu opioid receptor,Ki,=,1634.0,nM,CHEMBL4423343,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK cells by radioligand binding assay,CHEMBL4422623,KI,Cc1cccc(C)c1N1C(=O)[C@H](CO)NC2(CCN(C)CC2)C1=O
CHEMBL4592045,CHEMBL233,Mu opioid receptor,Ki,=,450.0,nM,CHEMBL4424355,B,Binding affinity to human MOR,CHEMBL4422661,KI,CCc1cc(F)c2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)c(C)c2c1
CHEMBL4585935,CHEMBL233,Mu opioid receptor,Ki,=,972.0,nM,CHEMBL4428196,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membranes after 1 hr by microplate scintillation counting method,CHEMBL4428025,KI,OC1(c2ncccn2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL4474536,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL4428196,B,Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO cell membranes after 1 hr by microplate scintillation counting method,CHEMBL4428025,KI,NCc1ccccc1C1(O)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL4544227,CHEMBL233,Mu opioid receptor,Ki,=,35.0,nM,CHEMBL4428200,B,Displacement of [3H]DAMGO from recombinant human mu opioid receptor expressed in CHO cell membranes after 60 mins,CHEMBL4428025,KI,CNC(=O)Cn1c(=O)n(C2CCN([C@H]3Cc4cccc5cccc3c45)CC2)c2ccccc21
CHEMBL4527189,CHEMBL233,Mu opioid receptor,Ki,=,80.0,nM,CHEMBL4428202,B,Displacement of [3H]DAMGO from recombinant human mu opioid receptor expressed in CHO cell membranes,CHEMBL4428025,KI,O=C1Cc2ccccc2N1C1CCN([C@@H]2CC[C@H]3CCCc4cccc2c43)CC1
CHEMBL101454,CHEMBL233,Mu opioid receptor,Ki,=,30.0,nM,CHEMBL4428202,B,Displacement of [3H]DAMGO from recombinant human mu opioid receptor expressed in CHO cell membranes,CHEMBL4428025,KI,O=C1Cc2ccccc2N1C1CCN(C2CCCCCCC2)CC1
CHEMBL2364605,CHEMBL233,Mu opioid receptor,Ki,=,0.7,nM,CHEMBL4428205,B,"Displacement of [N-allyl-2,3-3H]naloxone from recombinant human mu opioid receptor expressed in CHOK1 cell membranes after 90 mins by scintillation counting method",CHEMBL4428025,KI,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12
CHEMBL4468676,CHEMBL233,Mu opioid receptor,Ki,=,31.0,nM,CHEMBL4428209,B,Displacement of [3H]DAMGO from recombinant human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL4428025,KI,CCn1c(=O)n([C@@H]2CCN(C3CCCCCCC3)C[C@H]2CO)c2ccccc21
CHEMBL559569,CHEMBL233,Mu opioid receptor,Ki,=,58.0,nM,CHEMBL4428209,B,Displacement of [3H]DAMGO from recombinant human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL4428025,KI,Cc1cccc2c1CC[C@H](CN1CCC(c3c(Cl)cccc3Cl)CC1)C[C@@H]2O
CHEMBL1907858,CHEMBL233,Mu opioid receptor,Ki,=,5.9,nM,CHEMBL4428193,B,Displacement of [3H]-naloxone from human mu opioid receptor expressed in HEK293 cell membranes,CHEMBL4428025,KI,O=C1NCN(c2ccccc2)C12CCN([C@H]1Cc3cccc4cccc1c34)CC2
CHEMBL412098,CHEMBL233,Mu opioid receptor,Ki,=,46.77,nM,CHEMBL4428190,B,Binding affinity to human mu opioid receptor,CHEMBL4428025,KI,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CC[C@H]3CCCc4cccc1c43)CC2
CHEMBL4469560,CHEMBL233,Mu opioid receptor,Ki,=,4.1,nM,CHEMBL4430535,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cell membranes incubated for 90 mins by liquid scintillation counting,CHEMBL4428100,KI,O=C1NCCC(=O)N2CCC[C@@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H]1Cc1c[nH]c2ccccc12
CHEMBL506616,CHEMBL233,Mu opioid receptor,Ki,=,127.0,nM,CHEMBL4430535,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cell membranes incubated for 90 mins by liquid scintillation counting,CHEMBL4428100,KI,O=C1N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H]1Cc1c[nH]c2ccccc12
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL4430535,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cell membranes incubated for 90 mins by liquid scintillation counting,CHEMBL4428100,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL4575464,CHEMBL233,Mu opioid receptor,Ki,=,0.5,nM,CHEMBL4430768,B,Displacement of [3H]DAMGO from MOR in HEK293 cells,CHEMBL4428114,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCC(=O)NCC(c1ccccc1)c1ccccc1
CHEMBL4453773,CHEMBL233,Mu opioid receptor,Ki,=,160.0,nM,CHEMBL4430768,B,Displacement of [3H]DAMGO from MOR in HEK293 cells,CHEMBL4428114,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCC(=O)N(C)C(c1ccccc1)c1ccccc1
CHEMBL4442357,CHEMBL233,Mu opioid receptor,Ki,=,84.0,nM,CHEMBL4430768,B,Displacement of [3H]DAMGO from MOR in HEK293 cells,CHEMBL4428114,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCC(=O)NC(c1ccccc1)c1ccccc1
CHEMBL4545050,CHEMBL233,Mu opioid receptor,Ki,=,96.0,nM,CHEMBL4430768,B,Displacement of [3H]DAMGO from MOR in HEK293 cells,CHEMBL4428114,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCC(=O)N1CCc2ccccc2C1c1ccccc1
CHEMBL4464491,CHEMBL233,Mu opioid receptor,Ki,=,470.0,nM,CHEMBL4430768,B,Displacement of [3H]DAMGO from MOR in HEK293 cells,CHEMBL4428114,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCC(=O)N1CCc2ccccc2[C@H]1c1ccccc1
CHEMBL4562025,CHEMBL233,Mu opioid receptor,Ki,=,380.0,nM,CHEMBL4430768,B,Displacement of [3H]DAMGO from MOR in HEK293 cells,CHEMBL4428114,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCC(=O)N1CCc2ccccc2[C@@H]1c1ccccc1
CHEMBL3759092,CHEMBL233,Mu opioid receptor,Ki,=,0.83,nM,CHEMBL4430768,B,Displacement of [3H]DAMGO from MOR in HEK293 cells,CHEMBL4428114,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCC(=O)Nc1ccccc1
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,0.6,nM,CHEMBL4430768,B,Displacement of [3H]DAMGO from MOR in HEK293 cells,CHEMBL4428114,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL4466859,CHEMBL233,Mu opioid receptor,Ki,=,6.0,nM,CHEMBL4430771,B,Displacement of [3H]Diprenorphine from human MOR expressed in HEK293 cell membranes by liquid scintillation counting,CHEMBL4428114,KI,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCC2(CCCC2)OC1
CHEMBL4552146,CHEMBL233,Mu opioid receptor,Ki,=,4.5,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,CCCCN1CCC2(CCC(Cc3ccccc3)(N(C)C)CC2)C1
CHEMBL4539568,CHEMBL233,Mu opioid receptor,Ki,=,1590.0,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,CC(=O)N1CCC2(CCC(Cc3ccccc3)(N(C)C)CC2)C1
CHEMBL4515245,CHEMBL233,Mu opioid receptor,Ki,=,26.0,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,CN(C)C1(c2ccccc2)CCC2(CC1)CNC(=O)C2
CHEMBL4515245,CHEMBL233,Mu opioid receptor,Ki,=,220.0,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,CN(C)C1(c2ccccc2)CCC2(CC1)CNC(=O)C2
CHEMBL4476510,CHEMBL233,Mu opioid receptor,Ki,=,2.8,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,CCCCN1CCC2(CCC(c3cccs3)(N(C)C)CC2)C1
CHEMBL4454146,CHEMBL233,Mu opioid receptor,Ki,=,1.14,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,CN(C)C1(c2cccs2)CCC2(CCN(CC3CCCC3)C2)CC1
CHEMBL4463703,CHEMBL233,Mu opioid receptor,Ki,=,30.5,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,CCCC(=O)N1CCC2(CCC(c3ccccc3)(N(C)C)CC2)C1
CHEMBL4474989,CHEMBL233,Mu opioid receptor,Ki,=,7.6,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,CCCC(=O)N1CCC2(CCC(c3sccc3C)(N(C)C)CC2)C1
CHEMBL4474067,CHEMBL233,Mu opioid receptor,Ki,=,4.8,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,Cc1ccsc1C1(N(C)C)CCC2(CCN(C(=O)CC(C)C)C2)CC1
CHEMBL4557245,CHEMBL233,Mu opioid receptor,Ki,=,1.0,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,CN(C)C1(c2ccccc2)CCC2(CCN(C(=O)CC3(C#N)CCC3)C2)CC1
CHEMBL4458273,CHEMBL233,Mu opioid receptor,Ki,=,0.6,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,CN(C)C1(c2ccccc2)CCC2(CCN(C(=O)CC3CCC3)C2)CC1
CHEMBL4460776,CHEMBL233,Mu opioid receptor,Ki,=,4.0,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,CN(C)C1(C2CCCC2)CCC2(CCN(C(=O)CC3CC3)C2)CC1
CHEMBL4466714,CHEMBL233,Mu opioid receptor,Ki,=,170.0,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,CCCCN1CCC2(CCC(c3cccs3)(N(C)C)CC2)C1=O
CHEMBL4578716,CHEMBL233,Mu opioid receptor,Ki,=,230.0,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,CCCCN1CCC2(CCC(Cc3ccccc3)(N(C)C)CC2)C1=O
CHEMBL4536065,CHEMBL233,Mu opioid receptor,Ki,=,1.2,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,CN(C)C1(c2ccccc2)CCC2(CC1)CC(=O)N(CCC1(C#N)CCC1)C2
CHEMBL4517646,CHEMBL233,Mu opioid receptor,Ki,=,3.5,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,CN(C)C1(c2ccccc2)CCC2(CCN(CCC3(C#N)CCC3)C2)CC1
CHEMBL4466096,CHEMBL233,Mu opioid receptor,Ki,=,0.4,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,COC1(CCN2CC3(CCC(c4cccs4)(N(C)C)CC3)CC2=O)CCC1
CHEMBL4466096,CHEMBL233,Mu opioid receptor,Ki,=,165.0,nM,CHEMBL4433107,B,Displacement of [3H]-naloxone human mu-opioid receptor expressed in CHO-K1 cell membranes measured after 90 mins by beta-counter method,CHEMBL4431392,KI,COC1(CCN2CC3(CCC(c4cccs4)(N(C)C)CC3)CC2=O)CCC1
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,51.2,nM,CHEMBL4433604,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by micro beta2 scintillation counting method,CHEMBL4433209,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL4434948,CHEMBL233,Mu opioid receptor,Ki,=,75.8,nM,CHEMBL4433604,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by micro beta2 scintillation counting method,CHEMBL4433209,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1C/C=C\C[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL4473857,CHEMBL233,Mu opioid receptor,Ki,=,53.6,nM,CHEMBL4433604,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by micro beta2 scintillation counting method,CHEMBL4433209,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1C/C=C/C[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,43.0,nM,CHEMBL4615751,B,Displacement of [3H]diprenorphine human MOR expressed in CHO cell membranes after 1 hr by micro beta2 scintillation counting method,CHEMBL4613286,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL4636807,CHEMBL233,Mu opioid receptor,Ki,=,790.0,nM,CHEMBL4615751,B,Displacement of [3H]diprenorphine human MOR expressed in CHO cell membranes after 1 hr by micro beta2 scintillation counting method,CHEMBL4613286,KI,Cc1cc(=O)oc2ccc(N3C(=O)C4=C(SC[C@@H](NC(=O)[C@@H](N)Cc5ccc(O)cc5)C(=O)NCC(=O)N[C@@H](Cc5ccccc5)C(=O)NNC(=O)[C@H](Cc5ccccc5)NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc5ccc(O)cc5)CS4)C3=O)cc12.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL4641588,CHEMBL233,Mu opioid receptor,Ki,=,510.0,nM,CHEMBL4615751,B,Displacement of [3H]diprenorphine human MOR expressed in CHO cell membranes after 1 hr by micro beta2 scintillation counting method,CHEMBL4613286,KI,Cc1cc(=O)oc2cc(NC(=O)CCN3C(=O)C4=C(SC[C@@H](NC(=O)[C@@H](N)Cc5ccc(O)cc5)C(=O)NCC(=O)N[C@@H](Cc5ccccc5)C(=O)NNC(=O)[C@H](Cc5ccccc5)NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc5ccc(O)cc5)CS4)C3=O)ccc12.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL4638703,CHEMBL233,Mu opioid receptor,Ki,=,91.0,nM,CHEMBL4615751,B,Displacement of [3H]diprenorphine human MOR expressed in CHO cell membranes after 1 hr by micro beta2 scintillation counting method,CHEMBL4613286,KI,CN(C)c1cccc2c(S(=O)(=O)NCCN3C(=O)C4=C(SC[C@@H](NC(=O)[C@@H](N)Cc5ccc(O)cc5)C(=O)NCC(=O)N[C@@H](Cc5ccccc5)C(=O)NNC(=O)[C@H](Cc5ccccc5)NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc5ccc(O)cc5)CS4)C3=O)cccc12.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL4648915,CHEMBL233,Mu opioid receptor,Ki,=,2311.0,nM,CHEMBL4620843,B,Displacement of [3H]-DAMGO from human mu opiod receptor expressed in CHO cells incubated for 60 mins by liquid scintillation counting method,CHEMBL4619756,KI,COc1ccc(C2CCCN2Cc2ccc(Oc3ccc(C(=O)NO)cc3)cc2)cc1
CHEMBL4636535,CHEMBL233,Mu opioid receptor,Ki,=,2797.0,nM,CHEMBL4620843,B,Displacement of [3H]-DAMGO from human mu opiod receptor expressed in CHO cells incubated for 60 mins by liquid scintillation counting method,CHEMBL4619756,KI,O=C(NO)c1ccc(Oc2ccc(CN3CCCC3c3cccc(F)c3)cc2)c(F)c1
CHEMBL4644052,CHEMBL233,Mu opioid receptor,Ki,=,4763.0,nM,CHEMBL4620843,B,Displacement of [3H]-DAMGO from human mu opiod receptor expressed in CHO cells incubated for 60 mins by liquid scintillation counting method,CHEMBL4619756,KI,COc1cccc(C2CCCN2Cc2ccc(Oc3ccc(C(=O)NO)cc3F)cc2)c1
CHEMBL4063074,CHEMBL233,Mu opioid receptor,Ki,=,93.7,nM,CHEMBL4620843,B,Displacement of [3H]-DAMGO from human mu opiod receptor expressed in CHO cells incubated for 60 mins by liquid scintillation counting method,CHEMBL4619756,KI,Cc1cc(C)cc(C2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1
CHEMBL4638966,CHEMBL233,Mu opioid receptor,Ki,=,1481.0,nM,CHEMBL4620843,B,Displacement of [3H]-DAMGO from human mu opiod receptor expressed in CHO cells incubated for 60 mins by liquid scintillation counting method,CHEMBL4619756,KI,Cc1cc(C)cc(C2CCCN2Cc2ccc(Oc3ccc4c(=O)[nH]oc4c3)cc2)c1
CHEMBL567175,CHEMBL233,Mu opioid receptor,Ki,=,30.7,nM,CHEMBL4629272,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL4627370,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4638693,CHEMBL233,Mu opioid receptor,Ki,=,8668.0,nM,CHEMBL4629272,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL4627370,KI,O=C(Cc1ccccc1)N1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(O)[C@H]1C5
CHEMBL4636799,CHEMBL233,Mu opioid receptor,Ki,=,3483.0,nM,CHEMBL4629272,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL4627370,KI,O=C(CCc1ccccc1)N1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(O)[C@H]1C5
CHEMBL4649733,CHEMBL233,Mu opioid receptor,Ki,=,1792.0,nM,CHEMBL4629272,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells,CHEMBL4627370,KI,O=C(CCc1ccccc1)N1CC[C@]23Cc4nc5ccccc5cc4C[C@@]2(O)[C@H]1Cc1ccc(O)cc13
CHEMBL2179652,CHEMBL233,Mu opioid receptor,Ki,=,7.55,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4647353,CHEMBL233,Mu opioid receptor,Ki,=,135.0,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5C5CC5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4638667,CHEMBL233,Mu opioid receptor,Ki,=,29.9,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Cc1cc(F)ccc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4647696,CHEMBL233,Mu opioid receptor,Ki,=,191.0,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Cc1ccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)cc1
CHEMBL4633223,CHEMBL233,Mu opioid receptor,Ki,=,24.4,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Cc1cccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)c1
CHEMBL4633020,CHEMBL233,Mu opioid receptor,Ki,=,235.0,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Cc1ccccc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4645952,CHEMBL233,Mu opioid receptor,Ki,=,370.0,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(F)c(F)c5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4636305,CHEMBL233,Mu opioid receptor,Ki,=,171.0,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(F)cc5F)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4644543,CHEMBL233,Mu opioid receptor,Ki,=,2.33,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(F)cc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4641670,CHEMBL233,Mu opioid receptor,Ki,=,138.0,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Br)cc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4633209,CHEMBL233,Mu opioid receptor,Ki,=,23.1,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4649820,CHEMBL233,Mu opioid receptor,Ki,=,249.0,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Cc1cccc(C)c1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4644691,CHEMBL233,Mu opioid receptor,Ki,=,61.9,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,COc1ccccc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4633907,CHEMBL233,Mu opioid receptor,Ki,=,91.3,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,COc1cccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)c1
CHEMBL4636159,CHEMBL233,Mu opioid receptor,Ki,=,148.0,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,COc1ccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)cc1
CHEMBL4640139,CHEMBL233,Mu opioid receptor,Ki,=,12.9,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1cccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)c1
CHEMBL4649485,CHEMBL233,Mu opioid receptor,Ki,=,6.97,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,CN(C)c1ccccc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4634021,CHEMBL233,Mu opioid receptor,Ki,=,15.8,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,CN(C)c1cccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)c1
CHEMBL4641271,CHEMBL233,Mu opioid receptor,Ki,=,4.7,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,CN(C)c1ccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)cc1
CHEMBL4648920,CHEMBL233,Mu opioid receptor,Ki,=,56.4,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,CN(C)Cc1ccccc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4639005,CHEMBL233,Mu opioid receptor,Ki,=,141.0,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,NC(=O)Nc1ccccc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4647851,CHEMBL233,Mu opioid receptor,Ki,=,337.0,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,CC(=O)Nc1cccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)c1
CHEMBL4634141,CHEMBL233,Mu opioid receptor,Ki,=,159.0,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,CC(=O)Nc1ccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)cc1
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,59.5,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL4634079,CHEMBL233,Mu opioid receptor,Ki,=,14.7,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-n5cccc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4648628,CHEMBL233,Mu opioid receptor,Ki,=,105.0,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccn5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4640141,CHEMBL233,Mu opioid receptor,Ki,=,82.7,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5cccnc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4640826,CHEMBL233,Mu opioid receptor,Ki,=,47.1,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccncc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4645508,CHEMBL233,Mu opioid receptor,Ki,=,1.05,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Cc1cc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)ccn1
CHEMBL4636598,CHEMBL233,Mu opioid receptor,Ki,=,10.7,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,COc1cc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)ccn1
CHEMBL4649042,CHEMBL233,Mu opioid receptor,Ki,=,66.2,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccncn5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4647357,CHEMBL233,Mu opioid receptor,Ki,=,47.9,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5cncnc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4649607,CHEMBL233,Mu opioid receptor,Ki,=,88.7,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5cnccn5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4634007,CHEMBL233,Mu opioid receptor,Ki,=,121.0,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5cn[nH]c5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4644731,CHEMBL233,Mu opioid receptor,Ki,=,3.79,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Cn1cc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)cn1
CHEMBL4643256,CHEMBL233,Mu opioid receptor,Ki,=,99.3,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Cc1nocc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4646678,CHEMBL233,Mu opioid receptor,Ki,=,3.18,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Cc1nnc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)o1
CHEMBL4635711,CHEMBL233,Mu opioid receptor,Ki,=,5.37,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C[C@@]4(OCCCc5ccncc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4647180,CHEMBL233,Mu opioid receptor,Ki,=,819.0,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C[C@@]4(OCCOc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4640017,CHEMBL233,Mu opioid receptor,Ki,=,799.0,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C[C@@]4(OCc5ccc6ccccc6n5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4646687,CHEMBL233,Mu opioid receptor,Ki,=,3.96,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCc5ccccn5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4644964,CHEMBL233,Mu opioid receptor,Ki,=,3.82,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCc5ccncc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4633348,CHEMBL233,Mu opioid receptor,Ki,=,70.9,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCc5ccc(F)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4646507,CHEMBL233,Mu opioid receptor,Ki,=,95.3,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCC5CCCCC5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4645533,CHEMBL233,Mu opioid receptor,Ki,=,5.99,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCC5CCOCC5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4634862,CHEMBL233,Mu opioid receptor,Ki,=,92.1,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4638709,CHEMBL233,Mu opioid receptor,Ki,=,499.0,nM,CHEMBL4630061,B,Displacement of [3H]-diprenorphine from human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,CCO[C@@]12Cc3cc(-c4ccccc4)cnc3[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL4761627,CHEMBL233,Mu opioid receptor,Ki,=,696.0,nM,CHEMBL4673764,B,Binding affinity to MOR (unknown origin),CHEMBL4673196,KI,c1ccc2c(c1)CCO[C@@]21CCC[C@H](NCC2CCCCC2)C1
CHEMBL4756310,CHEMBL233,Mu opioid receptor,Ki,=,21.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,CCN1CC2(CCN(CCc3c(F)cccc3F)CC2)O[C@H](C)C1=O
CHEMBL4781352,CHEMBL233,Mu opioid receptor,Ki,=,64.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,CCN1CC2(CCN(CCc3cc(F)ccc3F)CC2)O[C@H](C)C1=O
CHEMBL4777859,CHEMBL233,Mu opioid receptor,Ki,=,62.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,CCN1CC2(CCN(CCc3ccc(F)cc3F)CC2)O[C@H](C)C1=O
CHEMBL4776743,CHEMBL233,Mu opioid receptor,Ki,=,22.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,CCN1CC2(CCN(CCc3cccc(F)c3F)CC2)O[C@H](C)C1=O
CHEMBL4788650,CHEMBL233,Mu opioid receptor,Ki,=,164.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,CCN1CC2(CCN(CCc3ccc(F)cc3)CC2)O[C@H](C)C1=O
CHEMBL4754130,CHEMBL233,Mu opioid receptor,Ki,=,56.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,CCN1CC2(CCN(CCc3cccc(F)c3)CC2)O[C@H](C)C1=O
CHEMBL4776924,CHEMBL233,Mu opioid receptor,Ki,=,18.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,CCN1CC2(CCN(CCc3ccccc3F)CC2)O[C@H](C)C1=O
CHEMBL4741494,CHEMBL233,Mu opioid receptor,Ki,=,26.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,CCN1CC2(CCN(CCc3ccccc3)CC2)O[C@H](C)C1=O
CHEMBL4762816,CHEMBL233,Mu opioid receptor,Ki,=,221.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,CN1CC2(CCN(CCc3ccccc3)CC2)OC2(CC2)C1=O
CHEMBL4755342,CHEMBL233,Mu opioid receptor,Ki,=,115.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,CC(C)C1OC2(CCN(CCc3ccccc3)CC2)CN(C)C1=O
CHEMBL4752386,CHEMBL233,Mu opioid receptor,Ki,=,192.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,CC[C@H]1OC2(CCN(CCc3ccccc3)CC2)CN(C)C1=O
CHEMBL4753006,CHEMBL233,Mu opioid receptor,Ki,=,91.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,C[C@H]1OC2(CCN(CCc3ccccc3)CC2)CN(C)C1=O
CHEMBL4786209,CHEMBL233,Mu opioid receptor,Ki,=,156.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(C)C1=O
CHEMBL4755446,CHEMBL233,Mu opioid receptor,Ki,=,41.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,CCN1CC2(CCN(CCc3ccccc3)CC2)OC(C)C1=O
CHEMBL4759184,CHEMBL233,Mu opioid receptor,Ki,=,33.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(C(C)C)C1=O
CHEMBL4789005,CHEMBL233,Mu opioid receptor,Ki,=,6.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,C[C@H]1OC2(CCN(CCc3ccccc3)CC2)CN(C2CC2)C1=O
CHEMBL4796605,CHEMBL233,Mu opioid receptor,Ki,=,20.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(CCc2ccccc2)C1=O
CHEMBL4748898,CHEMBL233,Mu opioid receptor,Ki,=,2.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(Cc2ccccc2)C1=O
CHEMBL4461774,CHEMBL233,Mu opioid receptor,Ki,=,175.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,O=C1N(c2cccnc2C(F)(F)F)CC2(CCN(CCc3ccccc3F)CC2)OC12CC2
CHEMBL4541206,CHEMBL233,Mu opioid receptor,Ki,=,7.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,CC1OC2(CCN(CCc3ccccc3)CC2)CN(c2ccccc2)C1=O
CHEMBL656,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL4676429,B,Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method,CHEMBL4673253,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314
CHEMBL190461,CHEMBL233,Mu opioid receptor,Ki,=,1300.0,nM,CHEMBL4687692,B,Inhibition of mu-type opioid receptor (unknown origin),CHEMBL4680278,KI,C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O
CHEMBL3408737,CHEMBL233,Mu opioid receptor,Ki,=,0.14,nM,CHEMBL4701855,B,Displacement of [3H]-DAMGO from recombinant human mu opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(N)=O)C1=O
CHEMBL4761165,CHEMBL233,Mu opioid receptor,Ki,=,4.13,nM,CHEMBL4701855,B,Displacement of [3H]-DAMGO from recombinant human mu opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C
CHEMBL4789659,CHEMBL233,Mu opioid receptor,Ki,=,1.32,nM,CHEMBL4701855,B,Displacement of [3H]-DAMGO from recombinant human mu opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4744531,CHEMBL233,Mu opioid receptor,Ki,=,4.89,nM,CHEMBL4701855,B,Displacement of [3H]-DAMGO from recombinant human mu opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4798887,CHEMBL233,Mu opioid receptor,Ki,=,1.11,nM,CHEMBL4701855,B,Displacement of [3H]-DAMGO from recombinant human mu opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CCN1Cc2ccccc2C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C
CHEMBL4758754,CHEMBL233,Mu opioid receptor,Ki,=,7.15,nM,CHEMBL4701855,B,Displacement of [3H]-DAMGO from recombinant human mu opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CCN1Cc2ccccc2C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C
CHEMBL4776986,CHEMBL233,Mu opioid receptor,Ki,=,1.75,nM,CHEMBL4701855,B,Displacement of [3H]-DAMGO from recombinant human mu opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)C[C@H](CCCNC(=N)N)NC(=O)CCN1Cc2ccccc2C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C
CHEMBL4749016,CHEMBL233,Mu opioid receptor,Ki,=,7.12,nM,CHEMBL4701855,B,Displacement of [3H]-DAMGO from recombinant human mu opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)C[C@H](CCCCN)NC(=O)CCN1Cc2ccccc2C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C
CHEMBL4742666,CHEMBL233,Mu opioid receptor,Ki,=,1.67,nM,CHEMBL4701855,B,Displacement of [3H]-DAMGO from recombinant human mu opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N2Cc3ccc(O)cc3C[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4750783,CHEMBL233,Mu opioid receptor,Ki,=,6.24,nM,CHEMBL4701855,B,Displacement of [3H]-DAMGO from recombinant human mu opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N2Cc3ccc(O)cc3C[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4745899,CHEMBL233,Mu opioid receptor,Ki,=,1.73,nM,CHEMBL4701855,B,Displacement of [3H]-DAMGO from recombinant human mu opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc(O)c2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4747286,CHEMBL233,Mu opioid receptor,Ki,=,3.99,nM,CHEMBL4701855,B,Displacement of [3H]-DAMGO from recombinant human mu opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc(O)c2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4750644,CHEMBL233,Mu opioid receptor,Ki,=,4315.0,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(C)=O)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O
CHEMBL4754961,CHEMBL233,Mu opioid receptor,Ki,=,380.0,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O
CHEMBL4787539,CHEMBL233,Mu opioid receptor,Ki,=,1800.0,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](C)Cc1c(C)cc(O)cc1C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL4779988,CHEMBL233,Mu opioid receptor,Ki,=,820.0,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(C)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4754076,CHEMBL233,Mu opioid receptor,Ki,=,1600.0,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](C)Cc1c(C)cc(O)cc1C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4784791,CHEMBL233,Mu opioid receptor,Ki,=,0.94,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4757601,CHEMBL233,Mu opioid receptor,Ki,=,6.3,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL4760958,CHEMBL233,Mu opioid receptor,Ki,=,4.1,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL216640,CHEMBL233,Mu opioid receptor,Ki,=,5.6,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL405618,CHEMBL233,Mu opioid receptor,Ki,=,8.0,nM,CHEMBL4719713,B,Displacement of [3H]diprenorphine from human MOR expressed in mouse NG108-15 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay,CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL100116,CHEMBL233,Mu opioid receptor,Ki,=,3.9,nM,CHEMBL4723559,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL4715859,KI,CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C
CHEMBL4551160,CHEMBL233,Mu opioid receptor,Ki,=,16900.0,nM,CHEMBL4731085,B,Displacement of [3H]-DAMGO from human MOR expressed in HEK293 cells after 60 mins by microbeta counting based assay,CHEMBL4725442,KI,C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1C[C@H]1C[C@@H]1CCNC(=O)c1cc2ccccc2[nH]1
CHEMBL4764883,CHEMBL233,Mu opioid receptor,Ki,=,739.0,nM,CHEMBL4731085,B,Displacement of [3H]-DAMGO from human MOR expressed in HEK293 cells after 60 mins by microbeta counting based assay,CHEMBL4725442,KI,C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1CC(O)CCNC(=O)c1cc2ccccc2[nH]1
CHEMBL4744811,CHEMBL233,Mu opioid receptor,Ki,=,21900.0,nM,CHEMBL4731085,B,Displacement of [3H]-DAMGO from human MOR expressed in HEK293 cells after 60 mins by microbeta counting based assay,CHEMBL4725442,KI,C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1CC[C@H]1CC[C@H](NC(=O)c2cc3ccccc3[nH]2)CC1
CHEMBL4791884,CHEMBL233,Mu opioid receptor,Ki,=,12300.0,nM,CHEMBL4731085,B,Displacement of [3H]-DAMGO from human MOR expressed in HEK293 cells after 60 mins by microbeta counting based assay,CHEMBL4725442,KI,O=C(NCCCCN1CCO[C@@H]2c3cc(O)ccc3OC[C@@H]21)c1cc2ccccc2[nH]1
CHEMBL4778398,CHEMBL233,Mu opioid receptor,Ki,=,12400.0,nM,CHEMBL4731085,B,Displacement of [3H]-DAMGO from human MOR expressed in HEK293 cells after 60 mins by microbeta counting based assay,CHEMBL4725442,KI,O=C(NCCCCN1CCO[C@H]2c3cc(O)ccc3OC[C@@H]21)c1cc2ccccc2[nH]1
CHEMBL97424,CHEMBL233,Mu opioid receptor,Ki,=,77900.0,nM,CHEMBL4731085,B,Displacement of [3H]-DAMGO from human MOR expressed in HEK293 cells after 60 mins by microbeta counting based assay,CHEMBL4725442,KI,CCCN1CCO[C@H]2c3cc(O)ccc3OC[C@@H]21
CHEMBL70565,CHEMBL233,Mu opioid receptor,Ki,=,36600.0,nM,CHEMBL4731085,B,Displacement of [3H]-DAMGO from human MOR expressed in HEK293 cells after 60 mins by microbeta counting based assay,CHEMBL4725442,KI,CCCN1CCO[C@@H]2c3cc(O)ccc3OC[C@H]21
CHEMBL4751700,CHEMBL233,Mu opioid receptor,Ki,=,1330.0,nM,CHEMBL4736325,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL4732147,KI,CN1Cc2ccccc2CN2CC[C@@]1(c1ccccc1)C2
CHEMBL4788719,CHEMBL233,Mu opioid receptor,Ki,=,3.7,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCN1CCC(Cc2ccccc2)CC1)c1ccccc1
CHEMBL4797982,CHEMBL233,Mu opioid receptor,Ki,=,20.4,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCN1CCC(Cc2ccccc2)CC1)c1ccc(OC)cc1
CHEMBL4778918,CHEMBL233,Mu opioid receptor,Ki,=,16.7,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCN1CCC(Cc2ccccc2)CC1)c1ccc(C)cc1
CHEMBL4785048,CHEMBL233,Mu opioid receptor,Ki,=,19.4,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCN1CCC(Cc2ccccc2)CC1)c1ccc(F)cc1
CHEMBL4790216,CHEMBL233,Mu opioid receptor,Ki,=,238.0,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCN1CCC(Cc2ccccc2)CC1)c1ccccn1
CHEMBL4783373,CHEMBL233,Mu opioid receptor,Ki,=,253.0,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCN1CCC(Cc2ccccc2)CC1)c1ncccc1F
CHEMBL4797585,CHEMBL233,Mu opioid receptor,Ki,=,694.0,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCN1CCC(Cc2ccccc2)CC1)C(C)c1ccccc1
CHEMBL4792467,CHEMBL233,Mu opioid receptor,Ki,=,573.0,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCN1CCC(Cc2ccccc2)CC1)Cc1ccccc1
CHEMBL4797005,CHEMBL233,Mu opioid receptor,Ki,=,43.0,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCCN1CCC(Cc2ccccc2)CC1)c1ccc(OC)cc1
CHEMBL4777042,CHEMBL233,Mu opioid receptor,Ki,=,78.0,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCCCN1CCC(Cc2ccccc2)CC1)c1ccc(OC)cc1
CHEMBL4779284,CHEMBL233,Mu opioid receptor,Ki,=,165.0,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCCCCN1CCC(Cc2ccccc2)CC1)c1ccc(OC)cc1
CHEMBL4783182,CHEMBL233,Mu opioid receptor,Ki,=,26.0,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCN1CCC(c2ccccc2)CC1)c1ccc(OC)cc1
CHEMBL4777040,CHEMBL233,Mu opioid receptor,Ki,=,82.0,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCN1CCC(CCc2ccccc2)CC1)c1ccc(OC)cc1
CHEMBL4787348,CHEMBL233,Mu opioid receptor,Ki,=,74.0,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCN1CCC(CCCc2ccccc2)CC1)c1ccc(OC)cc1
CHEMBL4790304,CHEMBL233,Mu opioid receptor,Ki,=,77.0,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCN1CCC(Cc2ccc(C)cc2)CC1)c1ccc(OC)cc1
CHEMBL4789321,CHEMBL233,Mu opioid receptor,Ki,=,2.1,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(OC)cc1
CHEMBL4788466,CHEMBL233,Mu opioid receptor,Ki,=,82.0,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCN1CCC(Cc2ccc(C)cc2)CC1)c1ccc(C)cc1
CHEMBL4789528,CHEMBL233,Mu opioid receptor,Ki,=,27.9,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(C)cc1
CHEMBL4792476,CHEMBL233,Mu opioid receptor,Ki,=,148.0,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCN1CCC(Cc2ccc(C)cc2)CC1)c1ccc(F)cc1
CHEMBL4776178,CHEMBL233,Mu opioid receptor,Ki,=,5.6,nM,CHEMBL4768236,B,Displacement of [3H]-diprenorphin from human mu opioid receptor expressed in CHO cell membrane incubated for 150 mins by liquid scintillation counting method,CHEMBL4765270,KI,CCC(=O)N(CCN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(F)cc1
CHEMBL1909424,CHEMBL233,Mu opioid receptor,Ki,=,16.4,nM,CHEMBL4808365,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells incubated for 120 mins by radiometric scintillation analysis,CHEMBL4808166,KI,CC[C@@H]1CN2CC[C@@]3(C(=O)Nc4ccccc43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL1909423,CHEMBL233,Mu opioid receptor,Ki,=,109.8,nM,CHEMBL4808365,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells incubated for 120 mins by radiometric scintillation analysis,CHEMBL4808166,KI,CC[C@@H]1CN2CC[C@]3(C(=O)Nc4ccccc43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4852167,CHEMBL233,Mu opioid receptor,Ki,=,789.4,nM,CHEMBL4808365,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells incubated for 120 mins by radiometric scintillation analysis,CHEMBL4808166,KI,CC[C@@H]1CN2CC[C@@]3(C(=O)Nc4cccc(O)c43)[C@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4864537,CHEMBL233,Mu opioid receptor,Ki,=,1715.9,nM,CHEMBL4808365,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells incubated for 120 mins by radiometric scintillation analysis,CHEMBL4808166,KI,CC[C@@H]1CN2CC[C@]3(C(=O)Nc4cccc(OC)c43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL60533,CHEMBL233,Mu opioid receptor,Ki,=,1910.0,nM,CHEMBL4808365,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells incubated for 120 mins by radiometric scintillation analysis,CHEMBL4808166,KI,CC[C@@H]1CN2CCc3c([nH]c4ccccc34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL299031,CHEMBL233,Mu opioid receptor,Ki,=,161.0,nM,CHEMBL4808365,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells incubated for 120 mins by radiometric scintillation analysis,CHEMBL4808166,KI,CC[C@@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4859858,CHEMBL233,Mu opioid receptor,Ki,=,728.0,nM,CHEMBL4808365,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells incubated for 120 mins by radiometric scintillation analysis,CHEMBL4808166,KI,CC[C@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4848517,CHEMBL233,Mu opioid receptor,Ki,=,410.0,nM,CHEMBL4808365,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells incubated for 120 mins by radiometric scintillation analysis,CHEMBL4808166,KI,C=C[C@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4546925,CHEMBL233,Mu opioid receptor,Ki,=,54.5,nM,CHEMBL4808365,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells incubated for 120 mins by radiometric scintillation analysis,CHEMBL4808166,KI,CC[C@@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4865995,CHEMBL233,Mu opioid receptor,Ki,=,552.7,nM,CHEMBL4808365,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells incubated for 120 mins by radiometric scintillation analysis,CHEMBL4808166,KI,CC[C@@H]1C[N+]2([O-])CCc3c([nH]c4cccc(OC)c34)[C@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,0.403,nM,CHEMBL4808365,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells incubated for 120 mins by radiometric scintillation analysis,CHEMBL4808166,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,4.19,nM,CHEMBL4808365,B,Displacement of [3H]DAMGO from human recombinant mu opioid receptor expressed in HEK293 cells incubated for 120 mins by radiometric scintillation analysis,CHEMBL4808166,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL4871880,CHEMBL233,Mu opioid receptor,Ki,=,300.0,nM,CHEMBL4814797,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO-K1 cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2CC[C@@]34c5cc(O)ccc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL4856018,CHEMBL233,Mu opioid receptor,Ki,=,320.0,nM,CHEMBL4814797,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO-K1 cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2[C@H]3Cc4c([nH]c5ccccc45)[C@@H]2C[C@@H]1[C@]3(CO)C(=O)OC
CHEMBL4846243,CHEMBL233,Mu opioid receptor,Ki,=,590.0,nM,CHEMBL4814797,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO-K1 cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2CC[C@@]34c5ccccc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL508955,CHEMBL233,Mu opioid receptor,Ki,=,3310.0,nM,CHEMBL4814797,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO-K1 cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2CC[C@]34C(=C(C(=O)OC)[C@H]1C[C@H]23)Nc1ccccc14
CHEMBL4874877,CHEMBL233,Mu opioid receptor,Ki,=,30700.0,nM,CHEMBL4814797,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO-K1 cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2CC[C@]34C(=Nc5ccccc53)[C@@H]2C[C@@H]1[C@@]4(COC(C)=O)C(=O)OC
CHEMBL4852987,CHEMBL233,Mu opioid receptor,Ki,=,132000.0,nM,CHEMBL4814797,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO-K1 cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2[C@@H]3C[C@@]45c6ccccc6N[C@]4(O3)[C@@H]2C[C@@H]1[C@@]5(COC(C)=O)C(=O)OC
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,0.35,nM,CHEMBL4814797,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO-K1 cells by radioligand binding assay,CHEMBL4813924,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL4871880,CHEMBL233,Mu opioid receptor,Ki,=,316.23,nM,CHEMBL4814797,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO-K1 cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2CC[C@@]34c5cc(O)ccc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL4856018,CHEMBL233,Mu opioid receptor,Ki,=,316.23,nM,CHEMBL4814797,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO-K1 cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2[C@H]3Cc4c([nH]c5ccccc45)[C@@H]2C[C@@H]1[C@]3(CO)C(=O)OC
CHEMBL4846243,CHEMBL233,Mu opioid receptor,Ki,=,630.96,nM,CHEMBL4814797,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO-K1 cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2CC[C@@]34c5ccccc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL508955,CHEMBL233,Mu opioid receptor,Ki,=,3162.28,nM,CHEMBL4814797,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO-K1 cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2CC[C@]34C(=C(C(=O)OC)[C@H]1C[C@H]23)Nc1ccccc14
CHEMBL4874877,CHEMBL233,Mu opioid receptor,Ki,=,31622.78,nM,CHEMBL4814797,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO-K1 cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2CC[C@]34C(=Nc5ccccc53)[C@@H]2C[C@@H]1[C@@]4(COC(C)=O)C(=O)OC
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,0.3162,nM,CHEMBL4814797,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO-K1 cells by radioligand binding assay,CHEMBL4813924,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL4878281,CHEMBL233,Mu opioid receptor,Ki,=,0.32,nM,CHEMBL4817892,B,Displacement of [3H]-naloxone from mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by competitive radioligand binding assay,CHEMBL4814025,KI,Cl.O=C(N[C@@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1n[nH]c2ccccc12
CHEMBL4852470,CHEMBL233,Mu opioid receptor,Ki,=,0.41,nM,CHEMBL4817892,B,Displacement of [3H]-naloxone from mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by competitive radioligand binding assay,CHEMBL4814025,KI,Cl.O=C(N[C@@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1c[nH]c2cccnc12
CHEMBL4864454,CHEMBL233,Mu opioid receptor,Ki,=,0.94,nM,CHEMBL4817892,B,Displacement of [3H]-naloxone from mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by competitive radioligand binding assay,CHEMBL4814025,KI,Cl.O=C(N[C@@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1c[nH]c2ccncc12
CHEMBL4878105,CHEMBL233,Mu opioid receptor,Ki,=,0.56,nM,CHEMBL4817892,B,Displacement of [3H]-naloxone from mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by competitive radioligand binding assay,CHEMBL4814025,KI,Cl.O=C(N[C@@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1c[nH]c2cnccc12
CHEMBL4874437,CHEMBL233,Mu opioid receptor,Ki,=,0.28,nM,CHEMBL4817892,B,Displacement of [3H]-naloxone from mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by competitive radioligand binding assay,CHEMBL4814025,KI,Cl.O=C(N[C@@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1c[nH]c2ncccc12
CHEMBL4862035,CHEMBL233,Mu opioid receptor,Ki,=,0.33,nM,CHEMBL4817892,B,Displacement of [3H]-naloxone from mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by competitive radioligand binding assay,CHEMBL4814025,KI,Cl.O=C(N[C@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1n[nH]c2ccccc12
CHEMBL4875882,CHEMBL233,Mu opioid receptor,Ki,=,0.56,nM,CHEMBL4817892,B,Displacement of [3H]-naloxone from mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by competitive radioligand binding assay,CHEMBL4814025,KI,Cl.O=C(N[C@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1c[nH]c2cccnc12
CHEMBL4868660,CHEMBL233,Mu opioid receptor,Ki,=,0.7,nM,CHEMBL4817892,B,Displacement of [3H]-naloxone from mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by competitive radioligand binding assay,CHEMBL4814025,KI,Cl.O=C(N[C@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1c[nH]c2ccncc12
CHEMBL4879114,CHEMBL233,Mu opioid receptor,Ki,=,1.16,nM,CHEMBL4817892,B,Displacement of [3H]-naloxone from mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by competitive radioligand binding assay,CHEMBL4814025,KI,Cl.O=C(N[C@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1c[nH]c2cnccc12
CHEMBL4866007,CHEMBL233,Mu opioid receptor,Ki,=,1.14,nM,CHEMBL4817892,B,Displacement of [3H]-naloxone from mu opioid receptor (unknown origin) expressed in CHO cell membranes incubated for 1 hr by competitive radioligand binding assay,CHEMBL4814025,KI,Cl.O=C(N[C@H]1C=C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1c[nH]c2ncccc12
CHEMBL4857492,CHEMBL233,Mu opioid receptor,Ki,=,4200.0,nM,CHEMBL4818339,B,Inhibition of mu opioid receptor (unknown origin),CHEMBL4814049,KI,O=C(O)c1ccc(C#Cc2ccc3c(c2)C=C([N+](=O)[O-])C(C(F)(F)F)O3)cc1
CHEMBL4864739,CHEMBL233,Mu opioid receptor,Ki,=,157.0,nM,CHEMBL4825614,B,Binding affinity to mu opioid receptor (unknown origin),CHEMBL4823330,KI,CCC[C@H](c1nc2ccc(Br)cc2c(=O)n1CC)N1CCN[C@@H](C)C1
CHEMBL80,CHEMBL233,Mu opioid receptor,Ki,=,1.0,nM,CHEMBL4837564,B,Binding affinity to mu-opioid receptor (unknown origin),CHEMBL4837182,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL4867565,CHEMBL233,Mu opioid receptor,Ki,=,2880.0,nM,CHEMBL4844555,B,Binding affinity to human mu opioid receptor,CHEMBL4842371,KI,O=S(=O)(c1cccc(F)c1)n1ccc2c(N3CCNCC3)nc3ccccc3c21
CHEMBL4513786,CHEMBL233,Mu opioid receptor,Ki,=,2781.0,nM,CHEMBL4880042,B,GPCRScan assay: inhibition of MOR,CHEMBL4507258,KI,CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC
CHEMBL4513786,CHEMBL233,Mu opioid receptor,Ki,=,2754.23,nM,CHEMBL4880042,B,GPCRScan assay: inhibition of MOR,CHEMBL4507258,KI,CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC
CHEMBL4526351,CHEMBL233,Mu opioid receptor,Ki,=,6987.0,nM,CHEMBL4880042,B,GPCRScan assay: inhibition of MOR,CHEMBL4507270,KI,Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1
CHEMBL4526351,CHEMBL233,Mu opioid receptor,Ki,=,6918.31,nM,CHEMBL4880042,B,GPCRScan assay: inhibition of MOR,CHEMBL4507270,KI,Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1
CHEMBL4520788,CHEMBL233,Mu opioid receptor,Ki,=,854.25,nM,CHEMBL4880042,B,GPCRScan assay: inhibition of MOR,CHEMBL4507273,KI,CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1
CHEMBL4520788,CHEMBL233,Mu opioid receptor,Ki,=,758.58,nM,CHEMBL4880042,B,GPCRScan assay: inhibition of MOR,CHEMBL4507273,KI,CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1
CHEMBL3480577,CHEMBL233,Mu opioid receptor,Ki,=,10000.0,nM,CHEMBL4880042,B,GPCRScan assay: inhibition of MOR,CHEMBL4507309,KI,Cc1ccc2nc(CNCCCOc3ccccc3)cc(O)c2c1
CHEMBL3480577,CHEMBL233,Mu opioid receptor,Ki,=,1000000000.0,nM,CHEMBL4880042,B,GPCRScan assay: inhibition of MOR,CHEMBL4507309,KI,Cc1ccc2nc(CNCCCOc3ccccc3)cc(O)c2c1
CHEMBL5086786,CHEMBL233,Mu opioid receptor,Ki,=,15.0,nM,CHEMBL5031789,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells at 10 uM,CHEMBL5030540,KI,CC[C@@H]1CN2CC[C@@]3(O)C(=Nc4cccc(-c5ccccc5)c43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL5074977,CHEMBL233,Mu opioid receptor,Ki,=,15.0,nM,CHEMBL5031789,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells at 10 uM,CHEMBL5030540,KI,CC[C@@H]1CN2CC[C@@]3(O)C(=Nc4cccc(C)c43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL5071286,CHEMBL233,Mu opioid receptor,Ki,=,6.0,nM,CHEMBL5031789,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells at 10 uM,CHEMBL5030540,KI,CC[C@@H]1CN2CC[C@@]3(O)C(=Nc4cccc(-c5ccoc5)c43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL656,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314
CHEMBL5082661,CHEMBL233,Mu opioid receptor,Ki,=,297.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CN1CCN(C2(CNC(=O)C(C)(c3ccccc3)c3ccccc3)CCCCC2)CC1
CHEMBL5085710,CHEMBL233,Mu opioid receptor,Ki,=,1005.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CN1CCN(C2(CNC(=O)c3ccccc3Oc3ccccc3)CCCCC2)CC1
CHEMBL5077829,CHEMBL233,Mu opioid receptor,Ki,=,43.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CCCCC1)c1ccccc1
CHEMBL5076707,CHEMBL233,Mu opioid receptor,Ki,=,212.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CCN1CCN(Cc2ccccc2)CC1)c1ccccc1
CHEMBL5084697,CHEMBL233,Mu opioid receptor,Ki,=,95.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC(C)(C)N1CCN(Cc2ccccc2)CC1)c1ccccc1
CHEMBL5087472,CHEMBL233,Mu opioid receptor,Ki,=,2.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1ccccc1
CHEMBL5070185,CHEMBL233,Mu opioid receptor,Ki,=,72.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,COCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1ccccc1
CHEMBL5094913,CHEMBL233,Mu opioid receptor,Ki,=,437.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(Cc1ccccc1)CC1(N2CCN(Cc3ccccc3)CC2)CC1
CHEMBL5089489,CHEMBL233,Mu opioid receptor,Ki,=,9.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1ccccc1O
CHEMBL5075502,CHEMBL233,Mu opioid receptor,Ki,=,9.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1ccccc1F
CHEMBL5094899,CHEMBL233,Mu opioid receptor,Ki,=,28.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1cccc(F)c1
CHEMBL5076404,CHEMBL233,Mu opioid receptor,Ki,=,8.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1ccccn1
CHEMBL5083736,CHEMBL233,Mu opioid receptor,Ki,=,33.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1ncccc1F
CHEMBL5073189,CHEMBL233,Mu opioid receptor,Ki,=,32.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1ncccc1C(F)(F)F
CHEMBL5081133,CHEMBL233,Mu opioid receptor,Ki,=,6.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CC1)c1cccc(C(F)(F)F)n1
CHEMBL5081183,CHEMBL233,Mu opioid receptor,Ki,=,452.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CCN(C)CC1)c1ccccc1
CHEMBL5080086,CHEMBL233,Mu opioid receptor,Ki,=,107.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)COC1)c1ccccc1
CHEMBL5070613,CHEMBL233,Mu opioid receptor,Ki,=,14.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CCOCC1)c1ccccc1
CHEMBL5084344,CHEMBL233,Mu opioid receptor,Ki,=,5.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CCOCC1)c1cccc(C(F)(F)F)n1
CHEMBL5089000,CHEMBL233,Mu opioid receptor,Ki,=,6.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CCSCC1)c1cccc(C(F)(F)F)n1
CHEMBL5090595,CHEMBL233,Mu opioid receptor,Ki,=,37.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(Cc3ccccc3)CC2)CCOC(C)(C)C1)c1cccc(C(F)(F)F)n1
CHEMBL5089365,CHEMBL233,Mu opioid receptor,Ki,=,82.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(C2CCN(Cc3ccccc3)CC2)CCOCC1)c1cccc(C(F)(F)F)n1
CHEMBL5082031,CHEMBL233,Mu opioid receptor,Ki,=,209.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCNCC2)CCOCC1)c1cccc(C(F)(F)F)n1
CHEMBL5079816,CHEMBL233,Mu opioid receptor,Ki,=,19.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(CCc3ccccc3)CC2)CCOCC1)c1cccc(C(F)(F)F)n1
CHEMBL5085771,CHEMBL233,Mu opioid receptor,Ki,=,83.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(C(C)c3ccccc3)CC2)CCOCC1)c1cccc(C(F)(F)F)n1
CHEMBL5093833,CHEMBL233,Mu opioid receptor,Ki,=,171.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(C(CO)c3ccccc3)CC2)CCOCC1)c1cccc(C(F)(F)F)n1
CHEMBL5078587,CHEMBL233,Mu opioid receptor,Ki,=,65.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(CC(O)c3ccccc3)CC2)CCOCC1)c1cccc(C(F)(F)F)n1
CHEMBL5093051,CHEMBL233,Mu opioid receptor,Ki,=,220.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCCN1CCN(C2(CN(C(=O)CC)c3cccc(C(F)(F)F)n3)CCOCC2)CC1
CHEMBL5083271,CHEMBL233,Mu opioid receptor,Ki,=,73.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCCCN1CCN(C2(CN(C(=O)CC)c3cccc(C(F)(F)F)n3)CCOCC2)CC1
CHEMBL5086571,CHEMBL233,Mu opioid receptor,Ki,=,251.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(CC(C)C)CC2)CCOCC1)c1cccc(C(F)(F)F)n1
CHEMBL5081159,CHEMBL233,Mu opioid receptor,Ki,=,279.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCOC(=O)CCN1CCN(C2(CN(C(=O)CC)c3cccc(C(F)(F)F)n3)CCOCC2)CC1
CHEMBL5079087,CHEMBL233,Mu opioid receptor,Ki,=,754.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(CCOC)CC2)CCOCC1)c1cccc(C(F)(F)F)n1
CHEMBL5089766,CHEMBL233,Mu opioid receptor,Ki,=,28.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(CCOC(C)C)CC2)CCOCC1)c1cccc(C(F)(F)F)n1
CHEMBL5090993,CHEMBL233,Mu opioid receptor,Ki,=,168.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCOCCN1CCN(C2(CN(C(=O)CC)c3cccc(C(F)(F)F)n3)CCOCC2)CC1
CHEMBL5087458,CHEMBL233,Mu opioid receptor,Ki,=,49.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(CCOCC(C)C)CC2)CCOCC1)c1cccc(C(F)(F)F)n1
CHEMBL5092587,CHEMBL233,Mu opioid receptor,Ki,=,46.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(CCOc3ccccc3)CC2)CCOCC1)c1cccc(C(F)(F)F)n1
CHEMBL5084395,CHEMBL233,Mu opioid receptor,Ki,=,157.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(CCOCC(F)(F)F)CC2)CCOCC1)c1cccc(C(F)(F)F)n1
CHEMBL5080761,CHEMBL233,Mu opioid receptor,Ki,=,137.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCCOCCN1CCN(C2(CN(C(=O)CC)c3cccc(C(F)(F)F)n3)CCOCC2)CC1
CHEMBL5091094,CHEMBL233,Mu opioid receptor,Ki,=,267.0,nM,CHEMBL5033452,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method,CHEMBL5032513,KI,CCC(=O)N(CC1(N2CCN(CCCOC)CC2)CCOCC1)c1cccc(C(F)(F)F)n1
CHEMBL2443262,CHEMBL233,Mu opioid receptor,Ki,=,1.456,nM,CHEMBL5043397,B,Displacement of [3H]-Diprenorphine from human mu opiod receptor expressed in CHO cells incubated for 1 hr by competition binding assay,CHEMBL5042488,KI,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,0.64,nM,CHEMBL5043397,B,Displacement of [3H]-Diprenorphine from human mu opiod receptor expressed in CHO cells incubated for 1 hr by competition binding assay,CHEMBL5042488,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL5083403,CHEMBL233,Mu opioid receptor,Ki,=,0.514,nM,CHEMBL5043397,B,Displacement of [3H]-Diprenorphine from human mu opiod receptor expressed in CHO cells incubated for 1 hr by competition binding assay,CHEMBL5042488,KI,Fc1ccc([C@]2(CCNCc3cccc(Cl)c3)CCO[C@]3(CCOC3)C2)nc1
CHEMBL596,CHEMBL233,Mu opioid receptor,Ki,=,5.23,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL841,CHEMBL233,Mu opioid receptor,Ki,=,0.268,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
CHEMBL1201294,CHEMBL233,Mu opioid receptor,Ki,=,12.37,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1
CHEMBL54,CHEMBL233,Mu opioid receptor,Ki,=,2470.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
CHEMBL651,CHEMBL233,Mu opioid receptor,Ki,=,13.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1
CHEMBL5090346,CHEMBL233,Mu opioid receptor,Ki,=,1170.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,N#CC(CCNCCc1ccccc1)(c1ccccc1)c1ccccc1
CHEMBL5079903,CHEMBL233,Mu opioid receptor,Ki,=,266.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,N#CC(CCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1
CHEMBL5089655,CHEMBL233,Mu opioid receptor,Ki,=,490.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,N#CC(CCNCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1
CHEMBL5073904,CHEMBL233,Mu opioid receptor,Ki,=,63.5,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,N#CC(CCNCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1
CHEMBL346898,CHEMBL233,Mu opioid receptor,Ki,=,3910.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CN(C)CCC(C#N)(c1ccccc1)c1ccccc1
CHEMBL5093200,CHEMBL233,Mu opioid receptor,Ki,=,1470.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CN(C)CCC(C(=O)NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1
CHEMBL346331,CHEMBL233,Mu opioid receptor,Ki,=,35.9,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCC(=O)C(CCN(C)C)(c1ccccc1)c1ccccc1
CHEMBL5077104,CHEMBL233,Mu opioid receptor,Ki,=,60.8,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,N#CC(CCNCCCCC(=O)N1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1
CHEMBL5094044,CHEMBL233,Mu opioid receptor,Ki,=,649.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CN(C)CCC(C(=O)N(C)C)(c1ccccc1)c1ccccc1
CHEMBL5085974,CHEMBL233,Mu opioid receptor,Ki,=,0.832,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CN(C)C(=O)C(CCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1
CHEMBL5084145,CHEMBL233,Mu opioid receptor,Ki,=,18.2,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CN(C)C(=O)C(CCN1CCc2ccc(C#N)cc2C1)(c1ccccc1)c1ccccc1
CHEMBL5070377,CHEMBL233,Mu opioid receptor,Ki,=,50.4,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CN(C)C(=O)C(CCNCCc1ccccc1)(c1ccccc1)c1ccccc1
CHEMBL5073754,CHEMBL233,Mu opioid receptor,Ki,=,23.8,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CN(C)C(=O)C(CCNCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1
CHEMBL5087543,CHEMBL233,Mu opioid receptor,Ki,=,58.8,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CN(C)C(=O)C(CCNCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1
CHEMBL5088070,CHEMBL233,Mu opioid receptor,Ki,=,0.842,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCc1cccc(N2CCN(CCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CC2)c1Cl
CHEMBL5074399,CHEMBL233,Mu opioid receptor,Ki,=,264.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCc1cccc(N2CCN(CCCCNCCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CC2)c1Cl
CHEMBL5071238,CHEMBL233,Mu opioid receptor,Ki,=,330.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCc1cccc(N2CCN(CC(O)CCNCCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CC2)c1Cl
CHEMBL5090215,CHEMBL233,Mu opioid receptor,Ki,=,150.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CN(C)C(=O)C(CCNCCCCN1CCc2ccc(C#N)cc2C1)(c1ccccc1)c1ccccc1
CHEMBL5091656,CHEMBL233,Mu opioid receptor,Ki,=,11100.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2CCC(C#N)(c2ccccc2)c2ccccc2)c1O
CHEMBL5089932,CHEMBL233,Mu opioid receptor,Ki,=,866.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2CCCCNCCC(C(=O)N(C)C)(c2ccccc2)c2ccccc2)c1O
CHEMBL5075990,CHEMBL233,Mu opioid receptor,Ki,=,106.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCc1cc(Cl)c(OC)c(C(=O)NCC2CCCN2CCCCNCCC(C(=O)N(C)C)(c2ccccc2)c2ccccc2)c1O
CHEMBL5091479,CHEMBL233,Mu opioid receptor,Ki,=,8500.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CN1CCC(c2ccccc2)(c2ccccc2)C1
CHEMBL5094927,CHEMBL233,Mu opioid receptor,Ki,=,15000.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCC(=O)N1CCC(c2ccccc2)(c2ccccc2)C1
CHEMBL5079053,CHEMBL233,Mu opioid receptor,Ki,=,14200.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCc1cc(Cl)c(OC)c(C(=O)NCC2CCCN2CC(=O)N2CCC(c3ccccc3)(c3ccccc3)C2)c1O
CHEMBL5081136,CHEMBL233,Mu opioid receptor,Ki,=,559.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2C[C@@H](OCCCCNCCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CN2)c1O
CHEMBL5076359,CHEMBL233,Mu opioid receptor,Ki,=,10100.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,COc1cccc(C(=CCNCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c2cccc(OC)c2)c1
CHEMBL5087504,CHEMBL233,Mu opioid receptor,Ki,=,213.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,Oc1cccc(C(CCNCCCCN2CCN(c3ccccc3)CC2)c2cccc(O)c2)c1
CHEMBL5092243,CHEMBL233,Mu opioid receptor,Ki,=,3880.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCc1cccc(N2CCN(CCC(c3cccc(OC)c3)c3cccc(OC)c3)CC2)c1Cl
CHEMBL5083473,CHEMBL233,Mu opioid receptor,Ki,=,238.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCc1cccc(N2CCN(CCC(c3cccc(O)c3)c3cccc(OC)c3)CC2)c1Cl
CHEMBL5083441,CHEMBL233,Mu opioid receptor,Ki,=,327.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCc1cccc(N2CCN(CCC(c3cccc(O)c3)c3cccc(O)c3)CC2)c1Cl
CHEMBL5080654,CHEMBL233,Mu opioid receptor,Ki,=,0.633,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCc1ccccc1
CHEMBL5077645,CHEMBL233,Mu opioid receptor,Ki,=,0.377,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,Oc1cccc([C@@]23CCC[C@@H]([C@H]2O)N(C/C=C/c2ccccc2)CC3)c1
CHEMBL5087408,CHEMBL233,Mu opioid receptor,Ki,=,474.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2
CHEMBL5082465,CHEMBL233,Mu opioid receptor,Ki,=,57.2,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCCCNC(=O)c1cc2ccccc2[nH]1
CHEMBL5083186,CHEMBL233,Mu opioid receptor,Ki,=,19.7,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CC1CC1CCNC(=O)c1cc2ccccc2[nH]1
CHEMBL5077114,CHEMBL233,Mu opioid receptor,Ki,=,13.5,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2C[C@H]1C[C@@H]1CCNC(=O)c1cc2ccccc2[nH]1
CHEMBL5086564,CHEMBL233,Mu opioid receptor,Ki,=,56.2,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2C[C@@H]1C[C@H]1CCNC(=O)c1cc2ccccc2[nH]1
CHEMBL5091775,CHEMBL233,Mu opioid receptor,Ki,=,3200.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,Oc1cccc([C@]23CCC[C@H](NCC2)[C@@H]3O)c1
CHEMBL5091335,CHEMBL233,Mu opioid receptor,Ki,=,172.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,Oc1cccc([C@]23CCC[C@H](NCC2)[C@H]3O)c1
CHEMBL5075014,CHEMBL233,Mu opioid receptor,Ki,=,988.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,O=C(NCCCCN1CC[C@]2(c3cccc(O)c3)CCC[C@H]1[C@@H]2O)c1cc2ccccc2[nH]1
CHEMBL5072449,CHEMBL233,Mu opioid receptor,Ki,=,464.0,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,O=C(NCCCCN1CC[C@]2(c3cccc(O)c3)CCC[C@H]1[C@H]2O)c1cc2ccccc2[nH]1
CHEMBL5075726,CHEMBL233,Mu opioid receptor,Ki,=,92.7,nM,CHEMBL5046487,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in HEK293 cell membrane incubated for 60 mins by radioligand binding assay,CHEMBL5046218,KI,CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCN1CCN(c2cccc(Cl)c2Cl)CC1
CHEMBL1186579,CHEMBL233,Mu opioid receptor,Ki,=,5.5,nM,CHEMBL5049526,B,Displacement of [3H]-DAMGO from human recombinant mu opioid receptor by radioligand binding assay,CHEMBL5046294,KI,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL5075588,CHEMBL233,Mu opioid receptor,Ki,=,657.0,nM,CHEMBL5055735,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@H]1Cc2cccc(c2)OC/C=C/COc2ccc(cc2)C[C@@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL5072730,CHEMBL233,Mu opioid receptor,Ki,=,501.0,nM,CHEMBL5055735,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@H]1Cc2ccc(cc2)OC/C=C/COc2cccc(c2)C[C@@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL5074966,CHEMBL233,Mu opioid receptor,Ki,=,1430.0,nM,CHEMBL5055735,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@H]1Cc2ccc(cc2)OC/C=C/COc2ccc(cc2)C[C@@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL5069790,CHEMBL233,Mu opioid receptor,Ki,=,828.0,nM,CHEMBL5055735,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1Cc2cccc(c2)OC/C=C\COc2cccc(c2)C[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL5090249,CHEMBL233,Mu opioid receptor,Ki,=,1960.0,nM,CHEMBL5055735,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1Cc2cccc(c2)OC/C=C/COc2ccc(cc2)C[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL5076268,CHEMBL233,Mu opioid receptor,Ki,=,607.0,nM,CHEMBL5055735,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1Cc2ccc(cc2)OC/C=C/COc2cccc(c2)C[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL5086984,CHEMBL233,Mu opioid receptor,Ki,=,1370.0,nM,CHEMBL5055735,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1Cc2ccc(cc2)OC/C=C/COc2ccc(cc2)C[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL5077286,CHEMBL233,Mu opioid receptor,Ki,=,1630.0,nM,CHEMBL5055735,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@H]1Cc2cccc(c2)OC/C=C/COc2cccc(c2)C[C@@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL4290635,CHEMBL233,Mu opioid receptor,Ki,=,1740.0,nM,CHEMBL5055735,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL5089230,CHEMBL233,Mu opioid receptor,Ki,=,1220.0,nM,CHEMBL5055735,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,C=CCOc1ccc(C[C@H](NC(=O)[C@H](Cc2ccccc2)NC(C)=O)C(=O)N[C@@H](Cc2ccc(OCC=C)cc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)cc1
CHEMBL5086931,CHEMBL233,Mu opioid receptor,Ki,=,1380.0,nM,CHEMBL5055735,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,C=CCOc1ccc(C[C@H](NC(=O)[C@H](Cc2ccccc2)NC(C)=O)C(=O)N[C@@H](Cc2cccc(OCC=C)c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)cc1
CHEMBL5080421,CHEMBL233,Mu opioid receptor,Ki,=,1330.0,nM,CHEMBL5055735,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,C=CCOc1ccc(C[C@H](NC(=O)[C@H](Cc2cccc(OCC=C)c2)NC(=O)[C@H](Cc2ccccc2)NC(C)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)cc1
CHEMBL5086847,CHEMBL233,Mu opioid receptor,Ki,=,838.0,nM,CHEMBL5055735,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,C=CCOc1cccc(C[C@H](NC(=O)[C@H](Cc2ccccc2)NC(C)=O)C(=O)N[C@@H](Cc2cccc(OCC=C)c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)c1
CHEMBL5076040,CHEMBL233,Mu opioid receptor,Ki,=,221.0,nM,CHEMBL5055735,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,C=CCOc1ccc(C[C@H](NC(C)=O)C(=O)N[C@@H](Cc2ccc(OCC=C)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)cc1
CHEMBL5070938,CHEMBL233,Mu opioid receptor,Ki,=,490.0,nM,CHEMBL5055735,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,C=CCOc1ccc(C[C@H](NC(C)=O)C(=O)N[C@@H](Cc2cccc(OCC=C)c2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)cc1
CHEMBL5094885,CHEMBL233,Mu opioid receptor,Ki,=,478.0,nM,CHEMBL5055735,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,C=CCOc1ccc(C[C@H](NC(=O)[C@H](Cc2cccc(OCC=C)c2)NC(C)=O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)cc1
CHEMBL5092332,CHEMBL233,Mu opioid receptor,Ki,=,491.0,nM,CHEMBL5055735,B,Displacement of [3H]-DAMGO from mu opioid receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,C=CCOc1cccc(C[C@H](NC(C)=O)C(=O)N[C@@H](Cc2cccc(OCC=C)c2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)c1
CHEMBL4445645,CHEMBL233,Mu opioid receptor,Ki,=,872.47,nM,CHEMBL4880042,B,GPCRScan assay: inhibition of MOR,CHEMBL5058646,KI,C[C@@H]1CN(c2ncc(Cl)c(Nc3ccc4c(c3)n(CCC(C)(C)O)c(=O)n4C)n2)C[C@H](C)C1(F)F
CHEMBL4445645,CHEMBL233,Mu opioid receptor,Ki,=,851.14,nM,CHEMBL4880042,B,GPCRScan assay: inhibition of MOR,CHEMBL5058646,KI,C[C@@H]1CN(c2ncc(Cl)c(Nc3ccc4c(c3)n(CCC(C)(C)O)c(=O)n4C)n2)C[C@H](C)C1(F)F
CHEMBL5174205,CHEMBL233,Mu opioid receptor,Ki,=,7220.0,nM,CHEMBL5100440,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in human HEK293 cell membrane incubated for 90 mins by radioligand binding assay,CHEMBL5096242,KI,Clc1ccc(Nc2nc3ccccc3c3[nH]c([C@@H]4C[C@@H]5CCC[C@@H](C5)C4)nc23)cc1Cl
CHEMBL4531563,CHEMBL233,Mu opioid receptor,Ki,=,42.66,nM,CHEMBL5108092,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane incubated for 90 mins by liquid scintillation counting method,CHEMBL5107935,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL5192115,CHEMBL233,Mu opioid receptor,Ki,=,7.079,nM,CHEMBL5108092,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane incubated for 90 mins by liquid scintillation counting method,CHEMBL5107935,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL5173456,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL5108092,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane incubated for 90 mins by liquid scintillation counting method,CHEMBL5107935,KI,CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1
CHEMBL5198168,CHEMBL233,Mu opioid receptor,Ki,=,19.95,nM,CHEMBL5108092,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane incubated for 90 mins by liquid scintillation counting method,CHEMBL5107935,KI,CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1
CHEMBL5203813,CHEMBL233,Mu opioid receptor,Ki,=,85.11,nM,CHEMBL5108092,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane incubated for 90 mins by liquid scintillation counting method,CHEMBL5107935,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1)C(=O)N(C)C
CHEMBL5172639,CHEMBL233,Mu opioid receptor,Ki,=,26.3,nM,CHEMBL5108092,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane incubated for 90 mins by liquid scintillation counting method,CHEMBL5107935,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1)C(=O)NC1CC1
CHEMBL5177001,CHEMBL233,Mu opioid receptor,Ki,=,371.54,nM,CHEMBL5108092,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane incubated for 90 mins by liquid scintillation counting method,CHEMBL5107935,KI,CCC(=O)N(c1ccccc1)C1CCN(C(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc2ccc(O)cc2)CC1
CHEMBL8234,CHEMBL233,Mu opioid receptor,Ki,=,2.042,nM,CHEMBL5108092,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane incubated for 90 mins by liquid scintillation counting method,CHEMBL5107935,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL4531563,CHEMBL233,Mu opioid receptor,Ki,=,42.7,nM,CHEMBL5108092,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane incubated for 90 mins by liquid scintillation counting method,CHEMBL5107935,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL5192115,CHEMBL233,Mu opioid receptor,Ki,=,7.07,nM,CHEMBL5108092,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane incubated for 90 mins by liquid scintillation counting method,CHEMBL5107935,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL5173456,CHEMBL233,Mu opioid receptor,Ki,=,9.92,nM,CHEMBL5108092,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane incubated for 90 mins by liquid scintillation counting method,CHEMBL5107935,KI,CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1
CHEMBL5198168,CHEMBL233,Mu opioid receptor,Ki,=,20.0,nM,CHEMBL5108092,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane incubated for 90 mins by liquid scintillation counting method,CHEMBL5107935,KI,CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1
CHEMBL5203813,CHEMBL233,Mu opioid receptor,Ki,=,85.4,nM,CHEMBL5108092,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane incubated for 90 mins by liquid scintillation counting method,CHEMBL5107935,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1)C(=O)N(C)C
CHEMBL5172639,CHEMBL233,Mu opioid receptor,Ki,=,26.1,nM,CHEMBL5108092,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane incubated for 90 mins by liquid scintillation counting method,CHEMBL5107935,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1)C(=O)NC1CC1
CHEMBL5177001,CHEMBL233,Mu opioid receptor,Ki,=,368.1,nM,CHEMBL5108092,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane incubated for 90 mins by liquid scintillation counting method,CHEMBL5107935,KI,CCC(=O)N(c1ccccc1)C1CCN(C(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc2ccc(O)cc2)CC1
CHEMBL8234,CHEMBL233,Mu opioid receptor,Ki,=,2.07,nM,CHEMBL5108092,B,Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane incubated for 90 mins by liquid scintillation counting method,CHEMBL5107935,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL172155,CHEMBL233,Mu opioid receptor,Ki,=,572.2,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,CCC(=O)N(c1ccccc1)C1CCN(Cc2ccccc2)CC1
CHEMBL5198980,CHEMBL233,Mu opioid receptor,Ki,=,837.1,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,CCC(=O)N(Cc1ccccc1)C1CCN(Cc2ccccc2)CC1
CHEMBL5182393,CHEMBL233,Mu opioid receptor,Ki,=,1259.4,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,CCC(=O)N(CCc1ccccc1)C1CCN(Cc2ccccc2)CC1
CHEMBL596,CHEMBL233,Mu opioid receptor,Ki,=,3.3,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL5186423,CHEMBL233,Mu opioid receptor,Ki,=,271.3,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,CCC(=O)N(Cc1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL5188409,CHEMBL233,Mu opioid receptor,Ki,=,555.3,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,CCC(=O)N(CCc1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL5208375,CHEMBL233,Mu opioid receptor,Ki,=,224.4,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,CCC(=O)N(Cc1ccc(F)cc1)C1CCN(CCc2ccccc2)CC1
CHEMBL5204271,CHEMBL233,Mu opioid receptor,Ki,=,365.2,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,CCC(=O)N(Cc1ccc(OC)cc1)C1CCN(CCc2ccccc2)CC1
CHEMBL5179620,CHEMBL233,Mu opioid receptor,Ki,=,376.3,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,CCC(=O)N(Cc1ccccc1F)C1CCN(CCc2ccccc2)CC1
CHEMBL5202810,CHEMBL233,Mu opioid receptor,Ki,=,160.0,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,CCC(=O)N(Cc1cccc(F)c1)C1CCN(CCc2ccccc2)CC1
CHEMBL5187144,CHEMBL233,Mu opioid receptor,Ki,=,169.7,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,CCCC(=O)N(Cc1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL5208537,CHEMBL233,Mu opioid receptor,Ki,=,17.3,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,O=C(c1ccco1)N(Cc1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL5169886,CHEMBL233,Mu opioid receptor,Ki,=,453.3,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,O=C(C1CCCC1)N(Cc1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL5187961,CHEMBL233,Mu opioid receptor,Ki,=,64.6,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,O=C(C1CC1)N(Cc1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL5174391,CHEMBL233,Mu opioid receptor,Ki,=,22.3,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,CCCC(=O)N(Cc1ccc(F)cc1)C1CCN(CCc2ccccc2)CC1
CHEMBL5183712,CHEMBL233,Mu opioid receptor,Ki,=,7.9,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,O=C(c1ccco1)N(Cc1ccc(F)cc1)C1CCN(CCc2ccccc2)CC1
CHEMBL5187189,CHEMBL233,Mu opioid receptor,Ki,=,237.5,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,COCC(=O)N(Cc1ccc(F)cc1)C1CCN(CCc2ccccc2)CC1
CHEMBL5190421,CHEMBL233,Mu opioid receptor,Ki,=,58.5,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,CCCC(=O)N(Cc1cccc(F)c1)C1CCN(CCc2ccccc2)CC1
CHEMBL5179132,CHEMBL233,Mu opioid receptor,Ki,=,6.5,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,O=C(c1ccco1)N(Cc1cccc(F)c1)C1CCN(CCc2ccccc2)CC1
CHEMBL5179531,CHEMBL233,Mu opioid receptor,Ki,=,15.2,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,O=C(c1ccccc1)N(Cc1cccc(F)c1)C1CCN(CCc2ccccc2)CC1
CHEMBL5181914,CHEMBL233,Mu opioid receptor,Ki,=,33.4,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,O=C(c1cccs1)N(Cc1cccc(F)c1)C1CCN(CCc2ccccc2)CC1
CHEMBL5179109,CHEMBL233,Mu opioid receptor,Ki,=,27.0,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,O=C(C1CCCC1)N(Cc1cccc(F)c1)C1CCN(CCc2ccccc2)CC1
CHEMBL5208252,CHEMBL233,Mu opioid receptor,Ki,=,259.1,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,O=C(C1CC1)N(Cc1cccc(F)c1)C1CCN(CCc2ccccc2)CC1
CHEMBL5192862,CHEMBL233,Mu opioid receptor,Ki,=,345.0,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,O=C(c1ccco1)N(Cc1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1
CHEMBL5204518,CHEMBL233,Mu opioid receptor,Ki,=,88.7,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,COc1ccc(CN(C(=O)c2ccco2)C2CCN(CCc3ccccc3)CC2)cc1
CHEMBL5176125,CHEMBL233,Mu opioid receptor,Ki,=,233.0,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,Cc1ccc(CN(C(=O)c2ccco2)C2CCN(CCc3ccccc3)CC2)cc1
CHEMBL5181954,CHEMBL233,Mu opioid receptor,Ki,=,11.5,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,O=C(c1ccco1)N(Cc1ccccc1F)C1CCN(CCc2ccccc2)CC1
CHEMBL5173931,CHEMBL233,Mu opioid receptor,Ki,=,59.0,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,O=C(c1ccco1)N(Cc1ccc(F)cc1F)C1CCN(CCc2ccccc2)CC1
CHEMBL5195239,CHEMBL233,Mu opioid receptor,Ki,=,18.7,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,CC(c1ccccc1)N(C(=O)c1ccco1)C1CCN(CCc2ccccc2)CC1
CHEMBL5087973,CHEMBL233,Mu opioid receptor,Ki,=,19.4,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,CCC(=O)N(C[C@H](C)N1CCC(Cc2ccccc2)CC1)c1ccccc1
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,3.2,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL316632,CHEMBL233,Mu opioid receptor,Ki,=,61.7,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCc1ccccc1
CHEMBL94350,CHEMBL233,Mu opioid receptor,Ki,=,3.9,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CCc1ccccc1
CHEMBL4461774,CHEMBL233,Mu opioid receptor,Ki,=,58.0,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,O=C1N(c2cccnc2C(F)(F)F)CC2(CCN(CCc3ccccc3F)CC2)OC12CC2
CHEMBL4781352,CHEMBL233,Mu opioid receptor,Ki,=,118.0,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,CCN1CC2(CCN(CCc3cc(F)ccc3F)CC2)O[C@H](C)C1=O
CHEMBL4789321,CHEMBL233,Mu opioid receptor,Ki,=,1.9,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,CCC(=O)N(CCN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(OC)cc1
CHEMBL4439908,CHEMBL233,Mu opioid receptor,Ki,=,437.0,nM,CHEMBL5110290,B,Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 90 mins measured by MicroBeta scintillation counter method,CHEMBL5108017,KI,O=C1COC2(CCN(CCc3ccccc3)CC2)CN1c1ccccc1
CHEMBL5201355,CHEMBL233,Mu opioid receptor,Ki,=,2763.0,nM,CHEMBL5116796,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5113446,KI,CN(CCCNC(=O)c1ccc2ccccc2n1)Cc1ccccc1
CHEMBL5186843,CHEMBL233,Mu opioid receptor,Ki,=,3433.0,nM,CHEMBL5116796,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5113446,KI,CN(CCCNC(=O)c1ccc2ccccc2c1)Cc1ccccc1
CHEMBL5169420,CHEMBL233,Mu opioid receptor,Ki,=,1770.0,nM,CHEMBL5116796,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5113446,KI,CN(CCCNC(=O)c1cc2ccccc2o1)Cc1ccccc1
CHEMBL5187029,CHEMBL233,Mu opioid receptor,Ki,=,56.0,nM,CHEMBL5116796,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5113446,KI,COc1ccc(CN(C)CCCNC(=O)c2ccc3ccccc3n2)cc1OC
CHEMBL5207122,CHEMBL233,Mu opioid receptor,Ki,=,1219.0,nM,CHEMBL5116796,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5113446,KI,COc1ccc(CN(C)CCCNC(=O)c2ccc3ccccc3c2)cc1OC
CHEMBL5182253,CHEMBL233,Mu opioid receptor,Ki,=,2905.0,nM,CHEMBL5116796,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5113446,KI,COc1ccc(CN(C)CCCNC(=O)c2cc3ccccc3o2)cc1OC
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,1.49,nM,CHEMBL5116796,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5113446,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL5173837,CHEMBL233,Mu opioid receptor,Ki,=,0.58,nM,CHEMBL5127513,B,Displacement of [3H]DAMGO from MOP (unknown origin) stably expressed in HEK293 cells by liquid scintillation counter analysis,CHEMBL5126521,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](C)N(C)C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccccc1
CHEMBL5208747,CHEMBL233,Mu opioid receptor,Ki,=,0.3,nM,CHEMBL5127513,B,Displacement of [3H]DAMGO from MOP (unknown origin) stably expressed in HEK293 cells by liquid scintillation counter analysis,CHEMBL5126521,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](C)N(C)C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1
CHEMBL5176887,CHEMBL233,Mu opioid receptor,Ki,=,0.032,nM,CHEMBL5127513,B,Displacement of [3H]DAMGO from MOP (unknown origin) stably expressed in HEK293 cells by liquid scintillation counter analysis,CHEMBL5126521,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](C)N(C)C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)c1ccccc1
CHEMBL5175179,CHEMBL233,Mu opioid receptor,Ki,=,0.011,nM,CHEMBL5127513,B,Displacement of [3H]DAMGO from MOP (unknown origin) stably expressed in HEK293 cells by liquid scintillation counter analysis,CHEMBL5126521,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](C)N(C)C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)c1ccco1
CHEMBL5188741,CHEMBL233,Mu opioid receptor,Ki,=,0.61,nM,CHEMBL5127513,B,Displacement of [3H]DAMGO from MOP (unknown origin) stably expressed in HEK293 cells by liquid scintillation counter analysis,CHEMBL5126521,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)N(C)C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccccc1
CHEMBL5190232,CHEMBL233,Mu opioid receptor,Ki,=,0.45,nM,CHEMBL5127513,B,Displacement of [3H]DAMGO from MOP (unknown origin) stably expressed in HEK293 cells by liquid scintillation counter analysis,CHEMBL5126521,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)N(C)C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1
CHEMBL5198856,CHEMBL233,Mu opioid receptor,Ki,=,0.0511,nM,CHEMBL5127513,B,Displacement of [3H]DAMGO from MOP (unknown origin) stably expressed in HEK293 cells by liquid scintillation counter analysis,CHEMBL5126521,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)N(C)C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)c1ccccc1
CHEMBL5182849,CHEMBL233,Mu opioid receptor,Ki,=,0.014,nM,CHEMBL5127513,B,Displacement of [3H]DAMGO from MOP (unknown origin) stably expressed in HEK293 cells by liquid scintillation counter analysis,CHEMBL5126521,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)N(C)C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)c1ccco1
CHEMBL5197271,CHEMBL233,Mu opioid receptor,Ki,=,0.63,nM,CHEMBL5127518,B,Displacement of [3H]DAMGO from human MOP expressed in CHO-K1 cell membrane incubated for 60 mins by Microscint-counting analysis,CHEMBL5126521,KI,NC(=O)[C@@H]1CCC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL5171745,CHEMBL233,Mu opioid receptor,Ki,=,0.49,nM,CHEMBL5127518,B,Displacement of [3H]DAMGO from human MOP expressed in CHO-K1 cell membrane incubated for 60 mins by Microscint-counting analysis,CHEMBL5126521,KI,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL5198915,CHEMBL233,Mu opioid receptor,Ki,=,0.68,nM,CHEMBL5127518,B,Displacement of [3H]DAMGO from human MOP expressed in CHO-K1 cell membrane incubated for 60 mins by Microscint-counting analysis,CHEMBL5126521,KI,NC(=O)CNC(=O)[C@@H]1CCC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL5196331,CHEMBL233,Mu opioid receptor,Ki,=,0.96,nM,CHEMBL5127518,B,Displacement of [3H]DAMGO from human MOP expressed in CHO-K1 cell membrane incubated for 60 mins by Microscint-counting analysis,CHEMBL5126521,KI,NC(=O)[C@@H]1CCCCNC(=O)CC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL5186493,CHEMBL233,Mu opioid receptor,Ki,=,0.25,nM,CHEMBL5127525,B,Binding affinity to MOP (unknown origin),CHEMBL5126521,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CCCCNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC1=O
CHEMBL361922,CHEMBL233,Mu opioid receptor,Ki,=,9.07,nM,CHEMBL5127525,B,Binding affinity to MOP (unknown origin),CHEMBL5126521,KI,COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL505502,CHEMBL233,Mu opioid receptor,Ki,=,14.96,nM,CHEMBL5127525,B,Binding affinity to MOP (unknown origin),CHEMBL5126521,KI,CCOC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL500195,CHEMBL233,Mu opioid receptor,Ki,=,50.35,nM,CHEMBL5127525,B,Binding affinity to MOP (unknown origin),CHEMBL5126521,KI,CC(C)(C)OC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL70,CHEMBL233,Mu opioid receptor,Ki,=,2.84,nM,CHEMBL5127525,B,Binding affinity to MOP (unknown origin),CHEMBL5126521,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL278789,CHEMBL233,Mu opioid receptor,Ki,=,0.54,nM,CHEMBL5127525,B,Binding affinity to MOP (unknown origin),CHEMBL5126521,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
CHEMBL5185861,CHEMBL233,Mu opioid receptor,Ki,=,1.6,nM,CHEMBL5127525,B,Binding affinity to MOP (unknown origin),CHEMBL5126521,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(N)=O
CHEMBL5185581,CHEMBL233,Mu opioid receptor,Ki,=,0.98,nM,CHEMBL5127525,B,Binding affinity to MOP (unknown origin),CHEMBL5126521,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
CHEMBL5196508,CHEMBL233,Mu opioid receptor,Ki,=,11.9,nM,CHEMBL5127525,B,Binding affinity to MOP (unknown origin),CHEMBL5126521,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)O
CHEMBL285479,CHEMBL233,Mu opioid receptor,Ki,=,2171.0,nM,CHEMBL5127525,B,Binding affinity to MOP (unknown origin),CHEMBL5126521,KI,C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
CHEMBL60444,CHEMBL233,Mu opioid receptor,Ki,=,0.14,nM,CHEMBL5127525,B,Binding affinity to MOP (unknown origin),CHEMBL5126521,KI,NCCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL299031,CHEMBL233,Mu opioid receptor,Ki,=,233.0,nM,CHEMBL5127525,B,Binding affinity to MOP (unknown origin),CHEMBL5126521,KI,CC[C@@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL5178409,CHEMBL233,Mu opioid receptor,Ki,=,47.0,nM,CHEMBL5127525,B,Binding affinity to MOP (unknown origin),CHEMBL5126521,KI,CC[C@@H]1CN2CC[C@]3(O)c4c(cccc4OC)NC3[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4848517,CHEMBL233,Mu opioid receptor,Ki,=,410.0,nM,CHEMBL5127525,B,Binding affinity to MOP (unknown origin),CHEMBL5126521,KI,C=C[C@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4859858,CHEMBL233,Mu opioid receptor,Ki,=,728.0,nM,CHEMBL5127525,B,Binding affinity to MOP (unknown origin),CHEMBL5126521,KI,CC[C@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4546925,CHEMBL233,Mu opioid receptor,Ki,=,560.0,nM,CHEMBL5127525,B,Binding affinity to MOP (unknown origin),CHEMBL5126521,KI,CC[C@@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL5200686,CHEMBL233,Mu opioid receptor,Ki,=,25.7,nM,CHEMBL5127528,B,Displacement of [3H]DAMGO from MOP in human SH-SY5Y cells incubated fro 60 mins by scintillation counting analysis,CHEMBL5126521,KI,CCCCCCCCC(N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL5199625,CHEMBL233,Mu opioid receptor,Ki,=,0.47,nM,CHEMBL5127528,B,Displacement of [3H]DAMGO from MOP in human SH-SY5Y cells incubated fro 60 mins by scintillation counting analysis,CHEMBL5126521,KI,CCCCCCCCC(N)C(=O)N[C@@H](Cc1c(C)cc(O)cc1C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL5182362,CHEMBL233,Mu opioid receptor,Ki,=,32.2,nM,CHEMBL5127604,B,Displacement of [3H]DAMGO from MOP (unknown origin) stably expressed in CHO cell membrane incubated for 90 mins by scintillation counter analysis,CHEMBL5126521,KI,C[C@@H]1NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]2CCCN2C1=O
CHEMBL5177485,CHEMBL233,Mu opioid receptor,Ki,=,140.0,nM,CHEMBL5127604,B,Displacement of [3H]DAMGO from MOP (unknown origin) stably expressed in CHO cell membrane incubated for 90 mins by scintillation counter analysis,CHEMBL5126521,KI,C[C@@H]1C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1C
CHEMBL5206240,CHEMBL233,Mu opioid receptor,Ki,=,533.0,nM,CHEMBL5127604,B,Displacement of [3H]DAMGO from MOP (unknown origin) stably expressed in CHO cell membrane incubated for 90 mins by scintillation counter analysis,CHEMBL5126521,KI,C[C@@H]1NC(=O)[C@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC1=O
CHEMBL5186131,CHEMBL233,Mu opioid receptor,Ki,=,687.0,nM,CHEMBL5127604,B,Displacement of [3H]DAMGO from MOP (unknown origin) stably expressed in CHO cell membrane incubated for 90 mins by scintillation counter analysis,CHEMBL5126521,KI,C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC1=O
CHEMBL5189722,CHEMBL233,Mu opioid receptor,Ki,=,3920.0,nM,CHEMBL5127604,B,Displacement of [3H]DAMGO from MOP (unknown origin) stably expressed in CHO cell membrane incubated for 90 mins by scintillation counter analysis,CHEMBL5126521,KI,O=C1N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H]1Cc1c[nH]c2ccccc12
CHEMBL5170333,CHEMBL233,Mu opioid receptor,Ki,=,7780.0,nM,CHEMBL5127604,B,Displacement of [3H]DAMGO from MOP (unknown origin) stably expressed in CHO cell membrane incubated for 90 mins by scintillation counter analysis,CHEMBL5126521,KI,O=C1N[C@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H]1Cc1c[nH]c2ccccc12
CHEMBL5208209,CHEMBL233,Mu opioid receptor,Ki,=,5800.0,nM,CHEMBL5127604,B,Displacement of [3H]DAMGO from MOP (unknown origin) stably expressed in CHO cell membrane incubated for 90 mins by scintillation counter analysis,CHEMBL5126521,KI,O=C1N[C@H](Cc2ccccc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@H]12
CHEMBL267495,CHEMBL233,Mu opioid receptor,Ki,=,0.7,nM,CHEMBL5133574,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cell membrane,CHEMBL5131431,KI,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL5185211,CHEMBL233,Mu opioid receptor,Ki,=,0.158,nM,CHEMBL5133574,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cell membrane,CHEMBL5131431,KI,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CCC2[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL5188658,CHEMBL233,Mu opioid receptor,Ki,=,3.57,nM,CHEMBL5133574,B,Displacement of [3H]DAMGO from human MOR expressed in HEK293 cell membrane,CHEMBL5131431,KI,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC=C2[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL3736287,CHEMBL233,Mu opioid receptor,Ki,=,1.0,nM,CHEMBL5145924,B,Binding affinity at MOR (unknown origin) assessed as inhibition constant,CHEMBL5143596,KI,Cc1cc(O)cc(C)c1CC(N)C(=O)NC(C)C(=O)NCC(=O)N(C)C(Cc1ccccc1)C(=O)N1CCCC1C(=O)NC(CC(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCc1cc(C(F)(F)F)cc(C(F)(F)F)c1
CHEMBL4796803,CHEMBL233,Mu opioid receptor,Ki,=,2781.0,nM,CHEMBL5214334,B,Selectivity interaction (GPCR panel (PDSP screen)) EUB0000289bCl OPRM1,CHEMBL5212743,KI,CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC.Cl
CHEMBL4520788,CHEMBL233,Mu opioid receptor,Ki,=,854.25,nM,CHEMBL5213961,B,Selectivity interaction (GPCR panel (PDSP screen)) EUB0000743a OPRM1,CHEMBL5212743,KI,CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1
CHEMBL4526351,CHEMBL233,Mu opioid receptor,Ki,=,6987.0,nM,CHEMBL5213347,B,Selectivity interaction (GPCR panel (PDSP screen)) EUB0000703a OPRM1,CHEMBL5212743,KI,Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1
CHEMBL4576555,CHEMBL233,Mu opioid receptor,Ki,=,4522.0,nM,CHEMBL5213386,B,Selectivity interaction (GPCR panel (PDSP screen)) EUB0000705a OPRM1,CHEMBL5212743,KI,CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5cc(C(C)(C)C)cc(C(C)(C)C)c5)ccc4n3)cc2)CC1
CHEMBL316446,CHEMBL233,Mu opioid receptor,Ki,=,2.6,nM,CHEMBL5217401,B,Displacement of [3H]DAMGO from human cloned mu-opioid receptor by radioligand binding assay,CHEMBL5214968,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL5219510,CHEMBL233,Mu opioid receptor,Ki,=,820.0,nM,CHEMBL5217401,B,Displacement of [3H]DAMGO from human cloned mu-opioid receptor by radioligand binding assay,CHEMBL5214968,KI,O=C(NCCc1ccccc1)[C@H]1CCN(C(=O)Cc2ccc(O)cc2)[C@@H]1C(=O)NCCc1c[nH]c2ccccc12
CHEMBL596,CHEMBL233,Mu opioid receptor,Ki,=,1.35,nM,CHEMBL5217402,B,Displacement of [3H]DAMGO from human mu opioid receptor measured after 2 hrs by competitive binding assay,CHEMBL5214968,KI,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL5086571,CHEMBL233,Mu opioid receptor,Ki,=,100.0,nM,CHEMBL5232354,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO-K1 cells membrane incubated for 60 mins by MicroBeta scintillation counter assay,CHEMBL5230145,KI,CCC(=O)N(CC1(N2CCN(CC(C)C)CC2)CCOCC1)c1cccc(C(F)(F)F)n1
CHEMBL5275633,CHEMBL233,Mu opioid receptor,Ki,=,100.0,nM,CHEMBL5232354,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO-K1 cells membrane incubated for 60 mins by MicroBeta scintillation counter assay,CHEMBL5230145,KI,CCC(=O)N(CCN1CCC(N(C)Cc2ccccc2)C1)c1ccccc1
CHEMBL5284021,CHEMBL233,Mu opioid receptor,Ki,=,100.0,nM,CHEMBL5232354,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO-K1 cells membrane incubated for 60 mins by MicroBeta scintillation counter assay,CHEMBL5230145,KI,CN1CC2(CCN(CCc3ccccc3)CC2)c2ccccc2C1=O
CHEMBL5280075,CHEMBL233,Mu opioid receptor,Ki,=,100.0,nM,CHEMBL5232354,B,Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO-K1 cells membrane incubated for 60 mins by MicroBeta scintillation counter assay,CHEMBL5230145,KI,CCN1CC2(CCN(CCc3ccccc3)CC2)c2ccccc2C1=O
CHEMBL4085956,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL5232357,B,Binding affinity to mu opioid receptor (unknown origin) assessed as inhibition constant in presence of Levorphanol,CHEMBL5230145,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CCc1ccccc1
CHEMBL4073004,CHEMBL233,Mu opioid receptor,Ki,=,55.0,nM,CHEMBL5232357,B,Binding affinity to mu opioid receptor (unknown origin) assessed as inhibition constant in presence of Levorphanol,CHEMBL5230145,KI,C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCc1ccccc1
CHEMBL5201437,CHEMBL233,Mu opioid receptor,Ki,=,637.0,nM,CHEMBL5233343,B,Binding affinity to MOR (unknown origin),CHEMBL5233204,KI,CCOC(=O)[C@]12C[C@@H]1[C@@H](n1ccc3c(NC)nc(C#Cc4ccc(Cl)s4)nc31)[C@H](O)[C@@H]2O
CHEMBL318723,CHEMBL233,Mu opioid receptor,Ki,=,80.0,nM,CHEMBL5244907,B,Displacement of [3H]DAMGO from human cloned mu-opioid receptor by radioligand binding assay,CHEMBL5244220,KI,C[C@H]1CN(C)CC[C@@]1(C)c1cccc(O)c1
CHEMBL270190,CHEMBL233,Mu opioid receptor,Ki,=,0.77,nM,CHEMBL5244907,B,Displacement of [3H]DAMGO from human cloned mu-opioid receptor by radioligand binding assay,CHEMBL5244220,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,0.9,nM,CHEMBL5251242,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL5290432,CHEMBL233,Mu opioid receptor,Ki,=,12.0,nM,CHEMBL5251242,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1\CN2CC[C@@]34c5ccccc5N(CCc5ccccc5)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5288483,CHEMBL233,Mu opioid receptor,Ki,=,54.0,nM,CHEMBL5251242,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1\CN2CC[C@@]34c5ccccc5N(Cc5ccccc5)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5280172,CHEMBL233,Mu opioid receptor,Ki,=,100.0,nM,CHEMBL5251242,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1\CN2CC[C@@]34c5ccccc5N(CC)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5276128,CHEMBL233,Mu opioid receptor,Ki,=,220.0,nM,CHEMBL5251242,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1/CN2CC[C@@]34c5cc(O)c(I)cc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5291340,CHEMBL233,Mu opioid receptor,Ki,=,120.0,nM,CHEMBL5251242,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1/CN2CC[C@@]34c5cc(O)c(Br)cc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL4871880,CHEMBL233,Mu opioid receptor,Ki,=,300.0,nM,CHEMBL5251242,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1/CN2CC[C@@]34c5cc(O)ccc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL4846243,CHEMBL233,Mu opioid receptor,Ki,=,330.0,nM,CHEMBL5251242,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1/CN2CC[C@@]34c5ccccc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5291340,CHEMBL233,Mu opioid receptor,Ki,=,125.89,nM,CHEMBL5251242,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1/CN2CC[C@@]34c5cc(O)c(Br)cc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5276128,CHEMBL233,Mu opioid receptor,Ki,=,158.49,nM,CHEMBL5251242,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1/CN2CC[C@@]34c5cc(O)c(I)cc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5280172,CHEMBL233,Mu opioid receptor,Ki,=,100.0,nM,CHEMBL5251242,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1\CN2CC[C@@]34c5ccccc5N(CC)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5288483,CHEMBL233,Mu opioid receptor,Ki,=,50.12,nM,CHEMBL5251242,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1\CN2CC[C@@]34c5ccccc5N(Cc5ccccc5)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5290432,CHEMBL233,Mu opioid receptor,Ki,=,12.59,nM,CHEMBL5251242,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1\CN2CC[C@@]34c5ccccc5N(CCc5ccccc5)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL38874,CHEMBL233,Mu opioid receptor,Ki,=,0.7943,nM,CHEMBL5251242,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL4871880,CHEMBL233,Mu opioid receptor,Ki,=,316.23,nM,CHEMBL5251242,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1/CN2CC[C@@]34c5cc(O)ccc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL4846243,CHEMBL233,Mu opioid receptor,Ki,=,630.96,nM,CHEMBL5251242,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1/CN2CC[C@@]34c5ccccc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5278521,CHEMBL233,Mu opioid receptor,Ki,=,0.98,nM,CHEMBL5258060,B,Binding affinity to mu opioid receptor (unknown origin) assessed as inhibition constant,CHEMBL5257037,KI,NC(=O)[C@@H]1CCC(=O)NCCC[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL5282233,CHEMBL233,Mu opioid receptor,Ki,=,4.21,nM,CHEMBL5258060,B,Binding affinity to mu opioid receptor (unknown origin) assessed as inhibition constant,CHEMBL5257037,KI,NC(=O)[C@@H]1CCC(=O)NCCC[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NC2(Cc3ccccc3C2)C(=O)N1
CHEMBL5289078,CHEMBL233,Mu opioid receptor,Ki,=,1700.0,nM,CHEMBL5264052,B,Displacement of [3H]-DAMGO from human MOR receptor assessed as inhibition constant by cheng-prusoff equation assay,CHEMBL5260834,KI,CC(C)=CCN1CC[C@@]2(C)c3cc(O)ccc3C[C@H]1[C@H]2C
CHEMBL3040082,CHEMBL233,Mu opioid receptor,Ki,=,1610.0,nM,CHEMBL5264052,B,Displacement of [3H]-DAMGO from human MOR receptor assessed as inhibition constant by cheng-prusoff equation assay,CHEMBL5260834,KI,C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@]1(C)CCN2Cc1ccccc1
CHEMBL4576555,CHEMBL233,Mu opioid receptor,Ki,=,4021.59,nM,CHEMBL4880042,B,GPCRScan assay: inhibition of MOR,CHEMBL4507307,KI,CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5cc(C(C)(C)C)cc(C(C)(C)C)c5)ccc4n3)cc2)CC1
CHEMBL4576555,CHEMBL233,Mu opioid receptor,Ki,=,3981.07,nM,CHEMBL4880042,B,GPCRScan assay: inhibition of MOR,CHEMBL4507307,KI,CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5cc(C(C)(C)C)cc(C(C)(C)C)c5)ccc4n3)cc2)CC1
CHEMBL5400876,CHEMBL233,Mu opioid receptor,Ki,=,1265.0,nM,CHEMBL5325030,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant,CHEMBL5321291,KI,c1ccc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1
CHEMBL5437720,CHEMBL233,Mu opioid receptor,Ki,=,4377.0,nM,CHEMBL5326492,B,Displacement of [3H]DAMGO from human MOR expressed in CHO cell membranes assessed as inhibition constant incubated for 60 mins by microbeta 2 scintillation counting method,CHEMBL5325418,KI,COC(=O)C(Cc1ccccc1I)NC(=O)CN(Cc1ccccc1)C(=O)OC(C)(C)C
CHEMBL4435280,CHEMBL233,Mu opioid receptor,Ki,=,376.0,nM,CHEMBL5328969,B,Displacement of [3H]-DAMGO from human MOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3ccc4ccccc43)CC2)CC1
CHEMBL4548515,CHEMBL233,Mu opioid receptor,Ki,=,65.3,nM,CHEMBL5328969,B,Displacement of [3H]-DAMGO from human MOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CN)c4ccccc43)CC2)CC1
CHEMBL4439997,CHEMBL233,Mu opioid receptor,Ki,=,716.0,nM,CHEMBL5328969,B,Displacement of [3H]-DAMGO from human MOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CO)c4ccccc43)CC2)CC1
CHEMBL5405339,CHEMBL233,Mu opioid receptor,Ki,=,0.81,nM,CHEMBL5328969,B,Displacement of [3H]-DAMGO from human MOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CN)cc4ccccc43)CC2)CC1
CHEMBL5426012,CHEMBL233,Mu opioid receptor,Ki,=,2.78,nM,CHEMBL5328969,B,Displacement of [3H]-DAMGO from human MOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CCN)cc4ccccc43)CC2)CC1
CHEMBL5403724,CHEMBL233,Mu opioid receptor,Ki,=,5.99,nM,CHEMBL5328969,B,Displacement of [3H]-DAMGO from human MOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CO)cc4ccccc43)CC2)CC1
CHEMBL5404274,CHEMBL233,Mu opioid receptor,Ki,=,20.32,nM,CHEMBL5328969,B,Displacement of [3H]-DAMGO from human MOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CCO)cc4ccccc43)CC2)CC1
CHEMBL5412738,CHEMBL233,Mu opioid receptor,Ki,=,24.32,nM,CHEMBL5328969,B,Displacement of [3H]-DAMGO from human MOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(=O)NCc1cc2ccccc2n1C1CCN([C@H]2CC[C@@H](C(C)C)CC2)CC1
CHEMBL5419235,CHEMBL233,Mu opioid receptor,Ki,=,25.35,nM,CHEMBL5328969,B,Displacement of [3H]-DAMGO from human MOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CCOC(=O)NCc1cc2ccccc2n1C1CCN([C@H]2CC[C@@H](C(C)C)CC2)CC1
CHEMBL5413519,CHEMBL233,Mu opioid receptor,Ki,=,2.52,nM,CHEMBL5328969,B,Displacement of [3H]-DAMGO from human MOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CNS(C)(=O)=O)cc4ccccc43)CC2)CC1
CHEMBL5423260,CHEMBL233,Mu opioid receptor,Ki,=,0.66,nM,CHEMBL5328969,B,Displacement of [3H]-DAMGO from human MOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CNS(N)(=O)=O)cc4ccccc43)CC2)CC1
CHEMBL5415010,CHEMBL233,Mu opioid receptor,Ki,=,38.8,nM,CHEMBL5328969,B,Displacement of [3H]-DAMGO from human MOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CN4CCS(=O)(=O)CC4)cc4ccccc43)CC2)CC1
CHEMBL5416582,CHEMBL233,Mu opioid receptor,Ki,=,0.58,nM,CHEMBL5328969,B,Displacement of [3H]-DAMGO from human MOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CN4CCCC4)cc4ccccc43)CC2)CC1
CHEMBL5407403,CHEMBL233,Mu opioid receptor,Ki,=,5.34,nM,CHEMBL5328969,B,Displacement of [3H]-DAMGO from human MOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CNC(=O)c4cccnc4)cc4ccccc43)CC2)CC1
CHEMBL5416899,CHEMBL233,Mu opioid receptor,Ki,=,0.27,nM,CHEMBL5328969,B,Displacement of [3H]-DAMGO from human MOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CNC(=O)c4cnco4)cc4ccccc43)CC2)CC1
CHEMBL5394355,CHEMBL233,Mu opioid receptor,Ki,=,15.1,nM,CHEMBL5328969,B,Displacement of [3H]-DAMGO from human MOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CNC(=O)c4ccc(C(F)(F)F)o4)cc4ccccc43)CC2)CC1
CHEMBL596,CHEMBL233,Mu opioid receptor,Ki,=,0.051,nM,CHEMBL5341714,B,Binding affinity to mu-opioid receptor (unknown origin) assessed as inhibition constant,CHEMBL5338767,KI,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL5421947,CHEMBL233,Mu opioid receptor,Ki,=,25.8,nM,CHEMBL5341714,B,Binding affinity to mu-opioid receptor (unknown origin) assessed as inhibition constant,CHEMBL5338767,KI,N[11C](=O)c1ccc(Oc2ccc(CN3CCC[C@H]3c3cccnc3)cc2)c(Cl)c1
CHEMBL5415879,CHEMBL233,Mu opioid receptor,Ki,=,0.2,nM,CHEMBL5341714,B,Binding affinity to mu-opioid receptor (unknown origin) assessed as inhibition constant,CHEMBL5338767,KI,CC(C)(O)[C@H]1C[C@@]23CC[C@]1(O[11CH3])[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL5400535,CHEMBL233,Mu opioid receptor,Ki,=,0.3,nM,CHEMBL5353695,B,Displacement of [3H]-Diprenorphine from human MOR receptor expressed in CHO-K1 cells assessed as inhibition constant measured for 1 hr by liquid scintillation counter analysis,CHEMBL5352416,KI,Cc1ccc(C(CNC(=O)c2cc3ccccc3s2)N(C)C)cc1
CHEMBL13786,CHEMBL233,Mu opioid receptor,Ki,=,1.5,nM,CHEMBL5353695,B,Displacement of [3H]-Diprenorphine from human MOR receptor expressed in CHO-K1 cells assessed as inhibition constant measured for 1 hr by liquid scintillation counter analysis,CHEMBL5352416,KI,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL441765,CHEMBL233,Mu opioid receptor,Ki,=,370.0,nM,CHEMBL5360967,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5360528,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL2180640,CHEMBL233,Mu opioid receptor,Ki,=,360.0,nM,CHEMBL5360967,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5360528,KI,CCCCN(CCc1ccccc1)CCc1cccc(O)c1
CHEMBL100116,CHEMBL233,Mu opioid receptor,Ki,=,3.2,nM,CHEMBL5360967,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5360528,KI,CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C
CHEMBL60542,CHEMBL233,Mu opioid receptor,Ki,=,3.2,nM,CHEMBL5360967,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5360528,KI,CC(C)=CCN1CC[C@]2(C)c3cc(O)ccc3C[C@H]1[C@H]2C
CHEMBL157302,CHEMBL233,Mu opioid receptor,Ki,=,0.34,nM,CHEMBL5360967,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5360528,KI,C[C@H]1[C@H]2Cc3ccc(C(N)=O)cc3[C@]1(C)CCN2CC1CC1
CHEMBL5431513,CHEMBL233,Mu opioid receptor,Ki,=,0.021,nM,CHEMBL5360967,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5360528,KI,O=C(N[C@@H]1C=C[C@H]2[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cccc(I)c1
CHEMBL592,CHEMBL233,Mu opioid receptor,Ki,=,0.21,nM,CHEMBL5360967,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5360528,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL5401204,CHEMBL233,Mu opioid receptor,Ki,=,3.46,nM,CHEMBL5360967,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5360528,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cc[n+](Cc2ccccc2)cc1.[Br-]
CHEMBL5406584,CHEMBL233,Mu opioid receptor,Ki,=,538.0,nM,CHEMBL5360967,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5360528,KI,COC(=O)[C@@H]1C[C@H](OC(=O)C2=Cc3ccccc3C2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL4458783,CHEMBL233,Mu opioid receptor,Ki,=,1900.0,nM,CHEMBL5360967,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5360528,KI,Cc1ccc(CSc2nnc(-c3ccccn3)n2Cc2ccco2)cc1C(F)(F)F
CHEMBL1186579,CHEMBL233,Mu opioid receptor,Ki,=,10.0,nM,CHEMBL5360967,B,Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5360528,KI,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL610279,CHEMBL233,Mu opioid receptor,Ki,=,20.3,nM,CHEMBL5360981,B,Binding affinity to human MOR expressed in HEK293 cells assessed as inhibition constant by GTPgammaS assay,CHEMBL5360528,KI,N=C(N)Nc1ccc2c3c([nH]c2c1)[C@@H]1Oc2c(O)ccc4c2[C@@]12CCN(CC1CC1)[C@H](C4)[C@]2(O)C3
CHEMBL5405541,CHEMBL233,Mu opioid receptor,Ki,=,0.073,nM,CHEMBL5360981,B,Binding affinity to human MOR expressed in HEK293 cells assessed as inhibition constant by GTPgammaS assay,CHEMBL5360528,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(OCCCc2ccccc2)[C@H]1C5
CHEMBL2443262,CHEMBL233,Mu opioid receptor,Ki,=,4.38,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1
CHEMBL5406129,CHEMBL233,Mu opioid receptor,Ki,=,23.8,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CN(C)C(=O)C(CCN1C[C@H](O)C/C1=C\N1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1
CHEMBL5432993,CHEMBL233,Mu opioid receptor,Ki,=,529.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CN(C)C(=O)C(CCN1C[C@H](O)C[C@H]1CN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1
CHEMBL5434650,CHEMBL233,Mu opioid receptor,Ki,=,377.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CCc1cc(Cl)c(OC)c(N2CCN(C[C@@H]3C[C@@H](O)CN3CCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CC2)c1
CHEMBL5398747,CHEMBL233,Mu opioid receptor,Ki,=,782.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CN(C)C(=O)C(CCN1C[C@H](O)C[C@H]1CN1CCN(c2cccc(C(F)(F)F)n2)CC1)(c1ccccc1)c1ccccc1
CHEMBL5414796,CHEMBL233,Mu opioid receptor,Ki,=,564.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CN(C)C(=O)C(CCN1C[C@H](O)C[C@H]1C(=O)NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1
CHEMBL5404724,CHEMBL233,Mu opioid receptor,Ki,=,791.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CN(C)C(=O)C(CCN1C[C@H](O)C[C@H]1C(=O)NCCCCN1CCN(c2cccc(C(F)(F)F)n2)CC1)(c1ccccc1)c1ccccc1
CHEMBL5412606,CHEMBL233,Mu opioid receptor,Ki,=,192.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CN(C)C(=O)C(CCN1C[C@H](F)C[C@H]1C(=O)NCCCCN1CCN(c2cccc(C(F)(F)F)n2)CC1)(c1ccccc1)c1ccccc1
CHEMBL5421714,CHEMBL233,Mu opioid receptor,Ki,=,787.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CN(C)C(=O)C(CCN1C[C@H](F)C[C@H]1C(=O)NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1
CHEMBL5395539,CHEMBL233,Mu opioid receptor,Ki,=,146.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CN(C)C(=O)C(CCN1C[C@H](F)C[C@H]1C(=O)NCCCCN1CCN(c2nsc3ccccc23)CC1)(c1ccccc1)c1ccccc1
CHEMBL5435235,CHEMBL233,Mu opioid receptor,Ki,=,867.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CC1CCC(CN2CCN(c3cccc(Cl)c3Cl)CC2)CN1CCC(C(=O)N(C)C)(c1ccccc1)c1ccccc1
CHEMBL5418819,CHEMBL233,Mu opioid receptor,Ki,=,23.5,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CN(C)C(=O)C(CCN1CCC(CCN2CCN(c3cccc(Cl)c3Cl)CC2)C1)(c1ccccc1)c1ccccc1
CHEMBL5407131,CHEMBL233,Mu opioid receptor,Ki,=,2380.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CCc1cc(Cl)c(OC)c(N2CCN(Cc3cn(CCC(C(=O)N(C)C)(c4ccccc4)c4ccccc4)nn3)CC2)c1
CHEMBL5415451,CHEMBL233,Mu opioid receptor,Ki,=,2120.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CCc1cc(Cl)c(OC)c(N2CCN(CCCCc3cn(CCC(C(=O)N(C)C)(c4ccccc4)c4ccccc4)nn3)CC2)c1
CHEMBL5417253,CHEMBL233,Mu opioid receptor,Ki,=,1.23,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CN(C)C(=O)C(CCN1CCN(c2cccc(C(F)(F)F)n2)CC1)(c1ccccc1)c1ccccc1
CHEMBL5409322,CHEMBL233,Mu opioid receptor,Ki,=,0.364,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CN(C)C(=O)C(CCN1CCN(c2nsc3ccccc23)CC1)(c1ccccc1)c1ccccc1
CHEMBL5398913,CHEMBL233,Mu opioid receptor,Ki,=,12.3,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CN(C)C(=O)C(CCN[C@@H]1C[C@H]1c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1
CHEMBL5397609,CHEMBL233,Mu opioid receptor,Ki,=,31.2,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CCCN(CCC(C(=O)N(C)C)(c1ccccc1)c1ccccc1)[C@@H]1C[C@H]1c1ccc(Cl)cc1
CHEMBL5410159,CHEMBL233,Mu opioid receptor,Ki,=,26.9,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CN(C)C(=O)C(CCN(CCO)[C@@H]1C[C@H]1c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1
CHEMBL5417643,CHEMBL233,Mu opioid receptor,Ki,=,81.8,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,COc1ccc([C@@H]2C[C@H]2NCCC(C(=O)N(C)C)(c2ccccc2)c2ccccc2)cc1
CHEMBL5436551,CHEMBL233,Mu opioid receptor,Ki,=,47.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CN(C)C(=O)C(CCN[C@@H]1C[C@H]1c1ccc(F)cc1)(c1ccccc1)c1ccccc1
CHEMBL5412995,CHEMBL233,Mu opioid receptor,Ki,=,55.2,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,COc1ccccc1[C@@H]1C[C@H]1NCCC(C(=O)N(C)C)(c1ccccc1)c1ccccc1
CHEMBL5415557,CHEMBL233,Mu opioid receptor,Ki,=,54.7,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,Fc1cncc(CNCC[C@@]2(c3ccccn3)CCOC3(CCCC3)C2)c1
CHEMBL5425944,CHEMBL233,Mu opioid receptor,Ki,=,1750.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,Clc1cccc(N2CCN(CCCOC3(c4ccccn4)CCOCC3)CC2)c1Cl
CHEMBL5400356,CHEMBL233,Mu opioid receptor,Ki,=,2070.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,FC(F)(F)c1cccc(N2CCN(CCCOC3(c4ccccn4)CCOCC3)CC2)n1
CHEMBL5415691,CHEMBL233,Mu opioid receptor,Ki,=,2270.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CCC1(CC)CC(OCCCN2CCN(c3cccc(Cl)c3Cl)CC2)(c2ccccn2)CCO1
CHEMBL5415842,CHEMBL233,Mu opioid receptor,Ki,=,745.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CCC1(CC)CC(OCCCN2CCN(c3cccc(C(F)(F)F)n3)CC2)(c2ccccn2)CCO1
CHEMBL5423250,CHEMBL233,Mu opioid receptor,Ki,=,1640.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,FC(F)(F)c1cccc(N2CCN(CCCOC3(c4ccccn4)CCOC4(CCCC4)C3)CC2)n1
CHEMBL5413237,CHEMBL233,Mu opioid receptor,Ki,=,2520.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CCC1(CC)CC(OCCCNCc2cccc(C(F)(F)F)n2)(c2ccccn2)CCO1
CHEMBL5407845,CHEMBL233,Mu opioid receptor,Ki,=,540.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,CCC1(CC)CC(OCCCNCc2cccc(Cl)c2Cl)(c2ccccn2)CCO1
CHEMBL5418730,CHEMBL233,Mu opioid receptor,Ki,=,1580.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,Clc1ccc([C@@H]2C[C@H]2NCCC2(c3ccccn3)CCOCC2)cc1
CHEMBL5407747,CHEMBL233,Mu opioid receptor,Ki,=,1460.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,Clc1cccc(N2CCN(CCCCNCCC3(c4ccccn4)CCOCC3)CC2)c1Cl
CHEMBL5399270,CHEMBL233,Mu opioid receptor,Ki,=,691.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,Clc1cccc(N2CCN(CCC3(c4ccccn4)CCOCC3)CC2)c1Cl
CHEMBL5429207,CHEMBL233,Mu opioid receptor,Ki,=,1670.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,FC(F)(F)c1cccc(N2CCN(CCC3(c4ccccn4)CCOCC3)CC2)n1
CHEMBL5433458,CHEMBL233,Mu opioid receptor,Ki,=,85.2,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,Clc1ccc([C@@H]2C[C@H]2NCCC2(c3ccccn3)CCOC3(CCCC3)C2)cc1
CHEMBL5413807,CHEMBL233,Mu opioid receptor,Ki,=,166.0,nM,CHEMBL5363863,B,Displacement of [3H]-DAMGO from human MOR receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method,CHEMBL5360615,KI,FC(F)(F)c1cccc(N2CCN(CCC3(c4ccccn4)CCOC4(CCCC4)C3)CC2)n1
CHEMBL5415173,CHEMBL233,Mu opioid receptor,Ki,=,0.8,nM,CHEMBL5377593,B,Displacement of [3H]DAMGO from mu-opioid receptor (unknown origin) expressed in CHO cell membrane measured after 90 mins by beta-scintillation counting analysis,CHEMBL5375969,KI,CCC(=O)N(CC(CC)N1CCC(c2ccccc2)CC1)c1ccccn1
CHEMBL1376064,CHEMBL233,Mu opioid receptor,Ki,=,7852.36,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1.Cl
CHEMBL1255661,CHEMBL233,Mu opioid receptor,Ki,=,9.376,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cl.Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL1516474,CHEMBL233,Mu opioid receptor,Ki,=,2846.43,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12.O=C(O)/C=C\C(=O)O
CHEMBL405355,CHEMBL233,Mu opioid receptor,Ki,=,128.53,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)[C@H]1c1cccc([N+](=O)[O-])c1
CHEMBL300555,CHEMBL233,Mu opioid receptor,Ki,=,12.81,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,O=C1NCN(c2ccccc2)C12CCN(CC1COc3ccccc3O1)CC2
CHEMBL1256750,CHEMBL233,Mu opioid receptor,Ki,=,323.0,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)C(CN1CCCC1)c1cccc(OCC(=O)O)c1.Cl
CHEMBL25230,CHEMBL233,Mu opioid receptor,Ki,=,14.68,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(O)c2)C[C@H]1C
CHEMBL2440454,CHEMBL233,Mu opioid receptor,Ki,=,6269.02,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CCc1cc2c(c(CC)n1)CCC(=O)N2Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1.Cl
CHEMBL445102,CHEMBL233,Mu opioid receptor,Ki,=,51.53,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,OC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1
CHEMBL2391908,CHEMBL233,Mu opioid receptor,Ki,=,1280.71,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,C[C@H](NC[C@H](O)CP(=O)(O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1.Cl
CHEMBL2107572,CHEMBL233,Mu opioid receptor,Ki,=,2205.47,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,COc1cccc([C@@H](C)NCCCc2ccccc2Cl)c1.Cl
CHEMBL344159,CHEMBL233,Mu opioid receptor,Ki,=,410.01,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc32)c(C)c1
CHEMBL59898,CHEMBL233,Mu opioid receptor,Ki,=,1130.71,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CCOC(=O)c1c(C)[nH]c2ccc3c(c12)CN1CCc2cc(OC)ccc2C1O3
CHEMBL542139,CHEMBL233,Mu opioid receptor,Ki,=,3579.73,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1.Cl
CHEMBL267777,CHEMBL233,Mu opioid receptor,Ki,=,344.27,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL1256844,CHEMBL233,Mu opioid receptor,Ki,=,184.71,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1.Cl
CHEMBL531742,CHEMBL233,Mu opioid receptor,Ki,=,494.94,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1.Cl
CHEMBL1200776,CHEMBL233,Mu opioid receptor,Ki,=,1295.69,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12.Cl
CHEMBL79834,CHEMBL233,Mu opioid receptor,Ki,=,155.54,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,O=C1NCN(c2ccccc2)C12CCN(CCCOc1ccc(F)cc1)CC2
CHEMBL1615374,CHEMBL233,Mu opioid receptor,Ki,=,729.62,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cl.N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1
CHEMBL1707,CHEMBL233,Mu opioid receptor,Ki,=,2.587,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1.Cl
CHEMBL259656,CHEMBL233,Mu opioid receptor,Ki,=,3141.95,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,O=C(c1cc2c(cc1F)OC(c1ccc(F)cc1)(c1ccc(Cl)cc1Cl)O2)N1CCOCC1
CHEMBL513136,CHEMBL233,Mu opioid receptor,Ki,=,321.0,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cc1ccccc1C(c1ccccc1C)N1C2CCC1CC(O)(c1ccccc1)C2
CHEMBL1766103,CHEMBL233,Mu opioid receptor,Ki,=,5565.45,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cc1cc(C)cc(-c2cnc3cc(Cl)c(-c4cccc(O)c4)cc3c2OCCCN)c1
CHEMBL1474387,CHEMBL233,Mu opioid receptor,Ki,=,102.35,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cc1c(P(=S)(c2ccccc2)c2ccccc2)n2ccccc2[n+]1C/C=C/c1ccccc1.[Br-]
CHEMBL1200517,CHEMBL233,Mu opioid receptor,Ki,=,154.01,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21.CS(=O)(=O)O
CHEMBL1558,CHEMBL233,Mu opioid receptor,Ki,=,1791.02,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC.Cl
CHEMBL3675743,CHEMBL233,Mu opioid receptor,Ki,=,7723.25,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CCc1nn2c(C)cc(C)nc2c1Cc1ccc(-c2nnc(C3CCNCC3)o2)cc1
CHEMBL5087624,CHEMBL233,Mu opioid receptor,Ki,=,142.4,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CC1(C)SSC(C)(C)[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H]1C(=O)O.O=C(O)C(F)(F)F
CHEMBL2138684,CHEMBL233,Mu opioid receptor,Ki,=,186.98,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CN[C@@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1.O.O=C(O)CCC(=O)O
CHEMBL540612,CHEMBL233,Mu opioid receptor,Ki,=,249.03,nM,CHEMBL5442190,B,"PDSP Secondary Binding target: OPRM1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1.Cl
CHEMBL1169583,CHEMBL233,Mu opioid receptor,EC50,=,16.2,nM,CHEMBL749728,B,EC50 for binding of [35S]- GTPdeltaS in cloned human opioid mu receptor transfected onto CHO cells,CHEMBL1132936,EC50,CO[C@H](C)[C@@H]1CC23C=C[C@]1(OC)[C@H]1Oc4c(O)ccc5c4C12CCN(C)C3C5
CHEMBL2113671,CHEMBL233,Mu opioid receptor,EC50,=,0.6,nM,CHEMBL749726,B,EC50 for binding of [35S]- GTPdeltaS in cloned human Opioid receptor mu 1 (DAMGO) transfected onto CHO cells,CHEMBL1132936,EC50,CO[C@]12C=C[C@@]3(C[C@H]1[C@@H](C)OCc1ccccc1)[C@H]1Cc4ccc(O)c5c4C3(CCN1C)[C@@H]2O5
CHEMBL1169580,CHEMBL233,Mu opioid receptor,EC50,=,7.3,nM,CHEMBL749729,B,EC50 for binding of [35S]- GTPdeltaS in cloned human opioid mu receptors (DAMGO) transfected onto CHO cells,CHEMBL1132936,EC50,CCC[C@](C)(O)[C@@H]1CC23C=C[C@]1(OC)[C@H]1Oc4c(O)ccc5c4C12CCN(C)C3C5
CHEMBL2113672,CHEMBL233,Mu opioid receptor,EC50,=,1.8,nM,CHEMBL749726,B,EC50 for binding of [35S]- GTPdeltaS in cloned human Opioid receptor mu 1 (DAMGO) transfected onto CHO cells,CHEMBL1132936,EC50,CO[C@]12C=C[C@@]3(C[C@H]1[C@H](C)OCc1ccccc1)[C@H]1Cc4ccc(O)c5c4C3(CCN1C)[C@@H]2O5
CHEMBL1169584,CHEMBL233,Mu opioid receptor,EC50,=,13.5,nM,CHEMBL749726,B,EC50 for binding of [35S]- GTPdeltaS in cloned human Opioid receptor mu 1 (DAMGO) transfected onto CHO cells,CHEMBL1132936,EC50,CCO[C@@H](C)[C@@H]1CC23C=C[C@]1(OC)[C@H]1Oc4c(O)ccc5c4C12CCN(C)C3C5
CHEMBL2113670,CHEMBL233,Mu opioid receptor,EC50,=,4.85,nM,CHEMBL749726,B,EC50 for binding of [35S]- GTPdeltaS in cloned human Opioid receptor mu 1 (DAMGO) transfected onto CHO cells,CHEMBL1132936,EC50,CCO[C@H](C)[C@@H]1C[C@@]23C=C[C@]1(OC)[C@H]1Oc4c(O)ccc5c4C12CCN(C)[C@@H]3C5
CHEMBL1169582,CHEMBL233,Mu opioid receptor,EC50,=,34.9,nM,CHEMBL749726,B,EC50 for binding of [35S]- GTPdeltaS in cloned human Opioid receptor mu 1 (DAMGO) transfected onto CHO cells,CHEMBL1132936,EC50,CO[C@@H](C)[C@@H]1CC23C=C[C@]1(OC)[C@H]1Oc4c(O)ccc5c4C12CCN(C)C3C5
CHEMBL1169585,CHEMBL233,Mu opioid receptor,EC50,=,0.66,nM,CHEMBL749727,B,EC50 for binding of [35S]- GTPdeltaS in cloned human oOpioid receptor mu 1 (DAMGO) transfected onto CHO cells,CHEMBL1132936,EC50,CCC[C@@](C)(O)[C@@H]1CC23C=C[C@]1(OC)[C@H]1Oc4c(O)ccc5c4C12CCN(C)C3C5
CHEMBL3707102,CHEMBL233,Mu opioid receptor,EC50,=,4300.0,nM,CHEMBL749738,B,Tested for effective concentration against cloned human Opioid receptor mu 1,CHEMBL1145019,EC50,C[C@@H]1[C@H]2c3cc(NCc4ccccc4)ccc3C[C@@H](c3ccc(NCc4ccccc4)cc32)N1C
CHEMBL146756,CHEMBL233,Mu opioid receptor,EC50,=,2.9,nM,CHEMBL749732,B,Inhibitory activity in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cell membranes was determined,CHEMBL1145905,EC50,O=C(/C=C/C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL405131,CHEMBL233,Mu opioid receptor,EC50,=,10.0,nM,CHEMBL749732,B,Inhibitory activity in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cell membranes was determined,CHEMBL1145905,EC50,O=C(CCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL357334,CHEMBL233,Mu opioid receptor,EC50,=,8.0,nM,CHEMBL749732,B,Inhibitory activity in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cell membranes was determined,CHEMBL1145905,EC50,COC(=O)CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL147511,CHEMBL233,Mu opioid receptor,EC50,=,1.3,nM,CHEMBL749732,B,Inhibitory activity in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cell membranes was determined,CHEMBL1145905,EC50,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL49269,CHEMBL233,Mu opioid receptor,EC50,=,0.8,nM,CHEMBL749732,B,Inhibitory activity in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cell membranes was determined,CHEMBL1145905,EC50,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL433697,CHEMBL233,Mu opioid receptor,EC50,=,7.4,nM,CHEMBL749732,B,Inhibitory activity in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cell membranes was determined,CHEMBL1145905,EC50,O=C(CCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL346436,CHEMBL233,Mu opioid receptor,EC50,=,11.0,nM,CHEMBL749732,B,Inhibitory activity in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cell membranes was determined,CHEMBL1145905,EC50,O=C(CCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL309307,CHEMBL233,Mu opioid receptor,EC50,=,109.0,nM,CHEMBL758076,B,Agonist potency using GTP-gamma [35S]- binding assay for mu-opioid receptor,CHEMBL1134689,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNC(=O)c1ccccc1
CHEMBL317956,CHEMBL233,Mu opioid receptor,EC50,=,1130.0,nM,CHEMBL758076,B,Agonist potency using GTP-gamma [35S]- binding assay for mu-opioid receptor,CHEMBL1134689,EC50,CC(C)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)NCC(N)=O)C(C)C
CHEMBL80463,CHEMBL233,Mu opioid receptor,EC50,=,18.8,nM,CHEMBL758076,B,Agonist potency using GTP-gamma [35S]- binding assay for mu-opioid receptor,CHEMBL1134689,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNC(=O)Nc1ccccc1
CHEMBL77001,CHEMBL233,Mu opioid receptor,EC50,=,37.1,nM,CHEMBL758076,B,Agonist potency using GTP-gamma [35S]- binding assay for mu-opioid receptor,CHEMBL1134689,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNCc1ccccc1
CHEMBL56585,CHEMBL233,Mu opioid receptor,EC50,=,4.5,nM,CHEMBL749733,B,Incorporation of [35S]- GTPgammaS into CHO membranes expressing human Opioid receptor mu 1,CHEMBL1145777,EC50,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CC1CC1
CHEMBL352965,CHEMBL233,Mu opioid receptor,EC50,=,22.0,nM,CHEMBL749733,B,Incorporation of [35S]- GTPgammaS into CHO membranes expressing human Opioid receptor mu 1,CHEMBL1145777,EC50,CC[C@@]12CCN(CC3CC3)C(C(=O)c3ccc(Nc4ccccc4)cc31)[C@@H]2C
CHEMBL169346,CHEMBL233,Mu opioid receptor,EC50,=,62.0,nM,CHEMBL749733,B,Incorporation of [35S]- GTPgammaS into CHO membranes expressing human Opioid receptor mu 1,CHEMBL1145777,EC50,CC[C@@]12CCN(CC3CC3)C(C(=O)c3ccc(N)cc31)[C@@H]2C
CHEMBL2367916,CHEMBL233,Mu opioid receptor,EC50,=,15.0,nM,CHEMBL749733,B,Incorporation of [35S]- GTPgammaS into CHO membranes expressing human Opioid receptor mu 1,CHEMBL1145777,EC50,C[C@H]1[C@H]2Cc3ccc(Nc4ccccc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL354172,CHEMBL233,Mu opioid receptor,EC50,=,21.0,nM,CHEMBL749733,B,Incorporation of [35S]- GTPgammaS into CHO membranes expressing human Opioid receptor mu 1,CHEMBL1145777,EC50,C[C@H]1C2C(=O)c3ccc(O)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL279968,CHEMBL233,Mu opioid receptor,EC50,=,5.5,nM,CHEMBL749733,B,Incorporation of [35S]- GTPgammaS into CHO membranes expressing human Opioid receptor mu 1,CHEMBL1145777,EC50,CC[C@@]12CCN(CC3CC3)C(C(=O)c3ccc(O)cc31)[C@@H]2C
CHEMBL169346,CHEMBL233,Mu opioid receptor,EC50,=,92.0,nM,CHEMBL749733,B,Incorporation of [35S]- GTPgammaS into CHO membranes expressing human Opioid receptor mu 1,CHEMBL1145777,EC50,CC[C@@]12CCN(CC3CC3)C(C(=O)c3ccc(N)cc31)[C@@H]2C
CHEMBL422560,CHEMBL233,Mu opioid receptor,EC50,=,180.0,nM,CHEMBL749733,B,Incorporation of [35S]- GTPgammaS into CHO membranes expressing human Opioid receptor mu 1,CHEMBL1145777,EC50,C[C@H]1C2C(=O)c3ccc(N)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL184127,CHEMBL233,Mu opioid receptor,EC50,=,799.0,nM,CHEMBL836457,B,Agonist activity as stimulation of [35S]-GTP-gamma binding to human Opioid receptor mu 1,CHEMBL1137888,EC50,CC(C)C1CCC(N2CCC(N3c4ccccc4CNS3(=O)=O)CC2)CC1
CHEMBL38874,CHEMBL233,Mu opioid receptor,EC50,=,202.0,nM,CHEMBL836457,B,Agonist activity as stimulation of [35S]-GTP-gamma binding to human Opioid receptor mu 1,CHEMBL1137888,EC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL362160,CHEMBL233,Mu opioid receptor,EC50,=,801.0,nM,CHEMBL836457,B,Agonist activity as stimulation of [35S]-GTP-gamma binding to human Opioid receptor mu 1,CHEMBL1137888,EC50,O=S1(=O)NCc2ccccc2N1C1CCN(CCC(c2ccccc2)c2ccccc2)CC1
CHEMBL184234,CHEMBL233,Mu opioid receptor,EC50,=,1475.0,nM,CHEMBL836457,B,Agonist activity as stimulation of [35S]-GTP-gamma binding to human Opioid receptor mu 1,CHEMBL1137888,EC50,O=S1(=O)NCc2ccccc2N1C1CCN(C2CCC3CCCCC3C2)CC1
CHEMBL184260,CHEMBL233,Mu opioid receptor,EC50,=,3138.0,nM,CHEMBL836457,B,Agonist activity as stimulation of [35S]-GTP-gamma binding to human Opioid receptor mu 1,CHEMBL1137888,EC50,CCCC1CCC(N2CCC(N3c4ccccc4CNS3(=O)=O)CC2)CC1
CHEMBL184381,CHEMBL233,Mu opioid receptor,EC50,=,3162.0,nM,CHEMBL836457,B,Agonist activity as stimulation of [35S]-GTP-gamma binding to human Opioid receptor mu 1,CHEMBL1137888,EC50,CC(C)CCC(C)N1CCC(N2c3ccccc3CNS2(=O)=O)CC1
CHEMBL184127,CHEMBL233,Mu opioid receptor,EC50,=,620.0,nM,CHEMBL836457,B,Agonist activity as stimulation of [35S]-GTP-gamma binding to human Opioid receptor mu 1,CHEMBL1137888,EC50,CC(C)C1CCC(N2CCC(N3c4ccccc4CNS3(=O)=O)CC2)CC1
CHEMBL186822,CHEMBL233,Mu opioid receptor,EC50,=,555.0,nM,CHEMBL836457,B,Agonist activity as stimulation of [35S]-GTP-gamma binding to human Opioid receptor mu 1,CHEMBL1137888,EC50,CC(C)C1CCC(N2CCC(N3c4ccccc4CN(CC(N)=O)S3(=O)=O)CC2)CC1
CHEMBL185415,CHEMBL233,Mu opioid receptor,EC50,=,344.0,nM,CHEMBL836457,B,Agonist activity as stimulation of [35S]-GTP-gamma binding to human Opioid receptor mu 1,CHEMBL1137888,EC50,CC(C)C1CCC(N2CCC(N3c4ccccc4CN(CC#N)S3(=O)=O)CC2)CC1
CHEMBL70,CHEMBL233,Mu opioid receptor,EC50,=,6.0,nM,CHEMBL925795,B,Activation of human mu opioid receptor expressed in HEK293a cells co-expressing YFP-labelled alphai1 and CFP-labelled beta1gamma2 Gi subunits assessed as Gi protein activation by fluorescence resonance energy transfer,CHEMBL1147037,EC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL404097,CHEMBL233,Mu opioid receptor,EC50,=,32500.0,nM,CHEMBL925795,B,Activation of human mu opioid receptor expressed in HEK293a cells co-expressing YFP-labelled alphai1 and CFP-labelled beta1gamma2 Gi subunits assessed as Gi protein activation by fluorescence resonance energy transfer,CHEMBL1147037,EC50,COC1=C[C@]23CCN(C)[C@H](Cc4ccc(OC)c(O)c42)C3=CC1=O
CHEMBL403893,CHEMBL233,Mu opioid receptor,EC50,=,5600.0,nM,CHEMBL925795,B,Activation of human mu opioid receptor expressed in HEK293a cells co-expressing YFP-labelled alphai1 and CFP-labelled beta1gamma2 Gi subunits assessed as Gi protein activation by fluorescence resonance energy transfer,CHEMBL1147037,EC50,COC1=CC=C2[C@H]3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL485,CHEMBL233,Mu opioid receptor,EC50,=,6100.0,nM,CHEMBL925795,B,Activation of human mu opioid receptor expressed in HEK293a cells co-expressing YFP-labelled alphai1 and CFP-labelled beta1gamma2 Gi subunits assessed as Gi protein activation by fluorescence resonance energy transfer,CHEMBL1147037,EC50,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
CHEMBL257627,CHEMBL233,Mu opioid receptor,EC50,=,294.0,nM,CHEMBL925795,B,Activation of human mu opioid receptor expressed in HEK293a cells co-expressing YFP-labelled alphai1 and CFP-labelled beta1gamma2 Gi subunits assessed as Gi protein activation by fluorescence resonance energy transfer,CHEMBL1147037,EC50,COc1ccc2c3c1O[C@H]1C(=O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314
CHEMBL437602,CHEMBL233,Mu opioid receptor,EC50,=,277.0,nM,CHEMBL925795,B,Activation of human mu opioid receptor expressed in HEK293a cells co-expressing YFP-labelled alphai1 and CFP-labelled beta1gamma2 Gi subunits assessed as Gi protein activation by fluorescence resonance energy transfer,CHEMBL1147037,EC50,COC1=CC=C2[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL255467,CHEMBL233,Mu opioid receptor,EC50,=,28.0,nM,CHEMBL925795,B,Activation of human mu opioid receptor expressed in HEK293a cells co-expressing YFP-labelled alphai1 and CFP-labelled beta1gamma2 Gi subunits assessed as Gi protein activation by fluorescence resonance energy transfer,CHEMBL1147037,EC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)C=C[C@H]3[C@H]1C5
CHEMBL38874,CHEMBL233,Mu opioid receptor,EC50,=,1.0,nM,CHEMBL925790,B,Activation of human mu opioid receptor expressed in HEK293a cells coexpressing YFP-labelled alphai1 and CFP-labelled beta-1-gamma-2 Gi subunits assessed as decrease in fluorescence resonance energy transfer signal at 10 uM,CHEMBL1147037,EC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL70,CHEMBL233,Mu opioid receptor,EC50,=,6.4,nM,CHEMBL925790,B,Activation of human mu opioid receptor expressed in HEK293a cells coexpressing YFP-labelled alphai1 and CFP-labelled beta-1-gamma-2 Gi subunits assessed as decrease in fluorescence resonance energy transfer signal at 10 uM,CHEMBL1147037,EC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL1852475,CHEMBL233,Mu opioid receptor,EC50,=,5.08,nM,CHEMBL2184591,B,Agonist activity at mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTP-gammaS binding,CHEMBL2176919,EC50,CN1CCC(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)CC1
CHEMBL2178341,CHEMBL233,Mu opioid receptor,EC50,=,7.49,nM,CHEMBL2184591,B,Agonist activity at mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTP-gammaS binding,CHEMBL2176919,EC50,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncn1
CHEMBL2178340,CHEMBL233,Mu opioid receptor,EC50,=,28.3,nM,CHEMBL2184591,B,Agonist activity at mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTP-gammaS binding,CHEMBL2176919,EC50,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccnnc1
CHEMBL1852458,CHEMBL233,Mu opioid receptor,EC50,=,2.84,nM,CHEMBL2184591,B,Agonist activity at mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTP-gammaS binding,CHEMBL2176919,EC50,O=C(CNC(=O)c1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1852555,CHEMBL233,Mu opioid receptor,EC50,=,1.46,nM,CHEMBL2184591,B,Agonist activity at mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTP-gammaS binding,CHEMBL2176919,EC50,O=C(CCc1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1852814,CHEMBL233,Mu opioid receptor,EC50,=,2.32,nM,CHEMBL2184591,B,Agonist activity at mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTP-gammaS binding,CHEMBL2176919,EC50,O=C(Cc1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1852393,CHEMBL233,Mu opioid receptor,EC50,=,1.52,nM,CHEMBL2184591,B,Agonist activity at mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTP-gammaS binding,CHEMBL2176919,EC50,Cc1cnccc1C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1852602,CHEMBL233,Mu opioid receptor,EC50,=,1.31,nM,CHEMBL2184591,B,Agonist activity at mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTP-gammaS binding,CHEMBL2176919,EC50,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1Br
CHEMBL1852672,CHEMBL233,Mu opioid receptor,EC50,=,2.32,nM,CHEMBL2184591,B,Agonist activity at mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTP-gammaS binding,CHEMBL2176919,EC50,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1Cl
CHEMBL2178338,CHEMBL233,Mu opioid receptor,EC50,=,7.89,nM,CHEMBL2184591,B,Agonist activity at mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTP-gammaS binding,CHEMBL2176919,EC50,COc1cc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)ccn1
CHEMBL1852558,CHEMBL233,Mu opioid receptor,EC50,=,1.13,nM,CHEMBL2184591,B,Agonist activity at mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTP-gammaS binding,CHEMBL2176919,EC50,Cc1cc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)ccn1
CHEMBL2177697,CHEMBL233,Mu opioid receptor,EC50,=,10.0,nM,CHEMBL2184591,B,Agonist activity at mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTP-gammaS binding,CHEMBL2176919,EC50,N#Cc1cc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)ccn1
CHEMBL1852385,CHEMBL233,Mu opioid receptor,EC50,=,1.19,nM,CHEMBL2184591,B,Agonist activity at mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTP-gammaS binding,CHEMBL2176919,EC50,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccnc(Br)c1
CHEMBL1852788,CHEMBL233,Mu opioid receptor,EC50,=,0.83,nM,CHEMBL2184591,B,Agonist activity at mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTP-gammaS binding,CHEMBL2176919,EC50,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccnc(Cl)c1
CHEMBL2397019,CHEMBL233,Mu opioid receptor,EC50,=,11.13,nM,CHEMBL2399071,B,Agonist activity at mu opioid receptor (unknown origin) expressed CHO cells assessed as stimulation of [35S]-GTP[gammaS] binding,CHEMBL2396652,EC50,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2c1
CHEMBL2397018,CHEMBL233,Mu opioid receptor,EC50,=,2.81,nM,CHEMBL2399071,B,Agonist activity at mu opioid receptor (unknown origin) expressed CHO cells assessed as stimulation of [35S]-GTP[gammaS] binding,CHEMBL2396652,EC50,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cnc2ccccc2c1
CHEMBL2397017,CHEMBL233,Mu opioid receptor,EC50,=,38.85,nM,CHEMBL2399071,B,Agonist activity at mu opioid receptor (unknown origin) expressed CHO cells assessed as stimulation of [35S]-GTP[gammaS] binding,CHEMBL2396652,EC50,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2n1
CHEMBL2397015,CHEMBL233,Mu opioid receptor,EC50,=,7.2,nM,CHEMBL2399071,B,Agonist activity at mu opioid receptor (unknown origin) expressed CHO cells assessed as stimulation of [35S]-GTP[gammaS] binding,CHEMBL2396652,EC50,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccc1
CHEMBL2397022,CHEMBL233,Mu opioid receptor,EC50,=,1.67,nM,CHEMBL2399071,B,Agonist activity at mu opioid receptor (unknown origin) expressed CHO cells assessed as stimulation of [35S]-GTP[gammaS] binding,CHEMBL2396652,EC50,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccncc1
CHEMBL19019,CHEMBL233,Mu opioid receptor,EC50,=,0.38,nM,CHEMBL2399071,B,Agonist activity at mu opioid receptor (unknown origin) expressed CHO cells assessed as stimulation of [35S]-GTP[gammaS] binding,CHEMBL2396652,EC50,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL2443262,CHEMBL233,Mu opioid receptor,EC50,=,50.12,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1
CHEMBL2443261,CHEMBL233,Mu opioid receptor,EC50,=,316.23,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,Cc1cc(CNCC[C@@]2(c3ccccn3)CCOC3(CCCC3)C2)oc1C
CHEMBL2443260,CHEMBL233,Mu opioid receptor,EC50,=,501.19,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,Cc1cc(CNCC[C@@]2(c3ccccn3)CCOC3(CCCC3)C2)sc1C
CHEMBL2443259,CHEMBL233,Mu opioid receptor,EC50,=,630.96,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,Cc1cc(C)c(CNCC[C@@]2(c3ccccn3)CCOC3(CCCC3)C2)s1
CHEMBL2443258,CHEMBL233,Mu opioid receptor,EC50,=,199.53,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,Cc1ccc(CNCC[C@@]2(c3ccccn3)CCOC3(CCCC3)C2)o1
CHEMBL2443256,CHEMBL233,Mu opioid receptor,EC50,=,398.11,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,Cc1csc(CNCC[C@@]2(c3ccccn3)CCOC3(CCCC3)C2)c1
CHEMBL2443253,CHEMBL233,Mu opioid receptor,EC50,=,19952.62,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,c1ccc([C@]2(CCNCc3ccc4ccccc4c3)CCOC3(CCCC3)C2)nc1
CHEMBL2443279,CHEMBL233,Mu opioid receptor,EC50,=,63.1,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,c1ccc([C@]2(CCNCc3ccsc3)CCOC3(CCCC3)C2)nc1
CHEMBL2443278,CHEMBL233,Mu opioid receptor,EC50,=,251.19,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,c1ccc([C@]2(CCNCc3cccs3)CCOC3(CCCC3)C2)nc1
CHEMBL2443277,CHEMBL233,Mu opioid receptor,EC50,=,1995.26,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,c1ccc([C@]2(CCNCc3ccncn3)CCOC3(CCCC3)C2)nc1
CHEMBL2443272,CHEMBL233,Mu opioid receptor,EC50,=,50.12,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,Clc1cccc(CNCC[C@@]2(c3ccccn3)CCOC3(CCCC3)C2)c1
CHEMBL2443270,CHEMBL233,Mu opioid receptor,EC50,=,15848.93,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,c1ccc(CNCC[C@]2(c3ccccn3)CCOC3(CCCC3)C2)cc1
CHEMBL2443269,CHEMBL233,Mu opioid receptor,EC50,=,158.49,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,c1ccc(CNCC[C@@]2(c3ccccn3)CCOC3(CCCC3)C2)cc1
CHEMBL2443268,CHEMBL233,Mu opioid receptor,EC50,=,199.53,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,c1ccc(CNCCC2(c3ccccn3)CCOC3(CCCC3)C2)cc1
CHEMBL2443265,CHEMBL233,Mu opioid receptor,EC50,=,7943.28,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,Fc1ccc(C2(CCNCc3ccccc3)CCOC3(CCCCC3)C2)cc1
CHEMBL2443264,CHEMBL233,Mu opioid receptor,EC50,=,7943.28,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,Fc1ccc([C@@]2(CCNCc3ccccc3)CCOC3(CCCC3)C2)cc1
CHEMBL2443263,CHEMBL233,Mu opioid receptor,EC50,=,398.11,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,Fc1ccc([C@]2(CCNCc3ccccc3)CCOC3(CCCC3)C2)cc1
CHEMBL2443285,CHEMBL233,Mu opioid receptor,EC50,=,630.96,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,Fc1ccc(C2(CCNCc3ccccc3)CCOC3(CCCC3)C2)cc1
CHEMBL2443284,CHEMBL233,Mu opioid receptor,EC50,=,6309.57,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,CCC1(CC)CC(CCNCc2ccccc2)(c2ccc(F)cc2)CCO1
CHEMBL2443282,CHEMBL233,Mu opioid receptor,EC50,=,1584.89,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,CC[C@]1(C)CC(CCNCc2ccccc2O)(c2ccc(F)cc2)CCO1
CHEMBL2443280,CHEMBL233,Mu opioid receptor,EC50,=,1995.26,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,CC[C@]1(C)CC(CCNCc2ccccc2O)(c2ccc(C)cc2)CCO1
CHEMBL70,CHEMBL233,Mu opioid receptor,EC50,=,501.19,nM,CHEMBL2445992,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as beta-arrestin recruitment by chemiluminescence assay,CHEMBL2440083,EC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL333342,CHEMBL233,Mu opioid receptor,EC50,=,19500.0,nM,CHEMBL3268190,B,Agonist activity at human cloned mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTP[gammaS] binding,CHEMBL3259577,EC50,CC1CN(CCCc2ccccc2)C2C[C@H](N)CC1(c1cccc(O)c1)C2
CHEMBL3264442,CHEMBL233,Mu opioid receptor,EC50,=,130000.0,nM,CHEMBL3268190,B,Agonist activity at human cloned mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTP[gammaS] binding,CHEMBL3259577,EC50,CC1CN(CCCc2ccccc2)C2C[C@H](NCC3CC3)CC1(c1cccc(O)c1)C2
CHEMBL187635,CHEMBL233,Mu opioid receptor,EC50,=,234.0,nM,CHEMBL3268190,B,Agonist activity at human cloned mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTP[gammaS] binding,CHEMBL3259577,EC50,CO[C@H]1Cc2ccc(O)cc2C(C)(C)[C@@H]1N
CHEMBL3264742,CHEMBL233,Mu opioid receptor,EC50,=,2.8,nM,CHEMBL3271437,B,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]-GTP[gammaS] binding,CHEMBL3259551,EC50,O=C1[C@H]2O[C@@]34CC[C@@]5(OCOc6c(O)ccc7c6[C@@]3(CCN(CC3CC3)[C@@H]4C7)[C@H]25)N1Cc1ccccc1
CHEMBL3264743,CHEMBL233,Mu opioid receptor,EC50,=,113.0,nM,CHEMBL3271437,B,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]-GTP[gammaS] binding,CHEMBL3259551,EC50,CN1CC[C@@]23c4c5ccc(O)c4OCO[C@]46CC[C@@]2(O[C@H](C(=O)N4Cc2ccccc2)[C@H]63)[C@H]1C5
CHEMBL3264744,CHEMBL233,Mu opioid receptor,EC50,=,223.0,nM,CHEMBL3271437,B,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]-GTP[gammaS] binding,CHEMBL3259551,EC50,CC(C)CN1CC[C@@]23c4c5ccc(O)c4OCO[C@]46CC[C@@]2(O[C@H](C(=O)N4Cc2ccccc2)[C@H]63)[C@H]1C5
CHEMBL3264745,CHEMBL233,Mu opioid receptor,EC50,=,2.7,nM,CHEMBL3271437,B,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]-GTP[gammaS] binding,CHEMBL3259551,EC50,C=CCN1CC[C@@]23c4c5ccc(O)c4OCO[C@]46CC[C@@]2(O[C@H](C(=O)N4Cc2ccccc2)[C@H]63)[C@H]1C5
CHEMBL3264746,CHEMBL233,Mu opioid receptor,EC50,=,2.3,nM,CHEMBL3271437,B,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]-GTP[gammaS] binding,CHEMBL3259551,EC50,O=C1[C@H]2O[C@@]34CC[C@@]5(OCOc6c(O)ccc7c6[C@@]3(CCN(CCc3ccccc3)[C@@H]4C7)[C@H]25)N1Cc1ccccc1
CHEMBL3264747,CHEMBL233,Mu opioid receptor,EC50,=,9.0,nM,CHEMBL3271437,B,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]-GTP[gammaS] binding,CHEMBL3259551,EC50,O=C1[C@H]2O[C@@]34CC[C@@]5(OCOc6c(O)ccc7c6[C@@]3(CCN(CC3CC3)[C@@H]4C7)[C@H]25)N1c1ccccc1
CHEMBL3264748,CHEMBL233,Mu opioid receptor,EC50,=,2.1,nM,CHEMBL3271437,B,Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]-GTP[gammaS] binding,CHEMBL3259551,EC50,O=C1[C@H]2O[C@@]34CC[C@@]5(OCOc6c(O)ccc7c6[C@@]3(CCN(CC3CC3)[C@@H]4C7)[C@H]25)N1CCc1ccccc1
CHEMBL13470,CHEMBL233,Mu opioid receptor,EC50,=,0.14,nM,CHEMBL3271443,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells by CellKey method,CHEMBL3259551,EC50,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL3264742,CHEMBL233,Mu opioid receptor,EC50,=,1.8,nM,CHEMBL3271443,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells by CellKey method,CHEMBL3259551,EC50,O=C1[C@H]2O[C@@]34CC[C@@]5(OCOc6c(O)ccc7c6[C@@]3(CCN(CC3CC3)[C@@H]4C7)[C@H]25)N1Cc1ccccc1
CHEMBL3264743,CHEMBL233,Mu opioid receptor,EC50,=,1350.0,nM,CHEMBL3271443,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells by CellKey method,CHEMBL3259551,EC50,CN1CC[C@@]23c4c5ccc(O)c4OCO[C@]46CC[C@@]2(O[C@H](C(=O)N4Cc2ccccc2)[C@H]63)[C@H]1C5
CHEMBL3264744,CHEMBL233,Mu opioid receptor,EC50,=,400.0,nM,CHEMBL3271443,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells by CellKey method,CHEMBL3259551,EC50,CC(C)CN1CC[C@@]23c4c5ccc(O)c4OCO[C@]46CC[C@@]2(O[C@H](C(=O)N4Cc2ccccc2)[C@H]63)[C@H]1C5
CHEMBL3264745,CHEMBL233,Mu opioid receptor,EC50,=,5.1,nM,CHEMBL3271443,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells by CellKey method,CHEMBL3259551,EC50,C=CCN1CC[C@@]23c4c5ccc(O)c4OCO[C@]46CC[C@@]2(O[C@H](C(=O)N4Cc2ccccc2)[C@H]63)[C@H]1C5
CHEMBL3264746,CHEMBL233,Mu opioid receptor,EC50,=,639.0,nM,CHEMBL3271443,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells by CellKey method,CHEMBL3259551,EC50,O=C1[C@H]2O[C@@]34CC[C@@]5(OCOc6c(O)ccc7c6[C@@]3(CCN(CCc3ccccc3)[C@@H]4C7)[C@H]25)N1Cc1ccccc1
CHEMBL3264747,CHEMBL233,Mu opioid receptor,EC50,=,1.2,nM,CHEMBL3271443,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells by CellKey method,CHEMBL3259551,EC50,O=C1[C@H]2O[C@@]34CC[C@@]5(OCOc6c(O)ccc7c6[C@@]3(CCN(CC3CC3)[C@@H]4C7)[C@H]25)N1c1ccccc1
CHEMBL3264748,CHEMBL233,Mu opioid receptor,EC50,=,5.2,nM,CHEMBL3271443,B,Agonist activity at human mu opioid receptor expressed in HEK293 cells by CellKey method,CHEMBL3259551,EC50,O=C1[C@H]2O[C@@]34CC[C@@]5(OCOc6c(O)ccc7c6[C@@]3(CCN(CC3CC3)[C@@H]4C7)[C@H]25)N1CCc1ccccc1
CHEMBL3325716,CHEMBL233,Mu opioid receptor,EC50,=,200.0,nM,CHEMBL3370199,B,Agonist activity at myc-tagged mu opioid receptor (unknown origin) expressed in AtT-20 cells assessed as induction of membrane potential hyperpolarization,CHEMBL3351626,EC50,Cc1ccc(-n2nc(C)c3c2CC(C)(C)CC3=O)c(Br)c1
CHEMBL3325715,CHEMBL233,Mu opioid receptor,EC50,=,100.0,nM,CHEMBL3370199,B,Agonist activity at myc-tagged mu opioid receptor (unknown origin) expressed in AtT-20 cells assessed as induction of membrane potential hyperpolarization,CHEMBL3351626,EC50,Cc1nn(-c2ccc(Cl)cc2Br)c2c1C(=O)CC(C)(C)C2
CHEMBL3325714,CHEMBL233,Mu opioid receptor,EC50,=,5490.0,nM,CHEMBL3370199,B,Agonist activity at myc-tagged mu opioid receptor (unknown origin) expressed in AtT-20 cells assessed as induction of membrane potential hyperpolarization,CHEMBL3351626,EC50,Cc1nn(-c2ccc(Br)cc2Br)c2c1C(=O)CC(C)(C)C2
CHEMBL363324,CHEMBL233,Mu opioid receptor,EC50,=,500.0,nM,CHEMBL3381496,B,Agonist activity at MOR (unknown origin),CHEMBL3352005,EC50,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3426791,CHEMBL233,Mu opioid receptor,EC50,=,4000.0,nM,CHEMBL3428523,B,Positive allosteric modulation of human mu opioid receptor-1 expressed in CHO cells assessed as potentiation of endomorphin 1-induced response after 90 mins by beta-arrestin recruitment assay,CHEMBL3425479,EC50,Cc1ccc(COc2ccc(C3C4=C(CC(C)(C)CC4=O)OC4=C3C(=O)CC(C)(C)C4)cc2)cc1
CHEMBL3426792,CHEMBL233,Mu opioid receptor,EC50,=,5000.0,nM,CHEMBL3428523,B,Positive allosteric modulation of human mu opioid receptor-1 expressed in CHO cells assessed as potentiation of endomorphin 1-induced response after 90 mins by beta-arrestin recruitment assay,CHEMBL3425479,EC50,CC1(C)CC(=O)C2=C(C1)OC1=C(C(=O)CC(C)(C)C1)C2c1ccc(OCc2ccccc2F)cc1
CHEMBL3426793,CHEMBL233,Mu opioid receptor,EC50,=,7000.0,nM,CHEMBL3428523,B,Positive allosteric modulation of human mu opioid receptor-1 expressed in CHO cells assessed as potentiation of endomorphin 1-induced response after 90 mins by beta-arrestin recruitment assay,CHEMBL3425479,EC50,CC1(C)CC(=O)C2=C(C1)OC1=C(C(=O)CC(C)(C)C1)C2c1ccc(OCc2cccc(F)c2)cc1
CHEMBL3426794,CHEMBL233,Mu opioid receptor,EC50,=,2000.0,nM,CHEMBL3428523,B,Positive allosteric modulation of human mu opioid receptor-1 expressed in CHO cells assessed as potentiation of endomorphin 1-induced response after 90 mins by beta-arrestin recruitment assay,CHEMBL3425479,EC50,CC1(C)CC(=O)C2=C(C1)OC1=C(C(=O)CC(C)(C)C1)C2c1ccc(OCc2ccc(F)cc2)cc1
CHEMBL3426798,CHEMBL233,Mu opioid receptor,EC50,=,3000.0,nM,CHEMBL3428523,B,Positive allosteric modulation of human mu opioid receptor-1 expressed in CHO cells assessed as potentiation of endomorphin 1-induced response after 90 mins by beta-arrestin recruitment assay,CHEMBL3425479,EC50,CC1(C)CC(=O)C2=C(C1)OC1=C(C(=O)CC(C)(C)C1)C2c1ccc(OCc2ccccc2OC(F)F)cc1
CHEMBL3426799,CHEMBL233,Mu opioid receptor,EC50,=,2000.0,nM,CHEMBL3428523,B,Positive allosteric modulation of human mu opioid receptor-1 expressed in CHO cells assessed as potentiation of endomorphin 1-induced response after 90 mins by beta-arrestin recruitment assay,CHEMBL3425479,EC50,CC1(C)CC(=O)C2=C(C1)OC1=C(C(=O)CC(C)(C)C1)C2c1ccc(OCc2ccccc2OC(F)(F)F)cc1
CHEMBL3426800,CHEMBL233,Mu opioid receptor,EC50,=,5000.0,nM,CHEMBL3428523,B,Positive allosteric modulation of human mu opioid receptor-1 expressed in CHO cells assessed as potentiation of endomorphin 1-induced response after 90 mins by beta-arrestin recruitment assay,CHEMBL3425479,EC50,CC1(C)CC(=O)C2=C(C1)OC1=C(C(=O)CC(C)(C)C1)C2c1ccc(OCc2ccccc2S(C)(=O)=O)cc1
CHEMBL3426790,CHEMBL233,Mu opioid receptor,EC50,=,3000.0,nM,CHEMBL3428523,B,Positive allosteric modulation of human mu opioid receptor-1 expressed in CHO cells assessed as potentiation of endomorphin 1-induced response after 90 mins by beta-arrestin recruitment assay,CHEMBL3425479,EC50,Cc1cccc(COc2ccc(C3C4=C(CC(C)(C)CC4=O)OC4=C3C(=O)CC(C)(C)C4)cc2)c1
CHEMBL3426789,CHEMBL233,Mu opioid receptor,EC50,=,2600.0,nM,CHEMBL3428523,B,Positive allosteric modulation of human mu opioid receptor-1 expressed in CHO cells assessed as potentiation of endomorphin 1-induced response after 90 mins by beta-arrestin recruitment assay,CHEMBL3425479,EC50,Cc1ccccc1COc1ccc(C2C3=C(CC(C)(C)CC3=O)OC3=C2C(=O)CC(C)(C)C3)cc1
CHEMBL3426788,CHEMBL233,Mu opioid receptor,EC50,=,6000.0,nM,CHEMBL3428523,B,Positive allosteric modulation of human mu opioid receptor-1 expressed in CHO cells assessed as potentiation of endomorphin 1-induced response after 90 mins by beta-arrestin recruitment assay,CHEMBL3425479,EC50,CC1(C)CC(=O)C2=C(C1)OC1=C(C(=O)CC(C)(C)C1)C2c1ccc(OCc2ccccc2)cc1
CHEMBL3426801,CHEMBL233,Mu opioid receptor,EC50,=,10000.0,nM,CHEMBL3428523,B,Positive allosteric modulation of human mu opioid receptor-1 expressed in CHO cells assessed as potentiation of endomorphin 1-induced response after 90 mins by beta-arrestin recruitment assay,CHEMBL3425479,EC50,CC1(C)CC(=O)C2=C(C1)OC1=C(C(=O)CC(C)(C)C1)C2c1ccc(OCc2ccccc2CO)cc1
CHEMBL3759541,CHEMBL233,Mu opioid receptor,EC50,=,4.8,nM,CHEMBL3762574,B,Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTP-gammaS binding assay,CHEMBL3758122,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)NCC(=O)N(c1ccccc1)c1ccccc1
CHEMBL3758563,CHEMBL233,Mu opioid receptor,EC50,=,22.0,nM,CHEMBL3762574,B,Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTP-gammaS binding assay,CHEMBL3758122,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)NCC(=O)N1CCc2ccccc2C1
CHEMBL3758348,CHEMBL233,Mu opioid receptor,EC50,=,35.0,nM,CHEMBL3762574,B,Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTP-gammaS binding assay,CHEMBL3758122,EC50,CN1CC[C@]23c4c5ccc(O)c4O[C@@]2(CO)C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL3759660,CHEMBL233,Mu opioid receptor,EC50,=,73.0,nM,CHEMBL3760684,B,Partial agonist activity at mu opioid receptor (unknown origin) expressed in CHO cell membrane assessed as stimulation of [35S]GTP-gamma-S binding,CHEMBL3758122,EC50,Nc1nc2cc3c(cc2s1)C[C@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL38874,CHEMBL233,Mu opioid receptor,EC50,=,30.0,nM,CHEMBL3812007,B,Agonist activity at human MOR expressed in CHO cell membranes after 60 mins by [35S]GTP-gamma-S binding assay,CHEMBL3808393,EC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL1400,CHEMBL233,Mu opioid receptor,EC50,=,240.0,nM,CHEMBL3812007,B,Agonist activity at human MOR expressed in CHO cell membranes after 60 mins by [35S]GTP-gamma-S binding assay,CHEMBL3808393,EC50,CN(C)C[C@H]1CCCC[C@]1(O)c1cccc(O)c1
CHEMBL1066,CHEMBL233,Mu opioid receptor,EC50,=,1000.0,nM,CHEMBL3812007,B,Agonist activity at human MOR expressed in CHO cell membranes after 60 mins by [35S]GTP-gamma-S binding assay,CHEMBL3808393,EC50,COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1
CHEMBL4111642,CHEMBL233,Mu opioid receptor,EC50,=,357.0,nM,CHEMBL3888264,B,"In Vitro Mu-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; NEN). The prepared membrane solution (190 μL/well) was transferred to 96-shallow well polypropylene plates containing 10 μL of 20× concentrated stock solutions of the agonist DAMGO ([D-Ala2, N-methyl-Phe4 Gly-o15]-enkephalin) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Packard, Meriden, Conn.) using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by three filtration washes with 200 μL of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hr. BetaScint scintillation cocktail (Wallas, Turku, Finland) was added (50 μL/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,EC50,C[C@@H]1C[C@@H]2C[C@H](C1)C[C@@H](N1[C@@H]3CC[C@H]1C[C@@H](n1c(=O)c(N4CC[C@@H]4C(=O)O)nc4ccccc41)C3)C2
CHEMBL3942346,CHEMBL233,Mu opioid receptor,EC50,=,116.0,nM,CHEMBL3888264,B,"In Vitro Mu-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; NEN). The prepared membrane solution (190 μL/well) was transferred to 96-shallow well polypropylene plates containing 10 μL of 20× concentrated stock solutions of the agonist DAMGO ([D-Ala2, N-methyl-Phe4 Gly-o15]-enkephalin) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Packard, Meriden, Conn.) using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by three filtration washes with 200 μL of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hr. BetaScint scintillation cocktail (Wallas, Turku, Finland) was added (50 μL/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,EC50,C[C@@H]1C[C@@H]2C[C@H](C1)C[C@@H](N1[C@@H]3CC[C@H]1C[C@@H](n1c(=O)c(N4CC[C@H]4C(=O)O)nc4ccccc41)C3)C2
CHEMBL3970857,CHEMBL233,Mu opioid receptor,EC50,=,247.0,nM,CHEMBL3888264,B,"In Vitro Mu-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; NEN). The prepared membrane solution (190 μL/well) was transferred to 96-shallow well polypropylene plates containing 10 μL of 20× concentrated stock solutions of the agonist DAMGO ([D-Ala2, N-methyl-Phe4 Gly-o15]-enkephalin) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Packard, Meriden, Conn.) using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by three filtration washes with 200 μL of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hr. BetaScint scintillation cocktail (Wallas, Turku, Finland) was added (50 μL/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,EC50,O=C(O)[C@@H]1CCN1c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3[C@H]2C[C@@H]3CCC[C@@H](C3)C2)c1=O
CHEMBL4115318,CHEMBL233,Mu opioid receptor,EC50,=,54.0,nM,CHEMBL3888264,B,"In Vitro Mu-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; NEN). The prepared membrane solution (190 μL/well) was transferred to 96-shallow well polypropylene plates containing 10 μL of 20× concentrated stock solutions of the agonist DAMGO ([D-Ala2, N-methyl-Phe4 Gly-o15]-enkephalin) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Packard, Meriden, Conn.) using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by three filtration washes with 200 μL of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hr. BetaScint scintillation cocktail (Wallas, Turku, Finland) was added (50 μL/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,EC50,CC12C[C@H]3C[C@@H](N4[C@@H]5CCC[C@H]4C[C@@H](n4c(=O)c(N6CC[C@@H]6C(=O)O)nc6ccccc64)C5)C[C@@H]1C[C@@H]2C3
CHEMBL4114020,CHEMBL233,Mu opioid receptor,EC50,=,363.0,nM,CHEMBL3888264,B,"In Vitro Mu-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; NEN). The prepared membrane solution (190 μL/well) was transferred to 96-shallow well polypropylene plates containing 10 μL of 20× concentrated stock solutions of the agonist DAMGO ([D-Ala2, N-methyl-Phe4 Gly-o15]-enkephalin) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Packard, Meriden, Conn.) using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by three filtration washes with 200 μL of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hr. BetaScint scintillation cocktail (Wallas, Turku, Finland) was added (50 μL/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,EC50,CC12C[C@H]3C[C@@H](N4[C@@H]5CCC[C@H]4C[C@@H](n4c(=O)c(N6CC[C@H]6C(=O)O)nc6ccccc64)C5)C[C@@H]1C[C@@H]2C3
CHEMBL4113014,CHEMBL233,Mu opioid receptor,EC50,=,64.0,nM,CHEMBL3888264,B,"In Vitro Mu-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; NEN). The prepared membrane solution (190 μL/well) was transferred to 96-shallow well polypropylene plates containing 10 μL of 20× concentrated stock solutions of the agonist DAMGO ([D-Ala2, N-methyl-Phe4 Gly-o15]-enkephalin) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Packard, Meriden, Conn.) using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by three filtration washes with 200 μL of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hr. BetaScint scintillation cocktail (Wallas, Turku, Finland) was added (50 μL/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,EC50,CC12C[C@H]3C[C@@H](N4[C@@H]5CCC[C@H]4C[C@@H](n4c(=O)c(N6CC(C(=O)O)C6)nc6ccccc64)C5)C[C@@H]1C[C@@H]2C3
CHEMBL3957299,CHEMBL233,Mu opioid receptor,EC50,=,568.0,nM,CHEMBL3888264,B,"In Vitro Mu-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; NEN). The prepared membrane solution (190 μL/well) was transferred to 96-shallow well polypropylene plates containing 10 μL of 20× concentrated stock solutions of the agonist DAMGO ([D-Ala2, N-methyl-Phe4 Gly-o15]-enkephalin) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Packard, Meriden, Conn.) using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by three filtration washes with 200 μL of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hr. BetaScint scintillation cocktail (Wallas, Turku, Finland) was added (50 μL/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,EC50,CC1(C)[C@H]2CC[C@@H](CCN3[C@@H]4CCC[C@H]3C[C@@H](n3c(=O)c(N5CC[C@H]5C(=O)O)nc5ccccc53)C4)[C@@H]1C2
CHEMBL3926298,CHEMBL233,Mu opioid receptor,EC50,=,560.0,nM,CHEMBL3888264,B,"In Vitro Mu-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; NEN). The prepared membrane solution (190 μL/well) was transferred to 96-shallow well polypropylene plates containing 10 μL of 20× concentrated stock solutions of the agonist DAMGO ([D-Ala2, N-methyl-Phe4 Gly-o15]-enkephalin) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Packard, Meriden, Conn.) using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by three filtration washes with 200 μL of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hr. BetaScint scintillation cocktail (Wallas, Turku, Finland) was added (50 μL/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,EC50,CC1(C)[C@H]2CC[C@@H](CCN3[C@@H]4CCC[C@H]3C[C@@H](n3c(=O)c(N5CC(C(=O)O)C5)nc5ccccc53)C4)[C@@H]1C2
CHEMBL3935191,CHEMBL233,Mu opioid receptor,EC50,=,340.0,nM,CHEMBL3888264,B,"In Vitro Mu-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; NEN). The prepared membrane solution (190 μL/well) was transferred to 96-shallow well polypropylene plates containing 10 μL of 20× concentrated stock solutions of the agonist DAMGO ([D-Ala2, N-methyl-Phe4 Gly-o15]-enkephalin) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Packard, Meriden, Conn.) using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by three filtration washes with 200 μL of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hr. BetaScint scintillation cocktail (Wallas, Turku, Finland) was added (50 μL/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,EC50,O=C(O)[C@@H]1CCN1c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)c1=O
CHEMBL4107594,CHEMBL233,Mu opioid receptor,EC50,=,469.0,nM,CHEMBL3888264,B,"In Vitro Mu-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; NEN). The prepared membrane solution (190 μL/well) was transferred to 96-shallow well polypropylene plates containing 10 μL of 20× concentrated stock solutions of the agonist DAMGO ([D-Ala2, N-methyl-Phe4 Gly-o15]-enkephalin) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Packard, Meriden, Conn.) using a 96-well tissue harvester (Brandel, Gaithersburg, Md.) followed by three filtration washes with 200 μL of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hr. BetaScint scintillation cocktail (Wallas, Turku, Finland) was added (50 μL/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886630,EC50,O=C(O)[C@H]1CCN1c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)c1=O
CHEMBL511142,CHEMBL233,Mu opioid receptor,EC50,=,0.45,nM,CHEMBL3888318,B,"μ-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared in-house from a cell line expressing recombinant μ opioid receptor in a HEK293 background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886656,EC50,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4107585,CHEMBL233,Mu opioid receptor,EC50,=,0.86,nM,CHEMBL3888318,B,"μ-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared in-house from a cell line expressing recombinant μ opioid receptor in a HEK293 background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886656,EC50,CC(C)(C)[C@@]1(C)OCO[C@]23CC[C@@]4(C[C@@H]21)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4113162,CHEMBL233,Mu opioid receptor,EC50,=,1.4,nM,CHEMBL3888318,B,"μ-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared in-house from a cell line expressing recombinant μ opioid receptor in a HEK293 background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886656,EC50,CCC1O[C@]23CC[C@@]4(C[C@@H]2[C@@](C)(C(C)(C)C)O1)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4111049,CHEMBL233,Mu opioid receptor,EC50,=,3.54,nM,CHEMBL3888318,B,"μ-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared in-house from a cell line expressing recombinant μ opioid receptor in a HEK293 background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886656,EC50,CCCC1O[C@]23CC[C@@]4(C[C@@H]2[C@@](C)(C(C)(C)C)O1)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4113900,CHEMBL233,Mu opioid receptor,EC50,=,5.35,nM,CHEMBL3888318,B,"μ-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared in-house from a cell line expressing recombinant μ opioid receptor in a HEK293 background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886656,EC50,CC(C)(C)[C@@]1(C)OC(c2ccccc2)O[C@]23CC[C@@]4(C[C@@H]21)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4109805,CHEMBL233,Mu opioid receptor,EC50,=,1.56,nM,CHEMBL3888318,B,"μ-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared in-house from a cell line expressing recombinant μ opioid receptor in a HEK293 background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886656,EC50,CC(C)(C)[C@@]1(C)OCO[C@]23C=C[C@@]4(C[C@@H]21)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4115892,CHEMBL233,Mu opioid receptor,EC50,=,460.0,nM,CHEMBL3888318,B,"μ-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared in-house from a cell line expressing recombinant μ opioid receptor in a HEK293 background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886656,EC50,
CHEMBL4115893,CHEMBL233,Mu opioid receptor,EC50,=,85.4,nM,CHEMBL3888318,B,"μ-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared in-house from a cell line expressing recombinant μ opioid receptor in a HEK293 background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886656,EC50,
CHEMBL4115381,CHEMBL233,Mu opioid receptor,EC50,=,950.0,nM,CHEMBL3888318,B,"μ-Opioid Receptor Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared in-house from a cell line expressing recombinant μ opioid receptor in a HEK293 background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25 °C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 °C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886656,EC50,CC(C)(C)[C@@]1(C)OCO[C@]23CC[C@@]4(C[C@@H]21)[C@H]1Cc2ccc(OCc5ccccc5)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4108929,CHEMBL233,Mu opioid receptor,EC50,=,412.5,nM,CHEMBL3888408,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed p-receptor membranes prepared in-house from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background, or purchased from a commercial source (Perkin Elmer, Shelton. Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/MT), saponin (10 mg/ml), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtrati",CHEMBL3886698,EC50,NC(=O)c1cc2c([nH]c1=O)C[C@@]13CCN(CC4CC4)C[C@@]1(Cc1ccc(O)cc13)C2
CHEMBL3916263,CHEMBL233,Mu opioid receptor,EC50,=,413.9,nM,CHEMBL3888408,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed p-receptor membranes prepared in-house from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background, or purchased from a commercial source (Perkin Elmer, Shelton. Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/MT), saponin (10 mg/ml), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtrati",CHEMBL3886698,EC50,O=C1NC(=O)[C@@]2(CC[C@@]34Cc5ccc(O)cc5[C@@]3(CCN(CC3CC3)C4)C2)N1
CHEMBL3981333,CHEMBL233,Mu opioid receptor,EC50,=,309.2,nM,CHEMBL3888408,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed p-receptor membranes prepared in-house from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background, or purchased from a commercial source (Perkin Elmer, Shelton. Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/MT), saponin (10 mg/ml), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtrati",CHEMBL3886698,EC50,O=C1NC(=O)[C@]2(CC[C@@]34Cc5ccc(O)cc5[C@@]3(CCN(CC3CC3)C4)C2)N1
CHEMBL4113753,CHEMBL233,Mu opioid receptor,EC50,=,3397.92,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CCOC(=O)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(OC)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3935417,CHEMBL233,Mu opioid receptor,EC50,=,702.68,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](CC(=O)O)C(=O)C3
CHEMBL4110693,CHEMBL233,Mu opioid receptor,EC50,=,14670.57,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CC(CC(=O)O)(CC(=O)O)C(=O)C3
CHEMBL3913034,CHEMBL233,Mu opioid receptor,EC50,=,4604.07,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](CC(=O)N[C@@H](C)C(=O)O)C(=O)C3
CHEMBL3923032,CHEMBL233,Mu opioid receptor,EC50,=,43.75,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,C[C@H](NC(=O)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O)C(=O)O
CHEMBL4111713,CHEMBL233,Mu opioid receptor,EC50,=,6770.22,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](CC(=O)N1CCC[C@H]1C(=O)O)C(=O)C3
CHEMBL3933752,CHEMBL233,Mu opioid receptor,EC50,=,2749.52,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](CC(=O)N[C@@H](CC(C)C)C(=O)O)C(=O)C3
CHEMBL3906641,CHEMBL233,Mu opioid receptor,EC50,=,49.72,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)C[C@H](NC(=O)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O)C(=O)O
CHEMBL4106563,CHEMBL233,Mu opioid receptor,EC50,=,463.0,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](CCOCc1ccccc1)C(=O)C3
CHEMBL3971169,CHEMBL233,Mu opioid receptor,EC50,=,14.2,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)C[C@@H]1CCO
CHEMBL3976681,CHEMBL233,Mu opioid receptor,EC50,=,212.0,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1C[C@@H](C(C)C)C(=O)C3
CHEMBL3948713,CHEMBL233,Mu opioid receptor,EC50,=,2.85,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)[C@@H]1C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4111936,CHEMBL233,Mu opioid receptor,EC50,=,2.31,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)[C@H]1C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3964571,CHEMBL233,Mu opioid receptor,EC50,=,2331.0,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)CNC(=O)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3C)CC1=O
CHEMBL3908066,CHEMBL233,Mu opioid receptor,EC50,=,456.5,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CN1CC[C@]23CC(=O)[C@@H](CC(=O)NCc4ccccc4)C[C@@]2(O)[C@H]1Cc1ccc(O)cc13
CHEMBL3965507,CHEMBL233,Mu opioid receptor,EC50,=,1258.0,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CN1CC[C@]23CC(=O)[C@@H](CC(=O)NCC4CC4)C[C@@]2(O)[C@H]1Cc1ccc(O)cc13
CHEMBL4111457,CHEMBL233,Mu opioid receptor,EC50,=,2102.0,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)C1C[C@H](OCC(C)C)C(=O)C3
CHEMBL4115581,CHEMBL233,Mu opioid receptor,EC50,=,463.0,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)C1[C@@H](O)[C@H](OCc1ccccc1)C(=O)C3
CHEMBL3942489,CHEMBL233,Mu opioid receptor,EC50,=,578.2,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](O)C(=O)C3
CHEMBL3924522,CHEMBL233,Mu opioid receptor,EC50,=,7112.0,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](NC(=O)C(C)C)C(=O)C3
CHEMBL4108329,CHEMBL233,Mu opioid receptor,EC50,=,9.61,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)CCC(=O)N[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4112548,CHEMBL233,Mu opioid receptor,EC50,=,9.65,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)CCCC(=O)N[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3891748,CHEMBL233,Mu opioid receptor,EC50,=,18.6,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)(C)C(=O)N[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4110493,CHEMBL233,Mu opioid receptor,EC50,=,12.7,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,O=C(N[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O)c1ccccc1
CHEMBL4110263,CHEMBL233,Mu opioid receptor,EC50,=,10.3,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,O=C(N[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O)C1CCCCC1
CHEMBL3922780,CHEMBL233,Mu opioid receptor,EC50,=,408.7,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](CCO)C(=O)C3
CHEMBL4106563,CHEMBL233,Mu opioid receptor,EC50,=,38.6,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](CCOCc1ccccc1)C(=O)C3
CHEMBL3904456,CHEMBL233,Mu opioid receptor,EC50,=,147.8,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(C)[C@H](C2)[C@]1(O)C[C@H](CCOCc1ccccc1)C(=O)C3
CHEMBL3971169,CHEMBL233,Mu opioid receptor,EC50,=,1.81,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)C[C@@H]1CCO
CHEMBL3945031,CHEMBL233,Mu opioid receptor,EC50,=,787.3,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(OCc5ccccc5)cc42)[C@]3(O)C[C@@H]1CCO
CHEMBL3918073,CHEMBL233,Mu opioid receptor,EC50,=,11549.0,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CCOC(=O)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(OC)cc4[C@@]2(CCN3C)CC1=O
CHEMBL3927022,CHEMBL233,Mu opioid receptor,EC50,=,466.1,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CN1CC[C@]23CC(=O)[C@@H](CC(=O)O)C[C@@]2(O)[C@H]1Cc1ccc(O)cc13
CHEMBL4113124,CHEMBL233,Mu opioid receptor,EC50,=,6.76,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)C[C@@H]1Cc1ccccc1
CHEMBL3976681,CHEMBL233,Mu opioid receptor,EC50,=,269.7,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1C[C@@H](C(C)C)C(=O)C3
CHEMBL3948713,CHEMBL233,Mu opioid receptor,EC50,=,0.84,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)[C@@H]1C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4111936,CHEMBL233,Mu opioid receptor,EC50,=,3.66,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)[C@H]1C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3895514,CHEMBL233,Mu opioid receptor,EC50,=,1153.0,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,C[C@H](NC(=O)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3C)CC1=O)C(=O)O
CHEMBL3926042,CHEMBL233,Mu opioid receptor,EC50,=,16697.0,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(C)[C@H](C2)[C@]1(O)C[C@H](CC(=O)N1CCCCC1)C(=O)C3
CHEMBL3940025,CHEMBL233,Mu opioid receptor,EC50,=,17630.0,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(C)[C@H](C2)[C@]1(O)C[C@H](CC(=O)N1CCCC1)C(=O)C3
CHEMBL3917710,CHEMBL233,Mu opioid receptor,EC50,=,10398.0,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(C)[C@H](C2)[C@]1(O)C[C@H](CC(=O)N1CCC(O)CC1)C(=O)C3
CHEMBL3892711,CHEMBL233,Mu opioid receptor,EC50,=,11657.0,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(C)[C@H](C2)[C@]1(O)C[C@H](CC(=O)N1CCOCC1)C(=O)C3
CHEMBL3963622,CHEMBL233,Mu opioid receptor,EC50,=,580.8,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CN1CC[C@]23CC(=O)[C@@H](CC(=O)N4CCCCC4)C[C@@]2(O)[C@H]1Cc1ccc(O)cc13
CHEMBL3925461,CHEMBL233,Mu opioid receptor,EC50,=,1005.0,nM,CHEMBL3888720,B,"[35S]GTPγS Functional Assay: [35S]GTPγS functional assays were conducted using freshly thawed μ-receptor membranes prepared from a cell line expressing recombinant μ opioid receptor in a HEK-293, CHO or U-2 OS cell background or purchased from a commercial source (Perkin Elmer, Shelton, Conn.; or DiscovRx, Fremont, Calif.). Assay reactions were prepared by sequentially adding the following reagents to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice (final concentrations indicated): membrane protein (0.026 mg/mL), saponin (10 mg/mL), GDP (3 mM) and [35S]GTPγS (0.20 nM; Perkin Elmer, Shelton, Conn.). The prepared membrane solution (190 μl/well) was transferred to 96-shallow well polypropylene plates containing 10 μl of 20× concentrated stock solutions of the agonist [D-Ala2, N-methyl-Phe4 Gly-ol5]-enkephalin (DAMGO) prepared in dimethyl sulfoxide (DMSO). Plates were incubated for 30 min at about 25° C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by three filtration washes with 200 μl of ice-cold wash buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50° C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 μl/well) and plates were counted using a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CN1CC[C@]23CC(=O)[C@@H](CC(=O)N4CCC(O)CC4)C[C@@]2(O)[C@H]1Cc1ccc(O)cc13
CHEMBL4094170,CHEMBL233,Mu opioid receptor,EC50,=,253.0,nM,CHEMBL4001476,B,Agonist activity at MOR (unknown origin) by [35S]GTPgamma binding assay,CHEMBL4000201,EC50,O=C1/C(=C/c2ccccc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CCc2ccccc2)[C@H]1O5
CHEMBL4083911,CHEMBL233,Mu opioid receptor,EC50,=,72.0,nM,CHEMBL4001476,B,Agonist activity at MOR (unknown origin) by [35S]GTPgamma binding assay,CHEMBL4000201,EC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)/C(=C/c2ccccc2)C[C@@]3(O)[C@H]1C5
CHEMBL490665,CHEMBL233,Mu opioid receptor,EC50,=,1.7,nM,CHEMBL4057025,B,Agonist activity at mu opioid receptor (unknown origin),CHEMBL4052747,EC50,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5.Cl
CHEMBL200199,CHEMBL233,Mu opioid receptor,EC50,=,1.0,nM,CHEMBL4193829,B,Binding affinity to MOR (unknown origin),CHEMBL4190333,EC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NNC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL4079574,CHEMBL233,Mu opioid receptor,EC50,=,6.607,nM,CHEMBL4341019,B,Agonist activity at Rluc-tagged MOR receptor (unknown origin) expressed in human SH-5YSY cells co-expressing RGFP-fused to Gbeta1 assessed as increase in MOR/G beta1 protein interaction incubated for 5 mins in presence of coelenterazine by BRET assay,CHEMBL4340514,EC50,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2C[C@@H](O)c1ccccc1
CHEMBL4066846,CHEMBL233,Mu opioid receptor,EC50,=,22.39,nM,CHEMBL4341019,B,Agonist activity at Rluc-tagged MOR receptor (unknown origin) expressed in human SH-5YSY cells co-expressing RGFP-fused to Gbeta1 assessed as increase in MOR/G beta1 protein interaction incubated for 5 mins in presence of coelenterazine by BRET assay,CHEMBL4340514,EC50,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2C[C@H](O)c1ccccc1
CHEMBL340032,CHEMBL233,Mu opioid receptor,EC50,=,128.82,nM,CHEMBL4341019,B,Agonist activity at Rluc-tagged MOR receptor (unknown origin) expressed in human SH-5YSY cells co-expressing RGFP-fused to Gbeta1 assessed as increase in MOR/G beta1 protein interaction incubated for 5 mins in presence of coelenterazine by BRET assay,CHEMBL4340514,EC50,CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL4577032,CHEMBL233,Mu opioid receptor,EC50,=,4.677,nM,CHEMBL4341019,B,Agonist activity at Rluc-tagged MOR receptor (unknown origin) expressed in human SH-5YSY cells co-expressing RGFP-fused to Gbeta1 assessed as increase in MOR/G beta1 protein interaction incubated for 5 mins in presence of coelenterazine by BRET assay,CHEMBL4340514,EC50,CO[C@H](CN1CC[C@@]2(C)c3cc(O)ccc3C[C@@H]1[C@@H]2C)c1ccccc1
CHEMBL4102093,CHEMBL233,Mu opioid receptor,EC50,=,12.59,nM,CHEMBL4341019,B,Agonist activity at Rluc-tagged MOR receptor (unknown origin) expressed in human SH-5YSY cells co-expressing RGFP-fused to Gbeta1 assessed as increase in MOR/G beta1 protein interaction incubated for 5 mins in presence of coelenterazine by BRET assay,CHEMBL4340514,EC50,COC(CN1CC[C@@]2(C)c3cc(O)ccc3C[C@@H]1[C@@H]2C)c1ccccc1
CHEMBL4102093,CHEMBL233,Mu opioid receptor,EC50,=,275.42,nM,CHEMBL4341020,B,Agonist activity at Rluc-tagged MOR receptor (unknown origin) expressed in human SH-5YSY cells co-expressing RGFP-fused to MOR/beta-arrestin-2 assessed as increase in MOR/beta-arrestin-2 protein interaction incubated for 5 mins in presence of coelenterazine by BRET assay,CHEMBL4340514,EC50,COC(CN1CC[C@@]2(C)c3cc(O)ccc3C[C@@H]1[C@@H]2C)c1ccccc1
CHEMBL4577032,CHEMBL233,Mu opioid receptor,EC50,=,151.36,nM,CHEMBL4341020,B,Agonist activity at Rluc-tagged MOR receptor (unknown origin) expressed in human SH-5YSY cells co-expressing RGFP-fused to MOR/beta-arrestin-2 assessed as increase in MOR/beta-arrestin-2 protein interaction incubated for 5 mins in presence of coelenterazine by BRET assay,CHEMBL4340514,EC50,CO[C@H](CN1CC[C@@]2(C)c3cc(O)ccc3C[C@@H]1[C@@H]2C)c1ccccc1
CHEMBL340032,CHEMBL233,Mu opioid receptor,EC50,=,1380.38,nM,CHEMBL4341020,B,Agonist activity at Rluc-tagged MOR receptor (unknown origin) expressed in human SH-5YSY cells co-expressing RGFP-fused to MOR/beta-arrestin-2 assessed as increase in MOR/beta-arrestin-2 protein interaction incubated for 5 mins in presence of coelenterazine by BRET assay,CHEMBL4340514,EC50,CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL4531563,CHEMBL233,Mu opioid receptor,EC50,=,60.0,nM,CHEMBL4371119,B,Activation of mu opioid receptor (unknown origin) expressed in CHO cells,CHEMBL4371002,EC50,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)C/C=C(\F)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL4451128,CHEMBL233,Mu opioid receptor,EC50,=,374.0,nM,CHEMBL4371527,B,Agonist activity at human mu opioid receptor expressed in human U2OS cells co-transfected with beta-arrestin-2 assessed as increase in beta-arrestin-2 recruitment after 90 mins by BRET assay,CHEMBL4371007,EC50,CC(c1ccc2c(c1)OCCO2)N1CCC(n2c(=O)[nH]c3ccccc32)CC1
CHEMBL4449152,CHEMBL233,Mu opioid receptor,EC50,=,940.0,nM,CHEMBL4371522,B,Agonist activity at human mu opioid receptor expressed in HEK293T cells co-transfected with venus-tagged N-terminal beta-arrestin-2 assessed as increase in beta-arrestin-2 recruitment after 30 mins measured for 1 sec by BRET-based luciferase reporter gene assay,CHEMBL4371007,EC50,CC(Cc1ccsc1)NC(=O)NCC(Cc1ccccc1)N(C)C
CHEMBL596,CHEMBL233,Mu opioid receptor,EC50,=,53.0,nM,CHEMBL4371527,B,Agonist activity at human mu opioid receptor expressed in human U2OS cells co-transfected with beta-arrestin-2 assessed as increase in beta-arrestin-2 recruitment after 90 mins by BRET assay,CHEMBL4371007,EC50,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL658,CHEMBL233,Mu opioid receptor,EC50,=,1.5,nM,CHEMBL4371527,B,Agonist activity at human mu opioid receptor expressed in human U2OS cells co-transfected with beta-arrestin-2 assessed as increase in beta-arrestin-2 recruitment after 90 mins by BRET assay,CHEMBL4371007,EC50,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1
CHEMBL4451045,CHEMBL233,Mu opioid receptor,EC50,=,60.0,nM,CHEMBL4399461,B,Agonist activity at mu opioid receptor (unknown origin) expressed in CHO cells,CHEMBL4396923,EC50,Cc1ccc(C[C@H](N)/C(F)=C/CC(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CC(C)C)C(=O)O)cc1
CHEMBL8234,CHEMBL233,Mu opioid receptor,EC50,=,1.3,nM,CHEMBL4399461,B,Agonist activity at mu opioid receptor (unknown origin) expressed in CHO cells,CHEMBL4396923,EC50,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL4467777,CHEMBL233,Mu opioid receptor,EC50,=,52.41,nM,CHEMBL4409283,B,Inhibition of mu opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated beta arrestin 2 recruitment preincubated for 30 mins followed by forskolin-stimulation and measured after 60 mins,CHEMBL4406853,EC50,C[C@@H](Cc1ccsc1)NC(=O)NC[C@H](Cc1ccc(O)cc1)N(C)C
CHEMBL4550234,CHEMBL233,Mu opioid receptor,EC50,=,0.00177,nM,CHEMBL4409275,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting,CHEMBL4406853,EC50,C=C(C(N)=O)C(NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)N(C)C(=O)C(N)Cc1c(C)cc(O)cc1C)c1ccco1
CHEMBL4521879,CHEMBL233,Mu opioid receptor,EC50,=,0.00177,nM,CHEMBL4409275,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting,CHEMBL4406853,EC50,C=C(C(N)=O)C(NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)N(C)C(=O)C(N)Cc1c(C)cc(O)cc1C)c1ccccc1
CHEMBL4439415,CHEMBL233,Mu opioid receptor,EC50,=,0.00177,nM,CHEMBL4409275,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting,CHEMBL4406853,EC50,C=C(C(N)=O)C(NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](C)N(C)C(=O)C(N)Cc1c(C)cc(O)cc1C)c1ccco1
CHEMBL4450250,CHEMBL233,Mu opioid receptor,EC50,=,0.00177,nM,CHEMBL4409275,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting,CHEMBL4406853,EC50,C=C(C(N)=O)C(NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](C)N(C)C(=O)C(N)Cc1c(C)cc(O)cc1C)c1ccccc1
CHEMBL4544686,CHEMBL233,Mu opioid receptor,EC50,=,4.0,nM,CHEMBL4409275,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting,CHEMBL4406853,EC50,C=C(C(N)=O)C(NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)N(C)C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccccc1
CHEMBL4577301,CHEMBL233,Mu opioid receptor,EC50,=,1.45,nM,CHEMBL4409275,B,Displacement of [3H]DAMGO from mu opioid receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting,CHEMBL4406853,EC50,C=C(C(N)=O)C(NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](C)N(C)C(=O)[C@@H](N)Cc1ccc(O)cc1)c1ccco1
CHEMBL4513533,CHEMBL233,Mu opioid receptor,EC50,=,1995.26,nM,CHEMBL4409291,B,Inhibition of human mu-opioid receptor assessed as increase in beta arrestin 2 recruitment,CHEMBL4406853,EC50,O=c1[nH]c2cc(Cl)c(Cl)cc2n1C1CCN(Cc2ccc(Cl)cc2F)CC1
CHEMBL4217435,CHEMBL233,Mu opioid receptor,EC50,=,1995.26,nM,CHEMBL4409291,B,Inhibition of human mu-opioid receptor assessed as increase in beta arrestin 2 recruitment,CHEMBL4406853,EC50,O=c1[nH]c2cc(Cl)c(Cl)cc2n1C1CCN(Cc2ccc(Br)cc2)CC1
CHEMBL4452384,CHEMBL233,Mu opioid receptor,EC50,=,1995.26,nM,CHEMBL4409291,B,Inhibition of human mu-opioid receptor assessed as increase in beta arrestin 2 recruitment,CHEMBL4406853,EC50,O=c1[nH]c2cc(Cl)c(Cl)cc2n1C1CCN(Cc2ccc(Cl)cc2)CC1
CHEMBL4533745,CHEMBL233,Mu opioid receptor,EC50,=,52.41,nM,CHEMBL4409283,B,Inhibition of mu opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated beta arrestin 2 recruitment preincubated for 30 mins followed by forskolin-stimulation and measured after 60 mins,CHEMBL4406853,EC50,CN(C)[C@H](CNC(=O)NCCc1cccs1)Cc1cccc2ccccc12
CHEMBL4577586,CHEMBL233,Mu opioid receptor,EC50,=,52.41,nM,CHEMBL4409283,B,Inhibition of mu opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated beta arrestin 2 recruitment preincubated for 30 mins followed by forskolin-stimulation and measured after 60 mins,CHEMBL4406853,EC50,C[C@H](Cc1ccsc1)NC(=O)NC[C@H](Cc1ccc2ccccc2c1)N(C)C
CHEMBL4581231,CHEMBL233,Mu opioid receptor,EC50,=,52.41,nM,CHEMBL4409283,B,Inhibition of mu opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated beta arrestin 2 recruitment preincubated for 30 mins followed by forskolin-stimulation and measured after 60 mins,CHEMBL4406853,EC50,C[C@@H](Cc1ccsc1)NC(=O)NC[C@H](Cc1ccc2ccccc2c1)N(C)C
CHEMBL4462475,CHEMBL233,Mu opioid receptor,EC50,=,455.6,nM,CHEMBL4409283,B,Inhibition of mu opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated beta arrestin 2 recruitment preincubated for 30 mins followed by forskolin-stimulation and measured after 60 mins,CHEMBL4406853,EC50,C[C@@H](Cc1ccsc1)NC(=O)NC[C@H](Cc1cccc2ccccc12)N(C)C
CHEMBL4456635,CHEMBL233,Mu opioid receptor,EC50,=,52.41,nM,CHEMBL4409283,B,Inhibition of mu opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated beta arrestin 2 recruitment preincubated for 30 mins followed by forskolin-stimulation and measured after 60 mins,CHEMBL4406853,EC50,CN(C)[C@H](CNC(=O)NCCc1ccsc1)Cc1ccc2ccccc2c1
CHEMBL4530626,CHEMBL233,Mu opioid receptor,EC50,=,203.4,nM,CHEMBL4409283,B,Inhibition of mu opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated beta arrestin 2 recruitment preincubated for 30 mins followed by forskolin-stimulation and measured after 60 mins,CHEMBL4406853,EC50,CN(C)[C@H](CNC(=O)NCCc1ccsc1)Cc1cccc2ccccc12
CHEMBL4449152,CHEMBL233,Mu opioid receptor,EC50,=,940.0,nM,CHEMBL4409280,B,Inhibition of mu opioid receptor (unknown origin) assessed as increase in beta arrestin 2 recruitment,CHEMBL4406853,EC50,CC(Cc1ccsc1)NC(=O)NCC(Cc1ccccc1)N(C)C
CHEMBL2364605,CHEMBL233,Mu opioid receptor,EC50,=,1.2,nM,CHEMBL4428207,B,Agonist activity at recombinant human mu opioid receptor expressed in CHOK1 cell membranes after 45 mins by GTPgamma(35)S binding assay,CHEMBL4428025,EC50,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12
CHEMBL8234,CHEMBL233,Mu opioid receptor,EC50,=,177.83,nM,CHEMBL4670672,B,Agonist activity at MOP (unknown origin) expressed in SH-SY5Y cell membranes co-expressing Gbeta1-RGFP protein assessed as induction of G protein activation incubated for 15 mins by BRET assay,CHEMBL4665800,EC50,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL278789,CHEMBL233,Mu opioid receptor,EC50,=,128.82,nM,CHEMBL4670672,B,Agonist activity at MOP (unknown origin) expressed in SH-SY5Y cell membranes co-expressing Gbeta1-RGFP protein assessed as induction of G protein activation incubated for 15 mins by BRET assay,CHEMBL4665800,EC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
CHEMBL4747671,CHEMBL233,Mu opioid receptor,EC50,=,4.074,nM,CHEMBL4670672,B,Agonist activity at MOP (unknown origin) expressed in SH-SY5Y cell membranes co-expressing Gbeta1-RGFP protein assessed as induction of G protein activation incubated for 15 mins by BRET assay,CHEMBL4665800,EC50,CCCCCCCCCCCCCCCC(=O)NCCCN1C(=O)CC(SC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc2ccc(O)cc2)C(N)=O)C1=O
CHEMBL4749747,CHEMBL233,Mu opioid receptor,EC50,=,51.29,nM,CHEMBL4670672,B,Agonist activity at MOP (unknown origin) expressed in SH-SY5Y cell membranes co-expressing Gbeta1-RGFP protein assessed as induction of G protein activation incubated for 15 mins by BRET assay,CHEMBL4665800,EC50,CCCCCCCCCCCCCCCC(=O)NCCCN1C(=O)CC(SC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](CCSC)NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(N)=O)C1=O
CHEMBL4789975,CHEMBL233,Mu opioid receptor,EC50,=,1.445,nM,CHEMBL4670672,B,Agonist activity at MOP (unknown origin) expressed in SH-SY5Y cell membranes co-expressing Gbeta1-RGFP protein assessed as induction of G protein activation incubated for 15 mins by BRET assay,CHEMBL4665800,EC50,CCCCCCCCCCCCCCCC(=O)NCCCN1C(=O)CC(SC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(N)=O)C1=O
CHEMBL8234,CHEMBL233,Mu opioid receptor,EC50,=,794.33,nM,CHEMBL4670674,B,Agonist activity at MOP (unknown origin) expressed in SH-SY5Y cell membranes co-expressing beta-arrestin2-RGFP protein assessed as induction of beta-arrestin2 activation incubated for 15 mins by BRET assay,CHEMBL4665800,EC50,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL278789,CHEMBL233,Mu opioid receptor,EC50,=,81.28,nM,CHEMBL4670674,B,Agonist activity at MOP (unknown origin) expressed in SH-SY5Y cell membranes co-expressing beta-arrestin2-RGFP protein assessed as induction of beta-arrestin2 activation incubated for 15 mins by BRET assay,CHEMBL4665800,EC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
CHEMBL4747671,CHEMBL233,Mu opioid receptor,EC50,=,229.09,nM,CHEMBL4670674,B,Agonist activity at MOP (unknown origin) expressed in SH-SY5Y cell membranes co-expressing beta-arrestin2-RGFP protein assessed as induction of beta-arrestin2 activation incubated for 15 mins by BRET assay,CHEMBL4665800,EC50,CCCCCCCCCCCCCCCC(=O)NCCCN1C(=O)CC(SC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc2ccc(O)cc2)C(N)=O)C1=O
CHEMBL4749747,CHEMBL233,Mu opioid receptor,EC50,=,38.02,nM,CHEMBL4670674,B,Agonist activity at MOP (unknown origin) expressed in SH-SY5Y cell membranes co-expressing beta-arrestin2-RGFP protein assessed as induction of beta-arrestin2 activation incubated for 15 mins by BRET assay,CHEMBL4665800,EC50,CCCCCCCCCCCCCCCC(=O)NCCCN1C(=O)CC(SC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](CCSC)NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(N)=O)C1=O
CHEMBL4789975,CHEMBL233,Mu opioid receptor,EC50,=,10.96,nM,CHEMBL4670674,B,Agonist activity at MOP (unknown origin) expressed in SH-SY5Y cell membranes co-expressing beta-arrestin2-RGFP protein assessed as induction of beta-arrestin2 activation incubated for 15 mins by BRET assay,CHEMBL4665800,EC50,CCCCCCCCCCCCCCCC(=O)NCCCN1C(=O)CC(SC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(N)=O)C1=O
CHEMBL4754111,CHEMBL233,Mu opioid receptor,EC50,=,4.39,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](NCC(=O)NCC(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4792012,CHEMBL233,Mu opioid receptor,EC50,=,0.16,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@H](C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)O)C(C)C)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4789014,CHEMBL233,Mu opioid receptor,EC50,=,0.89,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@H](C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)O)C(C)C)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4740464,CHEMBL233,Mu opioid receptor,EC50,=,12.3,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](NCCCC(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4743953,CHEMBL233,Mu opioid receptor,EC50,=,2.88,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](NCCCC(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4757463,CHEMBL233,Mu opioid receptor,EC50,=,5.74,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](NCCC(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4776879,CHEMBL233,Mu opioid receptor,EC50,=,3.52,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](NCCC(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4781006,CHEMBL233,Mu opioid receptor,EC50,=,5.47,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CC[C@H](N[C@@H]1CC[C@@]2(OC)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5)C(=O)O
CHEMBL4797321,CHEMBL233,Mu opioid receptor,EC50,=,5.12,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CC[C@H](N[C@H]1CC[C@@]2(OC)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5)C(=O)O
CHEMBL4750229,CHEMBL233,Mu opioid receptor,EC50,=,5.33,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@H](C(=O)O)C3CCCCC3)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4748047,CHEMBL233,Mu opioid receptor,EC50,=,2.88,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@H](C(=O)O)C3CCCCC3)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4783612,CHEMBL233,Mu opioid receptor,EC50,=,0.68,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@H](Cc3ccccc3)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4757240,CHEMBL233,Mu opioid receptor,EC50,=,0.77,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@H](Cc3ccccc3)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4795517,CHEMBL233,Mu opioid receptor,EC50,=,2.38,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](C(=O)O)C(C)C)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4741203,CHEMBL233,Mu opioid receptor,EC50,=,4.51,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](C(=O)O)C(C)C)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4780909,CHEMBL233,Mu opioid receptor,EC50,=,15.4,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@H](C)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4777389,CHEMBL233,Mu opioid receptor,EC50,=,1.44,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@H](C)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4740918,CHEMBL233,Mu opioid receptor,EC50,=,12.7,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](CCC(=O)O)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4761211,CHEMBL233,Mu opioid receptor,EC50,=,3.11,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](CCC(=O)O)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4747179,CHEMBL233,Mu opioid receptor,EC50,=,1.45,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](CC(=O)O)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4740360,CHEMBL233,Mu opioid receptor,EC50,=,4.1,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](CC(=O)O)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4763225,CHEMBL233,Mu opioid receptor,EC50,=,9.54,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](CCC(N)=O)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4755501,CHEMBL233,Mu opioid receptor,EC50,=,2.27,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](CCC(N)=O)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4760163,CHEMBL233,Mu opioid receptor,EC50,=,2.04,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](CC(N)=O)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4761784,CHEMBL233,Mu opioid receptor,EC50,=,0.83,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](CC(N)=O)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4788003,CHEMBL233,Mu opioid receptor,EC50,=,1.64,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](Cc3c[nH]c4ccccc34)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4755067,CHEMBL233,Mu opioid receptor,EC50,=,0.51,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](Cc3c[nH]c4ccccc34)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4745745,CHEMBL233,Mu opioid receptor,EC50,=,24.7,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](Cc3ccc(O)cc3)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4753934,CHEMBL233,Mu opioid receptor,EC50,=,1.87,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](Cc3ccc(O)cc3)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4741873,CHEMBL233,Mu opioid receptor,EC50,=,6.85,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](CCCCN)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4793888,CHEMBL233,Mu opioid receptor,EC50,=,2.25,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](CCCCN)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4782629,CHEMBL233,Mu opioid receptor,EC50,=,11.7,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@H](C(=O)O)C(C)C)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4793953,CHEMBL233,Mu opioid receptor,EC50,=,10.5,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@H](C(=O)O)C(C)C)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4788604,CHEMBL233,Mu opioid receptor,EC50,=,3.56,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](CO)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4741308,CHEMBL233,Mu opioid receptor,EC50,=,1.6,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](CO)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4795312,CHEMBL233,Mu opioid receptor,EC50,=,6.76,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](Cc3ccccc3)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4754944,CHEMBL233,Mu opioid receptor,EC50,=,0.38,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](Cc3ccccc3)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4763643,CHEMBL233,Mu opioid receptor,EC50,=,6.24,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](C)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4782642,CHEMBL233,Mu opioid receptor,EC50,=,1.34,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](C)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4755734,CHEMBL233,Mu opioid receptor,EC50,=,3.78,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@H](NCC(=O)O)CC[C@@]3(O)[C@H]1C5
CHEMBL1672084,CHEMBL233,Mu opioid receptor,EC50,=,1.16,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](NCC(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL607405,CHEMBL233,Mu opioid receptor,EC50,=,3.83,nM,CHEMBL4675312,B,Agonist activity at human MOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4467777,CHEMBL233,Mu opioid receptor,EC50,=,57.1,nM,CHEMBL4680524,B,Agonist activity at human MOR expressed in CHOK1 cells assessed as induction of beta-arrestin recruitment measured after 90 mins by PathHunter assay,CHEMBL4680063,EC50,C[C@@H](Cc1ccsc1)NC(=O)NC[C@H](Cc1ccc(O)cc1)N(C)C
CHEMBL3408737,CHEMBL233,Mu opioid receptor,EC50,=,5.53,nM,CHEMBL4701864,B,Agonist activity at human MOR expressed in human U2OS cells assessed as increase in beta arrestin2 recruitment incubated for 90 mins by pathhunter beta-arrestin assay,CHEMBL4699489,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(N)=O)C1=O
CHEMBL4761165,CHEMBL233,Mu opioid receptor,EC50,=,956.0,nM,CHEMBL4701864,B,Agonist activity at human MOR expressed in human U2OS cells assessed as increase in beta arrestin2 recruitment incubated for 90 mins by pathhunter beta-arrestin assay,CHEMBL4699489,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C
CHEMBL4789659,CHEMBL233,Mu opioid receptor,EC50,=,1329.0,nM,CHEMBL4701864,B,Agonist activity at human MOR expressed in human U2OS cells assessed as increase in beta arrestin2 recruitment incubated for 90 mins by pathhunter beta-arrestin assay,CHEMBL4699489,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4744531,CHEMBL233,Mu opioid receptor,EC50,=,2459.0,nM,CHEMBL4701864,B,Agonist activity at human MOR expressed in human U2OS cells assessed as increase in beta arrestin2 recruitment incubated for 90 mins by pathhunter beta-arrestin assay,CHEMBL4699489,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4798887,CHEMBL233,Mu opioid receptor,EC50,=,1142.0,nM,CHEMBL4701864,B,Agonist activity at human MOR expressed in human U2OS cells assessed as increase in beta arrestin2 recruitment incubated for 90 mins by pathhunter beta-arrestin assay,CHEMBL4699489,EC50,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CCN1Cc2ccccc2C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C
CHEMBL4758754,CHEMBL233,Mu opioid receptor,EC50,=,1965.0,nM,CHEMBL4701864,B,Agonist activity at human MOR expressed in human U2OS cells assessed as increase in beta arrestin2 recruitment incubated for 90 mins by pathhunter beta-arrestin assay,CHEMBL4699489,EC50,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CCN1Cc2ccccc2C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C
CHEMBL4776986,CHEMBL233,Mu opioid receptor,EC50,=,1066.0,nM,CHEMBL4701864,B,Agonist activity at human MOR expressed in human U2OS cells assessed as increase in beta arrestin2 recruitment incubated for 90 mins by pathhunter beta-arrestin assay,CHEMBL4699489,EC50,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)C[C@H](CCCNC(=N)N)NC(=O)CCN1Cc2ccccc2C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C
CHEMBL4749016,CHEMBL233,Mu opioid receptor,EC50,=,3044.0,nM,CHEMBL4701864,B,Agonist activity at human MOR expressed in human U2OS cells assessed as increase in beta arrestin2 recruitment incubated for 90 mins by pathhunter beta-arrestin assay,CHEMBL4699489,EC50,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)C[C@H](CCCCN)NC(=O)CCN1Cc2ccccc2C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C
CHEMBL4742666,CHEMBL233,Mu opioid receptor,EC50,=,934.0,nM,CHEMBL4701864,B,Agonist activity at human MOR expressed in human U2OS cells assessed as increase in beta arrestin2 recruitment incubated for 90 mins by pathhunter beta-arrestin assay,CHEMBL4699489,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N2Cc3ccc(O)cc3C[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4750783,CHEMBL233,Mu opioid receptor,EC50,=,2163.0,nM,CHEMBL4701864,B,Agonist activity at human MOR expressed in human U2OS cells assessed as increase in beta arrestin2 recruitment incubated for 90 mins by pathhunter beta-arrestin assay,CHEMBL4699489,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N2Cc3ccc(O)cc3C[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4745899,CHEMBL233,Mu opioid receptor,EC50,=,359.0,nM,CHEMBL4701864,B,Agonist activity at human MOR expressed in human U2OS cells assessed as increase in beta arrestin2 recruitment incubated for 90 mins by pathhunter beta-arrestin assay,CHEMBL4699489,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc(O)c2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4747286,CHEMBL233,Mu opioid receptor,EC50,=,1271.0,nM,CHEMBL4701864,B,Agonist activity at human MOR expressed in human U2OS cells assessed as increase in beta arrestin2 recruitment incubated for 90 mins by pathhunter beta-arrestin assay,CHEMBL4699489,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc(O)c2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4758906,CHEMBL233,Mu opioid receptor,EC50,=,3000.0,nM,CHEMBL4736304,B,Agonist activity at human Gi/G0-coupled mu opioid receptor expressed in human U2OS cells co-expressing EA-tagged beta-arrestin2 assessed as beta-arrestin 2 recruitment by PathHunter assay,CHEMBL4732147,EC50,CN1Cc2ccccc2CN2CC[C@]1(c1ccccc1)C2
CHEMBL4750490,CHEMBL233,Mu opioid receptor,EC50,=,4000.0,nM,CHEMBL4736304,B,Agonist activity at human Gi/G0-coupled mu opioid receptor expressed in human U2OS cells co-expressing EA-tagged beta-arrestin2 assessed as beta-arrestin 2 recruitment by PathHunter assay,CHEMBL4732147,EC50,CCN1Cc2ccccc2CN2CC[C@@]1(c1ccccc1)C2
CHEMBL4787061,CHEMBL233,Mu opioid receptor,EC50,=,700.0,nM,CHEMBL4736304,B,Agonist activity at human Gi/G0-coupled mu opioid receptor expressed in human U2OS cells co-expressing EA-tagged beta-arrestin2 assessed as beta-arrestin 2 recruitment by PathHunter assay,CHEMBL4732147,EC50,CCCN1Cc2ccccc2CN2CCC1(c1ccccc1)C2
CHEMBL4756393,CHEMBL233,Mu opioid receptor,EC50,=,2400.0,nM,CHEMBL4736304,B,Agonist activity at human Gi/G0-coupled mu opioid receptor expressed in human U2OS cells co-expressing EA-tagged beta-arrestin2 assessed as beta-arrestin 2 recruitment by PathHunter assay,CHEMBL4732147,EC50,CN1Cc2ccc(O)cc2CN2CC[C@@]1(c1ccccc1)C2
CHEMBL5074744,CHEMBL233,Mu opioid receptor,EC50,=,368.0,nM,CHEMBL5042912,B,Inhibition of MOR-mediated HIV1 BaL01 infection in GFP-tagged human OPRM1 transfected TZM-bl cells co-expressing HIV1 - LTR assessed as inhibition of viral entry by measuring LTR-driven luciferase activity pretreated for 1 hr before infection measured after 2 to 3 days of infection,CHEMBL5042476,EC50,CC(C)c1nnc(CCNC(=O)COCC(=O)NCCCCCCCNC(=O)COCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)n1C1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1
CHEMBL5074744,CHEMBL233,Mu opioid receptor,EC50,=,247.0,nM,CHEMBL5042913,B,Inhibition of MOR-mediated HIV1 BaL01 infection in GFP-tagged human OPRM1 transfected TZM-bl cells co-expressing HIV1 - LTR assessed as inhibition of viral entry in presence of morphine by measuring LTR-driven luciferase activity pretreated for 1 hr before infection measured after 2 to 3 days of infection,CHEMBL5042476,EC50,CC(C)c1nnc(CCNC(=O)COCC(=O)NCCCCCCCNC(=O)COCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)n1C1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1
CHEMBL4860528,CHEMBL233,Mu opioid receptor,EC50,=,1023.29,nM,CHEMBL5151497,B,Displacement of [3H]diprenorphine from human mu-opioid receptor stably expressed in HEK293T cell membrane incubated for 2 hrs by scintillation counting analysis,CHEMBL5149991,EC50,CCCCCNC(=O)/N=C(\N)NCCCc1sc(N)nc1C
CHEMBL5207281,CHEMBL233,Mu opioid receptor,EC50,=,3388.44,nM,CHEMBL5151497,B,Displacement of [3H]diprenorphine from human mu-opioid receptor stably expressed in HEK293T cell membrane incubated for 2 hrs by scintillation counting analysis,CHEMBL5149991,EC50,CCCCCNC(=O)/N=C(\N)NCCCc1nnc(N)s1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL5206565,CHEMBL233,Mu opioid receptor,EC50,=,3981.07,nM,CHEMBL5151497,B,Displacement of [3H]diprenorphine from human mu-opioid receptor stably expressed in HEK293T cell membrane incubated for 2 hrs by scintillation counting analysis,CHEMBL5149991,EC50,N/C(=N\C(=O)NCc1ccccc1)NCCCc1nnc(N)s1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL5201074,CHEMBL233,Mu opioid receptor,EC50,=,17378.01,nM,CHEMBL5151497,B,Displacement of [3H]diprenorphine from human mu-opioid receptor stably expressed in HEK293T cell membrane incubated for 2 hrs by scintillation counting analysis,CHEMBL5149991,EC50,C[C@@H](NC(=O)/N=C(\N)NCCCc1ncn[nH]1)c1ccccc1.Cl.Cl
CHEMBL5277326,CHEMBL233,Mu opioid receptor,EC50,=,0.7,nM,CHEMBL5227864,B,Agonist activity at MOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,CN(C)CC1CN(CCc2cccc(C(F)(F)F)c2)CCC1(O)c1cccc(O)c1
CHEMBL5272486,CHEMBL233,Mu opioid receptor,EC50,=,6.4,nM,CHEMBL5227864,B,Agonist activity at MOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,CN(C)CC1CN(C(=O)Cc2ccc(F)cc2)CCC1(O)c1cccc(O)c1
CHEMBL5275873,CHEMBL233,Mu opioid receptor,EC50,=,5.64,nM,CHEMBL5227864,B,Agonist activity at MOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,Cc1ccc(CC(=O)N2CCC(O)(c3cccc(O)c3)C(CN(C)C)C2)cc1
CHEMBL5282901,CHEMBL233,Mu opioid receptor,EC50,=,9.3,nM,CHEMBL5227864,B,Agonist activity at MOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,CN(C)CC1CN(C(=O)Cc2ccccc2Cl)CCC1(O)c1cccc(O)c1
CHEMBL5270915,CHEMBL233,Mu opioid receptor,EC50,=,4.1,nM,CHEMBL5227864,B,Agonist activity at MOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,CN(C)CC1CN(C(=O)Cc2cccc(Cl)c2)CCC1(O)c1cccc(O)c1
CHEMBL5272258,CHEMBL233,Mu opioid receptor,EC50,=,5.1,nM,CHEMBL5227864,B,Agonist activity at MOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,CN(C)CC1CN(C(=O)Cc2ccc(Cl)cc2)CCC1(O)c1cccc(O)c1
CHEMBL5287792,CHEMBL233,Mu opioid receptor,EC50,=,2.8,nM,CHEMBL5227864,B,Agonist activity at MOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,CN(C)CC1CN(C(=O)CCc2cccc(C(F)(F)F)c2)CCC1(O)c1cccc(O)c1
CHEMBL1400,CHEMBL233,Mu opioid receptor,EC50,=,244.7,nM,CHEMBL5227864,B,Agonist activity at MOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,CN(C)C[C@H]1CCCC[C@]1(O)c1cccc(O)c1
CHEMBL38874,CHEMBL233,Mu opioid receptor,EC50,=,8.1,nM,CHEMBL5227864,B,Agonist activity at MOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL5273356,CHEMBL233,Mu opioid receptor,EC50,=,57.1,nM,CHEMBL5227864,B,Agonist activity at MOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,CN(C)CC1CN(C(=O)Cc2cc(F)c(F)cc2F)CCC1(O)c1cccc(O)c1
CHEMBL5279890,CHEMBL233,Mu opioid receptor,EC50,=,18.6,nM,CHEMBL5227864,B,Agonist activity at MOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,CN(C)C[C@@H]1CN(C(=O)Cc2cc(F)c(F)cc2F)CC[C@@]1(O)c1cccc(O)c1
CHEMBL5287134,CHEMBL233,Mu opioid receptor,EC50,=,109.8,nM,CHEMBL5227864,B,Agonist activity at MOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,CN(C)C[C@H]1CN(C(=O)Cc2cc(F)c(F)cc2F)CC[C@]1(O)c1cccc(O)c1
CHEMBL190461,CHEMBL233,Mu opioid receptor,EC50,=,41700.0,nM,CHEMBL5335496,B,Negative allosteric modulation of mu opioid receptor (unknown origin),CHEMBL5331141,EC50,C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O
CHEMBL4592045,CHEMBL233,Mu opioid receptor,EC50,=,4590.0,nM,CHEMBL5361015,B,Agonist activity at MOR (unknown origin),CHEMBL5360528,EC50,CCc1cc(F)c2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)c(C)c2c1
CHEMBL104042,CHEMBL233,Mu opioid receptor,Kd,=,0.22,nM,CHEMBL1039850,B,Binding affinity to human mu opioid receptor expressed in CHO cells,CHEMBL1156815,KD,Oc1cccc2c1O[C@H]1CCC[C@H]3CN(CC4CC4)CC[C@@]231
CHEMBL1795714,CHEMBL233,Mu opioid receptor,Kd,=,0.11,nM,CHEMBL1799269,B,Binding affinity to MOR-1 expressed in CHO cells after 90 mins,CHEMBL1795226,KD,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cccc([125I])c1
CHEMBL1795715,CHEMBL233,Mu opioid receptor,Kd,=,0.22,nM,CHEMBL1799269,B,Binding affinity to MOR-1 expressed in CHO cells after 90 mins,CHEMBL1795226,KD,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@H](NC(=O)c2cccc([125I])c2)CC[C@@]3(O)[C@H]1C5
CHEMBL1795716,CHEMBL233,Mu opioid receptor,Kd,=,0.08,nM,CHEMBL1799269,B,Binding affinity to MOR-1 expressed in CHO cells after 90 mins,CHEMBL1795226,KD,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@H](NC(=O)c2cccc([125I])c2)CC[C@@]3(O)[C@H]1C5
CHEMBL3745782,CHEMBL233,Mu opioid receptor,Kd,=,9.772,nM,CHEMBL3748893,B,Antagonist activity at human MOR expressed in CHO-FlpIn cell membranes assessed as inhibition of DAMGO-induced ERK phosphorylation after 30 mins by Gaddum-Schild plot analysis,CHEMBL3745681,KD,COc1nnc(OCCCC(=O)NCCCCCCNC(=O)[C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(O)ccc6c5[C@@]23CCN(C)[C@@H]4C6)nn1
CHEMBL3747555,CHEMBL233,Mu opioid receptor,Kd,=,48.98,nM,CHEMBL3748893,B,Antagonist activity at human MOR expressed in CHO-FlpIn cell membranes assessed as inhibition of DAMGO-induced ERK phosphorylation after 30 mins by Gaddum-Schild plot analysis,CHEMBL3745681,KD,CCN1/C(=C/C=C/C=C/C2=[N+](CCCCCC(=O)NCCCCCCNC(=O)[C@H]3C[C@@]45CC[C@]3(OC)[C@@H]3Oc6c(O)ccc7c6[C@@]34CCN(C)[C@@H]5C7)c3ccc(S(=O)(=O)O)cc3C2(C)C)C(C)(C)c2cc(S(=O)(=O)O)ccc21
CHEMBL3746198,CHEMBL233,Mu opioid receptor,Kd,=,4.266,nM,CHEMBL3748893,B,Antagonist activity at human MOR expressed in CHO-FlpIn cell membranes assessed as inhibition of DAMGO-induced ERK phosphorylation after 30 mins by Gaddum-Schild plot analysis,CHEMBL3745681,KD,CO[C@]12CC[C@@]3(C[C@@H]1C(=O)NCCCCCCNC(=O)CCCCCNC(=O)COc1ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL3746169,CHEMBL233,Mu opioid receptor,Kd,=,13.49,nM,CHEMBL3748893,B,Antagonist activity at human MOR expressed in CHO-FlpIn cell membranes assessed as inhibition of DAMGO-induced ERK phosphorylation after 30 mins by Gaddum-Schild plot analysis,CHEMBL3745681,KD,CO[C@]12CC[C@@]3(C[C@@H]1C(=O)NCCCCCCNC(=O)CCN1C(=O)c4cccc5c(N)ccc(c45)C1=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4860528,CHEMBL233,Mu opioid receptor,Kd,=,0.09,nM,CHEMBL5151497,B,Displacement of [3H]diprenorphine from human mu-opioid receptor stably expressed in HEK293T cell membrane incubated for 2 hrs by scintillation counting analysis,CHEMBL5149991,KD,CCCCCNC(=O)/N=C(\N)NCCCc1sc(N)nc1C
CHEMBL5207281,CHEMBL233,Mu opioid receptor,Kd,=,0.09,nM,CHEMBL5151497,B,Displacement of [3H]diprenorphine from human mu-opioid receptor stably expressed in HEK293T cell membrane incubated for 2 hrs by scintillation counting analysis,CHEMBL5149991,KD,CCCCCNC(=O)/N=C(\N)NCCCc1nnc(N)s1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL5206565,CHEMBL233,Mu opioid receptor,Kd,=,0.09,nM,CHEMBL5151497,B,Displacement of [3H]diprenorphine from human mu-opioid receptor stably expressed in HEK293T cell membrane incubated for 2 hrs by scintillation counting analysis,CHEMBL5149991,KD,N/C(=N\C(=O)NCc1ccccc1)NCCCc1nnc(N)s1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL5201074,CHEMBL233,Mu opioid receptor,Kd,=,0.09,nM,CHEMBL5151497,B,Displacement of [3H]diprenorphine from human mu-opioid receptor stably expressed in HEK293T cell membrane incubated for 2 hrs by scintillation counting analysis,CHEMBL5149991,KD,C[C@@H](NC(=O)/N=C(\N)NCCCc1ncn[nH]1)c1ccccc1.Cl.Cl
